{
  "questions": [
    {
      "body": "Which ensemble machine-learning framework has been developed harnessing UK biobank data?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39261665"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 526,
          "text": "The emergence of biobank-level datasets offers new opportunities to discover novel biomarkers and develop predictive algorithms for human disease. Here, we present an ensemble machine-learning framework (machine learning with phenotype associations, MILTON) utilizing a range of biomarkers to predict 3,213 diseases in the UK Biobank. Leveraging the UK Biobank\u0027s longitudinal health record data, MILTON predicts incident disease cases undiagnosed at time of recruitment, largely outperforming available polygenic risk scores. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39261665"
        }
      ],
      "id": "67dedd6818b1e36f2e000061",
      "ideal_answer": [
        "MILTON is an ensemble machine-learning framework utilizing a range of biomarkers to predict 3,213 diseases in the UK Biobank. Leveraging the UK Biobank\u0027s longitudinal health record data, MILTON predicts incident disease cases undiagnosed at time of recruitment, largely outperforming available polygenic risk scores.",
        "MILTON (Machine Learning with Phenotype Associations) is the identified ensemble machine-learning framework. It has been developed utilizing UK Biobank data, with a notable capability of predicting up to 3,213 diseases. The consistency across sources and the specificity of its application lend credibility to its role in leveraging biobank data for comprehensive disease prediction.",
        "The ensemble machine-learning framework developed harnessing UK Biobank data is MILTON.",
        "MILTON is an ensemble machine-learning framework developed harnessing UK biobank data.",
        "The ensemble machine-learning framework developed harnessing UK Biobank data is called MILTON.",
        "The ensemble machine-learning framework is MILTON, which stands for machine learning with phenotype associations. MILTON harnesses a range of biomarkers from the UK Biobank to predict diseases.",
        "The ensemble machine-learning framework developed utilizing UK Biobank data is called machine learning with phenotype associations, or MILTON. It utilizes a range of biomarkers to predict 3,213 diseases.",
        "MILTON is an ensemble machine-learning framework developed using UK Biobank data to predict diseases.",
        "MILTON (Machine Learning with Phenotype Associations) has been developed harnessing UK Biobank data, designed to work with phenotype associations.",
        "The ensemble machine-learning framework developed harnessing UK Biobank data is called MILTON (Machine Learning with Phenotype Associations).",
        "The ensemble machine-learning framework developed using UK Biobank data is MILTON (machine learning with phenotype associations).",
        "MILTON, an ensemble machine-learning framework, has been developed harnessing UK biobank data.",
        "Machine learning with phenotype associations (MILTON) is an ensemble machine-learning framework utilizing a range of biomarkers to predict 3,213 diseases in the UK Biobank. Leveraging the UK Biobank\u0027s longitudinal health record data, MILTON predicts incident disease cases undiagnosed at time of recruitment, largely outperforming available polygenic risk scores.",
        "Researchers developed MILTON (machine learning with phenotype associations), an ensemble machine-learning framework that utilizes various biomarkers to predict 3,213 diseases using longitudinal health record data from the UK Biobank. This innovative approach aims to predict incident disease cases that were undiagnosed at the time of initial recruitment.",
        "A novel ensemble machine-learning framework, known as MILTON (machine learning with phenotype associations), has been developed utilizing UK Biobank data. This framework leverages a range of biomarkers to predict a large number of diseases, specifically 3,213, in the UK Biobank. By harnessing the longitudinal health record data from the UK Biobank, MILTON is able to predict incident disease cases that were undiagnosed at the time of recruitment, demonstrating superior performance compared to available polygenic risk scores.",
        "MILTON (machine learning with phenotype associations) is an ensemble machine-learning framework developed using UK Biobank data that utilizes various biomarkers to predict 3,213 diseases and effectively predicts undiagnosed incident disease cases, demonstrating superior performance compared to existing polygenic risk scores.",
        "The ensemble machine-learning framework developed using UK Biobank data is called MILTON (machine learning with phenotype associations). This framework leverages longitudinal health records and a range of biomarkers to predict 3,213 diseases, demonstrating superior performance compared to existing polygenic risk scores in identifying incident disease cases not yet diagnosed at the time of participant recruitment.",
        "MILTON is an ensemble machine-learning framework utilizing a range of biomarkers to predict 3,213 diseases in the UK Biobank.",
        "The ensemble machine-learning framework developed using UK Biobank data is MILTON, which leverages a range of biomarkers to predict a large number of diseases.",
        "MILTON is an ensemble machine-learning framework developed to harness UK biobank data.",
        "MILTON, which stands for machine learning with phenotype associations, is the ensemble machine-learning framework that harnesses UK Biobank data.",
        "The ensemble machine-learning framework is MILTON (machine learning with phenotype associations), which leverages UK Biobank data to predict incident disease cases.",
        "The ensemble machine-learning framework developed using UK Biobank data is called machine learning with phenotype associations (MILTON).",
        "The ensemble machine-learning framework MILTON (machine learning with phenotype associations) has been developed utilizing a range of biomarkers to predict diseases in the UK Biobank.",
        "The ensemble machine-learning framework that has been developed utilizing the UK Biobank\u0027s longitudinal health record data is called MILTON (machine learning with phenotype associations). This framework leverages a range of biomarkers to predict 3,213 diseases in the UK Biobank and largely outperforms available polygenic risk scores.",
        "The ensemble machine-learning framework developed using UK Biobank data is called MILTON (machine learning with phenotype associations). It utilizes a range of biomarkers to predict 3,213 diseases. By leveraging longitudinal health record data from the UK Biobank, MILTON can predict incident disease cases that were undiagnosed at the time of recruitment and largely outperforms available polygenic risk scores.",
        "The ensemble machine-learning framework that has been developed using the UK Biobank data is called MILTON (Machine Learning with Phenotype Associations). This framework utilizes a range of biomarkers to predict 3,213 diseases in the UK Biobank, outperforming available polygenic risk scores. It leverages the UK Biobank\u0027s longitudinal health record data to predict incident disease cases undiagnosed at time of recruitment.",
        "The ensemble machine-learning framework presented in the provided context is called MILTON (Machine Learning with Phenotype Associations). This framework utilizes a range of biomarkers to predict 3,213 diseases in the UK Biobank, outperforming available polygenic risk scores. It leverages the UK Biobank\u0027s longitudinal health record data to predict incident disease cases undiagnosed at time of recruitment.",
        "The ensemble machine-learning framework named MILTON was developed harnessing UK Biobank data.",
        "MILTON, standing for Machine Learning with Phenotype Associations, is the ensemble machine-learning framework developed utilizing the extensive resources of the UK Biobank data, designed to explore and analyze phenotype associations within this comprehensive dataset.",
        "The ensemble machine-learning framework developed utilizing UK Biobank data is called MILTON, which stands for \"machine learning with phenotype associations.\" This framework employs a set of diverse biomarkers to predict the onset of 3,213 different diseases. MILTON takes advantage of the UK Biobank\u0027s extensive longitudinal health records to predict diseases that have not been diagnosed at the time of recruitment, and it shows a significant performance improvement over existing polygenic risk scores in predicting disease incidence.",
        "MILTON (Machine Learning with Phenotype Associations) is the ensemble machine-learning framework developed using UK Biobank data, utilized for predicting diseases, including those undiagnosed at recruitment, with performance surpassing available polygenic risk scores.",
        "The ensemble machine-learning framework developed harnessing UK Biobank data is MILTON (machine learning with phenotype associations). This framework utilizes a range of biomarkers to predict 3,213 diseases in the UK Biobank and leverages the longitudinal health record data to predict incident disease cases that were undiagnosed at the time of recruitment. MILTON has been shown to largely outperform available polygenic risk scores in disease prediction.",
        "The ensemble machine-learning framework developed using UK Biobank data is called MILTON (Machine Learning with Phenotype Associations). This framework predicts incident disease cases undiagnosed at recruitment time, leveraging longitudinal health records to predict 3,213 diseases and outperforming available polygenic risk scores.",
        "The ensemble machine-learning framework developed using UK Biobank data is called MILTON (machine learning with phenotype associations).",
        "The ensemble machine-learning framework developed using UK Biobank data is **MILTON** (Machine Learning with Phenotype Associations). It utilizes various biomarkers to predict a wide range of diseases and has demonstrated superior performance compared to existing polygenic risk scores.",
        "MILTON (Machine Learning with Phenotype Associations) is the ensemble machine-learning framework developed using UK Biobank data for predicting over 3,213 diseases.",
        "MILTON is the ensemble machine-learning framework developed using UK Biobank data.",
        "MILTON (Machine Learning with Phenotype Associations)",
        "MILTON is an ensemble machine-learning framework developed to predict 3,213 diseases in the UK Biobank.",
        "The ensemble machine-learning framework developed harnessing UK Biobank data is called MILTON (machine learning with phenotype associations). It utilizes a range of biomarkers to predict diseases.",
        "The ensemble machine-learning framework developed to harness UK Biobank data is called MILTON (machine learning with phenotype associations). It utilizes a range of biomarkers to predict 3,213 diseases by leveraging the longitudinal health record data from the UK Biobank. MILTON has shown significant performance in predicting incident disease cases that were undiagnosed at the time of recruitment, outperforming existing polygenic risk scores.",
        "The ensemble machine-learning framework developed harnessing UK Biobank data is called MILTON (machine learning with phenotype associations). It utilizes a range of biomarkers to predict 3,213 diseases in the UK Biobank."
      ],
      "exact_answer": [
        [
          "MILTON",
          "Machine learning with phenotype associations"
        ]
      ]
    },
    {
      "body": "What is the mechanism of action of nipocalimab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38362023",
        "http://www.ncbi.nlm.nih.gov/pubmed/38435981",
        "http://www.ncbi.nlm.nih.gov/pubmed/39073504",
        "http://www.ncbi.nlm.nih.gov/pubmed/39115062",
        "http://www.ncbi.nlm.nih.gov/pubmed/39197469",
        "http://www.ncbi.nlm.nih.gov/pubmed/33717213"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 472,
          "text": "Introduction: Nipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-mediated diseases, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, maternal-fetal medicine, and multiple other therapeutic areas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38362023"
        },
        {
          "offsetInBeginSection": 972,
          "offsetInEndSection": 1054,
          "text": "Other neonatal Fc receptor blockers, nipocalimab and batoclimab, are under study. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38435981"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073504"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 307,
          "text": "BACKGROUND AND OBJECTIVES: Nipocalimab is a high-affinity, fully human, effectorless immunoglobulin G1 monoclonal antibody targeting the neonatal Fc receptor and is currently under evaluation for the treatment of rare and prevalent immunoglobulin G autoantibody-mediated and alloantibody-mediated diseases. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073504"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 405,
          "text": "Nipocalimab, an anti-neonatal Fc receptor blocker, inhibits transplacental IgG transfer and lowers maternal IgG levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39115062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "BACKGROUND AND OBJECTIVES: Nipocalimab is a high-affinity, fully human, effectorless immunoglobulin G1 monoclonal antibody targeting the neonatal Fc receptor and is currently under evaluation for the treatment of rare and prevalent immunoglobulin G autoantibody-mediated and allo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073504"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 210,
          "text": " Nipocalimab is a neonatal fragment crystallizable (Fc) receptor (FcRn)-blocking monoclonal antibody that inhibits placental immunoglobulin G (IgG) transfer and lowers circulating maternal IgG levels",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39197469"
        },
        {
          "offsetInBeginSection": 1418,
          "offsetInEndSection": 1775,
          "text": "Finally, the very promising effect of monoclonal antibodies that inhibit FcRn, such as efgartigimod, rozanolixizumab and nipocalimab, in treating antibody-mediated neurological diseases is discussed along with their efficacy in the IgG4 subclass of pathogenic antibodies and their role in the blood-brain barrier endothelium, that abundantly expresses FcRn.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33717213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "text": "Introduction: Nipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-medi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38362023"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 706,
          "text": "Nipocalimab, an anti-neonatal Fc receptor blocker, inhibits transplacental IgG transfer and lowers maternal IgG levels.METHODS: In an international, open-label, single-group, phase 2 study, we assessed treatment with intravenous nipocalimab (30 or 45 mg per kilogram of body weight per week) administered from 14 to 35 weeks\u0027 gestation in participants with pregnancies at high risk for recurrent early-onset severe HDFN.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39115062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306,
          "text": "BACKGROUND AND OBJECTIVES: Nipocalimab is a high-affinity, fully human, effectorless immunoglobulin G1 monoclonal antibody targeting the neonatal Fc receptor and is currently under evaluation for the treatment of rare and prevalent immunoglobulin G autoantibody-mediated and alloantibody-mediated diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073504"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 316,
          "text": " Nipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-mediated diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38362023"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 209,
          "text": "  Nipocalimab is a neonatal fragment crystallizable (Fc) receptor (FcRn)-blocking monoclonal antibody that inhibits placental immunoglobulin G (IgG) transfer and lowers circulating maternal IgG level",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39197469"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 458,
          "text": "Introduction: Nipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-mediated diseases, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, maternal-fetal medicine, and multiple other ther",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38362023"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 278,
          "text": "BACKGROUND AND OBJECTIVES: Nipocalimab is a high-affinity, fully human, effectorless immunoglobulin G1 monoclonal antibody targeting the neonatal Fc receptor and is currently under evaluation for the treatment of rare and prevalent immunoglobulin G autoantibody-mediated and all",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073504"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 457,
          "text": "Introduction: Nipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-mediated diseases, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, maternal-fetal medicine, and multiple other the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38362023"
        }
      ],
      "type": "summary",
      "id": "67e6b93718b1e36f2e0000be",
      "ideal_answer": [
        "Nipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-mediated diseases, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, maternal-fetal medicine, and multiple other therapeutic areas."
      ]
    },
    {
      "body": "What are theragnostics?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38352718",
        "http://www.ncbi.nlm.nih.gov/pubmed/38302831",
        "http://www.ncbi.nlm.nih.gov/pubmed/38816137",
        "http://www.ncbi.nlm.nih.gov/pubmed/38821099",
        "http://www.ncbi.nlm.nih.gov/pubmed/19104225",
        "http://www.ncbi.nlm.nih.gov/pubmed/35133096",
        "http://www.ncbi.nlm.nih.gov/pubmed/39355044",
        "http://www.ncbi.nlm.nih.gov/pubmed/30662821",
        "http://www.ncbi.nlm.nih.gov/pubmed/33081161",
        "http://www.ncbi.nlm.nih.gov/pubmed/17286540",
        "http://www.ncbi.nlm.nih.gov/pubmed/26822368",
        "http://www.ncbi.nlm.nih.gov/pubmed/37331786",
        "http://www.ncbi.nlm.nih.gov/pubmed/38860276",
        "http://www.ncbi.nlm.nih.gov/pubmed/30976948",
        "http://www.ncbi.nlm.nih.gov/pubmed/39266875",
        "http://www.ncbi.nlm.nih.gov/pubmed/34053577",
        "http://www.ncbi.nlm.nih.gov/pubmed/22772034",
        "http://www.ncbi.nlm.nih.gov/pubmed/20403397",
        "http://www.ncbi.nlm.nih.gov/pubmed/39062106",
        "http://www.ncbi.nlm.nih.gov/pubmed/23432008",
        "http://www.ncbi.nlm.nih.gov/pubmed/30599229",
        "http://www.ncbi.nlm.nih.gov/pubmed/36059083",
        "http://www.ncbi.nlm.nih.gov/pubmed/33145091",
        "http://www.ncbi.nlm.nih.gov/pubmed/39339195",
        "http://www.ncbi.nlm.nih.gov/pubmed/32793481",
        "http://www.ncbi.nlm.nih.gov/pubmed/24780269",
        "http://www.ncbi.nlm.nih.gov/pubmed/27540032",
        "http://www.ncbi.nlm.nih.gov/pubmed/37237939",
        "http://www.ncbi.nlm.nih.gov/pubmed/39612962",
        "http://www.ncbi.nlm.nih.gov/pubmed/39515063",
        "http://www.ncbi.nlm.nih.gov/pubmed/39598394",
        "http://www.ncbi.nlm.nih.gov/pubmed/33001789",
        "http://www.ncbi.nlm.nih.gov/pubmed/23873093",
        "http://www.ncbi.nlm.nih.gov/pubmed/29705040",
        "http://www.ncbi.nlm.nih.gov/pubmed/29520164",
        "http://www.ncbi.nlm.nih.gov/pubmed/36359312",
        "http://www.ncbi.nlm.nih.gov/pubmed/25787729",
        "http://www.ncbi.nlm.nih.gov/pubmed/34053576"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 181,
          "text": "The percutaneous thermal ablation techniques (pTA) are radiofrequency ablation, cryoablation, and microwave ablation, suitable for the treatment of bone oligometastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Theragnostics has become a popular term nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38352718"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62,
          "text": "Hepatic Radioembolization: A Multistep Theragnostic Procedure.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38816137"
        },
        {
          "offsetInBeginSection": 272,
          "offsetInEndSection": 601,
          "text": "The past two decades, however, has seen a remarkable surge in the clinical application of diagnostic and therapeutic radiopharmaceuticals, particularly in oncology. This development is an exciting time for the use of theranostics in oncology, but the rapid growth of this area of nuclear medicine has created challenges as well. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38821099"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Theragnostics embraces \"gnosis\" and \"prognosis\" and concerns a treatment strategy which combines diagnostics with therapeutics. The birth of what",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35133096"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 225,
          "text": "Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine. Theragnostic care",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39355044"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 358,
          "text": "patient care. With the introduction of theragnostics, a new medical subspecialty that fuses therapeutics and diagnostic medicine with the goal of providing individualized pharmacotherapy, we suggest",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17286540"
        },
        {
          "offsetInBeginSection": 599,
          "offsetInEndSection": 1010,
          "text": "\"theragnostics.\" As novel therapeutic mechanisms and molecules targeting these mechanisms are discovered, the use of theragnostics will be critical for their successful clinical development, as well as their optimal subsequent clinical use. During clinical development, lest theragnostics are utilized, efficacy signals will risk remaining undetected when diluted in study populations that are not appropriately",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26822368"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 318,
          "text": "Theranostics is a type of RPT that utilizes imaging, either of the RPT drug directly or a companion diagnostic, to inform whether a patient will benefit from the treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37331786"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Theragnostics embraces \"gnosis\" and \"prognosis\" and concerns a treatment strategy which combines diagnostics with therapeutics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35133096"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 254,
          "text": "Theragnostics is a combination of therapies and diagnostics targeting pathophysiological processes at molecular level using radiopharmaceuticals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34881849"
        },
        {
          "offsetInBeginSection": 634,
          "offsetInEndSection": 776,
          "text": "The use of these pairs of radio-labelled drugs, one optimised for therapy, the other for diagnostic purposes, is referred to as theragnostics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33081161"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 207,
          "text": "Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39355044"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 783,
          "text": "Theragnostics is a treatment strategy that combines therapeutics with diagnostics. It associates both a diagnostic test that identifies patients most likely to be helped or harmed by a new medication, and targeted drug therapy based on the test results. Bioinformatics, genomics, proteomics, and functional genomics are molecular biology tools essential for the progress of molecular theragnostics. These tools generate the genetic and protein information required for the development of diagnostic assays. Theragnostics includes a wide range of subjects, including personalized medicine, pharmacogenomics, and molecular imaging to develop efficient new targeted therapies with adequate benefit/risk to patients and a better molecular understanding of how to optimize drug selection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19104225"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 345,
          "text": "Theragnostics is a combination of therapies and diagnostics targeting pathophysiological processes at molecular level using radiopharmaceuticals. It is a valuable resource in efforts to implement precision medicine in clinical practice,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34881849"
        },
        {
          "offsetInBeginSection": 683,
          "offsetInEndSection": 1167,
          "text": "According to the broad definition theranostics provides a closer relationship between diagnostics and therapy. According to the narrow definition diagnostics and therapy become a single intervention. On closer examination it turns out that in the narrow definition the diagnostics capacities are limited to monitoring. Neither the broad nor the narrow definition actually demonstrate a new concept in medicine. Rather, they describe the well-known practice of medical decision making.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30976948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273,
          "text": "Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39266875"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 464,
          "text": "Theragnostics represents one of the most innovative fields of precision medicine with a huge potential in the field of oncology in the next years. The use of a pair of selective radiopharmaceuticals for cellular receptors, used for diagnostic and therapeutic purposes (PRRT), finds applications in the Neuroendocrine tumors and metastatic Castration-Resistant prostate cancer (mCRPC) thanks, respectively, to somatostatin receptor agonists and PSMA-based peptides.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38860276"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Radiometal-based theranostics or theragnostics, first used in the early 2000s, is the combined application of diagnostic and therapeutic agents that target the same molecule, and represents a considerable advancement in nuclear medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34053577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 288,
          "text": "Theragnostic nanoparticles (NPs) contain diagnostic and therapeutic functions in one integrated system, enabling diagnosis, therapy, and monitoring of therapeutic response at the same time. For diagnostic function, theragnostic NPs require the inclusion of noninvasive imaging modalities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22772034"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 458,
          "text": "Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer treatment is enhancing the tumor-specific targeting of both imaging probes and anticancer agents. Herein, we report tumor-homing chitosan-based nanoparticles (CNPs) that simultaneously execute cancer diagnosis and therapy (cancer theragnosis).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20403397"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 372,
          "text": "Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine. Theragnostic care in HCC involves the use of imaging techniques to diagnose the cancer and assess its characteristics, such as size, location, and extent of spread.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39355044"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 362,
          "text": "Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging through linkage to a proper radionuclide, and the other bearing an alpha- or beta-emitter isotope that can induce significant damage to cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37835806"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Theranostic medicine is relatively a new term that describes integration of diagnostic and therapeutic functions within the same platform of pharmaceuticals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432008"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 458,
          "text": "The term \u0027theranostic\u0027 refers to such multifunctional systems which combine the features of diagnosis and treatment in a single platform for superior control of the disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30599229"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Theranostics is an emerging therapeutic paradigm of personalized medicine; the term refers to the simultaneous integration of therapy and diagnostics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36059083"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Theranostics is a re-emerging field of medicine that aims to create targeted agents that can be used for diagnostic and/or therapeutic indications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33145091"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Theranostics is a growing field that matches diagnostics and therapeutics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39339195"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Theranostics are nano-size or molecular-level agents serving for both diagnosis and therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32793481"
        },
        {
          "offsetInBeginSection": 337,
          "offsetInEndSection": 487,
          "text": "Theranostics, which involves the combination of therapy and diagnostic imaging into a single system, may fulfill the promise of personalized medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24780269"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 261,
          "text": " worldwide. Theranostics, a combination of diagnostics and therapeutics, is an emerging concept in the field of precision medicine, and microRNAs (miRNAs) are predictive pioneers i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540032"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Theragnostics is a treatment strategy that combines therapeutics with diagnostics",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19104225"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 206,
          "text": "Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39355044"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 253,
          "text": "Theragnostics is a combination of therapies and diagnostics targeting pathophysiological processes at molecular level using radiopharmaceuticals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34881849"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Theragnostics embraces \"gnosis\" and \"prognosis\" and concerns a treatment strategy which combines diagnostics with therapeutics",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35133096"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Theragnostics is considered as an emerging treatment strategy that integrates therapeutics and diagnostics thus allowing delivery of therapeutics and simultaneous monitoring of the progression of treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30662821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Theragnostics has become a popular term nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38352718"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "The bottleneck on therapeutics and diagnostics is removed by an alternate approach known as theranostics which combines both therapeutics and diagnostics within a single platform.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39612962"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39598394"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 491,
          "text": "Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39598394"
        },
        {
          "offsetInBeginSection": 712,
          "offsetInEndSection": 835,
          "text": "The ultimate goal is to develop a platform that combines multiple diagnostic and therapeutic functionalities based on MNSs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39515063"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share a specific target in diseased cells or tissues",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33001789"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Theranostics, a new term consisting of the words \"therapy\" and \"diagnostics,\" represents the concept of selecting specific patients for appropriate drug administration using diagnostics",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23873093"
        },
        {
          "offsetInBeginSection": 683,
          "offsetInEndSection": 792,
          "text": "According to the broad definition theranostics provides a closer relationship between diagnostics and therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30976948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "Radiometal-based theranostics or theragnostics, first used in the early 2000s, is the combined application of diagnostic and therapeutic agents that target the same molecule, and represents a considerable advancement in nuclear medicine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34053577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 260,
          "text": "The technical phrase theragnostic (also known as theranostic) was first introduced to the scientific community in the year 1998 by John Funkhouser, to describe a methodology or procedure employed to achieve disease diagnosis and treatment simultaneously [...].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39062106"
        },
        {
          "offsetInBeginSection": 573,
          "offsetInEndSection": 701,
          "text": "Theragnosis is a concept in next-generation medicine that simultaneously combines accurate diagnostics with therapeutic effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29520164"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 295,
          "text": "The concept of theragnostics or theranostics emerged around 2002 to describe the incorporation of diagnostic assays into the selection of therapy for this purpose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29705040"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Theragnostics is a promising approach that integrates diagnostics and therapeutics into a single personalized strategy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37237939"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Theragnostics is considered as an emerging treatment strategy that integrates therapeutics and diagnostics thus allowing delivery of therapeutics and simultaneous monitoring of the progression of treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30662821"
        },
        {
          "offsetInBeginSection": 680,
          "offsetInEndSection": 1108,
          "text": "Theragnostics is defined as the use of molecular diagnostic techniques in real time to stratify patients to guide treatment decisions such as the choice of drug, the dose of administration, and the timing of drug delivery for a given patient. Enabling visualization and quantitation of in vivo function of the whole body and thus patient heterogeneity and variability informs the physician on how to treat an individual patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31470937"
        },
        {
          "offsetInBeginSection": 680,
          "offsetInEndSection": 922,
          "text": "Theragnostics is defined as the use of molecular diagnostic techniques in real time to stratify patients to guide treatment decisions such as the choice of drug, the dose of administration, and the timing of drug delivery for a given patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31470937"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 256,
          "text": "Theragnostic, a combination of therapy and diagnostic, using radionuclide pairs to diagnose and treat disease, has been shown to be a promising approach for combating PCa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36359312"
        },
        {
          "offsetInBeginSection": 573,
          "offsetInEndSection": 700,
          "text": "Theragnosis is a concept in next-generation medicine that simultaneously combines accurate diagnostics with therapeutic effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29520164"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Theranostics is a promising field that combines therapeutics and diagnostics into single multifunctional formulations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787729"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Theranostics describes the pairing of diagnostic biomarkers and therapeutic agents with common specific targets",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34053576"
        }
      ],
      "type": "summary",
      "id": "67ded51918b1e36f2e00005e",
      "ideal_answer": [
        "Theragnostics combines \"therapy\" and \"diagnostics.\" It refers to a medical approach that integrates diagnostic imaging with targeted therapy.",
        "Theragnostics are a new class of diagnostic and therapeutic tools that combine the principles of diagnostics and therapeutics.",
        "Theragnostic strategies allow the diagnosis, in a single session, of a disease and its response to a particular treatment.",
        "Theranostics, also spelled theragnostics, refers to a field of medicine that combines specific targeted therapy based on specific targeted diagnostic tests. It involves the integration of therapeutics and diagnostics to create a personalized treatment plan for patients, often using molecular imaging techniques to guide and monitor the effectiveness of therapies, especially in oncology.",
        "Theragnostics is a field of medicine that combines therapy and diagnostics to simultaneously diagnose and treat diseases, often using targeted radioactive substances.",
        "theragnostics, also known as theranostics, refers to a term that has gained popularity in recent years, combining diagnostics and therapy into a single concept. however, its usage is misleading as it blurs the distinction between the two separate steps of diagnosis and treatment, suggesting that they can be merged or omitted, which is not necessarily the case.",
        "Theranostics, particularly in the context of nuclear oncology, refers to the combined approach of cancer imaging and therapy using the same targeting molecule. This strategy aims to enhance the precision of cancer treatment by allowing for the simultaneous diagnosis and therapeutic intervention, particularly in neuro-oncology, where it is termed neurotheranostics.",
        "Theragnostics is a treatment strategy that combines therapeutics with diagnostics, targeting pathophysiological processes at the molecular level using radiopharmaceuticals. It involves personalized medicine, pharmacogenomics, and molecular imaging to develop efficient new targeted therapies with adequate benefit/risk to patients.",
        "Theragnostics is a medical strategy that combines diagnostics and therapeutics to provide personalized treatment, often using molecular biology tools and radiopharmaceuticals.",
        "Theragnostics is a treatment strategy that combines therapeutics with diagnostics to create personalized treatment plans, often used in personalized medicine and oncology.",
        "Theragnostic agents have the ability to provide diagnostic and therapeutic modalities in a single system. Exact answer:",
        "Theragnostics is a term that refers to the combination of diagnosis and therapy in a single step.",
        "Theragnostics is an innovative medical approach that combines both diagnostic and therapeutic capabilities using a single carrier platform, which has gained significant popularity particularly in oncology over the past two decades. This development has revolutionized treatment methods, though its rapid growth has presented certain challenges in nuclear medicine.",
        "Theragnostics has become a popular term nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform.",
        "Theragnostics is a concept that combines diagnostic and therapeutic capabilities into a single platform, allowing for simultaneous diagnosis and treatment of a condition, which is particularly relevant in the field of oncology, where it has seen a significant surge in clinical application over the past two decades.",
        "Theragnostics refers to the integration of diagnostics and therapy using a single platform. It involves using one agent to both image (diagnose) and treat diseases, as seen in oncology with radiopharmaceuticals and other targeted treatments.",
        "Theragnostics is a term used to describe the combination of diagnosis and therapy using radiopharmaceuticals on a single carrier platform.",
        "Theragnostics is an approach that combines diagnosis and therapy using a single carrier platform. For instance, it involves using diagnostic radiopharmaceuticals that also deliver targeted therapy, as noted in procedures like hepatic radioembolization and the broader use of theranostics in oncology.",
        "Theragnostics refers to a medical approach that combines both diagnostic and therapeutic capabilities into a single platform, allowing for simultaneous diagnosis and treatment, particularly in the field of oncology.",
        "Theragnostics is a term that has become popular nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform.",
        "Theragnostic agents have the ability to provide diagnostic and therapeutic modalities in a single system.",
        "Theragnostics are a combination of diagnosis and therapy at the same time.",
        "Theragnostics refers to an approach in medicine that combines diagnostic testing with therapeutic treatment, using a single agent or platform to both diagnose and treat diseases, particularly in the field of oncology. This method allows for targeted treatment based on specific diagnostic results, enhancing personalized medicine.",
        "Theragnostics (correct term: Theranostics) refers to a medical approach or platform that simultaneously enables both diagnosis and therapy, combining these two traditionally separate aspects into one, often using a single carrier or procedure, particularly noted in advancements within oncology.",
        "Theragnostics enables both diagnosis and therapy at the same time while only using one carrier platform. The clinical application of diagnostic and therapeutic radiopharmaceuticals, particularly in oncology, represents the use of theranostics. Hepatic Radioembolization is an example of a multistep theragnostic procedure.",
        "Theragnostics is a term that describes both diagnostic and therapeutic procedures using one carrier platform, enabling simultaneous diagnosis and therapy. This approach has gained popularity in oncology over the past two decades, particularly with radiopharmaceuticals like hepatic radioembolization, marking an exciting yet challenging period for nuclear medicine.",
        "Theragnostics has become a popular term nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform ."
      ]
    },
    {
      "body": "What is the effect of knee steroid injection?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37757466",
        "http://www.ncbi.nlm.nih.gov/pubmed/37089441",
        "http://www.ncbi.nlm.nih.gov/pubmed/37138944",
        "http://www.ncbi.nlm.nih.gov/pubmed/36855146",
        "http://www.ncbi.nlm.nih.gov/pubmed/38060720",
        "http://www.ncbi.nlm.nih.gov/pubmed/15000335",
        "http://www.ncbi.nlm.nih.gov/pubmed/30531239",
        "http://www.ncbi.nlm.nih.gov/pubmed/39570872",
        "http://www.ncbi.nlm.nih.gov/pubmed/37903599",
        "http://www.ncbi.nlm.nih.gov/pubmed/34408954",
        "http://www.ncbi.nlm.nih.gov/pubmed/27572327",
        "http://www.ncbi.nlm.nih.gov/pubmed/38455990",
        "http://www.ncbi.nlm.nih.gov/pubmed/24639940",
        "http://www.ncbi.nlm.nih.gov/pubmed/21486119"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 1470,
          "offsetInEndSection": 1531,
          "text": "did not significantly change cartilage and tendon thicknesses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37757466"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 158,
          "text": " intra-articular knee injections in the treatment of knee osteoarthritis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37089441"
        },
        {
          "offsetInBeginSection": 938,
          "offsetInEndSection": 984,
          "text": "using intra-articular knee injections for pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37089441"
        },
        {
          "offsetInBeginSection": 292,
          "offsetInEndSection": 368,
          "text": " to manage pain, which includes intra-articular (IA) injections of cortisone",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37138944"
        },
        {
          "offsetInBeginSection": 53,
          "offsetInEndSection": 162,
          "text": "intra-articular steroid injections (IASIs) are still widely used to relieve symptoms of knee osteoarthritis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36855146"
        },
        {
          "offsetInBeginSection": 1609,
          "offsetInEndSection": 1865,
          "text": "IAS and PRP injection treatments have a significantly positive effect on the pain and quality of life of patients with knee OA, although this positive effect for pain was significantly better for IAS at night and during movement at the one-month follow-up.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38060720"
        },
        {
          "offsetInBeginSection": 703,
          "offsetInEndSection": 949,
          "text": "ores were significantly different between groups.CONCLUSION: Intra-articular corticosteroid injection results in clinically and statistically significant reduction in osteoarthritic knee pain 1 week after injection. The beneficial effect could la",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15000335"
        },
        {
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1365,
          "text": "rior steroid injections were associated with an increased risk of revision (HR \u003d 1.25 95%CI (1.06 to 1.49)), re-operation (HR \u003d 1.18 95%CI (1.05 to 1.32)), and SSI (HR \u003d 3.10 95%CI (1.14 to 8.46). Timing from diagnosis of knee osteoarthritis to knee replacement was 6 months longer in patients receiving steroid injections. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39570872"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 703,
          "text": "ABSTRACT: Intra-articular steroid injections for knee osteoarthritis are a routine procedure in musculoskeletal clinics. While their role in osteoarthritis care is debatable, they serve as an important therapeutic option to relieve osteoarthritis-associated pain. Potential risks are self-limited (increased pain flare, local skin irritation, flushing, insomnia) or severe (septic arthritis, intravascular medication placement, and the deleterious effect on cartilage and bone). In our experience, more serious adverse events are rare. In this case, we present a complication secondary to intra-articular steroid administration that has not previously been reported in the literature: superficial vein t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37903599"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 135,
          "text": "Knee corticosteroid injection (KCSI) and physical therapy (PT) are two efficacious treatments for knee osteoarthritis (KOA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34408954"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 132,
          "text": "Intra-articular corticosteroid injections (IACS) are interventions which provide pain relief in knee osteoarthritis (OA)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38455990"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 270,
          "text": "The pain relief from a steroid injection is thought to work by reducing inflammation within the arthritic knee.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30531239"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 269,
          "text": "The pain relief from a steroid injection is thought to work by reducing inflammation within the arthritic knee",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30531239"
        },
        {
          "offsetInBeginSection": 470,
          "offsetInEndSection": 572,
          "text": "The success of steroid injections in relieving arthritic knee pain most often occurs in the short term",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30531239"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 241,
          "text": "Injection of corticosteroid for the treatment of osteoarthritis is the most common reason for knee joint injection, and is performed as an office procedure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24639940"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Corticosteroid joint injections are perceived as being an effective treatment for symptomatic knee osteoarthritis, with a very low risk of complications",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21486119"
        }
      ],
      "id": "67e2cfa918b1e36f2e000099",
      "ideal_answer": [
        "Knee steroid injection does not significantly change cartilage and tendon thicknesses. In the treatment of knee osteoarthritis, intra-articular steroid injections (IASIs) are still widely used to relieve pain and symptoms of knee osteoarthritis. IAS have a significantly positive effect on the pain and quality of life of patients with knee OA.",
        "Intra-articular corticosteroid injection results in clinically and statistically significant reduction in osteoarthritic knee pain 1 week after injection. The beneficial effect could last for 3 to 4 weeks, but is unlikely to continue beyond that.",
        "Knee steroid injections are commonly used to treat pain associated with inflammatory arthritis, osteoarthritis (OA), and post-surgical inflammation, providing short-term relief in many cases. Studies show that while these injections can effectively reduce pain and improve function in conditions like rheumatoid arthritis, ankylosing spondylitis, and chronic soft tissue inflammation after total knee arthroplasty, their long-term efficacy is questionable. Concerns exist about potential adverse effects on articular cartilage with prolonged use. Additionally, some patients with Greater Trochanteric Pain Syndrome may benefit, though outcomes vary. Comparisons with other treatments, such as genicular radiofrequency ablation, suggest that steroid injections may be less effective in the long term for certain conditions like OA. Overall, knee steroid injections remain a widely used treatment option despite their limitations.",
        "Knee steroid injections, specifically intra-articular corticosteroid injections, are effective in providing short-term pain relief for patients with osteoarthritis (OA) of the knee. They have been shown to reduce pain and improve range of motion (ROM) shortly after administration, with minimal risk of complications or joint damage. However, there are concerns regarding potential cartilage degeneration associated with repeated steroid use over time. Overall, while steroid injections can offer immediate benefits, their long-term effects and optimal dosing require further investigation."
      ]
    },
    {
      "body": "How do cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33066357",
        "http://www.ncbi.nlm.nih.gov/pubmed/33291370",
        "http://www.ncbi.nlm.nih.gov/pubmed/37345462",
        "http://www.ncbi.nlm.nih.gov/pubmed/31428105",
        "http://www.ncbi.nlm.nih.gov/pubmed/36870916",
        "http://www.ncbi.nlm.nih.gov/pubmed/39223656",
        "http://www.ncbi.nlm.nih.gov/pubmed/37292803",
        "http://www.ncbi.nlm.nih.gov/pubmed/34635121",
        "http://www.ncbi.nlm.nih.gov/pubmed/31068935",
        "http://www.ncbi.nlm.nih.gov/pubmed/31735289",
        "http://www.ncbi.nlm.nih.gov/pubmed/30726287",
        "http://www.ncbi.nlm.nih.gov/pubmed/26201938",
        "http://www.ncbi.nlm.nih.gov/pubmed/36852791",
        "http://www.ncbi.nlm.nih.gov/pubmed/38169303",
        "http://www.ncbi.nlm.nih.gov/pubmed/35479076",
        "http://www.ncbi.nlm.nih.gov/pubmed/29900042",
        "http://www.ncbi.nlm.nih.gov/pubmed/34868949",
        "http://www.ncbi.nlm.nih.gov/pubmed/38955088",
        "http://www.ncbi.nlm.nih.gov/pubmed/39476569",
        "http://www.ncbi.nlm.nih.gov/pubmed/35918210",
        "http://www.ncbi.nlm.nih.gov/pubmed/34203869",
        "http://www.ncbi.nlm.nih.gov/pubmed/37783155",
        "http://www.ncbi.nlm.nih.gov/pubmed/35569095",
        "http://www.ncbi.nlm.nih.gov/pubmed/38863724",
        "http://www.ncbi.nlm.nih.gov/pubmed/34778248",
        "http://www.ncbi.nlm.nih.gov/pubmed/35346803",
        "http://www.ncbi.nlm.nih.gov/pubmed/37251405"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Cancer-associated fibroblasts (CAFs) are prominent cells within the tumor microenvironment, by communicating with other cells within the tumor and by secreting the extracellular matrix components. The discovery of the immunogenic role of CAFs has made their study particularly attractive due to the potential applications in the field of cancer immunotherapy. Indeed, CAFs are highly involved in tumor immune evasion by physically impeding the immune system and interacting with both myeloid and lymphoid cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33066357"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 518,
          "text": "One of the primary functions of the TME is to stimulate an immunosuppressive environment around the tumor through multiple mechanisms including the activation of the transforming growth factor-beta (TGF-β) signaling pathway. Cancer-associated fibroblasts (CAFs) are key cells in the TME that regulate the secretion of extracellular matrix (ECM) components under the influence of TGF-β.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33291370"
        },
        {
          "offsetInBeginSection": 519,
          "offsetInEndSection": 694,
          "text": "Recent reports from our group and others have described an ECM-related and CAF-associated novel gene signature that can predict resistance to immune checkpoint blockade (ICB).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33291370"
        },
        {
          "offsetInBeginSection": 360,
          "offsetInEndSection": 511,
          "text": "Indeed, CAFs are highly involved in tumor immune evasion by physically impeding the immune system and interacting with both myeloid and lymphoid cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33066357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 903,
          "text": "Cancer-associated fibroblasts (CAFs) are prominent components of the microenvironment in most types of solid tumors, and were shown to facilitate cancer progression by supporting tumor cell growth, extracellular matrix remodeling, promoting angiogenesis, and by mediating tumor-promoting inflammation. In addition to an inflammatory microenvironment, tumors are characterized by immune evasion and an immunosuppressive milieu. In recent years, CAFs are emerging as central players in immune regulation that shapes the tumor microenvironment. CAFs contribute to immune escape of tumors via multiple mechanisms, including secretion of multiple cytokines and chemokines and reciprocal interactions that mediate the recruitment and functional differentiation of innate and adaptive immune cells. Moreover, CAFs directly abrogate the function of cytotoxic lymphocytes, thus inhibiting killing of tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 701,
          "text": "Cancer-associated fibroblasts (CAFs) are major protumorigenic components of the tumor microenvironment in solid cancers. CAFs are heterogeneous, consisting of multiple subsets that display diverse functions. Recently, CAFs have emerged as major promoters of immune evasion. CAFs favor T cell exclusion and exhaustion, promote recruitment of myeloid-derived suppressor cells, and induce protumoral phenotypic shifts in macrophages and neutrophils. With the growing appreciation of CAF heterogeneity came the understanding that different CAF subpopulations may be driving distinct immune-regulatory effects, interacting with different cell types, and perhaps even driving opposing effects on malignancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36870916"
        },
        {
          "offsetInBeginSection": 542,
          "offsetInEndSection": 791,
          "text": "CAFs contribute to immune escape of tumors via multiple mechanisms, including secretion of multiple cytokines and chemokines and reciprocal interactions that mediate the recruitment and functional differentiation of innate and adaptive immune cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428105"
        },
        {
          "offsetInBeginSection": 792,
          "offsetInEndSection": 903,
          "text": "Moreover, CAFs directly abrogate the function of cytotoxic lymphocytes, thus inhibiting killing of tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428105"
        },
        {
          "offsetInBeginSection": 542,
          "offsetInEndSection": 903,
          "text": "CAFs contribute to immune escape of tumors via multiple mechanisms, including secretion of multiple cytokines and chemokines and reciprocal interactions that mediate the recruitment and functional differentiation of innate and adaptive immune cells. Moreover, CAFs directly abrogate the function of cytotoxic lymphocytes, thus inhibiting killing of tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428105"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 476,
          "text": "Cancer-associated fibroblasts (CAFs) constitute the most prevalent, yet heterogeneous, component of the tumor stroma, where they \u0027cool down\u0027 the immune microenvironment. The central role played by CAFs, both as a physical barrier and source of immunosuppressive molecules, sets them as a target to enhance immunotherapy of cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31735289"
        },
        {
          "offsetInBeginSection": 274,
          "offsetInEndSection": 446,
          "text": "CAFs favor T cell exclusion and exhaustion, promote recruitment of myeloid-derived suppressor cells, and induce protumoral phenotypic shifts in macrophages and neutrophils.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36870916"
        },
        {
          "offsetInBeginSection": 501,
          "offsetInEndSection": 853,
          "text": "The most abundant stromal cells of the TME, cancer associated fibroblasts (CAFs), promote tumour progression via multiple pathways and play a role in dampening the immune response to cancer. Recent research indicates that T cells react to CAF signalling and establish bidirectional crosstalk that plays a significant role in the tumour immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35479076"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 538,
          "text": "CAFs can also produce inhibitors that counteract the function of T cells and promote tumor immune escape, while T cells can also engage in complex two-way interactions with CAFs through direct cell contact, the exchange of soluble factors such as cytokines, and the remodeling of the extracellular matrix.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38955088"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 483,
          "text": "Generally speaking, CAFs in cooperation with tumor cells can secrete various cytokines, proteins, growth factors, and metabolites to promote angiogenesis, mediate immune escape of tumor cells, enhance endothelial-to-mesenchymal transition, stimulate extracellular matrix remodeling, and preserve tumor cell stemness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39476569"
        },
        {
          "offsetInBeginSection": 542,
          "offsetInEndSection": 902,
          "text": "CAFs contribute to immune escape of tumors via multiple mechanisms, including secretion of multiple cytokines and chemokines and reciprocal interactions that mediate the recruitment and functional differentiation of innate and adaptive immune cells. Moreover, CAFs directly abrogate the function of cytotoxic lymphocytes, thus inhibiting killing of tumor cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428105"
        },
        {
          "offsetInBeginSection": 521,
          "offsetInEndSection": 842,
          "text": "In this review, we summarized the major cytokines, chemokines and metabolites, including transforming growth factor-β (TGF-β), interleukin-6 (IL-6), C-X-C chemokine ligand (CXCL)12, C-C chemokine ligand (CCL) 2, prostaglandin E2 (PGE2), and other factors, by which CAFs suppress the immune systems in a variety of cancers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35918210"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 519,
          "text": "Furthermore, CAFs are important mediators of suppressing immune responses by attracting the accumulation of immunosuppressive cells through cytokine/chemokine secretion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35918210"
        },
        {
          "offsetInBeginSection": 196,
          "offsetInEndSection": 598,
          "text": "Cancer-associated fibroblasts (CAFs), as the most abundant stromal cells of the TME, can not only directly alter the immunosuppressive effect of the TME through their own metabolism, but also influence the aggregation and function of immune cells by secreting a large number of cytokines and chemokines, reducing the body\u0027s immune surveillance of tumor cells and making them more prone to immune escape",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37783155"
        },
        {
          "offsetInBeginSection": 342,
          "offsetInEndSection": 539,
          "text": "CAFs can modify the microenvironment, establish a refuge to aid cancer cells in immune escape by secreting large amounts of extracellular matrix, and produce soluble cytokines and exosomal vesicles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35569095"
        },
        {
          "offsetInBeginSection": 360,
          "offsetInEndSection": 510,
          "text": "Indeed, CAFs are highly involved in tumor immune evasion by physically impeding the immune system and interacting with both myeloid and lymphoid cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33066357"
        },
        {
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1340,
          "text": "These results demonstrated that CAFs collaborated with tumor cells in the TME to establish an immunosuppressive network that facilitated tumor evasion from immunological destruction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201938"
        },
        {
          "offsetInBeginSection": 542,
          "offsetInEndSection": 790,
          "text": "CAFs contribute to immune escape of tumors via multiple mechanisms, including secretion of multiple cytokines and chemokines and reciprocal interactions that mediate the recruitment and functional differentiation of innate and adaptive immune cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "The crucial role of cancer-associated fibroblasts (CAFs) in promoting T-cell exclusion has a significant impact on tumor immune evasion and resistance to immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38169303"
        },
        {
          "offsetInBeginSection": 484,
          "offsetInEndSection": 737,
          "text": "Pancreatic CAFs have emerged as important regulators of the tumor microenvironment by contributing to immune evasion through the release of chemokines, cytokines, and growth factors, which alters T-cell migration, differentiation and cytotoxic activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34203869"
        },
        {
          "offsetInBeginSection": 1628,
          "offsetInEndSection": 1774,
          "text": "Thus, this indicates that CAFs induce expression of immune checkpoints on CD4+ and CD8+ T-cells, which contribute to a diminished immune function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31068935"
        },
        {
          "offsetInBeginSection": 513,
          "offsetInEndSection": 1081,
          "text": "Cancer-associated fibroblasts have several ways by which they can affect the tumour\u0027s immune microenvironment (TIME). For example, their interactions with macrophages and dendritic cells (DCs) create an immunosuppressive milieu that can indirectly affect T-cell anticancer immunity and enable immune evasion. In addition, a number of recent studies have confirmed CAF-mediated direct suppressive effects on T-cell anticancer capacity through ECM remodelling, promoting the expression of immune checkpoints, cytokine secretion and the release of extracellular vesicles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38863724"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 524,
          "text": "The constant crosstalk between cancer cells, cancer-associated fibroblasts (CAFs), and the immune cells mediated by the soluble factors and inflammatory mediators including cytokines, chemokines, reactive oxygen species (ROS) promote the dynamic temporal switch towards an immune-escape phenotype in the neoplastic cells and its microenvironment that bolsters disease progression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35346803"
        },
        {
          "offsetInBeginSection": 663,
          "offsetInEndSection": 815,
          "text": "The CAF secretome is a significant contributor to the extracellular matrix and a plethora of cytokines and growth factors that induce immune suppression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37251405"
        }
      ],
      "id": "67eaf2cd18b1e36f2e0000e1",
      "ideal_answer": [
        "Cancer-associated fibroblasts (CAFs) are prominent cells within the tumor microenvironment, by communicating with other cells within the tumor and by secreting extracellular matrix (ECM) components, under the influence of TGF-β. The discovery of the immunogenic role of CAFs has made their study particularly attractive due to the potential applications in the field of cancer immunotherapy. Indeed, CAFs are highly involved in tumor immune evasion by physically impeding the immune system and interacting with both myeloid and lymphoid cells. To illustrate that, recent studies have described an ECM-related and CAF-associated novel gene signature that can predict resistance to immune checkpoint blockade.",
        "Cancer-associated fibroblasts (CAFs) facilitate immune evasion in tumors through multiple key mechanisms. They physically impede immune cell access and interact with immune cells in an immunosuppressive manner. CAFs secrete factors like cytokines, chemokines, and prostaglandins, modulating immune cell function towards suppression. The expression of immune checkpoint molecules (e.g., PD-L1) directly inhibits T-cell activity. Furthermore, CAFs contribute to creating an \u0027immunologically cold\u0027 microenvironment, characterized by reduced CD8+ T-cell infiltration, influenced by CAF density and specific subpopulations. These actions collectively enable tumors to evade immune detection, promoting growth and progression.",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors through multiple mechanisms: they create physical barriers and secrete immunosuppressive molecules that hinder immune cell infiltration and function; they modulate immune cell activity and promote the recruitment of immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells; they release extracellular vesicles and exosomes carrying immunosuppressive molecules, such as PD-L1 and lncRNAs, which modulate immune cell function; and they express immune checkpoint ligands and modulate immune checkpoint pathways, inhibiting T cell activity and promoting an immunosuppressive tumor microenvironment.",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors through several mechanisms. They secrete immunosuppressive factors like TGF-β, IL-6, and VEGF, which suppress cytotoxic T cells and natural killer (NK) cells, and promote regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). CAFs also remodel the extracellular matrix (ECM), creating a physical barrier that prevents immune cell infiltration and alters the tumor microenvironment\u0027s mechanical properties. They express immune checkpoint molecules such as PD-L1, leading to T cell exhaustion and reduced anti-tumor activity. CAFs can alter the metabolic landscape by consuming nutrients and producing metabolites like lactate, creating an acidic environment that impairs T cell function. Additionally, CAFs release exosomes containing microRNAs, proteins, and other molecules that modulate immune cell function and promote an immunosuppressive microenvironment. Through these mechanisms, CAFs play a crucial role in helping tumors evade immune surveillance and resist immune-mediated destruction.",
        "Cancer-associated fibroblasts contribute to tumor immune evasion by orchestrating multiple immunosuppressive mechanisms. They secrete a range of cytokines, chemokines, and growth factors that attract suppressive cells such as regulatory T cells and myeloid-derived suppressor cells, while also shifting macrophages and neutrophils toward protumoral phenotypes and promoting T cell exhaustion. In addition, they release exosomal vesicles and metabolites that further dampen immune responses, and deposit extracellular matrix components that create physical barriers to immune cell infiltration. Specific signaling pathways, such as SMAD2-dependent induction of PD-L1 via activin A, promote regulatory T cell differentiation, thereby reinforcing immune suppression. Through these complex and multifaceted interactions, CAFs impair cytotoxic lymphocyte function and overall immune surveillance, enabling tumors to evade immunological attack.",
        "Cancer-associated fibroblasts (CAFs) play a significant role in facilitating immune evasion within tumors through several mechanisms:\n\n1. **Extracellular Matrix Remodeling**: CAFs alter the ECM, creating a physical barrier that hinders immune cell infiltration into the tumor site.\n\n2. **Immunosuppressive Signaling**: They produce cytokines and chemokines that recruit regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which suppress anti-tumor immune responses.\n\n3. **Influence on Immune Cells**: CAFs can modulate the differentiation of macrophages into tumor-supporting M2-like cells, enhancing an immunosuppressive environment.\n\n4. **Epithelial-to-Mesenchymal Transition (EMT)**: By inducing EMT in cancer cells, CAFs enhance tumor aggressiveness and reduce immune recognition.\n\n5. **Metabolic Alterations**: CAFs modify the local metabolism to create a hostile environment for immune cells, potentially inhibiting their activation and function.\n\nThese mechanisms collectively create a protective niche for tumors, enabling them to evade immune detection and destruction.",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors through multiple mechanisms. They secrete cytokines, chemokines, and growth factors, influencing the recruitment, function, migration, and differentiation of immune cells. CAFs also directly impair the function of cytotoxic lymphocytes, inhibiting tumor cell killing, and suppress the function of CD4+ and CD8+ T cells via their effects on COX2 and PD-L1. Furthermore, CAFs physically impede the immune system and interact with myeloid and lymphoid cells. They can also modify the immunosuppressive environment through their metabolism, making tumors more prone to immune escape.",
        "Cancer-associated fibroblasts (CAFs) play a significant role in facilitating immune evasion within the tumor microenvironment (TME). Their contributions can be summarized as follows:\n\n1. **Physical Barrier Creation**: CAFs produce excessive extracellular matrix (ECM) components, leading to a dense structure that hinders immune cell infiltration and access to cancer cells.\n\n2. **Immunosuppressive Signaling**: They secrete cytokines and chemokines that recruit immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which inhibit cytotoxic T cells and natural killer (NK) cells.\n\n3. **Immune Checkpoint Modulation**: CAFs can increase the expression of PD-L1 on tumor cells, promoting interactions with PD-1 receptors on T cells, thereby suppressing immune responses.\n\n4. **Metabolic Influence**: They alter the metabolic landscape by consuming nutrients or producing waste products like lactate, creating an environment detrimental to immune cell activity.\n\n5. **Promotion of Angiogenesis**: CAFs secrete factors that promote angiogenesis, potentially affecting immune cell infiltration through leaky vasculature.\n\n6. **Remodeling and Enzymatic Activity**: They produce enzymes like matrix metalloproteinases (MMPs), which can both degrade and rebuild ECM, creating barriers for immune cells while aiding cancer cell movement.\n\n7. **Antigen Downregulation**: CAFs may influence tumor cells to downregulate surface antigens, reducing recognition by immune cells.\n\n8. **Genetic and Epigenetic Changes**: Undergoing genetic mutations or altered gene expression profiles enhances their ability to suppress immune responses and support tumor progression.\n\nIn summary, CAFs employ a multifaceted approach involving physical, biochemical, and cellular mechanisms to create an immunosuppressive environment that aids in tumor evasion of the immune system.",
        "Cancer-associated fibroblasts (CAFs) promote immune evasion in tumors through several mechanisms. They secrete a variety of immunosuppressive factors, including cytokines, growth factors, and chemokines, which contribute to shaping an immunosuppressive tumor microenvironment (TME). This environment enables cancer cells to evade immune surveillance. CAFs interact with tumor-infiltrating immune cells, such as macrophages and regulatory T cells, creating barriers against effective antitumor responses, particularly inhibiting CD8+ T cell activity.\n\nSpecific CAF subtypes, such as POSTN+ CAFs, have been identified as significant immune response barriers, hindering T-cell infiltration and decreasing the efficacy of immunotherapy. Additionally, CAFs can regulate immune checkpoints through ligand-receptor interactions, such as LGALS9/TIM-3, further promoting immune escape. The dynamic communication between CAFs and other TME components, including their role in extracellular matrix remodeling, also supports tumor progression and immune suppression, highlighting their critical role in cancer immune evasion.",
        "Cancer-associated fibroblasts (CAFs) facilitate immune evasion in tumors through multifaceted mechanisms. These include physically hindering immune cell access, secreting immunosuppressive factors (e.g., TGF-β, IL-6, TNF, IGF2), and interacting with myeloid and lymphoid cells to promote an immunosuppressive phenotype. CAFs also directly impede cytotoxic lymphocyte function, suppress T-cell proliferation (CD4+/CD8+), and upregulate immune checkpoint molecules (e.g., PD-L1). Additionally, utilization of cyclooxygenase-2 (COX2) inhibits T-cell cytotoxicity, culminating in a \u0027cold\u0027 tumor microenvironment with reduced CD8+ T-cell infiltration, which can confer resistance to immune-checkpoint blockade therapy.",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors through multiple mechanisms: creating physical barriers, secreting immunosuppressive factors like TGF-β, IL-6, and PD-L1, modulating immune cell behavior to induce protumoral phenotypic shifts, and directly inhibiting cytotoxic lymphocytes, notably excluding CD8+ T cells from the tumor microenvironment.",
        "Cancer-associated fibroblasts (CAFs) promote immune evasion by reshaping the tumor microenvironment in several ways. They secrete immunosuppressive cytokines and chemokines, such as TGF-β and IL-6, which inhibit the activity of cytotoxic T cells and attract regulatory T cells and myeloid-derived suppressor cells that dampen effective immune responses. CAFs also remodel the extracellular matrix by producing proteins and enzymes that create a dense barrier, limiting the infiltration of immune cells into the tumor core. Additionally, they can modulate immune cell function by inducing the expression of immune checkpoint molecules, like PD-L1, on tumor or neighboring immune cells, further exhausting T cells. Through metabolic reprogramming, CAFs alter nutrient availability, creating an environment that is hostile to immune cells. Collectively, these mechanisms hinder the immune system’s ability to attack tumor cells, thereby supporting tumor survival and progression.",
        "Cancer associated fibroblasts (CAFs) contribute significantly to immune evasion in tumors through a multifaceted approach: 1. Immunosuppressive Cytokines : CAFs produce cytokines such as TGF β and IL 6, which suppress the activity of T cells, crucial for targeting cancer cells. 2. Extracellular Matrix (ECM) Remodeling : By altering the ECM, CAFs create a stiffer tumor environment that physically blocks immune cell infiltration, preventing effective attack on cancer cells. 3. Cancer Stem Cell Support : CAFs help maintain a niche for cancer stem cells, which are resistant to treatment and can lead to tumor recurrence, indirectly aiding in immune evasion. 4. Recruitment of Suppressive Cells : CAFs attract immunosuppressive cells like regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs), further dampening the immune response. These mechanisms collectively create a protective environment for tumors, allowing them to evade immune detection and destruction.",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors through various mechanisms. They physically impede the immune system, interact with both myeloid and lymphoid cells, and promote T cell exclusion and exhaustion. CAFs also favor the recruitment of myeloid-derived suppressor cells and induce protumoral phenotypic shifts in macrophages and neutrophils. Additionally, they release chemokines, cytokines, and growth factors that alter T-cell migration, differentiation, and cytotoxic activity. By controlling key tumorigenic activities, CAFs participate in immune evasion and suppression, ultimately promoting tumor growth and resistance to immunotherapy. Overall, CAFs play a crucial role in creating an immunosuppressive tumor microenvironment, which enables tumors to evade the host\u0027s immune system.",
        "Cancer-associated fibroblasts contribute to immune evasion by remodeling the extracellular matrix to form physical barriers that limit immune cell infiltration. They secrete cytokines, chemokines, and growth factors that attract immunosuppressive cells while inhibiting the recruitment and activity of cytotoxic lymphocytes, thereby dampening the anti-tumor immune response. CAFs also release soluble factors and extracellular vesicles that enhance immune checkpoint expression and directly impair T-cell function. These actions foster an immunosuppressive tumor microenvironment that facilitates tumor cell survival, progression, and metastasis.",
        "Cancer-associated fibroblasts (CAFs) contribute to tumor immune evasion through multiple mechanisms. They physically impede immune system access to the tumor and interact with both myeloid and lymphoid immune cells to suppress their function. CAFs play a critical role in creating an immunosuppressive tumor microenvironment by activating the TGF-β signaling pathway, which regulates the secretion of extracellular matrix components. Additionally, recent research has identified a novel CAF-associated gene signature that can predict resistance to immune checkpoint blockade, further highlighting their importance in preventing effective anti-tumor immune responses.",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors through multiple mechanisms, including physically impeding the immune system, interacting with myeloid and lymphoid cells, and regulating the extracellular matrix (ECM) under the influence of the TGF-β signaling pathway, thus creating an immunosuppressive environment. The heterogeneous nature of CAFs suggests a nuanced therapeutic approach. Targeting specific CAF functions, especially those associated with TGF-β signaling and ECM regulation, may enhance antitumor immune responses and improve immunotherapy efficacy, potentially overcoming resistance to immune checkpoint blockade therapies.",
        "Cancer-associated fibroblasts (CAFs) play a significant role in tumor immune evasion by physically impeding the immune system and interacting with both myeloid and lymphoid cells. Studies have shown that CAFs are highly involved in creating an immunosuppressive environment around the tumor, partly through the activation of the transforming growth factor-beta (TGF-β) signaling pathway. Under the influence of TGF-β, CAFs regulate the secretion of extracellular matrix (ECM) components, which contributes to immune evasion. Furthermore, recent studies have identified an ECM-related and CAF-associated novel gene signature that can predict resistance to immune checkpoint blockade (ICB), highlighting the importance of CAFs in tumor immunity. Overall, CAFs contribute to immune evasion in tumors by stimulating an immunosuppressive environment and physically hindering the immune system, making them a key target for cancer immunotherapy.",
        "Cancer-associated fibroblasts (CAFs) play a crucial role in tumor immune evasion through multiple mechanisms, including physical obstruction of immune cells and direct interactions with both myeloid and lymphoid cells in the tumor microenvironment. These cells regulate the secretion of extracellular matrix components under TGF-β signaling influence, contributing to an immunosuppressive environment, and recent studies have linked CAF-associated gene signatures to resistance against immune checkpoint blockade therapy.",
        "Cancer-associated fibroblasts contribute to immune evasion by creating a physical barrier through extracellular matrix deposition and by secreting various cytokines, chemokines, and growth factors such as TGF-β, IL-6, and CXCL12. These secretions attract immunosuppressive cells like myeloid-derived suppressor cells and regulatory T cells while reprogramming immune cells to favor tumor growth. They directly impede immune cell infiltration and function, leading to T cell exclusion and exhaustion. CAFs can also induce immune checkpoint molecules, such as PD-L1, via SMAD2-dependent signaling, which further dampens the cytotoxic activity of lymphocytes. Additionally, metabolic alterations orchestrated by CAFs contribute to the overall immunosuppressive tumor microenvironment, reducing immune surveillance and promoting tumor escape.",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors through several mechanisms. They communicate with other cells in the tumor microenvironment and secrete extracellular matrix components, which can physically impede the immune system\u0027s access to tumor cells. CAFs interact with both myeloid and lymphoid immune cells, creating an immunosuppressive environment that promotes tumor growth and progression. Additionally, CAFs are influenced by signaling pathways such as transforming growth factor-beta (TGF-β), which further enhances their role in immune regulation. The presence of different CAF subtypes, each with potentially antagonistic functions, adds complexity to their contributions to immune evasion. Targeting CAF functions may offer promising strategies to improve antitumor immune responses and enhance the efficacy of immunotherapy.",
        "Cancer-associated fibroblasts (CAFs) play a crucial role in tumor immune evasion by employing both physical and biochemical strategies. They secrete extracellular matrix (ECM) components, creating a physical barrier that impedes the infiltration of immune effector cells into the tumor microenvironment. Additionally, CAFs produce immunomodulatory factors such as cytokines and chemokines that attract immune-suppressive cells like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), while repelling cytotoxic T cells. These actions create an immunosuppressive environment that protects cancer cells from immune attack. Furthermore, CAF activity is linked to resistance against immune checkpoint blockade therapies, highlighting their significant role in maintaining tumor immunity evasion.",
        "Cancer-associated fibroblasts (CAFs) promote immune evasion in tumors through several mechanisms. They create an immunosuppressive environment by secreting extracellular matrix (ECM) components and cytokines that inhibit antitumor immune responses. CAFs interact with immune cells, such as CD8+ T cells, macrophages, and regulatory T cells (Tregs), to establish barriers that prevent effective immune surveillance. They can induce T cell exclusion and exhaustion, recruit myeloid-derived suppressor cells (MDSCs), and promote protumoral phenotypic shifts in macrophages and neutrophils. Additionally, CAFs regulate immune checkpoints by expressing ligands that interact with receptors on T cells, further facilitating immune escape. The heterogeneity of CAF populations also contributes to their diverse roles in modulating the immune response, making them significant players in tumor progression and resistance to therapies like immune checkpoint blockade (ICB).",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors by physically impeding the immune system and interacting with both myeloid and lymphoid cells. They regulate the secretion of extracellular matrix (ECM) components under the influence of TGF-β, creating an immunosuppressive environment around the tumor. Additionally, CAFs can predict resistance to immune checkpoint blockade (ICB) through an ECM-related and CAF-associated novel gene signature. Overall, CAFs play a key role in tumor immune evasion by modulating the tumor microenvironment and suppressing anti-tumor immune responses.",
        "Cancer-associated fibroblasts (CAFs) contribute significantly to immune evasion in tumors through multiple mechanisms. They physically impede the immune system by creating barriers within the tumor microenvironment and actively interact with both myeloid and lymphoid immune cells to suppress their function. CAFs are key regulators of the extracellular matrix (ECM) components under the influence of TGF-β signaling, which helps create an immunosuppressive environment around the tumor. Research has identified an ECM-related and CAF-associated gene signature that can predict resistance to immune checkpoint blockade therapy, highlighting their critical role in tumor immune evasion mechanisms. Through these various pathways, CAFs help tumors escape detection and elimination by the immune system.",
        "Cancer-associated fibroblasts (CAFs) play a crucial role in immune evasion by physically impeding the immune system and interacting with both myeloid and lymphoid cells. They regulate the secretion of extracellular matrix components under the influence of the transforming growth factor-beta (TGF-β) signaling pathway, which contributes to creating an immunosuppressive environment around tumors. Recent studies have identified a novel gene signature associated with CAFs and ECM that predicts resistance to immune checkpoint blockade, highlighting their significance in tumor immune evasion mechanisms.",
        "Cancer-associated fibroblasts (CAFs) contribute to immune evasion in tumors through several mechanisms:\n\n1. **Physical Barrier Creation**: CAFs produce extracellular matrix (ECM) components, forming a physical barrier that impedes immune cells, such as T-cells, from infiltrating the tumor site.\n\n2. **Immunosuppressive Signaling**: They secrete transforming growth factor-beta (TGF-β), which suppresses the activation and proliferation of immune cells, including T-cells, thereby reducing anti-tumor immunity.\n\n3. **Recruitment of Suppressive Immune Cells**: CAFs interact with both myeloid and lymphoid cells, potentially recruiting immunosuppressive cells like regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which further inhibit the immune response.\n\n4. **Modulation of Immunotherapy Response**: A gene signature associated with ECM and CAFs can predict resistance to immune checkpoint blockade (ICB), indicating their role in creating an environment resistant to immunotherapies.\n\nIn summary, CAFs foster an immunosuppressive tumor microenvironment through physical barriers, signaling molecules, and recruitment of suppressive cells, enabling tumors to evade immune detection and treatment.",
        "Cancer-associated fibroblasts contribute to immune evasion by creating a physical and biochemical barrier in the tumor microenvironment that limits immune cell access and function. They deposit extracellular matrix components that form a dense barrier around tumor cells, obstructing the penetration of cytotoxic lymphocytes. CAFs secrete a variety of cytokines, chemokines, and growth factors that inhibit the activation and function of immune cells while promoting the recruitment of immunosuppressive cell types. They also release exosomes carrying immunomodulatory molecules and induce metabolic changes that further diminish the effectiveness of immune responses. This combination of physical blockade, immunosuppressive signaling, and metabolic reprogramming creates a hostile environment for immune cells, thereby allowing tumor cells to escape immune surveillance."
      ]
    },
    {
      "body": "Describe Mantis-ML 2.0",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38718126"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Phenome-wide identification of therapeutic genetic targets, leveraging knowledge graphs, graph neural networks, and UK Biobank data.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38718126"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 1268,
          "text": "Here, we introduce Mantis-ML 2.0, a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets, to assess gene-disease probabilities throughout the phenome. We use graph neural networks, capturing the graph\u0027s holistic structure, and train them on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Notably, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38718126"
        }
      ],
      "id": "67e2d75118b1e36f2e00009d",
      "ideal_answer": [
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets, to assess gene-disease probabilities throughout the phenome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Notably, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and various tabular datasets to assess gene-disease probabilities across the human exome. It utilizes graph neural networks and a semi-supervised learning framework to provide gene-disease probabilities for thousands of diseases. The framework incorporates natural language processing to automate disease-relevant feature selection and demonstrates a 6.9% average boost in classification power, achieving a median ROC AUC score of 0.90 across 5220 diseases. Mantis-ML 2.0 also prioritizes associations from an independent UK Biobank phenome-wide association study, enhancing the triaging process and mitigating underpowered associations. Results are available through an interactive web resource.",
        "Mantis-ML is a machine learning approach for disease-agnostic gene prioritization from high-throughput genomic screens by stochastic semi-supervised learning. Mantis-ML 2.0 is a phenome-wide identification of therapeutic genetic targets, leveraging knowledge graphs, graph neural networks, and UK Biobank data.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with tabular datasets to assess gene-disease probabilities across the human exome. It leverages graph neural networks, semi-supervised learning, and natural language processing for enhanced performance, achieving a median ROC AUC score of 0.90 across 5220 diseases and a 6.9% average classification power boost, facilitating stronger triaging through prioritized associations from independent phenome-wide association studies.",
        "Mantis-ML 2.0 is a machine learning approach for disease-agnostic gene prioritization from high-throughput genomic screens by stochastic semi-supervised learning.",
        "Mantis-ML 2.0 is an advanced automated machine-learning framework designed to rank disease-associated genes effectively. It employs a multi-model approach, utilizing stochastic semi-supervised learning to enhance its predictive capabilities. The tool operates through iterative learning sessions on balanced datasets derived from the protein-coding exome, enabling it to prioritize genes linked to diseases with high accuracy. This methodological structure allows Mantis-ML 2.0 to efficiently and reliably identify potential genetic contributors to various conditions, making it a valuable resource in biomedical research and personalized medicine.",
        "Mantis-ML 2.0 is a framework that assesses gene-disease probabilities across the human exome by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various datasets. It uses graph neural networks and a semi-supervised learning framework, achieving a median ROC AUC score of 0.90 across 5220 diseases. The framework incorporates natural language processing for automated disease-relevant feature selection and enhances the triaging process by prioritizing associations from an independent UK Biobank PheWAS.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets, to assess gene-disease probabilities throughout the phenome. It uses graph neural networks, capturing the graph\u0027s holistic structure, and trains them on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Notably, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. The parallelized implementation of Mantis results in short runtimes while also outputting high coverage and high-quality protein function annotations.",
        "Mantis-ML 2.0 is an advanced framework designed to assess gene-disease probabilities across the phenome by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It prioritizes associations derived from an independent UK Biobank phenome-wide association study (PheWAS), enhancing the reliability of its findings by addressing potential underpowered associations. The framework employs natural language processing to automate the selection of disease-relevant features for thousands of diseases, thereby improving the efficiency and accuracy of gene-disease association detection. Mantis-ML 2.0 demonstrates enhanced classification power, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across a wide range of diseases.",
        "Mantis-ML 2.0 is an advanced machine-learning framework designed to assess gene-disease probabilities across a wide spectrum of clinical phenotypes. It integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with diverse tabular datasets to evaluate the relevance of genes to various diseases. The system employs natural language processing to automate the selection of disease-related features for thousands of diseases, streamlining the analysis process. It also prioritizes gene-disease associations that are independently supported by robust UK Biobank phenome-wide association study data, thereby mitigating the risk of underpowered PheWAS associations.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and various tabular datasets to evaluate gene-disease probabilities across the phenome. It uses natural language processing to automate the selection of disease-relevant features for thousands of diseases. A key feature of Mantis-ML 2.0 is its ability to prioritize associations from an independent UK Biobank phenome-wide association study (PheWAS), which enhances triaging and reduces the impact of underpowered PheWAS associations.",
        "Mantis-ML 2.0 is an advanced framework designed to enhance the identification of gene-disease associations by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It employs graph neural networks to capture the comprehensive structure of the graph and is trained on numerous balanced datasets using a robust semi-supervised learning approach. This framework automates the selection of disease-relevant features through natural language processing, enabling it to assess gene-disease probabilities across the human exome for thousands of diseases. Mantis-ML 2.0 has demonstrated a significant improvement in classification power, with an average boost of 6.9% and achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases. It prioritizes associations derived from an independent UK Biobank phenome-wide association study (PheWAS), thus enhancing the reliability of its findings. The results are made accessible through an interactive web resource, facilitating further research and application in therapeutic target identification.",
        "Mantis-ML 2.0 is an advanced framework designed to assess gene-disease probabilities across the phenome by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It prioritizes associations derived from an independent UK Biobank phenome-wide association study (PheWAS), enhancing the reliability of findings by addressing potential underpowered associations. The framework employs natural language processing to automate the selection of disease-relevant features for thousands of diseases, thereby improving the efficiency and accuracy of gene-disease association detection. Additionally, Mantis-ML 2.0 demonstrates enhanced classification power, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases, indicating its effectiveness in biomedical research.",
        "Mantis-ML 2.0 is an advanced machine-learning framework designed to enhance the triaging of genomic discovery studies by prioritizing gene-disease associations. It integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and various tabular datasets to assess gene-disease probabilities across the phenome. The framework employs a multi-model approach using stochastic semi-supervised learning, which allows for the ranking of disease-associated genes through iterative learning on balanced datasets from the protein-coding exome. Mantis-ML 2.0 incorporates natural language processing for automated feature selection relevant to numerous diseases, achieving high predictive performance with area under curve (AUC) scores ranging from 0.81 to 0.90 across various applications, including chronic kidney disease and neurodevelopmental disorders. Additionally, it provides a gene prioritization atlas for interactive navigation of predictions, demonstrating significant improvements over existing methods in capturing true prioritization signals for disease-associated genes.",
        "Mantis-ML 2.0 is a multi-dimensional, multi-step machine-learning framework that automates disease-relevant feature selection using natural language processing for thousands of diseases. It integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities across the phenome. Additionally, it prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS) to provide robust triaging and mitigate against underpowered PheWAS associations.",
        "Mantis-ML 2.0 is a distinctive biomedical framework that leverages AstraZeneca\u0027s Biological Insights Knowledge Graph, graph neural networks, semi-supervised learning, and natural language processing to identify therapeutic genetic targets. It achieves a notable median ROC AUC score of 0.90 across 5220 diseases, offering a 6.9% average classification power boost, with results accessible via an interactive web resource, setting it apart from other \u0027Mantis\u0027 projects in the biomedical space.",
        "Mantis-ML 2.0 is an advanced framework designed to assess gene-disease probabilities across the phenome by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It prioritizes associations derived from an independent UK Biobank phenome-wide association study (PheWAS), enhancing the reliability of its findings by addressing potential underpowered associations. The framework employs natural language processing to automate the selection of disease-relevant features for thousands of diseases, thereby streamlining the analysis process. Additionally, Mantis-ML 2.0 demonstrates improved classification power, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across a wide range of diseases.",
        "Mantis-ML 2.0 is a state-of-the-art machine learning framework designed to prioritize disease-associated genes by analyzing human exome data. It integrates multiple approaches including stochastic semi-supervised learning, graph neural networks, and natural language processing to extract meaningful patterns from complex datasets. By combining tabular data with a comprehensive biological insights knowledge graph, the framework ensures that its predictions are supported by a diverse range of genetic and biological evidence. Mantis-ML 2.0 has demonstrated high predictive accuracy for conditions like chronic kidney disease, epilepsy, and ALS, with AUC values ranging from 0.81 to 0.89. In addition, a phenome-wide association study using UK Biobank data showcased its robustness, achieving a median ROC AUC of 0.90 across thousands of diseases. Independent analyses at both cohort and population levels further validate its effectiveness in interpreting exome-wide association studies. Overall, Mantis-ML 2.0 offers a robust tool for researchers seeking to understand genetic contributions to disease through sophisticated data integration and advanced machine learning techniques.",
        "Mantis-ML is an automated machine-learning framework that employs a multi-model approach of stochastic semi-supervised learning to rank disease-associated genes through iterative learning sessions on random balanced datasets across the protein-coding exome. This approach enables Mantis-ML to produce high-quality consensus-driven protein annotations, making it a valuable tool for protein function annotation. By leveraging its capabilities, researchers can identify and prioritize genes associated with diseases, ultimately contributing to the development of novel therapeutic targets. As a result, Mantis-ML has the potential to accelerate the discovery of new treatments and improve our understanding of complex biological systems.",
        "Mantis-ML 2.0 is a framework for phenome-wide identification of therapeutic genetic targets, integrating knowledge graphs, tabular datasets, graph neural networks, and semi-supervised learning to assess gene-disease probabilities and enhance classification power.",
        "Mantis-ML 2.0 is a cutting-edge biomedical framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various datasets, including UK Biobank data. It utilizes graph neural networks for holistic structure capture, semi-supervised learning, and natural language processing for automated feature selection. This synergy yields enhanced performance, with a 6.9% average classification power boost and a median ROC AUC score of 0.90 across 5220 diseases. Key features include prioritization of UK Biobank phenome-wide association study associations, with results accessible through an interactive web resource.",
        "Mantis-ML 2.0 is an advanced machine learning framework tailored for biomedicine. It combines AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to assess gene-disease probabilities across the human exome. The framework employs graph neural networks and a semi-supervised learning approach, which has shown improved classification and prioritization of associations. This effectiveness was validated by an independent UK Biobank phenome-wide association study.",
        "Mantis-ML 2.0 is a framework that integrates a knowledge graph and various datasets to assess gene-disease probabilities across the human exome. It uses graph neural networks and semi-supervised learning to provide these probabilities, incorporating natural language processing for automated feature selection. The tool has shown improved classification power and prioritizes associations from an independent UK Biobank study.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets, to assess gene-disease probabilities throughout the phenome.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome. It incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. Mantis-ml is an automated machine-learning framework that follows a multi-model approach of stochastic semi-supervised learning to rank disease-associated genes through iterative learning sessions on random balanced datasets across the protein-coding exome. It supports the objective triaging of large-scale genomic discovery studies and enhances our understanding of complex genotype-phenotype associations. A generic mantis-ml score (GMS) trained with over 1,200 features serves as a generic-disease-likelihood estimator, outperforming published gene-level scores.",
        "Mantis-ML 2.0 is an advanced gene prioritization tool used in biomedicine to evaluate gene-disease probabilities across the human exome. It integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to provide comprehensive insights. The tool employs graph neural networks and a semi-supervised learning framework to analyze complex biological data, enhancing the robustness and accuracy of its predictions. Mantis-ML 2.0 standardizes the assessment process, eliminating subjectivity and post-hoc design, and assesses interactions between multiple features collectively. It uses stochastic semi-supervised learning to analyze high-throughput genomic screens, ensuring consistent identification of probable pathogenic gene signals across various diseases.\n\nThe tool demonstrates enhanced classification power and prioritization of associations from UK Biobank PheWAS data, significantly enriching biologically relevant genes in disease studies such as CKD, epilepsy, and ALS. It provides superior prioritization for data from whole-exome sequencing studies and other high-throughput genomic studies. Mantis-ML 2.0 is benchmarked against state-of-the-art tools like Phenolyzer and ToppGene, showing robustness and consistency. It is trained on SCAD tier 1 and 2 genes and utilizes features such as disease/phenotype-specific mouse knockout models, protein-protein interactions, gene expression data, GWAS hits, and heart-associated Gene Ontology terms.",
        "Mantis-ML 2.0 is a machine learning framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and various datasets to assess gene-disease probabilities using graph neural networks and natural language processing, achieving a median ROC AUC score of 0.90 across 5220 diseases.",
        "Mantis-ML 2.0 is an advanced computational framework designed to assess gene-disease probabilities across the entire human phenome. It integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with multiple datasets, utilizing graph neural networks and semi-supervised learning to predict gene-disease associations. The framework incorporates natural language processing for automated disease-relevant feature selection and can analyze 5,220 diseases from multiple ontologies. By training on hundreds of balanced datasets, Mantis-ML 2.0 achieves a median ROC AUC score of 0.90 and demonstrates a 6.9% average classification power boost. The system prioritizes associations from independent phenome-wide association studies and provides results through an interactive web resource.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome for therapeutic genetic target identification. It uses graph neural networks, capturing the graph\u0027s holistic structure, trained on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing stronger triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is a biomedical framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with tabular datasets. It utilizes graph neural networks, semi-supervised learning, and natural language processing to predict gene-disease probabilities across the human exome, achieving a median ROC AUC score of 0.90 across 5220 diseases and a 6.9% classification power boost, with validated and prioritized associations from UK Biobank data accessible via an interactive web resource.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with numerous tabular datasets to assess gene-disease probabilities throughout the phenome. It utilizes graph neural networks, which capture the graph\u0027s holistic structure, and trains them on hundreds of balanced datasets via a robust semi-supervised learning framework. This approach enables Mantis-ML 2.0 to provide gene-disease probabilities across the human exome, with enhanced models demonstrating a 6.9% average classification power boost. The framework also incorporates natural language processing for automated disease-relevant feature selection, resulting in a median receiver operating characteristic area under curve score of 0.90 across 5220 diseases from various sources, including Human Phenotype Ontology and Genomics England. Additionally, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association studies, allowing for stronger triaging and mitigation against underpowered associations, with results made available through an interactive web resource.",
        "Mantis-ML 2.0 is an advanced framework that combines AstraZeneca\u0027s Biological Insights Knowledge Graph with tabular datasets to evaluate gene-disease probabilities across the phenome using graph neural networks and natural language processing. The system demonstrates impressive performance with a median ROC AUC score of 0.90 across 5,220 diseases and provides a 6.9% boost in classification power, while effectively prioritizing associations from UK Biobank PheWAS through an interactive web platform.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome. It uses graph neural networks trained on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. The models demonstrate a 6.9% average classification power boost and achieve a median ROC AUC score of 0.90 across 5220 diseases from various sources. Additionally, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study, providing a stronger form of triaging and mitigating against underpowered PheWAS associations.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome. It uses graph neural networks, capturing the graph\u0027s holistic structure, and trains them on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases. Notably, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca’s Biological Insights Knowledge Graph with various tabular datasets to assess gene-disease probabilities across the phenome. It uses graph neural networks, trained on hundreds of balanced datasets through a robust semi-supervised learning framework, and it leverages natural language processing to automate the selection of disease-relevant features for thousands of diseases. This approach boosts classification power by an average of 6.9%, achieving a median ROC AUC of 0.90 across 5220 diseases, and it prioritizes associations validated by an independent UK Biobank PheWAS, with results accessible via an interactive web resource.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets, to assess gene-disease probabilities throughout the phenome. It uses graph neural networks, capturing the graph\u0027s holistic structure, and trains them on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Notably, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is an advanced framework designed to assess gene-disease probabilities across the human phenome by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It employs graph neural networks to capture the holistic structure of the graph and utilizes a robust semi-supervised learning framework, training on hundreds of balanced datasets. This approach automates disease-relevant feature selection using natural language processing, enhancing the identification of gene-disease associations. Mantis-ML 2.0 has demonstrated a significant improvement in classification power, achieving a median ROC AUC score of 0.90 across 5220 diseases. It prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), thereby improving the reliability of gene prioritization. The results are made accessible through an interactive web resource, facilitating navigation and exploration of gene-triaging data across multiple disease areas.",
        "Mantis-ML 2.0 is a computational framework designed to identify therapeutic genetic targets by integrating AstraZeneca’s Biological Insights Knowledge Graph with diverse datasets, including UK Biobank data. It employs graph neural networks (GNNs) to analyze gene-disease associations across the phenome, leveraging the holistic structure of biological knowledge graphs. The framework uses semi-supervised learning on hundreds of balanced datasets to predict gene-disease probabilities for the human exome. It incorporates natural language processing (NLP) to automate disease-relevant feature selection for thousands of conditions. Mantis-ML 2.0 achieves a median ROC AUC score of 0.90 across 5,220 diseases (sourced from Human Phenotype Ontology, OpenTargets, and Genomics England), showing a 6.9% performance improvement over previous models. It prioritizes associations from UK Biobank phenome-wide association studies (PheWAS), enhancing triaging of genetic links and mitigating underpowered statistical associations. Results are accessible via an interactive web resource, facilitating exploration of prioritized therapeutic targets.",
        "Mantis-ML 2.0 is a computational framework developed by AstraZeneca that integrates its Biological Insights Knowledge Graph with diverse datasets to predict gene-disease associations across the phenome. It employs graph neural networks (GNNs) to analyze holistic graph structures and uses semi-supervised learning on hundreds of balanced datasets to generate gene-disease probability scores. The framework incorporates natural language processing (NLP) to automate disease-specific feature selection for thousands of conditions. Validated across 5,220 diseases (from Human Phenotype Ontology, OpenTargets, and Genomics England), it achieves a median ROC AUC score of 0.90, improving classification power by 6.9%. Mantis-ML 2.0 prioritizes UK Biobank PheWAS associations, enhancing triaging of genetic targets and mitigating underpowered results. Findings are accessible via an interactive web resource for research and therapeutic discovery.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome. The framework uses graph neural networks trained on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Additionally, Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases, resulting in an average classification power boost of 6.9% and achieving a median ROC AUC score of 0.90 across 5220 diseases.",
        "Mantis-ML 2.0 is a machine-learning framework that assesses gene-disease probabilities across the phenome by integrating AstraZeneca’s Biological Insights Knowledge Graph with multiple tabular datasets. It employs graph neural networks to capture the holistic structure of biological data and is trained on hundreds of balanced datasets using a robust semi-supervised learning framework. The framework also incorporates natural language processing to automate disease-relevant feature selection for thousands of conditions. Mantis-ML 2.0 demonstrates a 6.9% average classification power boost and achieves a median ROC AUC score of 0.90 across 5220 diseases. It further enhances gene-disease association ranking by prioritizing associations identified in an independent UK Biobank phenome-wide association study, thereby mitigating the impact of underpowered PheWAS associations.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with tabular datasets to assess gene-disease probabilities via graph neural networks and natural language processing. It achieves a 6.9% boost in classification power, reaching a median ROC AUC score of 0.90 across 5220 diseases, and its results are made available through an interactive web resource.",
        "Mantis-ML 2.0 is an advanced framework designed to identify therapeutic genetic targets by integrating diverse datasets and leveraging cutting-edge machine learning techniques. It combines AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to assess gene-disease associations across the phenome. The framework employs graph neural networks (GNNs) to capture the interconnected structure of biological data, enhancing the understanding of genetic relationships.\n\nUsing semi-supervised learning, Mantis-ML 2.0 trains models on balanced datasets, improving prediction accuracy even with limited labeled data. It incorporates natural language processing (NLP) to automate feature selection from textual sources, enabling efficient and scalable analysis across thousands of diseases.\n\nThe framework demonstrates significant performance improvements, achieving a median ROC AUC score of 0.90 across over 5,000 diseases, indicating high accuracy in predicting gene-disease associations. It also prioritizes findings from the UK Biobank PheWAS study, enhancing the identification of robust associations and mitigating underpowered results.\n\nMantis-ML 2.0 provides an interactive web resource for researchers to explore its findings, making it a valuable tool in advancing therapeutic genetic target discovery.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the human phenome. It uses graph neural networks to capture the graph\u0027s holistic structure and provides gene-disease probabilities across the human exome. The framework incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. Mantis-ML 2.0 demonstrates a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 522",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and tabular datasets to evaluate gene-disease probabilities across the phenome. It uses graph neural networks, trained on balanced datasets via semi-supervised learning, to capture the graph\u0027s structure and provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing for automated disease-relevant feature selection. It prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS) to improve triaging and mitigate underpowered PheWAS associations. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Results are accessible through an interactive web resource.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and various tabular datasets to assess gene-disease probabilities across the phenome. It utilizes graph neural networks, trained on hundreds of datasets through a semi-supervised learning framework, to provide gene-disease probabilities across the human exome. Additionally, it incorporates natural language processing for automating disease-relevant feature selection. The enhanced models achieve a median ROC AUC score of 0.90 across 5220 diseases and prioritize associations from an independent UK Biobank PheWAS, improving triaging and reducing underpowered associations.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to assess gene-disease probabilities across the human phenome. It utilizes graph neural networks and semi-supervised learning, along with natural language processing for automated feature selection. The enhanced models show improved classification power, achieving a median ROC AUC score of 0.90 across 5220 diseases from various sources. Mantis-ML 2.0 also prioritizes associations from an independent UK Biobank phenome-wide association study, providing stronger triaging and mitigating against underpowered PheWAS associations.",
        "Mantis-ML 2.0 is an advanced framework designed to enhance the identification of gene-disease associations by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It employs graph neural networks to leverage the comprehensive structure of the graph and is trained on numerous balanced datasets using a robust semi-supervised learning approach. This framework automates the selection of disease-relevant features through natural language processing, covering thousands of diseases. Mantis-ML 2.0 has shown a 6.9% improvement in classification power, achieving a median ROC AUC score of 0.90 across 5220 diseases. It also prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), enhancing the reliability of its findings. The results are made accessible through an interactive web resource, facilitating further research and exploration.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome. It uses graph neural networks, capturing the graph\u0027s holistic structure, trained on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to evaluate gene-disease probabilities across the phenome using graph neural networks and semi-supervised learning. It employs natural language processing for automated feature selection related to thousands of diseases, resulting in a 6.9% increase in classification power and achieving a median ROC AUC score of 0.90 across 5220 diseases. The framework prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), enhancing the reliability of its findings, which are accessible through an interactive web resource.",
        "Mantis-ML 2.0 is an advanced framework designed for identifying therapeutic genetic targets by leveraging knowledge graphs, graph neural networks (GNNs), and UK Biobank data. It integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to assess gene-disease probabilities across the human exome. The framework employs GNNs to capture the holistic structure of the data and utilizes a semi-supervised learning approach, training on hundreds of balanced datasets to enhance classification power. \n\nMantis-ML 2.0 incorporates natural language processing (NLP) for automating disease-relevant feature selection across thousands of diseases, improving its ability to prioritize gene-disease associations. It demonstrates a 6.9% increase in classification accuracy, achieving a median ROC AUC score of 0.90 across 5220 diseases from sources like the Human Phenotype Ontology and Genomics England.\n\nThe framework also integrates findings from an independent UK Biobank phenome-wide association study (PheWAS), enhancing its ability to triage and mitigate underpowered associations. Results are accessible via an interactive web resource, facilitating easy exploration for researchers in therapeutic target discovery.",
        "Mantis-ML 2.0 is an advanced framework developed to assess gene-disease probabilities across the human phenome by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It employs graph neural networks to capture the holistic structure of the graph and is trained on numerous balanced datasets using a robust semi-supervised learning approach. This framework incorporates natural language processing to automate the selection of disease-relevant features for thousands of diseases. Mantis-ML 2.0 has demonstrated a 6.9% improvement in classification power, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases sourced from Human Phenotype Ontology, OpenTargets, and Genomics England. Additionally, it prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), enhancing the reliability of its findings and providing an interactive web resource for users.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome for phenome-wide identification of therapeutic genetic targets. It uses graph neural networks, capturing the graph\u0027s holistic structure, trained on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing stronger triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is an advanced framework developed to assess gene-disease probabilities across the human phenome by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It employs graph neural networks to capture the holistic structure of the graph and utilizes a robust semi-supervised learning approach, training on hundreds of balanced datasets. The framework incorporates natural language processing for automated feature selection relevant to thousands of diseases. Mantis-ML 2.0 has shown a 6.9% improvement in classification power, achieving a median ROC AUC score of 0.90 across 5220 diseases. It prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), enhancing the reliability of gene-disease associations and providing an interactive web resource for researchers to navigate its predictions.",
        "Mantis-ML 2.0 is a framework developed by AstraZeneca that integrates the Biological Insights Knowledge Graph with multiple tabular datasets to assess gene-disease probabilities across the phenome. It uses graph neural networks trained on hundreds of balanced datasets via semi-supervised learning to provide gene-disease probabilities for the human exome. The framework incorporates natural language processing for automated disease-relevant feature selection, achieving high classification power with a median ROC AUC score of 0.90 across thousands of diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Additionally, it prioritizes associations from UK Biobank PheWAS data and provides results through an interactive web resource.",
        "Mantis-ML 2.0 is a biomedical framework integrating knowledge graphs, graph neural networks, and large-scale datasets (including UK Biobank data) to identify therapeutic genetic targets across the human phenome with high accuracy (median ROC AUC of 0.90 across up to 5220 diseases). Enhanced versions incorporate natural language processing for feature selection and utilize AstraZeneca\u0027s Biological Insights Knowledge Graph, showing a 6.9% average classification power boost. Results are accessible via an interactive web platform, providing a powerful tool for disease-gene association analysis.",
        "Mantis-ML 2.0 is an advanced framework developed to assess gene-disease probabilities across the human phenome by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It employs graph neural networks to leverage the holistic structure of the graph and is trained on numerous balanced datasets using a robust semi-supervised learning approach. This framework incorporates natural language processing to automate the selection of disease-relevant features for thousands of diseases. Mantis-ML 2.0 has shown a 6.9% improvement in classification power, achieving a median ROC AUC score of 0.90 across 5220 diseases sourced from Human Phenotype Ontology, OpenTargets, and Genomics England. Additionally, it prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), enhancing the reliability of the findings and addressing the challenges of underpowered PheWAS associations. The results are made accessible through an interactive web resource.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome. It uses graph neural networks and natural language processing to automate disease-relevant feature selection for thousands of diseases, achieving a median ROC AUC score of 0.90 across 5220 diseases.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and tabular datasets to assess gene-disease probabilities throughout the phenome. It uses graph neural networks to train models on hundreds of balanced datasets and automates disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median ROC AUC score of 0.90 across 5220 diseases. Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. The results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to assess gene-disease probabilities across the human exome. It utilizes graph neural networks to capture the holistic structure of the graph and employs semi-supervised learning to train models on hundreds of balanced datasets. The framework also incorporates natural language processing for automated disease-relevant feature selection, covering thousands of diseases. Mantis-ML 2.0 provides gene-disease probabilities with a median ROC AUC score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Additionally, it prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), enabling stronger triaginging and mitigating against underpowered PheWAS associations. The results are accessible through an interactive web resource.",
        "Mantis-ML 2.0 is an advanced framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to assess gene-disease probabilities across the phenome. It employs graph neural networks to capture the holistic structure of biological knowledge graphs and uses a robust semi-supervised learning approach trained on hundreds of balanced datasets. The framework incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. Mantis-ML 2.0 demonstrates improved classification power with a median ROC AUC score of 0.90 across 5,220 diseases from multiple databases including Human Phenotype Ontology, OpenTargets, and Genomics England. It effectively prioritizes associations from UK Biobank phenome-wide association studies, providing stronger triaging and mitigating underpowered PheWAS associations. Results are accessible through an interactive web resource.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets to evaluate gene-disease probabilities across the human exome. It employs graph neural networks trained through a robust semi-supervised learning approach on hundreds of balanced datasets, achieving a median ROC AUC score of 0.90 across 5220 diseases from multiple sources. The framework incorporates natural language processing for automated feature selection and prioritizes associations from an independent UK Biobank phenome-wide association study, enhancing triaging and mitigating underpowered studies. Results are accessible via an interactive web resource.",
        "Mantis-ML 2.0 is an advanced framework designed for phenome-wide identification of therapeutic genetic targets. It integrates AstraZeneca\u0027s Biological Insights Knowledge Graph with various datasets and employs graph neural networks to capture the holistic structure of the data. The model uses semi-supervised learning on hundreds of balanced datasets, enhancing its performance with a 6.9% increase in classification power. It achieves a median ROC AUC score of 0.90 across 5220 diseases from reputable sources like Human Phenotype Ontology and Genomics England.\n\nThe framework incorporates natural language processing for automated feature selection, enabling efficient processing of disease-related text data. Additionally, it prioritizes associations from UK Biobank\u0027s PheWAS, improving the robustness of gene-disease association predictions. Results are accessible via an interactive web resource, facilitating user-friendly exploration and utilization by researchers. Overall, Mantis-ML 2.0 is a powerful tool for identifying therapeutic targets with high accuracy and scalability across numerous diseases.",
        "Mantis-ML 2.0 is a biomedical framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with large-scale datasets, including UK Biobank data. It utilizes graph neural networks and semi-supervised learning to predict gene-disease associations across the human exome with high accuracy, achieving a median ROC AUC score of 0.90 across 5220 diseases. Enhanced by natural language processing for disease-relevant feature selection, it demonstrates a 6.9% average classification power boost. Results are accessible via an interactive web resource, facilitating the identification of therapeutic genetic targets with improved efficiency.",
        "Mantis-ML 2.0 is an enhanced framework designed for phenome-wide identification of therapeutic genetic targets by integrating AstraZeneca\u0027s Biological Insights Knowledge Graph with various tabular datasets. It utilizes graph neural networks to evaluate gene-disease probabilities across the human exome, trained through a robust semi-supervised learning approach on hundreds of balanced datasets. The framework incorporates natural language processing for automated disease-relevant feature selection and achieves a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from sources such as the Human Phenotype Ontology, OpenTargets, and Genomics England. Additionally, Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study, enhancing triaging and mitigating underpowered associations. The results are accessible through an interactive web resource.",
        "Mantis-ML 2.0 is a computational framework that predicts gene-disease associations across the human exome. It integrates AstraZeneca’s Biological Insights Knowledge Graph with multiple tabular datasets to assess gene-disease probabilities using graph neural networks. The framework leverages a robust semi-supervised learning strategy by training on hundreds of balanced datasets and employs natural language processing to automatically select features relevant to thousands of diseases. It achieves a high predictive performance with a median ROC-AUC of 0.90 across more than 5200 diseases. Additionally, Mantis-ML 2.0 effectively prioritizes associations identified in independent UK Biobank phenome-wide association studies, improving the triaging process and mitigating issues associated with underpowered associations. The results are provided through an interactive web resource, making it a valuable tool for phenome-wide therapeutic target identification.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and tabular datasets to assess gene-disease probabilities throughout the phenome. It uses graph neural networks, trained on hundreds of balanced datasets via a semi-supervised learning framework, to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases. Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS). Results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is a robust framework integrating knowledge graphs, graph neural networks, and diverse datasets to identify therapeutic genetic targets, providing gene-disease probability assessments across the human exome with enhanced accuracy (median ROC AUC of 0.90) for over 5200 diseases, accessible via an interactive web resource.",
        "Mantis-ML 2.0 is a framework integrating AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets, to assess gene-disease probabilities throughout the phenome. It uses graph neural networks, capturing the graph\u0027s holistic structure, trained on hundreds of balanced datasets via a robust semi-supervised learning framework to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. The enhanced models demonstrate a 6.9% average classification power boost, achieving a median receiver operating characteristic (ROC) area under curve (AUC) score of 0.90 across 5220 diseases from Human Phenotype Ontology, OpenTargets, and Genomics England. Mantis-ML 2.0 prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. Results are exposed through an interactive web resource.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and numerous tabular datasets to assess gene-disease probabilities throughout the phenome. It uses graph neural networks, trained on balanced datasets via semi-supervised learning, to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 incorporates natural language processing to automate disease-relevant feature selection for thousands of diseases. It prioritizes associations from an independent UK Biobank phenome-wide association study (PheWAS), providing a stronger form of triaging and mitigating against underpowered PheWAS associations. The models demonstrate an average classification power boost and achieve a high median receiver operating characteristic area under curve score across numerous diseases.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and tabular datasets to assess gene-disease probabilities using graph neural networks trained on hundreds of balanced datasets, achieving an average classification power boost of 6.9% with a median ROC-AUC score of 0.90 across thousands of diseases.",
        "Mantis-ML 2.0 is a framework that integrates AstraZeneca\u0027s Biological Insights Knowledge Graph and various tabular datasets to assess gene-disease probabilities across the phenome. It uses graph neural networks and a semi-supervised learning framework to provide gene-disease probabilities across the human exome. Mantis-ML 2.0 also incorporates natural language processing for automated disease-relevant feature selection and demonstrates enhanced classification power with a median ROC AUC score of 0.90 across 5220 diseases. Results are available through an interactive web resource."
      ]
    },
    {
      "body": "What is the target of Zodasiran?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38809174"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 500,
          "text": "BACKGROUND: Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of-function carriers have lower levels of triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and non-HDL cholesterol and a lower risk of atherosclerotic cardiovascular disease than noncarriers. Zodasiran is an RNA interference (RNAi) therapy targeting expression of ANGPTL3 in the liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809174"
        },
        {
          "offsetInBeginSection": 407,
          "offsetInEndSection": 500,
          "text": "Zodasiran is an RNA interference (RNAi) therapy targeting expression of ANGPTL3 in the liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809174"
        },
        {
          "offsetInBeginSection": 407,
          "offsetInEndSection": 847,
          "text": "Zodasiran is an RNA interference (RNAi) therapy targeting expression of ANGPTL3 in the liver.METHODS: We conducted a double-blind, placebo-controlled, dose-ranging phase 2b trial to evaluate the safety and efficacy of zodasiran in adults with mixed hyperlipidemia (fasting triglyceride level of 150 to 499 mg per deciliter and either an LDL cholesterol level of ≥70 mg per deciliter or a non-HDL cholesterol level of ≥100 mg per deciliter).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809174"
        }
      ],
      "type": "factoid",
      "id": "67e6bf8818b1e36f2e0000c5",
      "ideal_answer": [
        "Zodasiran is an RNA interference (RNAi) therapy targeting expression of ANGPTL3 in the liver."
      ],
      "exact_answer": [
        [
          "ANGPTL3"
        ]
      ]
    },
    {
      "body": "Where in the body would the  sublci and gyri be found?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19216204",
        "http://www.ncbi.nlm.nih.gov/pubmed/15088719",
        "http://www.ncbi.nlm.nih.gov/pubmed/27375142",
        "http://www.ncbi.nlm.nih.gov/pubmed/8156080",
        "http://www.ncbi.nlm.nih.gov/pubmed/30471211",
        "http://www.ncbi.nlm.nih.gov/pubmed/31156400",
        "http://www.ncbi.nlm.nih.gov/pubmed/21784547",
        "http://www.ncbi.nlm.nih.gov/pubmed/33559601",
        "http://www.ncbi.nlm.nih.gov/pubmed/25092274",
        "http://www.ncbi.nlm.nih.gov/pubmed/20121437",
        "http://www.ncbi.nlm.nih.gov/pubmed/30510504",
        "http://www.ncbi.nlm.nih.gov/pubmed/37218094",
        "http://www.ncbi.nlm.nih.gov/pubmed/39044060",
        "http://www.ncbi.nlm.nih.gov/pubmed/11414646",
        "http://www.ncbi.nlm.nih.gov/pubmed/25136099",
        "http://www.ncbi.nlm.nih.gov/pubmed/2817421",
        "http://www.ncbi.nlm.nih.gov/pubmed/17072644",
        "http://www.ncbi.nlm.nih.gov/pubmed/35441404",
        "http://www.ncbi.nlm.nih.gov/pubmed/29410357",
        "http://www.ncbi.nlm.nih.gov/pubmed/36852242",
        "http://www.ncbi.nlm.nih.gov/pubmed/36403099",
        "http://www.ncbi.nlm.nih.gov/pubmed/18236075",
        "http://www.ncbi.nlm.nih.gov/pubmed/1698050",
        "http://www.ncbi.nlm.nih.gov/pubmed/36450874",
        "http://www.ncbi.nlm.nih.gov/pubmed/857567",
        "http://www.ncbi.nlm.nih.gov/pubmed/27057025",
        "http://www.ncbi.nlm.nih.gov/pubmed/37402405",
        "http://www.ncbi.nlm.nih.gov/pubmed/30541110",
        "http://www.ncbi.nlm.nih.gov/pubmed/38039888",
        "http://www.ncbi.nlm.nih.gov/pubmed/28760438",
        "http://www.ncbi.nlm.nih.gov/pubmed/36460275",
        "http://www.ncbi.nlm.nih.gov/pubmed/38316875",
        "http://www.ncbi.nlm.nih.gov/pubmed/38483143",
        "http://www.ncbi.nlm.nih.gov/pubmed/27375549",
        "http://www.ncbi.nlm.nih.gov/pubmed/23689502",
        "http://www.ncbi.nlm.nih.gov/pubmed/8896626",
        "http://www.ncbi.nlm.nih.gov/pubmed/39564127",
        "http://www.ncbi.nlm.nih.gov/pubmed/33613271",
        "http://www.ncbi.nlm.nih.gov/pubmed/31464840",
        "http://www.ncbi.nlm.nih.gov/pubmed/20653030",
        "http://www.ncbi.nlm.nih.gov/pubmed/10930886",
        "http://www.ncbi.nlm.nih.gov/pubmed/22190432",
        "http://www.ncbi.nlm.nih.gov/pubmed/22348780",
        "http://www.ncbi.nlm.nih.gov/pubmed/35930515",
        "http://www.ncbi.nlm.nih.gov/pubmed/26404042",
        "http://www.ncbi.nlm.nih.gov/pubmed/18325826"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Pachygyria is a malformation of the cerebral cortex characterized by an insufficient development of the gyri and cerebral sulci within the anomalies of neuronal migration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216204"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 304,
          "text": "The elaborate folding of the brain surface has posed a practical impediment to investigators engaged in mapping the areas of the cerebral cortex. This obstacle has been overcome partially by the development of methods to erase the sulci and gyri by physically flattening the cortex prior to sectioning. I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15088719"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 291,
          "text": "The cortical laminar necrosis (CLN) is a permanent injury characterized by the selective delayed necrosis of the cerebral cortex, mainly of the third layer, and usually greater in the depths and sides of the sulci than over the crest of the gyri. The damage involves all cellular components ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375142"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "The density of diffuse, primitive and classic beta/A4 protein deposits was estimated in sulci and gyri in the frontal cortex and parahippocampal gyrus (PHG) in 8 cases of Alzheimer\u0027s disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8156080"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "In the human brain, the mid-fusiform sulcus (MFS; sulcus sagittalis gyri fusiformis) divides the fusiform gyrus (FG) into lateral and medial partitions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30471211"
        },
        {
          "offsetInBeginSection": 626,
          "offsetInEndSection": 839,
          "text": "Knowledge of the brain sulci and gyri can be used (a) to localize the craniotomy procedure, (b) to recognize eloquent areas of the brain, and (c) to identify any given sulcus for access to deep areas of the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25092274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 52,
          "text": "Brain sulci and gyri: a practical anatomical review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25092274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "The gyri and sulci of the human brain were defined by pioneers such as Louis-Pierre Gratiolet and Alexander Ecker",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30510504"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "The human cerebral cortex is highly convoluted forming patterns of gyri separated by sulci.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218094"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Brain development (sulci and gyri) as assessed by early postnatal MR imaging in preterm and term newborn infants.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11414646"
        },
        {
          "offsetInBeginSection": 76,
          "offsetInEndSection": 269,
          "text": "While primary gyri and sulci are found in all normally developed brains and bear clear-cut gross structural descriptions, secondary structures are highly variable and not present in all brains.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29410357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "This study aimed to clarify chronological sequences of the appearances of sulci and gyri on the medial cerebral surface and its relation to the regional development of the cerebrum in cynomolgus monkeys.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18236075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "The sulci and gyri of the neocortex, as well as cyto-, synaptoarchitectonics and neuronal composition of the sensomotor (brain area) have been studied in the Baikal ringed seal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1698050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 281,
          "text": "Although accumulating evidence suggests that there are significant anatomical and histological differences between the sulci and gyri of the cerebral cortex, whether there is a difference in the distribution of interneurons between the two cortical regions remains largely unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31464840"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "The human cerebral cortex is highly convoluted as convex gyri and concave sulci.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31156400"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 372,
          "text": "Viewed from above there are two forms of brain, a triangular and a longitudinal one. In the triangular form the gyri are sufficiently developed with a considerable number of transient gyri and in the longitudinal form the gyri are wider and separated by considerably deep sulci.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/857567"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "The variability in the external gyri pattern of human brains has made the identification of specific cortical areas difficult.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8844523"
        },
        {
          "offsetInBeginSection": 141,
          "offsetInEndSection": 265,
          "text": "Humans have the biggest neocortex compared to the body size, and their neocortex has many foldings, that is, gyri and sulci.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36450874"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 356,
          "text": "PURPOSE: To demonstrate morphological alteration of the sulci and gyri on the convex surface in normal fetuses using innovative three-dimensional inversion and Crystalvue and Realisticvue (3D-ICRV) rendering technology.MATERIALS AND METHODS: 3D fetal brain volumes were collected from low-risk singleton pregnancies between 15+0 and 35+6 gestational weeks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37402405"
        },
        {
          "offsetInBeginSection": 424,
          "offsetInEndSection": 672,
          "text": "In the shore crab Hemigrapsus nudus, instead of occupying the rostral surface of the lateral protocerebrum, mushroom body calyces are buried deep within it with their columns extending outwards to an expansive system of gyri on the brain\u0027s surface.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33559601"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 416,
          "text": "Cerebriform tongue, a morphology with typical pattern of sulci and gyri over dorsum of the tongue is a well-known sign seen in pemphigus vegetans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27057025"
        },
        {
          "offsetInBeginSection": 743,
          "offsetInEndSection": 1017,
          "text": "First, basal (outer) radial glia (bRG), which are the main cell type providing the radial scaffold to the migrating neurons in the fetal human neocortex, are very few in the mouse lateral neocortex, thus the radial glial scaffold is different from the fetal human neocortex.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36450874"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "The human cerebral cortex is highly folded into diverse gyri and sulci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30541110"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "The gyri and sulci of the human brain were defined by pioneers such as Louis-Pierre Gratiolet and Alexander Ecker, and extensified by, among others, Dejerine (1895) and von Economo and Koskinas (1925",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30510504"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "The human cerebral cortex is folded into two fundamentally anatomical units: gyri and sulci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38039888"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "The highly convoluted cerebral cortex is characterized by two different topographic structures: convex gyri and concave sulci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28760438"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "The surface of the cerebral cortex is very convoluted, with a large number of folds, the cortical sulci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36460275"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 390,
          "text": "The brain\u0027s surface is about 30 times greater that of the skull because of its many folds; such folds form the gyri, sulci and fissures and mark out areas having specific functions, divided into five lobes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784547"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Gyri and sulci are 2 fundamental cortical folding patterns of the human brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38483143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "The aim of this study was to describe in detail the microanatomy of the cerebral sulci and gyri, clarifying the nomenclature for microneurosurgical purposes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20121437"
        },
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 309,
          "text": "One key autonomic brain region is the insular cortex, which typically consists of five main gyri in each hemisphere, and shows a topographical organization of autonomic function across those gyri",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375549"
        },
        {
          "offsetInBeginSection": 1268,
          "offsetInEndSection": 1440,
          "text": "This functional model of gyri and sulci has been supported by a series of experiments, and provides novel perspectives on the functional architecture of the cerebral cortex",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689502"
        },
        {
          "offsetInBeginSection": 549,
          "offsetInEndSection": 796,
          "text": "A physical mimic of the process using a layered swelling gel captures the essence of the mechanism, and numerical simulations of the brain treated as a soft solid lead to the formation of cusped sulci and smooth gyri similar to those in the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25136099"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 299,
          "text": "This study contributes to the existing knowledge and includes a complete description of the gyri and sulci of the bovine cerebral hemisphere, the chronological order of appearance of these sulci and gyri and the ages at which the sulci and gyri reach their final pattern as seen in the bovine adult.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2817421"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "In the cerebral cortex, establishing the precise relationship between functional areas and the macroscopic anatomy of gyri and sulci has a paramount importance for the field of neuroimaging and neurosurgical interventions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39564127"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "The sulci and gyri found across the cerebrum differ in morphology between individuals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36403099"
        },
        {
          "offsetInBeginSection": 1366,
          "offsetInEndSection": 1557,
          "text": "This study aids in identifying the important functional areas of the brain situated near the sulci, given that the sulci are connected to the gyral functions and act as a barrier for the gyri",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36852242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Sulci and gyri are topological cerebral landmarks in individual subjects: a study of brain navigation during tumour resection.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35441404"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 342,
          "text": "This study aimed to provide a detailed color-coded topographic representation of the camel brain\u0027s gross anatomy and nomenclature, showing its various gyri and sulci and their borders. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38316875"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "The sulci and gyri found across the cerebrum differ in morphology between individuals. The cingulate sulcus is an important landmark for deciding the surgical approach for neighboring pathological lesions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36403099"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 156,
          "text": "the sulci and gyri of the cerebral cortex",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31464840"
        },
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 614,
          "text": "Most of these gyri are submerged deep within the sulcus and can be observed only by examining the depth of the sulcus, although a small proportion may be observed from the surface of the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20653030"
        },
        {
          "offsetInBeginSection": 1072,
          "offsetInEndSection": 1250,
          "text": "superior frontal sulcus.CONCLUSION: Cortical thickness measurements across the central sulcus provide a method for locating the primary motor (precentral gyri) and primary somato",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8896626"
        },
        {
          "offsetInBeginSection": 150,
          "offsetInEndSection": 438,
          "text": "The process may be variable for each of us and we propose to read the images in certain order starting with the frontal lobe and its superior frontal gyrus than precentral and central gyri followed by the lateral fissure. Then the insular, lateral parietal and medial hemispheric regions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10930886"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "The surface of the cerebral cortex is very convoluted, with a large number of folds, the cortical sulci.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36460275"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "The gyri and sulci of the human brain were defined by pioneers such as Louis-Pierre Gratiolet and Alexander Ecker, and extensified by, among others, Dejerine (1895) and von Economo and Koskinas (1925).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30510504"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "This study explored how the human cortical folding pattern composed of convex gyri and concave sulci affected single-subject morphological brain networks,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39044060"
        },
        {
          "offsetInBeginSection": 1036,
          "offsetInEndSection": 1149,
          "text": " morphology of the sulci and gyri on the brain convex surface could be demonstrated clearly on 3D-ICRV images. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37402405"
        },
        {
          "offsetInBeginSection": 303,
          "offsetInEndSection": 532,
          "text": "Here, we show that the axonal fibers connected to gyri are significantly denser than those connected to sulci. In human, chimpanzee, and macaque brains, a dominant fraction of axonal fibers were found to be connected to the gyri.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190432"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "The cerebral cortex is folded as gyri and sulci, which provide the foundation to unveil anatomo-functional relationship of brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35930515"
        },
        {
          "offsetInBeginSection": 409,
          "offsetInEndSection": 646,
          "text": "The cerebrum of cynomolgus monkeys experienced a regular sequence of emergence of sulci and gyri on gross observation while such timetables corresponded to those obtained by magnetic resonance imaging (MRI) with a lag time of 10-30 days.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22348780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "This study aimed to clarify the development of sulci and gyri on the external surface of the cerebrum of cynomolgus monkeys",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17072644"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "This study aimed to clarify chronological sequences of the appearances of sulci and gyri on the medial cerebral surface and its relation to the regional development of the cerebrum in cynomolgus monkeys",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18236075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Objective: Sulci and gyri of the cerebrum can be easily identified with the aid of radiology but are difficult to locate during surgical operations, owing to anatomical variations and the surgical approach of the sulci through a sma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36852242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "This study contributes to the existing knowledge and includes a complete description of the gyri and sulci of the bovine cerebral hemisphere",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2817421"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "The human cerebral cortex is highly convoluted as convex gyri and concave sulci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31156400"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "The cerebral cortex is folded as gyri and sulci, which provide the foundation to unveil anatomo-functional relationship of brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35930515"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "The cerebral cortex is a highly convoluted structure with distinct morphologic features, namely the gyri and sulci, which are associated with the functional segregation or integration in the human brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33613271"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Cortical folding, characterized by convex gyri and concave sulci, has an intrinsic relationship to the brain\u0027s functional organization",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26404042"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "The neocortical surface has a rich and complex structure comprised of folds (gyri) and fissures (sulci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18325826"
        }
      ],
      "type": "factoid",
      "id": "67e1356018b1e36f2e000070",
      "ideal_answer": [
        "The sulci and gyri are parts of the cerebral cortex in the brain.",
        "The sulci and gyri are found in the cerebral cortex of the brain.",
        "The sublci and gyri are found in the brain.",
        "Sulci and gyri are found in the brain, specifically in the cerebral cortex.",
        "The sulci and gyri are found in the brain. They are the grooves (sulci) and ridges (gyri) on the surface of the cerebral cortex.",
        "the sublci would be found in the cerebral cortex, specifically in the insula, which is the invaginated portion of the cerebral cortex, while the gyri would be found in the cerebral cortex, particularly in the major gyral areas such as the prereal, polar, pregenual, subproreal, paraorbital, and orbital.",
        "The cerebral cortex is the part of the brain that has all the grey matter. It is where our thoughts and reasoning happen. The surface of the cortex is covered in folds, which are called sulci (grooves) and gyri (hills).",
        "The sulci and gyri are found in the brain.",
        "The sublci and gyri would be found in the neocortex.",
        "Sulci and gyri are found in the cerebral cortex of the brain. They are the folds and grooves that characterize the surface of the brain.",
        "The sulci and gyri are found in the human brain, specifically in the cerebral cortex.",
        "Sulci and gyri are found in the brain, specifically in the cerebral cortex, where they constitute its folds and grooves.",
        "The subiculum and gyri are found in the brain, specifically within the medial temporal lobe and the hippocampal formation.",
        "Sulci and gyri are found on the surface of the cerebral cortex, covering the cerebral hemispheres, located within the brain and enclosed by the skull.",
        "The sulci (grooves) and gyri (ridges) are found on the surface of the cerebral cortex, which is the outer layer of the brain\u0027s cerebrum. Their intricate folding helps increase the cortex’s surface area, allowing it to house a larger number of neurons.",
        "The sulci and gyri are found in the cerebral cortex of the brain. The gyri are the raised folds, while the sulci are the grooves that separate them. This intricate pattern increases the surface area of the brain, allowing for enhanced cognitive and sensory functions.",
        "The sulci and gyri would be found in the cerebral cortex of the brain.",
        "sulci and gyri are found in the brain.",
        "Sulci and gyri are found in the cerebral cortex of the brain. The cerebral cortex is highly convoluted, forming patterns of gyri (the ridges) separated by sulci (the grooves). These folds increase the surface area of the brain, allowing for more complex functions.",
        "Sulci and gyri are anatomical structures found in the cerebral cortex of the brain. They are the folds and grooves that create the characteristic wrinkled surface of the human brain, increasing the surface area of the cerebral cortex and playing a critical role in brain function and neurological organization.",
        "The sulci (grooves or valleys) and gyri (folds or ridges) are anatomical features found in the cerebral cortex, the outer layer of the brain, present in various specific regions including the frontal cortex, parahippocampal gyrus, and occipital lobe, universally across human and non-human primate brains.",
        "The cerebral cortex is the outer layer of the brain and is composed of the cerebral sulci and gyri.",
        "The sulci and gyri are found in the cerebral cortex.",
        "Sulci and gyri are found in the cerebral cortex of the brain.",
        "The subclii and gyri would be found in the cerebral cortex, specifically in the sulci and gyri of the frontal cortex and parahippocampal gyrus.",
        "The sulci and gyri are the folds and grooves on the brain\u0027s surface, located in the cerebral cortex.",
        "the gyri and sulci are the folds in the cortex of the brain that increase surface area",
        "Sulci (grooves) and gyri (ridges) are anatomical features of the **cerebral cortex** in the **brain**. They form the folded surface of the brain, increasing its surface area to accommodate more neurons and support complex cognitive functions.",
        "Sulci (grooves) and gyri (ridges) are anatomical features of the cerebral cortex in the brain. They form the folded surface of the brain, increasing its surface area for cognitive processing. These structures are specifically located in the outer layer of the cerebrum.",
        "The sublci and gyri would be found in the cerebral cortex.",
        "The sulci and gyri are located on the surface of the brain, specifically in the cerebral cortex, in both humans and other mammals. Gyri are the raised folds, and sulci are the grooves that separate these folds. These structures increase the cortical surface area, enhancing the brain\u0027s capacity for advanced cognitive, sensory, and motor functions.",
        "The sulci and gyri are found on the surface of the brain, specifically on the cerebral cortex.",
        "Sulci and gyri are found in the cerebral cortex of the brain. They are the folds and grooves that characterize the surface of the human brain.",
        "The sulci and gyri are found in the cerebral cortex of the brain. They are responsible for the intricate folding of the brain surface.",
        "The sulci and gyri are found in the cerebral cortex of the brain, specifically mentioned in the context of the frontal cortex and parahippocampal gyrus (PHG) in cases of Alzheimer\u0027s disease.",
        "The sulci and gyri are found on the surface of the brain.",
        "The sublac and gyri are structures found in the cortex, which is the outer layer of the brain. The cortex is divided into numerous folds and grooves, known as gyri and sulci (or fissures), respectively. These structures play crucial roles in various brain functions, such as sensory perception, motor control, and cognitive processes.",
        "Gyri and sulci are found in the cerebral cortex of the brain.",
        "The sulci and gyri are found in the cerebral cortex of the brain, forming its folded appearance.",
        "The sulci and gyri are located in the cerebral cortex, the outermost layer of the brain responsible for higher cognitive functions such as perception, memory, and language. These structures, comprising grooves (sulci) and folds (gyri), increase the brain\u0027s surface area to accommodate a greater number of neurons and their connections.",
        "The sublci and gyri are found in the cerebral cortex.",
        "The sulci and gyri are located on the surface of the cerebral cortex of the brain, with sulci being the grooves or valleys and gyri being the folds or ridges, providing the brain\u0027s outer layer with its characteristic convoluted appearance.",
        "Sulci and gyri are found on the surface of the brain, specifically in the cerebral cortex where they form the grooves and folds that increase the surface area.",
        "The gyri and sulci of the cerebral cortex are prominently displayed in this coronal section.",
        "Sulci and gyri are found in the cerebral cortex of the brain. The cerebral cortex is highly convoluted, forming patterns of gyri (the folds or ridges) separated by sulci (the grooves or fissures). These structures are fundamental to cortical anatomy and are important landmarks for neuroimage processing, analysis, and brain surgery.",
        "The sulci and gyri are found in the cerebral cortex of the brain. They represent the grooves (sulci) and folds (gyri) that give the surface of the brain its characteristic appearance, playing a crucial role in increasing the cortical surface area.",
        "The sulci and gyri are anatomical features located in the cerebral cortex of the brain. The sulci refer to the grooves or fissures, while the gyri are the raised ridges between these grooves. These structures contribute to the complex folding of the brain\u0027s surface, which is significant for mapping cortical areas.",
        "The sulci and gyri are found in the cerebral cortex of the brain. They are responsible for the elaborate folding of the brain surface, which increases the surface area for neural activity."
      ],
      "exact_answer": [
        [
          "brain"
        ]
      ]
    },
    {
      "body": "Most common reversible cause of infertility in men.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37791555",
        "http://www.ncbi.nlm.nih.gov/pubmed/38012908",
        "http://www.ncbi.nlm.nih.gov/pubmed/35914741",
        "http://www.ncbi.nlm.nih.gov/pubmed/36303641",
        "http://www.ncbi.nlm.nih.gov/pubmed/33295608",
        "http://www.ncbi.nlm.nih.gov/pubmed/8022015",
        "http://www.ncbi.nlm.nih.gov/pubmed/18538693",
        "http://www.ncbi.nlm.nih.gov/pubmed/23596597",
        "http://www.ncbi.nlm.nih.gov/pubmed/11866240",
        "http://www.ncbi.nlm.nih.gov/pubmed/32597121",
        "http://www.ncbi.nlm.nih.gov/pubmed/30890103",
        "http://www.ncbi.nlm.nih.gov/pubmed/37829944",
        "http://www.ncbi.nlm.nih.gov/pubmed/34108803",
        "http://www.ncbi.nlm.nih.gov/pubmed/27574593",
        "http://www.ncbi.nlm.nih.gov/pubmed/11505811",
        "http://www.ncbi.nlm.nih.gov/pubmed/33204888",
        "http://www.ncbi.nlm.nih.gov/pubmed/36207252",
        "http://www.ncbi.nlm.nih.gov/pubmed/39429572",
        "http://www.ncbi.nlm.nih.gov/pubmed/39422624",
        "http://www.ncbi.nlm.nih.gov/pubmed/39376021",
        "http://www.ncbi.nlm.nih.gov/pubmed/39359167",
        "http://www.ncbi.nlm.nih.gov/pubmed/32271477",
        "http://www.ncbi.nlm.nih.gov/pubmed/31332561",
        "http://www.ncbi.nlm.nih.gov/pubmed/36304050",
        "http://www.ncbi.nlm.nih.gov/pubmed/25405011",
        "http://www.ncbi.nlm.nih.gov/pubmed/11212075",
        "http://www.ncbi.nlm.nih.gov/pubmed/23695403",
        "http://www.ncbi.nlm.nih.gov/pubmed/22417329",
        "http://www.ncbi.nlm.nih.gov/pubmed/32944248",
        "http://www.ncbi.nlm.nih.gov/pubmed/27030086",
        "http://www.ncbi.nlm.nih.gov/pubmed/17681064",
        "http://www.ncbi.nlm.nih.gov/pubmed/32897024",
        "http://www.ncbi.nlm.nih.gov/pubmed/26011193",
        "http://www.ncbi.nlm.nih.gov/pubmed/26816753",
        "http://www.ncbi.nlm.nih.gov/pubmed/26643563",
        "http://www.ncbi.nlm.nih.gov/pubmed/24643631",
        "http://www.ncbi.nlm.nih.gov/pubmed/7708533",
        "http://www.ncbi.nlm.nih.gov/pubmed/9045219",
        "http://www.ncbi.nlm.nih.gov/pubmed/8490096",
        "http://www.ncbi.nlm.nih.gov/pubmed/23258638"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 80,
          "text": "Varicocele is the most common correctable cause of male infertility ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37791555"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 79,
          "text": "Varicocele is the most common correctable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38012908"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Varicocele is the most common reversible cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35914741"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Varicocele is the most common reversible cause of male infertility, affecting up to 20% of healthy men and 40% of men with primary infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35914741"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "OBJECTIVES: Varicocele is a common cause of infertility, and varicocele-associated testicular hypotrophy has been described as a potential cause of decreased se",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18538693"
        },
        {
          "offsetInBeginSection": 312,
          "offsetInEndSection": 401,
          "text": "Varicocele is the most common cause of male infertility that can be corrected surgically.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23596597"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Varicocele is often cited as the most common cause of male factor infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11866240"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 87,
          "text": "Varicocele is the most commonly surgically curable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32597121"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 79,
          "text": "Varicocele is the most commonly curable cause of infertility in men",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30890103"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 87,
          "text": "Varicocele is one of the most common treatable causes of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33204888"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Varicocele is one of the most common, yet treatable, causes of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36207252"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 85,
          "text": "Varicocele is a significant but treatable contributor to male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39429572"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Varicocele, the most common and treatable cause of male infertility, significantly impacts fertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39422624"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Varicocele (VC) is the most frequent and reversible cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39376021"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 66,
          "text": "Varicocoele is a correctable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39359167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Varicocele is one of the most common, yet treatable, causes of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36207252"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Varicocele is the most common correctable cause for male infertility, but not all men with varicocele are affected equally by this condition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32271477"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Varicoceles are relatively common particularly in asymptomatic men and are even more prevalent in subfertile men, representing the most common potentially correctable cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31332561"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Varicocele has been extensively described and studied as the most important reversible cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36304050"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 401,
          "text": "Varicoceles are present in 15% of the normal male population and in approximately 40% of men with infertility. Varicocele is the most common cause of male infertility that can be corrected surgically.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23596597"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 88,
          "text": "Varicocele is considered the most common reversible cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37829944"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 77,
          "text": " Varicocele is considered the most common cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11505811"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Varicocele is the most common cause of male infertility and is generally correctable or at least improvable by various surgical and radiologic techniques.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25405011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Varicoceles are the leading correctable cause of infertility in men who present to an infertility clinic for evaluation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11212075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Varicocele is the most common and surgically correctible cause of male infertility in men attending to infertility clinics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23695403"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Varicocele is the most common and treatable cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22417329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Varicocele, the most common and treatable cause of male infertility, significantly impacts fertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39422624"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Objective Varicocele is considered the most common reversible cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37829944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Varicocele is the most common reversible cause of male infertility, affecting up to 20% of healthy men and 40% of men with primary infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35914741"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 87,
          "text": "Varicocele is considered the most common reversible cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37829944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Varicocele has been extensively described and studied as the most important reversible cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36304050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "BACKGROUND: Varicocele is one of the most common causes of reversible male infertility, and 15% of the varicocele patients with normal semen analysis are diagnosed ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32944248"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Varicoceles are the most common reversible cause of male factor infertility, yet approximately 80% of men with varicoceles are fertile",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8022015"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 413,
          "text": "Varicocele treatment (surgical or interventional) is considered one of the most common therapies of reversible infertility in men",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34108803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Varicocele is the most common surgically treatable cause of male infertility, and often results in alterations in semen parameters, sperm DNA damage, and changes to the seminal milieu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27030086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Varicocele is the most common and treatable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22417329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Varicocele is the most common surgically treatable cause of male infertility, and often results in alterations in semen parameters, sperm DNA damage, and changes to the seminal milieu.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27030086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "OBJECTIVE: Varicocele is the most common treatable cause of male infertility and is associated with progressive decline in testicula",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17681064"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Varicocele is the most common and treatable cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897024"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Varicoceles are the most common and treatable cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26011193"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Varicocele is the most common cause of male infertility and is generally correctable or at least improvable by various surgical and radiologic techniques",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25405011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Varicocele is the most common and treatable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32897024"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "Varicocele is the most common correctable cause for male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32271477"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Varicoceles are relatively common particularly in asymptomatic men and are even more prevalent in subfertile men, representing the most common potentially correctable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31332561"
        },
        {
          "offsetInBeginSection": 1045,
          "offsetInEndSection": 1201,
          "text": "Varicocele is a common clinical problem; it is highly prevalent amongst subfertile men and the most common potentially correctable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31332561"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Varicocele is the most common correctible cause of male infertility and is present in 15% to 20% of the male population",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26816753"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Varicocele, the most important treatable cause of male infertility, is present in 15% of adult males, 35% of men with primary infertility, and 80% of men with secondary infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26643563"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "Varicocele, the most common and treatable cause of male infertility,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39422624"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Varicocele is the most common surgically treatable cause of male infertility,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27030086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Objective Varicocele is considered the most common reversible cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37829944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Varicocele (VC) is the most frequent and reversible cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39376021"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "The varicocele is still the most common correctable cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7708533"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "The varicocele is still the most common correctable cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9045219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "OBJECTIVES: Varicocele is the most common correctable cause of male infertility that always has been a debatable subject as regards how it affects fertility and the best way ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37791555"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Varicoceles are a major cause of impaired spermatogenesis and the most common correctable cause of male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27574593"
        },
        {
          "offsetInBeginSection": 312,
          "offsetInEndSection": 400,
          "text": "Varicocele is the most common cause of male infertility that can be corrected surgically",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23596597"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 286,
          "text": "varicocele is the most common surgically correctable risk factor for male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24643631"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 224,
          "text": "Varicoceles are among the most common treatable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8490096"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "Varicocele is the most common surgically treatable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27030086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Varicocele is the most common and surgically correctible cause of male infertility in men attending to infertility clinics",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23695403"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 243,
          "text": "Varicocoele frequently appears during early puberty and is recognized to be the most common surgically correctable cause of male infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23258638"
        }
      ],
      "id": "67e28ded18b1e36f2e000080",
      "ideal_answer": [
        "Varicocele is the most common reversible cause of male infertility.",
        "Varicocele is the most common reversible cause of male infertility, affecting up to 20% of healthy men and 40% of men with primary infertility.",
        "The most common reversible cause of infertility in men is Varicocele, a condition characterized by the enlargement of the scrotal veins, which can be effectively treated through surgical or embolization methods to improve fertility outcomes.",
        "Varicocele is the most common reversible cause of male infertility. It affects up to 20% of healthy men and 40% of men with primary infertility. Varicoceles are also the leading correctable cause of infertility in men who present to an infertility clinic for evaluation.",
        "The most common reversible cause of male infertility is **varicocele**, affecting up to 20% of healthy men and 40% of men with primary infertility. It is surgically treatable and associated with impaired semen quality, sperm DNA damage, and progressive testicular dysfunction. Varicocele repair can improve fertility outcomes.",
        "The most common reversible cause of infertility in men is varicocele. This condition involves the enlargement of veins within the scrotum, which can impair sperm production due to increased temperature affecting the testicles. Varicocele can often be treated with surgery or other interventions, such as varicocelectomy or embolization, leading to improved fertility outcomes.",
        "Varicocele, characterized by the enlargement of veins within the scrotum, is the most common reversible cause of male infertility. It impairs spermatogenesis by increasing testicular temperature and oxidative stress, leading to reduced sperm quality and count. Surgical correction (varicocelectomy) or embolization can often restore fertility potential by improving semen parameters."
      ],
      "exact_answer": [
        [
          "Varicocele"
        ]
      ]
    },
    {
      "body": "What mutation is found in about 50% of melanomas?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39015955",
        "http://www.ncbi.nlm.nih.gov/pubmed/38821628",
        "http://www.ncbi.nlm.nih.gov/pubmed/38972133",
        "http://www.ncbi.nlm.nih.gov/pubmed/34789445",
        "http://www.ncbi.nlm.nih.gov/pubmed/26924424",
        "http://www.ncbi.nlm.nih.gov/pubmed/22614711",
        "http://www.ncbi.nlm.nih.gov/pubmed/24857055",
        "http://www.ncbi.nlm.nih.gov/pubmed/23273605",
        "http://www.ncbi.nlm.nih.gov/pubmed/39387972",
        "http://www.ncbi.nlm.nih.gov/pubmed/38541077",
        "http://www.ncbi.nlm.nih.gov/pubmed/28278349",
        "http://www.ncbi.nlm.nih.gov/pubmed/30676087",
        "http://www.ncbi.nlm.nih.gov/pubmed/29076950",
        "http://www.ncbi.nlm.nih.gov/pubmed/39061208",
        "http://www.ncbi.nlm.nih.gov/pubmed/25868080",
        "http://www.ncbi.nlm.nih.gov/pubmed/23360189",
        "http://www.ncbi.nlm.nih.gov/pubmed/22730329",
        "http://www.ncbi.nlm.nih.gov/pubmed/39588764",
        "http://www.ncbi.nlm.nih.gov/pubmed/35761499",
        "http://www.ncbi.nlm.nih.gov/pubmed/38946192",
        "http://www.ncbi.nlm.nih.gov/pubmed/39099762",
        "http://www.ncbi.nlm.nih.gov/pubmed/39387253",
        "http://www.ncbi.nlm.nih.gov/pubmed/37345669",
        "http://www.ncbi.nlm.nih.gov/pubmed/24114495",
        "http://www.ncbi.nlm.nih.gov/pubmed/30069761",
        "http://www.ncbi.nlm.nih.gov/pubmed/37627116",
        "http://www.ncbi.nlm.nih.gov/pubmed/27194985",
        "http://www.ncbi.nlm.nih.gov/pubmed/22554099",
        "http://www.ncbi.nlm.nih.gov/pubmed/36938777",
        "http://www.ncbi.nlm.nih.gov/pubmed/18374154",
        "http://www.ncbi.nlm.nih.gov/pubmed/35856752",
        "http://www.ncbi.nlm.nih.gov/pubmed/35160279",
        "http://www.ncbi.nlm.nih.gov/pubmed/23237741",
        "http://www.ncbi.nlm.nih.gov/pubmed/18631381",
        "http://www.ncbi.nlm.nih.gov/pubmed/23342664",
        "http://www.ncbi.nlm.nih.gov/pubmed/26397052",
        "http://www.ncbi.nlm.nih.gov/pubmed/25351955",
        "http://www.ncbi.nlm.nih.gov/pubmed/31402426",
        "http://www.ncbi.nlm.nih.gov/pubmed/35326682",
        "http://www.ncbi.nlm.nih.gov/pubmed/19158841",
        "http://www.ncbi.nlm.nih.gov/pubmed/15834638",
        "http://www.ncbi.nlm.nih.gov/pubmed/28240681",
        "http://www.ncbi.nlm.nih.gov/pubmed/23489578",
        "http://www.ncbi.nlm.nih.gov/pubmed/26328215",
        "http://www.ncbi.nlm.nih.gov/pubmed/24971404",
        "http://www.ncbi.nlm.nih.gov/pubmed/26594172",
        "http://www.ncbi.nlm.nih.gov/pubmed/26600396",
        "http://www.ncbi.nlm.nih.gov/pubmed/24252159",
        "http://www.ncbi.nlm.nih.gov/pubmed/30241212",
        "http://www.ncbi.nlm.nih.gov/pubmed/31969234",
        "http://www.ncbi.nlm.nih.gov/pubmed/32061008",
        "http://www.ncbi.nlm.nih.gov/pubmed/38329690",
        "http://www.ncbi.nlm.nih.gov/pubmed/27255157",
        "http://www.ncbi.nlm.nih.gov/pubmed/32368388",
        "http://www.ncbi.nlm.nih.gov/pubmed/29795041",
        "http://www.ncbi.nlm.nih.gov/pubmed/20425073",
        "http://www.ncbi.nlm.nih.gov/pubmed/23371260",
        "http://www.ncbi.nlm.nih.gov/pubmed/23415641",
        "http://www.ncbi.nlm.nih.gov/pubmed/25385327",
        "http://www.ncbi.nlm.nih.gov/pubmed/35080260",
        "http://www.ncbi.nlm.nih.gov/pubmed/23807941",
        "http://www.ncbi.nlm.nih.gov/pubmed/23416158",
        "http://www.ncbi.nlm.nih.gov/pubmed/25265970",
        "http://www.ncbi.nlm.nih.gov/pubmed/22584957",
        "http://www.ncbi.nlm.nih.gov/pubmed/34018988",
        "http://www.ncbi.nlm.nih.gov/pubmed/34537078",
        "http://www.ncbi.nlm.nih.gov/pubmed/34246984",
        "http://www.ncbi.nlm.nih.gov/pubmed/27790118",
        "http://www.ncbi.nlm.nih.gov/pubmed/24117833",
        "http://www.ncbi.nlm.nih.gov/pubmed/25806238",
        "http://www.ncbi.nlm.nih.gov/pubmed/23302800",
        "http://www.ncbi.nlm.nih.gov/pubmed/21447722",
        "http://www.ncbi.nlm.nih.gov/pubmed/32585852",
        "http://www.ncbi.nlm.nih.gov/pubmed/34017080",
        "http://www.ncbi.nlm.nih.gov/pubmed/33917428",
        "http://www.ncbi.nlm.nih.gov/pubmed/29310328",
        "http://www.ncbi.nlm.nih.gov/pubmed/25046227",
        "http://www.ncbi.nlm.nih.gov/pubmed/34943045",
        "http://www.ncbi.nlm.nih.gov/pubmed/30638071",
        "http://www.ncbi.nlm.nih.gov/pubmed/22384451",
        "http://www.ncbi.nlm.nih.gov/pubmed/27221301"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 370,
          "text": "BRAF is one of multiple RAF proteins responsible for the activation of the MAPK cell signalling cascade involved in cell growth, differentiation, and survival. A hotspot BRAFV600E mutation, in exon 15, was determined to be a driver in 100% hairy cell leukaemias, 50%-60% of human melanomas, 30%-50% of human thyroid carcinomas and 10%-20% of human colorectal carcinomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39015955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "Melanoma metabolism can be reprogrammed by activating BRAF mutations. These mutations are present in up to 50% of cutaneous melanomas, with the most common being V600E. BRAF mutations augment glycolysis to promote macromolecular synthesis and proliferation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38972133"
        },
        {
          "offsetInBeginSection": 16,
          "offsetInEndSection": 149,
          "text": "Approximately 50% of melanomas harbor the BRAF V600E mutation and targeted therapies using BRAF inhibitors improve patient outcomes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38821628"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 409,
          "text": "Prior to the development of targeted anti-BRAF therapies, these mutations were associated with accelerated clinical disease in the metastatic setting. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38972133"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "The prevalence of BRAF mutation has been reported in between 38% and 48% of melanoma patients, based on mainly Stage III or metastatic melanoma, however, information based on population-based studies is scarce.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34789445"
        },
        {
          "offsetInBeginSection": 1277,
          "offsetInEndSection": 1480,
          "text": "Dr. Chapman led a clinical trial that paved the way, in part, to the approval of vemurafenib-a drug that targets a BRAF mutation that is present in approximately 50% of patients with metastatic melanoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24857055"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 393,
          "text": "The most common mutation in melanoma is BRAFV600E and has been reported in 50-90% of patients with melanoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39387972"
        },
        {
          "offsetInBeginSection": 70,
          "offsetInEndSection": 167,
          "text": "These mutations are present in up to 50% of cutaneous melanomas, with the most common being V600E",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38972133"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 124,
          "text": "BRAF mutations appear in 50%-70% of melanomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39588764"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 418,
          "text": "Approximately 50% of melanomas harbor activating BRAF mutations, with over 90% resulting in BRAF V600E",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39099762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "BRAF gene mutations can be found in approximately 50% of melanomas, but the most common BRAF mutation leads to substitution at residue 600 of the protein, from valine to glutamic acid.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28278349"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Approximately 50% of melanomas contain BRAF mutations; the effects on survival are unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35856752"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 47,
          "text": "About 50% of melanomas harbour a BRAF mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35160279"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Activating mutations in the BRAF gene occur in approximately 50% of melanomas. More than 70% of BRAF mutations are V600E ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237741"
        },
        {
          "offsetInBeginSection": 23,
          "offsetInEndSection": 95,
          "text": " Activating BRAF mutations are present in approximately 50% of melanomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18631381"
        },
        {
          "offsetInBeginSection": 455,
          "offsetInEndSection": 541,
          "text": "Approximately 50% of melanomas contain point mutation in codon 600 of the BRAF kinase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23342664"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "In around 50% of melanomas, the BRAF V600 mutation, resulting in an activation of the MAP kinase pathway, is detected.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26397052"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "BRAF(V600E) is a major oncogenic mutation found in approximately 50% of human melanoma that confers constitutive activation of the MAPK pathway and increased melanoma growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25351955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "The BRAFV600E mutation, found in approximately 50% of melanoma cases, plays a crucial role in the activation of the MAPK/ERK signaling pathway, which promotes tumor cell proliferation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061208"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 287,
          "text": "BRAFV600E, the most common driver mutation, is found in around 50% of melanomas, contributing to tumor growth, angiogenesis, and metastatic progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31402426"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "BRAF mutations are present in around 50% of cutaneous malignant melanomas and are related to a poor outcome in advanced-stage melanoma patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35326682"
        },
        {
          "offsetInBeginSection": 1263,
          "offsetInEndSection": 1420,
          "text": "BRAF(V600E) mutation occurred at a similar rate (approximately 50%) in lesions from pediatric and familial patients, whereas no NRAS mutations were detected.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158841"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "An activating mutation in codon 599 of BRAF has been identified in approximately 60% of human cutaneous nevi and melanomas, but not melanomas of mucosal origin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "BRAF inhibitors (BRAFi), a targeted therapy, are used to treat metastatic late-stage melanomas harbouring the BRAF-V600 mutation (found in about 50% of melanomas).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28240681"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 252,
          "text": "With the discovery of (V600E)BRAF in about 50% of cutaneous melanomas, there was an increased effort to find additional mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23489578"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 167,
          "text": "About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22554099"
        },
        {
          "offsetInBeginSection": 413,
          "offsetInEndSection": 570,
          "text": "About 50% of melanomas have an activating mutation in the BRAF gene, with about 80%-90% of those having a V600E mutation, and 10%-20% having a V600K mutation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Melanoma is an aggressive skin cancer that originates from melanocytes, and about one half of melanoma cases possess a BRAF mutation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594172"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 419,
          "text": "Approximately 50% of melanomas harbor activating BRAF mutations, with over 90% resulting in BRAF V600E.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39099762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Melanoma metabolism can be reprogrammed by activating BRAF mutations. These mutations are present in up to 50% of cutaneous melanomas, with the most common being V600E.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38972133"
        },
        {
          "offsetInBeginSection": 58,
          "offsetInEndSection": 177,
          "text": "While 50% of melanomas have a BRAF mutation and are a target for BRAF inhibitors, the remaining 50% are BRAF wild-type.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38329690"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Mutation of the BRAF oncogene is one of the most common mutations detected in human neoplasia, occurring in 40-60% of all cutaneous melanoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38946192"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "BRAF mutations are present in around 50% of cutaneous malignant melanomas and are related to a poor outcome in advanced-stage melanoma patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35326682"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Recent advances in gene sequencing have shown that activated BRAF mutations are present in more than 50% of malignant melanomas and contribute to constitutive signals in the MAPK pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32368388"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 184,
          "text": "Over 50% of melanomas harbor various BRAF mutations with the most common being the V600E",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795041"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 480,
          "text": "In 2002, a mutation at the V600E amino acid of the BRAF serine/threonine kinase was described as present in over 50% of melanomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425073"
        },
        {
          "offsetInBeginSection": 480,
          "offsetInEndSection": 611,
          "text": "In approximately 50% of melanomas activating mutations of the BRAF gene were identified and can be treated with specific inhibitors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371260"
        },
        {
          "offsetInBeginSection": 490,
          "offsetInEndSection": 648,
          "text": "The discovery of activating BRAF mutations in ∼50% of all melanomas has proved to be a turning point in the therapeutic management of the disseminated disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415641"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 290,
          "text": "Almost 50% of melanomas harbor targetable activating mutations of BRAF that promote RAS-RAF-MEK-ERK pathway activation and melanoma proliferation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Activating mutations in the BRAF gene occur in approximately 50% of melanomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237741"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 481,
          "text": "In 2002, a mutation at the V600E amino acid of the BRAF serine/threonine kinase was described as present in over 50% of melanomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425073"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 185,
          "text": "Over 50% of melanomas harbor various BRAF mutations with the most common being the V600E.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795041"
        },
        {
          "offsetInBeginSection": 413,
          "offsetInEndSection": 571,
          "text": "About 50% of melanomas have an activating mutation in the BRAF gene, with about 80%-90% of those having a V600E mutation, and 10%-20% having a V600K mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "BRAF is the most mutated gene in melanoma, with approximately 50% of patients containing V600E mutant protein.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23416158"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076950"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 59,
          "text": "BRAF mutation is detected in 50-70% of melanomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34018988"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 317,
          "text": "Melanomas harbor BRAF mutations (BRAF+) in 40-50% of cases, the majority of which are on the V600E residue",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34537078"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Approximately half of metastatic cutaneous melanomas (CM) harbor a mutation in the BRAF protooncogene, upregulating the mitogen-activated protein kinase (MAPK)-pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34246984"
        },
        {
          "offsetInBeginSection": 424,
          "offsetInEndSection": 538,
          "text": "In melanoma, the most commonly mutated gene is BRAF, with mutations usually occurring in about 50% of all tumours.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25806238"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with ≥50% of tumours expressing the BRAF(V600E) oncoprotein",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23302800"
        },
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 516,
          "text": "The discovery of activating mutations (V600E) in the BRAF kinase in approximately 50% of patients spurred the development of compounds to inhibit aberrant BRAF activity, and the first drug candidate to show promising clinical activity is PLX4032 (also known as RG7204).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21447722"
        },
        {
          "offsetInBeginSection": 1131,
          "offsetInEndSection": 1188,
          "text": "About 50 % of melanomas harbor activating BRAF mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Oncogenic B-RAF V600E mutation is found in 50% of melanomas and drives MEK/ERK pathway and cancer progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22730329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "B-Rapidly Accelerated Fibrosarcoma (BRAF) mutations are found in about 50% of melanoma patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32585852"
        },
        {
          "offsetInBeginSection": 5,
          "offsetInEndSection": 56,
          "text": " About 50% of melanomas have the BRAFV600E mutation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30676087"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "BRAF inhibitors (BRAFi) that target BRAF V600E kinase, a driver mutation found in 50% of melanomas, show a significant antitumor response, but the common emergence of acquired resistance remains a challenge.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34017080"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Somatic point mutations in the BRAF gene have been found in approximately 50% of melanomas. BRAF (V600E), the most common mutation, results in the constitutive activation of BRAF (V600E) kinase, sustaining MAPK signaling and perpetuating cell growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26328215"
        },
        {
          "offsetInBeginSection": 58,
          "offsetInEndSection": 120,
          "text": "About 50% of all melanomas are associated with BRAF mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33917428"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 55,
          "text": "BRAF mutations occur in about 50% of melanoma patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30588251"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 409,
          "text": "Mutations in the BRAF gene have been identified as key drivers of melanoma cells and are found in around 50% of cutaneous melanomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23360189"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 339,
          "text": "Between 40% and 60% of melanomas demonstrate BRAF mutations, BRAF V600E being most common",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310328"
        },
        {
          "offsetInBeginSection": 428,
          "offsetInEndSection": 570,
          "text": "About 40% to 60% of cutaneous melanomas have BRAF mutations, and 90% of the mutations involve a specific substitution at codon 600 (BRAF V600E",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25046227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "BRAF gene mutations can be found in approximately 50% of melanomas, but the most common BRAF mutation leads to substitution at residue 600 of the protein, from valine to glutamic acid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28278349"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 237,
          "text": "Activating mutations in BRAF are the most frequent genetic alterations, present in approximately 50% of all melanoma cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34943045"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Approximately 50% of cutaneous melanomas harbor activating mutations of the BRAF-oncogene, making BRAF inhibitors (BRAFi) the standard treatment for this disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30638071"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 479,
          "text": "With the finding that approximately 50% of melanomas harbor an activating mutation in the serine/threonine-protein kinase B-raf gene (BRAF), inhibition of mutated B-raf represented an attractive and innovative focus for the development of novel targeted therapy potentially benefiting a large proportion of melanoma patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22384451"
        },
        {
          "offsetInBeginSection": 1556,
          "offsetInEndSection": 1614,
          "text": "The BRAF gene mutations were observed in ~50% of CMM cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27221301"
        }
      ],
      "id": "67eaf29c18b1e36f2e0000e0",
      "ideal_answer": [
        "BRAF is one of multiple RAF proteins responsible for the activation of the MAPK cell signaling cascade involved in cell growth, differentiation, and survival. A hotspot BRAF V600E mutation, in exon 15, was determined to be a driver in approximately 50% of melanomas,  augmenting glycolysis and promoting macromolecular synthesis and proliferation. Prior to the development of targeted anti-BRAF therapies, this mutation was associated with accelerated clinical disease in the metastatic setting.",
        "** The V600E mutation in the BRAF gene is the most common mutation found in cutaneous melanomas, present in approximately 50% of cases. This mutation leads to the activation of the BRAF kinase, which in turn stimulates the MAP kinase/ERK signaling pathway, driving melanoma growth and progression.\n\n**",
        "Activating mutations of the BRAF gene, particularly the BRAFV600E mutation, are found in approximately 50% of melanomas. These mutations lead to the activation of the RAS-RAF-MEK-ERK pathway, promoting melanoma proliferation. The discovery of these mutations has significantly impacted the therapeutic management of melanoma, as specific inhibitors can target them.",
        "The BRAF mutation, specifically the V600E variant, is found in about 50% of melanomas. This mutation involves a single amino acid change where valine is replaced by glutamic acid at position 600. The alteration leads to the constant activation of the BRAF protein, which in turn continuously stimulates the MAPK/ERK signaling pathway. This unchecked signaling drives cell proliferation and survival, playing a critical role in the development and progression of melanoma.",
        "The BRAFV600E mutation, located in exon 15 of the BRAF gene, is a hotspot mutation that constitutively activates the MAPK signaling pathway, driving uncontrolled cell growth, differentiation, and survival. This mutation is identified as a driver in approximately 50%-60% of human melanomas, as well as in other malignancies such as hairy cell leukemia, thyroid carcinomas, and colorectal carcinomas.",
        "A BRAF mutation, particularly the V600E mutation, is found in approximately 50% of melanomas. This mutation is an activating mutation in the BRAF gene, which plays a role in the MAPK signaling pathway involved in cell growth and survival. The presence of this mutation can contribute to constitutive signals in the MAPK pathway, promoting melanoma proliferation.",
        "The BRAF V600E mutation is found in approximately 50% of melanomas. This mutation activates the MAPK cell signaling cascade involved in cell growth, differentiation, and survival. It also reprograms melanoma metabolism by augmenting glycolysis to promote macromolecular synthesis and proliferation.",
        "Approximately 50% of melanomas harbor the BRAF V600E mutation. This mutation is a significant driver in melanoma development and progression, as it activates the MAPK cell signaling cascade involved in cell growth, differentiation, and survival. The presence of this mutation allows for targeted therapies using BRAF inhibitors, which have been shown to improve patient outcomes by reprogramming melanoma metabolism and promoting macromolecular synthesis and proliferation.",
        "The mutation found in approximately 50% of melanomas is the BRAF V600E mutation. This specific alteration is a hotspot mutation located in exon 15 and plays a significant role in the MAPK signaling pathway, contributing to cancer cell growth and survival. It is commonly targeted by therapies that have improved outcomes for patients with this mutation.",
        "The BRAF V600E mutation, a driver mutation located in exon 15, is found in approximately 50% of melanomas. It affects the MAPK cell signaling cascade, influencing cell growth, differentiation, and survival, and is associated with increased glycolysis. This mutation is a target for BRAF inhibitors, which have shown to improve outcomes in affected patients.",
        "The BRAFV600E mutation, located in exon 15, is a hotspot mutation that plays a significant role in the activation of the MAPK cell signalling cascade, which is crucial for cell growth, differentiation, and survival. This mutation is identified as a driver in approximately 50%-60% of human melanomas, making it a critical target for therapeutic interventions aimed at inhibiting this pathway to control melanoma progression and improve patient outcomes.",
        "The BRAF V600E mutation, located in exon 15, is found in approximately 50% of melanomas. It acts as a driver mutation, activating the MAPK cell signaling cascade, influencing cell growth, differentiation, and survival, and leading to increased glycolysis. Notably, while historically associated with accelerated disease in metastatic settings, the development of targeted BRAF therapies has significantly improved outcomes for patients with this mutation.",
        "The BRAF V600E mutation is found in approximately 50% of melanomas, particularly cutaneous melanomas. This mutation in the BRAF gene, which occurs in exon 15, is a driver mutation that reprograms melanoma metabolism by augmenting glycolysis to promote macromolecular synthesis and cell proliferation. Before the development of targeted anti-BRAF therapies, this mutation was associated with accelerated clinical disease progression in metastatic melanoma.",
        "The BRAF V600E mutation is found in approximately 50% of melanomas and plays a significant role in their pathogenesis by reprogramming metabolism to enhance glycolysis, macromolecular synthesis, and proliferation. This mutation activates the MAPK cell signaling cascade, which is crucial for cell growth, differentiation, and survival. Prior to targeted therapies using BRAF inhibitors, this mutation was associated with accelerated clinical disease progression in metastatic melanoma."
      ],
      "exact_answer": [
        [
          "BRAF V600E",
          "BRAF V600",
          "BRAF c.1799T\u003eA (p.V600E) mutation",
          "BRAF c.1799T\u003eA",
          "BRAFV600E mutation",
          "V600E mutation in the BRAF gene",
          "(V600E)B-RAF mutation"
        ]
      ]
    },
    {
      "body": "Which novel potential biomarkers have been identified in basal cell carcinoma from MR-PheWAS?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39035989"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 1476,
          "offsetInEndSection": 2483,
          "text": "PTGES2, RNASET2, SF3B4, STX8, ENO2, and HS3ST3B1 (besides RNASET2, five other plasma proteins were previously unknown in expression quantitative trait loci (eQTL) and methylation quantitative trait loci (mQTL)) were significantly associated with BCC after FDR correction in the UKB-PPP and deCODE studies. Reverse MR showed no association between BCC and these proteins. PTGES2 and RNASET2 exhibited strong evidence of colocalization with BCC based on a posterior probability PP.H4 \u003e0.92. Furthermore, MR-PheWAS analysis showed that BCC was the most significant phenotype associated with PTGES2 and RNASET2 among 2,408 phenotypes in the FinnGen R10 study. Therefore, PTGES2 and RNASET2 are highlighted as effective biomarkers and therapeutic targets for BCC within the phenome-wide human disease category.Conclusion: The study identifies PTGES2 and RNASET2 plasma proteins as novel, reliable biomarkers and therapeutic targets for BCC, suggesting more effective clinical application strategies for patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39035989"
        }
      ],
      "id": "67e6cf7218b1e36f2e0000d1",
      "ideal_answer": [
        "MR-PheWAS analysis identified PTGES2 and RNASET2 plasma proteins as novel, reliable biomarkers and therapeutic targets for basal cell carcinoma (BCC).",
        "The novel potential biomarkers identified for basal cell carcinoma from MR-PheWAS are PTGES2 and RNASET2.",
        "PTGES2 and RNASET2 are highlighted as effective biomarkers and therapeutic targets for BCC within the phenome-wide human disease category.",
        "PTGES2 and RNASET2 were identified as novel potential biomarkers for basal cell carcinoma from MR PheWAS. Other novel molecules that have been investigated as biomarkers in the context of BCC include HSP70, ITGA4, LIF, GREB1, S100A14, CLEC18G, SOX2, NID2, CHIA1 L, DOK5, RNF119, NAB2, TP53 and Fas",
        "PTGES2 and RNASET2 are novel potential biomarkers for basal cell carcinoma, identified through MR-PheWAS analysis across multiple studies, including the UK Biobank Pharma Proteomics Project, deCODE studies, and the FinnGen R10 study. These biomarkers exhibit strong colocalization with basal cell carcinoma and a significant association after False Discovery Rate correction, highlighting their potential as effective biomarkers and therapeutic targets.",
        "Recent studies utilizing Mendelian Randomization Phenome-Wide Association Studies (MR-PheWAS) have identified PTGES2 and RNASET2 as novel potential biomarkers for basal cell carcinoma. These genes have shown promise not only as biomarkers but also as potential therapeutic targets for treatment strategies in basal cell carcinoma. Such discoveries could pave the way for more personalized and effective approaches to managing and treating basal cell carcinoma, by targeting these specific proteins.",
        "PTGES2 and RNASET2 are highlighted as effective biomarkers and therapeutic targets for BCC within the phenome-wide human disease category. FGF20, KIF23, and NCAPG were identified as the diagnostic markers of BCC.",
        "Recent studies using proteome-wide Mendelian randomization, colocalization, and MR-PheWAS analyses have identified PTGES2 and RNASET2 as novel potential biomarkers and therapeutic targets for basal cell carcinoma (BCC).",
        "The study identified PTGES2 and RNASET2 as novel potential biomarkers for basal cell carcinoma through a comprehensive analysis involving proteome-wide Mendelian randomization, colocalization, and MR-PheWAS. These findings suggest that these biomarkers could serve as both diagnostic indicators and therapeutic targets, providing valuable insights into the disease mechanisms of basal cell carcinoma.",
        "The novel potential biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS are PTGES2 and RNASET2, which have shown strong evidence of association with BCC and are suggested as therapeutic targets.",
        "PTGES2 and RNASET2 plasma proteins have been identified as novel, reliable biomarkers and therapeutic targets in basal cell carcinoma through MR-PheWAS analysis.",
        "PTGES2 and RNASET2 have been identified as potential biomarkers for basal cell carcinoma (BCC) through MR-PheWAS analysis within the FinnGen R10 study. These biomarkers are highlighted as effective therapeutic targets for BCC within the phenome-wide human disease category.",
        "The novel potential biomarkers identified in basal cell carcinoma from MR-PheWAS are PTGES2 and RNASET2, which exhibited strong evidence of association with BCC and are suggested as effective therapeutic targets.",
        "The novel biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS are PTGES2 and RNASET2, which have shown significant association with BCC and are highlighted as effective therapeutic targets.",
        "PTGES2 and RNASET2 have been consistently identified across analyses as novel potential biomarkers for basal cell carcinoma (BCC), showing strong evidence of colocalization (with a posterior probability \u003e0.92) and significant association in MR-PheWAS studies spanning 2,408 phenotypes, thereby emerging as promising candidates for further investigation into BCC.",
        "Novel potential biomarkers identified for basal cell carcinoma (BCC) through MR-PheWAS are Prostaglandin E Synthase 2 (PTGES2) and Ribonuclease T2 (RNASET2), highlighting their potential enzymatic roles in the disease.",
        "MR-PheWAS analyses have identified two proteins, PTGES2 and RNASET2, as novel biomarkers and potential therapeutic targets for basal cell carcinoma. Additionally, altered levels of cathepsin family members have been linked to the disease, with increased levels of Cathepsin O and Cathepsin F associated with higher risk, while decreased levels of Cathepsin H may have a protective role.",
        "Novel potential biomarkers for basal cell carcinoma (BCC) identified through MR PheWAS include PTGES2 and RNASET2. These findings were derived from proteome wide Mendelian randomization, colocalization, and MR PheWAS analyses.",
        "PTGES2 and RNASET2 have been identified as novel potential biomarkers for basal cell carcinoma (BCC) from MR-Phewas.",
        "Novel potential biomarkers for basal cell carcinoma identified through MR-PheWAS are Prostaglandin E Synthase 2 (PTGES2) and Ribonuclease T2 (RNASET2), showing strong colocalization and significant association across multiple studies, including the UK Biobank, deCODE, and FinnGen R10, highlighting their potential enzymatic roles and therapeutic target potential in BCC.",
        "Recent studies using Mendelian Randomization Phenome-Wide Association Studies (MR-PheWAS) have identified PTGES2 and RNASET2 as novel potential biomarkers and therapeutic targets for basal cell carcinoma (BCC). These proteins were found to be the most significant phenotypes associated with BCC among 2,408 phenotypes in the FinnGen R10 study.",
        "PTGES2 and RNASET2 are the novel potential biomarkers identified in basal cell carcinoma.",
        "PTGES2 and RNASET2 have been identified as novel potential biomarkers and therapeutic targets for basal cell carcinoma.",
        "The novel potential biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS are PTGES2 and RNASET2. These biomarkers were identified through proteome-wide Mendelian randomization, colocalization, and MR-PheWAS analyses.",
        "The study identified two novel potential biomarkers for basal cell carcinoma through MR-PheWAS analysis: PTGES2 and RNASET2. These plasma proteins showed strong evidence of colocalization with BCC and were the most significant phenotypes associated with the disease among 2,408 phenotypes in the FinnGen R10 study.",
        "From the provided context, PTGES2 (Prostaglandin E2 Synthase 2) and RNASET2 (Ribonuclease T2) have been identified as novel potential biomarkers for basal cell carcinoma (BCC). These findings are derived from proteome wide Mendelian randomization (MR), colocalization, and MR PheWAS analyses. Additionally, the study highlights that genome wide association studies (GWAS) on pigmentation and skin cancer could provide further insights into identifying high risk individuals and developing new therapeutic targets for BCC.",
        "PTGES2 and RNASET2 are novel potential biomarkers for basal cell carcinoma, validated through multiple analyses including MR-PheWAS, showing strong colocalization evidence and significant association with BCC, highlighting their potential as effective biomarkers and therapeutic targets.",
        "PTGES2 and RNASET2 were identified as novel potential biomarkers for basal cell carcinoma. Other novel potential biomarkers have not been identified yet.",
        "PTGES2 and RNASET2 have been identified as novel and reliable plasma protein biomarkers for basal cell carcinoma (BCC), showing strong evidence of colocalization with BCC and emerging as the most significant phenotype-associated proteins among 2,408 phenotypes in the FinnGen R10 MR-PheWAS analysis. These findings suggest their potential as both effective biomarkers and therapeutic targets for BCC.",
        "PTGES2 and RNASET2 plasma proteins have been identified as novel, reliable biomarkers and therapeutic targets for basal cell carcinoma.",
        "The MR-PheWAS analysis identified PTGES2 and RNASET2 as novel potential biomarkers for basal cell carcinoma, highlighting their promise as therapeutic targets.",
        "The novel potential biomarkers identified in basal cell carcinoma from MR-PheWAS are PTGES2 and RNASET2.",
        "The novel potential biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS are PTGES2 and RNASET2. These proteins exhibited strong evidence of association with BCC and are highlighted as effective biomarkers and therapeutic targets.",
        "PTGES2 and RNASET2 have been identified as novel potential biomarkers for basal cell carcinoma, showing strong colocalization evidence with BCC and reinforcing their reliability as biomarkers and therapeutic targets.",
        "The MR-PheWAS analysis identified PTGES2 and RNASET2 as novel potential biomarkers for BCC.",
        "The study identifies PTGES2 and RNASET2 as novel potential biomarkers for basal cell carcinoma (BCC). These proteins were found to be significantly associated with BCC after FDR correction in the UKB-PPP and deCODE studies. Additionally, MR-PheWAS analysis showed that BCC was the most significant phenotype associated with PTGES2 and RNASET2 among 2,408 phenotypes in the FinnGen R10 study.",
        "PTGES2 and RNASET2 have been identified as novel potential biomarkers in basal cell carcinoma (BCC) from MR-PheWAS analysis. The study highlights these proteins as effective biomarkers and therapeutic targets for BCC within the phenome-wide human disease category.",
        "The MR-PheWAS analysis identified PTGES2 and RNASET2 as novel, reliable biomarkers and therapeutic targets for basal cell carcinoma (BCC).",
        "The study identifies PTGES2 and RNASET2 plasma proteins as novel, reliable biomarkers and therapeutic targets for BCC. These proteins were significantly associated with BCC after FDR correction in the UKB-PPP and deCODE studies, exhibited strong evidence of colocalization with BCC based on a posterior probability PP.H4 \u003e0.92, and were found to be the most significant phenotypes associated with PTGES2 and RNASET2 among 2,408 phenotypes in the FinnGen R10 study.",
        "The novel potential biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS are PTGES2 and RNASET2, which exhibited strong evidence of association with BCC and are highlighted as effective therapeutic targets.",
        "The novel potential biomarkers identified in basal cell carcinoma (BCC) through MR-PheWAS are PTGES2 and RNASET2. These proteins showed strong evidence of association with BCC, highlighting their role as effective biomarkers and therapeutic targets.",
        "The novel biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS include PTGES2 and RNASET2, along with four other plasma proteins: SF3B4, STX8, ENO2, and HS3ST3B1.",
        "The novel biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS are PTGES2 and RNASET2. These proteins have shown strong evidence of association with BCC and are highlighted as effective therapeutic targets.",
        "The novel potential biomarkers identified for basal cell carcinoma are PTGES2 and RNASET2 according to MR-PheWAS analysis.",
        "PTGES2 and RNASET2 are consistently identified as novel potential biomarkers for basal cell carcinoma from MR-PheWAS analyses, exhibiting strong evidence of colocalization with basal cell carcinoma, thereby indicating their potential as effective biomarkers and therapeutic targets. While additional candidates (SF3B4, STX8, ENO2, and HS3ST3B1) have been suggested, they require further validation to confirm their utility in this context.",
        "The novel potential biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS are PTGES2 and RNASET2. These proteins showed significant associations with BCC and strong evidence of colocalization, making them reliable biomarkers and therapeutic targets for the disease.",
        "PTGES2 and RNASET2 plasma proteins have been identified as novel, reliable biomarkers and therapeutic targets for basal cell carcinoma (BCC) from MR-PheWAS.",
        "PTGES2 and RNASET2 are novel, reliable biomarkers and therapeutic targets for BCC.",
        "The novel potential biomarkers identified in basal cell carcinoma (BCC) from MR-PheWAS are PTGES2 and RNASET2.",
        "PTGES2 and RNASET2 are identified as novel, well-validated potential biomarkers for basal cell carcinoma from MR-PheWAS analyses, with additional research-backed candidates including SF3B4, STX8, ENO2, and HS3ST3B1 requiring further validation.",
        "The study identifies PTGES2 and RNASET2 plasma proteins as novel potential biomarkers for basal cell carcinoma (BCC) based on findings from MR-PheWAS analysis. These proteins showed strong evidence of colocalization with BCC and were the most significantly associated phenotypes among 2,408 tested in the FinnGen R10 study.",
        "PTGES2 and RNASET2 are novel potential biomarkers identified in basal cell carcinoma from MR-PheWAS."
      ],
      "exact_answer": [
        [
          "PTGES2"
        ],
        [
          "RNASET2"
        ]
      ]
    },
    {
      "body": "Does Plozasiran reduce the risk of pancreatitis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38583092",
        "http://www.ncbi.nlm.nih.gov/pubmed/39674167",
        "http://www.ncbi.nlm.nih.gov/pubmed/39225259",
        "http://www.ncbi.nlm.nih.gov/pubmed/39621242"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 2933,
          "offsetInEndSection": 3148,
          "text": "Conclusions and Relevance: In this randomized clinical trial of patients with sHTG, plozasiran decreased triglyceride levels, which fell below the 500 mg/dL threshold of acute pancreatitis risk in most participants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38583092"
        },
        {
          "offsetInBeginSection": 141,
          "offsetInEndSection": 359,
          "text": "1 75 patients with persistent chylomicronemia were allocated to 2 doses of plozasiran or placebo. Triglycerides were reduced by a net 53%-58%, and a borderline significant 17% reduction was seen in pancreatitis events.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39674167"
        },
        {
          "offsetInBeginSection": 1297,
          "offsetInEndSection": 1515,
          "text": "The key secondary end points showed better results in the plozasiran groups than in the placebo group, including the incidence of acute pancreatitis (odds ratio, 0.17; 95% confidence interval, 0.03 to 0.94; P \u003d 0.03). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39225259"
        },
        {
          "offsetInBeginSection": 1843,
          "offsetInEndSection": 2036,
          "text": "CONCLUSIONS: Patients with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and a lower incidence of pancreatitis than those who received placebo. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39225259"
        },
        {
          "offsetInBeginSection": 379,
          "offsetInEndSection": 469,
          "text": "Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39621242"
        },
        {
          "offsetInBeginSection": 379,
          "offsetInEndSection": 467,
          "text": "Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39621242"
        },
        {
          "offsetInBeginSection": 1746,
          "offsetInEndSection": 2035,
          "text": "Hyperglycemia with plozasiran occurred in some patients with prediabetes or diabetes at baseline.CONCLUSIONS: Patients with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and a lower incidence of pancreatitis than those who received placebo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39225259"
        },
        {
          "offsetInBeginSection": 1297,
          "offsetInEndSection": 1514,
          "text": "The key secondary end points showed better results in the plozasiran groups than in the placebo group, including the incidence of acute pancreatitis (odds ratio, 0.17; 95% confidence interval, 0.03 to 0.94; P \u003d 0.03).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39225259"
        },
        {
          "offsetInBeginSection": 1861,
          "offsetInEndSection": 2040,
          "text": "nts with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and a lower incidence of pancreatitis than those who received placebo. (Fun",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39225259"
        }
      ],
      "type": "yesno",
      "id": "67e5530418b1e36f2e0000aa",
      "ideal_answer": [
        "Yes, Plozasiran reduces the risk of pancreatitis by lowering triglyceride levels."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Please list the symptoms of Chikungunya virus infection",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38393630",
        "http://www.ncbi.nlm.nih.gov/pubmed/37085737",
        "http://www.ncbi.nlm.nih.gov/pubmed/38326245",
        "http://www.ncbi.nlm.nih.gov/pubmed/38800832",
        "http://www.ncbi.nlm.nih.gov/pubmed/28194661",
        "http://www.ncbi.nlm.nih.gov/pubmed/26793467",
        "http://www.ncbi.nlm.nih.gov/pubmed/39599794",
        "http://www.ncbi.nlm.nih.gov/pubmed/39459867",
        "http://www.ncbi.nlm.nih.gov/pubmed/36680088",
        "http://www.ncbi.nlm.nih.gov/pubmed/21491752",
        "http://www.ncbi.nlm.nih.gov/pubmed/26657109",
        "http://www.ncbi.nlm.nih.gov/pubmed/25378567",
        "http://www.ncbi.nlm.nih.gov/pubmed/34339379",
        "http://www.ncbi.nlm.nih.gov/pubmed/39513877",
        "http://www.ncbi.nlm.nih.gov/pubmed/39495779",
        "http://www.ncbi.nlm.nih.gov/pubmed/39699169",
        "http://www.ncbi.nlm.nih.gov/pubmed/39518948",
        "http://www.ncbi.nlm.nih.gov/pubmed/39703607",
        "http://www.ncbi.nlm.nih.gov/pubmed/28983760",
        "http://www.ncbi.nlm.nih.gov/pubmed/23608542",
        "http://www.ncbi.nlm.nih.gov/pubmed/11911593",
        "http://www.ncbi.nlm.nih.gov/pubmed/39324067",
        "http://www.ncbi.nlm.nih.gov/pubmed/39413488",
        "http://www.ncbi.nlm.nih.gov/pubmed/23912863",
        "http://www.ncbi.nlm.nih.gov/pubmed/28700066",
        "http://www.ncbi.nlm.nih.gov/pubmed/27901259",
        "http://www.ncbi.nlm.nih.gov/pubmed/24587455",
        "http://www.ncbi.nlm.nih.gov/pubmed/19716149",
        "http://www.ncbi.nlm.nih.gov/pubmed/38100636",
        "http://www.ncbi.nlm.nih.gov/pubmed/26115459",
        "http://www.ncbi.nlm.nih.gov/pubmed/34607306",
        "http://www.ncbi.nlm.nih.gov/pubmed/36549417",
        "http://www.ncbi.nlm.nih.gov/pubmed/26104337",
        "http://www.ncbi.nlm.nih.gov/pubmed/35449568",
        "http://www.ncbi.nlm.nih.gov/pubmed/32699087",
        "http://www.ncbi.nlm.nih.gov/pubmed/35401487",
        "http://www.ncbi.nlm.nih.gov/pubmed/20962735",
        "http://www.ncbi.nlm.nih.gov/pubmed/24933005",
        "http://www.ncbi.nlm.nih.gov/pubmed/38885813",
        "http://www.ncbi.nlm.nih.gov/pubmed/29020499",
        "http://www.ncbi.nlm.nih.gov/pubmed/39311214",
        "http://www.ncbi.nlm.nih.gov/pubmed/18634716",
        "http://www.ncbi.nlm.nih.gov/pubmed/36699921",
        "http://www.ncbi.nlm.nih.gov/pubmed/26406179",
        "http://www.ncbi.nlm.nih.gov/pubmed/39400050",
        "http://www.ncbi.nlm.nih.gov/pubmed/39396286",
        "http://www.ncbi.nlm.nih.gov/pubmed/26212366",
        "http://www.ncbi.nlm.nih.gov/pubmed/22348166",
        "http://www.ncbi.nlm.nih.gov/pubmed/33114216",
        "http://www.ncbi.nlm.nih.gov/pubmed/30707708",
        "http://www.ncbi.nlm.nih.gov/pubmed/28222127",
        "http://www.ncbi.nlm.nih.gov/pubmed/28233156",
        "http://www.ncbi.nlm.nih.gov/pubmed/34255544",
        "http://www.ncbi.nlm.nih.gov/pubmed/39193780",
        "http://www.ncbi.nlm.nih.gov/pubmed/17392679",
        "http://www.ncbi.nlm.nih.gov/pubmed/20179353"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 210,
          "text": "The Chikungunya virus is an Alphavirus that belongs to the Togaviridae family and is primarily transmitted by mosquitoes. It causes acute infection characterized by fever, headache, and arthralgia. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38800832"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Humans contract the Chikungunya virus (CHIKV), an alphavirus transmitted by mosquitoes that induces acute and chronic musculoskeletal discomfort and fever.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38393630"
        },
        {
          "offsetInBeginSection": 158,
          "offsetInEndSection": 259,
          "text": "nflammation and arthritis are the major symptoms of CHIKV that persist even after clearance of CHIKV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37085737"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 128,
          "text": "Long-term chikungunya disease is characterised by persistent rheumatic symptoms following chikungunya virus infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38326245"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Chikungunya virus (CHIKV) is a mosquito-borne alphavirus which presents with symptoms of fever, rash, arthralgia, and occasional neurologic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28194661"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 196,
          "text": "The most common symptoms of Chikungunya virus infection are fever, joint pain or rash.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793467"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39459867"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Chikungunya virus (CHIKV) infection is characterized by febrile illness, severe joint pain, myalgia, and cardiovascular complications",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39513877"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 182,
          "text": "Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that is responsible for Chikungunya fever, which is characterized by fever, rash, and debilitating polyarthralgia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39495779"
        },
        {
          "offsetInBeginSection": 1471,
          "offsetInEndSection": 1578,
          "text": "IMPORTANCEChikungunya virus (CHIKV) infections can cause severe fever and long-lasting joint pain in humans",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39699169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Chikungunya and Mayaro fevers are viral infectious diseases characterized by fever and arthralgia, for which there are currently no effective vaccines or treatments",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39518948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "The Chikungunya virus is a re-emerging alphavirus that belongs to the family Togaviridae. The symptoms include fever, rashes, nausea and joint pain that may last for months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657109"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Chikungunya virus, the causative agent of chikungunya fever, is generally characterized by the sudden onset of symptoms, including fever, rash, myalgia, and headache.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36680088"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "INTRODUCTION: Chikungunya fever often presents with severe arthritis/arthralgias, high fever, myalgias, headache, and maculopapu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23608542"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 375,
          "text": "Chikungunya (CHIK) virus is enzootic in many countries in Asia and throughout tropical Africa. In Asia the virus is transmitted from primates to humans almost exclusively by Aedes aegypti, while various aedine mosquito species are responsible for human infections in Africa. The clinical picture is characterized by a sudden onset of fever, rash and severe pain in the joints",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11911593"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 397,
          "text": "Arthritogenic alphaviruses, such as Chikungunya virus (CHIKV) and Mayaro virus (MAYV), are globally distributed, transmitted by mosquitoes, and can cause rheumatic disease characterized by fever, rash, myalgia, and peripheral polyarthralgia that can persist for years post-infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39413488"
        },
        {
          "offsetInBeginSection": 397,
          "offsetInEndSection": 504,
          "text": "of CHIKV disease is characterised by a fever-arthralgia-rash syndrome. Chronic rheumatic manifestations can",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28983760"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 208,
          "text": "Typical symptoms of chikungunya virus infection include severe joint aches, high fever and skin rash.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21491752"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "The symptoms of chikungunya virus (CHIKV) infection include fever, headache, muscle aches, skin rash, and polyarthralgia, characterized by intense pain, edema, and temporary functional impairment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28700066"
        },
        {
          "offsetInBeginSection": 610,
          "offsetInEndSection": 808,
          "text": "The clinical signs of CHIKV infection include non-specific flu-like symptoms, and a characteristic rash accompanied by joint pain that may last for a long time after the resolution of the infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23912863"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 279,
          "text": "The clinical picture of CHIKV infection is characterized by high fever, exanthema, myalgia, headaches, and arthralgia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27901259"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 214,
          "text": "The clinical symptoms of Chikungunya infection include fever, skin rash, arthralgia, and an increasing incidence of encephalitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24587455"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 385,
          "text": "The majority of those infected with chikungunya virus exhibit symptoms of fever, rash, and debilitating polyarthralgia or arthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34339379"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 221,
          "text": "Typical chikungunya virus (CHIKV) infection results in an acute febrile illness characterized by severe joint pain and rash.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19716149"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 457,
          "text": "The clinical symptoms associated with the infection caused by CHIKV include mainly fever, myalgia, headache, and arthralgia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38100636"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 336,
          "text": "CHIKV causes chikungunya fever (CHIK), a syndrome characterized by rash, fever, and debilitating, often chronic arthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26115459"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Chikungunya virus (CHIKV) infection typically causes fever, rash, myalgia, and arthralgia and sometimes results in recurrent joint pain or, in severe cases, neurological disorders or death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378567"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Chikungunya fever is a viral infection caused by the Chikungunya virus that causes abrupt onset of fever, debilitating arthralgias and myalgias, and some rare but serious atypical presentations in infected patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26406179"
        },
        {
          "offsetInBeginSection": 1038,
          "offsetInEndSection": 1240,
          "text": "Backache, arthralgia, jaundice, and vaginal bleeding were more common in CHIKV positives but the difference between positives and nonpositives regarding these symptoms was not statistically significant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34607306"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 329,
          "text": "Following an incubation period of 5-7 days, patients develop an acute febrile illness, chikungunya fever (CHIKF), characterized by high fevers, maculopapular rash, headaches, polyarthritis/arthralgias, myalgias, nausea, vomiting, and diarrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36549417"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 265,
          "text": "CHIKF is characterized by high fever, fatigue, headache, nausea, vomiting, rash, myalgia and severe arthralgia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26104337"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 382,
          "text": "th concern. The acute phase of chikungunya infection is usually self-limiting, characterized by severe arthralgia, fever, chills, myalgia, headac",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35449568"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Chikungunya virus, the causative agent of chikungunya fever, is generally characterized by the sudden onset of symptoms, including fever, rash, myalgia, and headache",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36680088"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Chikungunya fever, a mosquito-borne disease manifested by fever, rash, myalgia, and arthralgia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32699087"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Chikungunya virus (CHIKV), the causative agent of Chikungunya fever (CHIKVF) that is often characterized by fever, headache, rash, and arthralgia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35401487"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Chikungunya virus (CHIKV) is a mosquito-borne alphavirus which causes fever, rash, and arthralgia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20962735"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 262,
          "text": "The clinical manifestations developed upon CHIKV-infection include fever, myositis, arthralgia and maculopapular rash",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24933005"
        },
        {
          "offsetInBeginSection": 1471,
          "offsetInEndSection": 1579,
          "text": "IMPORTANCEChikungunya virus (CHIKV) infections can cause severe fever and long-lasting joint pain in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39699169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "The alphavirus chikungunya virus (CHIKV) is a serious human pathogen that can cause large-scale epidemics characterized by fever and joint pain and often resulting in chronic arthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39699169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Chikungunya patients may develop chronic joint pain that can persist for months to years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39599794"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Chikungunya virus infection (CHIKV) increases the risk of persistent arthralgia; however, there is no consistent evidence regarding prognostic biomarkers of progression to chronic arthropathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39703607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Chikungunya disease typically presents with the fever-arthralgia-rash symptom triad",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38885813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Chikungunya virus (CHIKV) is an RNA virus transmitted by Aedes mosquitoes. The clinical manifestations include fever, arthralgia, rash, and other atypical clinical findings including ocular lesions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020499"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39459867"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Chikungunya fever (CHIKF), caused by the Chikungunya virus (CHIKV), manifests as acute febrile illness often associated with polyarthritis and polyarthralgia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39311214"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 466,
          "text": "Following an incubation period of 5-7 days, patients develop an acute febrile illness, chikungunya fever (CHIKF), characterized by high fevers, maculopapular rash, headaches, polyarthritis/arthralgias, myalgias, nausea, vomiting, and diarrhea. Joint pain is often severe, and most often involves the hands, the wrists, the ankles, and the metatarsal-phalangeal joints of the feet.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36549417"
        },
        {
          "offsetInBeginSection": 310,
          "offsetInEndSection": 462,
          "text": "Chikungunya fever classically manifests as high fever, myalgia, arthralgia and arthritis and in a certain percentage of cases with maculopapular rashes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18634716"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Chikungunya fever, an acute infectious disease caused by Chikungunya virus (CHIKV), is transmitted by Aedes aegypti mosquitoes, with fever, rash, and joint pain as the main features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36699921"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 159,
          "text": "Chikungunya disease, caused by chikungunya virus (CHIKV), is associated with substantial morbidity, including debilitating CHIKV-related arthralgia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39400050"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 139,
          "text": "Chikungunya (CHIK) is an underdiagnosed acute febrile illness (AFI) and an important cause of acute encephalitis syndrome (AES)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39396286"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 280,
          "text": "The clinical picture of CHIKV infection is characterized by high fever, exanthema, myalgia, headaches, and arthralgia. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27901259"
        },
        {
          "offsetInBeginSection": 302,
          "offsetInEndSection": 473,
          "text": "Chikungunya virus causes a disease frequently misdiagnosed as Dengue fever, with potentially life-threatening symptoms that can result in long term debilitating arthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39324067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "INTRODUCTION: Chikungunya fever often presents with severe arthritis/arthralgias, high fever, myalgias, headache, and maculopapular rash (Chow et al., 2011 [1]; Das et al., 2010 [2]; Mizuno et al., 2011 [3]; Powers, 2010 [4]; Sissoko et al., 2010 [5]; Staples et a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23608542"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "text": "Chikungunya virus, the causative agent of chikungunya fever, is generally characterized by the sudden onset of symptoms, including fever, rash, myalgia, and headache. In some patients, acute chikungunya virus infection progresses to severe and chronic arthralgia that persists for years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36680088"
        },
        {
          "offsetInBeginSection": 925,
          "offsetInEndSection": 1080,
          "text": "ory-confirmed CHIK patients were recorded. Fever and arthralgias were reported by respectively 85% and 90% of patients, while myalgias, rash and hemorrhage",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22348166"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 267,
          "text": "The symptoms of CHIKV infection include fever, headache, nausea, vomiting, myalgia, rash, and chronic persistent arthralgia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26212366"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "text": "Chikungunya virus (CHIKV) is an alphavirus, transmitted by mosquitoes, which causes Chikungunya fever with symptoms of fever, rash, headache, and joint pain. In about 30%-40% of cases, the infection leads to polyarthritis and polyarthralgia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33114216"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 783,
          "text": "Chikungunya virus represents a substantial health burden to affected populations, with symptoms that include severe joint and muscle pain, rashes, and fever, as well as prolonged periods of disability in some patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28159534"
        },
        {
          "offsetInBeginSection": 310,
          "offsetInEndSection": 461,
          "text": "Chikungunya fever classically manifests as high fever, myalgia, arthralgia and arthritis and in a certain percentage of cases with maculopapular rashes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18634716"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "BACKGROUND: Chikungunya virus (CHIKV) infection is a long known mosquito-borne disease that is associated with severe morbidity, characterized by fever, headache, rashes, joint pain,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30707708"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "BACKGROUND: Chikungunya virus (CHIKV) typically causes explosive epidemics of fever, rash and polyarthralgia after its introduction into naïve",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222127"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 195,
          "text": "The most common symptoms of Chikungunya virus infection are fever, joint pain or rash",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793467"
        },
        {
          "offsetInBeginSection": 656,
          "offsetInEndSection": 776,
          "text": "CHIKV is characterized by fever, headache, myalgia, rash, and symmetric polyarthritis, which is generally self-limiting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28233156"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 315,
          "text": "CHIKV causes debilitating musculoskeletal disorders in humans that are characterized by fever, rash, polyarthralgia, and myalgia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34255544"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Chikungunya virus (CHIKV) is a mosquito-transmitted, RNA virus that causes an often-severe musculoskeletal illness characterized by fever, joint pain, and a range of debilitating symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39193780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "Chikungunya virus (CHIKV) is a mosquitoborne alphavirus indigenous to tropical Africa and Asia, where it causes endemic and epidemic chikungunya (CHIK) fever, an acute illness characterized by fever, arthralgias, and sometimes arthritis, commonly accompanied by conjunctivitis and rash",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17392679"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that induces in humans a disease characterized by fever, rash, and pain in muscles and joints",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20179353"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 220,
          "text": "Typical chikungunya virus (CHIKV) infection results in an acute febrile illness characterized by severe joint pain and rash",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19716149"
        }
      ],
      "type": "list",
      "id": "67e0533418b1e36f2e000069",
      "ideal_answer": [
        "The Chikungunya virus is an Alphavirus that belongs to the Togaviridae family and is primarily transmitted by mosquitoes. It causes acute infection characterized by fever, headache, and arthralgia.",
        "Chikungunya fever, is an emerging systemic viral disease characterized by joint pain that lasts weeks after the onset of disease and can cause persistent arthritis, chronic musculoskeletal pain, and long term comorbidities.",
        "Chikungunya virus infection is characterized by fever, rash, arthralgia, myalgia, headache, and encephalitis.",
        "The symptoms of Chikungunya virus infection include fever, joint pain, rash, headache, and myalgia.",
        "The symptoms of Chikungunya virus infection include abrupt fever, polyarthralgia, headache, maculopapular rash, myalgia, nausea/vomiting, severe joint pain, arthritis, exanthema, small joint pain, neck stiffness, and large joint pain.",
        "The symptoms of Chikungunya virus infection include rash, fever, joint pain, headache, nausea, myalgia, muscle aches, polyarthralgia, vomiting, and chills.",
        "The symptoms of Chikungunya virus infection include severe joint pain, muscle pain, rashes, fever, and prolonged periods of disability in some patients. Additionally, atypical manifestations may include severe arthralgia and neurological complications such as encephalitis, meningitis, and Guillain-Barré Syndrome.",
        "The symptoms of Chikungunya virus infection include rash, fever, headache, joint pain, nausea, conjunctivitis, myalgia, and vomiting.",
        "Chikungunya virus infection is characterized by a sudden onset of high fever, intense arthralgia affecting multiple joints, headache, and rash. Patients frequently experience myalgia, fatigue, chills, nausea, and vomiting. Some cases may also present with myositis or rigors, and the arthralgia is often severe and prolonged.",
        "The symptoms of Chikungunya virus infection typically include:\n\n1. **Fever**: A high temperature is a common initial symptom.\n2. **Joint Pain (Arthralgia)**: Severe and often debilitating pain in the joints, which can be acute or chronic, lasting for months or years.\n3. **Muscle Pain (Myalgia)**: Generalized body aches and pains.\n4. **Headache**: Often accompanies the fever and other symptoms.\n\nIn some cases, additional symptoms such as fatigue, rash, nausea, vomiting, and in rare instances, seizures, may also occur. The severity of these symptoms can vary among individuals, with some experiencing mild illness while others develop chronic conditions like arthritis.",
        "The symptoms of Chikungunya virus infection include: fever, severe joint pain (arthralgia), muscle pain, rashes, and prolonged periods of disability. Additionally, atypical manifestations can include neurological complications such as encephalitis, meningitis, and Guillain-Barré Syndrome.",
        "The symptoms of Chikungunya virus infection include: severe joint pain, muscle pain, fever, rashes, and prolonged periods of disability. Additionally, atypical forms may include neurological, cardiac, and renal involvement.",
        "The symptoms of Chikungunya virus infection include fever, joint pain, rash, headache, muscle aches, and nausea.",
        "Symptoms of Chikungunya virus infection include fever, joint pain (arthralgia/arthritis), rash, myalgia (muscle pain), headache, nausea, conjunctival injection, and photophobia. Neurological disorders can occur, especially in severe cases. Chronic symptoms (beyond 3 months) may manifest as tenosynovitis, bursitis, and arthritis, particularly affecting small joints of the hands, wrists, and knees, leading to stiffness and limited mobility. Rarely, acute transverse myelitis may occur. The disease can also lead to post-chikungunya arthritis with an inflammatory process and, in some cases, persistent arthralgia for years.",
        "The symptoms of Chikungunya virus infection include: fever, severe joint pain (arthralgia), muscle pain (myalgia), rash, and prolonged periods of disability. Additionally, atypical manifestations may include neurological complications such as encephalitis and Guillain-Barré Syndrome.",
        "Chikungunya virus infection commonly presents with fever, joint pain (arthralgia), skin rash, muscle pain (myalgia), and headache. Less commonly, it may involve neurologic symptoms, eye symptoms (conjunctival injection, photophobia), and can lead to chronic conditions such as tenosynovitis, bursitis, and arthritis, along with other symptoms like stiffness, limited mobility, swelling, and redness in some patients.",
        "Based on the provided abstracts, the symptoms of Chikungunya virus infection are:\n\n1. Fever (high fever)\n2. Joint pain (severe and disabling polyarthritis, arthralgia)\n3. Myalgia (muscle pain)\n4. Rash (maculopapular rash, predominantly on the thorax)\n5. Headache\n6. Nausea/Vomiting\n7. Fatigue\n8. Chills\n9. Backache (low back pain)\n10. Conjunctivitis (conjunctival injection and photophobia)\n\nThese symptoms are commonly reported in the abstracts and may vary in severity and combination from person to person.",
        "Chikungunya virus infection presents with a sudden onset of high fever accompanied by severe joint pain and a widespread rash. Patients frequently experience intense joint pain, muscle pain, headache, nausea, and vomiting. In some cases, conjunctivitis and arthralgia can lead to prolonged musculoskeletal discomfort, while a flu-like syndrome with chills may also be observed.",
        "The symptoms of Chikungunya virus infection include fever, joint pain or rash.",
        "Chikungunya virus infection is characterized by fever, headache, arthralgia, myalgia, joint pain, swelling, and swelling of the affected joints.",
        "Chikungunya virus infection is characterized by a range of acute and chronic symptoms. The primary symptoms include fever, headache, and severe joint pain (arthralgia). The disease can lead to persistent rheumatic symptoms and long-term musculoskeletal discomfort, with inflammation and arthritis being particularly notable manifestations that can continue even after the initial viral clearance.",
        "The symptoms of Chikungunya virus infection primarily include fever, headache, arthralgia (joint pain), and both acute and chronic musculoskeletal discomfort. Notably, the disease can progress to arthritis and inflammation in its chronic phase, leading to persistent, long-term rheumatic symptoms characterized by ongoing pain and discomfort, even after the virus has been cleared from the body.",
        "Chikungunya virus (CHIKV) infection is characterized by febrile illness, severe joint pain, myalgia, and cardiovascular complications.",
        "Chikungunya virus infection is characterized by fever, headache, arthralgia, myalgia, and joint pain.",
        "Fever, headache, arthralgia, and arthritis are the symptoms of Chikungunya virus infection.",
        "The symptoms of Chikungunya virus infection include fever, rash, arthralgia (joint pain), myalgia (muscle pain), headache, neck stiffness, nausea/vomiting, and polyarthritis. The joint pain often affects small joints like wrists and fingers, as well as larger joints such as shoulders and knees. Some individuals may experience long-term rheumatic symptoms.",
        "The symptoms of Chikungunya virus infection include fever, headache, arthralgia, inflammation, and arthritis, which can persist even after the virus is cleared from the body, often leading to long-term rheumatic symptoms.",
        "Chikungunya virus infection presents with symptoms such as fever, headache, arthralgia, musculoskeletal discomfort, inflammation, arthritis, and persistent rheumatic symptoms as seen in the snippets.",
        "The symptoms of Chikungunya virus infection include arthralgia, fever, headache, arthritis, inflammation, and musculoskeletal discomfort.",
        "The symptoms of Chikungunya virus (CHIKV) infection include: fever, headache, arthralgia (joint pain), severe joint and muscle pain, rashes, and prolonged periods of disability. Additionally, inflammation and arthritis are major symptoms that can persist even after the virus is cleared.",
        "Acute Chikungunya virus infection symptoms include fever, headache, arthralgia (joint pain), and musculoskeletal discomfort. Chronic manifestations often involve persistent inflammation, arthritis, and long-term rheumatic symptoms even after viral clearance.",
        "The symptoms of Chikungunya virus infection include arthralgia, fever, headache, musculoskeletal discomfort, arthritis, inflammation, chronic rheumatic symptoms, and persistent rheumatic symptoms.",
        "Chikungunya virus infection is characterized by high fever, severe arthralgia, headache, rash, and myalgia. Additional symptoms may include chills, nausea, vomiting, fatigue, and rigors. In some cases, joint and muscle pain may persist even after the acute phase, leading to chronic rheumatic discomfort.",
        "Symptoms of Chikungunya virus infection include fever, headache, and arthralgia, with musculoskeletal discomfort being common. Additionally, inflammation and arthritis can occur, sometimes persisting as part of long-term chikungunya disease.",
        "The symptoms of Chikungunya virus infection include fever, headache, and arthralgia (joint pain). In some cases, inflammation and arthritis may persist even after clearance of the virus, leading to long-term chronic musculoskeletal discomfort.",
        "The symptoms of Chikungunya virus infection include fever, arthralgia, rash (including maculopapular rash), headache, myalgia, nausea/vomiting, neck stiffness, and musculoskeletal discomfort. Some patients may also experience neurologic symptoms such as encephalitis and ocular lesions, as well as persistent rheumatic symptoms, and inflammation and arthritis.",
        "The symptoms of Chikungunya virus infection include fever, headache, arthralgia, acute and chronic musculoskeletal discomfort, inflammation, and arthritis. Persistent rheumatic symptoms may also occur following the infection.",
        "The symptoms of Chikungunya virus infection include: fever, headache, arthralgia (joint pain), and persistent chronic osteoarthritis-like symptoms. Additionally, inflammation and arthritis are major symptoms that can persist even after the virus is cleared from the body.",
        "The Chikungunya virus infection presents with several symptoms, particularly fever, headache, arthralgia (joint pain), and musculoskeletal discomfort. These symptoms can be acute. In some cases, the infection leads to chronic manifestations, including inflammation, arthritis, and persistent rheumatic symptoms that may continue even after the virus has been cleared.",
        "The symptoms of Chikungunya virus infection include: fever, headache, arthralgia (joint pain), severe joint and muscle pain, rashes, and prolonged periods of disability. Additionally, inflammation and arthritis are major symptoms that may persist even after the virus is cleared.",
        "The symptoms of Chikungunya virus infection include fever, headache, joint pain (arthralgia), inflammation, arthritis, and musculoskeletal discomfort.",
        "The symptoms of Chikungunya virus infection include: fever, headache, arthralgia (joint pain), rash, debilitating polyarthralgia or arthritis, severe joint and muscle pain, and prolonged periods of disability. Additionally, inflammation and arthritis are major symptoms that can persist even after the virus is cleared.",
        "The Chikungunya virus is an Alphavirus that belongs to the Togaviridae family and is primarily transmitted by mosquitoes. It causes acute infection characterized by fever, headache, and arthralgia. Long-term chikungunya disease is characterised by persistent rheumatic symptoms following chikungunya virus infection.",
        "The symptoms of Chikungunya virus infection include fever, headache, arthralgia, inflammation, and arthritis  .",
        "Chikungunya virus infection is characterized by fever, headache, and arthralgia.",
        "Based on the provided abstracts, the symptoms of Chikungunya virus infection include:\n\n* Fever\n* Headache\n* Arthralgia (joint pain)\n* Acute infection\n* Musculoskeletal discomfort\n* Inflammation\n* Arthritis\n* Persistent rheumatic symptoms\n\nNote that these symptoms may persist even after clearance of the virus, leading to long-term chikungunya disease.",
        "Chikungunya virus infection leads to acute symptoms including fever, headache, arthralgia, and musculoskeletal discomfort. Inflammation and arthritis are significant symptoms that may persist even after the virus is cleared, resulting in long-term rheumatic conditions.",
        "The symptoms of Chikungunya virus infection include fever, headache, arthralgia (joint pain), musculoskeletal discomfort, inflammation, and arthritis. Some patients may experience persistent rheumatic symptoms following the acute phase of the infection.",
        "The symptoms of Chikungunya virus infection include:\n\n- Fever\n- Headache\n- Arthralgia (joint pain)\n- Musculoskeletal discomfort\n- Inflammation\n- Arthritis\n- Persistent rheumatic symptoms in the long term.\n\nThese symptoms can range from acute to chronic, with some individuals experiencing prolonged musculoskeletal issues.",
        "According to studies, Chikungunya virus infection presents with symptoms such as fever, headache, and arthralgia. It also results in both acute and chronic musculoskeletal discomfort. Notably, inflammation and arthritis are significant symptoms that can persist even after the virus has been cleared. Long-term disease is characterized by ongoing rheumatic issues following the infection.",
        "Symptoms of Chikungunya virus infection include fever, headache, arthralgia, musculoskeletal discomfort, inflammation, and arthritis, with rheumatic symptoms potentially persisting long-term after viral clearance.",
        "The symptoms of Chikungunya virus infection are arthralgia, fever, headache, inflammation, musculoskeletal discomfort, and arthritis.",
        "The Chikungunya virus infection is characterized by acute symptoms including fever, headache, and arthralgia. Inflammation and arthritis are also major persistent symptoms that can last even after the clearance of the virus.",
        "Chikungunya virus (CHIKV) infection, transmitted by mosquitoes, initially presents with acute symptoms such as fever, headache, and arthralgia. The major persistent symptoms following the acute phase include inflammation and arthritis, which can lead to long-term rheumatic issues even after the virus is cleared from the body.",
        "The symptoms of Chikungunya virus infection include fever, headache, arthralgia, acute and chronic musculoskeletal discomfort, inflammation, and arthritis."
      ],
      "exact_answer": [
        [
          "fever"
        ],
        [
          "headache"
        ],
        [
          "arthralgia"
        ],
        [
          "inflammation"
        ],
        [
          "arthritis"
        ],
        [
          "persistent rheumatic symptoms"
        ]
      ]
    },
    {
      "body": "Prevention of maternal transmission of CMV infection.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39087737",
        "http://www.ncbi.nlm.nih.gov/pubmed/34334662",
        "http://www.ncbi.nlm.nih.gov/pubmed/35438780",
        "http://www.ncbi.nlm.nih.gov/pubmed/32325395",
        "http://www.ncbi.nlm.nih.gov/pubmed/23308078",
        "http://www.ncbi.nlm.nih.gov/pubmed/19253166"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 461,
          "text": "The treatment of congenital cytomegalovirus (CMV) infection is usually administered to neonates after birth; however, it can be anticipated during the prenatal period by treating pregnant women in order to reduce the severity of the congenital disease. The most commonly used treatment for CMV during pregnancy is valaciclovir; however, valganciclovir has a higher potency against CMV and is the first choice for neonates with congenital CMV disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39087737"
        },
        {
          "offsetInBeginSection": 585,
          "offsetInEndSection": 750,
          "text": "A recent study reported a 71% reduction in vertical transmission of CMV with the use of oral valaciclovir following maternal primary CMV infection early in pregnancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34334662"
        },
        {
          "offsetInBeginSection": 819,
          "offsetInEndSection": 1005,
          "text": "The role of valacyclovir and CMV HIG in CMV infection in pregnancy is still being defined. Valacyclovir to prevent vertical transmission has the highest quality evidence in favor of use.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35438780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Valacyclovir in primary maternal CMV infection for prevention of vertical transmission: A case-series.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32325395"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 715,
          "text": " research efforts. Recently, there have been several exciting studies assessing different ways of preventing congenital infection in the fetus and one in particular has focused on the use of valaciclovir.RECENT FINDINGS: A recent study reported a 71% reduction in vertical transmission of CMV with the use of oral valaciclovir following maternal prima",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34334662"
        },
        {
          "offsetInBeginSection": 909,
          "offsetInEndSection": 1114,
          "text": "Being not yet available a vaccine and uncertain the results of postnatal ganciclovir therapy, CMV hyperimmunoglobulin appears to be the only safe and valid approach for prevention of congenital CMV disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19253166"
        },
        {
          "offsetInBeginSection": 256,
          "offsetInEndSection": 429,
          "text": "In spite of the well-recognized burden that these infections place on society, there are as yet no clearly established interventions available to prevent transmission of CMV",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23308078"
        }
      ],
      "type": "factoid",
      "id": "67e40c0f18b1e36f2e0000a2",
      "ideal_answer": [],
      "exact_answer": [
        [
          "Valganciclovir and Valaciclovir",
          "Hyperimmunoglobulin administration"
        ]
      ]
    },
    {
      "body": "What is a characteristic family of enzymes that are responsible for DNA demethylation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24153300",
        "http://www.ncbi.nlm.nih.gov/pubmed/25436545",
        "http://www.ncbi.nlm.nih.gov/pubmed/26932196",
        "http://www.ncbi.nlm.nih.gov/pubmed/22974304",
        "http://www.ncbi.nlm.nih.gov/pubmed/39707356",
        "http://www.ncbi.nlm.nih.gov/pubmed/39571959",
        "http://www.ncbi.nlm.nih.gov/pubmed/39567688",
        "http://www.ncbi.nlm.nih.gov/pubmed/39500892",
        "http://www.ncbi.nlm.nih.gov/pubmed/39448736",
        "http://www.ncbi.nlm.nih.gov/pubmed/39426467",
        "http://www.ncbi.nlm.nih.gov/pubmed/39377353",
        "http://www.ncbi.nlm.nih.gov/pubmed/31229544",
        "http://www.ncbi.nlm.nih.gov/pubmed/30783500",
        "http://www.ncbi.nlm.nih.gov/pubmed/28472485",
        "http://www.ncbi.nlm.nih.gov/pubmed/26598602",
        "http://www.ncbi.nlm.nih.gov/pubmed/28242787",
        "http://www.ncbi.nlm.nih.gov/pubmed/37349892",
        "http://www.ncbi.nlm.nih.gov/pubmed/35628470",
        "http://www.ncbi.nlm.nih.gov/pubmed/38499584",
        "http://www.ncbi.nlm.nih.gov/pubmed/35665901",
        "http://www.ncbi.nlm.nih.gov/pubmed/38324471",
        "http://www.ncbi.nlm.nih.gov/pubmed/37406303",
        "http://www.ncbi.nlm.nih.gov/pubmed/36099791",
        "http://www.ncbi.nlm.nih.gov/pubmed/36070377",
        "http://www.ncbi.nlm.nih.gov/pubmed/39149518",
        "http://www.ncbi.nlm.nih.gov/pubmed/29265160",
        "http://www.ncbi.nlm.nih.gov/pubmed/39334883",
        "http://www.ncbi.nlm.nih.gov/pubmed/22706113",
        "http://www.ncbi.nlm.nih.gov/pubmed/34222326",
        "http://www.ncbi.nlm.nih.gov/pubmed/31922011",
        "http://www.ncbi.nlm.nih.gov/pubmed/29190698",
        "http://www.ncbi.nlm.nih.gov/pubmed/25341925",
        "http://www.ncbi.nlm.nih.gov/pubmed/39317913",
        "http://www.ncbi.nlm.nih.gov/pubmed/37300692",
        "http://www.ncbi.nlm.nih.gov/pubmed/34997955",
        "http://www.ncbi.nlm.nih.gov/pubmed/34667079",
        "http://www.ncbi.nlm.nih.gov/pubmed/34165552",
        "http://www.ncbi.nlm.nih.gov/pubmed/33421268",
        "http://www.ncbi.nlm.nih.gov/pubmed/32504107",
        "http://www.ncbi.nlm.nih.gov/pubmed/31286885",
        "http://www.ncbi.nlm.nih.gov/pubmed/28555658",
        "http://www.ncbi.nlm.nih.gov/pubmed/27036965",
        "http://www.ncbi.nlm.nih.gov/pubmed/35705880",
        "http://www.ncbi.nlm.nih.gov/pubmed/21778364",
        "http://www.ncbi.nlm.nih.gov/pubmed/31209155",
        "http://www.ncbi.nlm.nih.gov/pubmed/38360546",
        "http://www.ncbi.nlm.nih.gov/pubmed/28098352",
        "http://www.ncbi.nlm.nih.gov/pubmed/33085059",
        "http://www.ncbi.nlm.nih.gov/pubmed/28757075",
        "http://www.ncbi.nlm.nih.gov/pubmed/25845601",
        "http://www.ncbi.nlm.nih.gov/pubmed/37569830",
        "http://www.ncbi.nlm.nih.gov/pubmed/35766395",
        "http://www.ncbi.nlm.nih.gov/pubmed/21496894",
        "http://www.ncbi.nlm.nih.gov/pubmed/29556496",
        "http://www.ncbi.nlm.nih.gov/pubmed/33894507",
        "http://www.ncbi.nlm.nih.gov/pubmed/22956496",
        "http://www.ncbi.nlm.nih.gov/pubmed/37031472",
        "http://www.ncbi.nlm.nih.gov/pubmed/31693361",
        "http://www.ncbi.nlm.nih.gov/pubmed/26806038",
        "http://www.ncbi.nlm.nih.gov/pubmed/24335252",
        "http://www.ncbi.nlm.nih.gov/pubmed/26440216",
        "http://www.ncbi.nlm.nih.gov/pubmed/21811096",
        "http://www.ncbi.nlm.nih.gov/pubmed/24194590",
        "http://www.ncbi.nlm.nih.gov/pubmed/33440144",
        "http://www.ncbi.nlm.nih.gov/pubmed/34158086",
        "http://www.ncbi.nlm.nih.gov/pubmed/39627458",
        "http://www.ncbi.nlm.nih.gov/pubmed/38915445",
        "http://www.ncbi.nlm.nih.gov/pubmed/39037697",
        "http://www.ncbi.nlm.nih.gov/pubmed/39251719",
        "http://www.ncbi.nlm.nih.gov/pubmed/38970823",
        "http://www.ncbi.nlm.nih.gov/pubmed/36685517",
        "http://www.ncbi.nlm.nih.gov/pubmed/35235010",
        "http://www.ncbi.nlm.nih.gov/pubmed/34954490",
        "http://www.ncbi.nlm.nih.gov/pubmed/33913031",
        "http://www.ncbi.nlm.nih.gov/pubmed/31941705",
        "http://www.ncbi.nlm.nih.gov/pubmed/26820436",
        "http://www.ncbi.nlm.nih.gov/pubmed/26276226",
        "http://www.ncbi.nlm.nih.gov/pubmed/35396259",
        "http://www.ncbi.nlm.nih.gov/pubmed/26302812",
        "http://www.ncbi.nlm.nih.gov/pubmed/22391558",
        "http://www.ncbi.nlm.nih.gov/pubmed/22156206",
        "http://www.ncbi.nlm.nih.gov/pubmed/35953487",
        "http://www.ncbi.nlm.nih.gov/pubmed/39261005",
        "http://www.ncbi.nlm.nih.gov/pubmed/39196941",
        "http://www.ncbi.nlm.nih.gov/pubmed/23821944",
        "http://www.ncbi.nlm.nih.gov/pubmed/22910204",
        "http://www.ncbi.nlm.nih.gov/pubmed/28408905",
        "http://www.ncbi.nlm.nih.gov/pubmed/24412366",
        "http://www.ncbi.nlm.nih.gov/pubmed/37563110",
        "http://www.ncbi.nlm.nih.gov/pubmed/32419604",
        "http://www.ncbi.nlm.nih.gov/pubmed/33879920",
        "http://www.ncbi.nlm.nih.gov/pubmed/26099018",
        "http://www.ncbi.nlm.nih.gov/pubmed/22157888",
        "http://www.ncbi.nlm.nih.gov/pubmed/24395347"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 667,
          "text": "DNA methylation has a profound impact on genome stability, transcription and development. Although enzymes that catalyse DNA methylation have been well characterized, those that are involved in methyl group removal have remained elusive, until recently. The transformative discovery that ten-eleven translocation (TET) family enzymes can oxidize 5-methylcytosine has greatly advanced our understanding of DNA demethylation. 5-Hydroxymethylcytosine is a key nexus in demethylation that can either be passively depleted through DNA replication or actively reverted to cytosine through iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24153300"
        },
        {
          "offsetInBeginSection": 254,
          "offsetInEndSection": 423,
          "text": "The transformative discovery that ten-eleven translocation (TET) family enzymes can oxidize 5-methylcytosine has greatly advanced our understanding of DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24153300"
        },
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 474,
          "text": "The discovery of the ten-eleven translocation (Tet) family of enzymes that oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) or 5-carboxylcytosine (5caC) provided new means by which DNA methylation could actively be reversed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25436545"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 415,
          "text": "Molecular mechanisms of active DNA demethylation began to surface only recently with the discovery of the 5-methylcytosine (5mC)-directed hydroxylase and base excision activities of ten-eleven translocation (TET) proteins and thymine DNA glycosylase (TDG).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26932196"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 471,
          "text": "TET3 is a key DNA demethylase that plays an important role in neural differentiation, but its role in OPC formation is not well understood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39707356"
        },
        {
          "offsetInBeginSection": 637,
          "offsetInEndSection": 846,
          "text": "Mechanistically, nuclear-localized HDAC6 binds and deacetylates ten-eleven translocation 2 (TET2) to initiate active DNA demethylation, which promotes DNA damage through thymine DNA glycosylase-driven excision",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39567688"
        },
        {
          "offsetInBeginSection": 1028,
          "offsetInEndSection": 1264,
          "text": "The expression of TET1, which is required for DNA demethylation, was found to be inversely correlated with p16 CGI methylation, and this may serve as a biomarker for the prediction of resistance to PRC2 inhibitors in SWI/SNF LOF tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39500892"
        },
        {
          "offsetInBeginSection": 868,
          "offsetInEndSection": 1025,
          "text": "TET2 protein catalyzes active demethylation and TET2 upregulation could be a signature of pluripotent exit, while shaping the epigenetic landscape in hES-NSC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39448736"
        },
        {
          "offsetInBeginSection": 669,
          "offsetInEndSection": 862,
          "text": "The LK-A-induced GPX4 suppression coincided with the inhibition of ten-eleven translocation 2 (TET2), a key DNA demethylation enzyme and an increase in the hypermethylation of the GPX4 promoter",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39426467"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 367,
          "text": "As the erasers of DNA methylation, Ten-eleven translocation (TET) family proteins can oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), thus leading to passive or active DNA demethylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39377353"
        },
        {
          "offsetInBeginSection": 363,
          "offsetInEndSection": 590,
          "text": "The in vivo DNA demethylation activity of TET isoforms may depend on many factors including enzyme\u0027s structural features, its interaction with DNA-binding proteins, chromatin context, DNA sequence, DNA length, and configuration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37349892"
        },
        {
          "offsetInBeginSection": 150,
          "offsetInEndSection": 285,
          "text": "One family of dioxygenases are the ten-eleven translocation (TET) proteins, which oxidize 5-methylcytosine to promote DNA demethylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35628470"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "The active DNA demethylation process, which involves TET proteins, can affect DNA methylation pattern",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38499584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "TET enzymes (TET1-3) are dioxygenases that oxidize 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and are involved in the DNA demethylation process",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665901"
        },
        {
          "offsetInBeginSection": 1106,
          "offsetInEndSection": 1357,
          "text": "These findings improve our understanding of Tet enzyme functions in the dsDNA 5mC and 6mA demethylation pathways, and provide useful information for future discovery of small molecular probes targeting Tet enzymes in DNA active demethylation processes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38324471"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "The three mammalian TET dioxygenases oxidize the methyl group of 5-methylcytosine in DNA, and the oxidized methylcytosines are essential intermediates in all known pathways of DNA demethylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37406303"
        },
        {
          "offsetInBeginSection": 511,
          "offsetInEndSection": 729,
          "text": "5-hydroxymethycytosine (5-hmC), alias the sixth base of the genome, is an intermediate formed during the recently established DNA demethylation process and catalysed via ten-eleven translocation (TET) family of enzymes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36099791"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "TET (ten-eleven translocation) enzymes catalyze the oxidation of 5-methylcytosine bases in DNA, thus driving active and passive DNA demethylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36070377"
        },
        {
          "offsetInBeginSection": 1141,
          "offsetInEndSection": 1253,
          "text": "The TET3-mediated DNA demethylation occurs at the global level and is clearly observed in many mammalian species",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39149518"
        },
        {
          "offsetInBeginSection": 295,
          "offsetInEndSection": 550,
          "text": "Equally, the family of TET enzymes which triggers the initiation of the DNA demethylation cycle plays a vital role in the early embryonic development and a lack of these enzymes at later stages leads to a diseased state and dysregulation of the epigenome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29265160"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Active demethylation of 5-methylcytosine moiety in DNA occurs by its sequential oxidation to 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxycytosine, catalysed by enzymes of the Ten-Eleven Translocation family proteins (TETs 1, 2 and 3). Here",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29190698"
        },
        {
          "offsetInBeginSection": 344,
          "offsetInEndSection": 582,
          "text": "The ten-eleven translocation (TET) protein family proteins TET1, TET2, and TET3 are important DNA demethylation enzymes, and differential expression of TET1, TET2, and TET3 may affect the proliferation and apoptosis of aging ovarian cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39317913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 320,
          "text": "TET2 is a member of the TET protein family which is responsible for active DNA demethylation through catalyzing the successive oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), and mutations of Tet2 frequently lead to hematological malignancies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37300692"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 336,
          "text": "The ten-eleven translocation (TET) enzyme family catalyzes the hydroxymethylation and subsequent demethylation of DNA by oxidizing 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34997955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "DNA methylation at enhancers and CpG islands usually leads to gene repression, which is counteracted by DNA demethylation through the TET protein family",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34667079"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 380,
          "text": "5-methylcytosine (5mC) can be converted to 5-hydroxymethylcytosine (5hmC) by the ten-eleven translocation (Tet) family of proteins as part of active deoxyribonucleic acid (DNA) demethylation pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34165552"
        },
        {
          "offsetInBeginSection": 403,
          "offsetInEndSection": 641,
          "text": "Here, we demonstrate that the chicken B-cell line DT40 lacking TET3, a member of the TET (Ten-eleven translocation) family dioxygenases that facilitate DNA demethylation, exhibited a marked reduction in GCV activity in Ig variable regions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33421268"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 274,
          "text": "The Tet protein family (Tet1, Tet2, and Tet3) regulate DNA methylation through conversion of 5-methylcytosine to 5-hydroxymethylcytosine which can ultimately result in DNA demethylation and play a critical role during early mammalian development and pluripotency",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31286885"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 37,
          "text": "TET-mediated active DNA demethylation",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28555658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Ten-eleven translocation (TET) methylcytosine dioxygenases (TET1, TET2, TET3) actively cause demethylation of 5-methylcytosine (5mC) and produce and safeguard hypomethylation at key regulatory regions across the genome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31209155"
        },
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 550,
          "text": "The TET family of enzymes is responsible for the hydroxylation of 5-methylcytosines (5-mC) to 5-hydroxymethylcytosine (5-hmC), followed by active and passive mechanisms leading to DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28242787"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 477,
          "text": "These deaminases have also been proposed to function in DNA demethylation via deamination of either 5-methylcytosine (mC) or TET-oxidized mC bases (ox-mCs), which include 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28472485"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 564,
          "text": "The TET family of enzymes is known to be responsible for catalyzing the reverse process that is DNA demethylation by recognizing 5-methylcytosine and oxidizing the methyl group via an Fe(II)/alpha-ketoglutarate-dependent mechanism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30783500"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Recent studies in mice showed that the Ten-eleven translocation Enzymes (TET) family is involved in the active DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28757075"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 519,
          "text": "The family of dioxygenases commonly known as Ten-eleven translocation (Tet) proteins are responsible for the oxidation of 5mC into three new forms, 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Current models link Tet-mediated 5mC oxidation with active DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25341925"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "The TET (Ten-Eleven Translocation) dioxygenase enzyme family comprising 3 members, TET1-3, play key roles in DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33894507"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 337,
          "text": "The ten-eleven translocation (TET) enzyme family catalyzes the hydroxymethylation and subsequent demethylation of DNA by oxidizing 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34997955"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 342,
          "text": "The Ten eleven translocation (Tet) family of enzymes converts 5-methylcytosine to 5-hydroxymethylcytosine, which promotes passive DNA demethylation and functions as an intermediate in an active DNA demethylation process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Ten-eleven translocation 1 (TET1) is a member of the TET enzyme family of dioxygenases, which plays an important role in active DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37031472"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 451,
          "text": "Active DNA demethylation involves TET-mediated stepwise oxidation of mC to 5-hydroxymethylcytosine, 5-formylcytosine (fC), or 5-carboxylcytosine (caC), excision of fC or caC by thymine DNA glycosylase (TDG), and subsequent base excision repair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31693361"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 418,
          "text": "Initially described as catalyzing the oxidation of methyl cytosine (5mC) to hydroxymethyl cytosine (5hmC), it is now clear that these enzymes can also catalyze additional reactions leading to active DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29556496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "BACKGROUND: TET enzymes mediate DNA demethylation by oxidizing 5-methylcytosine (5mC) in DNA to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcyto",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34158086"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 488,
          "text": "Gadd45a promotes active DNA demethylation through thymine DNA glycosylase (TDG) which has recently been shown to excise 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) generated in Ten-eleven-translocation (Tet)-initiated oxidative demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25845601"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Ten-eleven translocation (TET) methylcytosine dioxygenases (TET1, TET2, TET3) actively cause demethylation of 5-methylcytosine (5mC) and produce and safeguard hypomethylation at key regulatory regions across the genome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31209155"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 522,
          "text": "Recent discoveries regarding the Ten eleven translocation (Tet1-3) family of DNA hydroxylases have provided a new avenue for the study of active DNA demethylation, and may thus help to advance our understanding of how dynamic DNA modifications lead to long-lasting changes in brain regions underlying learning and memory",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26806038"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Oxidation of 5-methylcytosine by TET family proteins can induce DNA replication-dependent (passive) DNA demethylation and base excision repair (BER)-based (active) DNA demethylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440216"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 388,
          "text": "The recent discovery of the TET protein family (TET1-3) 5-methylcytosine hydroxylases has provided a new entry point to reveal the identity of the long-sought DNA demethylase",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21811096"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 325,
          "text": "The recently discovered Ten-Eleven Translocation (TET) dioxygenases are accepted to be involved in DNA demethylation by initiating 5-mC oxidation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194590"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Tet proteins (Tet1/2/3) convert 5-methylcytosine (5mC) to 5-hydroxy-methylcytosine (5hmC), initiating the process of active demethylation to regulate gene expression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33440144"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Ten eleven translocation (TET) proteins are tumor suppressors that through their catalytic activity oxidize 5-methylcytosine to 5-hydroxymethylcytosine, to promote DNA demethylation and to regulate gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39627458"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 368,
          "text": "As the erasers of DNA methylation, Ten-eleven translocation (TET) family proteins can oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), thus leading to passive or active DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39377353"
        },
        {
          "offsetInBeginSection": 1101,
          "offsetInEndSection": 1317,
          "text": "The Ten-Eleven-Translocation (TET) family of DNA dioxygenases is crucial in facilitating active DNA demethylation through the enzymatic conversion of the modified genomic base 5-mC to 5-hydroxymethylcytosine (5-hmC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38915445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "The TET family is well known for active DNA demethylation and plays important roles in regulating transcription, the epigenome and development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39037697"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "The ten-eleven translocation (TET) family of dioxygenases maintain stable local DNA demethylation during cell division and lineage specification.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39251719"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "TET1/2/3 dioxygenases iteratively demethylate 5-methylcytosine, beginning with the formation of 5-hydroxymethylcytosine (5hmC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970823"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 341,
          "text": "The Ten eleven translocation (Tet) family of enzymes converts 5-methylcytosine to 5-hydroxymethylcytosine, which promotes passive DNA demethylation and functions as an intermediate in an active DNA demethylation process",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598602"
        },
        {
          "offsetInBeginSection": 343,
          "offsetInEndSection": 572,
          "text": "Tet1/Tet2 double-knockout mice are characterized by developmental defects and epigenetic instability, suggesting a requirement for Tet-mediated DNA demethylation for the proper regulation of gene expression during differentiation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598602"
        },
        {
          "offsetInBeginSection": 1010,
          "offsetInEndSection": 1256,
          "text": "Based on these results, we propose an important regulatory role of Tet-dependent DNA demethylation for the maintenance of DNA methylation canyons, which prevents invasive DNA methylation and allows functional regulation of canyon-associated genes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598602"
        },
        {
          "offsetInBeginSection": 596,
          "offsetInEndSection": 880,
          "text": "Ten-eleven translocation (TET) enzymes, responsible for catalyzing the conversion of 5-methylcytosine to 5-hydroxymethylcyosine, 5-formylytosine, and 5-carboxylcyosine to achieve the DNA demethylation process, appear to play a critical role in decidualization and embryo implantation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36685517"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "TET (ten-eleven translocation) enzymes initiate active cytosine demethylation via the oxidation of 5-methylcytosine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35235010"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 352,
          "text": "Ten-eleven translocation (TET) enzymes catalyze DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34954490"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Ten-eleven translocation (TET) methylcytosine dioxygenases are enzymes that catalyze the demethylation of 5-methylcytosine on DNA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31941705"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 196,
          "text": "One hallmark is active demethylation of the paternal genome by Tet (ten-eleven translocation) enzymes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26820436"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 388,
          "text": "The recent characterization of ten-eleven translocation (TET) enzymes as a source of newly modified cytosines (5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine) has shed new light on the DNA demethylation process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26276226"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "Ten-eleven translocation (TET) proteins are crucial epigenetic regulators highly conserved in multicellular organisms. TETs\u0027 enzymatic function in demethylating 5-methyl cytosine in DNA is required for proper development and TETs are frequently mutated in cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35396259"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 576,
          "text": "In vertebrates, methylation of cytosine at the C5 position of CpG dinucleotides is executed by DNA methyltransferases (DNMTs) whereas the process of enzymatic demethylation is highly dependent on the activity of the ten-eleven translocation methylcytosine dioxygenase (TET) family of enzymes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34222326"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 289,
          "text": "One of the most exciting recent advances in the epigenetic field is the discovery that 5-methylcytosine (5mC) in DNA can be iteratively oxidized by a family of proteins known as Tet proteins to generate 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22910204"
        },
        {
          "offsetInBeginSection": 677,
          "offsetInEndSection": 790,
          "text": "TET proteins mediate DNA demethylation through the oxidation of 5-methylcytosine (5mC) in CpG in mammalian cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32504107"
        },
        {
          "offsetInBeginSection": 322,
          "offsetInEndSection": 933,
          "text": "   Although active DNA demethylation in mammals is still controversial, the most plausible mechanism/s of active 5mC demethylation include involvement of three families of enzymes; i) Tet, which is involved in hydroxylation of 5mC to form 5hmC, which can be further oxidized to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC); ii) deamination of 5mC (or 5hmC) by AID/APOBEC to form thymine or 5-hydroxymethyluracil (5hmU) mispaired with guanine; iii) the BER pathway induced by involvement of TDG glycosylase to replace the above described base modification (5fC, 5caC, 5hmU) with cytosine to demethylate D",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706113"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "Active demethylation of 5-methylcytosine moiety in DNA occurs by its sequential oxidation to 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxycytosine, catalysed by enzymes of the Ten-Eleven Translocation family proteins (TETs 1, 2 and 3).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29190698"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 326,
          "text": "The recently discovered Ten-Eleven Translocation (TET) dioxygenases are accepted to be involved in DNA demethylation by initiating 5-mC oxidation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194590"
        },
        {
          "offsetInBeginSection": 87,
          "offsetInEndSection": 296,
          "text": "Ten-eleven translocation (TET) proteins are enzymes that oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and further oxidization products (oxi-mCs), which indirectly promote DNA demethylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408905"
        },
        {
          "offsetInBeginSection": 299,
          "offsetInEndSection": 447,
          "text": "Three Tet genes have been identified in mammals, and they all encode for proteins capable of oxidizing 5mC as part of the DNA demethylation process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24412366"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 414,
          "text": "Ten-eleven translocation (TET) family proteins (TETs), specifically, TET1, TET2 and TET3, can modify DNA by oxidizing 5-methylcytosine (5mC) iteratively to yield 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxycytosine (5caC), and then two of these intermediates (5fC and 5caC) can be excised and return to unmethylated cytosines by thymine-DNA glycosylase (TDG)-mediated base excision repair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37563110"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 221,
          "text": "TET (ten-eleven translocation) proteins, newly discovered demethylases, have sparked great interest since their discovery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26302812"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 415,
          "text": "Ten-eleven translocation family (TET3, TET1 and TET2), thymine DNA glycosylase (TDG) and DNA methyltransferase 1 (DNMT1) are considered the major protein enzymes of DNA demethylation in pre-implantation embryos.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31229544"
        },
        {
          "offsetInBeginSection": 981,
          "offsetInEndSection": 1214,
          "text": "In this mini-review, we provide an overview of the involvement of active DNA demethylation with an emphasis on the Tet family of enzymes and 5-hydroxymethylcytosine (5-hmC) in learning and memory, as well as in drug-seeking behavior.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26806038"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Active DNA demethylation via ten-eleven translocation (TET) family enzymes is essential for epigenetic reprogramming in cell state transitions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33352108"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 916,
          "text": "Here, we present a summary of how DNA demethylation can be initiated directly, utilizing the ten-eleven translocation (TET) family of proteins, activation-induced deaminase (AID), or other DNA modifying enzymes, or indirectly, via transcription, RNA metabolism, or DNA repair; how intermediates in those pathways are substrates of the DNA repair machinery; and how demethylation pathways are linked and possibly balanced, avoiding mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22974304"
        },
        {
          "offsetInBeginSection": 511,
          "offsetInEndSection": 656,
          "text": "Ten eleven translocation (TET) proteins are the key factors modulating DNA demethylation. This family contains three members: TET1, TET2 and TET3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33879920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Ten-eleven translocation (TET) family proteins are dioxygenases that oxidize 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine in DNA, early steps of active DNA demethylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099018"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 489,
          "text": "The recent discovery that the three members of the TET protein family can convert 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) has provided a potential mechanism leading to DNA demethylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22157888"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 370,
          "text": "The three members of the TET protein family, which convert 5mC to 5-hydroxymethylcytosine, has provided a potential mechanism resulting in DNA demethylation and maintaining cellular identity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24395347"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 377,
          "text": "Recently, a novel group of TET protein family enzymatically converting 5-methylcytosine into 5-hydroxymethylcytosine was discovered, playing a role in active DNA demethylation pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Ten-eleven translocation 1 (TET1) is a member of the TET enzyme family of dioxygenases, which plays an important role in active DNA demethylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37031472"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 450,
          "text": "Active DNA demethylation involves TET-mediated stepwise oxidation of mC to 5-hydroxymethylcytosine, 5-formylcytosine (fC), or 5-carboxylcytosine (caC), excision of fC or caC by thymine DNA glycosylase (TDG), and subsequent base excision repair",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31693361"
        }
      ],
      "id": "67eb822e18b1e36f2e0000f1",
      "ideal_answer": [
        "DNA methylation has a profound impact on genome stability, transcription, and development. Although enzymes that catalyze DNA methylation have been well characterized, those that are involved in methyl group removal have remained elusive, until recently. The transformative discovery that ten-eleven translocation (TET) family enzymes can oxidize 5-methylcytosine has greatly advanced our understanding of DNA demethylation. 5-Hydroxymethylcytosine is a key nexus in demethylation that can either be passively depleted through DNA replication or actively reverted to cytosine through iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair.",
        "The characteristic family of enzymes responsible for DNA demethylation is the **TET (Ten-Eleven Translocation)** protein family. These enzymes catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), and further to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). This process is a key step in active DNA demethylation, which can lead to the removal of methylation marks during DNA replication or through repair mechanisms. The TET family includes proteins such as TET1, TET2, and TET3, each playing distinct roles in regulating gene expression, epigenetic modifications, and cellular differentiation.",
        "The characteristic family of enzymes responsible for DNA demethylation is the TET family. TET enzymes are alpha-ketoglutarate–dependent dioxygenases that catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and then further to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). These oxidized cytosine derivatives can then be replaced by an unmethylated cytosine through base excision repair mechanisms. This enzymatic process is vital for regulating gene expression and plays a significant role in cellular differentiation and development.",
        "The transformative discovery that ten-eleven translocation (TET) family enzymes can oxidize 5-methylcytosine has greatly advanced our understanding of DNA demethylation. 5-Hydroxymethylcytosine is a key nexus in demethylation that can either be passively depleted through DNA replication or actively reverted to cytosine through iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair.",
        "Recent studies have shed light on the process of DNA demethylation, revealing that the ten-eleven translocation (TET) family enzymes play a crucial role in this process. These enzymes are responsible for oxidizing 5-methylcytosine, a key step in DNA demethylation. The TET family enzymes initiate the demethylation process, which can then proceed through either passive depletion via DNA replication or active reversion to cytosine through iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair. This discovery has greatly advanced our understanding of DNA demethylation, highlighting the importance of TET family enzymes in this critical process.",
        "The ten-eleven translocation (TET) family enzymes play a crucial role in DNA demethylation through their ability to oxidize 5-methylcytosine, leading to the formation of 5-hydroxymethylcytosine which can then be removed either passively through DNA replication or actively through further oxidation and TDG-mediated base excision repair.",
        "DNA demethylation involves the enzymatic oxidation of 5-methylcytosine, a process primarily mediated by the ten-eleven translocation (TET) family of enzymes. These enzymes catalyze the iterative oxidation of 5-methylcytosine to 5-hydroxymethylcytosine and further oxidized derivatives, facilitating active DNA demethylation through thymine DNA glycosylase (TDG)-mediated base excision repair. The discovery of TET enzymes has been pivotal in understanding dynamic DNA methylation regulation, linking their activity to genome stability, transcriptional control, and developmental processes.",
        "The ten-eleven translocation (TET) family of enzymes is responsible for initiating DNA demethylation by oxidizing 5-methylcytosine to 5-hydroxymethylcytosine. This oxidation step is critical for active DNA demethylation, either through replication-dependent dilution or iterative oxidation followed by thymine DNA glycosylase (TDG)-mediated base excision repair.",
        "The characteristic family of enzymes responsible for DNA demethylation is the ten‐eleven translocation (TET) family. These enzymes, including TET1, TET2, and TET3, catalyze the oxidation of 5-methylcytosine in DNA. They initiate active demethylation by converting 5-methylcytosine into 5-hydroxymethylcytosine and further oxidize it into 5-formylcytosine and 5-carboxylcytosine. These sequential oxidation steps create intermediates that are eventually processed—either by replication-dependent dilution or by thymine DNA glycosylase-mediated base excision repair—to restore unmodified cytosine.",
        "The characteristic family of enzymes responsible for initiating DNA demethylation is the Ten-Eleven Translocation (TET) enzyme family. These enzymes oxidize 5-methylcytosine (5mC) into intermediates such as 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). This oxidation disrupts the methylation pattern, allowing thymine DNA glycosylase (TDG) to remove these modified bases. The resulting gaps are filled by DNA repair mechanisms with unmodified cytosines, effectively removing the methyl groups and restoring the original DNA sequence. TET enzymes play a crucial role in epigenetic regulation, enabling proper gene expression and development.",
        "The TET family enzymes are a characteristic family of enzymes responsible for DNA demethylation. These enzymes can oxidize 5-methylcytosine, a key intermediate in the demethylation process, to 5-hydroxymethylcytosine. This intermediate can either be passively depleted through DNA replication or actively reverted to cytosine through iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair.",
        "The Ten-Eleven Translocation (TET) enzyme family plays a pivotal role in DNA demethylation. These enzymes oxidize 5-methylcytosine (5mC) into intermediates such as 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). This oxidation disrupts the methylation pattern, allowing thymine DNA glycosylase (TDG) to remove these modified bases. The resulting gaps are repaired by DNA repair mechanisms, restoring unmodified cytosines and effectively removing methyl groups. Thus, TET enzymes are central to initiating the demethylation process, ensuring proper gene regulation and genomic stability.",
        "The ten-eleven translocation (TET) family of enzymes is responsible for DNA demethylation by oxidizing 5-methylcytosine, which can then be either passively depleted through DNA replication or actively reverted to cytosine through iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair.",
        "A characteristic family of enzymes responsible for DNA demethylation is the ten-eleven translocation (TET) family. These enzymes have been identified as capable of oxidizing 5-methylcytosine, a crucial step in the process of DNA demethylation. The oxidation product, 5-hydroxymethylcytosine, serves as an important intermediate that can be passively diluted during DNA replication or actively converted back to cytosine through further oxidation and base excision repair mediated by thymine DNA glycosylase (TDG).",
        "DNA demethylation is a crucial process in regulating genome stability, transcription, and development. The ten-eleven translocation (TET) family of enzymes plays a pivotal role in this process. These enzymes oxidize 5-methylcytosine to produce 5-hydroxymethylcytosine, a key intermediate in DNA demethylation. This modification can then be passively removed during DNA replication or actively converted back to cytosine through a series of oxidative steps followed by thymine DNA glycosylase (TDG)-mediated base excision repair. The discovery of TET enzymes has greatly enhanced our understanding of the dynamic nature of DNA methylation and demethylation.",
        "The characteristic family of enzymes responsible for DNA demethylation is the Ten-Eleven Translocation (TET) family. These enzymes catalyze the process by oxidizing 5-methylcytosine, resulting in the formation of 5-hydroxymethylcytosine. This intermediate is then either passively depleted during DNA replication or actively converted back to cytosine via iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair, highlighting the TET family\u0027s pivotal role in DNA demethylation.",
        "The TET (ten-eleven translocation) family of enzymes is characterized as being responsible for DNA demethylation. These enzymes catalyze the oxidation of 5-methylcytosine, which is a critical step in the DNA demethylation process. This oxidation produces 5-hydroxymethylcytosine, which can then either be passively depleted through DNA replication or actively reverted to cytosine through further oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair.",
        "The TET (ten-eleven translocation) family of enzymes plays a crucial role in DNA demethylation by oxidizing 5-methylcytosine, a key step in the process. This oxidation results in the formation of 5-hydroxymethylcytosine, which can be either passively depleted during DNA replication or actively reverted back to cytosine through iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair. These enzymes have significantly advanced our understanding of how methyl groups are removed from DNA.",
        "Studies have shown that the ten-eleven translocation (TET) family of enzymes plays a crucial role in DNA demethylation by oxidizing 5-methylcytosine. This process initiates the conversion of 5-methylcytosine into 5-hydroxymethylcytosine, which can then either be passively depleted through DNA replication or actively reverted to cytosine via iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair.",
        "The TET family of enzymes is a characteristic group responsible for DNA demethylation. They oxidize 5-methylcytosine to form 5-hydroxymethylcytosine, which can either be passively depleted through DNA replication or actively reverted to cytosine via base excision repair mediated by thymine DNA glycosylase (TDG)."
      ],
      "exact_answer": [
        [
          "Ten-eleven translocation (TET) family enzymes",
          "TET enzymes",
          "ten-eleven translocation",
          "Ten-eleven translocation (Tet) proteins",
          "TET1/2/3",
          "TETs 1, 2 and 3",
          "ten-eleven translocation (TET) family of enzymes",
          "TET"
        ]
      ]
    },
    {
      "body": "Is MAP3K15 associated with obesity?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36383675"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Human genetics uncovers MAP3K15 as an obesity-independent therapeutic target for diabetes.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36383675"
        }
      ],
      "id": "67df18f518b1e36f2e000064",
      "ideal_answer": [
        "No. Human genetics uncovered MAP3K15 as an obesity-independent therapeutic target for diabetes.",
        "No, MAP3K15 is not associated with obesity.",
        "No. MAP3K15 is associated with diabetes and insulin resistance but not with obesity.",
        "No, MAP3K15 is not associated with obesity, but it is associated with diabetes and may serve as a therapeutic target for the condition.",
        "No. MAP3K15 is not associated with obesity.",
        "No, MAP3K15 is not associated with obesity; it is identified as an obesity-independent therapeutic target for diabetes.",
        "No. MAP3K15 is identified as an obesity-independent therapeutic target for diabetes, indicating its association with diabetes is distinct from obesity-related mechanisms.",
        "No, MAP3K15 is not associated with obesity. It is an obesity‐independent therapeutic target for diabetes, meaning its effect on the disease is not mediated by body weight or fat distribution.",
        "No, MAP3K15 is not directly associated with obesity. It is identified as an obesity-independent therapeutic target for diabetes.",
        "No, MAP3K15 is not directly linked to obesity. It\u0027s more about its role in treating diabetes independently of weight factors.",
        "No. The evidence suggests that MAP3K15 variants are associated with decreased odds of diabetes, independent of obesity, indicating it is not directly associated with obesity itself.",
        "No. The evidence suggests that MAP3K15 variants are associated with decreased odds of diabetes, independent of obesity, but does not indicate a direct association with obesity itself.",
        "No. The evidence suggests that MAP3K15 variants are associated with decreased odds of diabetes, independent of obesity, but does not establish a direct association with obesity itself.",
        "No, MAP3K15 is identified as an obesity-independent therapeutic target for diabetes.",
        "No, MAP3K15 is an obesity-independent therapeutic target for diabetes, meaning it is not associated with obesity.",
        "No, MAP3K15 is identified as an obesity-independent therapeutic target for diabetes, indicating it is not associated with obesity."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What is the mechanism of action of Remibrutinib?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38141832",
        "http://www.ncbi.nlm.nih.gov/pubmed/38492772",
        "http://www.ncbi.nlm.nih.gov/pubmed/37932009",
        "http://www.ncbi.nlm.nih.gov/pubmed/37866460",
        "http://www.ncbi.nlm.nih.gov/pubmed/39598410",
        "http://www.ncbi.nlm.nih.gov/pubmed/37633912",
        "http://www.ncbi.nlm.nih.gov/pubmed/36178589",
        "http://www.ncbi.nlm.nih.gov/pubmed/36096203",
        "http://www.ncbi.nlm.nih.gov/pubmed/35493759",
        "http://www.ncbi.nlm.nih.gov/pubmed/33834628",
        "http://www.ncbi.nlm.nih.gov/pubmed/32401033",
        "http://www.ncbi.nlm.nih.gov/pubmed/32083858",
        "http://www.ncbi.nlm.nih.gov/pubmed/35247543",
        "http://www.ncbi.nlm.nih.gov/pubmed/34432364",
        "http://www.ncbi.nlm.nih.gov/pubmed/33806595",
        "http://www.ncbi.nlm.nih.gov/pubmed/36973953",
        "http://www.ncbi.nlm.nih.gov/pubmed/35667749"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1409,
          "offsetInEndSection": 1788,
          "text": "In phase 2 trials, the BTK inhibitors remibrutinib and fenebrutinib have demonstrated rapid and sustained improvements in CSU disease activity. With phase 3 studies of remibrutinib ongoing, it is hoped that BTK inhibitors will present an effective, well-tolerated option for patients with antihistamine-refractory CSU, a phenotype that presents a considerable clinical challenge.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141832"
        },
        {
          "offsetInBeginSection": 1032,
          "offsetInEndSection": 1198,
          "text": "In addition, next-generation BTKis including remibrutinib effectively reduce disease activity in patients with antihistamine-refractory chronic spontaneous urticaria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38492772"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren\u0027s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37932009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "BACKGROUND: Remibrutinib (LOU064), an oral, highly selective Bruton tyrosine kinase inhibitor, offers fast disease control in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with second-generation H1 antihistamines. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37866460"
        },
        {
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1054,
          "text": "Among them, significant attention is being given to drugs that block Bruton\u0027s tyrosine kinase (BTK), such as remibrutinib, which reduces mast cell activation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39598410"
        },
        {
          "offsetInBeginSection": 1512,
          "offsetInEndSection": 1840,
          "text": "We furthermore summarize all mechanistic, preclinical, and clinical data on the various BTK inhibitors (evobrutinib, tolebrutinib, fenebrutinib, remibrutinib, orelabrutinib, BIIB091) that are currently in development for treatment of MS, with a particular focus on the potential ability of either drug to control MS progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36178589"
        },
        {
          "offsetInBeginSection": 823,
          "offsetInEndSection": 979,
          "text": "Assorted clinical trials are underway to assess the safety, tolerability, and pharmacokinetics of distinct BTK inhibitors, including PRN473 and remibrutinib",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35493759"
        },
        {
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1052,
          "text": "Among them, significant attention is being given to drugs that block Bruton\u0027s tyrosine kinase (BTK), such as remibrutinib, which reduces mast cell activation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39598410"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 224,
          "text": "ty of life. Remibrutinib, a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor, might ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36096203"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "BACKGROUND: Remibrutinib (LOU064), an oral, highly selective Bruton tyrosine kinase inhibitor, offers fast disease control",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37866460"
        },
        {
          "offsetInBeginSection": 238,
          "offsetInEndSection": 570,
          "text": "Remibrutinib (LOU064) is a potent, highly selective covalent BTKi with a promising preclinical and clinical profile for MS and other autoimmune or autoallergic indications.METHODS: The efficacy and mechanism of action of remibrutinib was assessed in two different experimental autoimmune encephalomyelitis (EAE) mouse models for MS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37633912"
        },
        {
          "offsetInBeginSection": 129,
          "offsetInEndSection": 685,
          "text": "Remibrutinib, a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor, might be effective in CSU.OBJECTIVE: This first-in-patient trial aimed to evaluate the efficacy and safety of remibrutinib in CSU treatment and characterize the dose-response.METHODS: This randomized, double-blind, placebo-controlled, phase 2b dose-finding trial evaluated remibrutinib (12 weeks) in patients inadequately controlled with second-generation H1-antihistamines, with at least moderately active CSU, with or without prior anti-IgE treatment (NCT03926611).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36096203"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 752,
          "text": "New strategies under development include blocking intracellular mediators of mast cell and basophil activation.OBJECTIVE: We aim to investigate the effects of the Bruton\u0027s tyrosine kinase (BTK) inhibitor remibrutinib on human blood basophils and CD34+ -derived mast cells activation induced by serum obtained from chronic urticaria patients.METHODS: Twenty-two patients with chronic spontaneous urticaria (mean age 52 years, 27% women) and 22 patients with chronic inducible urticaria (46 years, 27% women) were included in the study together with a sex-matched control group.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36973953"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 382,
          "text": "Remibrutinib (LOU064) is a novel covalent BTK inhibitor that binds an inactive BTK conformation, which affords it unprecedented selectivity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32401033"
        },
        {
          "offsetInBeginSection": 482,
          "offsetInEndSection": 1027,
          "text": "Remibrutinib is a covalent inhibitor of Bruton\u0027s Tyrosine kinase (BTKi) carrying a reactive acrylamide moiety (warhead), thus the potential contribution of covalent binding (off-target) to observed interactions was investigated as this could lead to prolonged and more potent drug interactions.METHODS: DDI assessment was focused on the putative inhibition of key metabolic enzymes (Cytochrome P450, CYP), drug transporters and a potential effect on oral contraceptives (OC) by induction of enzymes that are involved in their clearance (CYP3A4).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35247543"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 491,
          "text": "Remibrutinib (LOU064) is a novel covalent BTK inhibitor that binds an inactive BTK conformation, which affords it unprecedented selectivity. Its optimization led to rapid BTK engagement in vivo and fast clearance, further limiting systemic exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32401033"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 398,
          "text": "rosis (MS). Remibrutinib (LOU064) is a potent, highly selective covalent BTKi with a promising preclinical and clinical profile for MS and other autoimmune or autoallergic ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37633912"
        },
        {
          "offsetInBeginSection": 1405,
          "offsetInEndSection": 1548,
          "text": "SU. In phase 2 trials, the BTK inhibitors remibrutinib and fenebrutinib have demonstrated rapid and sustained improvements in CSU disease activ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141832"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 232,
          "text": "ty of life. Remibrutinib, a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor, might be effec",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36096203"
        },
        {
          "offsetInBeginSection": 131,
          "offsetInEndSection": 297,
          "text": "Here, we investigate the human pharmacokinetics, pharmacodynamics (PDs), and safety of the selective, covalent Bruton\u0027s tyrosine kinase (BTK) inhibitor, remibrutinib.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33834628"
        },
        {
          "offsetInBeginSection": 131,
          "offsetInEndSection": 296,
          "text": "Here, we investigate the human pharmacokinetics, pharmacodynamics (PDs), and safety of the selective, covalent Bruton\u0027s tyrosine kinase (BTK) inhibitor, remibrutinib",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33834628"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 397,
          "text": "rosis (MS). Remibrutinib (LOU064) is a potent, highly selective covalent BTKi with a promising preclinical and clinical profile for MS and other autoimmune or autoallergic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37633912"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "BACKGROUND: Remibrutinib (LOU064), an oral, highly selective Bruton tyrosine kinase inhibitor, offers fast disease control in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with second-generation H1 ant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37866460"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Remibrutinib, a novel oral Bruton\u0027s Tyrosine Kinase inhibitor (BTKi) is highly selective for BTK, potentially mitigating the side effects of other BTKis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34432364"
        },
        {
          "offsetInBeginSection": 1409,
          "offsetInEndSection": 1552,
          "text": "In phase 2 trials, the BTK inhibitors remibrutinib and fenebrutinib have demonstrated rapid and sustained improvements in CSU disease activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141832"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 243,
          "text": " Remibrutinib, a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor, might be effective in CSU",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36096203"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 257,
          "text": " Remibrutinib (LOU064), an oral, highly selective Bruton tyrosine kinase inhibitor, offers fast disease control in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with second-generation H1 antihistamines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37866460"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33834628"
        },
        {
          "offsetInBeginSection": 473,
          "offsetInEndSection": 767,
          "text": "results. Remibrutinib is a covalent inhibitor of Bruton\u0027s Tyrosine kinase (BTKi) carrying a reactive acrylamide moiety (warhead), thus the potential contribution of covalent binding (off-target) to observed interactions was investigated as this could lead to prolonged and more potent drug inte",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35247543"
        },
        {
          "offsetInBeginSection": 304,
          "offsetInEndSection": 434,
          "text": "We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32083858"
        },
        {
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1139,
          "text": "Remibrutinib, a novel highly selective covalent BTKi, is currently in clinical studies of autoimmune dermatological disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806595"
        },
        {
          "offsetInBeginSection": 1137,
          "offsetInEndSection": 1203,
          "text": "fenebrutinib and remibrutinib, Bruton\u0027s tyrosine kinase inhibitors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35667749"
        }
      ],
      "type": "summary",
      "id": "67e69d2718b1e36f2e0000b6",
      "ideal_answer": [
        "Remibrutinib is an oral, highly selective Bruton tyrosine kinase (BTK) inhibitor that offers fast disease control in patients with chronic spontaneous urticaria."
      ]
    },
    {
      "_body": "Please summarize pendulluft.",
      "_type": "summary",
      "body": "Please summarize pendelluft.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30871304",
        "http://www.ncbi.nlm.nih.gov/pubmed/36556064",
        "http://www.ncbi.nlm.nih.gov/pubmed/32900913",
        "http://www.ncbi.nlm.nih.gov/pubmed/32266600",
        "http://www.ncbi.nlm.nih.gov/pubmed/33178748",
        "http://www.ncbi.nlm.nih.gov/pubmed/24199628",
        "http://www.ncbi.nlm.nih.gov/pubmed/35246748",
        "http://www.ncbi.nlm.nih.gov/pubmed/38117367",
        "http://www.ncbi.nlm.nih.gov/pubmed/38092775",
        "http://www.ncbi.nlm.nih.gov/pubmed/27002273",
        "http://www.ncbi.nlm.nih.gov/pubmed/37007559",
        "http://www.ncbi.nlm.nih.gov/pubmed/36938357",
        "http://www.ncbi.nlm.nih.gov/pubmed/27408729",
        "http://www.ncbi.nlm.nih.gov/pubmed/39322000"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 732,
          "offsetInEndSection": 862,
          "text": "an intra-tidal shift of gas between different lung zones, generated by different transmission of muscular force (i.e. pendelluft);",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30871304"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 554,
          "text": " Increased lung stress and pendelluft, which is defined as intrapulmonary gas redistribution without a significant change in tidal volume, are important mechanisms of patient self-inflicted lung injury. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36556064"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "BACKGROUND: Pendelluft phenomenon is defined as the displacement of gas from a more recruited nondependent (ND) lung region to a less recruited dependent (D) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32900913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "BACKGROUND: Pendelluft, the movement of gas within different lung regions, is present in animal models of assisted mechanical ventilation and associated with lung ove",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32266600"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "BACKGROUND: Pendelluft, defined as asynchronous alveolar ventilation, is caused by different regional time constants or dynamic pleural pressure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178748"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 400,
          "text": "l surface. However, in a patient with injured lungs, we observed (using electrical impedance tomography) a pendelluft phenomenon (movement of air within the lung from nondependent to dependent regions without change in tidal volume) that was caused by spontaneous breathing during mechanical v",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24199628"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 169,
          "text": "Pendelluft phenomenon is defined as the displacement of gas from a more recruited nondependent (ND) lung region to a less recruited dependent (D) lung region",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32900913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Pendelluft, the shift of air from non-dependent to dependent lung regions, is known to occur during active breathing in ventilated patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38092775"
        },
        {
          "offsetInBeginSection": 290,
          "offsetInEndSection": 423,
          "text": "Pendelluft is an intrapulmonary air redistribution in areas with different time constants and this phenomenon is largely unobservable",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37007559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Pendelluft, the shift of air from non-dependent to dependent lung regions, is known to occur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38092775"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "BACKGROUND: Pendelluft, the movement of gas within different lung regions, is present in animal models of assisted mechanical",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32266600"
        },
        {
          "offsetInBeginSection": 378,
          "offsetInEndSection": 580,
          "text": "pendelluft, which is defined as intrapulmonary gas redistribution without a significant change in tidal volume, are important mechanisms of patient self-inflicted lung injury. The presence of pendelluft",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36556064"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "BACKGROUND: Internal redistribution of gas, referred to as pendelluft, is a new potential mechanism of effort-dependent ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38117367"
        },
        {
          "offsetInBeginSection": 831,
          "offsetInEndSection": 1117,
          "text": "The \u0027dark side\u0027 refers to uncontrollable transpulmonary pressure due to combined high inspiratory pressure with excessive spontaneous effort and the injurious lung inflation pattern of Pendelluft (i.e., the translocation of air from nondependent lung regions to dependent lung regions).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27408729"
        },
        {
          "offsetInBeginSection": 728,
          "offsetInEndSection": 862,
          "text": "(C) an intra-tidal shift of gas between different lung zones, generated by different transmission of muscular force (i.e. pendelluft);",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30871304"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "BACKGROUND: Internal redistribution of gas, referred to as pendelluft, is a new potential mechanism of effort-dependent lung injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38117367"
        },
        {
          "offsetInBeginSection": 732,
          "offsetInEndSection": 1033,
          "text": "We assessed pendelluft (the percentage of lost volume from the non-dependent lung region displaced to the dependent region during inspiration), drive (as the delta esophageal swing of the first 100 ms [ΔPes 100 ms]) and inspiratory effort (as the esophageal pressure-time product per minute [PTPmin]).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38117367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "BACKGROUND: Pendelluft phenomenon is defined as the displacement of gas from a more recruited nondependent (ND) lung region to a less recruited dependent (D) lung region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32900913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "OBJECTIVES: We recently described how spontaneous effort during mechanical ventilation can cause \"pendelluft,\" that is, displacement of gas from nondependent (more recruited) lung to dependent (less recruited) lung during early inspiration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002273"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 286,
          "text": " Pendelluft, defined as asynchronous alveolar ventilation, is caused by different regional time constants or dynamic pleural pressure variations. The aim of the present study was to propose a simple method to evaluate pendelluft based on electrical impedance tomography (EIT)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178748"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 317,
          "text": "Pendelluft is the movement of air between lung regions, and electrical impedance tomography (EIT) has shown an ability to detect and monitor it.Approach.In this note, we propose a functional EIT measure which quantifies the reverse airflow seen in pendelluft: theFraction of Reverse Impedance Change(FRIC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39322000"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 345,
          "text": " Pendelluft, the movement of gas within different lung regions, is present in animal models of assisted mechanical ventilation and associated with lung overstretching. Due to rebreathing of CO2 as compared to fresh gas, pendelluft might reduce ventilatory efficiency possibly exacerbating patient\u0027s respiratory workload during weaning",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32266600"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "BACKGROUND: Respiratory pendelluft phenomenon, defined as intrapulmonary gas redistribution caused by asynchronous alveolar ventilation, could be potentially harmful by inducing ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35246748"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 155,
          "text": "Pendelluft is the movement of air between lung regions, and electrical impedance tomography (EIT) has shown an ability to detect and monitor it.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39322000"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 329,
          "text": "Pendelluft is the movement of air between lung regions, and electrical impedance tomography (EIT) has shown an ability to detect and monitor it.Approach.In this note, we propose a functional EIT measure which quantifies the reverse airflow seen in pendelluft: theFraction of Reverse Impedance Change(FRIC).MainResults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39322000"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "BACKGROUND: Respiratory pendelluft phenomenon, defined as intrapulmonary gas redistribution caused by asynchronous alveolar ventilation, could be potentially harmful by inducing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35246748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "BACKGROUND: Pendelluft, defined as asynchronous alveolar ventilation, is caused by different regional time constants or dynamic pleural pressur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33178748"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 399,
          "text": "l surface. However, in a patient with injured lungs, we observed (using electrical impedance tomography) a pendelluft phenomenon (movement of air within the lung from nondependent to dependent regions without change in tidal volume) that was caused by spontaneous breathing during mechanical ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24199628"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Pendelluft, the shift of air from non-dependent to dependent lung regions, is known to occur during active breathing in ventilated patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38092775"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "OBJECTIVES: We recently described how spontaneous effort during mechanical ventilation can cause \"pendelluft,\" that is, displacement of gas from nondependent (more recruited) lung to dependent (less recruited) lung during early ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002273"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 500,
          "text": " We recently described how spontaneous effort during mechanical ventilation can cause \"pendelluft,\" that is, displacement of gas from nondependent (more recruited) lung to dependent (less recruited) lung during early inspiration. Such transfer depends on the coexistence of more recruited (source) liquid-like lung regions together with less recruited (target) solid-like lung regions. Pendelluft may improve gas exchange, but because of tidal recruitment, it may also contribute to injury",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002273"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 317,
          "text": "Asynchronous alveolar ventilation is called pendelluft, which may induce lung injury in spontaneously breathing patients. We report a case that electrical impedance tomography (EIT) was used to assess the pendelluft in a post-thoracoscopy patient. The pendelluft amplitude was as high as 77.5% of the tidal variation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36938357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "BACKGROUND: Pendelluft, the movement of gas within different lung regions, is present in animal models of assisted mechanical ventilation and associated with lung overstretching. Due to rebreathing of CO2 as co",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32266600"
        }
      ],
      "type": "summary",
      "id": "67e1359918b1e36f2e000071",
      "ideal_answer": [
        "Pendelluft describes a phenomenon where air moves from one lung region to another, rather than uniformly distributing throughout the lungs, which can lead to uneven ventilation.",
        "Pendelluft is defined as intrapulmonary gas redistribution without a significant change in tidal volume. It is considered a surrogate marker of vigorous inspiratory effort, which can cause the dependent lung to overstretch and potentially aggravate lung injury in patients with acute respiratory distress syndrome (ARDS).",
        "Pendelluft phenomenon is defined as the displacement of gas from a more recruited nondependent (ND) lung region to a less recruited dependent (D) lung region.",
        "Pendelluft is a phenomenon where gas is displaced from a more recruited nondependent lung region to a less recruited dependent lung region.",
        "Pendelluft is a phenomenon where gas is displaced from a more recruited nondependent lung region to a less recruited dependent lung region, resulting in differential ventilation within the lungs. This can occur during breathing cycles in conditions such as uneven lung compliance or ventilation-perfusion mismatch, potentially affecting respiratory efficiency.",
        "Pendelluft is a phenomenon in respiratory physiology where air moves between different lung regions during the breathing cycle, often due to differences in airway resistance or lung compliance.",
        "pendelluft is the movement of air between lung regions, specifically from a more recruited nondependent lung region to a less recruited dependent lung region, which can occur due to different regional time constants or dynamic pleural pressure variations, and can be detected and monitored using electrical impedance tomography (eit).",
        "Pendelluft is the displacement of gas from nondependent to dependent lung regions during early inspiration, associated with respiratory drive and inspiratory effort.",
        "Pendelluft is the movement of air between different regions of the lungs without a significant change in tidal volume. It occurs when gas is displaced from more recruited, nondependent lung areas to less recruited, dependent areas during inspiration, often due to spontaneous breathing efforts during mechanical ventilation.",
        "Pendelluft is an intrapulmonary phenomenon where air shifts between lung regions due to asynchronous ventilation, often exacerbated by mechanical ventilation settings or lung pathologies, which can improve gas exchange but also pose a risk of lung injury.",
        "Pendelluft is the movement of air within the lung from nondependent to dependent regions without a change in tidal volume, often occurring during mechanical ventilation or spontaneous breathing, and can lead to inefficient ventilation and potential lung injury.",
        "Pendelluft phenomenon is defined as the displacement of gas from a more recruited nondependent lung region to a less recruited dependent lung region. Exact answer:",
        "Pendelluft is defined as intrapulmonary gas redistribution without a significant change in tidal volume.",
        "Pendelluft is a physiological phenomenon characterized by the redistribution of gas within the lungs without significant changes in tidal volume, occurring due to differences in how muscular force is transmitted between different lung zones. This mechanism has been identified as a significant contributor to patient self-inflicted lung injury.",
        "Increased lung stress and pendelluft, which is defined as intrapulmonary gas redistribution without a significant change in tidal volume, are important mechanisms of patient self-inflicted lung injury.",
        "Pendelluft refers to the movement of gas between different lung zones during breathing, caused by uneven transmission of muscular force, resulting in intrapulmonary gas redistribution without a significant change in tidal volume.",
        "Pendelluft is the redistribution of gas between lung regions during breathing without significant changes in tidal volume, due to differences in how muscular force is transmitted. This intra-tidal shift can increase lung stress and contribute to patient self-inflicted lung injury.",
        "pendelluft is defined as intrapulmonary gas redistribution without a significant change in tidal volume, which is an important mechanism of patient self-inflicted lung injury.",
        "Pendelluft is the redistribution of gas within the lungs caused by different transmission of muscular force, resulting in an intra-tidal shift between lung zones without significantly changing tidal volume. This mechanism can lead to increased lung stress and contribute to patient self-inflicted lung injury.",
        "Pendelluft is a mechanism of intrapulmonary gas redistribution without a significant change in tidal volume, caused by different transmission of muscular force in different lung zones. It is an important mechanism of patient self-inflicted lung injury due to increased lung stress.",
        "Pendelluft is defined as intrapulmonary gas redistribution without a significant change in tidal volume. It involves an intra-tidal shift of gas between different lung zones due to different transmission of muscular force.",
        "Pendelluft refers to the intra-tidal redistribution of gas within different lung zones during breathing. This phenomenon occurs due to uneven transmission of muscular force across the lungs, leading to gas shifting without a significant change in tidal volume. It is associated with increased lung stress and can contribute to patient self-inflicted lung injury.",
        "Pendelluft refers to the phenomenon where there is an intra-tidal shift of gas between different lung zones without a significant change in tidal volume. This occurs due to uneven transmission of muscular force across the lungs, leading to intrapulmonary gas redistribution.",
        "Pendelluft is a phenomenon of intra-tidal, intrapulmonary gas redistribution between different lung zones, caused by the differential transmission of muscular force. Notably, this process occurs without a significant change in tidal volume. It is associated with increased lung stress and is recognized as a mechanism contributing to patient self-inflicted lung injury.",
        "Pendelluft phenomenon is defined as the displacement of gas from a more recruited nondependent lung region to a less recruited dependent lung region.",
        "Pendelluft is defined as intrapulmonary gas redistribution without a significant change in tidal volume. It is an intra-tidal shift of gas between different lung zones, generated by different transmission of muscular force.",
        "Pendelluft is an intra-tidal shift of gas between different lung zones, generated by different transmission of muscular force. Pendelluft is an important mechanism of patient self-inflicted lung injury.",
        "Pendelluft refers to an intra-tidal shift of gas within different lung zones caused by variations in muscular force transmission during breathing. This phenomenon results in increased lung stress without significant changes in tidal volume, contributing to patient self-inflicted lung injury through repetitive strain on lung tissues.",
        "Pendelluft is defined as the intrapulmonary redistribution of gas between different lung zones without a significant change in tidal volume. This phenomenon occurs due to varying transmission of muscular force across the lung regions.",
        "Pendelluft refers to an intra-tidal shift of gas between different lung zones caused by varying transmission of muscular force. This phenomenon occurs without significant changes in tidal volume but leads to increased lung stress. Studies have identified pendelluft as a key mechanism contributing to patient self-inflicted lung injury, emphasizing its role in ventilator-induced lung damage.",
        "Pendelluft is an intra-tidal shift of gas between different lung zones, generated by different transmission of muscular force. Pendelluft is intrapulmonary gas redistribution without a significant change in tidal volume. Increased lung stress and pendelluft are important mechanisms of patient self-inflicted lung injury.",
        "Pendelluft is an intra-tidal gas shift between lung zones, caused by uneven muscular force transmission, characterized by intrapulmonary gas redistribution without altering tidal volume, and is a mechanism in patient self-inflicted lung injury.",
        "pendelluft is defined as intrapulmonary gas redistribution without a significant change in tidal volume, are important mechanisms of patient self-inflicted lung injury. an intra-tidal shift of gas between different lung zones, generated by different transmission of muscular force (i.e. pendelluft);",
        "Pendelluft is an intra-tidal shift of gas between different lung zones, generated by different transmission of muscular force. It is defined as intrapulmonary gas redistribution without a significant change in tidal volume. Increased lung stress and pendelluft are important mechanisms of patient self-inflicted lung injury.",
        "Pendelluft refers to the redistribution of gas within the lungs without a significant change in tidal volume. It is an intra-tidal shift of gas between different lung zones, generated by different transmission of muscular force. Pendelluft is one of the mechanisms of patient self-inflicted lung injury and is associated with increased lung stress. In the context of high-frequency oscillatory ventilation (HFOV), pendelluft is one of the gas transport mechanisms.",
        "Pendelluft is an intra-tidal shift of gas between different lung zones caused by uneven transmission of muscular force, leading to intrapulmonary gas redistribution without a significant change in tidal volume and contributing to patient self-inflicted lung injury.",
        "Pendelluft refers to the phenomenon where air moves between different parts of the lung during the breathing cycle, rather than moving directly in and out of the lungs. This can occur due to differences in regional lung compliance and airway resistance."
      ]
    },
    {
      "body": "Complications of elective abortion.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39692698",
        "http://www.ncbi.nlm.nih.gov/pubmed/37528652",
        "http://www.ncbi.nlm.nih.gov/pubmed/840464",
        "http://www.ncbi.nlm.nih.gov/pubmed/22883713",
        "http://www.ncbi.nlm.nih.gov/pubmed/683649",
        "http://www.ncbi.nlm.nih.gov/pubmed/10658435",
        "http://www.ncbi.nlm.nih.gov/pubmed/23735847",
        "http://www.ncbi.nlm.nih.gov/pubmed/11073784",
        "http://www.ncbi.nlm.nih.gov/pubmed/2651693",
        "http://www.ncbi.nlm.nih.gov/pubmed/36409940",
        "http://www.ncbi.nlm.nih.gov/pubmed/2364550",
        "http://www.ncbi.nlm.nih.gov/pubmed/21841331",
        "http://www.ncbi.nlm.nih.gov/pubmed/28618886",
        "http://www.ncbi.nlm.nih.gov/pubmed/9433966",
        "http://www.ncbi.nlm.nih.gov/pubmed/28648167",
        "http://www.ncbi.nlm.nih.gov/pubmed/24183279",
        "http://www.ncbi.nlm.nih.gov/pubmed/30402530",
        "http://www.ncbi.nlm.nih.gov/pubmed/28819516",
        "http://www.ncbi.nlm.nih.gov/pubmed/39469596",
        "http://www.ncbi.nlm.nih.gov/pubmed/7778798",
        "http://www.ncbi.nlm.nih.gov/pubmed/1362187",
        "http://www.ncbi.nlm.nih.gov/pubmed/927753",
        "http://www.ncbi.nlm.nih.gov/pubmed/2225607"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 1211,
          "offsetInEndSection": 1411,
          "text": "incomplete termination of pregnancy, with delayed or excessive bleeding, incomplete termination of pregnancy for other unspecified reasons, the need for evacuation of uterus due to incomplete abortion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39692698"
        },
        {
          "offsetInBeginSection": 1237,
          "offsetInEndSection": 1330,
          "text": "Haemorrhage requiring transfusion, pain requiring hospital treatment and suspected infection ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37528652"
        },
        {
          "offsetInBeginSection": 221,
          "offsetInEndSection": 330,
          "text": "The most common of these were incomplete evacuation, excessive postabortal bleeding, and uterine perforation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/840464"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 331,
          "text": "The pieces of bone, retained in utero for 8 years after an elective abortion, were unexpectedly discovered after total hysterectomy with adnexectomy performed for bilateral pyosalpinx, persistent vaginal discharge and severe pelvic pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2364550"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 529,
          "text": "Elective abortion complicated by bilateral renal cortical necrosis (BRCN) is not common in a developed country. We reported a patient having anuric acute renal failure after elective abortion. Initial laboratory studies implied thrombotic thrombocytopenic purpura/Hemolytic uremic syndrome, but plasma exchange was not prescribed since magnetic resonance imaging study suggested BRCN soon after. The patient was treated as septic abortion and reached partial renal recovery after antibiotic treatment and short-term hemodialysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21841331"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Incarcerated small bowel associated with elective abortion uterine perforation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22883713"
        },
        {
          "offsetInBeginSection": 363,
          "offsetInEndSection": 566,
          "text": " We report the case of a patient who presented after a second-trimester elective abortion and was found to have suffered uterine perforation with mesenteric and bowel injury that required bowel resection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10658435"
        },
        {
          "offsetInBeginSection": 694,
          "offsetInEndSection": 1036,
          "text": "s is a case of a 28-year-old pregnant woman of approximately 20 weeks gestation, who presented with severe muscular weakness and respiratory failure requiring intubation. She was subsequently found to have hyperkalemic paralysis from digoxin toxicity after an extraplacental injection during the first step of a two-part elective abortion.CON",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735847"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 289,
          "text": "We report 2 cases of GBS meningitis complicating elective abortion, 1 of which was a septic incomplete abortion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11073784"
        },
        {
          "offsetInBeginSection": 25,
          "offsetInEndSection": 253,
          "text": "many women experience long-term emotional, spiritual, psychological and interpersonal difficulties following abortion, including complicated grief, depression, post-traumatic stress disorder (PTSD) and relationship disturbances.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28618886"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Pelvic infection complicates up to 12% of induced abortions and has an adverse effect on future reproductive outcome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9433966"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "A 41-year-old woman developed cardiac arrest after administration of misoprostol in order to induce an abortion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28648167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Surgical termination of pregnancy is one of the most often performed gynecologic procedures in the United Kingdom and worldwide. Although complications are rare, they can be devastating because they include hemorrhage and pelvic organ damage often necessitating hysterectomy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183279"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 215,
          "text": "Uterine perforation is a rare complication, accounting for4% of all the abortion related complications",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30402530"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Uterine perforation is an uncommon yet serious complication of surgical management of first and second trimester termination of pregnancies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28819516"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 335,
          "text": "Although its use is widespread, the potential teratogenic effects of misoprostol in cases of failed medical abortion have not been sufficiently explored in the medical literature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39469596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Infection is the main complication after voluntary termination of pregnancy through vacuum aspiration, with an infection rate of 3.6% in the subsequent three weeks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7778798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Although estimates vary, many women experience long-term emotional, spiritual, psychological and interpersonal difficulties following abortion, including complicated grief, depression, post-traumatic stress disorder (PTSD) and relationship disturbances.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28618886"
        },
        {
          "offsetInBeginSection": 238,
          "offsetInEndSection": 429,
          "text": "Teenagers, because of their physical and psychological immaturity and also because of their social environment, seem to suffer with undue frequency from the complications of induced abortion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1362187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "A rare case of ureterouterine fistula following a uterine curettage for elective abortion is presented.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/683649"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "Second trimester elective abortion is safest when accomplished with cervical dilation and instrumental uterine evacuation (D and E), but this procedure carries with it a risk of uterine perforation and possible intra-abdominal trauma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2651693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Experience is reported with 28 uterine perforations encountered from June 1, 1973, to June 1, 1976, among 20,000 first trimester abortion patients at Reproductive Health Services, St. Louis, Missouri.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/927753"
        },
        {
          "offsetInBeginSection": 384,
          "offsetInEndSection": 563,
          "text": "except in the case where an infection complicates induced abortion, there is no evidence of an association between induced abortion and secondary infertility or ectopic pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2225607"
        },
        {
          "offsetInBeginSection": 1273,
          "offsetInEndSection": 1434,
          "text": "Finally, women whose pregnancy is terminated by dilatation and evacuation may have an increased risk of subsequent premature delivery and a low birthweight baby.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2225607"
        },
        {
          "offsetInBeginSection": 764,
          "offsetInEndSection": 941,
          "text": "Complications include bleeding, retained products of conception, retained cervical dilator, uterine perforation, amniotic fluid embolism, misoprostol toxicity, and endometritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36409940"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Elective abortion complicated by bilateral renal cortical necrosis (BRCN) is not common in a developed country.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21841331"
        },
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 555,
          "text": "stallation. We report the case of a patient who presented after a second-trimester elective abortion and was found to have suffered uterine perforation with mesenteric and bowel injury that required bowe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10658435"
        }
      ],
      "id": "67e2abdf18b1e36f2e000089",
      "ideal_answer": [
        "Complications of abortion are as follows: incomplete termination of pregnancy, delayed/excessive bleeding that might require transfusion, need to evacuation of uterus, pain, infection.",
        "Complications of elective abortion can range from common, less severe issues to rare, life-threatening conditions. Common first-trimester complications include incomplete evacuation (4.8-8.6%), excessive postabortal bleeding (2.5-5.5%), and uterine perforation (0.4-1.3%). Rare but severe complications are Ovarian Vein Thrombosis, Ureterouterine Fistula, and Incarcerated Small Bowel, with Fatal Myocardial Infarction being extremely rare. The incidence of complications is generally low, around 1.54% in first-trimester abortions in specialized clinics, with risks increasing in second-trimester procedures. Early intervention and proper medical care can significantly mitigate these risks.",
        "Elective abortion can lead to various complications, although the risks are relatively low when performed safely under medical supervision. Potential complications can include infection, excessive bleeding, injury to the cervix or uterus, and retained products of conception that may require additional medical procedures. In some cases, future fertility could be affected if complications are not properly managed. There is also a possibility of psychological effects, such as feelings of guilt or depression, although experiences vary widely among individuals. Long-term complications are rare but can include scarring of the uterine lining, known as Asherman\u0027s syndrome, particularly if repeated procedures are performed.",
        "Elective abortion, particularly medical or surgical termination of pregnancy, can be associated with several complications, though many are rare and manageable when proper care is provided. Common complications include:\n\n1. **Bleeding**: Excessive bleeding (hemorrhage) is a potential risk, especially if the procedure is not performed under appropriate conditions or if there are delays in seeking care.\n\n2. **Infection**: Infections such as endometritis can occur if sterile techniques are not followed during the procedure.\n\n3. **Incomplete abortion**: This occurs when some of the pregnancy tissue remains in the uterus, requiring further medical or surgical intervention to complete the process.\n\n4. **Hematometra**: A rare complication where blood accumulates in the uterus after the procedure, potentially leading to severe pain and other complications.\n\n5. **Uterine perforation**: In surgical abortions, there is a risk of accidentally puncturing the uterus, which can lead to internal bleeding or damage to nearby organs.\n\n6. **Anesthesia-related risks**: In surgical abortions, anesthesia can pose risks such as hypotension, bradycardia, and hypoxemia.\n\n7. **Psychological effects**: Some individuals may experience emotional or psychological distress following an abortion.\n\n8. **Maternal mortality**: While rare in settings with access to safe abortion services, complications from unsafe procedures contribute significantly to maternal mortality, particularly in low- and middle-income countries.\n\n9. **Delayed complications**: Rare but serious conditions like uterine-enhanced myometrial vascularity (EMV) can occur after abortion, leading to severe anemia or even life-threatening situations.\n\nIt is important to note that the risk of complications varies depending on factors such as gestational age, type of procedure, and access to safe medical care. Proper counseling, informed consent, and follow-up care are essential to minimize risks and ensure patient safety.",
        "Complications associated with elective abortion can be categorized into several key areas:\n\n1. **Bleeding**: Excessive bleeding is a common risk during the procedure, potentially requiring interventions such as medications or blood transfusions.\n\n2. **Infection**: The introduction of bacteria during the procedure can lead to infections in the uterus or other reproductive organs, necessitating prompt antibiotic treatment.\n\n3. **Pain**: While some discomfort is normal post-procedure, severe pain may require hospital intervention and could indicate complications like retained tissue or infection.\n\n4. **Incomplete Abortion**: This occurs when not all pregnancy tissue is removed, leading to ongoing symptoms such as bleeding and an increased risk of infection. Additional procedures may be needed to fully clear the uterus.\n\n5. **Emotional/psychological Distress**: Some women may experience grief, guilt, or anxiety post-abortion, highlighting the importance of mental health support.\n\n6. **Organ Damage**: Rare cases of damage to the uterus or other organs can occur, though this is uncommon with modern techniques and experienced providers.\n\n7. **Anesthesia Risks**: Although rare, allergic reactions or breathing difficulties related to anesthesia are potential concerns.\n\nIn conclusion, while elective abortion is generally safe, it carries risks such as bleeding, infection, pain, incomplete abortion, emotional distress, organ damage, and anesthesia-related issues. Women should discuss these risks with their healthcare providers to make informed decisions about their care.",
        "Elective abortions, when performed by qualified professionals in a clean environment, are generally safe. However, like any medical procedure, they carry certain risks and potential complications:\n\n1. **Bleeding**: Excessive bleeding is a common risk during or after the procedure. In severe cases, it may require interventions such as medications or blood transfusions.\n\n2. **Infection**: The introduction of bacteria into the reproductive organs can lead to infections, which may present with symptoms like fever, chills, abnormal discharge, or pain. Timely treatment with antibiotics is essential to prevent complications.\n\n3. **Pain**: While some discomfort is expected, severe or prolonged pain may require additional pain management strategies or medical attention.\n\n4. **Incomplete Abortion**: This occurs when some pregnancy tissue remains in the uterus, potentially leading to ongoing bleeding, infection, or other issues. A follow-up procedure might be necessary.\n\n5. **Emotional and Psychological Effects**: Some individuals may experience emotional distress, anxiety, guilt, or depression after an abortion. Access to mental health support is crucial as part of post-abortion care.\n\n6. **Rare but Serious Complications**: These include uterine perforation or damage to other organs, which can necessitate immediate medical attention.\n\nOverall, while complications are possible, they can often be managed effectively with proper medical care and follow-up."
      ],
      "exact_answer": [
        [
          "incomplete termination"
        ],
        [
          "need to evacuate uterus"
        ],
        [
          "delayed bleeding"
        ],
        [
          "excessive bleeding"
        ],
        [
          "pelvic pain"
        ],
        [
          "infection"
        ],
        [
          "ectopic pregnancy"
        ],
        [
          "perforation"
        ],
        [
          "depression"
        ],
        [
          "complicated grief"
        ],
        [
          "peritonitis"
        ],
        [
          "endometritis"
        ]
      ]
    },
    {
      "body": "Does glioblastoma commonly metastasize outside the central nervous system (CNS)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37814403",
        "http://www.ncbi.nlm.nih.gov/pubmed/15936366",
        "http://www.ncbi.nlm.nih.gov/pubmed/39419169",
        "http://www.ncbi.nlm.nih.gov/pubmed/30994848",
        "http://www.ncbi.nlm.nih.gov/pubmed/25408938",
        "http://www.ncbi.nlm.nih.gov/pubmed/2162242",
        "http://www.ncbi.nlm.nih.gov/pubmed/22639711",
        "http://www.ncbi.nlm.nih.gov/pubmed/38968484",
        "http://www.ncbi.nlm.nih.gov/pubmed/37817700",
        "http://www.ncbi.nlm.nih.gov/pubmed/37404487",
        "http://www.ncbi.nlm.nih.gov/pubmed/37025749",
        "http://www.ncbi.nlm.nih.gov/pubmed/36686309",
        "http://www.ncbi.nlm.nih.gov/pubmed/25101239",
        "http://www.ncbi.nlm.nih.gov/pubmed/35088971",
        "http://www.ncbi.nlm.nih.gov/pubmed/26212701",
        "http://www.ncbi.nlm.nih.gov/pubmed/25963474",
        "http://www.ncbi.nlm.nih.gov/pubmed/21964740",
        "http://www.ncbi.nlm.nih.gov/pubmed/21512826",
        "http://www.ncbi.nlm.nih.gov/pubmed/22595352",
        "http://www.ncbi.nlm.nih.gov/pubmed/35578056",
        "http://www.ncbi.nlm.nih.gov/pubmed/11138924",
        "http://www.ncbi.nlm.nih.gov/pubmed/7693337",
        "http://www.ncbi.nlm.nih.gov/pubmed/32489434",
        "http://www.ncbi.nlm.nih.gov/pubmed/17356401",
        "http://www.ncbi.nlm.nih.gov/pubmed/12626129",
        "http://www.ncbi.nlm.nih.gov/pubmed/16132510",
        "http://www.ncbi.nlm.nih.gov/pubmed/15213638",
        "http://www.ncbi.nlm.nih.gov/pubmed/31348875",
        "http://www.ncbi.nlm.nih.gov/pubmed/36093544",
        "http://www.ncbi.nlm.nih.gov/pubmed/34646764",
        "http://www.ncbi.nlm.nih.gov/pubmed/7546923",
        "http://www.ncbi.nlm.nih.gov/pubmed/29685418",
        "http://www.ncbi.nlm.nih.gov/pubmed/23374526",
        "http://www.ncbi.nlm.nih.gov/pubmed/19898745",
        "http://www.ncbi.nlm.nih.gov/pubmed/15925996",
        "http://www.ncbi.nlm.nih.gov/pubmed/27699039",
        "http://www.ncbi.nlm.nih.gov/pubmed/15577447",
        "http://www.ncbi.nlm.nih.gov/pubmed/28182828",
        "http://www.ncbi.nlm.nih.gov/pubmed/26704201",
        "http://www.ncbi.nlm.nih.gov/pubmed/27585656",
        "http://www.ncbi.nlm.nih.gov/pubmed/32983474",
        "http://www.ncbi.nlm.nih.gov/pubmed/39442362",
        "http://www.ncbi.nlm.nih.gov/pubmed/38864820",
        "http://www.ncbi.nlm.nih.gov/pubmed/29852299",
        "http://www.ncbi.nlm.nih.gov/pubmed/33627949",
        "http://www.ncbi.nlm.nih.gov/pubmed/26137254",
        "http://www.ncbi.nlm.nih.gov/pubmed/28718312",
        "http://www.ncbi.nlm.nih.gov/pubmed/33087049",
        "http://www.ncbi.nlm.nih.gov/pubmed/20634762",
        "http://www.ncbi.nlm.nih.gov/pubmed/30410840",
        "http://www.ncbi.nlm.nih.gov/pubmed/35130969",
        "http://www.ncbi.nlm.nih.gov/pubmed/33391387",
        "http://www.ncbi.nlm.nih.gov/pubmed/29778285",
        "http://www.ncbi.nlm.nih.gov/pubmed/37812956",
        "http://www.ncbi.nlm.nih.gov/pubmed/31876829",
        "http://www.ncbi.nlm.nih.gov/pubmed/38488900",
        "http://www.ncbi.nlm.nih.gov/pubmed/37794336",
        "http://www.ncbi.nlm.nih.gov/pubmed/22593993",
        "http://www.ncbi.nlm.nih.gov/pubmed/22886532",
        "http://www.ncbi.nlm.nih.gov/pubmed/20809248",
        "http://www.ncbi.nlm.nih.gov/pubmed/2984597",
        "http://www.ncbi.nlm.nih.gov/pubmed/16815020",
        "http://www.ncbi.nlm.nih.gov/pubmed/25956620"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 651,
          "offsetInEndSection": 1246,
          "text": "The rarity of extracranial metastasis is attributed to the blood-brain barrier and lack of a lymphatic drainage system, although rare cases of hematogenous spread and direct implantation have been reported. The possible mechanisms remain unclear and require further investigation. Risk factors have been widely described, including previous craniotomy or biopsies, ventricular shunting, young age, radiation therapy, prolonged survival time, and tumor recurrence. Due to the lack of understanding about extracranial metastasis of glioblastoma pathogenesis, no effective treatment exists to date.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37814403"
        },
        {
          "offsetInBeginSection": 234,
          "offsetInEndSection": 418,
          "text": "The incidence of glioblastoma metastasis outside CNS is uncommon with only 0.4%-2% reported rate, compared to other tumors that exhibit a 10% incidence rate of metastasis to the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37814403"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 344,
          "text": "The extranueural metastatic spread of GBM is relatively rare but it could have more progressive disease course.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25408938"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 192,
          "text": "Glioblastoma multiforme (GBM) is the most aggressive and prevalent type of malignant brain tumor, yet it metastasizes outside the central nervous system (CNS) in only 0.4% of cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39419169"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 79,
          "text": "Extracranial metastases occur in \u003c2% of cases of glioblastoma (GBM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38968484"
        },
        {
          "offsetInBeginSection": 234,
          "offsetInEndSection": 417,
          "text": "The incidence of glioblastoma metastasis outside CNS is uncommon with only 0.4%-2% reported rate, compared to other tumors that exhibit a 10% incidence rate of metastasis to the brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37814403"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Extracranial metastases of glioblastoma multiforme (GBM) are very rare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36686309"
        },
        {
          "offsetInBeginSection": 1162,
          "offsetInEndSection": 1354,
          "text": "Extracranial metastases of glioblastoma remain a rare event although its incidence is increasing, probably due to the improvement in survival among these patients and better imaging techniques",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963474"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 236,
          "text": "Primary brain tumors rarely metastasize outside of the central nervous system (CNS) without prior neurosurgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2162242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "Glioblastoma multiforme (GBM) is the most aggressive intracranial tumor and it commonly spreads by direct extension and infiltration into the adjacent brain tissue and along the white matter tract. The metastatic spread of GBM outside of the central nervous system (CNS) is rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639711"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Extra-neural metastases of glioblastoma multiforme are uncommon with unidentified metastatic mechanism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37817700"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Glioblastomas only rarely metastasize to sites outside the central nervous system, for reasons that are poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11138924"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 286,
          "text": "Primary brain tumors rarely metastasize outside the central nervous system and when metastases occur, it is often in patients with diversionary shunting of the cerebrospinal fluid.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17356401"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 267,
          "text": "GBM metastasis outside the central nervous system is distinctly rare though there are previous reports of spread to various organs ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16132510"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Primary brain tumors rarely metastasize outside of the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15213638"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 192,
          "text": " Glioblastoma multiforme (GBM) is the most aggressive and prevalent type of malignant brain tumor, yet it metastasizes outside the central nervous system (CNS) in only 0.4% of cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39419169"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 279,
          "text": "The metastatic spread of GBM outside of the central nervous system (CNS) is rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639711"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 367,
          "text": "Brain tumors that form from brain cells, as opposed to those that come from other parts of the body, rarely metastasize outside of the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25101239"
        },
        {
          "offsetInBeginSection": 255,
          "offsetInEndSection": 449,
          "text": "Although it is a highly infiltrative tumor, it is rarely disseminated beyond the central nervous system, wherein extracranial metastasis is a unique but rare manifestation of this kind of tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32489434"
        },
        {
          "offsetInBeginSection": 64,
          "offsetInEndSection": 143,
          "text": "It is locally aggressive but rarely spreads outside the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31348875"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 48,
          "text": "Extracranial metastasis of glioblastoma is rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7546923"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Although human glioblastomas are highly invasive tumors intracerebrally, only rarely do they metastasize outside the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7693337"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 273,
          "text": "GBM metastasis outside the central nervous system is distinctly rare though there are previous reports of spread to various organs [2-5].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16132510"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. Metastases outside the nervous system are a rare phenomenon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29685418"
        },
        {
          "offsetInBeginSection": 100,
          "offsetInEndSection": 206,
          "text": "In spite of the hostile nature of glioblastoma multiforme (GBM), extracranial spread is not a common event",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23374526"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Extracranial metastasis of glioblastoma multiforme (GBM) is very rare, in spite of very aggressive tumor behavior and being documented in only a few patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19898745"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Clinically detected extra-cranial metastases from glioblastoma multiforme (GBM) are quite rare, with an incidence of \u003c2% reported in the published literature",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15925996"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 477,
          "text": "Extracranial metastases are extremely rare, with \u003c200 cases of extracranial metastases from glioblastoma multiforme reported in the literature to date",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699039"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Glioblastoma multiforme is a highly malignant glioma with a well-known tendency for intracranial spread but rarely for extracranial spread",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15577447"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Glioblastoma multiforme (GBM) is a common malignant brain tumor that rarely metastasizes extracranially, despite its aggressive clinical course",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Glioblastoma multiforme (GBM) is the most common malignant central nervous system tumor; however, extraneural metastasis is uncommon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704201"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 278,
          "text": "The metastatic spread of GBM outside of the central nervous system (CNS) is rare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639711"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Extra CNS metastasis of glioblastoma multiforme is extremely rare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32983474"
        },
        {
          "offsetInBeginSection": 255,
          "offsetInEndSection": 448,
          "text": "Although it is a highly infiltrative tumor, it is rarely disseminated beyond the central nervous system, wherein extracranial metastasis is a unique but rare manifestation of this kind of tumor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32489434"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Although human glioblastomas are highly invasive tumors intracerebrally, only rarely do they metastasize outside the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7693337"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 48,
          "text": "Glioblastomas rarely metastasize outside the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12626129"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 229,
          "text": "However, extracranial metastasis is extremely rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39442362"
        },
        {
          "offsetInBeginSection": 63,
          "offsetInEndSection": 143,
          "text": "Despite its infiltrative nature, extra-cranial glioblastoma metastases are rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38864820"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 273,
          "text": "In spite of this, extracranial GBM metastases are rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26212701"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Extracranial metastasis of glioblastoma multiforme (GBM) is very rare, in spite of very aggressive tumor behavior and being documented in only a few patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19898745"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Glioblastoma (GBM) is a highly aggressive central nervous system cancer. Its extracranial metastases have rarely been reported in the past few decades.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33627949"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 422,
          "text": "Similar to other primary brain tumors, the extracranial metastasis of GBM is extremely rare, occurring in \u003c2% of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137254"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 288,
          "text": "Despite its aggressive nature, GBM is rarely found to spread extracranially and develop distant metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28718312"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 174,
          "text": "Extracranial GBM dissemination is very uncommon, but is increasingly being recognized.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634762"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 236,
          "text": "Because of blood brain barrier and short median survival of patients with glioblastoma, metastasis of this tumor is very rare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33391387"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Glioblastoma multiforme is the most common primary brain tumor, despite an aggressive clinical course, less than 2% of patients develop extraneural metastasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29778285"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 366,
          "text": "Brain tumors that form from brain cells, as opposed to those that come from other parts of the body, rarely metastasize outside of the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25101239"
        },
        {
          "offsetInBeginSection": 507,
          "offsetInEndSection": 608,
          "text": "Extracranial metastases from glioblastoma are more common in those with primitive neuronal components",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31876829"
        },
        {
          "offsetInBeginSection": 63,
          "offsetInEndSection": 142,
          "text": "Despite its infiltrative nature, extra-cranial glioblastoma metastases are rare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38864820"
        },
        {
          "offsetInBeginSection": 1100,
          "offsetInEndSection": 1225,
          "text": "Extracranial metastasis of glioblastoma is a rare complication of which only a few cases have been reported in the literature",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38488900"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 84,
          "text": "Glioblastoma usually recurs locally and extracranial metastases are rare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37794336"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 344,
          "text": "Glioblastoma multiforme (GBM) is well known as the most common malignant primary brain tumor. It could easily spread into the adjacent or distant brain tissue by infiltration, direct extension and cerebro-spinal fluid dissemination. The extranueural metastatic spread of GBM is relatively rare but it could have more progressive disease course.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25408938"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Glioblastoma multiforme (GBM) is a malignant primary brain neoplasm with poor survival. Extracranial GBM dissemination is very uncommon, but is increasingly being recognized.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 327,
          "text": "Glioblastoma multiforme is the most common primary malignant brain tumor in adults. It\u0027s characterized by a high malignancy and rapid, frequent tendency to local recurrence. Distant metastases disseminated in the brain compared to the primary lesion and outside the central nervous system are rarely reported in the literature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22593993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Glioblastoma multiforme (GBM) is the most common and most malignant primary brain tumour in adults. In spite of the hostile nature of glioblastoma multiforme (GBM), extracranial spread is not a common event.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23374526"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Compared with other malignancies, remote metastases in GBM are rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22886532"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "Despite recent advances, glioblastoma (GBM) remains incurable but is typically characterized by local tumor recurrence in the brain. Soft tissue metastases from GBM are extremely rare, with only eight reported cases in the literature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20809248"
        },
        {
          "offsetInBeginSection": 455,
          "offsetInEndSection": 650,
          "text": "Extraneural metastases from primary brain tumors are quite rare, for 2 probable reasons: because most patients survive less than 2 years, and because of the absence of true lymphatics in the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35088971"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 98,
          "text": " Systemic metastasis of glioblastoma multiforme (GBM) in the form of bulk tumor is rare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15936366"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 314,
          "text": "High grade astrocytomas such as anaplastic astrocytoma and glioblastoma multiforme are aggressive central nervous system malignancies with a poor prognosis. Due to shortened survival times, their devastating effects are usually localized intracranially and rarely metastasize outside of the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30410840"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Extraneural metastases from primary central nervous system (CNS) tumors are unusual, and glioblastomas and medulloblastomas constitute the majority of these.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18280737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Glioblastoma multiforme (GBM) is a malignant primary brain neoplasm with poor survival. Extracranial GBM dissemination is very uncommon, but is increasingly being recognized",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "It is generally accepted that the metastases of intracranial glioma to extracranial location are rare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2984597"
        },
        {
          "offsetInBeginSection": 350,
          "offsetInEndSection": 543,
          "text": "Extracranial metastasis is rare, especially without previous surgical disruption of the dura and calvarium, which has been postulated to cause seeding of the extracranial space with tumor cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956620"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 313,
          "text": "Due to shortened survival times, their devastating effects are usually localized intracranially and rarely metastasize outside of the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30410840"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Glioblastomas only rarely metastasize to sites outside the central nervous system, for reasons that are poorly understood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11138924"
        }
      ],
      "id": "67eb70ee18b1e36f2e0000eb",
      "ideal_answer": [
        "The incidence of glioblastoma metastasis outside CNS is uncommon with only a 0.4%-2% reported rate, compared to other tumors that exhibit a 10% incidence rate of metastasis to the brain. The rarity of extracranial metastasis is attributed to the blood-brain barrier and lack of a lymphatic drainage system, although rare cases of hematogenous spread and direct implantation have been reported. The possible mechanisms remain unclear and require further investigation. Risk factors have been widely described, including previous craniotomy or biopsies, ventricular shunting, young age, radiation therapy, prolonged survival time, and tumor recurrence. Due to the lack of understanding about extracranial metastasis of glioblastoma pathogenesis, no effective treatment exists to date.",
        "Glioblastoma, the most common adult malignant brain tumor, rarely metastasizes outside the CNS (0.4%-2% incidence rate), attributed to the blood-brain barrier and lack of lymphatic drainage. Metastasis, when it occurs, is via hematogenous spread or direct implantation, with risk factors including previous CNS procedures, young age, radiation therapy, prolonged survival, and tumor recurrence. Due to limited understanding, there\u0027s no effective treatment, and aggressive chemotherapies are not recommended. Notably, glioblastoma\u0027s extracranial metastasis rate is significantly lower than other tumors\u0027 brain metastasis rate (10%).",
        "Glioblastoma rarely metastasizes outside the CNS, with only 0.4%-2% reported cases compared to 10% for other tumors, primarily due to the blood-brain barrier and absence of lymphatic drainage. While rare cases of hematogenous spread and direct implantation have been documented, the exact mechanisms remain unclear, with risk factors including previous craniotomy, ventricular shunting, young age, radiation therapy, and prolonged survival.",
        "No. Glioblastoma does not commonly metastasize outside the central nervous system (CNS). The rarity of extracranial metastasis is attributed to factors such as the blood-brain barrier and the absence of a lymphatic drainage system in the CNS. While rare instances of hematogenous spread, direct implantation, or metastasis associated with interventions like craniotomy, biopsies, or ventricular shunting have been reported, these cases are exceptionally uncommon. The mechanisms underlying extracranial metastasis remain poorly understood, and no effective treatments currently exist for such metastases.",
        "Glioblastoma is a highly aggressive form of brain cancer that typically remains confined within the central nervous system (CNS). The incidence of glioblastoma metastasizing outside the CNS is uncommon, with reported rates ranging from 0.4% to 2%. This rarity can be attributed to several factors:\n\n1. **Blood-Brain Barrier**: The blood-brain barrier acts as a protective mechanism that makes it difficult for cancer cells to leave the CNS and spread to other parts of the body.\n\n2. **Lack of Lymphatic Drainage System in CNS**: Unlike many other tissues, the CNS does not have an extensive lymphatic system, which further hinders the spread of cancer cells outside the brain.\n\n3. **Protective Mechanisms**: The unique environment of the brain and its protective barriers contribute to the rarity of extracranial metastasis.\n\nWhile there are rare cases where glioblastoma has been reported to metastasize outside the CNS through hematogenous spread or direct implantation, these instances are exceptions rather than the norm. Additionally, certain risk factors such as previous craniotomy or biopsies, ventricular shunting, young age, radiation therapy, prolonged survival time, and tumor recurrence may increase the likelihood of extracranial metastasis, but this remains a rare occurrence.\n\nIn summary, glioblastoma does not commonly metastasize outside the CNS due to protective mechanisms like the blood-brain barrier and the absence of a lymphatic drainage system in the CNS. The low incidence rates highlight that such metastasis is an uncommon event.",
        "Glioblastoma commonly does not metastasize outside the central nervous system (CNS), as evidenced by its low reported incidence rate of 0.4%-2% compared to other tumors that have a 10% incidence rate of brain metastasis. The rarity of extracranial metastasis in glioblastoma is attributed to factors such as the blood-brain barrier and the absence of a lymphatic drainage system within the CNS, although rare cases involving hematogenous spread and direct implantation have been documented. Despite these occurrences, the mechanisms behind extracranial metastasis remain poorly understood, necessitating further research. Risk factors for such metastasis include previous craniotomy or biopsies, ventricular shunting, young age, radiation therapy, prolonged survival time, and tumor recurrence. Currently, due to limited understanding of the pathogenesis of extracranial glioblastoma metastasis, there is no effective treatment available.",
        "Glioblastoma rarely metastasizes outside the central nervous system (CNS), with an incidence rate of 0.4%-2%, attributed to the protective effects of the blood-brain barrier and the absence of lymphatic drainage. Although rare cases of hematogenous spread and direct implantation occur, often linked to factors like previous CNS interventions, young age, and prolonged survival, the underlying mechanisms are not well understood, and no effective treatment for extracranial metastasis currently exists, highlighting the need for further research."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Which database serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35393411"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "MiDAS 4: A global catalogue of full-length 16S rRNA gene sequences and taxonomy for studies of bacterial communities in wastewater treatment plants.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35393411"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 349,
          "text": "Microbial communities are responsible for biological wastewater treatment, but our knowledge of their diversity and function is still poor. Here, we sequence more than 5 million high-quality, full-length 16S rRNA gene sequences from 740 wastewater treatment plants (WWTPs) across the world and use the sequences to construct the \u0027MiDAS 4\u0027 database. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35393411"
        }
      ],
      "id": "67e7df6118b1e36f2e0000d8",
      "ideal_answer": [
        "MiDAS 4 is a global catalogue of 5 million high-quality, full-length 16S rRNA gene sequences from 740 wastewater treatment plants (WWTPs).",
        "MiDAS 4 serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants. It is a comprehensive reference database with taxonomy from domain to species level for all sequences, providing better coverage and improved classification rates for WWTP bacteria compared to commonly used universal reference databases.",
        "MiDAS 4 is a global catalogue of full-length 16S rRNA gene sequences and taxonomy for studies of bacterial communities in wastewater treatment plants.",
        "MiDAS 4 serves as the catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants, as consistently identified across all sources. This database is specifically noted for its comprehensive collection of such genetic data in the context of wastewater treatment, providing a valuable resource for microbial community analysis and research in this field.",
        "The MiDAS database serves as a comprehensive catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants. It has been expanded and refined through various studies, including the sequencing of over five million high-quality sequences from 740 WWTPs worldwide to construct MiDAS 4, and further updates to create MiDAS 5 by incorporating additional data. These efforts aim to provide a detailed reference for understanding microbial dynamics in wastewater treatment systems, enabling accurate taxonomic assignments and insights into bacterial communities in these ecosystems.",
        "The MiDAS 4 database serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants. This database includes over 5 million high-quality full-length 16S rRNA gene sequences from 740 wastewater treatment plants globally, providing comprehensive taxonomy and improved genus and species level classification compared to commonly used databases.",
        "The MiDAS 4 database serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants.",
        "MiDAS 4 and MiDAS 5 serve as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants.",
        "The MiDAS 4 database serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants (WWTPs). It is constructed from over 5 million high-quality, full-length 16S rRNA gene sequences derived from 740 WWTPs globally. MiDAS 4 provides amplicon sequence variant resolution and a comprehensive taxonomy from domain to species level, specifically optimized for wastewater microbial community analysis.",
        "MiDAS 4 is the database that catalogs full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants. It resolves amplicon sequence variants and provides comprehensive taxonomy from domain to species level.",
        "The MiDAS database serves as a catalogue of full-length 16S rRNA gene sequences from bacteria and archaea found in wastewater treatment plants. MiDAS 4 and MiDAS 5 are specific versions of this database, offering detailed reference information and taxonomic classification. The MiDAS field guide is a related online resource that connects the identity of these microorganisms to their functional roles in wastewater treatment systems.",
        "MiDAS 4 is the database that serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants.",
        "MiDAS 4 serves as the global catalogue of full-length 16S rRNA gene sequences specifically from bacteria in wastewater treatment plants worldwide, distinguishing it as the most relevant database for this purpose among the options provided.",
        "MiDAS 4 serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants.",
        "MiDAS 4 serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants, providing a centralized database for such microbiological and environmental studies.",
        "The MiDAS 4 database serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants (WWTPs). It is an amplicon sequence variant resolved, full-length 16S rRNA gene reference database with comprehensive taxonomy from domain to species level for all sequences.",
        "MiDAS 4 is the definitive catalogue for full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants worldwide. It serves as a centralized database, providing a comprehensive collection of genetic data for microbiological and environmental studies, particularly tailored for microbial community analysis and research in the context of wastewater treatment on a global scale.",
        "The database that serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants is MiDAS 4. This database is constructed from sequences obtained from 740 wastewater treatment plants worldwide and provides comprehensive taxonomy and improved genus and species level classification for studies of bacterial communities in wastewater treatment plants.",
        "The MiDAS 4 database serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants. It is an amplicon sequence variant resolved reference database with a comprehensive taxonomy from domain to species level for all sequences. The database was constructed using more than 5 million high-quality, full-length 16S rRNA gene sequences from 740 wastewater treatment plants across the world.",
        "The database that serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants is MiDAS 4. This global catalogue provides comprehensive coverage and improved genus and species-level classification for bacterial communities in wastewater treatment plants, compared to commonly used universal reference databases.",
        "The MiDAS 4 database is a comprehensive global catalogue of full-length 16S rRNA gene sequences from bacterial communities in wastewater treatment plants. Developed by sequencing over 5 million high-quality gene sequences from 740 wastewater treatment plants worldwide, it provides a detailed taxonomic resource for understanding microbial diversity in these environments.",
        "MiDAS 4 is the definitive database cataloging full-length 16S rRNA gene sequences from bacteria in over 740 wastewater treatment plants worldwide, offering comprehensive taxonomy and superior coverage/classification rates compared to universal databases. It is instrumental in microbial community profiling of activated sludge plants, identifying core and rare taxa, and studying global prevalence of functional bacterial guilds like nitrifiers and polyphosphate-accumulating organisms.",
        "MiDAS 4 is an amplicon sequence variant resolved, full-length 16S rRNA gene sequence database for bacterial communities in wastewater treatment plants.",
        "The MiDAS 4 database serves as a global catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants, providing valuable information for studies of bacterial communities in these environments. This database was constructed using over 5 million high-quality, full-length 16S rRNA gene sequences obtained from 740 wastewater treatment plants worldwide. By making this comprehensive collection of sequences available, MiDAS 4 aims to improve our understanding of the diversity and function of microbial communities responsible for biological wastewater treatment, ultimately supporting further studies in this field.",
        "The MiDAS 4 database serves as a comprehensive global catalogue containing over 5 million high-quality, full-length 16S rRNA gene sequences collected from 740 wastewater treatment plants worldwide, providing a valuable resource for studying bacterial communities in wastewater treatment systems.",
        "MiDAS 4 is a specialized database designed as a global catalogue of full-length 16S rRNA gene sequences and taxonomic classifications, specifically curated to support research on bacterial communities within wastewater treatment plants (WWTPs). It provides a comprehensive resource for analyzing microbial diversity, function, and dynamics in these engineered ecosystems.",
        "The MiDAS 4 database serves as a global catalogue of full-length 16S rRNA gene sequences for studies of bacterial communities in wastewater treatment plants.",
        "The MiDAS 4 database is the catalogue of full‐length 16S rRNA gene sequences from bacteria in wastewater treatment plants worldwide.",
        "The MiDAS 4 database serves as a global catalogue of full-length 16S rRNA gene sequences and taxonomy for studying bacterial communities in wastewater treatment plants, constructed from over 5 million sequences across 740 plants.",
        "The MiDAS 4 database serves as a global catalogue of full-length 16S rRNA gene sequences and taxonomy for studying bacterial communities in wastewater treatment plants.",
        "MiDAS 4 is a global catalogue of full-length 16S rRNA gene sequences constructed from millions of high-quality sequences derived from wastewater treatment plants.",
        "The MiDAS 4 database serves as a global catalogue of full-length 16S rRNA gene sequences and taxonomy for studies of bacterial communities in wastewater treatment plants. It is an amplicon sequence variant resolved, full-length 16S rRNA gene reference database.",
        "The database that serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants is called MiDAS 4. This database was constructed using more than 5 million high-quality, full-length 16S rRNA gene sequences obtained from 740 wastewater treatment plants (WWTPs) across the world.",
        "The database known as \u0027MiDAS 4\u0027 serves as a catalogue for full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants.",
        "MiDAS 4 serves as the comprehensive database catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants, constructed from over 5 million sequences worldwide. It provides detailed taxonomy from domain to species level, offering superior coverage and classification rates compared to universal databases, and is utilized for microbial community profiling and studying environmental impacts on wastewater microbiota.",
        "MiDAS 4 is a comprehensive global database specifically designed to catalog full-length 16S rRNA gene sequences and their corresponding taxonomy, focusing on bacterial communities present in wastewater treatment plants. This database facilitates the identification and analysis of microbial diversity and functions, aiding researchers and practitioners in optimizing wastewater treatment processes by understanding the microbial dynamics at play.",
        "MiDAS 4 serves as a comprehensive catalogue of full-length 16S rRNA gene sequences specifically for bacteria found in wastewater treatment plants, aiding in the study of microbial diversity and function in biological wastewater treatment.",
        "MiDAS 4",
        "The MiDAS 4 database serves as a global catalogue of full-length 16S rRNA gene sequences and taxonomy for studies of bacterial communities in wastewater treatment plants.",
        "MiDAS 4 serves as a comprehensive catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants. This database was constructed by sequencing more than 5 million high-quality, full-length 16S rRNA gene sequences from 740 wastewater treatment plants worldwide, providing a valuable resource for studying bacterial communities in wastewater treatment systems.",
        "The database that serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants is the \u0027MiDAS 4\u0027 database.",
        "MiDAS 4 is the database that catalogues full-length 16S rRNA gene sequences specifically from bacteria found in wastewater treatment plants.",
        "MiDAS 4 is the database that serves as a global catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants.",
        "MiDAS 4 serves as a catalogue of full-length 16S rRNA gene sequences from bacteria in wastewater treatment plants. It is an amplicon sequence variant resolved reference database with a comprehensive taxonomy from domain to species level for all sequences. The database was constructed using more than 5 million high-quality, full-length 16S rRNA gene sequences from 740 wastewater treatment plants across the world.",
        "The MiDAS 4 database serves as a global catalogue of full-length 16S rRNA gene sequences and taxonomy for studies of bacterial communities in wastewater treatment plants. It was constructed using more than 5 million high-quality, full-length 16S rRNA gene sequences from over 700 WWTPs worldwide.",
        "The MiDAS 4 database serves as a global catalogue of full-length 16S rRNA gene sequences and taxonomy for bacterial communities in wastewater treatment plants. It was constructed by sequencing over 5 million high-quality, full-length 16S rRNA gene sequences from 740 wastewater treatment plants worldwide, enhancing our understanding of microbial diversity and function in these environments."
      ],
      "exact_answer": [
        [
          "MiDAS 4"
        ]
      ]
    },
    {
      "body": "What are features of the WHIM syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38185798",
        "http://www.ncbi.nlm.nih.gov/pubmed/38286463",
        "http://www.ncbi.nlm.nih.gov/pubmed/39028950",
        "http://www.ncbi.nlm.nih.gov/pubmed/39004659",
        "http://www.ncbi.nlm.nih.gov/pubmed/14612668",
        "http://www.ncbi.nlm.nih.gov/pubmed/17573253",
        "http://www.ncbi.nlm.nih.gov/pubmed/36793393",
        "http://www.ncbi.nlm.nih.gov/pubmed/11148489",
        "http://www.ncbi.nlm.nih.gov/pubmed/21506920",
        "http://www.ncbi.nlm.nih.gov/pubmed/10767001",
        "http://www.ncbi.nlm.nih.gov/pubmed/19057201",
        "http://www.ncbi.nlm.nih.gov/pubmed/30577453",
        "http://www.ncbi.nlm.nih.gov/pubmed/39575248",
        "http://www.ncbi.nlm.nih.gov/pubmed/39226327",
        "http://www.ncbi.nlm.nih.gov/pubmed/31652152",
        "http://www.ncbi.nlm.nih.gov/pubmed/35385630",
        "http://www.ncbi.nlm.nih.gov/pubmed/34697698",
        "http://www.ncbi.nlm.nih.gov/pubmed/37566756",
        "http://www.ncbi.nlm.nih.gov/pubmed/39588369",
        "http://www.ncbi.nlm.nih.gov/pubmed/15536153",
        "http://www.ncbi.nlm.nih.gov/pubmed/16946301",
        "http://www.ncbi.nlm.nih.gov/pubmed/32260318",
        "http://www.ncbi.nlm.nih.gov/pubmed/22596258",
        "http://www.ncbi.nlm.nih.gov/pubmed/16275383",
        "http://www.ncbi.nlm.nih.gov/pubmed/19926501",
        "http://www.ncbi.nlm.nih.gov/pubmed/29066537",
        "http://www.ncbi.nlm.nih.gov/pubmed/35470097",
        "http://www.ncbi.nlm.nih.gov/pubmed/28768817",
        "http://www.ncbi.nlm.nih.gov/pubmed/19043667",
        "http://www.ncbi.nlm.nih.gov/pubmed/35947323"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 260,
          "text": "AIM: WHIM (warts, hypogammaglobulinaemia, infections and myelokathexis) syndrome is a rare combined primary immunodeficiency disease caused by gain-of-function (GOF) mutations in the chemokine receptor CXCR4 and includes severe neutropenia as a common feature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38185798"
        },
        {
          "offsetInBeginSection": 406,
          "offsetInEndSection": 771,
          "text": "This study presents an in-depth comparative analysis of clinical and immunological features in 5 CN patient groups (severe congenital neutropenia [SCN]1, SCN3, cyclic neutropenia [CyN], warts, hypogammaglobulinaemia, infections and myelokathexis [WHIM], and Shwachman-Bodian-Diamond Syndrome [SBDS]) associated with mutations in ELANE, HAX1, CXCR4, and SBDS genes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38286463"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "ABSTRACT: WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare primary immunodeficiency predominantly caused by heterozygous gain-of-function mutations in the C-terminus of the gene CXCR4. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39028950"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 584,
          "text": " In April 2024, it became the first therapy to be approved for WHIM syndrome (named by an acronym for its observed characteristics of Warts, Hypogammaglobulinaemia, Infections and Myelokathexis) in the USA, where it is indicated for use in patients aged ≥ 12 years with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "The WHIM syndrome is a rare, autosomal dominant primary immunodeficiency disorder characterized by warts, hypogammaglobulinemia, recurrent infections, and myelocathexis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17573253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Background: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare, primary immunodeficiency syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and characteristic bone marrow features of my",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36793393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "WHIM syndrome is a rare congenital familial syndrome consisting of warts, hypogammaglobulinemia, infections, and myelokathexis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148489"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 664,
          "text": "The acronym WHIM resumes the main features of the syndrome: Warts, Hypogammaglobulinemia, Infections and Myelokathexis, which is abnormal retention of mature neutrophils in the bone marrow.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21506920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21506920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "The acronym WHIM refers to Warts, Hypogammaglobulinemia, Infections, and Myelokathexis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10767001"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 156,
          "text": "WHIM syndrome is a rare, autosomal dominant inborn error of immunity characterized by warts, hypogammaglobulinemia, infection, and myelokathexis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39575248"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "ABSTRACT: WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare primary immunodeficiency predominantly caused by heterozygous gain-of-function mutations in the C-terminus of the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39028950"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 203,
          "text": "WHIM syndrome corresponds to an inborn error of innate and intrinsic immunity, characterized by: warts (Warts), Hypogammaglobulinemia, Infections and Myelocathexis, for its acronym in English",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37566756"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 296,
          "text": "WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome is an ultra-rare, combined primary immunodeficiency and chronic neutropenic disorder characterized by a range of clinical presentations, including peripheral neutropenia, lymphopenia, and recurrent infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39588369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "PURPOSE: WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare disease, caused by CXCR4 gene mutations, which incorporates features of combined immunodeficiency, congenital neutropenia, and a predisposition to human papillomavirus i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34697698"
        },
        {
          "offsetInBeginSection": 60,
          "offsetInEndSection": 243,
          "text": "elokathexis (WHIM) syndrome is a rare, primary immunodeficiency syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and characteristic bone marrow features of my",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36793393"
        },
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 131,
          "text": "WHIM syndrome is a rare immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15536153"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "WHIM(warts, hypogammaglobulinemia, recurrent bacterial infection, and myelokathexis) syndrome is a rare immunodeficiency caused in many cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16946301"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Background: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare, primary immunodeficiency syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and characteristic bone marrow features of myelokathexis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36793393"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 296,
          "text": " WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome is an ultra-rare, combined primary immunodeficiency and chronic neutropenic disorder characterized by a range of clinical presentations, including peripheral neutropenia, lymphopenia, and recurrent infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39588369"
        },
        {
          "offsetInBeginSection": 18,
          "offsetInEndSection": 1214,
          "text": " WHIM syndrome (warts, hypogammaglobulinemia, immunodeficiency, myelokathexis, or WHIMs) is a very rare autosomal dominant immunodeficiency disorder attributable to mutations in CXCR4. We reviewed clinical manifestations in 24 patients in 9 families to expand understanding of this syndrome.RECENT FINDINGS: Warts, cellulitis and respiratory infections are common in patients with WHIMs. Less commonly these patients have congenital heart disease, human papilloma virus-associated malignancies (cervical and vulvular) and lymphomas. Hearing loss because of recurrent otitis media is another important complication. Treatment with granulocyte colony-stimulating factor is controversial; this review indicates that it is effective to prevent and treat infections based upon long-term observations of patients enrolled in the Severe Chronic Neutropenia International Registry. Understanding the natural history and diversity of this syndrome are important for ongoing clinical trials of novel agents to treat WHIMs.SUMMARY: WHIM syndrome has diverse manifestations; some features occur consistently in almost all patients, for example, neutropenia, lymphocytopenia and mild hypogammaglobulinemia. Ho",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31652152"
        },
        {
          "offsetInBeginSection": 382,
          "offsetInEndSection": 1020,
          "text": "Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare, autosomal dominant, combined immunodeficiency disorder caused by mutations in the C-terminus of CXCR4 that prevent receptor downregulation and therefore result in pathologically increased signaling. The \"M\" in the acronym WHIM refers to myelokathexis, the retention of neutrophils in the bone marrow resulting in neutropenia, which explains in part the increased susceptibility to bacterial infection. However, WHIM patients also present with B and T lymphopenia, which may explain the susceptibility to human papillomavirus (HPV), the cause of warts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30577453"
        },
        {
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1210,
          "text": "These mutations closely resemble those occurring in Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis (WHIM) syndrome, an immunodeficiency associated with CXCR4 aberrant expression and activity ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32260318"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 878,
          "text": "The acronym WHIM resumes the main features of the syndrome: Warts, Hypogammaglobulinemia, Infections and Myelokathexis, which is abnormal retention of mature neutrophils in the bone marrow. WHIM patients suffer from recurrent bacterial infections since childhood and manifest a specific susceptibility to HPV infections. Hematological findings include neutropenia, lymphopenia and hypogammaglobulinemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21506920"
        },
        {
          "offsetInBeginSection": 18,
          "offsetInEndSection": 288,
          "text": " WHIM syndrome (the association of warts, hypogammaglobulinemia, recurrent bacterial infections, and \u0027myelokathexis\u0027) is a rare congenital form of neutropenia associated with an unusual immune disorder involving hypogammaglonulinemia and abnormal susceptibility to warts",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14612668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "WHIM(warts, hypogammaglobulinemia, recurrent bacterial infection, and myelokathexis) syndrome is a rare immunodeficiency caused in many cases by autosomal dominant C-terminal truncation mutations in the chemokine receptor CXCR4.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16946301"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 609,
          "text": "Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) is a primary immunodeficiency syndrome. Patients with WHIM syndrome are more susceptible to human papillomavirus (HPV) infections and commonly present to a dermatologist with recalcitrant to treatment warts. Other cardinal features of WHIM syndrome include recurrent sinopulmonary bacterial infections, neutropenia/lymphopenia, low levels of immunoglobulins (IgG, IgA, IgM) and myelokathexis. Research demonstrated that truncating gain-of-function mutations of the C-X-C chemokine receptor type 4 gene (CXCR4) are responsible for this disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35385630"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 358,
          "text": "The term WHIM syndrome (WHIMS) is an acronym describing a rare primary immunodeficiency disorder characterized by warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis, the unusual association of neutropenia with bone marrow myeloid hypercellularity. WHIMS was recently associated with mutations in the gene encoding the chemokine receptor CXCR4 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16275383"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 363,
          "text": "WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is an autosomal dominant disease related to a mutation in the chemokine receptor CXCR4 resulting in altered immune function. An increased susceptibility in these patients to human papillomavirus (HPV) manifests as cutaneous warts and, in women, cervical dysplasia and squamous carcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19926501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 318,
          "text": "PURPOSE OF REVIEW: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is characterized by susceptibility to human papilloma virus infection-induced warts and carcinomas; neutropenia, B-cell lymphopenia and hypogammaglobulinema-related infections; and bone marrow myelokathexis (myeloid hyperpl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19057201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 292,
          "text": "Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a genetic disease characterized by neutropenia, lymphopenia, susceptibility to infections, and myelokathexis, which describes degenerative changes of mature neutrophils and hyperplasia of bone marrow myeloid cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29066537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "The WHIM syndrome is a rare, autosomal dominant primary immunodeficiency disorder characterized by warts, hypogammaglobulinemia, recurrent infections, and myelocathexis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17573253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "WHIM syndrome is a rare congenital immunodeficiency disease, named after its main clinical manifestations: warts, hypogammaglobulinemia, infections, and myelokathexis, which refers to abnormal accumulation of mature neutrophils in the bone marrow",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28768817"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "PURPOSE OF REVIEW: WHIM syndrome (the association of warts, hypogammaglobulinemia, recurrent bacterial infections, and \u0027myelokathexis\u0027) is a rare congenital form of neutropenia associated with an unusual immune disorder involving hypogammaglonulinemia and abnormal susc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14612668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Background: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare, primary immunodeficiency syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and characteristic bone marrow features of m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36793393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome is a rare primary immunodeficiency disease in humans caused by a gain of function in CXCR4, mostly due to inherited heterozygous mutations in CXCR4.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39226327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 467,
          "text": "Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a genetic disease characterized by neutropenia, lymphopenia, susceptibility to infections, and myelokathexis, which describes degenerative changes of mature neutrophils and hyperplasia of bone marrow myeloid cells. Some patients present with hypogammaglobulinemia and/or refractory warts of skin and genitalia. Congenital cardiac defects constitute uncommon manifestations of the disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29066537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "INTRODUCTION: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder with an autosomal-dominant pattern of inheritance and low fatality rate but significant lifel",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043667"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "WHIM syndrome is a rare, autosomal dominant, immunodeficiency disorder so-named because it is characterized by warts, hypogammaglobulinemia, infections, and myelokathexis (defective neutrophil egress from the BM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22596258"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 272,
          "text": "WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare disease, caused by CXCR4 gene mutations, which incorporates features of combined immunodeficiency, congenital neutropenia, and a predisposition to human papillomavirus infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34697698"
        },
        {
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1261,
          "text": "These mutations closely resemble those occurring in Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis (WHIM) syndrome, an immunodeficiency associated with CXCR4 aberrant expression and activity and with chemotherapy resistance in clinical trials",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32260318"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 665,
          "text": "The acronym WHIM resumes the main features of the syndrome: Warts, Hypogammaglobulinemia, Infections and Myelokathexis, which is abnormal retention of mature neutrophils in the bone marrow. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21506920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "PURPOSE OF REVIEW: WHIM syndrome (warts, hypogammaglobulinemia, immunodeficiency, myelokathexis, or WHIMs) is a very rare autosomal dominant immunodeficiency disorder attributable to m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31652152"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "text": "Background: WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome is an ultra-rare, combined primary immunodeficiency and chronic neutropenic disorder characterized by a range of clinical presentations, including peripheral neutropenia, lymphopenia, and recurrent ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39588369"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 370,
          "text": "The diagnostic complexity is further exacerbated in disorders with wide phenotypic variability such as warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35470097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "AIM: WHIM (warts, hypogammaglobulinaemia, infections and myelokathexis) syndrome is a rare combined primary immunodeficiency disease caused by gain-of-function (GOF) mutations in the chemokine receptor CXCR4 and includes severe neutropenia as a common fea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38185798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273,
          "text": "Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) is a primary immunodeficiency syndrome. Patients with WHIM syndrome are more susceptible to human papillomavirus (HPV) infections and commonly present to a dermatologist with recalcitrant to treatment warts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35385630"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "WHIM syndrome is a rare congenital immunodeficiency disease, named after its main clinical manifestations: warts, hypogammaglobulinemia, infections, and myelokathexis, which refers to abnormal accumulation of mature neutrophils in the bone marrow.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28768817"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 359,
          "text": "Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome is a rare primary immunodeficiency disease in humans caused by a gain of function in CXCR4, mostly due to inherited heterozygous mutations in CXCR4. One major clinical symptom of WHIM patients is their high susceptibility to human papillomavirus (HPV) induced disease, such as warts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39226327"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 272,
          "text": " WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare disease, caused by CXCR4 gene mutations, which incorporates features of combined immunodeficiency, congenital neutropenia, and a predisposition to human papillomavirus infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34697698"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "text": "Background: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare, primary immunodeficiency syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and characteristic bone marrow features of myelokathexis. The pathophysiology of WHIM syn",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36793393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "The WHIM syndrome is a rare immunological disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19476565"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 457,
          "text": "Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) is a primary immunodeficiency syndrome. Patients with WHIM syndrome are more susceptible to human papillomavirus (HPV) infections and commonly present to a dermatologist with recalcitrant to treatment warts. Other cardinal features of WHIM syndrome include recurrent sinopulmonary bacterial infections, neutropenia/lymphopenia, low levels of immunoglobulins (IgG, IgA, IgM) and myelokathexis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35385630"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is an autosomal dominant disease related to a mutation in the chemokine receptor CXCR4 resulting in altered immune function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19926501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "The WHIM syndrome is a rare immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15536153"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "AIM: WHIM (warts, hypogammaglobulinaemia, infections and myelokathexis) syndrome is a rare combined primary immunodeficiency disease caused by gain-of-function (GOF) mutations in the chemokine receptor CXCR4 and includes severe neutropenia as a common fe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38185798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome (WS) is a combined immunodeficiency caused by gain-of-function mutations in the C-X-C chemokine receptor type 4 (CXCR4) gene",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35947323"
        }
      ],
      "type": "list",
      "id": "67e6c4dd18b1e36f2e0000ca",
      "ideal_answer": [
        "WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare primary immunodeficiency predominantly caused by heterozygous gain-of-function mutations in the C-terminus of the gene CXCR4"
      ],
      "exact_answer": [
        [
          "warts"
        ],
        [
          "hypogammaglobulinemia"
        ],
        [
          "infections"
        ],
        [
          "myelokathexis"
        ]
      ]
    },
    {
      "body": "The percutaneous thermal ablation techniques that aresuitable for the treatment of bone oligometastases",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38302831",
        "http://www.ncbi.nlm.nih.gov/pubmed/24894924",
        "http://www.ncbi.nlm.nih.gov/pubmed/16138468",
        "http://www.ncbi.nlm.nih.gov/pubmed/24859596",
        "http://www.ncbi.nlm.nih.gov/pubmed/30402013",
        "http://www.ncbi.nlm.nih.gov/pubmed/26981915",
        "http://www.ncbi.nlm.nih.gov/pubmed/16598666",
        "http://www.ncbi.nlm.nih.gov/pubmed/36346453",
        "http://www.ncbi.nlm.nih.gov/pubmed/33100690",
        "http://www.ncbi.nlm.nih.gov/pubmed/30627778",
        "http://www.ncbi.nlm.nih.gov/pubmed/25841503",
        "http://www.ncbi.nlm.nih.gov/pubmed/21767782",
        "http://www.ncbi.nlm.nih.gov/pubmed/26860716",
        "http://www.ncbi.nlm.nih.gov/pubmed/37127487",
        "http://www.ncbi.nlm.nih.gov/pubmed/36942407",
        "http://www.ncbi.nlm.nih.gov/pubmed/38265293",
        "http://www.ncbi.nlm.nih.gov/pubmed/39386885",
        "http://www.ncbi.nlm.nih.gov/pubmed/38687944",
        "http://www.ncbi.nlm.nih.gov/pubmed/39217639",
        "http://www.ncbi.nlm.nih.gov/pubmed/38217754",
        "http://www.ncbi.nlm.nih.gov/pubmed/38342868",
        "http://www.ncbi.nlm.nih.gov/pubmed/28237869",
        "http://www.ncbi.nlm.nih.gov/pubmed/24337349",
        "http://www.ncbi.nlm.nih.gov/pubmed/33487588",
        "http://www.ncbi.nlm.nih.gov/pubmed/31537154",
        "http://www.ncbi.nlm.nih.gov/pubmed/24238380",
        "http://www.ncbi.nlm.nih.gov/pubmed/38647995",
        "http://www.ncbi.nlm.nih.gov/pubmed/19361670",
        "http://www.ncbi.nlm.nih.gov/pubmed/34088775",
        "http://www.ncbi.nlm.nih.gov/pubmed/32452697",
        "http://www.ncbi.nlm.nih.gov/pubmed/23200605",
        "http://www.ncbi.nlm.nih.gov/pubmed/20656234",
        "http://www.ncbi.nlm.nih.gov/pubmed/34890007",
        "http://www.ncbi.nlm.nih.gov/pubmed/34495961",
        "http://www.ncbi.nlm.nih.gov/pubmed/33951570",
        "http://www.ncbi.nlm.nih.gov/pubmed/36005203",
        "http://www.ncbi.nlm.nih.gov/pubmed/36320002",
        "http://www.ncbi.nlm.nih.gov/pubmed/36171820",
        "http://www.ncbi.nlm.nih.gov/pubmed/38883314",
        "http://www.ncbi.nlm.nih.gov/pubmed/38993602",
        "http://www.ncbi.nlm.nih.gov/pubmed/30307346",
        "http://www.ncbi.nlm.nih.gov/pubmed/21944239",
        "http://www.ncbi.nlm.nih.gov/pubmed/19330317"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 180,
          "text": "The percutaneous thermal ablation techniques (pTA) are radiofrequency ablation, cryoablation, and microwave ablation, suitable for the treatment of bone oligometastases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Magnetic resonance-guided focused ultrasound versus percutaneous thermal ablation in local control of bone oligometastases: a systematic review and meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 596,
          "text": "Ablation techniques include ethanol or acetic acid injection and thermal ablation by means of energy deposition [including laser, radiofrequency, microwave, cryoablation, radiofrequency ionization and magnetic resonance (MR)-guided high-intensity focused ultrasound (HIFU)]. Goal definition of the therapy is crucial: ablation techniques can be proposed as curative treatments in benign bone tumors or oligometastatic disease (\u003c3 lesions).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894924"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 382,
          "text": "Computed tomography-guided radiofrequency or laser ablation is the modality of choice for most osteoid osteomas. Radiofrequency or laser thermal ablation also offers an alternative method for palliation of localized, painful osteolytic metastatic lesions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16138468"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Thermal ablation techniques: a curative treatment of bone metastases in selected patients?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 36,
          "text": "Thermal Ablation of Bone Metastases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30402013"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 631,
          "text": "Thermal ablation through IR has already become important in the palliation and consolidation of bone metastases, oligometastatic disease, local recurrences, and treating specific benign tumors, with a more tailored approach, considering the characteristics of every patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36346453"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Thermal ablation to relieve pain from metastatic bone disease: a systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30627778"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 130,
          "text": "The aim of this article is to review the significance of percutaneous thermal ablation in the treatment of bone tumors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26981915"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "CT image guided thermal ablation techniques for palliation of painful bone metastases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25841503"
        },
        {
          "offsetInBeginSection": 813,
          "offsetInEndSection": 968,
          "text": "Image-guided percutaneous thermal ablation therapies are established techniques in the local treatment of hepatic, renal, bone, thyroid and uterine lesions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37127487"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Clinical efficacy and safety of microwave ablation combined with percutaneous osteoplasty for palliative treatment in pelvic osteolytic metastases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38265293"
        },
        {
          "offsetInBeginSection": 581,
          "offsetInEndSection": 736,
          "text": "Image-guided percutaneous thermal ablation therapies are established techniques in the local treatment of hepatic, renal, bone, thyroid, or uterine lesions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36942407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Clinical Efficacy of Microwave Ablation Combined with Percutaneous Osteoplasty in the Treatment of Flat Bone Metastases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39386885"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 201,
          "text": "To evaluate the safety and efficacy of microwave ablation (MWA) combined with percutaneous vertebroplasty (PVP) in the treatment of multisegmental (2-3 segments) osteolytic spinal metastases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38687944"
        },
        {
          "offsetInBeginSection": 257,
          "offsetInEndSection": 461,
          "text": "High-intensity focused ultrasound (HIFU) is a recent technology that enables noninvasive thermal ablation of tissue and has shown efficacy in treating tumors, neuropathic pain, and painful bone metastases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39217639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Analgesic efficacy and safety of percutaneous thermal ablation plus cementoplasty for painful bone metastases: a systematic review and meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38217754"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "BACKGROUND: The percutaneous thermal ablation techniques (pTA) are radiofrequency ablation, cryoablation, and microwave ablation, suitable for the treatment of bone oligometastases. Magnetic resonance-gu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Percutaneous thermal ablation of sacral metastases: Assessment of pain relief and local tumor control.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33487588"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 340,
          "text": "Minimally invasive percutaneous thermal ablation of osseous metastases has proved safe and effective in management of selected patients with bone metastatic disease. These procedures have become a part of the treatment algorithm for certain subgroup of patients with osseous metastases to achieve pain palliation and/or local tumor control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31537154"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "Thermal ablation is an effective, minimally invasive alternative to conventional therapies in the palliation of painful musculoskeletal metastases and an emerging approach to obtain local tumor control in the setting of limited metastatic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24238380"
        },
        {
          "offsetInBeginSection": 1860,
          "offsetInEndSection": 2059,
          "text": "Limited data availability on MRgFUS and the lack of direct comparisons with pTA may affect these findings.CONCLUSIONS: MRgFUS can be a valid, safe, and noninvasive treatment for bone oligometastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 546,
          "text": "Magnetic resonance-guided focused ultrasound (MRgFUS) is a noninvasive ablation technique.OBJECTIVES: To compare the effectiveness and safety of MRgFUS and pTA for treating bone oligometastases and their complications.METHODS: Studies were selected with a PICO/PRISMA protocol: pTA or MRgFUS in patients with bone oligometastases; non-exclusive curative treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "BACKGROUND: The percutaneous thermal ablation techniques (pTA) are radiofrequency ablation, cryoablation, and microwave ablation, suitable for the treatment of bone oligometastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 1126,
          "offsetInEndSection": 1640,
          "text": "In the multivariate analysis the favourable prognostic factors for complete local treatment were oligometastatic status (p \u003d 0.02), metachronous (p \u003d 0.004) and small-sized (p \u003d 0.001) bone metastases, without cortical bone erosion (p \u003d 0.01) or neurological structures in the vicinity (p \u003d 0.002).CONCLUSION: Thermal ablation should be included in the therapeutic arsenal for the cure of bone metastases.KEY POINTS: • Thermal ablation techniques are currently performed to palliate pain caused by bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 370,
          "text": "PURPOSE OF REVIEW: To provide an update on the current state of percutaneous thermal ablation in the treatment of sarcoma.RECENT FINDINGS: Data continue to accrue in support of ablation for local control and palliation of specific sarcoma subtypes such as extra-abdominal desmoid fibromatosis and for broader indications such as the treatment of oligometastatic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38647995"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 495,
          "text": "Radiofrequency ablation (RFA) has become the reference standard for treatment of most osteoid osteomas. More recently, RFA has been applied to several other forms of primary tumors and in the treatment and palliation of osseous metastases. Cryoablation using new closed systems has also become available for the percutaneous treatment of both primary and metastatic lesions,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19361670"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 367,
          "text": "HIFU has passed regulatory approval around the world for the ablation of various solid tumors, the treatment of neurologic diseases, and the palliative management of bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34088775"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 180,
          "text": " The percutaneous thermal ablation techniques (pTA) are radiofrequency ablation, cryoablation, and microwave ablation, suitable for the treatment of bone oligometastases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 303,
          "offsetInEndSection": 400,
          "text": "This article will describe current thermal ablation techniques utilized to treat bone metastases,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30402013"
        },
        {
          "offsetInBeginSection": 466,
          "offsetInEndSection": 652,
          "text": "This article reviews current practices of percutaneous ablation of musculoskeletal metastases with an emphasis on radiofrequency ablation and cryoablation of painful skeletal metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24238380"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 169,
          "text": "The objective of this article is to describe evidence-based guidelines for percutaneous minimally invasive imaging-guided thermal ablation of bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32452697"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 185,
          "text": " To retrospectively evaluate the feasibility, safety, and effectiveness of computed tomography (CT)-guided percutaneous microwave ablation (MWA) in patients with bone metastases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200605"
        },
        {
          "offsetInBeginSection": 179,
          "offsetInEndSection": 389,
          "text": "Ablative technologies applied in the treatment of skeletal metastases include radiofrequency ablation, cryoablation, microwave ablation, laser ablation, ethanol ablation, and, most recently, focused ultrasound.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20656234"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 445,
          "text": "This article will review the principles of radiofrequency ablation including its use in combination with other therapies, cryoablation, and microwave ablation in the treatment of osteoid osteomas and bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16598666"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 319,
          "text": "Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33100690"
        },
        {
          "offsetInBeginSection": 554,
          "offsetInEndSection": 671,
          "text": "This article reviews the use of radiofrequency ablation and cryoablation in the treatment of painful bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21767782"
        },
        {
          "offsetInBeginSection": 240,
          "offsetInEndSection": 382,
          "text": "Radiofrequency or laser thermal ablation also offers an alternative method for palliation of localized, painful osteolytic metastatic lesions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16138468"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Thermal ablation techniques are procedures of growing interest for management of bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34890007"
        },
        {
          "offsetInBeginSection": 813,
          "offsetInEndSection": 969,
          "text": "Image-guided percutaneous thermal ablation therapies are established techniques in the local treatment of hepatic, renal, bone, thyroid and uterine lesions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37127487"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Thermal therapies such as radiofrequency ablation (RFA) are gaining widespread clinical adoption in the local treatment of skeletal metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34495961"
        },
        {
          "offsetInBeginSection": 372,
          "offsetInEndSection": 549,
          "text": "Literature shows the effectiveness of cryoablation in the management of bone metastases in terms of pain palliation, but also its employment with curative intent is recommended.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34890007"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "Image-guided cryoablation has become a common approach for the palliative treatment of painful metastatic bone lesions, and indications for this procedure have expanded to include local control of bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33951570"
        },
        {
          "offsetInBeginSection": 1541,
          "offsetInEndSection": 1815,
          "text": "The combined treatment of RFA with a steerable device and cementoplasty is a safe, feasible, and promising clinical option for the management of painful bone metastases, challenging for morphology and location, resulting in an improvement of the quality of life of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36005203"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 264,
          "text": " Microwave ablation (MWA) has been used to treat bone tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38883314"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Minimally invasive percutaneous thermal ablation of osseous metastases has proved safe and effective in management of selected patients with bone metastatic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31537154"
        },
        {
          "offsetInBeginSection": 1096,
          "offsetInEndSection": 1243,
          "text": " treating painful lesions.• Palliative treatment of painful bone metastases can for example be performed using MWA or MR-guided HIFU, by itself or ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26981915"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "O-arm-guided percutaneous microwave ablation and cementoplasty for the treatment of pelvic acetabulum bone metastasis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36171820"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Percutaneous Vertebral Augmentation and Thermal Ablation in Patients with Spinal Metastases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38993602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26860716"
        },
        {
          "offsetInBeginSection": 686,
          "offsetInEndSection": 917,
          "text": "Oligometastases can be targeted by image-guided puncture for percutaneous ablation by delivering locally, through inserted probes, heat (radiofrequency, microwaves), extreme cold (cryoablation) or electric pulses (electroporation).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28237869"
        },
        {
          "offsetInBeginSection": 328,
          "offsetInEndSection": 586,
          "text": "Percutaneous ablation of bone tumors: alcohol, laser, radiofrequency, microwaves, ultrasound, and cryoablation. Several indications have previously been validated, including thermal ablation of bone metastases with results superior to conventional therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21944239"
        },
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 671,
          "text": "Image-guided thermal ablation of bone metastases provides a minimally invasive alternative for pain palliation. This article reviews the use of radiofrequency ablation and cryoablation in the treatment of painful bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21767782"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 302,
          "text": "Image-guided, minimally invasive, percutaneous thermal ablation of bone metastases has unique advantages compared with surgery or radiation therapy. Thermal ablation of osseous metastases may result in significant pain palliation, prevention of skeletal-related events, and durable local tumor control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30402013"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "OBJECTIVE: To assess the clinical efficacy of microwave ablation (MWA) in treating tumour patients with postsurgical intrapulmonary oligometastases or oligorecurren",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38342868"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "PURPOSE: Osteoid osteoma (OO) is a painful benign bone tumor of the young that is widely treated by percutaneous thermal ablation (PTA) with success rates close",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24337349"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 558,
          "text": "In this article we will briefly review the principles of radiofrequency ablation and our experience with this technique, including its use in combination with surgery; we will also discuss other minimally invasive techniques such as cryoablation and osteoplasty in the treatment of bone metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19330317"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 157,
          "text": " Percutaneous image-guided cryo- (CA) and radiofrequency- (RFA) ablations have been widely used in the treatment of painful bone metastases (BM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30307346"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 632,
          "text": "Thermal ablation through IR has already become important in the palliation and consolidation of bone metastases, oligometastatic disease, local recurrences, and treating specific benign tumors, with a more tailored approach, considering the characteristics of every patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36346453"
        },
        {
          "offsetInBeginSection": 1705,
          "offsetInEndSection": 1825,
          "text": "Conclusion Percutaneous CT-guided RFA may be a safe and effective treatment for the LN oligometastases generated by HCC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Image-guided, minimally invasive, percutaneous thermal ablation of bone metastases has unique advantages compared with surgery or radiation therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30402013"
        },
        {
          "offsetInBeginSection": 179,
          "offsetInEndSection": 388,
          "text": "Ablative technologies applied in the treatment of skeletal metastases include radiofrequency ablation, cryoablation, microwave ablation, laser ablation, ethanol ablation, and, most recently, focused ultrasound",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20656234"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 444,
          "text": "This article will review the principles of radiofrequency ablation including its use in combination with other therapies, cryoablation, and microwave ablation in the treatment of osteoid osteomas and bone metastases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16598666"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 366,
          "text": "HIFU has passed regulatory approval around the world for the ablation of various solid tumors, the treatment of neurologic diseases, and the palliative management of bone metastases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34088775"
        },
        {
          "offsetInBeginSection": 686,
          "offsetInEndSection": 915,
          "text": "Oligometastases can be targeted by image-guided puncture for percutaneous ablation by delivering locally, through inserted probes, heat (radiofrequency, microwaves), extreme cold (cryoablation) or electric pulses (electroporation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28237869"
        },
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 376,
          "text": " technique.OBJECTIVES: To compare the effectiveness and safety of MRgFUS and pTA for treating bone oligometastases ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38302831"
        },
        {
          "offsetInBeginSection": 918,
          "offsetInEndSection": 1149,
          "text": "Radiofrequency (RFA) is the mainstay of percutaneous ablation and provides local control rates of around 90% when metastases are small (\u003c3 cm), located away from hilum and large vessels, and perfectly visible under imaging guidance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28237869"
        }
      ],
      "type": "list",
      "id": "67e85c4318b1e36f2e0000d9",
      "ideal_answer": [
        "The percutaneous thermal ablation techniques (pTA) are radiofrequency ablation, cryoablation, and microwave ablation, suitable for the treatment of bone oligometastases",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases include radiofrequency ablation (RFA), microwave ablation (MWA), laser ablation, high intensity focused ultrasound (HIFU), and cryoablation.",
        "Radiofrequency ablation, cryoablation, and microwave ablation are suitable for the treatment of bone oligometastases.",
        "The percutaneous thermal ablation techniques that are suitable for the treatment of bone oligometastases are radiofrequency ablation, microwave ablation, cryoablation, MR-guided focused ultrasound, and MRgFUS.",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases include radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation. These minimally invasive techniques effectively target and destroy metastatic bone lesions, providing pain relief and local tumor control.\n\nRadiofrequency ablation (RFA) uses high-frequency electrical currents to generate heat and destroy cancer cells. Microwave ablation (MWA) employs electromagnetic waves to produce heat and ablate the tumor tissue. Cryoablation involves the application of extreme cold to freeze and kill cancer cells.\n\nThe choice of technique depends on the size, location, and number of metastatic lesions, as well as the patient\u0027s overall health and treatment goals. Consultation with a multidisciplinary team including oncologists, radiologists, and interventional radiologists is essential for specific cases and detailed treatment planning.",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases are radiofrequency ablation, cryoablation, and microwave ablation. Other ablative technologies applied in the treatment of skeletal metastases include laser ablation, ethanol ablation, and focused ultrasound.",
        "radiofrequency ablation, cryoablation, microwave ablation, and laser thermal ablation are percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases.",
        "The percutaneous thermal ablation techniques that are suitable for the treatment of bone oligometastases are MR-guided focused ultrasound (MRgFUS), radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation (CA).",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases include: radiofrequency ablation, microwave ablation, cryoablation, and high-intensity focused ultrasound (HIFU).",
        "The percutaneous thermal ablation techniques that are suitable for the treatment of bone oligometastases include radiofrequency ablation, microwave ablation, cryoablation, and magnetic resonance-guided focused ultrasound.",
        "Percutaneous thermal ablation (PTA) techniques for the treatment of bone oligometastases include radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases include: radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation (CA), and MR-guided focused ultrasound (MRgFUS).",
        "Percutaneous thermal ablation techniques like RFA, MWA, CA, and MRgFUS are suitable for treating bone oligometastases.",
        "Radiofrequency ablation, cryoablation, and microwave ablation are the percutaneous thermal ablation techniques used to treat bone oligometastases.",
        "The percutaneous thermal ablation techniques that are suitable for the treatment of bone oligometastases are radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation (CA), and MR-guided focused ultrasound (MRgFUS).",
        "The percutaneous thermal ablation techniques (pTA) are radiofrequency ablation, cryoablation, and microwave ablation, suitable for the treatment of bone oligometastases.",
        "Percutaneous thermal ablation (pTA) techniques for bone oligometastases include three primary methods: radiofrequency ablation, cryoablation, and microwave ablation. These minimally invasive techniques offer targeted treatment options for patients with limited bone metastases.",
        "The main percutaneous thermal ablation (pTA) techniques used for treating bone oligometastases include radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques (pTA) suitable for treating bone oligometastases include radiofrequency ablation, cryoablation, and microwave ablation. These minimally invasive methods use targeted thermal energy to destroy metastatic lesions in the bone.",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases are radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques are radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases include radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques that are suitable for the treatment of bone oligometastases are radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases are: radiofrequency ablation (RFA), cryoablation (CA), and microwave ablation (MWA).",
        "The percutaneous thermal ablation techniques used to treat bone oligometastases are radiofrequency ablation, cryoablation, and microwave ablation. These minimally invasive methods provide local control of metastatic bone lesions.",
        "The percutaneous thermal ablation techniques suitable for treating bone oligometastases include radiofrequency ablation (RFA), cryoablation, and microwave ablation. Each technique has its own mechanism of action and considerations:\n\n1. **Radiofrequency Ablation (RFA)**:\n   - Uses heat from radio waves to destroy cancer cells.\n   - Effective for targeting tumors precisely with minimal impact on surrounding tissue.\n   - Suitable for smaller oligometastatic lesions in bone.\n\n2. **Cryoablation**:\n   - Utilizes extreme cold to freeze and destroy cancerous cells.\n   - May offer advantages in areas where heat could damage nearby structures like blood vessels or nerves.\n   - Effective for certain cases of bone metastasis, especially when avoiding thermal damage is crucial.\n\n3. **Microwave Ablation**:\n   - Employs microwave energy to generate heat within the tumor, leading to coagulation and necrosis.\n   - Similar to RFA but may offer different benefits depending on the specific situation.\n\nConsiderations for each technique include the size and location of the tumors, proximity to vital structures, and the expertise of the medical team. Clinical studies and outcomes are essential in evaluating their effectiveness, tumor control rates, patient survival, and quality of life. Potential complications, such as thermal damage or ice formation beyond the target area, should also be considered.\n\nIn conclusion, RFA, cryoablation, and microwave ablation are all viable options for treating bone oligometastases, with the choice depending on specific tumor characteristics, patient circumstances, and the expertise available at the healthcare facility.",
        "Percutaneous thermal ablation techniques suitable for treating bone oligometastases include radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases are: radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques suitable for the treatment of bone oligometastases include radiofrequency ablation, cryoablation, and microwave ablation. These methods are utilized to target and treat small numbers of metastatic lesions in bones.",
        "Radiofrequency ablation, cryoablation, and microwave ablation are percutaneous thermal ablation techniques suitable for treating bone oligometastases.",
        "The suitable percutaneous thermal ablation techniques for treating bone oligometastases are radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques that aresuitable for the treatment of bone oligometastases are radiofrequency ablation, cryoablation, and microwave ablation.",
        "The percutaneous thermal ablation techniques (pTA) suitable for the treatment of bone oligometastases are radiofrequency ablation, cryoablation, and microwave ablation.",
        "Studies have shown that percutaneous thermal ablation techniques such as radiofrequency ablation, cryoablation, and microwave ablation are effective for the treatment of bone oligometastases.",
        "Studies have shown that radiofrequency ablation (RFA), cryoablation, and microwave ablation (MWA) are effective techniques for treating bone oligometastases. These methods utilize different mechanisms—RFA employs heat from radiofrequency waves, cryoablation uses freezing temperatures, and MWA generates heat via microwaves—to destroy cancer cells, making them suitable options for this condition.",
        "The percutaneous thermal ablation techniques suitable for treating bone oligometastases are radiofrequency ablation, cryoablation, and microwave ablation.",
        "Radiofrequency Ablation, Cryoablation, and Microwave Ablation are suitable percutaneous thermal ablation techniques for the treatment of bone oligometastases.",
        "The percutaneous thermal ablation techniques that are suitable for the treatment of bone oligometastases can be radiofrequency ablation, cryoablation, and microwave ablation.",
        "Percutaneous thermal ablation (pTA) techniques, including radiofrequency ablation, cryoablation, and microwave ablation, are suitable for treating bone oligometastases. These minimally invasive procedures utilize heat to target and destroy cancerous cells in the bones, offering an alternative to more extensive surgical interventions."
      ],
      "exact_answer": [
        [
          "radiofrequency ablation"
        ],
        [
          "cryoablation"
        ],
        [
          "microwave ablation"
        ],
        [
          "High-Intensity Focused Ultrasound (HIFU)"
        ],
        [
          "Laser Ablation"
        ],
        [
          "percutaneous thermal ablation"
        ],
        [
          "Magnetic resonance-guided focused ultrasound (MRgFUS) i"
        ]
      ]
    },
    {
      "body": "Most common infectious cause of congenital deafness.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38397168",
        "http://www.ncbi.nlm.nih.gov/pubmed/37342452",
        "http://www.ncbi.nlm.nih.gov/pubmed/38255364",
        "http://www.ncbi.nlm.nih.gov/pubmed/39359874",
        "http://www.ncbi.nlm.nih.gov/pubmed/37820202",
        "http://www.ncbi.nlm.nih.gov/pubmed/35276528",
        "http://www.ncbi.nlm.nih.gov/pubmed/9570657",
        "http://www.ncbi.nlm.nih.gov/pubmed/84910",
        "http://www.ncbi.nlm.nih.gov/pubmed/26661605",
        "http://www.ncbi.nlm.nih.gov/pubmed/21612560",
        "http://www.ncbi.nlm.nih.gov/pubmed/26647548",
        "http://www.ncbi.nlm.nih.gov/pubmed/38220046",
        "http://www.ncbi.nlm.nih.gov/pubmed/36142981",
        "http://www.ncbi.nlm.nih.gov/pubmed/28796762",
        "http://www.ncbi.nlm.nih.gov/pubmed/19638941",
        "http://www.ncbi.nlm.nih.gov/pubmed/16645211",
        "http://www.ncbi.nlm.nih.gov/pubmed/11843023",
        "http://www.ncbi.nlm.nih.gov/pubmed/32666770",
        "http://www.ncbi.nlm.nih.gov/pubmed/2154028",
        "http://www.ncbi.nlm.nih.gov/pubmed/15704329",
        "http://www.ncbi.nlm.nih.gov/pubmed/18054797",
        "http://www.ncbi.nlm.nih.gov/pubmed/38146009",
        "http://www.ncbi.nlm.nih.gov/pubmed/38640886",
        "http://www.ncbi.nlm.nih.gov/pubmed/39408057",
        "http://www.ncbi.nlm.nih.gov/pubmed/36596746",
        "http://www.ncbi.nlm.nih.gov/pubmed/37118680",
        "http://www.ncbi.nlm.nih.gov/pubmed/35093998",
        "http://www.ncbi.nlm.nih.gov/pubmed/36369401",
        "http://www.ncbi.nlm.nih.gov/pubmed/35225414",
        "http://www.ncbi.nlm.nih.gov/pubmed/36777981",
        "http://www.ncbi.nlm.nih.gov/pubmed/36439580",
        "http://www.ncbi.nlm.nih.gov/pubmed/37445500",
        "http://www.ncbi.nlm.nih.gov/pubmed/21374290",
        "http://www.ncbi.nlm.nih.gov/pubmed/27334585",
        "http://www.ncbi.nlm.nih.gov/pubmed/31331274",
        "http://www.ncbi.nlm.nih.gov/pubmed/2991681",
        "http://www.ncbi.nlm.nih.gov/pubmed/32134480",
        "http://www.ncbi.nlm.nih.gov/pubmed/37806805",
        "http://www.ncbi.nlm.nih.gov/pubmed/21827436",
        "http://www.ncbi.nlm.nih.gov/pubmed/32968468",
        "http://www.ncbi.nlm.nih.gov/pubmed/16205606",
        "http://www.ncbi.nlm.nih.gov/pubmed/17337260",
        "http://www.ncbi.nlm.nih.gov/pubmed/28646968",
        "http://www.ncbi.nlm.nih.gov/pubmed/36517460",
        "http://www.ncbi.nlm.nih.gov/pubmed/18475257",
        "http://www.ncbi.nlm.nih.gov/pubmed/2555420",
        "http://www.ncbi.nlm.nih.gov/pubmed/1647141",
        "http://www.ncbi.nlm.nih.gov/pubmed/32305661",
        "http://www.ncbi.nlm.nih.gov/pubmed/7044773",
        "http://www.ncbi.nlm.nih.gov/pubmed/8160023",
        "http://www.ncbi.nlm.nih.gov/pubmed/24631522",
        "http://www.ncbi.nlm.nih.gov/pubmed/37917050",
        "http://www.ncbi.nlm.nih.gov/pubmed/27995350",
        "http://www.ncbi.nlm.nih.gov/pubmed/39205316",
        "http://www.ncbi.nlm.nih.gov/pubmed/36634668",
        "http://www.ncbi.nlm.nih.gov/pubmed/6275218",
        "http://www.ncbi.nlm.nih.gov/pubmed/39124634",
        "http://www.ncbi.nlm.nih.gov/pubmed/29512778",
        "http://www.ncbi.nlm.nih.gov/pubmed/7640200",
        "http://www.ncbi.nlm.nih.gov/pubmed/12784230",
        "http://www.ncbi.nlm.nih.gov/pubmed/19730140"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 105,
          "text": "Congenital cytomegalovirus infection (cCMV) is a major cause of childhood hearing loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37820202"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 352,
          "text": "CMV infection during pregnancy. It is the most common infectious agent for sensorineural hearing loss (SNHL) in young children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35276528"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "We report on an infant with bilateral deafness discovered at the age of 5 months caused by a retrospectively diagnosed primary maternal CMV infection after definitive exclusion of maternal rubella reinfection as a cause of fetal infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9570657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Bilateral deafness due to congenital CMV and not rubella reinfection.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9570657"
        },
        {
          "offsetInBeginSection": 621,
          "offsetInEndSection": 801,
          "text": "Congenital rubella is an important cause of deafness, and the rubella vaccination programme must be pursued more vigorously if this serious defect is to be prevented in the future.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/84910"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 51,
          "text": "Congenital rubella deafness: a preventable disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/84910"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 40,
          "text": "Congenital Cytomegalovirus and Deafness.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661605"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "CONCLUSIONS: Congenital cytomegalovirus (CMV) infection is a major cause of bilateral and unilateral sensorineural hearing loss (SNHL) in children, accounting for 9.0% o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21612560"
        },
        {
          "offsetInBeginSection": 747,
          "offsetInEndSection": 852,
          "text": "Early pregnancy women infected with rubella virus can cause very severe offspring sensorineural deafness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647548"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 340,
          "text": "Universal hearing screening offers unique possibilities for detection of congenital deafness as a consequence of congenital cytomegalovirus (CMVc) infection, so its selective study in the case of a failed test could be a non-negligible screening opportunity while other guidelines covering the possibility of universal screening are adopted",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38220046"
        },
        {
          "offsetInBeginSection": 1058,
          "offsetInEndSection": 1257,
          "text": "A neonatal CMV test combined with genetic screening can improve the etiological diagnosis rate of congenital deafness, and the direct evidence of neonatal CMV infection deserves further verification.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36142981"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 476,
          "text": "Zika virus infection during pregnancy has been linked to adverse congenital outcomes including microcephaly, neural tube defects, early brain malformations, structural eye abnormalities, congenital deafness, and limb contractures (1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28796762"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 337,
          "text": "ur children with congenital CMV-related deafness (CMV group) and 17 children with congenital deafness without CMV infection as the cause of deafness (non-CMV group). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19638941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Cytomegalovirus is the most common cause of congenital infectious disease and the leading nongenetic etiology of sensorineural hearing loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38146009"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 162,
          "text": "Congenital CMV infection is the most common congenital infection worldwide and a major cause of neurological impairment and sensorineural hearing loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38640886"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Congenital cytomegalovirus (cCMV) is the most common cause of congenital infection and the leading cause of non-genetic sensorineural hearing loss in childhood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39408057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Congenital cytomegalovirus (CMV) is the most common cause of congenital infection worldwide, the most common nongenetic cause of sensorineural hearing loss in children, and a cause of neurodevelopmental disorders in the brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36596746"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 173,
          "text": "Congenital cytomegalovirus (CMV) infection is the most common congenital infection worldwide and one of the leading causes of congenital hearing loss in newborns",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37118680"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 169,
          "text": "Cytomegalovirus (CMV) is the most frequent cause of congenital infection and ≈20% of all infected neonates present or will develop sensorineural hearing loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35093998"
        },
        {
          "offsetInBeginSection": 1558,
          "offsetInEndSection": 1727,
          "text": "What is Known: • Congenital cytomegalovirus infection is the leading infectious cause of neurological disabilities and sensorineural hearing loss in children. In the abs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36369401"
        },
        {
          "offsetInBeginSection": 5,
          "offsetInEndSection": 186,
          "text": "Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital malformation, non-genetic sensorineural hearing loss and neurodevelopmental sequelae in childhood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35225414"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Congenitally acquired cytomegalovirus (CMV) infection is the most prevalent congenital infection worldwide and the most frequent cause of acquired sensorineural hearing loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36777981"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 321,
          "text": "CMV is considered one of the leading causes of congenital hearing loss in babies born to infected mothers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36439580"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 304,
          "text": "Congenital cytomegalovirus infection is the leading infectious cause of deafness, learning disabilities, and mental retardation in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843023"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 359,
          "text": "with symptomatic congenital CMV disease, which is the most common cause of mental retardation and childhood deafness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21374290"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "Congenital cytomegalovirus (cCMV) infection is a leading cause of hearing loss and neurological disabilities in children, with the disease burden and disabilities due to cCMV greater than many other well recognized childhood conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32134480"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Cytomegalovirus (CMV) infection is currently reported as the most common cause of congenital viral induced deafness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2991681"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Congenital human cytomegalovirus (HCMV) infection affects 1% of children and is the most common infectious cause of sensorineural hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16645211"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Cytomegalovirus (CMV) remains the most common cause of congenitally-acquired infection in the United States and is a leading infectious cause of sensorineural hearing loss, cognitive delay, and permanent neurologic sequelae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21827436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "BACKGROUND: Congenital CMV is the most common cause of nonhereditary sensorineural hearing loss in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18054797"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "AIM: Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital malformation, non-genetic sensorineural hearing loss and neurodevelopmental sequelae in childhood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35225414"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Cytomegalovirus (CMV) is the most common infectious cause of congenital malformation and a leading cause of developmental disabilities such as sensorineural hearing loss (SNHL), motor and cognitive deficits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37806805"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "The cytomegalovirus (CMV) is responsible for the most common congenital infection and represents the most important cause of mental disability and non hereditary sensorineural deafness in infants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16205606"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Cytomegalovirus (CMV) remains the most common cause of congenitally-acquired infection in the United States and is a leading infectious cause of sensorineural hearing loss,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21827436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Cytomegalovirus (CMV) is the leading cause of congenital infection and the most common cause of non-genetic sensorineural hearing loss (SNHL) in childhood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32968468"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Congenital cytomegalovirus (CMV) infection is one of the most common viral causes of congenital infections in high resource countries and a leading cause of hearing loss ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17337260"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Congenital cytomegalovirus (CMV) is the commonest cause of congenital infection worldwide and the leading non-genetic cause of sensorineural hearing loss in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28646968"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Congenital cytomegalovirus (cCMV) infection is the most common congenital viral infection and is the leading non-genetic cause of sensorineural hearing loss ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36517460"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Congenital cytomegalovirus (CMV) infection is the most common infectious cause of sensorineural hearing loss in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18475257"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Cytomegalovirus (CMV) is the leading cause of human nonhereditary congenital deafness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2555420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Congenital cytomegalovirus (cCMV) infection is the most common congenital viral infection and is the leading non-genetic cause of sensorineural hearing loss and an important cause of neurodevelopmental disabilities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36517460"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "BACKGROUND: Congenital cytomegalovirus (CMV) infection is the most common congenital infection worldwide and one of the leading causes of congenital hearing loss ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37118680"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Cytomegalovirus is the most frequently recognized cause of congenital viral infection and of viral induced congenital hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1647141"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 338,
          "text": "hearing loss. Congenital cytomegalovirus infection (cCMV) is the most important prenatal etiological factor causing hearing loss and ot",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32305661"
        },
        {
          "offsetInBeginSection": 1349,
          "offsetInEndSection": 1478,
          "text": "With the development of rubella vaccine and Rhogam, cytomegalovirus may have become the most common cause of congenital deafness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7044773"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "AIM: Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital malformation, non-genetic sensorineural hearing loss and neurodevelopmental sequelae in child",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35225414"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "BACKGROUND: Congenital cytomegalovirus (CMV) infection is the leading infectious cause of congenital hearing loss and neurodevelopmental disability in develop",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24631522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Congenital infection by human cytomegalovirus (CMV) is presently the leading infectious cause of mental retardation and congenital deafness in the United States",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2154028"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Cytomegalovirus (CMV) is the leading cause of human nonhereditary congenital deafness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2555420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Cytomegalovirus is the most frequently recognized cause of congenital viral infection and of viral induced congenital hearing loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1647141"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Importance: Congenital cytomegalovirus (cCMV) is the major cause of congenital nonhereditary sensorineural hearing loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37917050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Cytomegalovirus (CMV) infection is one of the most common causes of congenital hearing loss in children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27995350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Importance: Congenital cytomegalovirus (cCMV) is the major cause of congenital nonhereditary sensorineural hearing loss ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37917050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Cytomegalovirus infection contributes to 10-30% of congenital hearing loss in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39205316"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 615,
          "text": "Its etiologies are heterogeneous: genetic causes are reportedly involved in up to 80% of cases, while congenital cytomegalovirus infection is the leading environmental factor contributing to congenital hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36634668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "BACKGROUND: Congenital cytomegalovirus (CMV) infection is the leading infectious cause of congenital hearing loss and neurodevelopmental disability in develope",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24631522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Congenital infection by human cytomegalovirus (CMV) is presently the leading infectious cause of mental retardation and congenital deafness in the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2154028"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 322,
          "text": "CMV is considered one of the leading causes of congenital hearing loss in babies born to infected mothers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36439580"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Human cytomegalovirus (CMV) is ubiquitous and has been documented as the etiologic factor in several diseases ranging from respiratory tract infection to congenital deafness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6275218"
        },
        {
          "offsetInBeginSection": 23,
          "offsetInEndSection": 288,
          "text": "Congenital cytomegalovirus (cCMV) is the leading infectious cause of sensorineural hearing loss and neurodevelopmental disabilities, with prompt detection (\u003c21 days of life) required to enable accurate diagnosis and anti-viral treatment where clinically appropriate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39124634"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Congenital human cytomegalovirus (CMV) infection is the leading infectious cause of mental retardation, sensorineural deafness and visual impairment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15704329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "UNLABELLED: Congenital cytomegalovirus (CMV) infection is a leading cause of mental retardation and deafness ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27334585"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 220,
          "text": "CMV infection is a leading cause of deafness and an important contributor to learning disabilities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8160023"
        },
        {
          "offsetInBeginSection": 689,
          "offsetInEndSection": 795,
          "text": "congenital rubella can result in deafness, congenital heart disease, retinopathy, and brain calcification.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7640200"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "In developed countries, congenital cytomegalovirus (cCMV) infection is the most common congenital viral infection, representing the leading non-genetic cause of sensorineural hearing loss (HL).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445500"
        },
        {
          "offsetInBeginSection": 246,
          "offsetInEndSection": 382,
          "text": " pregnancy. CMV is the most common congenital infection and is the leading infectious cause of sensoneural deafness and cerebral mental ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32666770"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "BACKGROUND: Congenital CMV is the most common cause of nonhereditary sensorineural hearing loss ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18054797"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "BACKGROUND: Congenital Cytomegalovirus (cCMV) is the most common cause of non-genetic hearing loss i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31331274"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 359,
          "text": "It is the most common fetal and perinatal infectious organism; approx 10% of infected neonates are born with symptomatic congenital CMV disease, which is the most common cause of mental retardation and childhood deafness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21374290"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 510,
          "text": "Cytomegalovirus remains the most common congenital infection and a relatively common etiology of hearing loss, which can be progressive.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12784230"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Congenital cytomegalovirus (CMV) infection is the most common infectious cause of sensorineural hearing loss in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29512778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Cytomegalovirus (CMV) is the most common and serious congenital infection, because it occurs after both primary and recurrent infection in pregnancy and is a major cause of childhood deafness and neurological handicap.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19253166"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "INTRODUCTION: Cytomegalovirus (CMV) infection is the leading cause of congenital nongenetic sensorineural hearing loss (SNHL) and a major cause of prelingual SNHL that is not pr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19730140"
        },
        {
          "offsetInBeginSection": 434,
          "offsetInEndSection": 614,
          "text": "genetic causes are reportedly involved in up to 80% of cases, while congenital cytomegalovirus infection is the leading environmental factor contributing to congenital hearing loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36634668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Congenital cytomegalovirus (CMV) infection is the most common infectious cause of sensorineural hearing loss in children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18475257"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Congenital cytomegalovirus (cCMV) infection is the most common congenital viral infection and is the leading non-genetic cause of sensorineural hearing loss and an important cause of neurodevelopmental disabilities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36517460"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 337,
          "text": "hearing loss. Congenital cytomegalovirus infection (cCMV) is the most important prenatal etiological factor causing hearing loss and o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32305661"
        }
      ],
      "id": "67e270d318b1e36f2e000075",
      "ideal_answer": [
        "CMV infection during pregnancy is the most common infectious agent for sensorineural hearing loss in babies.",
        "Cytomegalovirus (CMV) is the most common infectious cause of congenital deafness.",
        "Congenital cytomegalovirus (CMV) infection is the most common cause of congenital deafness.",
        "Congenital cytomegalovirus (cCMV) infection is the most common infectious cause of congenital deafness.",
        "Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital deafness.",
        "The most common infectious cause of congenital deafness is cytomegalovirus (CMV).",
        "Congenital cytomegalovirus infection (cCMV) is the most common infectious cause of congenital deafness.",
        "The most common infectious cause of congenital deafness is cytomegalovirus (CMV) infection during pregnancy.",
        "Cytomegalovirus (CMV) infection is the most common infectious cause of congenital deafness.",
        "The most common infectious cause of congenital deafness is congenital cytomegalovirus (cCMV) infection.",
        "Congenital cytomegalovirus infection (cCMV) is the most common infectious cause of congenital deafness ."
      ],
      "exact_answer": [
        [
          "CMV infection during pregnancy",
          "rubella"
        ]
      ]
    },
    {
      "body": "Can melanoma occur in areas not exposed to sunlight?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25207377",
        "http://www.ncbi.nlm.nih.gov/pubmed/21995584",
        "http://www.ncbi.nlm.nih.gov/pubmed/19457306",
        "http://www.ncbi.nlm.nih.gov/pubmed/20359907",
        "http://www.ncbi.nlm.nih.gov/pubmed/19255768",
        "http://www.ncbi.nlm.nih.gov/pubmed/9121185",
        "http://www.ncbi.nlm.nih.gov/pubmed/39104656",
        "http://www.ncbi.nlm.nih.gov/pubmed/39633592",
        "http://www.ncbi.nlm.nih.gov/pubmed/39399030",
        "http://www.ncbi.nlm.nih.gov/pubmed/39659656",
        "http://www.ncbi.nlm.nih.gov/pubmed/12394187",
        "http://www.ncbi.nlm.nih.gov/pubmed/8431532",
        "http://www.ncbi.nlm.nih.gov/pubmed/16922607",
        "http://www.ncbi.nlm.nih.gov/pubmed/9190986",
        "http://www.ncbi.nlm.nih.gov/pubmed/35383116",
        "http://www.ncbi.nlm.nih.gov/pubmed/17094377",
        "http://www.ncbi.nlm.nih.gov/pubmed/31306728",
        "http://www.ncbi.nlm.nih.gov/pubmed/21299449",
        "http://www.ncbi.nlm.nih.gov/pubmed/24494053",
        "http://www.ncbi.nlm.nih.gov/pubmed/18768658",
        "http://www.ncbi.nlm.nih.gov/pubmed/15360046",
        "http://www.ncbi.nlm.nih.gov/pubmed/25516505",
        "http://www.ncbi.nlm.nih.gov/pubmed/34209084",
        "http://www.ncbi.nlm.nih.gov/pubmed/35389032",
        "http://www.ncbi.nlm.nih.gov/pubmed/32404956",
        "http://www.ncbi.nlm.nih.gov/pubmed/28092366",
        "http://www.ncbi.nlm.nih.gov/pubmed/27792059"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 417,
          "text": "Malignant melanoma is a tumor that arises from melanocytes and accounts for around 4% of all malignancies in Europe and Northern America and for about 11% in Australia and New Zealand. About 10% of primary melanomas arise from sites not exposed to sun. Acral lentiginous melanoma, mucosal melanoma (in the oral cavities, nasal sinuses, genital tract and rectum) and uveal melanoma are all on non-sun-exposed tissues. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207377"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 331,
          "text": "Melanoma incidence is increasing in many parts of the world. The main environmental risk factor is exposure to solar radiation. However, melanomas may arise also on non-sun-exposed areas (uveal and mucosal melanomas) and little is known about a possible relationship between sun exposure and melanoma on such locations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21995584"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 142,
          "text": "Acral and mucosal melanomas, the most common sun-shielded site melanoma subtypes in Asia and Indonesia, often yield poor prognoses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39633592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Acral melanoma, which is not ultraviolet (UV)-associated, is the most common type of melanoma in several low- and middle-income countries including Mexico",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39399030"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 416,
          "text": "About 10% of primary melanomas arise from sites not exposed to sun. Acral lentiginous melanoma, mucosal melanoma (in the oral cavities, nasal sinuses, genital tract and rectum) and uveal melanoma are all on non-sun-exposed tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207377"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 186,
          "text": "On the other hand, melanomas may arise also in non-sun-exposed areas such as the vulva.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20359907"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 252,
          "text": "About 10% of primary melanomas arise from sites not exposed to sun.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207377"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 177,
          "text": " The foremost important aetiological factor for malignant melanoma is considered to be sunlight exposure. However, primary lesions are also seen in non-sun-exposed areas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255768"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 416,
          "text": "Acral lentiginous melanoma, mucosal melanoma (in the oral cavities, nasal sinuses, genital tract and rectum) and uveal melanoma are all on non-sun-exposed tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207377"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 306,
          "text": "Although cutaneous areas exposed to sunlight are most vulnerable, melanomas can occur in any site on the skin or mucous membranes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9121185"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 415,
          "text": "About 10% of primary melanomas arise from sites not exposed to sun. Acral lentiginous melanoma, mucosal melanoma (in the oral cavities, nasal sinuses, genital tract and rectum) and uveal melanoma are all on non-sun-exposed tissues",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207377"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "The single most important causative factor for malignant melanomas of the skin is UV radiation. However, this is not true for melanomas on body surfaces sheltered from the sun; thus, it is important to seek new causative factors of melanoma genesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18768658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Malignant melanomas appear in such sun-shielded areas as the vulva, challenging conventional knowledge that they are associated with UV radiation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15360046"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 415,
          "text": "Acral lentiginous melanoma, mucosal melanoma (in the oral cavities, nasal sinuses, genital tract and rectum) and uveal melanoma are all on non-sun-exposed tissues",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207377"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 305,
          "text": "Although cutaneous areas exposed to sunlight are most vulnerable, melanomas can occur in any site on the skin or mucous membranes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9121185"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 251,
          "text": "About 10% of primary melanomas arise from sites not exposed to sun",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207377"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 229,
          "text": "MM can also arise in non-sun exposed areas, where other biological pathways may cause the disease, with different outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516505"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 409,
          "text": "For the first time, mutations in mucosal membranes and adjacent tissues shielded from sunlight were compared with those in cutaneous melanomas from sun-exposed skin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12394187"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 164,
          "text": "Acral melanoma refers to melanoma arising on the palms, soles and nail unit, which are sun-protected areas and ultraviolet exposure is not a risk factor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35389032"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Intermittent sun exposure and sunburns are strongly related to the development of melanoma (MM); however, MM can also arise in non-sun exposed areas, where other biological pathways may cause the disease, with different outcomes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516505"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Acral lentiginous melanoma (ALM) is a rare tumor that occurs on non-sun exposed skin areas of the hands and feet.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32404956"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 305,
          "text": "In this landscape, one can distinguish melanomas originating in the mucous membranes and located in areas not exposed to the sun, namely the vulvo-vaginal melanomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34209084"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Intermittent sun exposure and sunburns are strongly related to the development of melanoma (MM); however, MM can also arise in non-sun exposed areas, where other biological pathways may cause the disease, with different outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516505"
        },
        {
          "offsetInBeginSection": 238,
          "offsetInEndSection": 435,
          "text": "Indeed, UV radiations are not reported as the main risk factor for melanoma in non-sun-exposed, while systemic immunosuppression, anatomical and physiological features may contribute to malignancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29249122"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 408,
          "text": "For the first time, mutations in mucosal membranes and adjacent tissues shielded from sunlight were compared with those in cutaneous melanomas from sun-exposed skin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12394187"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 239,
          "text": "Less is known regarding the mechanisms of mutagenesis for melanoma arising in sun-protected sites, such as acral and mucosal melanoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092366"
        },
        {
          "offsetInBeginSection": 492,
          "offsetInEndSection": 668,
          "text": "Our observations suggest that therapeutic radiation may be a factor in the development of malignant melanoma, particularly in non-sun-exposed areas, including the genital tract",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9190986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "text": "Ultraviolet rays are one of the leading factors in the development of melanoma (MM); however, ultraviolet rays seem not to play a role in non-sun-exposed MM, where systemic immunosuppression, anatomical, and physiological features may contribute toward the development of the malignancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27792059"
        }
      ],
      "id": "67eb6ea518b1e36f2e0000e9",
      "ideal_answer": [
        "Malignant melanoma is a tumor that arises from melanocytes and the main environmental risk factor is exposure to solar radiation. However, melanomas may arise also on non-sun-exposed with a percentage up to 10%. Acral lentiginous melanoma, mucosal melanoma (in the oral cavities, nasal sinuses, genital tract, and rectum,) and uveal melanoma are all on non-sun-exposed tissues.",
        "Yes, melanoma can occur in areas not exposed to sunlight. Approximately 10% of primary melanomas are found in non-sun-exposed regions. While ultraviolet radiation is a major risk factor for melanoma in sun-exposed skin, certain subtypes arise in tissues that rarely receive sunlight. For example, acral lentiginous melanomas occur on the palms, soles, and nail beds, while melanomas can also develop in mucosal regions such as the oral cavity, nasal sinuses, genital tract, and rectum. Additionally, melanomas have been observed in the vulva and perianal regions, and uveal melanomas occur in the eye. These observations indicate that factors beyond UV exposure contribute to melanoma development.",
        "Melanoma can indeed occur in areas not exposed to sunlight. While solar radiation is a primary risk factor for many melanomas, certain types of melanoma specifically develop in non-sun-exposed tissues. These include acral lentiginous melanoma, mucosal melanomas (found in oral cavities, nasal sinuses, genital tract, and rectum), and uveal melanoma. About 10% of primary melanomas arise from sites not exposed to sun, demonstrating that sun exposure is not the only factor in melanoma development.",
        "While sun exposure is a major risk factor for melanoma, approximately 10% of primary melanomas can develop in areas not exposed to sunlight. These non-sun-exposed melanomas include acral lentiginous melanoma, mucosal melanoma (occurring in oral cavities, nasal sinuses, genital tract, and rectum), and uveal melanoma, demonstrating that melanoma can arise in various locations regardless of sun exposure.",
        "Yes, melanoma can occur in areas not exposed to sunlight. Approximately 10% of primary melanomas arise in non-sun-exposed sites, including acral lentiginous melanoma (e.g., palms, soles), mucosal melanoma (oral/nasal cavities, genital/rectal tracts), and uveal melanoma (eye). These subtypes are not primarily linked to UV radiation exposure.",
        "Yes, melanoma can occur in areas not exposed to sunlight. Approximately 10% of primary melanomas arise in non-sun-exposed sites, such as acral lentiginous melanoma (e.g., palms, soles), mucosal melanoma (oral/nasal cavities, genital tract, rectum), and uveal melanoma (eye). These subtypes are distinct from sun-associated cutaneous melanomas.",
        "Yes, melanoma can occur in areas not exposed to sunlight. Approximately 10% of primary melanomas develop on non-sun-exposed sites. These include uveal melanomas, mucosal melanomas found in the oral cavity, nasal sinuses, genital tract, and perianal region, as well as acral lentiginous melanoma, which occurs on the palms, soles, and under the nails. The underlying causes in these locations may differ from those related to UV exposure.",
        "Melanoma can indeed occur in areas not exposed to sunlight. While exposure to solar radiation is a primary risk factor for melanoma, about 10% of primary melanomas arise from non-sun-exposed sites. These include acral lentiginous melanoma, mucosal melanoma (found in the oral cavities, nasal sinuses, genital tract, and rectum), and uveal melanoma. The relationship between sun exposure and melanoma development on these non-sun-exposed locations is not well understood.",
        "Yes, melanoma can occur in areas not exposed to sunlight. While sun exposure is a known risk factor for melanoma, there is also a substantial proportion of melanomas, around 10%, that arise from non-sun-exposed sites. These include acral lentiginous melanoma, mucosal melanoma (occurring in locations such as the oral cavities, nasal sinuses, genital tract, and rectum), and uveal melanoma, which develop in regions not subjected to sunlight.",
        "Yes, melanoma can occur in areas not exposed to sunlight, with approximately 10% of primary cases arising from such sites. This includes specific types like acral lentiginous melanoma, mucosal melanoma found in internal body tracts and cavities, and uveal melanoma, highlighting that while sun exposure is a major risk factor, it is not the sole contributor to melanoma development, and these cancers can indeed occur in tissues not typically exposed to sunlight.",
        "Yes, melanoma can occur in areas not exposed to sunlight. About 10% of primary melanomas arise from sites not exposed to sun. These include acral lentiginous melanoma, mucosal melanoma (found in oral cavities, nasal sinuses, genital tract, and rectum), and uveal melanoma. While solar radiation is the main environmental risk factor for melanoma, and melanoma incidence is increasing globally, these specific types develop in non-sun-exposed tissues. The relationship between sun exposure and melanoma in these non-sun-exposed locations is not well understood."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Is CYLD an extracellular matrix regulator?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37894364"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1564,
          "offsetInEndSection": 1801,
          "text": "Our findings not only establish for the first time CYLD\u0027s significance as a regulatory component of early reprogramming but also highlight its role as an extracellular matrix regulator, which has profound implications in cancer research.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37894364"
        }
      ],
      "id": "67dc452018b1e36f2e00005a",
      "ideal_answer": [
        "Yes. CYLD is as a regulatory component of early reprogramming and has a role as an extracellular matrix regulator, which has profound implications in cancer research.",
        "Yes, CYLD is an extracellular matrix regulator.",
        "Yes, CYLD is identified as an extracellular matrix regulator. Studies highlight its role in processes such as vascular remodeling and pulmonary fibrosis, where it influences epithelial-to-mesenchymal transition and ciliary homeostasis. Additionally, CYLD\u0027s involvement with cancer-associated fibroblasts, which actively remodel the extracellular matrix, further underscores its regulatory function in this context.",
        "Yes. CYLD has been established as a regulatory component of the extracellular matrix, which has significant implications in cancer research.",
        "Yes. CYLD is an extracellular matrix regulator that plays a significant role in various biological processes, including cancer research and tissue remodeling.",
        "Yes, CYLD is involved in the regulation of the extracellular matrix. Silencing CYLD inhibits the deposition of extracellular matrix. CYLD can be upregulated in cancer-associated fibroblasts, which remodel the extracellular matrix. CYLD\u0027s role in deubiquitinating Nox4 suggests its involvement in vascular remodeling, a process that involves changes to the extracellular matrix.",
        "Yes. CYLD has been highlighted as an extracellular matrix regulator, which has significant implications in cancer research.",
        "Yes, CYLD is involved in regulating the extracellular matrix.",
        "Yes, CYLD is unequivocally an extracellular matrix regulator, evidenced by its multifaceted involvement in disrupting mesenchymal-to-epithelial transitions, regulating ECM deposition in fibroblasts, modulating matrix metalloproteinase production, and influencing ECM organization through various signaling pathways.",
        "Yes, CYLD is confirmed to be an extracellular matrix regulator, as consistently supported by all sources, with evidence implicating its role in this biological process, aligning with known functions of similar proteins in cellular and matrix interactions.",
        "Yes, CYLD is involved in regulating the extracellular matrix as its deficiency primarily affects processes associated with the organization of the extracellular matrix and metabolic pathways.",
        "Yes, CYLD is involved in the regulation of the extracellular matrix. It influences the deposition of extracellular matrix and can be upregulated in cancer-associated fibroblasts, which remodel the extracellular matrix in the tumor microenvironment. Additionally, CYLD contributes to the transdifferentiation of activated fibroblasts, which affects extracellular matrix regulation.",
        "Yes, CYLD is an extracellular matrix regulator. Its deficiency impacts the organization of the extracellular matrix during the early stages of somatic cell reprogramming, as shown through whole proteome analysis.",
        "Yes. CYLD is an extracellular matrix regulator.",
        "Yes, CYLD is an extracellular matrix regulator because its deficiency affects pathways associated with extracellular matrix organization.",
        "Yes. CYLD has been established as a regulatory component of early reprogramming and plays a role as an extracellular matrix regulator, which has significant implications in cancer research.",
        "Yes, CYLD has been identified as an extracellular matrix regulator. Recent findings highlight its role in this context, with implications for cancer research.",
        "Yes, CYLD functions as an extracellular matrix regulator. Evidence shows that its silencing inhibits extracellular matrix deposition, and findings support its role in regulating early cellular reprogramming with important implications in cancer research.",
        "Yes, CYLD has been identified as an extracellular matrix regulator.",
        "Yes, CYLD is an extracellular matrix regulator. It contributes to the transdifferentiation of activated fibroblasts (AFs), influences the deposition of extracellular matrix, and its role as an extracellular matrix regulator has implications in cancer research. Furthermore, CYLD expression is upregulated by CXCL12 activation of the JAK2/STAT3 pathway in cancer-associated fibroblasts.",
        "Yes, CYLD is an extracellular matrix regulator, which has profound implications in cancer research.",
        "Yes, CYLD is identified as an extracellular matrix regulator. This role of CYLD has been established in research that highlights its significance not only in early reprogramming but also in cancer research due to its regulatory functions within the extracellular matrix.",
        "Yes, CYLD is identified as an extracellular matrix regulator. This role was highlighted in a study that established its significance not only in early reprogramming but also in regulating the ECM, with important implications for cancer research.",
        "Yes, CYLD is confirmed to be an extracellular matrix regulator, as supported by research findings indicating its role in early reprogramming, with significant implications for cancer research, underscoring its importance in cellular processes related to the extracellular matrix.",
        "Yes, CYLD is a regulator of the extracellular matrix.",
        "Yes, CYLD is identified as an extracellular matrix regulator, playing a significant role in processes such as cell adhesion and migration, with implications in cancer research.",
        "Yes, CYLD is identified as an extracellular matrix regulator based on recent studies. These studies not only establish CYLD\u0027s novel role in early reprogramming but also highlight its significance in regulating the extracellular matrix, which holds important implications for cancer research.",
        "Yes, CYLD functions as an extracellular matrix regulator. It contributes to the control of extracellular matrix deposition and remodeling, influencing processes such as cell migration and tissue structure. This regulatory role is particularly significant in the context of cancer research and cellular reprogramming, where changes in the extracellular matrix can impact cell behavior, signaling, and tumor progression.",
        "Yes, CYLD is an extracellular matrix regulator. It contributes to the transdifferentiation of AFs and may play a role in vascular remodeling. CYLD\u0027s role as an extracellular matrix regulator has profound implications in cancer research.",
        "Yes, CYLD is identified as an extracellular matrix regulator. The findings establish CYLD\u0027s significance not only in early reprogramming but also highlight its role in regulating the extracellular matrix, which has important implications for cancer research."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Can gepotidacin be used for meningitis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38342126",
        "http://www.ncbi.nlm.nih.gov/pubmed/39004438",
        "http://www.ncbi.nlm.nih.gov/pubmed/39112136",
        "http://www.ncbi.nlm.nih.gov/pubmed/38729665",
        "http://www.ncbi.nlm.nih.gov/pubmed/38830223",
        "http://www.ncbi.nlm.nih.gov/pubmed/38517452",
        "http://www.ncbi.nlm.nih.gov/pubmed/38564341",
        "http://www.ncbi.nlm.nih.gov/pubmed/38856987",
        "http://www.ncbi.nlm.nih.gov/pubmed/38215519",
        "http://www.ncbi.nlm.nih.gov/pubmed/36883591",
        "http://www.ncbi.nlm.nih.gov/pubmed/36411033",
        "http://www.ncbi.nlm.nih.gov/pubmed/36271314",
        "http://www.ncbi.nlm.nih.gov/pubmed/36255258",
        "http://www.ncbi.nlm.nih.gov/pubmed/28483959",
        "http://www.ncbi.nlm.nih.gov/pubmed/29358297",
        "http://www.ncbi.nlm.nih.gov/pubmed/30249694"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38342126"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 360,
          "text": "BACKGROUND: Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and a unique binding site, providing well balanced inhibition of two type II topoisomerase enzymes. Oral gepotidacin is under investigation to treat uncomplicated urinary tract infections. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38342126"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "OBJECTIVES: The novel dual-target triazaacenaphthylene, gepotidacin, recently showed promising results in its Phase III randomized controlled trial for the treatment of gonorrhoea. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004438"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Gepotidacin: a novel, oral, \u0027first-in-class\u0027 triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36883591"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Gepotidacin (GSK2140944), a novel triazaacenaphthylene bacterial topoisomerase inhibitor, is currently in clinical development for the treatment of bacterial infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358297"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 328,
          "text": "BACKGROUND: Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is active against most strains of Neisseria gonorrhoeae (N. gonorrhoeae). Phase II data suggested higher exposures were needed for efficacy and to suppress resistance ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411033"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "Gepotidacin is a first-in-class, novel triazaacenaphthylene antibiotic that inhibits bacterial DNA replication and has in vitro activity against susceptible and drug-resistant pathogens. Reference in vitro methods were used to investigate the MICs and minimum bactericidal concentrations (MBCs)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28483959"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 994,
          "text": "Here, we describe the designs of two near-identical phase III clinical trials (EAGLE-2 and EAGLE-3) evaluating gepotidacin for the treatment of uUTI.METHODS: These are phase III, randomized, multicenter, parallel-group, double-blind, double-dummy, comparator-controlled, noninferiority studies, comparing the efficacy and safety of gepotidacin to nitrofurantoin in the treatment of uUTI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36271314"
        },
        {
          "offsetInBeginSection": 1656,
          "offsetInEndSection": 1902,
          "text": "Across the trials ~ 5000 participants are planned to be enrolled from \u003e 200 centers globally.CONCLUSIONS: Gepotidacin represents an important potential treatment option being evaluated to address the need for novel oral antibiotics to treat uUTI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36271314"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "We evaluated microbiological correlates for the successful treatment of Neisseria gonorrhoeae isolates from a phase 2 study of gepotidacin, a novel triazaacenaphthylene antibacterial, for therapy of uncomplicated urogenital gonorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30249694"
        },
        {
          "offsetInBeginSection": 471,
          "offsetInEndSection": 736,
          "text": "Gepotidacin is in phase III clinical development for uncomplicated urinary tract infections (ClinicalTrials.gov identifiers NCT04020341 and NCT04187144) and urogenital gonorrhea (ClinicalTrials.gov identifier NCT04010539) in adults and adolescents ≥12 years of age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255258"
        }
      ],
      "type": "yesno",
      "id": "67e6c2fa18b1e36f2e0000c8",
      "ideal_answer": [
        "No. Gepotidacin is approved for urinary tract infections."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What is the indication for bromocriptine?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25671924",
        "http://www.ncbi.nlm.nih.gov/pubmed/34218714",
        "http://www.ncbi.nlm.nih.gov/pubmed/21324816",
        "http://www.ncbi.nlm.nih.gov/pubmed/3103396",
        "http://www.ncbi.nlm.nih.gov/pubmed/9316693",
        "http://www.ncbi.nlm.nih.gov/pubmed/1773422",
        "http://www.ncbi.nlm.nih.gov/pubmed/10210840",
        "http://www.ncbi.nlm.nih.gov/pubmed/39684198",
        "http://www.ncbi.nlm.nih.gov/pubmed/39667592",
        "http://www.ncbi.nlm.nih.gov/pubmed/39536251",
        "http://www.ncbi.nlm.nih.gov/pubmed/30349477",
        "http://www.ncbi.nlm.nih.gov/pubmed/31794265",
        "http://www.ncbi.nlm.nih.gov/pubmed/39680976",
        "http://www.ncbi.nlm.nih.gov/pubmed/819453",
        "http://www.ncbi.nlm.nih.gov/pubmed/20977575",
        "http://www.ncbi.nlm.nih.gov/pubmed/27604463",
        "http://www.ncbi.nlm.nih.gov/pubmed/24179894",
        "http://www.ncbi.nlm.nih.gov/pubmed/6754799",
        "http://www.ncbi.nlm.nih.gov/pubmed/6111843",
        "http://www.ncbi.nlm.nih.gov/pubmed/6475464",
        "http://www.ncbi.nlm.nih.gov/pubmed/10649814",
        "http://www.ncbi.nlm.nih.gov/pubmed/12923813",
        "http://www.ncbi.nlm.nih.gov/pubmed/9881903",
        "http://www.ncbi.nlm.nih.gov/pubmed/9915009",
        "http://www.ncbi.nlm.nih.gov/pubmed/1585280",
        "http://www.ncbi.nlm.nih.gov/pubmed/35635035",
        "http://www.ncbi.nlm.nih.gov/pubmed/6751339",
        "http://www.ncbi.nlm.nih.gov/pubmed/7202312",
        "http://www.ncbi.nlm.nih.gov/pubmed/27488872",
        "http://www.ncbi.nlm.nih.gov/pubmed/20332352",
        "http://www.ncbi.nlm.nih.gov/pubmed/1796748",
        "http://www.ncbi.nlm.nih.gov/pubmed/4036221",
        "http://www.ncbi.nlm.nih.gov/pubmed/6987580",
        "http://www.ncbi.nlm.nih.gov/pubmed/1345564",
        "http://www.ncbi.nlm.nih.gov/pubmed/10979549",
        "http://www.ncbi.nlm.nih.gov/pubmed/6455501",
        "http://www.ncbi.nlm.nih.gov/pubmed/8055815",
        "http://www.ncbi.nlm.nih.gov/pubmed/16741332",
        "http://www.ncbi.nlm.nih.gov/pubmed/4047382",
        "http://www.ncbi.nlm.nih.gov/pubmed/7701022",
        "http://www.ncbi.nlm.nih.gov/pubmed/2395828",
        "http://www.ncbi.nlm.nih.gov/pubmed/10649819",
        "http://www.ncbi.nlm.nih.gov/pubmed/2316314",
        "http://www.ncbi.nlm.nih.gov/pubmed/8103956",
        "http://www.ncbi.nlm.nih.gov/pubmed/3414319"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 292,
          "text": "Prolactinomas are the most common type of functional pituitary tumours. The objective of this study was to determine demographic profile of patients with prolactinomas, and to compare the outcomes in patients treated with Cabergoline versus those receiving Bromocriptine treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25671924"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34218714"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 135,
          "text": " To describe a positive prolactin response to bromocriptine treatment in 2 patients with cabergoline-resistant prolactinomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21324816"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Long-term treatment with high-dosage bromocriptine in advanced Parkinson\u0027s disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3103396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "The beneficial effect of bromocriptine in fluctuating Parkinson\u0027s disease (PD) under chronic levodopa therapy has been reported to be lost in the long term in most patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9316693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Discontinuation of prolonged bromocriptine therapy in Parkinson\u0027s disease patients with uncontrolled motor oscillations.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9316693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Several hypotheses have explained the beneficial effect of adding bromocriptine (BR) to levodopa (LD) in Parkinson\u0027s disease (PD) by interaction at the striatal level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1773422"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson\u0027s disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1773422"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Does combined levodopa and bromocriptine therapy in Parkinson\u0027s disease prevent late motor complications?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10210840"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Prolactinomas are commonly treated with dopamine receptor agonists (DAs), such as bromocriptine (BRC) and cabergoline (CAB)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684198"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Bromocriptine mesylate-loaded nanoparticles co-modified with low molecular weight protamine and lactoferrin for enhanced nose-to-brain delivery in Parkinson\u0027s disease treatment.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39667592"
        },
        {
          "offsetInBeginSection": 1289,
          "offsetInEndSection": 1424,
          "text": "st women with idiopathic hyperprolactinemia used bromocriptine, while those with tumoral hyperprolactinemia used cabergoline (p\u003d0.04). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39536251"
        },
        {
          "offsetInBeginSection": 686,
          "offsetInEndSection": 828,
          "text": "The authors prescribed bromocriptine to stop lactation and switched her to formula feeding, which resulted in no further anaphylactic episodes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39680976"
        },
        {
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1418,
          "text": "Most women with idiopathic hyperprolactinemia used bromocriptine, while those with tumoral hyperprolactinemia used cabergoline (p\u003d0",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39536251"
        },
        {
          "offsetInBeginSection": 610,
          "offsetInEndSection": 942,
          "text": "Bromocriptine is an approved drug originally indicated for Parkinson\u0027s disease, acromegaly, hyperprolactinemia and galactorrhoea, and recently repositioned for diabetes mellitus.RESULTS: Treatment with bromocriptine reduced cell viability of AML cells by activation of the apoptosis program and induction of myeloid differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604463"
        },
        {
          "offsetInBeginSection": 1086,
          "offsetInEndSection": 1206,
          "text": "QR-bromocriptine (Cycloset™) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20977575"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Bromocriptine is an ergot alkaloid dopamine D(2) receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20977575"
        },
        {
          "offsetInBeginSection": 1131,
          "offsetInEndSection": 1255,
          "text": "In the United States, the dopamine agonists indicated for treatment of hyperprolactinemia are bromocriptine and cabergoline.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10649814"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Bromocriptine is a selective agonist for dopamine D2-receptors and is used in the treatment of Parkinson\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12923813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Bromocriptine (BC) is now an accepted primary therapeutic agent for patients with microadenoma. But, for patients with large or giant prolactinomas, the treatment choice is controversial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9881903"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 438,
          "text": " Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like induction of ovulation in female infertility. Bromocriptine has been evaluated in alloxan induced diabetic rats for its anti-hyperglycaemic effect with and without simultaneous use of glipizide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24179894"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "The main indication for medical treatment of the secretory pituitary adenomas is macroprolactinoma. In this case, bromocriptine therapy obtains better results than surgery, by a life-long administration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9915009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Dopamine agonist Bromocriptin tablet has been used in 102 cases, partly for the inhibition of puerperal lactation, partly for the treatment of infertility accompanied by hyperprolactinaemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1585280"
        },
        {
          "offsetInBeginSection": 1086,
          "offsetInEndSection": 1207,
          "text": "QR-bromocriptine (Cycloset™) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20977575"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 952,
          "text": "Bromocriptine\u0027s use in Parkinson\u0027s disease, where the incidence of depression has been reported to be as high as 37%, has been well documented.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6751339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Bromocriptinee has proved to be effective in treatment of patients for hyperprolactinaemic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7202312"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 233,
          "text": " tumors. As an agonist of the dopamine D2 receptor, bromocriptine is used widely to inhibit prolactinoma pro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27488872"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 311,
          "text": "Bromocriptine 2-5 mg twice daily is effective in the treatment of both normoprolactinaemic and hyperprolactinaemic secondary amenorrhoea. This was demonstrated by the restoration of menstrual cycle and/or ovulation in 9 of 18 normoprolactinaemic and in 8 of 14 hyperprolactinaemic patients taking bromocriptine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/58200"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "OBJECTIVE: Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20332352"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Bromocriptine, a D2 receptor agonist, has been widely used in tumoral and non-tumoral hyperprolactinemia, in reducing both plasma prolactin levels and in restoring fertility and/or menses in most patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1796748"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 46,
          "text": "Bromocriptine treatment of hyperprolactinemia",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4036221"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Bromocriptine mesylate (Parlodel) in the management of amenorrhea/galactorrhea associated with hyperprolactinemia",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6987580"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Bromocriptine is an ergot alkaloid dopamine D(2) receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20977575"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Bromocriptine is applied for treatment of patients with hyperprolactinaemic disorders, Parkinson\u0027s disease and acromegaly",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979549"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Bromocriptine, a potent agonist at Dz receptors, was developed as a therapeutic agent for inhibiting prolactin (PRL) secretion in patients with hyperprolactinemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6455501"
        },
        {
          "offsetInBeginSection": 926,
          "offsetInEndSection": 1128,
          "text": "We conclude that both froms of bromocriptine are very useful for treatment of hyperprolactinemia but Parlodel LAR is better tolerated and more convenient in application because of its prolonged activity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8055815"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 951,
          "text": "Bromocriptine\u0027s use in Parkinson\u0027s disease, where the incidence of depression has been reported to be as high as 37%, has been well documented",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6751339"
        },
        {
          "offsetInBeginSection": 1259,
          "offsetInEndSection": 1395,
          "text": " and 3.7% had other causes. Most women with idiopathic hyperprolactinemia used bromocriptine, while those with tumoral hyperprolactinemi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39536251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "The efficacy and safety of bromocriptine mesylate (5 to 7.5 mg per day for up to 24 weeks) were studied in 22 clinical trials involving 226 patients who had amenorrhea/galactorrhea associated with hyperprolactinemia and no demonstrable pituitary tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6987580"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 160,
          "text": "Bromocriptine is the drug of choice for treatment of hyperprolactinemic amenorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6475464"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 189,
          "text": "Bromocriptine remains the treatment of choice for managing hyperprolactinemia in most of these cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16741332"
        },
        {
          "offsetInBeginSection": 677,
          "offsetInEndSection": 951,
          "text": "Bromocriptine represents an attractive option with high efficacy and safety profile for hyperprolactinemia-associated conditions, acromegaly, parkinsonism, type 2 diabetes mellitus and various other diseases in a variety of dosage forms for best possible beneficial effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35635035"
        },
        {
          "offsetInBeginSection": 926,
          "offsetInEndSection": 1023,
          "text": "So bromocriptine is the specific treatment of women whose sterility is due to hyperprolactinaemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6754799"
        },
        {
          "offsetInBeginSection": 625,
          "offsetInEndSection": 785,
          "text": "The trend of decreased prolactin serum levels indicates that bromocriptine mesylate may prove a useful adjunct to reduce the side effects of hyperprolactinemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4047382"
        },
        {
          "offsetInBeginSection": 926,
          "offsetInEndSection": 1068,
          "text": "So bromocriptine is the specific treatment of women whose sterility is due to hyperprolactinaemia and no teratogenic effect has been reported.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6754799"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Bromocriptine is an ergot-derived dopamine agonist. Its current uses include the treatment of Parkinson\u0027s disease, postpartum ablaction, prolactinomas, acromegaly, and amenorrhea and galactorrhea secondary to neuroleptic use.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7701022"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 309,
          "text": "As a specific prolactin inhibitor, bromocriptine is the treatment of choice in many cases of hyperprolactinemia in female and male. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6111843"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Introduction of the dopamine agonist bromocriptine heralded a major advance in the management of hyperprolactinemic disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10649819"
        },
        {
          "offsetInBeginSection": 881,
          "offsetInEndSection": 997,
          "text": "Prolactin responses to TRH were markedly inhibited in normoprolactinemic patients by the dose of bromocriptine used.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/819453"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Bromocriptine, a D2 receptor agonist, has been widely used in tumoral and non-tumoral hyperprolactinemia, in reducing both plasma prolactin levels and in restoring fertility and/or menses in most patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1796748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "The authors presented the results of catamnestic investigation of 133 women treated with bromocriptine for various types of hyperprolactinemic hypogonadism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2395828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Eight patients with macroprolactinomas were treated with a long-acting injectable form of bromocriptine, depot-bromocriptine (Parlodel LAR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2316314"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson\u0027s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30349477"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Bromocriptine is applied for treatment of patients with hyperprolactinaemic disorders, Parkinson\u0027s disease and acromegaly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979549"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson\u0027s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus. The drug i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30349477"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Bromocriptine is known to be effective in the treatment of women with hyperprolactinemic anovulation or amenorrhea-galactorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6781935"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Bromocriptine, a dopamine D2 receptor agonist originally used for the treatment of hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose tolerance in type 2 diabetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794265"
        },
        {
          "offsetInBeginSection": 542,
          "offsetInEndSection": 714,
          "text": "Bromocriptine, an ergot derivative, is the main clinically used dopamine agonist, and it has been established as a valuable adjunct in the treatment of Parkinson\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3103396"
        },
        {
          "offsetInBeginSection": 67,
          "offsetInEndSection": 267,
          "text": "True prolactinomas, usually characterized by pituitary lesions and circulating levels of prolactin in excess of 2 U/l (100 micrograms/l), are best treated with a dopamine agonist such as bromocriptine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8103956"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1345564"
        },
        {
          "offsetInBeginSection": 1129,
          "offsetInEndSection": 1349,
          "text": "It is concluded that bromocriptine retard (50-100 mg monthly) is a useful alternative for oral treatment of patients with prolactinomas, especially in those patients with compliance problems on oral bromocriptine therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3414319"
        },
        {
          "offsetInBeginSection": 577,
          "offsetInEndSection": 793,
          "text": "Bromocriptine brings about normal prolactinaemia and ovulation is re-established and menstruation returns in most cases of idiopathic hyperprolactinaemia and in many cases where hyperprolactinaemia is due to a tumour",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6754799"
        }
      ],
      "type": "factoid",
      "id": "67cf3f6481b1027333000025",
      "ideal_answer": [
        "Bromocriptine treatment is indicated in prolactinomas.",
        "Bromocriptine is used to stop lactation.",
        "Bromocriptine is used for Parkinson\u0027s disease.",
        "The indication for bromocriptine is \"Parkinson\u0027s disease\" and \"severe dyskinesia\".",
        "Bromocriptine is indicated for the treatment of Parkinson\u0027s disease, type 2 diabetes, and acromegaly.",
        "Bromocriptine is indicated for the treatment of hyperprolactinaemia, galactorrhoea, Parkinsonism, and as a potential treatment for postpartum cardiomyopathy (PPCM) and type 2 diabetes mellitus (T2DM).",
        "Bromocriptine is indicated for Parkinson\u0027s disease, acromegaly, hyperprolactinemia, galactorrhoea, and type 2 diabetes.",
        "Bromocriptine is indicated for the treatment of hyperprolactinemia, galactorrhea, Parkinsonism, and peripartum cardiomyopathy (PPCM).",
        "Bromocriptine is used for treatment of Parkinson\u0027s disease.",
        "Bromocriptine is indicated for the treatment of type 2 diabetes mellitus (T2DM), hyperprolactinaemia, galactorrhoea, Parkinsonism, and as an adjunctive treatment for postpartum cardiomyopathy (PPCM).",
        "Bromocriptine is indicated for the treatment of type 2 diabetes mellitus (T2DM), hyperprolactinaemia, galactorrhoea, Parkinsonism, and as an adjunctive treatment for peripartum cardiomyopathy (PPCM).",
        "Bromocriptine is indicated for the treatment of hyperprolactinemia-associated dysfunctions, such as prolactin-secreting adenomas. It is also used to lower serum growth hormone levels in patients with acromegaly and provides therapeutic benefits as an adjunct to levodopa in the treatment of Parkinson\u0027s disease.",
        "Bromocriptine is indicated primarily for the treatment of hyperprolactinemia, including prolactinomas that cause menstrual disturbances, infertility, and galactorrhea. It is also used as a dopamine agonist in the management of Parkinson\u0027s disease and, in some cases, acromegaly.",
        "The indication for bromocriptine is central hyperthermia.",
        "Bromocriptine is indicated for Parkinson\u0027s disease, acromegaly, and hyperprolactinemia.",
        "Bromocriptine is used for prolactinomas.",
        "Bromocriptine is a dopamine agonist primarily used as a first-line treatment for prolactinomas, a type of functional pituitary tumor characterized by elevated prolactin levels. It helps reduce tumor size and normalize prolactin secretion in patients with pituitary adenomas.",
        "Bromocriptine is primarily indicated for treating prolactinomas, a common type of functional pituitary tumor, by reducing serum prolactin levels and tumor size, and is considered a viable alternative for patients who are resistant to cabergoline.",
        "Bromocriptine is used to suppress milk production in women with galactosemia.",
        "Bromocriptine is indicated for the treatment of prolactinomas.",
        "Bromocriptine is indicated for the treatment of acromegaly, prolactinomas, hyperprolactinaemia, galactorrhoea, Parkinson\u0027s disease, ovulatory disturbances or sterility, normoprolactinemic endocrine disorders, and type 2 diabetes mellitus. It may also be useful for treating male patients with Reiter\u0027s syndrome.",
        "Prolactinomas, macroprolactinoma, priapism, cabergoline, prolactin response are indications for bromocriptine treatment, typically used as a first-line therapy for prolactinomas and for patients with cabergoline-resistant prolactinomas.",
        "Bromocriptine is indicated for treating prolactinomas, which are functional pituitary tumors that cause excess prolactin production.",
        "bromocriptine is indicated for the treatment of hyperprolactinemia and prolactinomas.",
        "Bromocriptine is indicated for the treatment of hyperprolactinemia, Parkinson\u0027s disease, and type 2 diabetes mellitus (T2DM).",
        "Bromocriptine is indicated for Cabergoline-resistant prolactinomas.",
        "Bromocriptine is indicated for the treatment of prolactinomas, helping to normalize prolactin levels and reduce tumor size in affected patients.",
        "Bromocriptine is indicated for the treatment of prolactinomas, a type of functional pituitary tumor. It is generally used as a first-line therapy for prolactinomas, and is well tolerated.",
        "Bromocriptine is indicated for the treatment of prolactinomas, particularly in cases where cabergoline resistance is observed, as it is a dopamine agonist effective in reducing prolactin levels.",
        "Bromocriptine is indicated for the treatment of prolactinomas, particularly in patients who are resistant to cabergoline therapy.",
        "Bromocriptine is indicated for the treatment of prolactinomas, which are functional pituitary tumors that secrete excess prolactin. It is used as an alternative when patients are resistant to cabergoline or experience adverse effects from other dopamine agonists.",
        "Bromocriptine is indicated for the treatment of hyperprolactinaemia, galactorrhoea, Parkinsonism, and as an adjunctive treatment for type 2 diabetes mellitus (T2DM).",
        "Bromocriptine is indicated primarily for treating prolactinomas and related conditions like hyperprolactinemia.",
        "Bromocriptine is primarily indicated for the treatment of prolactinomas, serving as a first-line option in some cases, and is particularly favored in patients who are resistant to cabergoline or experience adverse effects from it, offering a viable alternative for effective management.",
        "Bromocriptine is indicated for the treatment of prolactinomas and is also used in the treatment of type 2 diabetes.",
        "Bromocriptine is indicated for the treatment of prolactinomas, which are a type of functional pituitary tumor. It is used as a dopamine agonist to reduce prolactin levels and shrink tumor size. Bromocriptine may be used as first-line therapy or as an alternative to cabergoline in cases where patients are resistant or intolerant to cabergoline.",
        "Bromocriptine is indicated for the treatment of prolactinomas, particularly in patients who are resistant to Cabergoline. It serves as an effective dopamine agonist, providing an alternative therapy when first-line options fail.",
        "The indication for bromocriptine is the treatment of prolactinomas, which are a type of functional pituitary tumor.",
        "Bromocriptine is indicated for the treatment of prolactinomas, particularly in patients who are resistant to cabergoline therapy or experience adverse effects such as recurrent priapism.",
        "Bromocriptine is used primarily to treat conditions associated with elevated prolactin levels. It is indicated for managing prolactinomas, including both microadenomas and macroadenomas, by reducing prolactin secretion, decreasing tumor size, and restoring normal reproductive function. It is also employed to treat non-tumoral hyperprolactinemia and is used for lactation suppression.",
        "Bromocriptine is indicated for the treatment of prolactinomas, especially in cabergoline-resistant cases.",
        "bromocriptine is indicated for hyperprolactinemia and prolactinomas",
        "Bromocriptine is used as a first-line therapy for prolactinomas, which are the most common type of functional pituitary tumors. It can be effective in treating patients who have elevated prolactin levels, although some may require alternative treatments if they become resistant to bromocriptine or experience side effects such as recurrent priapism.",
        "Bromocriptine is indicated as a first-line therapy for prolactinomas, which are the most common type of functional pituitary tumors. It serves as an alternative to cabergoline in cases where patients exhibit resistance or adverse reactions, such as recurrent priapism, to cabergoline treatment."
      ],
      "exact_answer": [
        [
          "prolactinomas",
          "Prolactinemia",
          "Parkinsons",
          "Diabetes"
        ]
      ]
    },
    {
      "body": "Are biologics used in pancreatic cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33014285",
        "http://www.ncbi.nlm.nih.gov/pubmed/28736633",
        "http://www.ncbi.nlm.nih.gov/pubmed/26355547",
        "http://www.ncbi.nlm.nih.gov/pubmed/25389454",
        "http://www.ncbi.nlm.nih.gov/pubmed/14599095",
        "http://www.ncbi.nlm.nih.gov/pubmed/26798437",
        "http://www.ncbi.nlm.nih.gov/pubmed/39654063",
        "http://www.ncbi.nlm.nih.gov/pubmed/18518788",
        "http://www.ncbi.nlm.nih.gov/pubmed/23560505",
        "http://www.ncbi.nlm.nih.gov/pubmed/18699769",
        "http://www.ncbi.nlm.nih.gov/pubmed/9127173",
        "http://www.ncbi.nlm.nih.gov/pubmed/23187854",
        "http://www.ncbi.nlm.nih.gov/pubmed/4063969",
        "http://www.ncbi.nlm.nih.gov/pubmed/7512537",
        "http://www.ncbi.nlm.nih.gov/pubmed/39514550"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 497,
          "text": "EGFR tyrosine kinase inhibitor erlotinib is currently the only targeted therapy to demonstrate a very modest survival benefit when added to gemcitabine in the treatment of patients with advanced pancreatic cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26355547"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39654063"
        },
        {
          "offsetInBeginSection": 875,
          "offsetInEndSection": 1147,
          "text": "Only studies using erlotinib in pancreatic cancer patients were reviewed and analyzed.CONCLUSIONS: The combination of gemcitabine and erlotinib is the first combination therapy to demonstrate survival benefits in pancreatic cancer in a Phase III study albeit a modest one.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18518788"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "INTRODUCTION: In this review, we analyzed the current literature about cetuximab to clarify its role in the treatment of pancreatic cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560505"
        },
        {
          "offsetInBeginSection": 360,
          "offsetInEndSection": 503,
          "text": "inhibitors that target EGF receptor, K-RAS, RAF, MEK, mTOR, VEGF and PDGF, for example, have been evaluated in patients with pancreatic cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18699769"
        },
        {
          "offsetInBeginSection": 389,
          "offsetInEndSection": 582,
          "text": "Eroltinib (a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798437"
        },
        {
          "offsetInBeginSection": 389,
          "offsetInEndSection": 660,
          "text": "Eroltinib (a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798437"
        },
        {
          "offsetInBeginSection": 389,
          "offsetInEndSection": 659,
          "text": "Eroltinib (a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798437"
        },
        {
          "offsetInBeginSection": 872,
          "offsetInEndSection": 1003,
          "text": "Passive immunotherapy using the MAb BW 494 was carried out in 148 pancreatic cancer patients in two phase I and two phase II trials",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9127173"
        },
        {
          "offsetInBeginSection": 1346,
          "offsetInEndSection": 1530,
          "text": "New clinical studies using humanized MAbs in combination with immune response modifiers should be initiated to further evaluate immunotherapy as a treatment option in pancreatic cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9127173"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Two monoclonal antibodies, YPan1 and YPan2, were produced from spleen cells of mice immunized against a human pancreatic cancer cell line, Capan-2, which also reacted with eight other human pancreatic carcinoma cell lines and with sections of cancerous human pancreas tissue.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4063969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "A monoclonal antibody (MAb), PAM4, having reactivity with pancreatic carcinoma has been developed. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7512537"
        },
        {
          "offsetInBeginSection": 1018,
          "offsetInEndSection": 1148,
          "text": "Immune checkpoint inhibitors, such as pembrolizumab and dostarlimab, have proven to be effective in dMMR/MSI-H pancreatic cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39514550"
        },
        {
          "offsetInBeginSection": 922,
          "offsetInEndSection": 1199,
          "text": "Although preclinical studies with multiple targeted therapies demonstrated encouraging results in pancreatic cancer, only erlotinib, an epidermal growth factor receptor inhibitor, showed a marginal survival benefit in a phase III clinical trial, when combined with gemcitabine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23187854"
        }
      ],
      "id": "67e2b8a818b1e36f2e000091",
      "ideal_answer": [
        "EGFR tyrosine kinase inhibitor erlotinib is currently the only targeted therapy to demonstrate a very modest survival benefit when added to gemcitabine in the treatment of patients with advanced pancreatic cancer. Other biologics are currently tested in trials.",
        "Biologics are utilized in the treatment of pancreatic cancer, encompassing targeted therapies like EGFR inhibitors and tyrosine-kinase inhibitors (e.g., erlotinib), immunotherapies including vaccines, monoclonal antibodies, and various cytokines. While these biological approaches show promise, their effectiveness in improving survival rates, particularly in advanced stages, is currently under investigation in ongoing clinical trials, with outcomes subject to further research for definitive efficacy assessment.",
        "Yes, biologics are used in pancreatic cancer treatment. Examples include immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors like sintilimab and atezolizumab), CAR-T cell therapies (e.g., BPX-601, a PSCA-directed GoCAR-T), and monoclonal antibodies (e.g., bevacizumab). These biologics are often combined with chemotherapy or targeted therapies (e.g., PARP inhibitors like olaparib) to enhance efficacy, particularly in patients with specific genetic profiles (e.g., BRCA mutations). While success varies due to pancreatic cancer\u0027s resistant microenvironment, ongoing trials explore their potential in personalized regimens."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Does MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation predict a better response to temozolomide?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36604366",
        "http://www.ncbi.nlm.nih.gov/pubmed/25588856",
        "http://www.ncbi.nlm.nih.gov/pubmed/35927323",
        "http://www.ncbi.nlm.nih.gov/pubmed/33116181",
        "http://www.ncbi.nlm.nih.gov/pubmed/16609952",
        "http://www.ncbi.nlm.nih.gov/pubmed/21968944",
        "http://www.ncbi.nlm.nih.gov/pubmed/15758010",
        "http://www.ncbi.nlm.nih.gov/pubmed/20517307",
        "http://www.ncbi.nlm.nih.gov/pubmed/20150365",
        "http://www.ncbi.nlm.nih.gov/pubmed/25910840",
        "http://www.ncbi.nlm.nih.gov/pubmed/21789683",
        "http://www.ncbi.nlm.nih.gov/pubmed/38811596",
        "http://www.ncbi.nlm.nih.gov/pubmed/38288307",
        "http://www.ncbi.nlm.nih.gov/pubmed/38206830",
        "http://www.ncbi.nlm.nih.gov/pubmed/27029617",
        "http://www.ncbi.nlm.nih.gov/pubmed/33710615",
        "http://www.ncbi.nlm.nih.gov/pubmed/21107199",
        "http://www.ncbi.nlm.nih.gov/pubmed/30343277",
        "http://www.ncbi.nlm.nih.gov/pubmed/28328619",
        "http://www.ncbi.nlm.nih.gov/pubmed/18795231",
        "http://www.ncbi.nlm.nih.gov/pubmed/30514777",
        "http://www.ncbi.nlm.nih.gov/pubmed/38611052",
        "http://www.ncbi.nlm.nih.gov/pubmed/38612892",
        "http://www.ncbi.nlm.nih.gov/pubmed/38448295",
        "http://www.ncbi.nlm.nih.gov/pubmed/38242327",
        "http://www.ncbi.nlm.nih.gov/pubmed/37919784",
        "http://www.ncbi.nlm.nih.gov/pubmed/37634280",
        "http://www.ncbi.nlm.nih.gov/pubmed/38224404",
        "http://www.ncbi.nlm.nih.gov/pubmed/39361075",
        "http://www.ncbi.nlm.nih.gov/pubmed/38357209",
        "http://www.ncbi.nlm.nih.gov/pubmed/20857319",
        "http://www.ncbi.nlm.nih.gov/pubmed/34467991",
        "http://www.ncbi.nlm.nih.gov/pubmed/33631540",
        "http://www.ncbi.nlm.nih.gov/pubmed/26035292",
        "http://www.ncbi.nlm.nih.gov/pubmed/25584486",
        "http://www.ncbi.nlm.nih.gov/pubmed/39583928",
        "http://www.ncbi.nlm.nih.gov/pubmed/39577464",
        "http://www.ncbi.nlm.nih.gov/pubmed/39545524",
        "http://www.ncbi.nlm.nih.gov/pubmed/39367282",
        "http://www.ncbi.nlm.nih.gov/pubmed/39760063",
        "http://www.ncbi.nlm.nih.gov/pubmed/36900232",
        "http://www.ncbi.nlm.nih.gov/pubmed/39080996",
        "http://www.ncbi.nlm.nih.gov/pubmed/37641156",
        "http://www.ncbi.nlm.nih.gov/pubmed/15297393",
        "http://www.ncbi.nlm.nih.gov/pubmed/15041700",
        "http://www.ncbi.nlm.nih.gov/pubmed/19011762",
        "http://www.ncbi.nlm.nih.gov/pubmed/22614944",
        "http://www.ncbi.nlm.nih.gov/pubmed/27353036",
        "http://www.ncbi.nlm.nih.gov/pubmed/27492578",
        "http://www.ncbi.nlm.nih.gov/pubmed/17192931",
        "http://www.ncbi.nlm.nih.gov/pubmed/30194078",
        "http://www.ncbi.nlm.nih.gov/pubmed/21483124",
        "http://www.ncbi.nlm.nih.gov/pubmed/29712977",
        "http://www.ncbi.nlm.nih.gov/pubmed/24568970",
        "http://www.ncbi.nlm.nih.gov/pubmed/18616639",
        "http://www.ncbi.nlm.nih.gov/pubmed/22975219",
        "http://www.ncbi.nlm.nih.gov/pubmed/17032559",
        "http://www.ncbi.nlm.nih.gov/pubmed/25460932",
        "http://www.ncbi.nlm.nih.gov/pubmed/26948367",
        "http://www.ncbi.nlm.nih.gov/pubmed/20032445",
        "http://www.ncbi.nlm.nih.gov/pubmed/25890369",
        "http://www.ncbi.nlm.nih.gov/pubmed/22428052",
        "http://www.ncbi.nlm.nih.gov/pubmed/19424593",
        "http://www.ncbi.nlm.nih.gov/pubmed/16932504",
        "http://www.ncbi.nlm.nih.gov/pubmed/22837675",
        "http://www.ncbi.nlm.nih.gov/pubmed/17234766",
        "http://www.ncbi.nlm.nih.gov/pubmed/17721049",
        "http://www.ncbi.nlm.nih.gov/pubmed/17878096",
        "http://www.ncbi.nlm.nih.gov/pubmed/24554053",
        "http://www.ncbi.nlm.nih.gov/pubmed/17032561",
        "http://www.ncbi.nlm.nih.gov/pubmed/33433610",
        "http://www.ncbi.nlm.nih.gov/pubmed/38136323",
        "http://www.ncbi.nlm.nih.gov/pubmed/22012047",
        "http://www.ncbi.nlm.nih.gov/pubmed/31611911",
        "http://www.ncbi.nlm.nih.gov/pubmed/24519517",
        "http://www.ncbi.nlm.nih.gov/pubmed/38912869",
        "http://www.ncbi.nlm.nih.gov/pubmed/32841306",
        "http://www.ncbi.nlm.nih.gov/pubmed/22570067",
        "http://www.ncbi.nlm.nih.gov/pubmed/23245659",
        "http://www.ncbi.nlm.nih.gov/pubmed/18945611",
        "http://www.ncbi.nlm.nih.gov/pubmed/26118907",
        "http://www.ncbi.nlm.nih.gov/pubmed/18004504",
        "http://www.ncbi.nlm.nih.gov/pubmed/33432978"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 517,
          "text": "The standard treatment for GBM consists of surgical resection followed by concurrent chemoradiotherapy and adjuvant temozolomide. O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is an important prognostic biomarker that predicts the response to temozolomide and guides treatment decisions. At present, the only reliable way to determine MGMT promoter methylation status is through the analysis of tumor tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36604366"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "text": "It is already well known that hypermethylation of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter is a predictive biomarker of response to temozolomide treatment and of favorable outcomes in terms of overall survival (OS) and progression-free survival (PFS) in glioblastoma (GBM) patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25588856"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 502,
          "text": "O6-Methylguanine-DNA-methyltransferase (MGMT) promoter methylation was shown in many studies to be an important predictive biomarker for temozolomide (TMZ) resistance and poor progression-free survival in glioblastoma multiforme (GBM) patients. However, identifying the MGMT methylation status using molecular techniques remains challenging due to technical limitations, such as the inability to obtain tumor specimens, high prices for detection, and the high complexity of intralesional heterogeneity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35927323"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16609952"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 506,
          "text": "The gene encoding the DNA repair enzyme O (6)-methylguanine-DNA methyltransferase (MGMT) is transcriptionally silenced by promoter methylation in several human tumors, including gliomas and systemic lymphomas. MGMT promoter methylation is also a prognostic marker in glioblastoma patients treated with temozolomide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21968944"
        },
        {
          "offsetInBeginSection": 63,
          "offsetInEndSection": 214,
          "text": "The effectiveness of temozolomide (TMZ) treatment in GBM is linked to the methylation status of O6-methyl-guanine DNA methyltransferase (MGMT) promoter",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38288307"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 263,
          "text": "These differences have extended to the methylation of the MGMT promoter, which critically impacts temozolomide resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38611052"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 343,
          "text": "The methylation status of the MGMT promoter has been implicated as a critical biomarker of response to TMZ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38448295"
        },
        {
          "offsetInBeginSection": 303,
          "offsetInEndSection": 512,
          "text": "On the contrary, epigenetic silencing through MGMT gene promoter methylation leading to subsequent reduction in MGMT transcription and protein expression, is predicted to have a response favoring TMZ treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38242327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "MGMT promoter methylation testing is required for prognosis and predicting temozolomide response in gliomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37919784"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 454,
          "text": "Efficacy of temozolomide (TMZ), the primary chemotherapeutic agent, depends on the DNA methylation status of the O6-methylguanine DNA methyltransferase (MGMT), which has been identified as a prognostic biomarker in glioblastoma patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37634280"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 630,
          "text": "MGMT promoter methylation status predicts responsiveness to TMZ; patients harboring unmethylated MGMT (~60% of glioblastoma) have a poorer prognosis with limited treatment benefits from TMZ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38224404"
        },
        {
          "offsetInBeginSection": 514,
          "offsetInEndSection": 684,
          "text": "MGMT promoter methylation testing is the most established molecular marker for response to temozolomide in IDH wild-type glioblastoma and in turn impacts overall survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39361075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) promoter region is a critical predictor of response to alkylating agents in glioblastoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38357209"
        },
        {
          "offsetInBeginSection": 1403,
          "offsetInEndSection": 1597,
          "text": "Therefore, our retrospective case series suggests that quantitative methylation-specific PCR of the MGMT promoter predicts radiological response to chemotherapy with TMZ in WHO grade II gliomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20857319"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "BACKGROUND: Although methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter predicts response to temozolomide in patients with glioblastoma, no consensus exists as to which assay is best for it",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30343277"
        },
        {
          "offsetInBeginSection": 456,
          "offsetInEndSection": 630,
          "text": "Clinical studies revealed that glioblastoma patients with hypermethylated MGMT promoter have a better response to TMZ treatment and a significantly improved overall survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37634280"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "O(6)-Methylguanine DNA methyltransferase (MGMT) is implicated as a major predictive factor for treatment response to alkylating agents including temozolomide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150365"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Aberrant methylation of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene is a predictive marker for the response to chemotherapy with alkylating agents (e.g., temozolomide)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18795231"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "O6-methylguanine DNA methyltransferase (MGMT) promoter methylation is associated with the prognosis of patients with glioblastomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39583928"
        },
        {
          "offsetInBeginSection": 83,
          "offsetInEndSection": 248,
          "text": "Unfortunately, chemotherapy with temozolomide (TMZ) has a limited efficacy due to resistance mainly attributed to O6-methylguanine methyl transferase (MGMT) activity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39577464"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "INTRODUCTION: The methylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) promoter is a valid biomarker for predicting response to therapy with alkylating agents and, independently, prognosis in IDH-wildtype(IDH-w)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39367282"
        },
        {
          "offsetInBeginSection": 74,
          "offsetInEndSection": 301,
          "text": "O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is the central molecular biomarker linked to both the response to temozolomide, the standard chemotherapy drug employed for GBM, and to patient survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38612892"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 426,
          "text": "Loss of O6-methylguanine-DNA-methyltransferase(MGMT) protein expression due to promoter methylation reduces glioma cell DNA repair activity and resistance to alkylating agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39760063"
        },
        {
          "offsetInBeginSection": 427,
          "offsetInEndSection": 654,
          "text": "Thus, in world health organization (WHO) grade 4 diffuse glioma patients treated with an alkylating agent, methylated MGMT promoter is currently being considered a clinically relevant prognostic as well as predictive biomarker.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39760063"
        },
        {
          "offsetInBeginSection": 2119,
          "offsetInEndSection": 2312,
          "text": "Also, patients who receive radiation therapy and simultaneous temozolomide chemotherapy have a considerably better prognosis and treatment outcome, if the promoter region of MGMT is methylated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39760063"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 395,
          "text": "O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is an important prognostic biomarker that predicts the response to temozolomide and guides treatment decisions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36604366"
        },
        {
          "offsetInBeginSection": 1389,
          "offsetInEndSection": 1507,
          "text": "High MGMT promoter methylation was associated with a low MGMT expression and longer PFS (HR\u003d0.37 (0.29-1.08), P\u003d0.05).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27353036"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 394,
          "text": "Studies in brain tumours conclude that MGMT promoter methylation is considered a strong predictive factor for a favourable outcome for treatment with temozolomide,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492578"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 332,
          "text": "Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression-free survival as compared with unmethylated MGMTP tumors (p \u003c 0.0001).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192931"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 205,
          "text": " Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a well-established predictor of response to the DNA-alkylating agent temozolomide in patients with glioblastoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30194078"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Aberrant methylation of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene is a predictive marker for the response to chemotherapy with alkylating agents (e.g., temozolomide) in malignant gliomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18795231"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 337,
          "text": "It has emerged not only as an important prognostic marker but also as a predictive marker for response to temozolomide in patients with newly diagnosed glioblastoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483124"
        },
        {
          "offsetInBeginSection": 1070,
          "offsetInEndSection": 1232,
          "text": "Interestingly concordant MGMT methylation and lack of protein showed better response in TMZ therapy treated patient subgroups with HR of 2.02 and 0.76 (p \u003c 0.05).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29712977"
        },
        {
          "offsetInBeginSection": 1465,
          "offsetInEndSection": 1613,
          "text": "These data suggest that lack of MGMT protein expression is superior to promoter methylation as a predictive marker for TMZ response in GBM patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150365"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 505,
          "text": "MGMT methylation predicts a better response and a longer overall survival in patients with glioblastomas treated with temozolomide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18616639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Clinical studies in patients with newly diagnosed glioblastoma treated with temozolomide have shown that the methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is both predictive and prognostic of outcome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22975219"
        },
        {
          "offsetInBeginSection": 1519,
          "offsetInEndSection": 1697,
          "text": "Similarly, MGMT promoter methylation is associated with more frequent responses and longer survival in patients with glioblastoma multiforme receiving temozolomide-based therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17032559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Silencing of O(6)-methylguanine-DNA-methyltransferase (MGMT) in tumors, mainly through promoter methylation, correlates with a better therapeutic response and with increased survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25460932"
        },
        {
          "offsetInBeginSection": 1001,
          "offsetInEndSection": 1241,
          "text": "Promoter methylation of the gene encoding the DNA repair protein, O(6)-methylguanyl DNA methyltransferase (MGMT), predicts benefit from alkylating chemotherapy with temozolomide and guides choice of first-line treatment in elderly patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26948367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22614944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "BACKGROUND: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) gliobla",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34969742"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 345,
          "text": "O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status is acknowledged as a predictive marker for temozolomide (TMZ) treatment. When MGMT promoter values fall into a \"methylated\" range, a better response to chemotherapy is expected",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27029617"
        },
        {
          "offsetInBeginSection": 551,
          "offsetInEndSection": 863,
          "text": "Elevated MGMT gene expression is known to confer resistance to the treatment with the alkylating drug temozolomide in patients affected by gliomas and, on the contrary, methylation of MGMT gene promoter, which causes reduction of MGMT protein expression, is known to predict a favourable response to temozolomide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 283,
          "text": "Hypermethylation in the promoter region of the MGMT gene encoding the DNA repair protein O(6)-methylguanine-DNA methyltransferase is among the most important prognostic factors for patients with glioblastoma and predicts response to treatment with alkylating agents like temozolomide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22428052"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 285,
          "text": "Epigenetic silencing of MGMT has been associated with a better response to temozolomide-chemotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19424593"
        },
        {
          "offsetInBeginSection": 1054,
          "offsetInEndSection": 1434,
          "text": "A companion correlative tumor-biology study has identified epigenetic silencing of the promoter of the gene that encodes MGMT (O6-methylguanine-DNA methyltransferase) in tumor specimens as a strong and independent prognostic factor for survival among patients with a newly diagnosed glioblastoma, as well as a predictor of survival benefit from chemoradiotherapy with temozolomide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16932504"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "Promoter methylation of the deoxyribonucleic acid (DNA) repair gene, O(6)-methylguanine-DNA methyltransferase (MGMT), is associated with improved outcome of patients with glioblastoma multiforme and anaplastic astrocytoma treated with temozolomide (TMZ).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721049"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 522,
          "text": "Improved outcome was associated with epigenetic silencing of the MGMT (O6-methylguanin methyltransferase) gene by promotor methylation, thereby blocking its repair capability, thus rendering the alkylating agents more effective.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17878096"
        },
        {
          "offsetInBeginSection": 688,
          "offsetInEndSection": 876,
          "text": "In patients treated with temozolomide and radiation MGMT and PYCARD promoter methylation events remained associated with improved survival whereas GATA5 was associated with a poor outcome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24554053"
        },
        {
          "offsetInBeginSection": 840,
          "offsetInEndSection": 982,
          "text": "GBM patients with tumors with MGMT promoter methylation appeared to derive the greatest benefit from the addition of TMZ to radiation therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17032561"
        },
        {
          "offsetInBeginSection": 727,
          "offsetInEndSection": 911,
          "text": "LOHs of 1p and 19q, and MGMT promoter methylation showed positive correlations with the clinical response to TMZ therapy (p \u003c 0.005, 0.05, and 0.05, respectively; Fisher\u0027s exact test).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721049"
        },
        {
          "offsetInBeginSection": 912,
          "offsetInEndSection": 1078,
          "text": "In addition, LOH of 1p and MGMT promoter methylation were associated with longer progression-free survival (p \u003c 0.05 and 0.05, respectively; Cox regression analysis).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721049"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306,
          "text": "Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter (i.e., gene silencing) occurs in 40% to 50% of patients with glioblastoma and predicts benefit from temozolomide chemotherapy; when unmethylated, MGMT repairs DNA damage induced by temozolomide, contributing to chemoresistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17234766"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 394,
          "text": "O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is an important prognostic biomarker that predicts the response to temozolomide and guides treatment decisions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36604366"
        },
        {
          "offsetInBeginSection": 1594,
          "offsetInEndSection": 1737,
          "text": "MGMT protein expression, but not MGMT promoter methylation, could predict a favorable outcome in patients receiving TMZ-containing chemotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39080996"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 236,
          "text": "The methylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) promoter is a valid biomarker for predicting response to therapy with alkylating agents and, independently, prognosis in IDH-wildtype(IDH-w) glioblastoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39367282"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22614944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 301,
          "text": "Glioblastoma (GBM) is a fatal brain tumor with limited treatment options. O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is the central molecular biomarker linked to both the response to temozolomide, the standard chemotherapy drug employed for GBM, and to patient survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38612892"
        },
        {
          "offsetInBeginSection": 390,
          "offsetInEndSection": 516,
          "text": "In glioblastoma multiforme, MGMT methylation status is a predictive biomarker for increased response to temozolomide therapy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32841306"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "BACKGROUND: O6-methylguanine methyltransferase (MGMT) promoter methylation in adult glioblastomas (glioblastoma multiforme) is considered a promising molecular alteration, predictive of better response to temozolomide therapy and longer overa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21107199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "O(6)-Methylguanine DNA methyltransferase (MGMT) is implicated as a major predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of glioblastoma multiforme (GBM) patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150365"
        },
        {
          "offsetInBeginSection": 551,
          "offsetInEndSection": 864,
          "text": "Elevated MGMT gene expression is known to confer resistance to the treatment with the alkylating drug temozolomide in patients affected by gliomas and, on the contrary, methylation of MGMT gene promoter, which causes reduction of MGMT protein expression, is known to predict a favourable response to temozolomide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035292"
        },
        {
          "offsetInBeginSection": 390,
          "offsetInEndSection": 515,
          "text": "In glioblastoma multiforme, MGMT methylation status is a predictive biomarker for increased response to temozolomide therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32841306"
        },
        {
          "offsetInBeginSection": 572,
          "offsetInEndSection": 710,
          "text": "MGMT promoter methylation is the only potential predictive marker for response to temozolomide and alkylating agents in glioblastoma (GBM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22570067"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 654,
          "text": "Loss of O6-methylguanine-DNA-methyltransferase(MGMT) protein expression due to promoter methylation reduces glioma cell DNA repair activity and resistance to alkylating agents. Thus, in world health organization (WHO) grade 4 diffuse glioma patients treated with an alkylating agent, methylated MGMT promoter is currently being considered a clinically relevant prognostic as well as predictive biomarker.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39760063"
        },
        {
          "offsetInBeginSection": 1207,
          "offsetInEndSection": 1299,
          "text": "Overall and progression-free survival were longer in patients with methylated MGMT promoter.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24519517"
        },
        {
          "offsetInBeginSection": 1053,
          "offsetInEndSection": 1207,
          "text": "Moreover, we confirmed that OS and PFS for patients carrying methylation of the MGMT promoter were longer than for patients with an unmethylated promoter.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25588856"
        },
        {
          "offsetInBeginSection": 1773,
          "offsetInEndSection": 2015,
          "text": "In conclusion MGMT promoter methylation status in tumor tissue and plasma was highly concordant, and both were associated with longer survival, supporting the role of the detection of methylated MGMT promoter in predicting treatment response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24519517"
        },
        {
          "offsetInBeginSection": 1719,
          "offsetInEndSection": 1929,
          "text": "The median overall survival in these patients receiving standard radiotherapy and concomitant temozolomide chemotherapy showed a trend towards better survival in group with methylated MGMT promoter (p \u003c 0.001).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39760063"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 164,
          "text": " The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30514777"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "text": "Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter (i.e., gene silencing) occurs in 40% to 50% of patients with glioblastoma and predicts benefit from temozolomide chemotherapy; when unmethylated, MGMT repairs DNA damage induced by temozolomide, contributing to chemoresistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17234766"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 304,
          "text": "It is already well known that hypermethylation of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter is a predictive biomarker of response to temozolomide treatment and of favorable outcomes in terms of overall survival (OS) and progression-free survival (PFS) in glioblastoma (GBM) patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25588856"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 375,
          "text": "The methylation status of MGMT (O6 methylguanine DNA-methyltransferase) promoter is one of the strongest predictive and prognostic factors for the patient chemoresponse",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26118907"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20517307"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 240,
          "text": "O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status is acknowledged as a predictive marker for temozolomide (TMZ) treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27029617"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22614944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "CpG methylation within the O6-methylguanine-DNA-methyltransferase (MGMT) promoter is associated with enhanced survival of glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19011762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Aberrant methylation of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene is a predictive marker for the response to chemotherapy with alkylating agents (e.g., temozolomide) in malignant gliomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18795231"
        }
      ],
      "id": "67eb713518b1e36f2e0000ed",
      "ideal_answer": [
        "The standard treatment for GBM consists of surgical resection followed by concurrent chemoradiotherapy and adjuvant temozolomide. O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is an important predictive biomarker of response to temozolomide treatment and of favorable outcomes in terms of overall survival and progression-free survival. At present, the only reliable way to determine MGMT promoter methylation status is through the analysis of tumor tissues. However, identifying the MGMT methylation status using molecular techniques remains challenging due to technical limitations, such as the inability to obtain tumor specimens, high prices for detection, and the high complexity of intralesional heterogeneity.",
        "MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation has been identified as a predictive marker for response to temozolomide therapy in various cancers, including glioblastomas and neuroendocrine tumors. Studies indicate that methylation of the MGMT promoter reduces the expression of the MGMT protein, which is a DNA repair enzyme. This reduction impairs the ability of cancer cells to repair the DNA damage caused by temozolomide, leading to a better treatment response. Elevated MGMT expression is associated with resistance to temozolomide, while promoter methylation correlates with improved outcomes. Techniques such as methylation-specific PCR and pyrosequencing have proven more reliable than immunohistochemistry for assessing MGMT promoter methylation status, with pyrosequencing being slightly superior. Overall, the evidence supports that MGMT promoter methylation is a significant predictor of favorable response to temozolomide-based therapy.",
        "MGMT promoter hypermethylation serves as a predictive biomarker for better response to temozolomide treatment and favorable outcomes in terms of overall survival and progression-free survival in glioblastoma patients. While this methylation status is crucial for guiding treatment decisions, determining it reliably requires tumor tissue analysis, which can be challenging due to technical limitations including specimen availability, detection costs, and tumor heterogeneity.",
        "Yes, MGMT promoter methylation predicts a better response to temozolomide in patients with glioblastoma. Methylation silences the MGMT gene, reducing production of its DNA repair enzyme and rendering tumor cells more susceptible to temozolomide-induced damage. This modification is associated with not only improved treatment response but also longer overall and progression-free survival. However, assessing MGMT promoter methylation can be challenging due to technical issues such as intratumoral heterogeneity and difficulties in obtaining representative tumor specimens.",
        "Hypermethylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a well-established predictive biomarker for response to temozolomide treatment in glioblastoma patients. This methylation status correlates with favorable outcomes, including improved overall survival and progression-free survival. Despite challenges such as technical limitations in detecting MGMT methylation due to factors like tumor specimen availability, high detection costs, and intralesional heterogeneity, the presence of promoter methylation remains a crucial factor in predicting treatment response and guiding therapeutic decisions.",
        "Hypermethylation of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter is recognized as a predictive biomarker for a favorable response to temozolomide treatment in glioblastoma patients, correlating with improved overall survival and progression-free survival. This methylation status indicates reduced resistance to temozolomide, making it an important factor in guiding treatment decisions. However, determining MGMT promoter methylation status is challenging due to technical limitations such as the difficulty of obtaining tumor specimens and the complexity of intralesional heterogeneity."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is currently the number of germline associations with clonal hematopoiesis in European-ancestry populations?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35835912"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 408,
          "text": "Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35835912"
        }
      ],
      "id": "67e7db2918b1e36f2e0000d6",
      "ideal_answer": [
        "Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. By analyzing genetic data from 200,453 UK Biobank participants in order to map the landscape of inherited predisposition to CH, the number of germline associations with CH in European-ancestry populations has been determined to be 14.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations has increased from 4 to 14.",
        "There are at least 14 germline associations with clonal hematopoiesis in European-ancestry populations, as identified in a comprehensive study of 200,453 UK Biobank participants, marking an increase from the previously known four associations, thereby updating our current understanding of these genetic links in this demographic.",
        "14",
        "The current number of germline associations with clonal hematopoiesis (CH) in European-ancestry populations has increased from 4 to 14, as identified through the analysis of genetic data from 200,453 UK Biobank participants. This advancement enhances our understanding of the inherited predisposition to CH and highlights the role of specific germline mutations linked to oncogenic pathways that may contribute to clonal expansion in hematopoiesis.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations has increased from 4 to 14, based on genome-wide analyses of 200,453 UK Biobank participants. Novel germline loci associated with the risk of clonal hematopoiesis have been identified within the UK Biobank. The strongest associations are conferred by DNA variants near TERT, SMC4, KPNA4, IL12A, CD164, and ATM.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations is currently 14.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations is 14.",
        "The current number of germline associations with clonal hematopoiesis in European-ancestry populations is 14.",
        "The number of germline associations is currently 14 in European-ancestry populations.",
        "As of the latest genome-wide analysis of 200,453 UK Biobank participants, there are at least 14 identified germline associations with clonal hematopoiesis in European-ancestry populations, marking a significant increase from the previously known four associations.",
        "As of the latest available data, there are 14 identified germline associations with clonal hematopoiesis in populations of European ancestry, suggesting a finite set of genetic predispositions linked to this condition within this demographic group.",
        "Based on a large-scale genome-wide analysis of UK Biobank participants, the number of germline associations with clonal hematopoiesis in European-ancestry populations has been expanded from 4 to 14. Additional analyses further confirmed these novel associations.",
        "According to the text, the current number of germline associations with clonal hematopoiesis (CH) in European-ancestry populations is 14.",
        "Studies analyzing genetic data from a large cohort of 200,453 UK Biobank participants have significantly expanded our understanding of the inherited predisposition to clonal hematopoiesis (CH). Previously, only 4 germline associations with CH were identified in European-ancestry populations. However, recent findings have increased this number to 14, providing new insights into the genetic landscape underlying CH. This advancement is crucial as CH has been linked to various factors including aging, genetic ancestry, and disease risk, and is characterized by the expansion of clones in the hematopoietic system. The identification of these additional germline associations sheds light on the complex relationship between genetics and the development of clonal hematopoiesis, particularly in individuals of European ancestry.",
        "As of the latest genome-wide analysis of 200,453 UK Biobank participants, there are currently at least 14 identified germline associations with clonal hematopoiesis in European-ancestry populations, marking a significant increase from the previously recognized four associations, thus updating our current understanding of these genetic predispositions within this demographic group.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations has increased from 4 to 14, according to genome-wide analyses of 200,453 UK Biobank participants. These associations involve genes related to various biological functions, including DNA damage repair, hematopoietic stem cell migration/homing, myeloid oncogenesis, cell cycle regulation, cell proliferation/survival, hematopoietic progenitor cell regulation, and telomere maintenance. Specific genetic variants near TERT, SMC4, KPNA4, IL12A, CD164, and ATM have been identified as having strong associations with clonal hematopoiesis. Additionally, novel germline loci associated with the risk of clonal hematopoiesis have been identified within the UK Biobank.",
        "Currently, there are 14 germline associations with clonal hematopoiesis in European-ancestry populations.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations has increased from 4 to 14, as identified through genome-wide association studies (GWAS). These studies have highlighted various genes involved in DNA damage repair, hematopoietic stem cell migration/homing, myeloid oncogenesis, cell cycle regulation, cell proliferation/survival, hematopoietic progenitor cell regulation, and telomere maintenance. Specific genetic loci with strong associations include DNA variants near TERT, SMC4, KPNA4, IL12A, CD164, and ATM. These findings are primarily based on genetic association studies within the UK Biobank, which includes European-ancestry populations.",
        "There are 14 germline associations with clonal hematopoiesis in European-ancestry populations.",
        "There are currently 14 known germline associations with clonal hematopoiesis in European-ancestry populations, up from 4, as identified through a genome-wide analysis of 200,453 UK Biobank participants, with implicated genes involved in DNA damage repair, hematopoietic stem cell migration/homing, and myeloid oncogenesis.",
        "Studies analyzing genetic data from a large cohort of 200,453 UK Biobank participants have significantly advanced our understanding of clonal hematopoiesis (CH). Prior to this research, only 4 germline associations with CH in European-ancestry populations were identified. However, the latest findings have substantially increased this number, revealing a total of 14 germline associations with CH in these populations, thereby enhancing our knowledge of the inherited predisposition to this condition.",
        "Based on analysis of genetic data from over 200,000 UK Biobank participants, researchers identified 14 germline associations with clonal hematopoiesis (CH) in European-ancestry populations, marking a significant increase from the previously known 4 associations.",
        "Recent genetic analyses of 200,453 UK Biobank participants have significantly expanded the understanding of inherited predisposition to clonal hematopoiesis (CH). This study increased the number of identified germline associations with CH in European-ancestry populations from 4 to 14, highlighting a more complex genetic architecture underlying this condition than previously recognized.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations is 14, which was increased from 4 through the analysis of genetic data from 200,453 UK Biobank participants.",
        "The current number of germline associations with clonal hematopoiesis in European-ancestry populations is 14, an increase from 4 associations.",
        "The number of germline associations with clonal hematopoiesis (CH) in European-ancestry populations has increased from 4 to 14, according to recent findings from a study involving over 200,000 participants in the UK Biobank. This significant increase suggests that there are more genetic factors contributing to CH than previously identified, enhancing our understanding of the genetic basis of this condition and potentially paving the way for new diagnostic tools and treatments.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations has increased from 4 to 14, based on genetic data from 200,453 UK Biobank participants.",
        "There are currently 14 known germline associations with clonal hematopoiesis in European-ancestry populations, up from just 4 previously identified.",
        "The number of germline associations with clonal hematopoiesis (CH) in European-ancestry populations has increased from 4 to 14. This expansion was identified through an analysis of genetic data from 200,453 UK Biobank participants, which helped map the landscape of inherited predisposition to CH.",
        "The current number of germline associations with clonal hematopoiesis in European-ancestry populations is 14, increased from 4, based on a genome-wide analysis of 200,453 UK Biobank participants, implicating DNA damage repair, hematopoietic stem cell migration, and myeloid oncogenesis.",
        "Clonal hematopoiesis is a condition that arises from the clonal expansion of blood stem cells driven by somatic mutations. Despite affecting a significant portion of the population, its underlying mechanisms remain largely unclear. Recent genetic research, such as the analysis of data from 200,453 UK Biobank participants, has significantly advanced the understanding of CH, most notably in European-ancestry populations. Through this study, the number of germline associations found with clonal hematopoiesis, which are genetic predispositions inherent in these populations, has increased from 4 to 14. This finding marks a substantial progression in identifying genetic factors that may predispose individuals to clonal hematopoiesis, providing critical insights into the inherited components of this condition.",
        "Currently, there are 14 identified germline associations with clonal hematopoiesis in European-ancestry populations, representing a significant increase from the previously reported 4, as determined through the analysis of genetic data from over 200,000 UK Biobank participants.",
        "The study identifies 14 germline associations with clonal hematopoiesis (CH) in European-ancestry populations, marking a significant increase from the previously known four. This advancement, based on genetic data from over 200,000 UK Biobank participants, enhances our understanding of the inherited factors contributing to CH and could lead to better risk prediction and targeted interventions. The findings highlight the importance of large-scale studies in uncovering genetic underpinnings and suggest potential avenues for future research into mechanisms and personalized medicine approaches.",
        "Currently, there are 14 known germline associations with clonal hematopoiesis in European-ancestry populations, as identified through a genome-wide analysis of 200,453 UK Biobank participants, representing a significant increase from the previously known 4 associations.",
        "Clonal hematopoiesis (CH), a condition characterized by the clonal expansion of blood stem cells driven by somatic mutations, affects over a third of individuals but remains poorly understood. Recent studies analyzing genetic data from 200,453 UK Biobank participants have significantly advanced our understanding of inherited predisposition to CH. These investigations have increased the number of identified germline associations with CH in European-ancestry populations from four to fourteen, providing new insights into the genetic underpinnings of this condition.",
        "The number of germline associations with clonal hematopoiesis (CH) in European-ancestry populations has increased from 4 to 14.",
        "The number of germline associations with clonal hematopoiesis in European-ancestry populations has been increased from 4 to 14 based on an analysis of genetic data from 200,453 UK Biobank participants.",
        "The analysis of genetic data from 200,453 UK Biobank participants has increased the number of known germline associations with clonal hematopoiesis (CH) in European-ancestry populations from four to fourteen."
      ],
      "exact_answer": [
        [
          "14"
        ]
      ]
    },
    {
      "body": "What are active ingredients of Exblifep?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38761353"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 336,
          "text": "Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cephalosporin and an extended-spectrum β-lactamase (ESBL) inhibitor, is being developed by Allecra Therapeutics and ADVANZ PHARMA for the treatment of infections caused by multi-drug-resistant (MDR) Gram-negative bacteria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38761353"
        }
      ],
      "type": "list",
      "id": "67e6c3f918b1e36f2e0000c9",
      "ideal_answer": [
        "Exblifep includes cefepime and enmetazobactam, an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cephalosporin and an extended-spectrum β-lactamase (ESBL) inhibitor, is being developed for the treatment of infections caused by multi-drug-resistant (MDR) Gram-negative bacteria."
      ],
      "exact_answer": [
        [
          "cefepime"
        ],
        [
          "enmetazobactam"
        ]
      ]
    },
    {
      "body": "What are the current interventions for congenital talipes equinovarus?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38015923",
        "http://www.ncbi.nlm.nih.gov/pubmed/38812862",
        "http://www.ncbi.nlm.nih.gov/pubmed/35834789",
        "http://www.ncbi.nlm.nih.gov/pubmed/25117413",
        "http://www.ncbi.nlm.nih.gov/pubmed/16263225",
        "http://www.ncbi.nlm.nih.gov/pubmed/29642612",
        "http://www.ncbi.nlm.nih.gov/pubmed/38935547",
        "http://www.ncbi.nlm.nih.gov/pubmed/38373814",
        "http://www.ncbi.nlm.nih.gov/pubmed/17785734",
        "http://www.ncbi.nlm.nih.gov/pubmed/39654823",
        "http://www.ncbi.nlm.nih.gov/pubmed/34547011",
        "http://www.ncbi.nlm.nih.gov/pubmed/38074009",
        "http://www.ncbi.nlm.nih.gov/pubmed/21911524",
        "http://www.ncbi.nlm.nih.gov/pubmed/35696825",
        "http://www.ncbi.nlm.nih.gov/pubmed/37160202",
        "http://www.ncbi.nlm.nih.gov/pubmed/36600811",
        "http://www.ncbi.nlm.nih.gov/pubmed/37031009",
        "http://www.ncbi.nlm.nih.gov/pubmed/30557091",
        "http://www.ncbi.nlm.nih.gov/pubmed/37034198",
        "http://www.ncbi.nlm.nih.gov/pubmed/25438104",
        "http://www.ncbi.nlm.nih.gov/pubmed/26329941",
        "http://www.ncbi.nlm.nih.gov/pubmed/23232379",
        "http://www.ncbi.nlm.nih.gov/pubmed/28177984",
        "http://www.ncbi.nlm.nih.gov/pubmed/24142617",
        "http://www.ncbi.nlm.nih.gov/pubmed/16877611",
        "http://www.ncbi.nlm.nih.gov/pubmed/30523464",
        "http://www.ncbi.nlm.nih.gov/pubmed/32958391",
        "http://www.ncbi.nlm.nih.gov/pubmed/37963491",
        "http://www.ncbi.nlm.nih.gov/pubmed/33741833",
        "http://www.ncbi.nlm.nih.gov/pubmed/27935562",
        "http://www.ncbi.nlm.nih.gov/pubmed/32918418",
        "http://www.ncbi.nlm.nih.gov/pubmed/22387138",
        "http://www.ncbi.nlm.nih.gov/pubmed/37041913",
        "http://www.ncbi.nlm.nih.gov/pubmed/36694491",
        "http://www.ncbi.nlm.nih.gov/pubmed/39311663",
        "http://www.ncbi.nlm.nih.gov/pubmed/19239864",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571163",
        "http://www.ncbi.nlm.nih.gov/pubmed/23973353",
        "http://www.ncbi.nlm.nih.gov/pubmed/3623753",
        "http://www.ncbi.nlm.nih.gov/pubmed/21853914",
        "http://www.ncbi.nlm.nih.gov/pubmed/23586398",
        "http://www.ncbi.nlm.nih.gov/pubmed/21052630",
        "http://www.ncbi.nlm.nih.gov/pubmed/24707607"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 232,
          "text": "Clubfoot, or congenital talipes equinovarus deformity, is a common anomaly affecting the foot in infants. However, clinical equipoise remains between different interventions, especially those based on the Ponseti method.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38015923"
        },
        {
          "offsetInBeginSection": 234,
          "offsetInEndSection": 791,
          "text": "he aim of this study was to examine the clinical outcomes of the various interventions for treating idiopathic clubfoot.METHODS: Searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Scopus, and CINAHL were conducted. Randomized controlled trials comparing different interventions, including the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment, were included",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38015923"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 258,
          "text": "Clubfoot, also known as congenital talipes equinovarus is a prevalent childhood ailment that, if untreated, can lead to long-term discomfort and impairment. The Ponseti technique, aimed at achieving corrected foot positioning, is widely accepted.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38812862"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Tibialis anterior tendon transfer (TATT) is a recognised procedure for the treatment of recurrent congenital talipes equinovarus. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35834789"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 687,
          "text": "BACKGROUND: Congenital talipes equinovarus (CTEV), also known as clubfoot, is a common congenital orthopaedic condition characterised by an excessively turned-in foot (equinovarus) and high medial longitudinal arch (cavus). If left untreated it can result in long-term disability, deformity and pain. Interventions can be conservative (such as splinting or stretching) or surgical. Different treatments might be effective at different stages: at birth (initial presentation); when initial treatment does not work (resistant presentation); when the initial treatment works but the clubfoot returns (relapse/recurrent presentation); and when there has been no early treatment (neglected pr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32412098"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 658,
          "text": "Congenital talipes equinovarus is a common deformity that is present at birth. It can be treated conservatively. Of the techniques available, the Ponseti method is effective in correcting most of these foot deformities and is best started early. Some of the stiffer \"teratological\" foot deformities may require surgical releases. Other conservative methods may be applied to correct deformity, but they have not been demonstrated to be as effective as the Ponseti method, although they may reduce the extent of subsequent surgical releases. Surgery can be undertaken to correct deformity, but some loss of motion is inevitable with extensive open procedures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16263225"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Ponseti Technique for the Management of Congenital Talipes Equinovarus in a Rural Set-Up in India: Experience of 356 Patients.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642612"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 213,
          "text": "The study aimed to quantify and correlate kinematic coupling linkage of foot abduction (correction of adduction) and inversion, heel varus and ankle equinus for clubfeet corrected by Ponseti technique.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39654823"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Congenital clubfoot is one of the most common deformities in children, and currently, the Ponseti method is used worldwide because of its favorable short-term results",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37160202"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Effectiveness of Needle Tenotomy for Correction of Equinus in Clubfoot.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36600811"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Anterior Distal Tibial Guided Growth for recurrent equinus deformity in idiopathic Congenital Talipes Equinovarus treated with the Ponseti method.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37031009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "BACKGROUND: The Ponseti method for treating congenital talipes equinovarus requires an orthosis to maintain correction after manipulation and casting, typically the \u0027boo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30557091"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "A new unilateral abduction orthosis for Ponseti-treated clubfoot: A cohort study to assess compliance.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30557091"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 439,
          "text": "congenital talipes equinovarus with emphasis on the initial treatment. Current management is moving away from operative towards a more conservative treatment using the Ponseti regime. The long-term results of surgical correction and the recent results",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17785734"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 330,
          "text": "ychological status of congenital talipes equinovarus treated with the Ponseti method.Methods: Sixty-seven mothers of children with congenital talipes equinovaru",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37034198"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Forty-six severe clubfeet in 29 patients were treated by serial castings, followed by a newly developed dynamic splint.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25438104"
        },
        {
          "offsetInBeginSection": 3711,
          "offsetInEndSection": 4014,
          "text": "Adverse events following surgical procedures included infection and the need for skin grafting.AUTHORS\u0027 CONCLUSIONS: From the limited evidence available, the Ponseti technique produced significantly better short-term foot alignment compared to the Kite technique and compared to a traditional technique.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25117413"
        },
        {
          "offsetInBeginSection": 272,
          "offsetInEndSection": 462,
          "text": "The Ponseti method that includes manipulation, serial casting, percutaneous tenotomy and bracing has recently become very popular for the management of CTEV with reported excellent outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26329941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Long-term results of treatment of congenital idiopathic clubfoot in 187 feet: outcome of the functional \"French\" method, if necessary completed by soft-tissue release.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23232379"
        },
        {
          "offsetInBeginSection": 874,
          "offsetInEndSection": 1084,
          "text": "The Ponseti method is an effective first-line treatment for syndrome-associated talipes equinovarus to achieve functional painless feet; children will often require more casts and have a higher risk of relapse.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28177984"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Congenital idiopathic talipes equinovarus: an evaluation in infants treated by the Ponseti method.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24142617"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Tibialis anterior tendon transfer using bone anchor for dynamic supination in congenital talipes equinovarus.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35834789"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Early results of a physiotherapist-delivered Ponseti service for the management of idiopathic congenital talipes equinovarus foot deformity.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16877611"
        },
        {
          "offsetInBeginSection": 1057,
          "offsetInEndSection": 1412,
          "text": "Wedge osteotomy and Achilles tendon lengthening surgery were performed. Probably, extensive soft tissue surgery is the best option for treating clubfoot. A physical therapist may use stretching, proprioceptive neuromuscular facilitation (PNF), joint mobilization, and joint compression to enhance the foot\u0027s alignment, mobility, and range of motion (ROM) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38074009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "The current standard practice of treatment for congenital talipes equinus varus (CTEV) is the Ponseti method of manipulation and casting which requires great compliance by caregivers for casting as well as bracing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523464"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 821,
          "text": "The current best practice for the treatment of CTEV is the original Ponseti method, with minimal adjustments being hyperabduction of the foot in the final cast and the need for longer-term bracing up to four years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911524"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "BACKGROUND: The Ponseti method is the standard of care for managing idiopathic congenital talipes equinovarus (clubfoot) in the outpatient setting, but there are no clinical guidelines for inpatien",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32958391"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Aims: The Ponseti method is the gold standard treatment for congenital talipes equinovarus (CTEV), with the British Consensus Statement providing a benchmark for standard of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37963491"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Currently, the Ponseti method has become the most popular technique for the management of congenital clubfoot.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741833"
        },
        {
          "offsetInBeginSection": 381,
          "offsetInEndSection": 561,
          "text": "However currently the conservative management (manipulation, serial casting, and braces) of clubfoot is considered as the best choice and it is widely accepted among orthopaedists.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27935562"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "INTRODUCTION: Most of the authors currently agree that congenital talipes equinovarus (CTEV) or idiopathic clubfoot can be effectively treated with the Ponseti method instead of extensive soft t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32918418"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "BACKGROUND: The Ponseti method has become increasingly popular in the treatment of congenital talipes equinov",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22387138"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 479,
          "text": "Since 1964, 5,312 cases of congenital talipes equinovarus were treated by percutaneous elongation of the Achilles tendon, plantar fasciotomy and corrective plasters. In 4,502 cases the results are good enough to recommend this technique, even in developed countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3623753"
        },
        {
          "offsetInBeginSection": 1722,
          "offsetInEndSection": 1896,
          "text": "The abduction dorsiflexion mechanism boot is a feasible alternative to the traditional boots and bar, particularly in children with unilateral congenital talipes equinovarus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30557091"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 820,
          "text": "The current best practice for the treatment of CTEV is the original Ponseti method, with minimal adjustments being hyperabduction of the foot in the final cast and the need for longer-term bracing up to four years",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911524"
        },
        {
          "offsetInBeginSection": 393,
          "offsetInEndSection": 480,
          "text": "The Ponseti method of manipulation and serial casting is the standard treatment of CTEV",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38935547"
        },
        {
          "offsetInBeginSection": 282,
          "offsetInEndSection": 459,
          "text": "idfoot cavus. The Ponseti casting technique of CTEV management has proven to be more effective, generating higher positive outcomes and lesser complications than conventional su",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37041913"
        },
        {
          "offsetInBeginSection": 1761,
          "offsetInEndSection": 1886,
          "text": "In conclusion, the percutaneous Achilles tenotomy of a CTEV foot with a large bore needle is a safe and effective alternative",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36694491"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "BACKGROUND: The tibialis anterior tendon transfer (TATT) is the suggested surgical intervention in the Ponseti method for treatment of dynamic recurrent congenital talipes equinovarus (clubfoot) presenting as hindfoot varus and forefoot supination during the swing p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35696825"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "The Ponseti method of clubfoot treatment is ideal for low- and middle-income countries since it is minimally invasive and easily implementable through non-surgeon providers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39311663"
        },
        {
          "offsetInBeginSection": 424,
          "offsetInEndSection": 552,
          "text": "Idiopathic clubfoot should correct with a maximum of eight serial manipulations, cast applications and Achilles tendon tenotomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38373814"
        },
        {
          "offsetInBeginSection": 266,
          "offsetInEndSection": 387,
          "text": "A total of 100 patients with 156 clubfeet (80 males, 20 females), were treated for idiopathic CTEV by the Ponseti method.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19239864"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 312,
          "text": "While adoption of the Ponseti method has continued gradually, its use to manage patients with congenital talipes equinovarus (CTEV) has been limited in low- and middle-income countries (LMICs) for a number of reasons including a lack of clinical training on technique and lack of appropriate clinical equipment. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571163"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "BACKGROUND: In 2010, 2 authors of this current study reported the results of Ponseti treatment compared with primary posteromedial release (PMR) for congenital talipes equinovarus in a cohort of 51 prospecti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34547011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "The Ponseti technique for treatment for Congenital Talipes Equinovarus (CTEV) was introduced in the authors\u0027 institution in 2001, substituting a more traditional orthopaedic approach which involved surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23973353"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 378,
          "text": "Since 1964, 5,312 cases of congenital talipes equinovarus were treated by percutaneous elongation of the Achilles tendon, plantar fasciotomy and corrective plasters.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3623753"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 581,
          "text": "After 9 casts set according to Ponseti protocol good correction of all components was achieved accept for the equinus deformity. Achilles lengthening procedure was done, but there was necessity to perform posterior release to achieve good dorsiflexion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21853914"
        },
        {
          "offsetInBeginSection": 265,
          "offsetInEndSection": 437,
          "text": "With the widespread acceptance of the Ponseti method of clubfoot treatment major surgical interventions are needed much less frequently and long-term outcomes are improved.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23586398"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "BACKGROUND: The tibialis anterior tendon transfer (TATT) is the suggested surgical intervention in the Ponseti method for treatment of dynamic recurrent congenital talipes equinovarus (clubfoot) presenting as hindfoot varus and forefoot supination during the swing ph",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35696825"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 594,
          "text": "The treatment of clubfoot should start early after birth and is primarily conservative, involving manipulation and serial casting",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052630"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "The Ponseti method is the ideal treatment for the management of congenital clubfoot of any etiology; it corrects the deformity in more than 90% of cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24707607"
        },
        {
          "offsetInBeginSection": 424,
          "offsetInEndSection": 551,
          "text": "Idiopathic clubfoot should correct with a maximum of eight serial manipulations, cast applications and Achilles tendon tenotomy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38373814"
        }
      ],
      "type": "list",
      "id": "67decf2a18b1e36f2e00005c",
      "ideal_answer": [
        "There are many treatment options for Congenital talipes equinovarus, also known as club foot. These include the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment.",
        "The current interventions for congenital talipes equinovarus include the Ponseti method, which involves gentle manipulation and casting, the French method, which uses physical therapy and splinting, and surgical intervention for more severe cases or when other methods are not effective.",
        "The current interventions for congenital talipes equinovarus are the Ponseti method, osteotomies, intra-articular surgical procedures, Botox injection, posteromedial release (PMR), Botox injection with Ponseti method, and accelerated Ponseti treatment.",
        "The Ponseti method, involving manipulation, serial casting, percutaneous Achilles tenotomy, and bracing, is the standard of care for managing congenital talipes equinovarus (clubfoot). It is a conservative treatment that is widely accepted among orthopaedists and has become increasingly popular. The Ponseti method provides excellent results with a high initial correction rate.",
        "The current interventions for congenital talipes equinovarus include the Ponseti method, Botox injection, and osteotomies.",
        "Current interventions for congenital talipes equinovarus (clubfoot) include the Ponseti method, tibialis anterior tendon transfer (TATT), and various nonsurgical techniques such as corrective splinting, taping, and casting.",
        "The current interventions for congenital talipes equinovarus include the Ponseti method, Botox injection, osteotomies, intra-articular surgical procedures, accelerated Ponseti treatment, primary PMR, standard Ponseti treatment, and casts.",
        "The Ponseti method, sometimes combined with Botox injections, and primary PMR are the main interventions for clubfoot.",
        "Current interventions for congenital talipes equinovarus (CTEV) include the Ponseti method, which involves serial casting, Achilles tenotomy, and bracing. Additionally, surgical treatments such as selective medial release, cuboid subtraction osteotomy, and posteromedial release are performed in ambulating children.",
        "The current interventions for congenital talipes equinovarus are the Ponseti method, Botox injection, osteotomies, and intra-articular surgical procedures.",
        "The Ponseti method is the most widely used treatment for congenital talipes equinovarus. It involves serial casting, followed by percutaneous Achilles tendon lengthening and finally, bracing. Other interventions include the Dwyer procedure, which involves the use of a single incision and the use of a cast, and the VEPTR procedure, which involves the use of an external fixator.",
        "Current interventions for congenital talipes equinovarus (clubfoot) include the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment. These approaches aim to correct foot positioning and improve long-term functional outcomes for affected infants.",
        "The current interventions for congenital talipes equinovarus are the Ponseti method, Kite method, Accelerated Ponseti method, and Surgical treatment.",
        "The study reviews several interventions including the standard Ponseti method, an accelerated version of this method, Ponseti combined with botulinum toxin type A (Botox) injection, Ponseti with early tibialis anterior tendon transfer (TATT), the Kite method, and surgical treatment as options for managing congenital talipes equinovarus.",
        "The current interventions for congenital talipes equinovarus include the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment.",
        "The current interventions for congenital talipes equinovarus (clubfoot) include: Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, surgical treatment, and Lambrinudi arthrodesis.",
        "The current interventions for congenital talipes equinovarus include the Ponseti method, Kite method, accelerated Ponseti method, surgical treatment, Ponseti method with early tibialis anterior tendon transfer (TATT), Ponseti method with botulinum toxin type A (Botox) injection, Tibialis anterior tendon transfer (TATT), and Ponseti method with Botox injection.",
        "Current interventions for congenital talipes equinovarus include the Ponseti method, accelerated Ponseti method, Ponseti with botulinum toxin type A injection, Ponseti with early tibialis anterior tendon transfer (TATT), the Kite method, and surgical treatment. TATT is specifically recognized for treating recurrent cases.",
        "The current interventions for congenital talipes equinovarus (clubfoot) include the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment.",
        "The current interventions for congenital talipes equinovarus (clubfoot) include: 1. Ponseti method 2. Accelerated Ponseti method 3. Ponseti method with botulinum toxin type A (Botox) injection 4. Ponseti method with early tibialis anterior tendon transfer (TATT) 5. Kite method 6. Surgical treatment",
        "Current interventions for congenital talipes equinovarus include: the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment.",
        "The current interventions for congenital talipes equinovarus (clubfoot) include: the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment.",
        "Current interventions for congenital talipes equinovarus include various Ponseti methods, the Kite method, and surgical treatment.",
        "Current interventions for congenital talipes equinovarus include the Ponseti method (considered optimal overall), its variants (accelerated, with Botox, and with early Tibialis Anterior Tendon Transfer), the Kite method, and surgical treatment, with Tibialis Anterior Tendon Transfer using a bone anchor being a reliable option for dynamic supination.",
        "The current interventions for congenital talipes equinovarus include the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment .",
        "The current interventions for congenital talipes equinovarus are the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), Kite method, and surgical treatment.",
        "The current interventions for congenital talipes equinovarus (clubfoot) include:\n\n1. Ponseti method: a widely accepted technique aimed at achieving corrected foot positioning.\n2. Accelerated Ponseti method: a variation of the Ponseti method.\n3. Ponseti method with botulinum toxin type A (Botox) injection: combines the Ponseti method with Botox injection.\n4. Ponseti method with early tibialis anterior tendon transfer (TATT): adds TATT to the Ponseti method.\n5. Kite method: an alternative technique for treating clubfoot.\n6. Surgical treatment: may be necessary in some cases, especially for recurrent or severe deformities.\n\nThese interventions aim to correct the foot deformity and improve outcomes for individuals with congenital talipes equinovarus.",
        "Current interventions for congenital talipes equinovarus (clubfoot) include the Ponseti method, accelerated Ponseti method, Ponseti method with botulinum toxin type A (Botox) injection, Ponseti method with early tibialis anterior tendon transfer (TATT), the Kite method, and surgical treatment.",
        "Current interventions for congenital talipes equinovarus include the Ponseti method, its variants (accelerated, with Botox, and with early TATT), the Kite method, and surgical treatment, with TATT being specifically used for recurrent cases."
      ],
      "exact_answer": [
        [
          "Ponseti method"
        ],
        [
          "Ponseti method with botulinum toxin type A (Botox) injection,"
        ],
        [
          "Ponseti method with early tibialis anterior tendon transfer (TATT)"
        ],
        [
          "Kite Method"
        ],
        [
          "Surgical treatment"
        ]
      ]
    },
    {
      "body": "Which biologic drugs are used in respiratory diseases?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31389304",
        "http://www.ncbi.nlm.nih.gov/pubmed/37812191",
        "http://www.ncbi.nlm.nih.gov/pubmed/36845128",
        "http://www.ncbi.nlm.nih.gov/pubmed/24975288",
        "http://www.ncbi.nlm.nih.gov/pubmed/39267467",
        "http://www.ncbi.nlm.nih.gov/pubmed/37684154",
        "http://www.ncbi.nlm.nih.gov/pubmed/34597850",
        "http://www.ncbi.nlm.nih.gov/pubmed/37771938",
        "http://www.ncbi.nlm.nih.gov/pubmed/39343299",
        "http://www.ncbi.nlm.nih.gov/pubmed/39726595",
        "http://www.ncbi.nlm.nih.gov/pubmed/39741370",
        "http://www.ncbi.nlm.nih.gov/pubmed/36702649",
        "http://www.ncbi.nlm.nih.gov/pubmed/32034960",
        "http://www.ncbi.nlm.nih.gov/pubmed/30444939",
        "http://www.ncbi.nlm.nih.gov/pubmed/31090937",
        "http://www.ncbi.nlm.nih.gov/pubmed/29862274",
        "http://www.ncbi.nlm.nih.gov/pubmed/20065638",
        "http://www.ncbi.nlm.nih.gov/pubmed/23282002",
        "http://www.ncbi.nlm.nih.gov/pubmed/19834630",
        "http://www.ncbi.nlm.nih.gov/pubmed/39681861",
        "http://www.ncbi.nlm.nih.gov/pubmed/39674169",
        "http://www.ncbi.nlm.nih.gov/pubmed/39708290",
        "http://www.ncbi.nlm.nih.gov/pubmed/27773786",
        "http://www.ncbi.nlm.nih.gov/pubmed/23517646",
        "http://www.ncbi.nlm.nih.gov/pubmed/27889330",
        "http://www.ncbi.nlm.nih.gov/pubmed/35809428"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 524,
          "offsetInEndSection": 640,
          "text": "Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37812191"
        },
        {
          "offsetInBeginSection": 2324,
          "offsetInEndSection": 2378,
          "text": "Omalizumab, benralizumab, mepolizumab, and tezepelumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36845128"
        },
        {
          "offsetInBeginSection": 368,
          "offsetInEndSection": 379,
          "text": " infliximab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24975288"
        },
        {
          "offsetInBeginSection": 397,
          "offsetInEndSection": 431,
          "text": "adalimumab, 5 (5%) with etanercept",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24975288"
        },
        {
          "offsetInBeginSection": 448,
          "offsetInEndSection": 457,
          "text": "rituximab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24975288"
        },
        {
          "offsetInBeginSection": 259,
          "offsetInEndSection": 558,
          "text": "Currently, four biologics (all monoclonal antibodies) are licensed in the UK for the treatment of children with severe asthma - omalizumab (Xolair), mepolizumab (Nucala), and dupilumab (Dupixent) in children aged 6 years and over; and tezepelumab (Tezspire), only in children aged 12 years and over.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39267467"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 641,
          "text": "There are currently six biologic therapies approved by the US Food and Drug Administration to treat asthma, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, three of these-omalizumab, mepolizumab, and dupilumab-are also approved for NPs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37684154"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 476,
          "text": "Biologics drugs neutralizing excess TSLP activity represented by tezepelumab have been approved for severe asthma and are being evaluated for the treatments of other TSLP-mediated diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726595"
        },
        {
          "offsetInBeginSection": 611,
          "offsetInEndSection": 831,
          "text": "inistration-approved for children as young as 6 years, whereas benralizumab and tezepelumab are approved for adolescents older than 12 years. All these agents reduce the rates of severe asthma exacerbations, whereas thei",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36702649"
        },
        {
          "offsetInBeginSection": 1414,
          "offsetInEndSection": 1862,
          "text": "Although both biologics resulted in a significant improvement in the respiratory parameters, omalizumab treatment resulted in a significant improvement in nasal parameters except hyposmia, mepolizumab treatment resulted in a significant improvement only in posterior rhinitis, and nasal obstruction among the nasal parameters.Conclusion: This study is the first to address both omalizumab and mepolizumab treatments in severe asthmatics with N-ERD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37771938"
        },
        {
          "offsetInBeginSection": 272,
          "offsetInEndSection": 724,
          "text": "The objective of this study is to assess the respiratory improvements, after these biologics in severe asthmatic patients stratifed by the presence of concomitant Non-erosive reflux disease (N-ERD) and the effect of omalizumab and mepolizumab in severe asthmatics with N-ERD.Material \u0026 method: The population of this three-center, retrospective, cross-sectional, observational study comprised patients using omalizumab or mepolizumab for severe asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37771938"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 588,
          "text": "BACKGROUND: There are no head-to-head studies for patients with aspirin-exacerbated respiratory disease (AERD) comparing any of the 5 Food and Drug Administration-approved respiratory biologic therapies.OBJECTIVE: Explore outcomes in subjects with AERD using biologic therapies in a real-world clinic setting.METHODS: A retrospective pilot study was conducted for subjects with AERD who had been prescribed omalizumab (anti-IgE), mepolizumab (anti-IL-5), reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor alpha [anti-IL-5Rα]), or dupilumab (anti-IL-4 receptor alpha [anti-IL-4Rα]).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34597850"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 271,
          "text": "Omalizumab and mepolizumab are biologics used in patients with severe asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37771938"
        },
        {
          "offsetInBeginSection": 1863,
          "offsetInEndSection": 1964,
          "text": "The improvement in nasal parameters was more pronounced in patients who were administered omalizumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37771938"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 773,
          "text": "Omalizumab and, more recently, mepolizumab are the first biologics approved for children (6-18 years). Omalizumab is now widely used to treat severe allergic asthma in children and is highly effective for asthma exacerbations and asthma control with a good safety profile. Moreover, several other drugs-lebrikizumab, dupilumab, tezepelumab, mepolizumab, reslizumab, benralizumab-are used or are being studied in both teenagers and adults an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30444939"
        },
        {
          "offsetInBeginSection": 331,
          "offsetInEndSection": 488,
          "text": "There are now 6 biologic medications approved for asthma and/or severe CRSwNP: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39343299"
        },
        {
          "offsetInBeginSection": 557,
          "offsetInEndSection": 764,
          "text": "Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31090937"
        },
        {
          "offsetInBeginSection": 659,
          "offsetInEndSection": 837,
          "text": "Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29862274"
        },
        {
          "offsetInBeginSection": 610,
          "offsetInEndSection": 706,
          "text": "Omalizumab is the only biological therapy that has an approved indication in asthma at this time",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20065638"
        },
        {
          "offsetInBeginSection": 471,
          "offsetInEndSection": 617,
          "text": "ibodies in asthma and COPD.EXPERT OPINION: The current use of omalizumab in asthma provides a good example on the potential therapeutic role of mo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282002"
        },
        {
          "offsetInBeginSection": 466,
          "offsetInEndSection": 614,
          "text": "the use of omalizumab, an FDA-approved monoclonal antibody for use in asthma, will be described in detail, as well as its associated adverse effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19834630"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "BACKGROUND: Dupilumab inhibiting the signaling of interleukin(IL)-4 and IL-13 was recommended for the treatment of severe asthma in children ≥ 6 years old according to the Global Initiative for Asthma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39681861"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody, significantly reduced exacerbation rates in patients with severe eosinophilic asthma when administered biannually.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39674169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741370"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "INTRODUCTION: Benralizumab, a monoclonal IgG antibody, has emerged as a key therapeutic agent in severe asthma by specifically targeting eosinophils, pivotal cells that drive inflammation and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39708290"
        },
        {
          "offsetInBeginSection": 857,
          "offsetInEndSection": 1066,
          "text": "Nucala® (mepolizumab; anti-interleukin [IL]-5) and Cinquair® (reslizumab; anti-IL-5), the second and third biologics approved, respectively, for the treatment of asthma, exemplifies these new treatment options",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27773786"
        },
        {
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1041,
          "text": "At present anti-IgE (omalizumab, Xolair®) is the only monoclonal antibody based drug approved in the respiratory space for the treatment of asthma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517646"
        },
        {
          "offsetInBeginSection": 1904,
          "offsetInEndSection": 2070,
          "text": "There is high certainty that all approved biologicals reduce the rate of severe asthma exacerbations and for benralizumab, dupilumab and mepolizumab for reducing OCS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32034960"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 477,
          "text": "Biologics drugs neutralizing excess TSLP activity represented by tezepelumab have been approved for severe asthma and are being evaluated for the treatments of other TSLP-mediated diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726595"
        },
        {
          "offsetInBeginSection": 895,
          "offsetInEndSection": 1296,
          "text": "At present anti-IgE (omalizumab, Xolair®) is the only monoclonal antibody based drug approved in the respiratory space for the treatment of asthma. However, an increasing number of antibodies targeting key mediators/pathways of disease are in clinical development for both asthma and COPD, including targeting the Th2 pathway for asthma (anti-IL-4/5/13) and the pro-inflammatory cytokine IL-1 for COPD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517646"
        },
        {
          "offsetInBeginSection": 857,
          "offsetInEndSection": 1065,
          "text": "Nucala® (mepolizumab; anti-interleukin [IL]-5) and Cinquair® (reslizumab; anti-IL-5), the second and third biologics approved, respectively, for the treatment of asthma, exemplifies these new treatment option",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27773786"
        },
        {
          "offsetInBeginSection": 471,
          "offsetInEndSection": 618,
          "text": "ibodies in asthma and COPD.EXPERT OPINION: The current use of omalizumab in asthma provides a good example on the potential therapeutic role of mon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23282002"
        },
        {
          "offsetInBeginSection": 673,
          "offsetInEndSection": 799,
          "text": "Biologics, such as monoclonal antibodies, are being developed for chronic respiratory diseases including asthma, COPD and IPF.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27889330"
        },
        {
          "offsetInBeginSection": 702,
          "offsetInEndSection": 925,
          "text": "This study involves a sample of 90 patients (32 males, 58 females and aged 53.92 ± 15.92) suffering from severe asthma and treated with the biological drugs of Benralizumab, Mepolizumab, Omalizumab during Covid-19 pandemic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35809428"
        }
      ],
      "id": "67e2b26318b1e36f2e00008c",
      "ideal_answer": [
        "The following biologic drugs are currently used in respiratory disease, mainly asthma: tezepelumab, infliximab, adalimumab, etanercept, omalizumab, benralizumab, mepolizumab, rituximab.",
        "The biologic drugs used in respiratory diseases include:\n\n1. **Dupilumab**: Targets IL-4 receptor alpha (IL-4Ra), inhibiting IL-4 and IL-13 pathways. Used for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).\n\n2. **Tezepelumab**: Neutralizes TSLP activity, approved for severe asthma.\n\n3. **Depemokimab**: An ultra-long-acting anti-IL-5 monoclonal antibody used in severe eosinophilic asthma.\n\n4. **Mepolizumab**: Targets IL-5, effective in severe asthma.\n\n5. **Benralizumab**: A monoclonal IgG antibody targeting eosinophils, used for severe asthma.\n\nThese drugs are part of broader categories including anti-IgE, anti-IL-5/IL-5Ra, and anti-IL-4Ra therapies, addressing conditions such as severe asthma and CRSwNP."
      ],
      "exact_answer": [
        [
          "tezepelumab"
        ],
        [
          "infliximab"
        ],
        [
          "adalimumab"
        ],
        [
          "etanercept"
        ],
        [
          "omalizumab"
        ],
        [
          "benralizumab"
        ],
        [
          "mepolizumab"
        ],
        [
          "rituximab"
        ]
      ]
    },
    {
      "body": "What is the significance of the IDH1/IDH2 mutations in gliomas, and how do they impact prognosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23532369",
        "http://www.ncbi.nlm.nih.gov/pubmed/20975057",
        "http://www.ncbi.nlm.nih.gov/pubmed/21874255",
        "http://www.ncbi.nlm.nih.gov/pubmed/22136423",
        "http://www.ncbi.nlm.nih.gov/pubmed/23894344",
        "http://www.ncbi.nlm.nih.gov/pubmed/25495392",
        "http://www.ncbi.nlm.nih.gov/pubmed/23840696",
        "http://www.ncbi.nlm.nih.gov/pubmed/22147457",
        "http://www.ncbi.nlm.nih.gov/pubmed/39684714",
        "http://www.ncbi.nlm.nih.gov/pubmed/24868540",
        "http://www.ncbi.nlm.nih.gov/pubmed/20427748",
        "http://www.ncbi.nlm.nih.gov/pubmed/19554337",
        "http://www.ncbi.nlm.nih.gov/pubmed/39432026",
        "http://www.ncbi.nlm.nih.gov/pubmed/39500924",
        "http://www.ncbi.nlm.nih.gov/pubmed/39732457",
        "http://www.ncbi.nlm.nih.gov/pubmed/27245697",
        "http://www.ncbi.nlm.nih.gov/pubmed/36286062",
        "http://www.ncbi.nlm.nih.gov/pubmed/24460285",
        "http://www.ncbi.nlm.nih.gov/pubmed/20160062",
        "http://www.ncbi.nlm.nih.gov/pubmed/24877111",
        "http://www.ncbi.nlm.nih.gov/pubmed/25980633",
        "http://www.ncbi.nlm.nih.gov/pubmed/23115158",
        "http://www.ncbi.nlm.nih.gov/pubmed/23877318",
        "http://www.ncbi.nlm.nih.gov/pubmed/20615753",
        "http://www.ncbi.nlm.nih.gov/pubmed/25078896",
        "http://www.ncbi.nlm.nih.gov/pubmed/25511738",
        "http://www.ncbi.nlm.nih.gov/pubmed/39272024",
        "http://www.ncbi.nlm.nih.gov/pubmed/39212803",
        "http://www.ncbi.nlm.nih.gov/pubmed/19765000",
        "http://www.ncbi.nlm.nih.gov/pubmed/25727224",
        "http://www.ncbi.nlm.nih.gov/pubmed/25318355",
        "http://www.ncbi.nlm.nih.gov/pubmed/22922798",
        "http://www.ncbi.nlm.nih.gov/pubmed/37271257",
        "http://www.ncbi.nlm.nih.gov/pubmed/33289434",
        "http://www.ncbi.nlm.nih.gov/pubmed/22528790",
        "http://www.ncbi.nlm.nih.gov/pubmed/26834160",
        "http://www.ncbi.nlm.nih.gov/pubmed/21163902",
        "http://www.ncbi.nlm.nih.gov/pubmed/25283382",
        "http://www.ncbi.nlm.nih.gov/pubmed/19933982"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 682,
          "text": "Mutations in isocitrate dehydrogenase (IDH) 1 and 2, originally discovered in 2008, occur in the vast majority of low-grade gliomas and secondary high-grade gliomas. These mutations, which occur early in gliomagenesis, change the function of the enzymes, causing them to produce 2-hydroxyglutarate, a possible oncometabolite, and to not produce NADPH. IDH mutations are oncogenic, although whether the mechanism is through alterations in hydroxylases, redox potential, cellular metabolism, or gene expression is not clear. The mutations also drive increased methylation in gliomas. Gliomas with mutated IDH1 and IDH2 have improved prognosis compared with gliomas with wild-type IDH.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20975057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are found frequently in malignant gliomas and are likely involved in early gliomagenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136423"
        },
        {
          "offsetInBeginSection": 1302,
          "offsetInEndSection": 1576,
          "text": "For patients with grade 3 gliomas and without 1p/19q co-deletion, IDH mutation was strongly associated with increased progression-free survival (P \u003c 0.0001) and overall survival (P \u003c 0.0001), but no such marked correlation was observed with grade 2 gliomas or glioblastomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136423"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 682,
          "text": "Gliomas with mutated IDH1 and IDH2 have improved prognosis compared with gliomas with wild-type IDH.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532369"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 213,
          "text": "Mutations in the Isocitrate Dehydrogenase (IDH) genes, IDH1 or IDH2, define a group of adult diffuse gliomas associated with a younger age at diagnosis and better prognosis than IDH wild-type glioblastoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39432026"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 387,
          "text": "The mutation status of IDH has clinical significance due to better prognosis in IDH-mutant patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39500924"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 550,
          "text": "Gliomas with IDH1 or IDH2 mutation have better outcomes than do gliomas with wild-type IDH.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495392"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Both IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2) mutations play a vital role in the development of gliomas through disruption of normal cellular metabolic processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36286062"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 317,
          "text": "Among the many phenotypic differences between mutant and wild-type IDH1/2 gliomas, the most salient is that IDH1/2 mutant glioma patients demonstrate markedly improved survival compared with IDH1/2 wild-type glioma patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23115158"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 582,
          "text": "IDH1 and IDH2 mutations may serve as prognostic factors because patients with an IDH-mutated glioma survive significantly longer than those with an IDH-wild-type tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877318"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "The isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes mutate frequently in gliomas, and it has become increasingly apparent that IDH mutation status accounts for much of the prognostic information previously rendered by histological grading",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25980633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Patients with isocitrate dehydrogenase 1 (IDH1)-mutant glioblastoma exhibit increased survival compared with those with wild-type IDH1 tumors. The magnitude of this finding has led to the use of IDH1 mutations as diagnostic and prognostic biomarkers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25511738"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Recent genome wide sequencing has identified mutations in IDH1/IDH2 predominantly in grade II-III gliomas and secondary glioblastomas which are associated with favorable clinical outcome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24460285"
        },
        {
          "offsetInBeginSection": 845,
          "offsetInEndSection": 930,
          "text": " The independent predictors of better prognosis were tumor grade and IDH1/2 mutations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684714"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 388,
          "text": "The mutation status of IDH has clinical significance due to better prognosis in IDH-mutant patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39500924"
        },
        {
          "offsetInBeginSection": 137,
          "offsetInEndSection": 264,
          "text": "IDH-mutant astrocytoma and oligodendrogliomas typically have a more favorable prognosis compared to IDH-wildtype glioblastomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39212803"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 549,
          "text": "Gliomas with IDH1 or IDH2 mutation have better outcomes than do gliomas with wild-type IDH",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495392"
        },
        {
          "offsetInBeginSection": 769,
          "offsetInEndSection": 1006,
          "text": "The IDH-mutated tumors exhibit better prognosis throughout every grade of glioma, and mutation may be an early genetic event, preceding lineage-specific secondary and tertiary alterations that transform LGGs into secondary glioblastomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25727224"
        },
        {
          "offsetInBeginSection": 347,
          "offsetInEndSection": 612,
          "text": "Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19554337"
        },
        {
          "offsetInBeginSection": 808,
          "offsetInEndSection": 1009,
          "text": "IDH1/2 mutations are tightly associated with grade II and III gliomas and secondary glioblastomas, with better prognosis and production of a recently described oncometabolite, 2-hydroxyglutarate (2HG).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25078896"
        },
        {
          "offsetInBeginSection": 387,
          "offsetInEndSection": 544,
          "text": "Additionally, isocitrate dehydrogenase 1 (IDH1) mutations are strongly associated with increased overall survival in gliomas and worse prognosis in leukemias",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33289434"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Recent genome wide sequencing has identified mutations in IDH1/IDH2 predominantly in grade II-III gliomas and secondary glioblastomas which are associated with favorable clinical outcome. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24460285"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 583,
          "text": "IDH1 and IDH2 mutations may serve as prognostic factors because patients with an IDH-mutated glioma survive significantly longer than those with an IDH-wild-type tumor. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877318"
        },
        {
          "offsetInBeginSection": 808,
          "offsetInEndSection": 1278,
          "text": "IDH1/2 mutations are tightly associated with grade II and III gliomas and secondary glioblastomas, with better prognosis and production of a recently described oncometabolite, 2-hydroxyglutarate (2HG). Although the contradictory positive effect of IDH mutation on prognosis and negative role of 2HG in tumor transformation remain unresolved, the future direction of personalized treatment strategies targeted to glioma development is likely to focus on IDH1/2 mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25078896"
        },
        {
          "offsetInBeginSection": 664,
          "offsetInEndSection": 793,
          "text": "Moreover, IDH1 and IDH2 mutations are a major prognostic marker for overall and progression-free survival in grade II-IV gliomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20615753"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 549,
          "text": "Mutations in two isocitrate dehydrogenase (IDH) genes, IDH1 and IDH2, commonly occur in low-grade gliomas and secondary high-grade gliomas, but are rare in primary GBMs. These mutations alter the catalytic activity of IDH proteins, promoting gliomagenesis. Gliomas with IDH1 or IDH2 mutation have better outcomes than do gliomas with wild-type IDH",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495392"
        },
        {
          "offsetInBeginSection": 664,
          "offsetInEndSection": 792,
          "text": "Moreover, IDH1 and IDH2 mutations are a major prognostic marker for overall and progression-free survival in grade II-IV gliomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20615753"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 305,
          "text": "Isocitrate dehydrogenase 1 (IDH1) mutations have been discovered frequently in glioma patients and are strongly correlated with improved survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25283382"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are found frequently in malignant gliomas and are likely involved in early gliomagenesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136423"
        }
      ],
      "id": "67eb559518b1e36f2e0000e5",
      "ideal_answer": [
        "Mutations in isocitrate dehydrogenase (IDH) 1 and 2, originally discovered in 2008, occur in the vast majority of low-grade gliomas and secondary high-grade gliomas. These mutations, which occur early in gliomagenesis, change the function of the enzymes, causing them to produce 2-hydroxyglutarate, a possible oncometabolite, and to not produce NADPH. IDH mutations are oncogenic, although whether the mechanism is through alterations in hydroxylases, redox potential, cellular metabolism, or gene expression is not clear. The mutations also drive increased methylation in gliomas. Gliomas with mutated IDH1 and IDH2 have improved prognosis compared with gliomas with wild-type IDH.",
        "IDH1 and IDH2 mutations in gliomas are significant because they are commonly associated with lower-grade gliomas and secondary glioblastomas. These mutations lead to the production of the oncometabolite 2-hydroxyglutarate, which can affect cellular differentiation and epigenetic regulation. Clinically, the presence of IDH1/IDH2 mutations is generally associated with a better prognosis compared to gliomas with wild-type IDH. Patients with IDH-mutant gliomas tend to have longer overall survival and may respond better to certain therapies.",
        "Mutations in the IDH1 and IDH2 genes are significant in gliomas as they are commonly found in lower-grade gliomas and secondary glioblastomas. These mutations are associated with a distinct glioma subtype that generally has a better prognosis compared to gliomas without these mutations. IDH1/IDH2 mutations lead to the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which contributes to tumorigenesis by altering cellular metabolism and epigenetic regulation. Patients with IDH-mutant gliomas tend to have a longer overall survival and better response to treatment compared to those with IDH-wildtype gliomas. Therefore, the presence of IDH1/IDH2 mutations is an important prognostic marker and can influence treatment decisions in clinical practice.",
        "IDH1 and IDH2 mutations are significant molecular markers in gliomas, particularly associated with lower-grade gliomas (grades II and III) and secondary glioblastomas. These mutations are present in approximately 40% of gliomas, with a higher prevalence in low-grade gliomas (about 70%) compared to high-grade glioblastomas (5-10%). The presence of IDH mutations is linked to a better prognosis, as they are associated with slower tumor growth and a more favorable clinical outcome. Additionally, IDH mutations lead to the production of the oncometabolite 2-hydroxyglutarate (2HG), which plays a role in tumor transformation. Overall, the IDH1/2 mutation status is crucial for glioma diagnosis, classification, and the development of personalized treatment strategies, highlighting their importance in both prognostic assessment and therapeutic targeting.",
        "IDH1/IDH2 mutations occur early in glioma development and lead to significant metabolic changes by converting α‑ketoglutarate into 2‑hydroxyglutarate, which disrupts normal cellular regulation. These mutations are typically found in lower-grade gliomas and secondary glioblastomas rather than in primary glioblastomas. Their presence is associated with a less aggressive tumor phenotype, longer overall survival, and extended progression‑free survival. The most common variant, IDH1 R132H, is widely used as a diagnostic and prognostic marker. Although IDH1 mutations are more frequent, IDH2 mutations are usually observed in a different genetic context, often linked with additional alterations like 1p/19q co‑deletion and TERT promoter mutations. Overall, the identification of these mutations not only provides insight into tumor biology but also aids in predicting patient outcomes and refining management strategies.",
        "The significance of IDH1 and IDH2 mutations in gliomas and their impact on prognosis can be summarized as follows:\n\nIDH1 and IDH2 mutations in gliomas are associated with better outcomes compared to IDH wild-type gliomas. These mutations are linked to prolonged overall survival and longer progression-free survival. Specifically, IDH1 mutations are important for prognosis in anaplastic astrocytomas, oligodendrogliomas, and oligoastrocytomas, as well as in grade II-III gliomas and secondary glioblastomas, where they are associated with favorable clinical outcomes.\n\nOn a molecular level, IDH1 and IDH2 mutations result in metabolic changes, including reduced formation of α-ketoglutarate, increased levels of hypoxia-inducible factor subunit HIF-1alpha, and the production of 2-hydroxyglutarate, which are linked to tumor progression and a higher risk of malignant gliomas.\n\nCase studies indicate that gliomas with concurrent IDH1 and IDH2 mutations may have prolonged time to recurrence, and IDH-mutant WHO grade 3 astrocytomas show longer overall survival compared to IDH-wildtype gliomas. Meta-analyses and large cohort studies confirm that IDH1 and IDH2 mutations are independently associated with better overall survival and progression-free survival. In summary, these mutations are significant markers for better prognosis in glioma patients.",
        "IDH1 and IDH2 mutations, found in most low-grade and secondary high-grade gliomas, alter enzyme function to produce 2-hydroxyglutarate and drive increased methylation through oncogenic mechanisms. While their exact mechanism remains unclear, these early-occurring mutations are clinically significant as patients with IDH-mutated gliomas demonstrate improved prognosis compared to those with wild-type IDH.",
        "Mutations in isocitrate dehydrogenase (IDH) 1 and 2 are significant in gliomas as they occur early in gliomagenesis and are found in the vast majority of low-grade gliomas and secondary high-grade gliomas. These mutations alter the function of the enzymes, leading to the production of 2-hydroxyglutarate, a potential oncometabolite, while inhibiting the production of NADPH. IDH mutations are considered oncogenic, although the exact mechanisms by which they contribute to tumorigenesis—such as alterations in hydroxylases, redox potential, cellular metabolism, or gene expression—remain unclear. Additionally, gliomas with mutated IDH1 and IDH2 exhibit increased methylation and have an improved prognosis compared to those with wild-type IDH.",
        "IDH1/IDH2 mutations are early, defining events in low-grade gliomas and secondary high-grade gliomas. These mutations alter enzyme function, causing production of the oncometabolite 2-hydroxyglutarate (2-HG) instead of α-ketoglutarate, disrupting cellular metabolism and epigenetic regulation. The mutations induce a hypermethylation phenotype (G-CIMP), altering gene expression and promoting tumorigenesis. Additionally, loss of NADPH production may impair antioxidant defense. Importantly, gliomas with IDH1/IDH2 mutations exhibit significantly better prognosis compared to IDH-wildtype tumors, likely due to slower progression and distinct molecular profiles. This prognostic distinction is critical in clinical classification and management.",
        "IDH1/IDH2 mutations are hallmark alterations in low-grade gliomas and secondary high-grade gliomas, occurring early in tumor development. These mutations confer neomorphic enzyme activity, producing the oncometabolite 2-hydroxyglutarate (2-HG), which disrupts cellular processes by inhibiting α-ketoglutarate-dependent enzymes, altering DNA methylation, and impairing differentiation. While the exact oncogenic mechanisms (e.g., hydroxylase inhibition, redox/metabolic changes) remain unclear, IDH-mutant gliomas exhibit a hypermethylated phenotype (G-CIMP) linked to distinct molecular behavior. Clinically, IDH mutations are associated with significantly improved prognosis compared to IDH-wildtype gliomas, reflecting slower progression and better survival outcomes.",
        "Mutations in isocitrate dehydrogenase (IDH) 1 and 2 occur in the vast majority of low-grade gliomas and secondary high-grade gliomas, and these mutations change the function of the enzymes, causing them to produce 2-hydroxyglutarate, a possible oncometabolite, and to not produce NADPH. IDH mutations are oncogenic and drive increased methylation in gliomas. Gliomas with mutated IDH1 and IDH2 have improved prognosis compared with gliomas with wild-type IDH.",
        "IDH1 and IDH2 mutations serve as key molecular markers that refine glioma classification by distinguishing between different histological subtypes and inform risk stratification. They are most commonly found in lower grade gliomas and secondary glioblastomas, where their presence is associated with longer overall and progression-free survival. The mutations alter enzyme function, leading to the production of 2-hydroxyglutarate, which drives changes in cellular metabolism, increases methylation, and contributes to epigenetic reprogramming. This distinct molecular profile not only enhances diagnostic accuracy but also guides tailored treatment strategies, as tumors harboring these mutations tend to respond better to therapies, including chemotherapy and radiation.",
        "The significance of IDH1/IDH2 mutations in gliomas lies in their role as key genetic alterations that influence tumor biology and patient outcomes. Here\u0027s a concise summary:\n\n1. **Mutation Prevalence**: IDH1/IDH2 mutations are prevalent in the majority of low-grade and secondary high-grade gliomas, indicating their importance early in glioma development.\n\n2. **Enzyme Function Alteration**: These mutations alter the function of isocitrate dehydrogenase enzymes, leading to the production of 2-hydroxyglutarate (2-HG), a potential oncometabolite, instead of NADPH. This shift in metabolism may contribute to tumor growth and progression.\n\n3. **Epigenetic Changes**: The mutations are associated with increased DNA methylation in gliomas, which can silence tumor suppressor genes or activate oncogenes, further driving cancer development.\n\n4. **Prognostic Impact**: Despite being oncogenic, IDH1/IDH2 mutations are linked to an improved prognosis compared to wild-type IDH cases. This suggests that these mutations may indicate a less aggressive tumor subtype or enhance responsiveness to treatments.\n\nIn conclusion, IDH1/IDH2 mutations significantly impact glioma biology by altering cellular metabolism and promoting epigenetic changes, while paradoxically offering patients a better prognosis.",
        "The significance of IDH1/IDH2 mutations in gliomas lies in their transformative impact on cellular metabolism and tumor biology. These mutations, first identified in 2008, are prevalent in low-grade and secondary high-grade gliomas. They alter the function of isocitrate dehydrogenase enzymes, leading to the production of 2-hydroxyglutarate (2-HG), a potential oncometabolite, instead of NADPH. This shift disrupts cellular processes such as detoxification and structure maintenance.\n\nAdditionally, these mutations influence hydroxylases, redox potential, and methylation patterns in gliomas. Increased methylation can affect gene expression, potentially contributing to tumor behavior. Despite their role in oncogenesis, IDH1/IDH2 mutations are associated with a more favorable prognosis compared to wild-type IDH gliomas. Patients with these mutations tend to experience improved outcomes, suggesting that the mutations may render tumors less aggressive or more responsive to treatment.\n\nIn summary, IDH1/IDH2 mutations significantly alter tumor metabolism and biology, contributing to cancer progression while paradoxically improving patient prognosis.",
        "Mutations in isocitrate dehydrogenase (IDH) 1 and 2 are significant in gliomas as they occur early in gliomagenesis and are prevalent in low-grade and secondary high-grade gliomas. These mutations alter enzyme function, leading to the production of 2-hydroxyglutarate, an oncometabolite, while inhibiting NADPH production. Although the exact oncogenic mechanisms remain unclear, IDH mutations are associated with increased methylation in gliomas. Importantly, gliomas with mutated IDH1 and IDH2 show improved prognosis compared to those with wild-type IDH. Detection of these mutations can be achieved through immunohistochemistry and magnetic resonance spectroscopy, but there are currently no targeted drugs available, making this a focus of ongoing research.",
        "Mutations in isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2), found in most low-grade gliomas and secondary high-grade gliomas, are significant because they alter enzyme function to produce the oncometabolite 2-hydroxyglutarate while reducing NADPH production. These mutations contribute to oncogenesis through mechanisms that may involve changes in hydroxylases, redox potential, cellular metabolism, or gene expression and lead to increased methylation in gliomas. Importantly, gliomas with mutated IDH1/IDH2 are associated with a better prognosis compared to those with wild-type IDH.",
        "IDH1/IDH2 mutations in gliomas are oncogenic, altering enzyme function to produce 2-hydroxyglutarate and driving increased methylation. Despite their oncogenic role, gliomas with mutated IDH1 and IDH2 have an improved prognosis compared to those with wild-type IDH. This suggests that the mutations may influence tumor behavior in a way that is less aggressive or more responsive to treatment. The exact mechanism underlying this improved prognosis is unclear, but it may relate to alterations in hydroxylases, redox potential, cellular metabolism, or gene expression. Overall, IDH1/IDH2 mutations are a key feature of low-grade gliomas and secondary high-grade gliomas, and their presence has important implications for patient outcomes.",
        "IDH1 and IDH2 mutations are highly significant in gliomas as they occur in the majority of low-grade gliomas and secondary high-grade gliomas. These mutations are early events in gliomagenesis that alter enzyme function, causing production of the potential oncometabolite 2-hydroxyglutarate while reducing NADPH production. Although the exact oncogenic mechanism remains unclear (possibly involving alterations in hydroxylases, redox potential, cellular metabolism, or gene expression), these mutations drive increased methylation in gliomas. Importantly, patients with IDH1/IDH2 mutated gliomas have significantly improved prognosis compared to those with wild-type IDH, making these mutations important prognostic biomarkers in glioma classification and management.",
        "Mutations in IDH1 and IDH2 are prevalent in low-grade gliomas and secondary high-grade gliomas, occurring early in tumor development. These mutations alter enzyme function, leading to the production of 2-hydroxyglutarate, a potential oncometabolite, while reducing NADPH output. Although the exact mechanism remains unclear, these mutations contribute to oncogenesis and increased methylation in gliomas. Importantly, studies indicate that patients with IDH1/IDH2-mutated gliomas experience improved prognosis compared to those with wild-type IDH.",
        "Studies have shown that mutations in IDH1 and IDH2 are prevalent in most low-grade gliomas and secondary high-grade gliomas, occurring early in tumor development. These mutations alter enzyme function, leading to the production of 2-hydroxyglutarate, a potential oncometabolite, while reducing NADPH production. Although the exact mechanism remains unclear, IDH mutations are oncogenic and associated with increased methylation in gliomas. Importantly, patients with IDH-mutated gliomas have a better prognosis compared to those with wild-type IDH.",
        "Mutations in isocitrate dehydrogenase (IDH) 1 and 2 occur in the vast majority of low-grade gliomas and secondary high-grade gliomas. These mutations change the function of the enzymes, causing them to produce 2-hydroxyglutarate, a possible oncometabolite, and to not produce NADPH. Gliomas with mutated IDH1 and IDH2 have an improved prognosis compared with gliomas with wild-type IDH."
      ]
    },
    {
      "body": "Which missense variant in SPDL1 is associated with IPF?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33758299"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33758299"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 999,
          "text": "Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln; p \u003d 2.4 × 10-7, odds ratio \u003d 2.87, 95% confidence interval: 2.03-4.07). This signal was independently replicated in the FinnGen cohort, which contains 1028 cases and 196,986 controls (combined p \u003d 2.2 × 10-20), firmly associating this variant as an IPF risk allele. SPDL1 encodes Spindly, a protein involved in mitotic checkpoint signalling during cell division that has not been previously described in fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33758299"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 657,
          "text": "Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln; p \u003d 2.4 × 10-7, odds ratio \u003d 2.87, 95% confidence interval: 2.03-4.07).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33758299"
        },
        {
          "offsetInBeginSection": 428,
          "offsetInEndSection": 642,
          "text": "analyses. Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln; p \u003d 2.4 × 10-7, odds ratio \u003d 2.87, 95% confidence interv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33758299"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 598,
          "text": "Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln; p \u003d 2.4 × 10",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33758299"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 597,
          "text": "Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln; p \u003d 2.4 × 1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33758299"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 728,
          "text": "Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln; p \u003d 2.4 × 10-7, odds ratio \u003d 2.87, 95% confidence interval: 2.03-4.07). This signal was independently replicated in the FinnGen cohort, which ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33758299"
        }
      ],
      "id": "67df1a1d18b1e36f2e000065",
      "ideal_answer": [
        "A variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln; p \u003d 2.4 × 10-7, odds ratio \u003d 2.87, 95% confidence interval: 2.03-4.07). This signal was independently replicated in the FinnGen cohort, which contains 1028 cases and 196,986 controls (combined p \u003d 2.2 × 10-20), firmly associating this variant as an IPF risk allele. SPDL1 encodes Spindly, a protein involved in mitotic checkpoint signalling during cell division that has not been previously described in fibrosis.",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A p.Arg20Gln.",
        "A missense variant in SPDL1 (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln) is associated with IPF.",
        "The missense variant in SPDL1 associated with Idiopathic Pulmonary Fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A, leading to a p.Arg20Gln change. This substitution, consistently identified across all provided answers, suggests a potential functional impact on the SPDL1 protein, which may contribute to the pathogenesis of IPF, possibly by affecting cellular processes crucial for lung tissue maintenance and repair.",
        "Our studies revealed a novel association between a rare missense variant in SPDL1 and IPF. Specifically, the NM_017785.5:g.169588475 G \u003e A variant, resulting in the p.Arg20Gln substitution, was identified with a statistically significant association (p \u003d 2.4 × 10-7, odds ratio \u003d 2.87, 95% confidence interval: 2.03-4.07). This finding highlights the potential role of this SPDL1 variant in IPF susceptibility.",
        "The missense variant in SPDL1 associated with IPF is p.Arg20Gln.",
        "The missense variant in SPDL1 associated with IPF is NM_017785.5:g.169588475 G\u003eA p.Arg20Gln.",
        "A rare missense variant in SPDL1 associated with idiopathic pulmonary fibrosis is NM_017785.5:g.169588475 G \u003e A, resulting in the amino acid change p.Arg20Gln.",
        "The SPDL1 missense variant associated with IPF is NM_017785.5:g.169588475 G \u003e A (p.Arg20Gln).",
        "The missense variant in SPDL1 associated with Idiopathic Pulmonary Fibrosis (IPF) is Arg20Gln. This variant is identified as NM_017785.5:g.169588475 G \u003e A, where a guanine nucleotide changes to adenine at position 169588475 in the genomic sequence. Consequently, arginine (Arg) at position 20 of the SPDL1 protein is replaced with glutamine (Gln). This novel association was found to be statistically significant (p \u003d 2.4 × 10^-5), indicating a strong link between this genetic mutation and IPF.",
        "The rare missense variant NM_017785.5:g.169588475 G \u003e A p.Arg20Gln in SPDL1 is associated with IPF.",
        "The missense variant in SPDL1 associated with Idiopathic Pulmonary Fibrosis (IPF) is characterized by a G to A change at genomic position 169,588,475. This mutation leads to an arginine-to-glutamine substitution at amino acid position 20 in the protein, denoted as p.Arg20Gln. The association was found to be statistically significant with a p-value of 2.4 × 10^-5, indicating a novel and important genetic link contributing to our understanding of IPF\u0027s genetic basis.",
        "The missense variant in SPDL1 associated with IPF is NM_017785.5:g.169588475 G \u003e A p.Arg20Gln.",
        "The missense variant NM_017785.5:g.169588475 G \u003e A p.Arg20Gln in SPDL1 is associated with IPF.",
        "The missense variant in SPDL1 associated with Idiopathic Pulmonary Fibrosis (IPF) is consistently identified as NM_017785.5:g.169588475 G \u003e A, leading to the amino acid change p.Arg20Gln. This specific mutation suggests a potential genetic predisposition to IPF, highlighting the importance of SPDL1 in lung health. Further research may elucidate the mechanisms by which this variant contributes to disease pathology, offering insights into targeted therapeutic strategies for affected individuals.",
        "The missense variant in SPDL1 associated with Idiopathic Pulmonary Fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A, leading to a p.Arg20Gln change. This specific mutation, consistently identified across references, alters the SPDL1 protein structure by substituting Arginine with Glutamine at position 20, which has been implicated in the context of IPF, suggesting a potential genetic marker or contributor to the disease\u0027s pathology.",
        "The SPDL1 missense variant associated with idiopathic pulmonary fibrosis is encoded by SNP rs116483731. This single‐nucleotide change leads to a p.Arg20Gln amino acid substitution in the SPDL1 protein, which is linked to an increased risk of developing IPF.",
        "The missense variant in SPDL1 associated with Idiopathic Pulmonary Fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A p.Arg20Gln.",
        "Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and Idiopathic Pulmonary Fibrosis (IPF). Specifically, the variant NM_017785.5:g.169588475G\u003eA p.Arg20Gln is associated with IPF, with a p-value of 2.4 × 10-7, an odds ratio of 2.87, and a 95% confidence interval of 2.03-4.07. This suggests that the Arg20Gln missense variant in SPDL1 may play a role in the development of IPF, although further studies are needed to illustrate the underlying pathophysiological mechanisms.",
        "The missense variant in SPDL1 associated with Idiopathic Pulmonary Fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A, resulting in a p.Arg20Gln change, which may impact SPDL1 protein function and contribute to IPF pathogenesis.",
        "The SPDL1 missense variant associated with IPF is p.Arg20Gln, corresponding to NM_017785.5:g.169588475 G\u003eA.",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A p.Arg20Gln.",
        "The missense variant NM_017785.5:g.169588475 G \u003e A (p.Arg20Gln) in the SPDL1 gene, encoding the Spindly protein involved in mitotic checkpoint signalling, is strongly associated with Idiopathic Pulmonary Fibrosis (IPF). Identified through exome-wide association and replicated in the FinnGen cohort, this variant reveals a novel mechanism underlying IPF, potentially leading to new therapeutic targets for this fatal disorder.",
        "A novel association between a rare missense variant in SPDL1 and idiopathic pulmonary fibrosis (IPF) has been identified through variant-level analysis. The specific variant, NM_017785.5:g.169588475 G \u003e A p.Arg20Gln, was found to be significantly associated with IPF, with a p-value of 2.4 × 10-7, an odds ratio of 2.87, and a 95% confidence interval of 2.03-4.07. This finding was independently replicated in the FinnGen cohort, which comprises 1028 cases and 196,986 controls, resulting in a combined p-value of 2.2 × 10-20. The replication study firmly established this variant as an IPF risk allele, implicating SPDL1, which encodes the protein Spindly involved in mitotic checkpoint signalling during cell division, in the disease pathology.",
        "NM_017785.5:g.169588475 G \u003e A p.Arg20Gln",
        "The missense variant in SPDL1 associated with IPF is NM_017785.5:g.169588475 G\u003eA, which results in the p.Arg20Gln substitution.",
        "The missense variant is NM_017785.5:g.169588475G\u003eA, which results in the p.Arg20Gln substitution in the SPDL1 gene and is associated with idiopathic pulmonary fibrosis (IPF). This rare variant has been independently validated as a risk allele.",
        "The missense variant NM_017785.5:g.169588475 G\u003eA, which results in the p.Arg20Gln substitution, is associated with IPF.",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis is NM_017785.5:g.169588475 G \u003e A, p.Arg20Gln.",
        "A rare missense variant in SPDL1, specifically NM_017785.5:g.169588475 G \u003e A p.Arg20Gln, is associated with idiopathic pulmonary fibrosis (IPF). This association was identified through variant-level analysis and independently replicated in the FinnGen cohort.",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A p.Arg20Gln. This variant has been shown to have a strong association with IPF, as evidenced by a significant p-value and replication in an independent cohort.",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A, resulting in a p.Arg20Gln amino acid change. This rare variant was identified through variant-level analysis and has been independently replicated in the FinnGen cohort, confirming its association as an IPF risk allele. The SPDL1 gene encodes Spindly, which is involved in mitotic checkpoint signaling during cell division but had not previously been linked to fibrosis.",
        "The missense variant p.Arg20Gln, resulting from the genetic alteration NM_017785.5:g.169588475 G \u003e A in the SPDL1 gene, is strongly associated with an increased risk of Idiopathic Pulmonary Fibrosis (IPF). This association is statistically significant (p-value of 2.4 × 10-7, odds ratio of 2.87) and has been independently replicated, confirming it as an IPF risk allele. SPDL1, encoding the protein Spindly, plays a role in mitotic checkpoint signalling during cell division, representing a novel link to fibrosis pathology.",
        "A rare missense variant in SPDL1 (NM_017785.5:g.169588475 G \u003e A p.Arg20Gln) is associated with idiopathic pulmonary fibrosis (IPF).",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis (IPF) is NM_017785.5:g.169588475 G\u003eA p.Arg20Gln.",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A p.Arg20Gln. This rare variant was identified through variant-level analysis and showed a significant association with IPF with an odds ratio of 2.87 (95% confidence interval: 2.03-4.07). The finding was independently replicated in the FinnGen cohort, firmly establishing this variant as an IPF risk allele. SPDL1 encodes the Spindly protein, which is involved in mitotic checkpoint signaling during cell division and had not been previously linked to fibrosis.",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis (IPF) is NM_017785.5:g.169588475G \u003e A, which results in the amino acid change p.Arg20Gln. This association was identified through a variant-level analysis and replicated in the FinnGen cohort, comprising 1028 cases and 196,986 controls, with a combined p-value of 2.2 × 10-20. SPDL1 encodes Spindly, a protein involved in mitotic checkpoint signaling during cell division, which has not been previously linked to fibrosis.",
        "The missense variant in the SPDL1 gene associated with Idiopathic Pulmonary Fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A, resulting in the amino acid substitution p.Arg20Gln.",
        "The missense variant associated with IPF is NM_017785.5:g.169588475 G\u003eA, which leads to the p.Arg20Gln amino acid substitution.",
        "The missense variant in SPDL1 associated with IPF is NM_017785.5:g.169588475 G \u003e A, resulting in the amino acid change p.Arg20Gln.",
        "A rare missense variant in SPDL1, specifically NM_017785.5:g.169588475 G \u003e A p.Arg20Gln, is associated with idiopathic pulmonary fibrosis (IPF).",
        "The missense variant in SPDL1 associated with idiopathic pulmonary fibrosis (IPF) is NM_017785.5:g.169588475 G \u003e A p.Arg20Gln. This variant has been identified as a risk allele for IPF."
      ],
      "exact_answer": [
        [
          "NM_017785.5:g.169588475 G \u003e A p.Arg20Gln"
        ]
      ]
    },
    {
      "body": "What disease can be treated with Fidanacogene elaparvovec?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38863155",
        "http://www.ncbi.nlm.nih.gov/pubmed/38472707",
        "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "BACKGROUND:  Fidanacogene elaparvovec, an adeno-associated virus-based gene therapy vector expressing the high-activity factor IX (FIX) variant FIX-R338L, is in development for hemophilia B. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38863155"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Fidanacogene elaparvovec (PrBEQVEZ™) is an adeno-associated viral (AAV) vector-based gene therapy developed by Spark Therapeutics (a subsidiary of Roche) and Pfizer (under a license from Spark Therapeutics) for the treatment of haemophilia B. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472707"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "BACKGROUND: Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase 1-2a study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "BACKGROUND: Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 1989,
          "offsetInEndSection": 2155,
          "text": "t conditions were observed.CONCLUSIONS: Fidanacogene elaparvovec was superior to prophylaxis for the treatment of participants with hemophilia B, leading to reduced b",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 1989,
          "offsetInEndSection": 2157,
          "text": "t conditions were observed.CONCLUSIONS: Fidanacogene elaparvovec was superior to prophylaxis for the treatment of participants with hemophilia B, leading to reduced ble",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Fidanacogene elaparvovec (PrBEQVEZ™) is an adeno-associated viral (AAV) vector-based gene therapy developed by Spark Therapeutics (a subsidiary of Roche) and Pfizer (under a license from Spark Therapeutics) for the treatment of haemophilia B.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472707"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 528,
          "text": "In December 2023, fidanacogene elaparvovec received its first approval for the treatment of adults (aged ≥ 18 years) with moderately severe to severe haemophilia B (congenital factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74 (AAVRh74var).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472707"
        },
        {
          "offsetInBeginSection": 671,
          "offsetInEndSection": 919,
          "text": "This article summarizes the milestones in the development of fidanacogene elaparvovec leading to this first approval for moderately severe to severe (factor IX activity ≤ 2%) haemophilia B who are negative for neutralizing antibodies to AAVRh74var.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472707"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "BACKGROUND: Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 398,
          "text": "BACKGROUND: Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase 1-2a study.METHODS: We conducted a phase 3 open-label study of fidanacogene elaparvovec at a dose of 5×1011 vector genome copies per kilogram of body weight.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 1878,
          "offsetInEndSection": 2195,
          "text": "No infusion-related serious adverse events, thrombotic events, development of factor IX inhibitors, or malignant conditions were observed.CONCLUSIONS: Fidanacogene elaparvovec was superior to prophylaxis for the treatment of participants with hemophilia B, leading to reduced bleeding and stable factor IX expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 251,
          "text": " Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase 1-2a study",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "Fidanacogene elaparvovec (PrBEQVEZ™) is an adeno-associated viral (AAV) vector-based gene therapy developed by Spark Therapeutics (a subsidiary of Roche) and Pfizer (under a license from Spark Therapeutics) for the treatment of haemophilia B. In December 2023",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472707"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 557,
          "text": " fidanacogene elaparvovec received its first approval for the treatment of adults (aged ≥ 18 years) with moderately severe to severe haemophilia B (congenital factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74 (AAVRh74var). Fidanacogene elaparvovec is ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472707"
        }
      ],
      "type": "factoid",
      "id": "67e6be3118b1e36f2e0000c3",
      "ideal_answer": [
        "Fidanacogene elaparvovec is an adeno-associated viral (AAV) vector-based gene therapy for the treatment of haemophilia B."
      ],
      "exact_answer": [
        [
          "haemophilia B"
        ]
      ]
    },
    {
      "_body": "What is the Pringle manuver?",
      "_type": "summary",
      "body": "What is the Pringle manuever used for?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21510298",
        "http://www.ncbi.nlm.nih.gov/pubmed/16036781",
        "http://www.ncbi.nlm.nih.gov/pubmed/35396269",
        "http://www.ncbi.nlm.nih.gov/pubmed/19144472",
        "http://www.ncbi.nlm.nih.gov/pubmed/30856518",
        "http://www.ncbi.nlm.nih.gov/pubmed/38012204",
        "http://www.ncbi.nlm.nih.gov/pubmed/15776301",
        "http://www.ncbi.nlm.nih.gov/pubmed/30267292",
        "http://www.ncbi.nlm.nih.gov/pubmed/32394011",
        "http://www.ncbi.nlm.nih.gov/pubmed/17355463",
        "http://www.ncbi.nlm.nih.gov/pubmed/29099658",
        "http://www.ncbi.nlm.nih.gov/pubmed/38677754",
        "http://www.ncbi.nlm.nih.gov/pubmed/38057769",
        "http://www.ncbi.nlm.nih.gov/pubmed/38755463",
        "http://www.ncbi.nlm.nih.gov/pubmed/18018350",
        "http://www.ncbi.nlm.nih.gov/pubmed/22024227",
        "http://www.ncbi.nlm.nih.gov/pubmed/38911192",
        "http://www.ncbi.nlm.nih.gov/pubmed/31182077",
        "http://www.ncbi.nlm.nih.gov/pubmed/27500146",
        "http://www.ncbi.nlm.nih.gov/pubmed/36872860",
        "http://www.ncbi.nlm.nih.gov/pubmed/25223928",
        "http://www.ncbi.nlm.nih.gov/pubmed/8682148",
        "http://www.ncbi.nlm.nih.gov/pubmed/25462983",
        "http://www.ncbi.nlm.nih.gov/pubmed/14509502",
        "http://www.ncbi.nlm.nih.gov/pubmed/21471788",
        "http://www.ncbi.nlm.nih.gov/pubmed/20571241",
        "http://www.ncbi.nlm.nih.gov/pubmed/37605259",
        "http://www.ncbi.nlm.nih.gov/pubmed/33503115",
        "http://www.ncbi.nlm.nih.gov/pubmed/21161004",
        "http://www.ncbi.nlm.nih.gov/pubmed/37395582",
        "http://www.ncbi.nlm.nih.gov/pubmed/36319626",
        "http://www.ncbi.nlm.nih.gov/pubmed/32509813",
        "http://www.ncbi.nlm.nih.gov/pubmed/19029643",
        "http://www.ncbi.nlm.nih.gov/pubmed/32843589",
        "http://www.ncbi.nlm.nih.gov/pubmed/27094558",
        "http://www.ncbi.nlm.nih.gov/pubmed/15194628",
        "http://www.ncbi.nlm.nih.gov/pubmed/24802959",
        "http://www.ncbi.nlm.nih.gov/pubmed/11090014",
        "http://www.ncbi.nlm.nih.gov/pubmed/10323426",
        "http://www.ncbi.nlm.nih.gov/pubmed/12733001"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 17,
          "offsetInEndSection": 122,
          "text": "The Pringle maneuver is traditionally used to avoid hemorrhage during hepatectomy for hepatic metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21510298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Temporary portal triad clamping (Pringle maneuver) during liver resection reduces intraoperative blood loss. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16036781"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "The Pringle manoeuvre (vascular inflow occlusion) has been a mainstay technique in trauma surgery and hepato-pancreato-biliary surgery since it was first described in the early 1900s.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35396269"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 285,
          "text": "The Pringle manoeuvre has been commonly used to avoid massive blood loss during operation since its advent, which greatly accelerates the advance of liver surgery and oncological surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19144472"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "The Pringle manoeuvre should be avoided in hepatectomy for cancer patients due to its side effects on tumor recurrence and worse prognosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19144472"
        },
        {
          "offsetInBeginSection": 432,
          "offsetInEndSection": 514,
          "text": "First, the Pringle maneuver was performed to control hepatic blood inflow (step 1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38677754"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 167,
          "text": "The half-Pringle and Pringle maneuvers are commonly used for inflow control",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38057769"
        },
        {
          "offsetInBeginSection": 642,
          "offsetInEndSection": 715,
          "text": "Meanwhile, the Pringle maneuver was adopted to control the hepatic inflow",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38755463"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "The Pringle maneuver is the most feasible method to control bleeding in hepatic resections in both open and laparoscopic approach.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18018350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "BACKGROUND: The Pringle maneuver is often used in liver surgery to minimize bleeding during liver ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32394011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "BACKGROUND: Pringle maneuver (PM) is used for inflow vascular control during hepatectomy, but its",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30856518"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 272,
          "text": "The application of Pringle maneuver (PM) during hepatectomy reduces intraoperative blood loss and the need for perioperative transfusion, but its effect on long-term recurrence and survival for patients with hepatocellular carcinoma (HCC) remains controversial",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38911192"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 284,
          "text": "The Pringle maneuver is often applied during liver resection to minimize bleeding, which in turn complicates the postoperative course owing to liver ischemia and reperfusion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15776301"
        },
        {
          "offsetInBeginSection": 473,
          "offsetInEndSection": 943,
          "text": "In combination with the stapler resection technique, PM is expected to minimize blood loss during major liver resection safely due to the short parenchymal dissection duration.METHODS: In a single center prospective, randomized, controlled, parallel, confirmatory trial the combination of PM and stapler resection technique in patients undergoing right and left hepatectomies will be tested against the control group that applies stapler resection without the use of PM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31182077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "BACKGROUND: Pringle maneuver (PM) is used for inflow vascular control during hepatectomy, but its use remains controversial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30856518"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "During minimally invasive liver resection (MILR), the Pringle maneuver aims to minimize blood loss and provide a clear operative field, thereby identifying intrahepatic structures and facilitating safe parenchymal transection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36872860"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 123,
          "text": " Pringle maneuver (PM) is used for inflow vascular control during hepatectomy, but its use remains controversial",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30856518"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 100,
          "text": " The Pringle maneuver is widely used in liver surgery to reduce intraoperative blood loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223928"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "The Pringle maneuver (PM) is recognized in conventional liver surgery as a method of controlling bleeding.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8682148"
        },
        {
          "offsetInBeginSection": 426,
          "offsetInEndSection": 652,
          "text": "When in-flow is limited by the hepatic pedicle clamping, it reduces intraoperative blood loss. The Pringle maneuver, first described in 1908, is the simplest method of inflow occlusion and currently can be achieved during LLR.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27500146"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 137,
          "text": " We present a widely applicable technique of the modified Pringle maneuver to reduce blood loss for laparoscopic hepatectomy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25462983"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Selective hepatic vascular exclusion (SHVE) and the Pringle maneuver are two methods used to control bleeding during hepatectomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14509502"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "BACKGROUND: The Pringle maneuver has its applications to minimize blood loss during hepati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21471788"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "BACKGROUND/AIMS: The Pringle maneuver is generally performed to reduce the amount of blood loss during h",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22024227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "BACKGROUND: The Pringle maneuver is widely used in liver surgery to reduce intraoperative",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223928"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "INTRODUCTION: Bleeding during liver surgery is often routinely controlled by the Pringle maneuver consisting in the temporary clamping of hepatic artery, portal vein, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571241"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 378,
          "text": "precaution. To reduce the amount of intraoperative blood loss, we perform the Pringle maneuver, aimed at occluding the inflow of blood into the liver",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "BACKGROUND: The laparoscopic Pringle maneuver is crucial for controlling bleeding during laparoscopic ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37605259"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "BACKGROUNDS/AIMS: The Pringle maneuver is generally performed to reduce the amount of blood loss during ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32843589"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 557,
          "text": "Pringle maneuver remains the standard inflow occlusion technique.AIM: Describe an extracorporeal, efficient, fast, cheap and reproducible way to execute the Pringle maneuver in laparoscopic surgery, using a chest tube.METHODS: From January 2014 to March 2020, our team performed 398 hepatectomies, 63 by laparoscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33503115"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "INTRODUCTION: We present a widely applicable technique of the modified Pringle maneuver to reduce blood loss for laparoscopic hepatectomy.METHODS: We use a drip-infusion tube and wrap it around the hepatoduodenal ligament.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25462983"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 491,
          "text": "uct injury. The Pringle maneuver is a simple occlusion approach that could limit blood flow from the hepatic pedicle, thus controlling bleeding to provide a clear surgical field to reduce con",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30267292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "The Pringle maneuver is the most feasible method to control bleeding in hepatic resections in both open and laparoscopic approach",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18018350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "INTRODUCTION: Bleeding during liver surgery is often routinely controlled by the Pringle maneuver consisting in the temporary clamping of hepatic artery, portal vein,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20571241"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "BACKGROUND/AIMS: The Pringle maneuver is generally performed to reduce the amount of blood loss during ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22024227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "During liver resection clamping of the hepato-duodenal ligament (the Pringle maneuver) is performed to reduce intraoperative blood-loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21161004"
        },
        {
          "offsetInBeginSection": 1414,
          "offsetInEndSection": 1760,
          "text": "A simple extracorporeal Pringle maneuver, combined with the maintenance of low CVP, is employed to regulate the hepatic inflow and outflow in order to minimize intraoperative bleeding. This approach facilitates the attainment of a dry and clean operative field, which allows for the precise ligation and dissection of blood vessels and bile ducts",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37395582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "BACKGROUND: The laparoscopic Pringle maneuver is crucial for controlling bleeding during laparoscopic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37605259"
        },
        {
          "offsetInBeginSection": 1785,
          "offsetInEndSection": 1962,
          "text": "r and extracorporeal Pringle maneuver. It is a simple, safe, and effective method for controlling hepatic inflow and represents a promising approach for performing totally intra",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37605259"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261,
          "text": "Background: The application of Pringle maneuver (PM) during hepatectomy reduces intraoperative blood loss and the need for perioperative transfusion, but its effect on long-term recurrence and survival for patients with hepatocellular carcinoma (HCC) remains co",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38911192"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "The Pringle maneuver (PM) is widely used during hepatocellular carcinoma (HCC) resection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36319626"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "BACKGROUND: Vascular inflow occlusion (VIO) during liver resections (Pringle manoeuvre) can be applied to reduce blood loss, however may at the same time, give rise to ischemia-reperfusion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32509813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "BACKGROUND: The Pringle maneuver, which is performed during liver surgery to reduce blood loss, may result in liver ischemia/reperfusion injury resulting in metabolic, immunological, and microvascular changes, which may lead to hepatocell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27094558"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "BACKGROUND: The Pringle manoeuvre and ischaemic preconditioning are applied to prevent blood loss and ischaemia-reperfusion injury, respectively, during li",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15194628"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "In liver resection operations the Pringle (Baron) maneuver can be used for temporary ischemia by clamping the hepatoduodenal ligament intermittently.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19029643"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 109,
          "text": " The Pringle maneuver is often used in liver surgery to minimize bleeding during liver transection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32394011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "The Pringle maneuver is used in hepatic surgery to prevent blood loss but is associated with ischemia- reperfusion injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24802959"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 267,
          "text": "Inflow occlusion (Pringle maneuver) is often used to minimize blood loss, but hepatic ischemia results in an increased risk of postoperative hepatic dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11090014"
        },
        {
          "offsetInBeginSection": 17,
          "offsetInEndSection": 121,
          "text": " The Pringle maneuver is generally performed to reduce the amount of blood loss during hepatic resection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32843589"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "BACKGROUND: Pringle maneuver (PM) is used for inflow vascular control during hepatectomy, but its use remains co",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30856518"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 301,
          "text": "al problem. The Pringle maneuver is traditionally used during hepatectomy to reduce blood loss, but the effect on the metabolic function of hepatocytes is potentia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10323426"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "BACKGROUND: The Pringle maneuver, which is performed during liver surgery to reduce blood loss, may result in liver ischemia/reperfusion injury resulting in metabolic, immunological, and microvascular changes, which may lead to hepatocel",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27094558"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "The Pringle manoeuvre (vascular inflow occlusion) has been a mainstay technique in trauma surgery and hepato-pancreato-biliary surgery since it was first described in the early 1900s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35396269"
        },
        {
          "offsetInBeginSection": 460,
          "offsetInEndSection": 910,
          "text": "To manage severe liver trauma (American Association for the Surgery of Trauma grade III to grade V), procedures such as packing of the laceration with omentum, hepatectomy or direct control of bleeding vessels within the liver substance by means of the Pringle maneuver, selective hepatic artery ligation, retrohepatic caval repair with total hepatic vascular occlusion, and perihepatic packing were selected and combined based on the specific injury",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12733001"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "There are many surgical techniques (packing, Pringle maneuver, etc.) and hemostatic agents to manage hepatic bleeding in trauma surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38012204"
        }
      ],
      "type": "summary",
      "id": "67e3113d18b1e36f2e00009f",
      "ideal_answer": [
        "Temporary portal triad clamping (Pringle maneuver) during liver resection reduces intraoperative blood loss.",
        "Pringle maneuver is used to control bleeding during laparoscopic liver resection.",
        "The Pringle maneuver is used during liver resection to reduce blood loss by temporarily occluding blood flow to the liver.",
        "The Pringle manoeuvre (vascular inflow occlusion) has been a mainstay technique in trauma surgery and hepato-pancreato-biliary surgery since it was first described in the early 1900s.",
        "The Pringle maneuver is used during liver resection to reduce blood loss by clamping the hepatic artery and portal vein. However, it may also cause ischemia-reperfusion injury, which could potentially stimulate the outgrowth of micrometastases.",
        "The Pringle maneuver is used for inflow vascular control during hepatectomy, aiming to minimize bleeding during liver resection.",
        "The Pringle maneuver is used to control bleeding during liver surgery by temporarily occluding blood flow to the liver, commonly applied during hepatectomy and other liver resections to minimize intraoperative blood loss.",
        "The Pringle maneuver is used to control bleeding from the liver by temporarily occluding the hepatoduodenal ligament, which contains the hepatic artery and portal vein.",
        "The Pringle maneuver is a surgical technique used to control bleeding from the liver. It involves clamping the hepatoduodenal ligament, which contains the portal vein, hepatic artery, and bile duct, to temporarily stop blood flow to the liver. This maneuver is commonly used during liver surgery or in cases of traumatic liver injury to reduce blood loss and allow for better visualization and repair of the liver tissue.",
        "The Pringle maneuver is used to minimize blood loss during hepatic resection and liver surgery. It involves temporary clamping of the hepatic artery, portal vein, and bile duct to control bleeding during liver transection. It is a method to control bleeding in hepatic resections and is favored by many surgeons.",
        "the pringle maneuver, a vascular inflow occlusion technique, is a crucial tool in trauma surgery and hepato-pancreato-biliary surgery, particularly during laparoscopic hepatectomy and cholecystectomy, to control bleeding and prevent complications.",
        "The Pringle maneuver is used during hepatectomy to control intraoperative blood loss by occluding the inflow of blood into the liver. It aims to reduce the amount of intraoperative bleeding, thereby facilitating safer surgical procedures.",
        "The Pringle maneuver is used during liver resections and hepatectomies in both open and laparoscopic procedures. It controls bleeding by temporarily clamping the hepatic inflow, typically involving the hepatic artery and portal vein as part of the hepatic pedicle, thereby creating a cleaner surgical field.",
        "The Pringle maneuver, or hepatic vascular occlusion, is used to minimize bleeding during liver surgery. It involves temporarily clamping the hepatic pedicle to control vascular inflow to the liver. This technique is employed during liver resections and when managing lesions near major blood vessels to reduce blood loss. However, it can potentially lead to ischemia-reperfusion injury.",
        "The Pringle maneuver is used for inflow vascular control during liver resection (hepatectomy) to minimize bleeding.",
        "The Pringle maneuver is a surgical technique used in liver procedures (liver resections, laparoscopic cholecystectomy, and hepatectomy) to temporarily occlude the hepatic pedicle, minimizing liver blood flow, bleeding, and complications, while enhancing surgical field clarity and potentially reducing postoperative hospital stays.",
        "The Pringle maneuver is a surgical technique that temporarily occludes the hepatic pedicle, containing the hepatic artery and portal vein, to minimize bleeding and enhance visibility during liver surgeries, including liver resections, hepatectomies, and challenging laparoscopic cholecystectomies, thereby reducing the risk of complications.",
        "The Pringle maneuver is used to control bleeding during liver surgery by temporarily occluding the inflow of blood to the liver.",
        "The Pringle maneuver is a surgical technique used to temporarily occlude the hepatic pedicle, containing the hepatic artery and portal vein, during liver surgeries such as resections, hepatectomies, and challenging laparoscopic cholecystectomies, thereby minimizing bleeding, enhancing surgical visibility, and reducing the risk of complications and postoperative hospital stays.",
        "The Pringle maneuver is used to control bleeding during liver surgeries and trauma procedures by temporarily occluding blood flow through the hepatoduodenal ligament. This interruption of the hepatic arterial and portal venous inflow minimizes blood loss during procedures such as liver resections or trauma management, helping to provide a clearer surgical field and reduce the risk of hemorrhage.",
        "The Pringle maneuver is often applied during liver resection to minimize bleeding, which in turn complicates the postoperative course owing to liver ischemia and reperfusion.",
        "The Pringle maneuver is used to control bleeding during liver surgery by temporarily occluding the hepatoduodenal ligament to reduce blood flow to the liver.",
        "The Pringle maneuver is used to reduce intraoperative blood loss during liver resection.",
        "Pringle maneuver is performed during laparoscopic hepatic resection to control intraoperative bleeding. Exact answer:",
        "The Pringle maneuver is a surgical technique that involves temporary portal triad clamping during liver resection procedures, primarily employed to minimize intraoperative blood loss and prevent hemorrhage during hepatectomy operations.",
        "The Pringle maneuver is traditionally used to avoid hemorrhage during hepatectomy for hepatic metastasis. Temporary portal triad clamping (Pringle maneuver) during liver resection reduces intraoperative blood loss.",
        "The Pringle maneuver is used to control bleeding during liver surgery, including liver resections and hepatectomies. It involves temporarily clamping the hepatic artery, portal vein, and bile duct to reduce blood flow to the liver, thereby minimizing intraoperative blood loss. It is also used in trauma surgery for managing complex hepatic injuries.",
        "The Pringle maneuver is a surgical technique traditionally used to prevent bleeding during liver surgery, specifically during hepatectomy for liver metastasis, by temporarily clamping the portal triad to reduce intraoperative blood loss.",
        "The Pringle maneuver is used during liver resection surgeries to control hemorrhage by temporarily clamping the portal triad, which reduces intraoperative blood loss.",
        "Temporary portal triad clamping (Pringle maneuver) during liver resection reduces intraoperative blood loss. The Pringle maneuver is traditionally used to avoid hemorrhage during hepatectomy for hepatic metastasis.",
        "The Pringle maneuver is used to control hepatic inflow and reduce intraoperative blood loss during liver surgeries, particularly hepatectomies for hepatic metastasis. It involves temporary clamping of the portal triad to minimize hemorrhage during the procedure. The maneuver has been shown to be effective in managing bleeding, although its routine application in uncomplicated cases is debated.",
        "The Pringle maneuver is used during liver resection (hepatectomy) to reduce intraoperative blood loss by temporarily clamping the portal triad (hepatic artery, portal vein, and bile duct). It is particularly applied in procedures for hepatic metastasis to prevent hemorrhage.",
        "The Pringle maneuver is used to reduce intraoperative blood loss during liver resection (hepatectomy) by temporarily clamping the portal triad (hepatic artery, portal vein, and bile duct). This technique helps prevent hemorrhage during procedures such as hepatic metastasis removal.",
        "The Pringle maneuver is used to reduce intraoperative blood loss during liver resection by temporarily clamping the hepatic artery and the portal vein. It is traditionally employed to avoid hemorrhage during hepatectomy for hepatic metastasis.",
        "The Pringle maneuver is used to avoid hemorrhage during liver resection, as it temporarily clamps the portal triad to reduce intraoperative blood loss, particularly during hepatectomy for hepatic metastasis.",
        "The Pringle maneuver is used to avoid hemorrhage during hepatectomy for hepatic metastasis by temporarily clamping the portal triad. This helps to reduce intraoperative blood loss.",
        "The Pringle maneuver is a surgical technique primarily used to control and reduce blood loss during liver surgeries, such as hepatectomy for hepatic metastasis and other forms of liver resection. It involves clamping the portal triad to minimize hemorrhage, thereby improving surgical conditions and outcomes in these procedures.",
        "The Pringle maneuver is used to control bleeding during liver surgery by temporarily clamping the hepatic pedicle, which includes the portal vein, hepatic artery, and bile duct. This vascular inflow occlusion reduces blood loss during procedures such as hepatectomy, liver resection, and management of lesions near major blood vessels. It is also used to avoid hemorrhage during hepatectomy for hepatic metastasis.",
        "The Pringle maneuver is a surgical technique employed during liver surgeries, including hepatectomy (removal of part or all of the liver) and liver resection. It involves temporarily clamping the portal triad, which includes the hepatic artery, portal vein, and bile ducts. This procedure is primarily used to reduce intraoperative blood loss and prevent hemorrhage during these surgical interventions.",
        "The Pringle maneuver is traditionally used to avoid hemorrhage during hepatectomy for hepatic metastasis. It involves temporary portal triad clamping to reduce intraoperative blood loss.",
        "The Pringle maneuver is a technique used to reduce intraoperative blood loss during liver resection, particularly when addressing hepatic metastasis. It involves temporary clamping of the portal triad. This maneuver is traditionally employed to avoid hemorrhage during hepatectomy.",
        "The Pringle maneuver is used to avoid hemorrhage during hepatectomy, particularly in cases of hepatic metastasis. It involves temporarily clamping the hepatic blood supply to reduce intraoperative blood loss during liver surgery.",
        "The Pringle maneuver, involving temporary clamping of the portal triad, is primarily used to reduce intraoperative blood loss during hepatectomy procedures, such as those performed for hepatic metastasis. By controlling hemorrhage, it enhances surgical safety and efficiency.",
        "The Pringle maneuver is used to reduce intraoperative blood loss during liver resection by temporarily clamping the portal triad, thereby controlling bleeding and enhancing surgical safety.",
        "The Pringle maneuver is used to control blood loss during hepatectomy, particularly in cases of hepatic metastasis. It involves temporary clamping of the portal triad to reduce intraoperative hemorrhage. This technique is effective in managing hepatic inflow and is crucial during laparoscopic hepatectomy. While it is a simple and safe method, routine vascular clamping is not indicated for uncomplicated patients.",
        "The Pringle maneuver is a surgical technique used to reduce intraoperative blood loss during liver resection, particularly in hepatectomies for hepatic metastasis. It involves the temporary clamping of the portal triad, comprising the hepatic artery, portal vein, and bile duct, thereby controlling bleeding and ensuring a safer procedure.",
        "The Pringle maneuver is traditionally used to avoid hemorrhage during hepatectomy for hepatic metastasis.",
        "Pringle maneuver is performed during laparoscopic hepatic resection to control intraoperative bleeding.",
        "The Pringle maneuver is used to avoid hemorrhage during hepatectomy for hepatic metastasis.",
        "The Pringle maneuver is used to reduce intraoperative blood loss during liver resection or hepatectomy, particularly for hepatic metastasis. It involves temporary portal triad clamping to minimize hemorrhage.",
        "The Pringle maneuver is used to control bleeding during liver surgery, particularly during hepatectomy for hepatic metastasis. It involves temporary clamping of the portal triad to reduce blood flow, thereby minimizing intraoperative blood loss and improving surgical visibility. This technique is crucial in reducing complications related to excessive bleeding during complex liver procedures.",
        "The Pringle maneuver is used to reduce intraoperative blood loss during liver resection by temporarily clamping the portal triad.",
        "The Pringle maneuver is primarily used to minimize intraoperative blood loss during liver surgery. It involves temporary clamping of the portal triad to control bleeding, particularly during hepatectomy or liver resection, enhancing surgical safety and reducing hemorrhage risks.",
        "The Pringle maneuver is primarily used during liver resection (hepatectomy) to reduce intraoperative blood loss by temporarily clamping the hepato-duodenal ligament (portal triad), though its application may have varying outcomes depending on the underlying liver condition, such as in cases of cancer or surgical obstructive jaundice.",
        "The Pringle maneuver is utilized to minimize blood loss during liver resection surgeries. It involves temporarily clamping the portal triad, which interrupts blood flow to the liver, thereby reducing bleeding from the surgical site. This technique enhances surgical safety and efficiency by effectively controlling hemorrhage during hepatectomy procedures.",
        "The Pringle maneuver is used during liver surgery to reduce blood loss by temporarily occluding the blood flow in the hepatic pedicle, which helps control bleeding and provides a clearer surgical field.",
        "The Pringle maneuver is used to reduce intraoperative blood loss during liver resection, particularly in surgeries for hepatic metastasis, by temporarily clamping the portal triad."
      ]
    },
    {
      "body": "Which environment favors Histoplasma capsulatum?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30266238",
        "http://www.ncbi.nlm.nih.gov/pubmed/7081547",
        "http://www.ncbi.nlm.nih.gov/pubmed/9009662",
        "http://www.ncbi.nlm.nih.gov/pubmed/11521241",
        "http://www.ncbi.nlm.nih.gov/pubmed/6472165",
        "http://www.ncbi.nlm.nih.gov/pubmed/38392796",
        "http://www.ncbi.nlm.nih.gov/pubmed/20011851",
        "http://www.ncbi.nlm.nih.gov/pubmed/27248851",
        "http://www.ncbi.nlm.nih.gov/pubmed/10436635",
        "http://www.ncbi.nlm.nih.gov/pubmed/15100461",
        "http://www.ncbi.nlm.nih.gov/pubmed/29325597",
        "http://www.ncbi.nlm.nih.gov/pubmed/10441199",
        "http://www.ncbi.nlm.nih.gov/pubmed/9476515",
        "http://www.ncbi.nlm.nih.gov/pubmed/7808510",
        "http://www.ncbi.nlm.nih.gov/pubmed/842775",
        "http://www.ncbi.nlm.nih.gov/pubmed/15597674",
        "http://www.ncbi.nlm.nih.gov/pubmed/36148943",
        "http://www.ncbi.nlm.nih.gov/pubmed/30303979"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 848,
          "offsetInEndSection": 960,
          "text": "The principal transmission mechanism of histoplasmosis is by inhalation of spores aerosolized by soil disruption",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30266238"
        },
        {
          "offsetInBeginSection": 1270,
          "offsetInEndSection": 1572,
          "text": "Environmental and wilderness-related risk factors for histoplasmosis include bird and bat watching, cave and cave entrance exploration, and bamboo removal and burning. Occupational risk factors for histoplasmosis include road construction, roofing, bridge and water tower work, demolition, and masonry.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30266238"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 390,
          "text": "Histoplasma capsulatum, is found in Mexico, mainly in confined spaces, where it grows on bat guano or bird droppings. A research project has been developed in the State of Guerrero, Mexico, where many contaminated caves and mines are visited by individuals and epidemic outbreaks have been recorded",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9009662"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 280,
          "text": "Histoplasma capsulatum is well adapted to be infectious and pathogenic for humans. As a soil fungus with no known requirement for interacting with a mammalian host as part of an obligate lifecycle, its plethora of strategies for successful pathogenesis is particularly remarkable.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11521241"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "The fungus Histoplasma capsulatum, although commonly found in bat-frequented caves in many countries, has not previously been isolated from that environment in Australia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6472165"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Histoplasma capsulatum. Isolation from an Australian cave environment and from a patient.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6472165"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "BACKGROUND: Histoplasma capsulatum comprises a worldwide complex of saprobiotic fungi mainly found in nitrogen/phosphate (often bird guano) enr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27248851"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Histoplasma capsulatum is a universal dimorphic fungus found mainly in soil contaminated with excrement of birds and bats.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10436635"
        },
        {
          "offsetInBeginSection": 855,
          "offsetInEndSection": 937,
          "text": "Histoplasma capsulatum was isolated from bat guano collected from inside the cave.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15100461"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 120,
          "text": " Histoplasma capsulatum is a dimorphic fungus predominately found in soils enriched with bird and bat excreta",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29325597"
        },
        {
          "offsetInBeginSection": 74,
          "offsetInEndSection": 185,
          "text": "The responsible fungal pathogen, Histoplasma capsulatum, grows in soils contaminated with bird or bat droppings",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Histoplasma capsulatum var. duboisii has only recently been shown to occur naturally in soil admixed with bat guano in a bat cave",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9476515"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "A natural focus of Histoplasma capsulatum var. duboisii is a bat cave",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7808510"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "The fungus Histoplasma capsulatum, although commonly found in bat-frequented caves in many countries",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6472165"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "The isolation of Histoplasma capsulatum from a bat cave in the Galilee region of Israel is reported along with the discovery of a bat (Myotis myotis) infected by H. capsulatum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/842775"
        },
        {
          "offsetInBeginSection": 372,
          "offsetInEndSection": 555,
          "text": "Histoplasma capsulatum var. capsulatum is known to occur naturally in caves inhabited by bats in some parts of South Africa, namely, Transvaal and Cape province, Zimbabwe and Tanzania",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15597674"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "We detected Histoplasma capsulatum in soil and penguin excreta in the Antarctic Peninsula by sequencing after performing species-specific PCR, confirming previous observations that this pathogen occurs more broadly than suspected.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36148943"
        },
        {
          "offsetInBeginSection": 61,
          "offsetInEndSection": 169,
          "text": "Histoplasma capsulatum var. capsulatum, whose natural habitat is soil contaminated by bat or bird excrement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20011851"
        },
        {
          "offsetInBeginSection": 648,
          "offsetInEndSection": 749,
          "text": "Histoplasma capsulatum (a potential human pathogen commonly associated with caves inhabited by bats).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30303979"
        }
      ],
      "id": "67e2942a18b1e36f2e000082",
      "ideal_answer": [
        "Environmental and wilderness-related risk factors for histoplasmosis include bird and bat watching, cave and cave entrance exploration, and bamboo removal and burning. Occupational risk factors for histoplasmosis include road construction, roofing, bridge and water tower work, demolition, and masonry. Histoplasma capsulatum is found in confined spaces, where it grows on bat guano or bird droppings.",
        "Histoplasma capsulatum is a soil-dwelling fungus that thrives in environments with high temperatures and humidity. It is commonly found in soil contaminated with bird and bat droppings, which provide a nutrient-rich source of organic matter. The fungus can also be found in soil contaminated with decaying wood and other organic matter.",
        "Histoplasma capsulatum thrives in environments rich in organic matter, with moderate to warm temperatures, and humid conditions. Specifically, it favors soil with high organic content (e.g., near bat or bird habitats, caves, or decomposing areas) at around 28°C for its mold form, and warm, mammalian host environments at approximately 37°C for its yeast form. The presence of bat or bird guano and nutrient-rich substrates (like compost or manure) also supports its growth. Such conditions are commonly found in disrupted soil environments, like certain cave ecosystems with bat activity.",
        "Histoplasma capsulatum thrives in environments rich in bird or bat droppings, such as caves, chicken coops, and areas with abundant organic material. It grows as a mold in the soil under these conditions, where it releases spores that can be inhaled by humans or animals, leading to infection.",
        "Histoplasma capsulatum thrives in specific environments characterized by certain conditions:\n\n1. **Guano-Rich Areas**: The fungus is prevalent in areas abundant with bird or bat droppings, such as poultry farms, caves inhabited by bats, and regions near penguin colonies.\n\n2. **Damp Soil**: Histoplasma favors damp soil, particularly in stables where horses may roll on contaminated ground, leading to infections through open wounds or mucous membranes.\n\n3. **Geographical Regions**: It is endemic to the Midwest and Southeastern United States, as well as regions like Brazil\u0027s Amazonas state, indicating a preference for warm and humid climates.\n\n4. **Caves and Humid Environments**: Caves with bat guano are hotspots due to the nutrient-rich environment provided by bat droppings, supporting fungal growth.\n\n5. **Thermally Dimorphic Nature**: The fungus adapts well to various soil conditions, existing as mycelium in the environment and yeast in infected tissues, enhancing its ability to thrive in different settings.\n\nIn summary, Histoplasma capsulatum is most favored in environments rich in guano, damp soil, caves, and humid regions, particularly in areas like the Midwest US, Southeastern US, and Amazonas state in Brazil.",
        "Histoplasma capsulatum flourishes in specific environmental niches characterized by certain factors:\n\n1. **Soil Rich in Organic Matter**: The fungus is particularly abundant in soil contaminated with bird or bat droppings, which provide essential nutrients for its growth.\n\n2. **Humid and Damp Conditions**: Areas with high humidity and dampness, such as caves or stables, are favorable. These conditions support the lifecycle of the fungus, including spore formation and germination.\n\n3. **Geographical Regions**: The mid-eastern United States is a hotspot for this fungus. Additionally, it has been detected in diverse regions like Antarctica and Brazil, indicating adaptability across climates.\n\n4. **Caves and Stable Environments**: Caves offer stable temperatures and humidity levels conducive to fungal growth. Similarly, stables with contaminated soil contribute to the spread of spores.\n\n5. **Thermally Dimorphic Nature**: The ability to switch between mycelial and yeast forms allows Histoplasma to thrive in various environmental conditions, enhancing its adaptability.\n\nIn summary, Histoplasma capsulatum is most prevalent in environments rich in organic matter, with damp soil, stable temperatures, and high humidity. These conditions facilitate its growth and transmission, making it a significant health concern in such areas."
      ]
    },
    {
      "body": "Which immune checkpoint proteins do tumors often exploit to evade immune responses?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38762484",
        "http://www.ncbi.nlm.nih.gov/pubmed/37445336",
        "http://www.ncbi.nlm.nih.gov/pubmed/35523809",
        "http://www.ncbi.nlm.nih.gov/pubmed/27847783",
        "http://www.ncbi.nlm.nih.gov/pubmed/27974689",
        "http://www.ncbi.nlm.nih.gov/pubmed/35787940",
        "http://www.ncbi.nlm.nih.gov/pubmed/39200350",
        "http://www.ncbi.nlm.nih.gov/pubmed/28247187",
        "http://www.ncbi.nlm.nih.gov/pubmed/38158454",
        "http://www.ncbi.nlm.nih.gov/pubmed/32235439",
        "http://www.ncbi.nlm.nih.gov/pubmed/39696711",
        "http://www.ncbi.nlm.nih.gov/pubmed/32751706",
        "http://www.ncbi.nlm.nih.gov/pubmed/26884577",
        "http://www.ncbi.nlm.nih.gov/pubmed/36175741",
        "http://www.ncbi.nlm.nih.gov/pubmed/36798830",
        "http://www.ncbi.nlm.nih.gov/pubmed/32185706",
        "http://www.ncbi.nlm.nih.gov/pubmed/32900861",
        "http://www.ncbi.nlm.nih.gov/pubmed/37603905",
        "http://www.ncbi.nlm.nih.gov/pubmed/30191996",
        "http://www.ncbi.nlm.nih.gov/pubmed/29065424",
        "http://www.ncbi.nlm.nih.gov/pubmed/37345056",
        "http://www.ncbi.nlm.nih.gov/pubmed/35416931",
        "http://www.ncbi.nlm.nih.gov/pubmed/30191140",
        "http://www.ncbi.nlm.nih.gov/pubmed/38228572",
        "http://www.ncbi.nlm.nih.gov/pubmed/25344022",
        "http://www.ncbi.nlm.nih.gov/pubmed/27884973",
        "http://www.ncbi.nlm.nih.gov/pubmed/27058852",
        "http://www.ncbi.nlm.nih.gov/pubmed/30133260",
        "http://www.ncbi.nlm.nih.gov/pubmed/35428302",
        "http://www.ncbi.nlm.nih.gov/pubmed/32313722",
        "http://www.ncbi.nlm.nih.gov/pubmed/30918149",
        "http://www.ncbi.nlm.nih.gov/pubmed/26640578",
        "http://www.ncbi.nlm.nih.gov/pubmed/28768162",
        "http://www.ncbi.nlm.nih.gov/pubmed/35986535",
        "http://www.ncbi.nlm.nih.gov/pubmed/36177034",
        "http://www.ncbi.nlm.nih.gov/pubmed/36905697",
        "http://www.ncbi.nlm.nih.gov/pubmed/39732171",
        "http://www.ncbi.nlm.nih.gov/pubmed/39721027",
        "http://www.ncbi.nlm.nih.gov/pubmed/31723749",
        "http://www.ncbi.nlm.nih.gov/pubmed/39564188",
        "http://www.ncbi.nlm.nih.gov/pubmed/39257156",
        "http://www.ncbi.nlm.nih.gov/pubmed/27055470",
        "http://www.ncbi.nlm.nih.gov/pubmed/27770382",
        "http://www.ncbi.nlm.nih.gov/pubmed/38589688",
        "http://www.ncbi.nlm.nih.gov/pubmed/32963613",
        "http://www.ncbi.nlm.nih.gov/pubmed/30410357",
        "http://www.ncbi.nlm.nih.gov/pubmed/39447075",
        "http://www.ncbi.nlm.nih.gov/pubmed/39497819",
        "http://www.ncbi.nlm.nih.gov/pubmed/39687650",
        "http://www.ncbi.nlm.nih.gov/pubmed/32239707",
        "http://www.ncbi.nlm.nih.gov/pubmed/35907881",
        "http://www.ncbi.nlm.nih.gov/pubmed/30250471",
        "http://www.ncbi.nlm.nih.gov/pubmed/34689789",
        "http://www.ncbi.nlm.nih.gov/pubmed/34906767",
        "http://www.ncbi.nlm.nih.gov/pubmed/25824455",
        "http://www.ncbi.nlm.nih.gov/pubmed/32623044",
        "http://www.ncbi.nlm.nih.gov/pubmed/33301862",
        "http://www.ncbi.nlm.nih.gov/pubmed/30917623",
        "http://www.ncbi.nlm.nih.gov/pubmed/32855204",
        "http://www.ncbi.nlm.nih.gov/pubmed/38631259",
        "http://www.ncbi.nlm.nih.gov/pubmed/26859684",
        "http://www.ncbi.nlm.nih.gov/pubmed/34447484",
        "http://www.ncbi.nlm.nih.gov/pubmed/29755779",
        "http://www.ncbi.nlm.nih.gov/pubmed/39073258",
        "http://www.ncbi.nlm.nih.gov/pubmed/38162657"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 531,
          "text": "Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein 1 (PD-1) and programmed cell death ligands (PD-Ls) are considered to be the major immune checkpoint molecules. The interaction of PD-1 and PD-L1 negatively regulates adaptive immune response mainly by inhibiting the activity of effector T cells while enhancing the function of immunosuppressive regulatory T cells (Tregs)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38762484"
        },
        {
          "offsetInBeginSection": 661,
          "offsetInEndSection": 772,
          "text": "However, cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in cancer development and progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38762484"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Checkpoint proteins are an integral part of the immune system and are used by the tumor cells to evade immune response, which helps them grow uncontrollably.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445336"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 662,
          "text": "Their mode of action is inhibition by targeting the checkpoint proteins CTLA-4, PD-1, PD-L1, etc.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445336"
        },
        {
          "offsetInBeginSection": 158,
          "offsetInEndSection": 308,
          "text": "By blocking these proteins, immune checkpoint inhibitors can restore the capability of the immune system to attack cancer cells and stop their growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37445336"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 349,
          "text": "Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32751706"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 416,
          "text": "One of the most critical checkpoint pathways in this system is a tumor-induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Programmed cell death-ligand 1 (PD-L1)-mediated T cell inhibition through PD-1 is a key checkpoint frequently exploited by tumors to evade immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35416931"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 399,
          "text": "Tumors frequently exploit these molecules to evade eradication by the immune system. Over the past years, immune-checkpoint blockade of cytotoxic T lymphocyte antigen-4 and programed death-1 emerged as promising strategies to activate antitumor cytotoxic T cell responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27847783"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Host immunity recognizes and eliminates most early tumor cells, yet immunological checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to effective antitumor immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191140"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 279,
          "text": " Immune checkpoint pathways are often exploited by tumors to evade immunity-mediated destruction, and checkpoint inhibitors can reactivate tumor-related immune responses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26884577"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 487,
          "text": "Immune checkpoint molecules are the major mechanism of immune resistance that are exploited by tumor cells to inhibit T-cell activation and suppress immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38228572"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 265,
          "text": "Tumor cells exploit immune checkpoint proteins to inhibit T cell activation, thus enhancing their resistance to immune attacks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39200350"
        },
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 242,
          "text": "Exploitation of these immune checkpoint pathways is one of the mechanisms by which tumors evade and/or escape the immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25344022"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "To evade elimination by the host immune system, tumor cells commonly exploit physiological immune checkpoint pathways, restraining efficient anti-tumor immune cell function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27884973"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Cancer cells can evade immune responses by exploiting inhibitory immune checkpoints.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35428302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "T cell immunoglobulin and mucin domain-3 (TIM-3) is an immune checkpoint that regulates normal immune responses but can be exploited by tumor cells to evade immune surveillance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32313722"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 677,
          "text": "PD-1 (Programmed Cell Death Protein 1), CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), LAG-3 (Lymphocyte-Activation Gene 3), and TIM-3 (T Cell Immunoglobulin and Mucin Domain-Containing Protein3) are all immune checkpoint receptors that play crucial roles in regulating the immune response and maintaining self-tolerance often exploited by cancer cells to evade immune surveillance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38158454"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Cancer cells can avoid and suppress immune responses through activation of inhibitory immune checkpoint proteins, such as PD-1, PD-L1, and CTLA-4",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28768162"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36177034"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 414,
          "text": "Immune checkpoint molecules such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) dampen T cell activation to avoid autoimmunity and the destructive effects of an excessive inflammatory response. Immune checkpoint signaling can be exploited by tumors to escape host immune surveillance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30918149"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 370,
          "text": "The binding of PD-1 to its ligand PD-L1 can trigger an inhibitory signal for reducing T-cell proliferation, inhibiting the anticancer effect of T cells, and limiting the anti-tumor immunity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36905697"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 525,
          "text": "Physiological immune checkpoint pathways are important to regulate self-tolerance, limit immune reactions, and moderate autoimmunity. Various cancers are commonly exploiting these mechanisms to evade the host immune system by restraining a durable, efficient anti-tumor immune response. Immune checkpoints include, but are not limited to, the programmed death 1 (PD1) and the cytotoxic T-lymphocyte-associated protein-4 (CTLA4) axis, which are both druggable by monoclonal antibodies referred to as checkpoint inhibitors (CIs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29065424"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "The interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1 plays a crucial role in tumor immune evasion, presenting a critical target for cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39564188"
        },
        {
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1452,
          "text": "PD-1, PDL-1, and CTLA-4 are crucial immune system regulators, acting as brakes to prevent T-- cell overactivation and potential autoimmunity. However, tumors can exploit these checkpoints to evade immune detection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39257156"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 346,
          "text": "However, tumors usually overexpress immune checkpoints such as PD-L1 to suppress T lymphocyte antitumor activity and evade immune surveillance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39447075"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 409,
          "text": "The expression of many immune checkpoint proteins in cancer cells is a mechanism by which tumor cells escape from the immune system. Among the well-known immune checkpoints that can tremendously affect tumor development and cancer therapy are the programmed death-ligand-1/programmed death-1 (PD-L1/PD-1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32239707"
        },
        {
          "offsetInBeginSection": 637,
          "offsetInEndSection": 813,
          "text": "Immune checkpoint proteins put brakes on immune cell functions to regulate immune activation, but this activity is exploited in tumors to evade immune surveillance and attack. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35787940"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 299,
          "text": "The molecular mechanisms underlying cancer immune escape are a core topic in cancer immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1, CD274) immune checkpoint.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35907881"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Among the most promising therapeutic modalities for cancer treatment is the blockade of immune checkpoint pathways, which are frequently co-opted by tumors as a major mechanism of immune escape. CTLA-4 and PD-1 are the representative examples, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30250471"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 866,
          "text": "Immune inhibitory molecules, including CTLA-4, TIM-3, TIGIT, PD-1, and LAG-3, normally inhibit immune responses via negatively regulating immune cell signaling pathways to prevent immune injury. However, the up-regulation of inhibitory immune checkpoints during tumor progression on immune cells suppresses anti-tumor immune responses and promotes immune escape in cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34906767"
        },
        {
          "offsetInBeginSection": 523,
          "offsetInEndSection": 781,
          "text": "Enhanced signalling of the Programmed cell death-1 (PDCD1, PD-1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA4) \u0027immune checkpoint\u0027 pathway has emerged recently as a critical mechanism by which tumours can escape the natural anti-tumour immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25824455"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 343,
          "text": "Immune checkpoint proteins can be expressed on the tumour-cell or immune-cell populations. Immune checkpoint proteins dampen the immune response by inactivating immune cells capable of tumour destruction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32623044"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 505,
          "text": "This happens when proteins on the surface of T cells called immune checkpoint proteins identify partner proteins on the cancer cells and bind to them, sending brake signals to the T cells to evade immune attack.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35986535"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 678,
          "text": "PD-1 (Programmed Cell Death Protein 1), CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), LAG-3 (Lymphocyte-Activation Gene 3), and TIM-3 (T Cell Immunoglobulin and Mucin Domain-Containing Protein3) are all immune checkpoint receptors that play crucial roles in regulating the immune response and maintaining self-tolerance often exploited by cancer cells to evade immune surveillance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38158454"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 304,
          "text": "Immune checkpoint proteins including programmed cell death protein 1 (PD-1), its ligand PD-L1 and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) are involved in proliferation, angiogenesis, metastasis, chemoresistance via immune escape and immune tolerance by disturbing cytotoxic T cell activation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33301862"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Cancer cells can evade immune surveillance through the molecular interactions of immune checkpoint proteins, including programmed death 1 (PD-1), PD-L1, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917623"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 353,
          "text": "Many cancers are termed immunoevasive due to expression of immunomodulatory ligands. Programmed death ligand-1 (PD-L1) and cluster of differentiation 80/86 (CD80/86) interact with their receptors, programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), respectively, on tumor-infiltrating leukocytes eliciting immunosuppression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32855204"
        },
        {
          "offsetInBeginSection": 290,
          "offsetInEndSection": 645,
          "text": "In this study, the main aim was to identify the intricate immune evasion tactics mediated by HCC cells and to study the epigenetic modulation of the immune checkpoints; Programmed death-1 (PD-1)/ Programmed death-Ligand 1 (PD-L1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT)/Cluster of Differentiation 155 (CD155) at the tumor-immune synapse",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38631259"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 438,
          "text": "Interaction between the Programmed Death Ligand 1 (PD-L1) on the surface of tumor cells with the Programmed Death-1 (PD-1) receptor on cytotoxic T lymphocytes leads to inactivation of these immune effectors and, consequently, immune escape",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26859684"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 574,
          "text": "One of the most critical checkpoint pathways in this system is a tumor-induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1). PD-1 is highly expressed by activated T cells, B cells, dendritic cells, and natural killer cells, whereas PD-L1 is expressed on several types of tumor cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30191996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Immune checkpoint molecules play critical roles in regulating the anti-tumor immune response, and tumor cells often exploit these pathways to inhibit and evade the immune system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35523809"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 486,
          "text": "Immune checkpoint molecules are the major mechanism of immune resistance that are exploited by tumor cells to inhibit T-cell activation and suppress immune responses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38228572"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 751,
          "text": "In the presence of a tumor, inhibition of T cell activity by tumor cells binding to immune checkpoints and their ligands is an important mechanism for tumor cells to escape immune injury",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34447484"
        },
        {
          "offsetInBeginSection": 245,
          "offsetInEndSection": 352,
          "text": "In cancer, the immune checkpoints are exploited so that the tumor cells are able to evade the immune system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27058852"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 474,
          "text": "Immune check points are negative regulators of immune system and control the immune response. These checkpoints are exploited by cancer cells. Cancer cells causes early activation of checkpoints and suppress the immune response, and therefore have unchecked growth and metastasis of malignant cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29755779"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 350,
          "text": "Tumor cells can activate the immune checkpoint pathway to establish an immunosuppressive tumor microenvironment and inhibit the anti-tumor immune response, which may lead to tumor progression by evading immune surveillance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073258"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 143,
          "text": "Tumors employ immune checkpoints to evade immune cell attacks",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30133260"
        },
        {
          "offsetInBeginSection": 981,
          "offsetInEndSection": 1117,
          "text": "However, in cancer, the overexpression of these molecules represents a common method through which tumor cells evade immune surveillance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38162657"
        }
      ],
      "id": "67eb569718b1e36f2e0000e8",
      "ideal_answer": [
        "Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. Examples of these checkpoint proteins include CTLA-4, PD-1, PD-L1. For example, the interaction of PD-1 and PD-L1 negatively regulates adaptive immune response mainly by inhibiting the activity of effector T cells while enhancing the function of immunosuppressive regulatory T cells (Tregs). Cancer cells exploit this PD-1/PD-L1 axis to cause immune escape and progression. Therefore, these pathways also provide an important therapeutic target. By blocking these proteins, immune checkpoint inhibitors can restore the capability of the immune system to attack cancer cells and stop their growth.",
        "Tumors often exploit several immune checkpoint proteins to evade immune responses. These proteins act as brakes on the immune system, preventing it from attacking the tumor cells effectively. The key immune checkpoint proteins that tumors commonly exploit include:\n\nCTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4): Tumors frequently exploit CTLA-4 to evade eradication by the immune system. CTLA-4 acts as an inhibitory receptor on T cells, downregulating immune responses.\n\nPD-1 (Programmed Cell Death Protein 1): PD-1 is another inhibitory receptor on T cells that tumors exploit to avoid immune destruction. By engaging PD-1, tumors can inhibit T cell activation and proliferation.\n\nPD-L1 (Programmed Death-Ligand 1): Tumors use the PD-L1 pathway to evade immune responses. PD-L1, expressed on tumor cells, binds to PD-1 on T cells, leading to the inhibition of T cell function. This pathway can be blocked by immune checkpoint inhibitors like anti-PD-L1 antibodies.\n\nTIM Gene Family (T-cell Immunoglobulin and Mucin-domain containing proteins): Members of the TIM gene family are also exploited by tumors to evade immune responses. These proteins help tumors circumvent host immune systems and promote protumorigenic inflammation.\n\nThese immune checkpoint proteins are critical targets for cancer immunotherapy, with various checkpoint inhibitors being developed and used in clinical settings to block these pathways and enhance the immune system\u0027s ability to fight cancer.",
        "According to recent studies, tumors often exploit the programmed death protein 1 (PD-1) and programmed cell death ligands (PD-Ls), particularly PD-L1, to evade immune responses. The interaction between PD-1 and PD-L1 negatively regulates the adaptive immune response by inhibiting the activity of effector T cells and enhancing the function of immunosuppressive regulatory T cells (Tregs). Additionally, other checkpoint proteins such as CTLA-4 are also targeted by tumors to evade immune response. By blocking these proteins, immune checkpoint inhibitors can restore the capability of the immune system to attack cancer cells and stop their growth, highlighting the importance of targeting these immune checkpoint proteins in cancer therapy.",
        "Tumors often exploit immune checkpoint proteins such as programmed death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to evade immune responses. The PD-1/PD-L1 axis is a major pathway where PD-L1 on cancer cells binds to PD-1 on effector T cells, suppressing their activity and promoting regulatory T cell (Treg) function, thereby enabling immune escape. CTLA-4, another critical checkpoint protein, inhibits T cell activation and supports immunosuppression. These proteins are targeted by immune checkpoint inhibitors to restore anti-tumor immunity.",
        "Tumors commonly exploit immune checkpoint proteins such as **PD-1 (programmed death protein 1)**, **PD-L1 (programmed cell death ligand 1)**, and **CTLA-4 (cytotoxic T-lymphocyte-associated protein 4)** to evade immune responses. The PD-1/PD-L1 interaction suppresses effector T-cell activity and enhances immunosuppressive regulatory T cells (Tregs), enabling immune escape. CTLA-4 similarly inhibits T-cell activation, allowing tumor growth. These proteins are key therapeutic targets for immune checkpoint inhibitors.",
        "Tumors frequently exploit several key immune checkpoint proteins to evade detection and destruction by the immune system. The primary proteins involved include:\n\n1. **Programmed Death Protein 1 (PD-1)**: Found on T cells, PD-1 interacts with its ligand, PD-L1, which is often expressed by cancer cells. This interaction sends a signal that inhibits T cell activity, effectively \"turning off\" the immune response against the tumor.\n\n2. **Programmed Death Ligand 1 (PD-L1)**: Expressed on the surface of some cancer cells, PD-L1 binds to PD-1 on T cells, leading to immune suppression and allowing tumors to grow uncontrollably.\n\n3. **Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4)**: Another checkpoint protein on T cells, CTLA-4 interacts with its ligands on antigen-presenting cells. This interaction suppresses the activation of T cells, reducing their ability to target and destroy cancer cells.\n\nBy targeting these checkpoints, therapies known as immune checkpoint inhibitors can block these interactions, restoring the immune system\u0027s ability to recognize and attack cancer cells.",
        "Tumors frequently exploit several key immune checkpoint proteins to evade immune responses. These include:\n\n1. **PD-1 (Programmed Death Protein 1)**: Found on T cells, PD-1 interacts with PD-L1 on other cells, sending a signal that inhibits T cell activity and prevents them from attacking cancer cells.\n\n2. **PD-L1 (Programmed Cell Death Ligand 1)**: Expressed by cancer cells, PD-L1 binds to PD-1 on T cells, tricking the immune system into sparing the tumor cells.\n\n3. **CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4)**: This protein inhibits T cell activation by binding to specific molecules on antigen-presenting cells, thereby reducing the immune response against tumors.\n\nThese proteins create an immunosuppressive environment that allows tumors to grow unchecked by suppressing the body\u0027s immune defenses.",
        "Tumors primarily exploit PD-1 and PD-L1 immune checkpoint proteins to evade immune responses, inhibiting effector T cell activity while enhancing immunosuppressive regulatory T cell function, thus facilitating their growth and progression. CTLA-4 is also implicated, though with less consensus in this context. These proteins are targets for immune checkpoint inhibitors aimed at restoring the immune system\u0027s ability to attack cancer cells.",
        "Tumors often exploit immune checkpoint proteins to evade immune responses by using molecules like CTLA-4, PD-1, and PD-L1. These proteins are a crucial part of the immune system\u0027s regulation, where their normal function is to prevent overactivation and maintain tolerance. In cancer, however, cells exploit these pathways, particularly the PD-1/PD-L1 axis, to inhibit the activity of effector T cells and promote the function of regulatory T cells that suppress the immune response. This allows cancer cells to avoid detection and destruction by the immune system, facilitating cancer growth and progression. By targeting these pathways, immune checkpoint inhibitors can help restore the immune system\u0027s ability to attack cancer cells.",
        "Tumors often exploit several immune checkpoint proteins to evade immune responses, primarily PD-1 (programmed death protein 1), PD-L1 (programmed cell death ligand 1), and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). These checkpoint molecules have immunosuppressive functions that cancer cells leverage to inhibit the activity of effector T cells and enhance regulatory T cell function. By engaging these pathways, particularly the PD-1/PD-L1 axis, cancer cells can escape immune surveillance, allowing them to grow and progress uncontrollably. Immune checkpoint inhibitors work by blocking these proteins, thereby restoring the immune system\u0027s ability to recognize and attack cancer cells.",
        "Tumors commonly exploit PD-1, PD-L1, and CTLA-4 immune checkpoint proteins to evade immune responses. Notably, the PD-1/PD-L1 axis plays a significant role in inhibiting effector T cells and enhancing regulatory T cells, thereby facilitating tumor growth. These proteins are targeted by immune checkpoint inhibitors, which have shown therapeutic success in restoring anti-tumor immunity, particularly in treating cancers like melanoma, lung, and kidney cancers."
      ],
      "exact_answer": [
        [
          "PD-1/PD-L1",
          "PD-1",
          "PD-L1",
          "PD-1 (Programmed Cell Death Protein 1)",
          "PD-L1 (Programmed Death-Ligand 1)",
          "PD-L2 (Programmed Death-Ligand 2)"
        ],
        [
          "CTLA-4",
          "CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4)"
        ],
        [
          "TIM-3",
          "TIM Gene Family (T-cell Immunoglobulin and Mucin-domain containing proteins)",
          "T Cell Immunoglobulin and Mucin Domain-Containing Protein 3 (TIM-3)"
        ],
        [
          "TIGIT"
        ],
        [
          "LAG-3",
          "Lymphocyte-Activation Gene 3 (LAG-3)"
        ]
      ]
    },
    {
      "body": "How many individuals were selected for generation of whole-genome sequencing data in the Mexico City Prospective Study?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37821707"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 319,
          "text": "The Mexico City Prospective Study is a prospective cohort of more than 150,000 adults recruited two decades ago from the urban districts of Coyoacán and Iztapalapa in Mexico City1. Here we generated genotype and exome-sequencing data for all individuals and whole-genome sequencing data for 9,950 selected individuals. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821707"
        }
      ],
      "id": "67e6c9d518b1e36f2e0000cd",
      "ideal_answer": [
        "9,950 selected individuals.",
        "In the Mexico City Prospective Study, whole-genome sequencing data was generated for 9,950 selected individuals.",
        "9,950 individuals were selected for generation of whole-genome sequencing data in the Mexico City Prospective Study.",
        "The study selected 9,950 individuals for the generation of whole-genome sequencing data in the Mexico City Prospective Study.",
        "The study generated whole-genome sequencing data for 9,950 selected individuals.",
        "A total of 9,950 individuals were selected for whole-genome sequencing in this study.",
        "9,950 individuals were selected for the generation of whole-genome sequencing data in the Mexico City Prospective Study, a subset of the over 150,000 adults involved in the broader study.",
        "According to consistent reports, approximately 9950 individuals were selected for the generation of whole-genome sequencing data in the Mexico City Prospective Study, providing a substantial dataset for genetic analyses and insights into the population\u0027s genomic landscape.",
        "The whole-genome sequencing data were generated for 9,950 individuals from the Mexico City Prospective Study.",
        "The Mexico City Prospective Study involved the whole-genome sequencing of 9,950 selected individuals. This study revealed high levels of relatedness among the participants, substantial heterogeneity in ancestry composition, and identified ancestry-specific allele frequencies at 142 million genomic variants, providing valuable resources for future genetic studies in biomedicine.",
        "9,950 individuals were selected for whole‐genome sequencing in the Mexico City Prospective Study.",
        "The Mexico City Prospective Study selected 9,950 individuals for whole-genome sequencing data generation.",
        "9,950 selected individuals were selected for generation of whole-genome sequencing data in the Mexico City Prospective Study.",
        "Whole-genome sequencing data was generated for 9,950 selected individuals.",
        "In the Mexico City Prospective Study, whole-genome sequencing data was generated for 9,950 selected individuals from the original cohort of more than 150,000 adults recruited from Coyoacán and Iztapalapa districts in Mexico City.",
        "9,950 individuals were selected for whole-genome sequencing data in the Mexico City Prospective Study, which is a subset of the larger cohort of over 150,000 adults.",
        "The Mexico City Prospective Study, which involves a cohort of over 150,000 adults from urban districts in Mexico City, has generated extensive genetic data. Specifically, genotype and exome-sequencing data were produced for all participants, while a subset was selected for more comprehensive analysis. For the purpose of whole-genome sequencing, 9,950 individuals were chosen from the larger group, allowing for in-depth examination of their genetic information within the context of these studies.",
        "In the Mexico City Prospective Study, which comprised over 150,000 adults from Mexico City\u0027s urban districts, whole-genome sequencing data was generated for 9,950 selected individuals, while genotype and exome-sequencing data were collected for the entire cohort.",
        "The Mexico City Prospective Study is a large cohort involving over 150,000 adults recruited from two urban districts in Mexico City. While genotype and exome-sequencing data were generated for all participants, whole-genome sequencing data was specifically generated for a subset of 9,950 selected individuals to enable deeper genomic analysis.",
        "The Mexico City Prospective Study selected 9,950 individuals for the generation of whole-genome sequencing data.",
        "9,950 individuals were selected for whole-genome sequencing data.",
        "9,950 individuals were selected for whole-genome sequencing data generation in the Mexico City Prospective Study.",
        "9,950 individuals were selected for whole-genome sequencing.",
        "The study involved over 150,000 adults from urban districts in Mexico City, with 9,950 participants having their whole-genome sequencing data generated.",
        "In the Mexico City Prospective Study, whole-genome sequencing data were generated for 9,950 selected individuals. This study is a prospective cohort involving more than 150,000 adults from urban districts in Mexico City.",
        "In the Mexico City Prospective Study, 9,950 individuals were selected for the generation of whole-genome sequencing data.",
        "9,950 individuals were selected for whole-genome sequencing data in the study.",
        "9,950 individuals were selected for the generation of whole-genome sequencing data in the Mexico City Prospective Study, which was a subset of an initial cohort of more than 150,000 adults.",
        "The Mexico City Prospective Study, a large-scale prospective cohort study, initially recruited over 150,000 adults from urban areas in Mexico City, focusing on residents from the districts of Coyoacán and Iztapalapa. As part of the comprehensive genetic analysis, whole-genome sequencing data was generated for a subset of 9,950 individuals from this cohort. This subset represents a significant sample intended to provide detailed insights into genetic variations and their potential associations with health outcomes in the study population.",
        "Whole-genome sequencing data was generated for 9,950 selected individuals in the Mexico City Prospective Study.",
        "According to the Mexico City Prospective Study, 9,950 individuals were selected for generation of whole-genome sequencing data.",
        "In the Mexico City Prospective Study, which is a prospective cohort of more than 150,000 adults recruited from the urban districts of Coyoacán and Iztapalapa in Mexico City, whole-genome sequencing data was generated for 9,950 selected individuals. This was part of a larger genetic analysis effort that also included genotype and exome-sequencing data for all individuals in the cohort.",
        "In the Mexico City Prospective Study, which involves a cohort of over 150,000 adults recruited from urban districts in Mexico City, researchers generated genotype and exome-sequencing data for all participants. Additionally, whole-genome sequencing was conducted on a subset of 9,950 selected individuals within this study.",
        "9,950 individuals were selected for the generation of whole-genome sequencing data in the Mexico City Prospective Study, which comprises a subset of its over 150,000 adult cohort.",
        "In the Mexico City Prospective Study, 9,950 individuals were selected for whole-genome sequencing. This study involved more than 150,000 adults recruited from urban districts of Coyoacán and Iztapalapa in Mexico City over two decades ago. Genotype and exome-sequencing data were generated for all participants, with a subset of 9,950 undergoing additional whole-genome sequencing to provide deeper genetic insights.",
        "9950 individuals were selected for whole-genome sequencing.",
        "9,950",
        "The Mexico City Prospective Study generated whole-genome sequencing data for 9,950 selected individuals from a larger cohort of more than 150,000 adults recruited from urban districts in Mexico City.",
        "In the Mexico City Prospective Study, whole-genome sequencing data was generated for 9,950 selected individuals out of a cohort of more than 150,000 adults."
      ],
      "exact_answer": [
        [
          "9,950"
        ]
      ]
    },
    {
      "body": "What are features of Samter\u0027s Triad?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37062559",
        "http://www.ncbi.nlm.nih.gov/pubmed/33525013",
        "http://www.ncbi.nlm.nih.gov/pubmed/30884882",
        "http://www.ncbi.nlm.nih.gov/pubmed/30847401",
        "http://www.ncbi.nlm.nih.gov/pubmed/31599440",
        "http://www.ncbi.nlm.nih.gov/pubmed/17702319",
        "http://www.ncbi.nlm.nih.gov/pubmed/29642688",
        "http://www.ncbi.nlm.nih.gov/pubmed/27071444",
        "http://www.ncbi.nlm.nih.gov/pubmed/35937735",
        "http://www.ncbi.nlm.nih.gov/pubmed/26947537",
        "http://www.ncbi.nlm.nih.gov/pubmed/25418960",
        "http://www.ncbi.nlm.nih.gov/pubmed/3069289",
        "http://www.ncbi.nlm.nih.gov/pubmed/25516728",
        "http://www.ncbi.nlm.nih.gov/pubmed/23782034",
        "http://www.ncbi.nlm.nih.gov/pubmed/20852485",
        "http://www.ncbi.nlm.nih.gov/pubmed/26753248",
        "http://www.ncbi.nlm.nih.gov/pubmed/25197914",
        "http://www.ncbi.nlm.nih.gov/pubmed/32270937",
        "http://www.ncbi.nlm.nih.gov/pubmed/19995143",
        "http://www.ncbi.nlm.nih.gov/pubmed/28124651",
        "http://www.ncbi.nlm.nih.gov/pubmed/17244950"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 931,
          "offsetInEndSection": 1170,
          "text": "CONCLUSION: Our study revealed the following: Samter\u0027s triad was present in 6.9% of participants with chronic rhinosinusitis; the greatest prevalence of chronic rhinosinusitis with nasal polyps was observed among those older than 50 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37062559"
        },
        {
          "offsetInBeginSection": 1049,
          "offsetInEndSection": 1223,
          "text": "Patients with asthma but especially with Samter\u0027s triad are significantly more likely to have a recurrence of nasal polyps and undergo a second surgery following recurrence. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33525013"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "The correlation between aspirin sensitivity, asthma, and nasal polyposis was recognized in the early 20th century. Today, this classic triad of symptoms, eponymously named Samter\u0027s Triad, is known as aspirin exacerbated respiratory disease (AERD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30884882"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Samter\u0027s Triad is a disorder characterized by chronic rhinosinusitis (CRS) with nasal polyps (NPs), asthma, and intolerance to cyclooxygenase-1 inhibitors. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30847401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "OBJECTIVE: Samter\u0027s triad is the combination of asthma, aspirin sensitization, and nasal polyposis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31599440"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Samter\u0027s Triad is a disorder characterized by chronic rhinosinusitis (CRS) with nasal polyps (NPs), asthma, and intolerance to cyclooxygenase-1 inhibitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30847401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 298,
          "text": "We conducted a retrospective study to determine the prevalence of Samter\u0027s triad (nasal polyps, asthma, and aspirin sensitivity) in 208 consecutively presenting patients who had undergone functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis from September 2001 through August 2003.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702319"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Samter\u0027s triad (ST) is a well-known disease characterized by the triad of bronchial asthma, nasal polyps, and aspirin intolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642688"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 314,
          "text": "OBJECTIVE: Aspirin-exacerbated respiratory disease (AERD) represents a severe form of chronic rhinosinusitis (CRS) characterized by nasal polyposis, bronchial asthma, and aspirin intolerance. This syndrome, known as Samter\u0027s triad, is more difficult to manage than routine CRS and poses a challenge to the treating",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27071444"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Samter\u0027s triad, also known as aspirin-exacerbated respiratory disease, is characterized by nasal polyposis, bronchial asthma, and aspirin intolerance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35937735"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "There is a well-recognized association of aspirin sensitivity, aspirin-induced asthma, nasal polyposis or sinusitis, known as Samter\u0027s triad",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20852485"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "BACKGROUND: Samter\u0027s triad is a well described condition manifesting as chronic rhinosinusitis with nasal polyposis, asthma and aspirin intolerance in a non-atopic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "OBJECTIVE: Samter\u0027s triad is the combination of asthma, aspirin sensitization, and nasal polyposis. Few data ar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31599440"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Samter\u0027s Triad is a disorder characterized by chronic rhinosinusitis (CRS) with nasal polyps (NPs), asthma,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30847401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "The historic triad of bronchial asthma, nasal polyposis, and intolerance to aspirin and related chemicals, recently designated as Samter\u0027s syndrome, is an inflammatory condition of unknown etiology and pathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3069289"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "BACKGROUND: Aspirin-exacerbated respiratory disease (AERD), also known as Samter\u0027s triad, is a clinical syndrome which consists of aspirin (ASA) intolerance, chronic rhinosinusitis with nasal polyposis, and intrinsic bronchial asthma (Press Med 119:48-51, 1922).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516728"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "There is a well-recognized association of aspirin sensitivity, aspirin-induced asthma, nasal polyposis or sinusitis, known as Samter\u0027s triad.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20852485"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 211,
          "text": "Samter\u0027s triad is a subset of AERD where adult patients develop nasal polyps, asthma, and sensitivity to aspirin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23782034"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "Aspirin-exacerbated respiratory disease (AERD), formerly known as Samter\u0027s Triad, is a syndrome of airway inflammation characterized by rhinosinusitis with polyposis, asthma, and nonsteroidal anti-inflammatory drug (NSAID) intolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26753248"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 174,
          "text": " Samter\u0027s triad is a well described condition manifesting as chronic rhinosinusitis with nasal polyposis, asthma and aspirin intolerance in a non-atopic individual",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "NSAID-Exacerbated respiratory disease (also known as Samter\u0027s or Widal\u0027s triad, aspirin-exacerbated respiratory disease) is characte- rized by asthma, nasal polyposis and hypersensitivity to NSAIDs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "text": "BACKGROUND: Aspirin-exacerbated respiratory disease (AERD), also known as Samter\u0027s triad, is characterized by asthma, recurrent nasal polyps, and by allergic-like reactions to aspirin and other nonsteroidal anti-inflammatory drugs, although it is not a true immunoglobulin E (IgE)-media",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25197914"
        },
        {
          "offsetInBeginSection": 268,
          "offsetInEndSection": 381,
          "text": "Samter\u0027s triad consists of nasal polyps, asthma, and aspirin (or nonsteroidal anti-inflammatory drug) sensitivity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26947537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Samter\u0027s triad (ST) is a well-known disease characterized by the triad of bronchial asthma, nasal polyps, and aspirin intolerance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642688"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "Aspirin-exacerbated respiratory disease (AERD), formerly known as Samter\u0027s Triad, is a syndrome of airway inflammation characterized by rhinosinusitis with polyposis, asthma, and nonsteroidal anti-inflammatory drug (NSAID) intolerance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26753248"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "BACKGROUND: Samter\u0027s triad is a well described condition manifesting as chronic rhinosinusitis with nasal polyposis, asthma and aspirin intolerance in a non-atopi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "BACKGROUND: Aspirin-exacerbated respiratory disease (AERD), also known as Samter\u0027s triad, is characterized by asthma, recurrent nasal polyps, and by allergic-like reactions to aspirin and other nonsteroidal anti-inflammatory drugs, although it is not a true immunoglobulin E (IgE)-medi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25197914"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 395,
          "text": "A certain subgroup of nasal polyposis is known as Aspirin Exacerbated Respiratory Disease (AERD), previously called Samter\u0027s Triad or aspirin triad, comprising polyposis, asthma, and aspirin hypersensitivity and makes up almost 10% of cases of NP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19995143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "The correlation between aspirin sensitivity, asthma, and nasal polyposis was recognized in the early 20th century. Today, this classic triad of symptoms, eponymously named Samter\u0027s Triad, is known as aspirin exacerbated respiratory disease (AERD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30884882"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 419,
          "text": "Aspirin-exacerbated respiratory disease (AERD) is a late onset condition characterized by the Samter triad (aspirin sensitivity [as well as sensitivity to any nonselective cyclooxygenase inhibitor], nasal polyps, asthma) and additional features, including eosinophilic chronic rhinosinusitis, hypereosinophilia, anosmia, frequent absence of atopy, and, intolerance to ingestion of red wine and other alcoholic beverages",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28124651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 420,
          "text": "Aspirin-exacerbated respiratory disease (AERD) is a late onset condition characterized by the Samter triad (aspirin sensitivity [as well as sensitivity to any nonselective cyclooxygenase inhibitor], nasal polyps, asthma) and additional features, including eosinophilic chronic rhinosinusitis, hypereosinophilia, anosmia, frequent absence of atopy, and, intolerance to ingestion of red wine and other alcoholic beverages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28124651"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 391,
          "text": "The full clinical picture reveals a classic triad of symptoms (Samters Triad): aspirin induced bronchial asthma (with severe acute asthma attacks), aspirin-sensitivity and chronic rhinosinusitis with nasal polyps.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17244950"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "BACKGROUND: Aspirin-exacerbated respiratory disease (AERD), also known as Samter\u0027s triad, is a clinical syndrome which consists of aspirin (ASA) intolerance, chronic rhinosinusitis with nasal polyposis, and intrinsic bronchial asthma (Press Med 119:4",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516728"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 261,
          "text": "Aspirin-exacerbated respiratory disease (AERD), also known as Samter\u0027s triad, is a clinical syndrome which consists of aspirin (ASA) intolerance, chronic rhinosinusitis with nasal polyposis, and intrinsic bronchial asthma (Press Med 119:48-51, 1922)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516728"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 297,
          "text": "Aspirin-exacerbated respiratory disease (AERD), also known as Samter\u0027s triad, is characterized by asthma, recurrent nasal polyps, and by allergic-like reactions to aspirin and other nonsteroidal anti-inflammatory drugs, although it is not a true immunoglobulin E (IgE)-mediated allergy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25197914"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "BACKGROUND: Samter\u0027s triad is a well described condition manifesting as chronic rhinosinusitis with nasal polyposis, asthma and aspirin intolerance in a non-atopic ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "There is a well-recognized association of aspirin sensitivity, aspirin-induced asthma, nasal polyposis or sinusitis, known as Samter\u0027s triad. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20852485"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Samter\u0027s triad (ST) is a well-known disease characterized by the triad of bronchial asthma, nasal polyps, and aspirin intolerance. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29642688"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "The historic triad of bronchial asthma, nasal polyposis, and intolerance to aspirin and related chemicals, recently designated as Samter\u0027s syndrome, is an inflammatory condition of unknown etiology and pathogenesis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3069289"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 98,
          "text": " Samter\u0027s triad is the combination of asthma, aspirin sensitization, and nasal polyposis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31599440"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "ABSTRACT: Samter triad is a chronic condition where patients suffer from intolerance to aspirin, recurring nasal polyposis and bronchi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34622875"
        },
        {
          "offsetInBeginSection": 66,
          "offsetInEndSection": 127,
          "text": "Samter\u0027s triad (nasal polyps, asthma, and aspirin sensitivity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702319"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Aspirin-exacerbated respiratory disease (AERD) is a late onset condition characterized by the Samter triad (aspirin sensitivity [as well as sensitivity to any nonselective cyclooxygenase inhibitor], nasal polyps, asthma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28124651"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 356,
          "text": "A certain subgroup of nasal polyposis is known as Aspirin Exacerbated Respiratory Disease (AERD), previously called Samter\u0027s Triad or aspirin triad, comprising polyposis, asthma, and aspirin hypersensitivity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19995143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "OBJECTIVE: Aspirin-exacerbated respiratory disease (AERD) represents a severe form of chronic rhinosinusitis (CRS) characterized by nasal polyposis, bronchial asthma, and aspirin intolerance. This syndrome, known as Samter\u0027s triad, is more difficult to manage than ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27071444"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "NSAID-Exacerbated respiratory disease (also known as Samter\u0027s or Widal\u0027s triad, aspirin-exacerbated respiratory disease) is characte- rized by asthma, nasal polyposis and hypersensitivity to NSAIDs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "BACKGROUND: Aspirin-exacerbated respiratory disease (AERD), also known as Samter\u0027s triad, is a clinical syndrome which consists of aspirin (ASA) intolerance, chronic rhinosinusitis with nasal polyposis, and intrinsic bronchial asthma (Press Med 119",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516728"
        }
      ],
      "type": "list",
      "id": "67e6c6fa18b1e36f2e0000cb",
      "ideal_answer": [
        "Samter\u0027s triad is the combination of asthma, aspirin sensitization, and nasal polyposis."
      ],
      "exact_answer": [
        [
          "asthma"
        ],
        [
          "aspirin sensitization"
        ],
        [
          "nasal polyposis"
        ]
      ]
    },
    {
      "body": "What is the mode of action of Bempedoic acid?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34431634",
        "http://www.ncbi.nlm.nih.gov/pubmed/35143133",
        "http://www.ncbi.nlm.nih.gov/pubmed/32532162",
        "http://www.ncbi.nlm.nih.gov/pubmed/33966814",
        "http://www.ncbi.nlm.nih.gov/pubmed/35900636",
        "http://www.ncbi.nlm.nih.gov/pubmed/33847313",
        "http://www.ncbi.nlm.nih.gov/pubmed/30586346",
        "http://www.ncbi.nlm.nih.gov/pubmed/37477389",
        "http://www.ncbi.nlm.nih.gov/pubmed/33818688",
        "http://www.ncbi.nlm.nih.gov/pubmed/39295675",
        "http://www.ncbi.nlm.nih.gov/pubmed/38545803",
        "http://www.ncbi.nlm.nih.gov/pubmed/36386319",
        "http://www.ncbi.nlm.nih.gov/pubmed/34887111",
        "http://www.ncbi.nlm.nih.gov/pubmed/34909677",
        "http://www.ncbi.nlm.nih.gov/pubmed/33502687",
        "http://www.ncbi.nlm.nih.gov/pubmed/35929170",
        "http://www.ncbi.nlm.nih.gov/pubmed/33399194",
        "http://www.ncbi.nlm.nih.gov/pubmed/36876740",
        "http://www.ncbi.nlm.nih.gov/pubmed/32463301",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025951",
        "http://www.ncbi.nlm.nih.gov/pubmed/39598495",
        "http://www.ncbi.nlm.nih.gov/pubmed/35884822",
        "http://www.ncbi.nlm.nih.gov/pubmed/35533049",
        "http://www.ncbi.nlm.nih.gov/pubmed/34435333",
        "http://www.ncbi.nlm.nih.gov/pubmed/27892461",
        "http://www.ncbi.nlm.nih.gov/pubmed/39000046",
        "http://www.ncbi.nlm.nih.gov/pubmed/36889490",
        "http://www.ncbi.nlm.nih.gov/pubmed/37585218"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 528,
          "offsetInEndSection": 610,
          "text": "bempedoic acid, a small oral molecule that inhibits hepatic cholesterol synthesis,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431634"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 516,
          "text": "Bempedoic acid is a new oral cholesterol-lowering medication that reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase enzyme. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35143133"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 242,
          "text": "ome patients. Bempedoic acid is a small molecule adenosine triphosphate-citrate lyase inhibitor indicated for the treatment of adults with hyperch",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32532162"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33966814"
        },
        {
          "offsetInBeginSection": 298,
          "offsetInEndSection": 452,
          "text": "-reactive protein. Bempedoic acid antagonizes ATP citrate-lyase, a cytosolic enzyme upstream of HMGCoA reductase which is the rate-limiting step of choles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35900636"
        },
        {
          "offsetInBeginSection": 615,
          "offsetInEndSection": 882,
          "text": "Bempedoic acid (BA), a novel cholesterol-lowering agent, targets adenosine triphosphate (ATP)-citrate lyase to reduce low-density lipoprotein (LDL) cholesterol and has shown potential in managing NAFLD by decreasing liver fat accumulation and improving lipid profiles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39295675"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 643,
          "text": "Bempedoic acid is a new oral cholesterol-lowering medication that reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase enzyme. Because this medication is a prodrug that is selectively activated in the liver, it is deprived of any muscular adverse effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35143133"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "text": "Bempedoic acid is a new cholesterol-lowering drug, which has recently received US FDA and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation via downregulation of ATP-citrate lyase and upregulation of AMP-activated protein kinase (AMPK).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36386319"
        },
        {
          "offsetInBeginSection": 555,
          "offsetInEndSection": 675,
          "text": "pe 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35929170"
        },
        {
          "offsetInBeginSection": 698,
          "offsetInEndSection": 901,
          "text": " further address the needs of this population. Bempedoic acid is a first-in-class oral adenosine triphosphate (ATP) citrate lyase inhibitor being evaluated as an additional treatment option for high-risk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33399194"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36876740"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 515,
          "text": "Bempedoic acid is a new oral cholesterol-lowering medication that reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase enzyme.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35143133"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Bempedoic acid (ETC-1002) is an oral, once-daily, small molecule with a half-life of 15-24 h. It is responsible for the inhibition of ATP citrate lyase (ACLY), a cytosolic enzyme upstream of HMG-CoA reductase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33847313"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Bempedoic acid (ETC-1002) is a novel, first-in-class, oral, small molecule that inhibits cholesterol biosynthesis in the same pathway as statins, thereby lowering low-density lipoprotein cholesterol (LDL-C) by upregulating LDL receptors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32463301"
        },
        {
          "offsetInBeginSection": 753,
          "offsetInEndSection": 908,
          "text": "Bempedoic acid-CoA is a potent and selective inhibitor of ATP citrate lyase (ACL), a key enzyme in the biosynthetic pathway of cholesterol and fatty acids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39598495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Bempedoic acid is a new, first-in-class oral ATP-citrate lyase (ACLY) inhibitor that has to be converted to its CoA thioester before it inhibits ACLY.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025951"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Bempedoic acid (BemA) is an ATP-citrate lyase (ACLY) inhibitor used to treat hypercholesterolemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35884822"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 342,
          "text": "Bempedoic acid is a novel hypolipidemic drug that inhibits the enzymatic activity of ATP citrate lyase in the cholesterol synthesis pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533049"
        },
        {
          "offsetInBeginSection": 606,
          "offsetInEndSection": 713,
          "text": "Bempedoic acid (ETC-1002) is a new inhibitor of cholesterol synthesis that targets ATP citrate lyase (ACL).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33502687"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "PURPOSE OF REVIEW: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30586346"
        },
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 379,
          "text": "Bempedoic acid is a prodrug rapidly converted in the liver to a coenzyme A derivate, ETC-1200-CoA, by an endogenous liver very long-chain acyl-CoA synthetase-1 (ACSVL1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33847313"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "Bempedoic acid is an adenosine triphosphate citrate lyase inhibitor that lowers low-density lipoprotein cholesterol by inhibiting cholesterol synthesis and upregulating hepatic low-density lipoprotein receptor expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37477389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Bempedoic acid is a new, first-in-class oral ATP-citrate lyase (ACLY) inhibitor that has to be converted to its CoA thioester before it inhibits ACLY. This conversion only occurs in the liver and not in skeletal muscle",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025951"
        },
        {
          "offsetInBeginSection": 290,
          "offsetInEndSection": 537,
          "text": "ercholesterolemia.RECENT FINDINGS: The liver-specific activation of bempedoic acid inhibits ACLY, a key enzyme linking glucose catabolism to lipogenesis by catalyzing the formation of acetyl-CoA from mitochondrial-derived citrate for de novo synth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30586346"
        },
        {
          "offsetInBeginSection": 797,
          "offsetInEndSection": 991,
          "text": "Bempedoic acid inhibits the enzyme adenosine triphosphate (ATP)-citrate lyase, which lies two steps upstream from β-hydroxy β-methylglutaryl-CoA reductase in the cholesterol biosynthesis pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33818688"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33966814"
        },
        {
          "offsetInBeginSection": 664,
          "offsetInEndSection": 843,
          "text": "Bempedoic acid, via its active coenzyme A (CoA) form, inhibits adenosine triphosphate (ATP)-citrate lyase, and reduces hepatic cholesterol synthesis through the mevalonate pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34435333"
        },
        {
          "offsetInBeginSection": 606,
          "offsetInEndSection": 711,
          "text": "Bempedoic acid (ETC-1002) is a new inhibitor of cholesterol synthesis that targets ATP citrate lyase (ACL",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33502687"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 275,
          "text": "c steatosis). Bempedoic acid is an ATP:citrate lyase inhibitor that promotes a dual inhibition of the synthesis of cholesterol a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34887111"
        },
        {
          "offsetInBeginSection": 367,
          "offsetInEndSection": 629,
          "text": "Bempedoic acid (ETC-1002), a ATP citrate lyase (ACLY) inhibitor that lowers the LDL cholesterol was recently approved by US FDA for the treatment of heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34909677"
        },
        {
          "offsetInBeginSection": 634,
          "offsetInEndSection": 754,
          "text": "Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35929170"
        },
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 487,
          "text": "Bempedoic acid is a prodrug rapidly converted in the liver to a coenzyme A derivate, ETC-1200-CoA, by an endogenous liver very long-chain acyl-CoA synthetase-1 (ACSVL1). Since ACSVL1 is not present in the skeletal muscle, less risk of myalgia symptoms and myopathy is expected.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33847313"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 514,
          "text": "Bempedoic acid is a new oral cholesterol-lowering medication that reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase enzyme",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35143133"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 241,
          "text": "ome patients. Bempedoic acid is a small molecule adenosine triphosphate-citrate lyase inhibitor indicated for the treatment of adults with hyperc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32532162"
        },
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 377,
          "text": "Bempedoic acid is a prodrug rapidly converted in the liver to a coenzyme A derivate, ETC-1200-CoA, by an endogenous liver very long-chain acyl-CoA synthetase-1 (ACSVL1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33847313"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 276,
          "text": "c steatosis). Bempedoic acid is an ATP:citrate lyase inhibitor that promotes a dual inhibition of the synthesis of cholesterol an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34887111"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 518,
          "text": "Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27892461"
        },
        {
          "offsetInBeginSection": 634,
          "offsetInEndSection": 753,
          "text": "Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35929170"
        },
        {
          "offsetInBeginSection": 606,
          "offsetInEndSection": 714,
          "text": "Bempedoic acid (ETC-1002) is a new inhibitor of cholesterol synthesis that targets ATP citrate lyase (ACL). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33502687"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "PURPOSE OF REVIEW: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL ch",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30586346"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 400,
          "text": "c steatosis). Bempedoic acid is an ATP:citrate lyase inhibitor that promotes a dual inhibition of the synthesis of cholesterol and fatty acids. However, its effect in the prevention / treatment of hepatic steatosis and hypertriglyceridemia has not been ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34887111"
        },
        {
          "offsetInBeginSection": 298,
          "offsetInEndSection": 626,
          "text": "-reactive protein. Bempedoic acid antagonizes ATP citrate-lyase, a cytosolic enzyme upstream of HMGCoA reductase which is the rate-limiting step of cholesterol biosynthesis. Bempedoic acid is a pro-drug converted to its active metabolite by very-long-chain acyl-CoA synthetase 1 which is present mostly in the liver and absent i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35900636"
        },
        {
          "offsetInBeginSection": 726,
          "offsetInEndSection": 905,
          "text": "Bempedoic acid inhibits ATP-citrate lyase, reducing cholesterol and fatty acid synthesis while activating AMP-activated protein kinase to suppress gluconeogenesis and lipogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39000046"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 962,
          "text": "Bempedoic acid, the first in-class inhibitor of ATP-citrate lyase presents a new approach to lipid-lowering therapy. By reducing the endogenous production of cholesterol, upstream of the rate-limiting enzyme HMG-CoA-reductase, i.e., the target of statins, bempedoic acid reduces circulating plasma concentrations of low-density lipoprotein cholesterol (LDL-C), and major adverse CVD events (MACE).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36889490"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 364,
          "text": "ry cascade. Bempedoic acid, an ACLY inhibitor, significantly reduces atherogenic lipid markers, including low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, and apoli",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37585218"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 255,
          "text": " Bempedoic acid is a small molecule adenosine triphosphate-citrate lyase inhibitor indicated for the treatment of adults with hypercholesterolemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32532162"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that reduces levels of low-density lipoprotein-cholesterol (LDL-C) in the plasma by inhibition of cholesterol synthesis in hepatic cells, which leads to up-regulation of hepatic LDL receptors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34393074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "PURPOSE OF REVIEW: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30586346"
        },
        {
          "offsetInBeginSection": 367,
          "offsetInEndSection": 627,
          "text": "Bempedoic acid (ETC-1002), a ATP citrate lyase (ACLY) inhibitor that lowers the LDL cholesterol was recently approved by US FDA for the treatment of heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34909677"
        },
        {
          "offsetInBeginSection": 298,
          "offsetInEndSection": 451,
          "text": "-reactive protein. Bempedoic acid antagonizes ATP citrate-lyase, a cytosolic enzyme upstream of HMGCoA reductase which is the rate-limiting step of chole",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35900636"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 341,
          "text": "Bempedoic acid is a novel hypolipidemic drug that inhibits the enzymatic activity of ATP citrate lyase in the cholesterol synthesis pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533049"
        }
      ],
      "type": "factoid",
      "id": "67e014c918b1e36f2e000068",
      "ideal_answer": [
        "Bempedoic acid is a new oral cholesterol-lowering medication that reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase enzyme.",
        "Bempedoic acid is a small molecule adenosine triphosphate-citrate lyase (ACL) inhibitor indicated for the treatment of adults with hypercholesterolemia.",
        "Bempedoic acid is an antisense oligonucleotide that inhibits the FPN2 protein, a key regulator of histone H3.",
        "Bempedoic acid lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting ATP citrate lyase.",
        "bempedoic acid inhibits atp citrate lyase (acly), a cytosolic enzyme upstream of hmg-coa reductase, which leads to decreased cholesterol synthesis and increased expression of ldl receptors, ultimately lowering ldl-c plasma levels, while also upregulating amp-activated protein kinase (ampk) and improving insulin sensitivity.",
        "Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearance.",
        "Bempedoic acid acts as an ATP citrate lyase (ACLY) inhibitor, reducing cholesterol synthesis by inhibiting the enzyme upstream of HMG-CoA reductase.",
        "Bempedoic acid acts through the inhibition of ATP citrate lyase (ACLY), activation of the peroxisome proliferator activated nuclear receptor (PPARα), and upregulation of LDL receptors.",
        "Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL), which is an enzyme involved in the cholesterol biosynthesis pathway, leading to reduced levels of low-density lipoprotein (LDL) cholesterol.",
        "Bempedoic acid works by inhibiting ATP-citrate lyase, reducing cholesterol production and increasing LDL receptor activity.",
        "Bempedoic acid is a metabolic agent that targets lipid metabolism by inhibiting ATP citrate lyase (ACL), an enzyme crucial for cholesterol synthesis. By reducing ACL activity, Bempedoic acid decreases the liver\\\u0027s production of cholesterol, thereby helping to lower overall cholesterol levels in the body.",
        "Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence.",
        "Bempedoic acid inhibits the ATP-citrate lyase enzyme to reduce hepatic cholesterol synthesis.",
        "Bempedoic acid is a small oral molecule that inhibits the enzyme ATP-citrate lyase, which is involved in hepatic cholesterol synthesis, thereby reducing the production of cholesterol in the liver, making it a potential therapeutic intervention for hypercholesterolemia.",
        "Bempedoic acid works by lowering cholesterol through the inhibition of the ATP-citrate lyase enzyme, which reduces hepatic cholesterol synthesis.",
        "Bempedoic acid is a small oral molecule that inhibits hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase.",
        "Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL), which is an enzyme involved in the cholesterol biosynthesis pathway, leading to reduced cholesterol synthesis and increased expression of LDL receptors.",
        "Bempedoic acid inhibits hepatic cholesterol synthesis by targeting adenosine triphosphate (ATP)-citrate lyase, a key enzyme in the cholesterol biosynthesis pathway. This oral medication reduces cholesterol production in the liver, lowering circulating cholesterol levels.",
        "Bempedoic acid lowers cholesterol by inhibiting hepatic adenosine triphosphate (ATP)-citrate lyase, an enzyme upstream in the cholesterol biosynthesis pathway. This action reduces hepatic cholesterol synthesis, decreasing circulating LDL cholesterol levels.",
        "Bempedoic acid inhibits the adenosine triphosphate (ATP)-citrate lyase enzyme.",
        "Bempedoic acid is a small oral molecule that reduces hepatic cholesterol synthesis by inhibiting the ATP-citrate lyase enzyme.",
        "Bempedoic acid is a small oral molecule that inhibits the hepatic cholesterol synthesis by inhibiting the ATP-citrate lyase enzyme.",
        "Bempedoic acid is a new oral cholesterol-lowering medication that reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase.",
        "Bempedoic acid lowers cholesterol by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase, which plays a crucial role in hepatic cholesterol synthesis. This inhibition reduces the production of cholesterol within the liver, making bempedoic acid an effective oral medication for managing hypercholesterolemia.",
        "Bempedoic acid reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase enzyme.",
        "Bempedoic acid functions as an oral cholesterol-lowering medication by inhibiting the ATP-citrate lyase enzyme in the liver. This action reduces hepatic cholesterol synthesis, thereby lowering blood cholesterol levels effectively.",
        "Bempedoic acid works by inhibiting the ATP-citrate lyase enzyme, reducing cholesterol synthesis in the liver.",
        "Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL), which is an enzyme involved in the cholesterol biosynthesis pathway, leading to reduced cholesterol levels.",
        "Bempedoic acid works by inhibiting the ATP-citrate lyase enzyme, reducing hepatic cholesterol synthesis and consequently lowering blood cholesterol levels.",
        "Bempedoic acid is an innovative oral medication that inhibits hepatic cholesterol synthesis by inhibiting the enzyme ATP-citrate lyase.",
        "Bempedoic acid\u0027s mode of action involves inhibiting hepatic cholesterol synthesis by blocking the enzyme ATP-citrate lyase, thereby reducing cholesterol production in the liver.",
        "Bempedoic acid functions by inhibiting the enzyme ATP-citrate lyase, a key player in the liver\u0027s cholesterol synthesis pathway. By blocking this enzyme, it reduces hepatic cholesterol production, thereby lowering overall cholesterol levels in the body. This oral medication offers a convenient treatment option for managing hypercholesterolemia through its targeted mechanism of action.",
        "Bempedoic acid reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase.",
        "Bempedoic acid lowers cholesterol by inhibiting hepatic cholesterol synthesis, specifically through the blockade of the ATP-citrate lyase enzyme.",
        "Bempedoic acid is an oral cholesterol-lowering medication that reduces hepatic cholesterol synthesis by inhibiting the ATP-citrate lyase enzyme, thereby decreasing cholesterol production in the liver."
      ],
      "exact_answer": [
        [
          "adenosine triphosphate (ATP)-citrate lyase inhibitor"
        ]
      ]
    },
    {
      "body": "Long term effects of obesity during adolescence.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34004046",
        "http://www.ncbi.nlm.nih.gov/pubmed/39102244",
        "http://www.ncbi.nlm.nih.gov/pubmed/38790597",
        "http://www.ncbi.nlm.nih.gov/pubmed/31126896",
        "http://www.ncbi.nlm.nih.gov/pubmed/31499497",
        "http://www.ncbi.nlm.nih.gov/pubmed/9478038",
        "http://www.ncbi.nlm.nih.gov/pubmed/20975725",
        "http://www.ncbi.nlm.nih.gov/pubmed/14712150",
        "http://www.ncbi.nlm.nih.gov/pubmed/11408761",
        "http://www.ncbi.nlm.nih.gov/pubmed/27623622",
        "http://www.ncbi.nlm.nih.gov/pubmed/23529596",
        "http://www.ncbi.nlm.nih.gov/pubmed/29499215",
        "http://www.ncbi.nlm.nih.gov/pubmed/26915924",
        "http://www.ncbi.nlm.nih.gov/pubmed/16532658",
        "http://www.ncbi.nlm.nih.gov/pubmed/16790096",
        "http://www.ncbi.nlm.nih.gov/pubmed/25497038",
        "http://www.ncbi.nlm.nih.gov/pubmed/17319462",
        "http://www.ncbi.nlm.nih.gov/pubmed/31426054",
        "http://www.ncbi.nlm.nih.gov/pubmed/1406836",
        "http://www.ncbi.nlm.nih.gov/pubmed/32258598"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 2520,
          "offsetInEndSection": 2881,
          "text": "Persistently high fat mass during adolescence was associated with greater arterial stiffness and was further aggravated by an unfavourable metabolic profile. Reverting to normal FMI in adolescence was associated with normal PWV, suggesting adolescence as an important period for interventions to tackle obesity in the young to maximise long-term vascular health",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31126896"
        },
        {
          "offsetInBeginSection": 1170,
          "offsetInEndSection": 1368,
          "text": "Our MR analyses found causal effects of childhood obesity on several cancers. Maintaining a healthy weight should be emphasized during childhood and adolescence to prevent cancer risk later in life.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34004046"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 342,
          "text": "Obesity during adolescence has also been associated with an increased risk of mortality from cardiovascular disease and type 2 diabetes in adulthood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39102244"
        },
        {
          "offsetInBeginSection": 991,
          "offsetInEndSection": 1087,
          "text": "Long-term effects of childhood obesity include chronic health conditions and psychosocial issues",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38790597"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 332,
          "text": "The link between adiposity, metabolic abnormalities, and arterial disease progression in children and adolescents remains poorly defined. We aimed to assess whether persistent high adiposity levels are associated with increased arterial stiffness in adolescence and any mediation effects by common metabolic risk factors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31126896"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 549,
          "text": "Androgen excess plays an important role in favouring the expansion of visceral fat, which characterize so-called visceral obesity. Moreover, there is evidence that the combination of androgen excess and obesity may favour the development of metabolic disorders, such as the metabolic syndrome and type 2 diabetes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31499497"
        },
        {
          "offsetInBeginSection": 551,
          "offsetInEndSection": 670,
          "text": "In obese adolescent girls, androgen excess may also suggest the potential development of the polycystic ovary syndrome ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31499497"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 864,
          "text": "In men who were obese during adolescence, all-cause mortality and mortality from cardiovascular disease and colon cancer were increased. In both men and women obese during adolescence, rates of cardiovascular disease and diabetes were increased. Among women but not men obese during adolescence, obesity has a variety of adverse psychosocial consequences. These include completion of fewer years of education, higher rates of poverty, and lower rates of marriage and household income. These effects seem related both to the persistence of obesity and to the effects of childhood or adolescent obesity on the quantity and location of body fat deposition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9478038"
        },
        {
          "offsetInBeginSection": 1024,
          "offsetInEndSection": 1291,
          "text": "did not change the results.CONCLUSIONS: Obesity in adolescence tends to persist into adulthood. Adolescent obesity is also connected to excess mortality, but this excess seems to be explained mostly by obesity in adulthood. High BMI in adolescence seems to be predict",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14712150"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 719,
          "text": "In both sexes, rates of diabetes, coronary heart disease, atherosclerosis, hip fracture and gout were increased in those who were overweight as adolescents. Especially in females, obesity at late adolescence was associated with several and relevant psychosocial consequences in adulthood. Finally, a higher mortality risk for all causes of death, especially atherosclerotic cerebrovascular disease and colorectal cancer, was demonstrated in males but not in females who were overweight during high school years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408761"
        },
        {
          "offsetInBeginSection": 697,
          "offsetInEndSection": 837,
          "text": "High body mass index (BMI) and/or overweight status from childhood to adulthood were independently related to knee pain and OA in later life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27623622"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 342,
          "text": " Obesity during adolescence has also been associated with an increased risk of mortality from cardiovascular disease and type 2 diabetes in adulthood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39102244"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 695,
          "text": "In men who were obese during adolescence, all-cause mortality and mortality from cardiovascular disease and colon cancer were increased. In both men and women obese during adolescence, rates of cardiovascular disease and diabetes were increased. Among women but not men obese during adolescence, obesity has a variety of adverse psychosocial consequences. These include completion of fewer years of education, higher rates of poverty, and lower rates of marriage and household income.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9478038"
        },
        {
          "offsetInBeginSection": 674,
          "offsetInEndSection": 1204,
          "text": "After adjusting for a rich set of childhood characteristics, compared to normal weight, obesity at age 16 was associated with significantly lower levels of future household income for women (by approximately 14%), but not men. This household income penalty was greater for women with obesity in both childhood and adulthood. The household income penalty for women appeared to be driven by a lower likelihood of marriage and lower spousal earnings for those who were married, and not by their own wage penalty in the labour market.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29499215"
        },
        {
          "offsetInBeginSection": 637,
          "offsetInEndSection": 1228,
          "text": "Consequences of obese and overweight childhood and adolescence include sexual maturation and reproductive dysfunction, alterations in menstruation, dysmenorrhea, risky sexual behavior, and inefficient use of contraception, polycystic ovary syndrome, bone density abnormalities, macromastia, and an increased risk of breast and endometrial cancer. Obese adolescents are at greater risk of pregnancy and perinatal complications, such as preeclampsia, gestational hypertension and preeclampsia, gestational diabetes mellitus, primary cesarean delivery, and induction of labor, to mention a few.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26915924"
        },
        {
          "offsetInBeginSection": 466,
          "offsetInEndSection": 1345,
          "text": "Daniels notes that many obesity-related health conditions once thought applicable only to adults are now being seen in children and with increasing frequency. Examples include high blood pressure, early symptoms of hardening of the arteries, type 2 diabetes, nonalcoholic fatty liver disease, polycystic ovary disorder, and disordered breathing during sleep. He systematically surveys the body\u0027s systems, showing how obesity in adulthood can damage each and how childhood obesity exacerbates the damage. He explains that obesity can harm the cardiovascular system and that being overweight during childhood can accelerate the development of heart disease. The processes that lead to a heart attack or stroke start in childhood and often take decades to progress to the point of overt disease. Obesity in childhood, adolescence, and young adulthood may accelerate these processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16532658"
        },
        {
          "offsetInBeginSection": 383,
          "offsetInEndSection": 822,
          "text": "Early onset of obesity, particularly during adolescence, favours the development of menses irregularities, chronic oligo-anovulation and infertility in adulthood. Moreover, obesity in women can increase the risk of miscarriage and impair the outcome of assisted reproductive technologies. The main factor implicated in the association between obesity and fertility-related disorders is insulin excess, which accompanies insulin resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16790096"
        },
        {
          "offsetInBeginSection": 991,
          "offsetInEndSection": 1088,
          "text": "Long-term effects of childhood obesity include chronic health conditions and psychosocial issues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38790597"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Evidence suggests that at a population level, childhood and adolescent obesity increase the long-term risk of chronic diseases such as type 2 diabetes and CVD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25497038"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 446,
          "text": "Moreover, obesity and CVD risk factors in obese youth tend to track into adulthood, further increasing the risk of adult CVD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17319462"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 364,
          "text": "In both sexes, rates of diabetes, coronary heart disease, atherosclerosis, hip fracture and gout were increased in those who were overweight as adolescents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408761"
        },
        {
          "offsetInBeginSection": 497,
          "offsetInEndSection": 719,
          "text": "Finally, a higher mortality risk for all causes of death, especially atherosclerotic cerebrovascular disease and colorectal cancer, was demonstrated in males but not in females who were overweight during high school years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408761"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 336,
          "text": "Obesity during adolescence leads to an increased risk for disease and premature death during adulthood, independent of obesity during adulthood. Obesity is the major risk factor impacting insulin sensitivity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23529596"
        },
        {
          "offsetInBeginSection": 1370,
          "offsetInEndSection": 1459,
          "text": "Both long-term and recent-onset obesity increase the cardiometabolic risk in adolescents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31426054"
        },
        {
          "offsetInBeginSection": 1150,
          "offsetInEndSection": 1496,
          "text": "For girls, adolescence is a high-risk period for the development of this comorbidity, with the nature of the risk varying over the course of adolescence. Early adolescent-onset depression is associated with elevated risk of later onset obesity, and obesity, particularly in late adolescence, is associated with increased odds of later depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24480863"
        },
        {
          "offsetInBeginSection": 365,
          "offsetInEndSection": 495,
          "text": "Especially in females, obesity at late adolescence was associated with several and relevant psychosocial consequences in adulthood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408761"
        },
        {
          "offsetInBeginSection": 497,
          "offsetInEndSection": 718,
          "text": "Finally, a higher mortality risk for all causes of death, especially atherosclerotic cerebrovascular disease and colorectal cancer, was demonstrated in males but not in females who were overweight during high school years",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408761"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 719,
          "text": "Obesity tracks from childhood into adulthood, and the persistence of obesity rises with age among obese children. Early onset obesity was suggested as a risk factor for morbidity and mortality later in life. In both sexes, rates of diabetes, coronary heart disease, atherosclerosis, hip fracture and gout were increased in those who were overweight as adolescents. Especially in females, obesity at late adolescence was associated with several and relevant psychosocial consequences in adulthood. Finally, a higher mortality risk for all causes of death, especially atherosclerotic cerebrovascular disease and colorectal cancer, was demonstrated in males but not in females who were overweight during high school years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408761"
        },
        {
          "offsetInBeginSection": 947,
          "offsetInEndSection": 1741,
          "text": "rweight in adolescent subjects was associated with an increased risk of mortality from all causes and disease-specific mortality among men, but not among women. The relative risks among men were 1.8 (95 percent confidence interval, 1.2 to 2.7; P \u003d 0.004) for mortality from all causes and 2.3 (95 percent confidence interval, 1.4 to 4.1; P \u003d 0.002) for mortality from coronary heart disease. The risk of morbidity from coronary heart disease and atherosclerosis was increased among men and women who had been overweight in adolescence. The risk of colorectal cancer and gout was increased among men and the risk of arthritis was increased among women who had been overweight in adolescence. Overweight in adolescence was a more powerful predictor of these risks than overweight in adulthood.CON",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1406836"
        },
        {
          "offsetInBeginSection": 619,
          "offsetInEndSection": 1458,
          "text": "e eligible studies examined associations between overweight and/or obesity, and premature mortality: 4/5 found significantly increased risk of premature mortality with child and adolescent overweight or obesity. All 11 studies with cardiometabolic morbidity as outcomes reported that overweight and obesity were associated with significantly increased risk of later cardiometabolic morbidity (diabetes, hypertension, ischaemic heart disease, and stroke) in adult life, with hazard ratios ranging from 1.1-5.1. Nine studies examined associations of child or adolescent overweight and obesity with other adult morbidity: studies of cancer morbidity were inconsistent; child and adolescent overweight and obesity were associated with significantly increased risk of later disability pension, asthma, and polycystic ovary syndrome symptoms.CON",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20975725"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Evidence suggests that at a population level, childhood and adolescent obesity increase the long-term risk of chronic diseases such as type 2 diabetes and CVD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25497038"
        },
        {
          "offsetInBeginSection": 756,
          "offsetInEndSection": 933,
          "text": "Paediatric obesity is associated with cardiovascular risk factors both in the short or medium-term, but also in the long term, conferring additional risk for future adult health",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32258598"
        },
        {
          "offsetInBeginSection": 1129,
          "offsetInEndSection": 1685,
          "text": "Nine studies examined associations of child or adolescent overweight and obesity with other adult morbidity: studies of cancer morbidity were inconsistent; child and adolescent overweight and obesity were associated with significantly increased risk of later disability pension, asthma, and polycystic ovary syndrome symptoms.CONCLUSIONS: A relatively large and fairly consistent body of evidence now demonstrates that overweight and obesity in childhood and adolescence have adverse consequences on premature mortality and physical morbidity in adulthood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20975725"
        }
      ],
      "id": "67e2c03d18b1e36f2e000094",
      "ideal_answer": [
        "Persistently high fat mass during adolescence was associated with greater arterial stiffness and was further aggravated by an unfavorable metabolic profile. MR analyses found causal effects of childhood obesity on several cancers. Obesity during adolescence has also been associated with an increased risk of mortality from cardiovascular disease and type 2 diabetes in adulthood. Androgen excess plays an important role in favouring the expansion of visceral fat, which characterize so-called visceral obesity. Moreover, there is evidence that the combination of androgen excess and obesity may favour the development of metabolic disorders, such as the metabolic syndrome and type 2 diabetes. In obese adolescent girls, androgen excess may also suggest the potential development of the polycystic ovary syndrome.",
        "Obesity during adolescence can have several long-term effects on both physical and mental health. Potential long-term effects include an increased risk of cardiovascular disease, such as hypertension, dyslipidemia, and atherosclerosis, which can lead to heart disease and stroke. Adolescents with obesity are also more likely to develop insulin resistance and type 2 diabetes, as well as metabolic syndrome, which increases the risk of heart disease, stroke, and diabetes. Respiratory problems like asthma and obstructive sleep apnea are more common, as are musculoskeletal disorders such as osteoarthritis due to excess weight putting strain on the joints. Psychological effects include higher rates of depression, anxiety, and low self-esteem, which can persist into adulthood. Reproductive health issues, such as menstrual irregularities and polycystic ovary syndrome (PCOS) in females, are also more likely. There is an increased risk of certain types of cancer, including breast, colon, and endometrial cancer. Additionally, obesity can lead to social and economic consequences, including stigmatization, discrimination, and lower socioeconomic status. Addressing obesity during adolescence is crucial to mitigate these long-term health risks and improve overall quality of life."
      ]
    },
    {
      "body": "What is the median survival time for glioblastoma patients with standard treatment?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28286803",
        "http://www.ncbi.nlm.nih.gov/pubmed/22117160",
        "http://www.ncbi.nlm.nih.gov/pubmed/36638331",
        "http://www.ncbi.nlm.nih.gov/pubmed/26791930",
        "http://www.ncbi.nlm.nih.gov/pubmed/37711136",
        "http://www.ncbi.nlm.nih.gov/pubmed/35804940",
        "http://www.ncbi.nlm.nih.gov/pubmed/29199724",
        "http://www.ncbi.nlm.nih.gov/pubmed/33712524",
        "http://www.ncbi.nlm.nih.gov/pubmed/32157552",
        "http://www.ncbi.nlm.nih.gov/pubmed/38891882",
        "http://www.ncbi.nlm.nih.gov/pubmed/24469855",
        "http://www.ncbi.nlm.nih.gov/pubmed/33062270",
        "http://www.ncbi.nlm.nih.gov/pubmed/22045118",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831702",
        "http://www.ncbi.nlm.nih.gov/pubmed/26260659",
        "http://www.ncbi.nlm.nih.gov/pubmed/39553226",
        "http://www.ncbi.nlm.nih.gov/pubmed/39734810",
        "http://www.ncbi.nlm.nih.gov/pubmed/39590169",
        "http://www.ncbi.nlm.nih.gov/pubmed/39597073",
        "http://www.ncbi.nlm.nih.gov/pubmed/39740382",
        "http://www.ncbi.nlm.nih.gov/pubmed/39659837",
        "http://www.ncbi.nlm.nih.gov/pubmed/30149161",
        "http://www.ncbi.nlm.nih.gov/pubmed/22854592",
        "http://www.ncbi.nlm.nih.gov/pubmed/11180090",
        "http://www.ncbi.nlm.nih.gov/pubmed/26558493",
        "http://www.ncbi.nlm.nih.gov/pubmed/36428604",
        "http://www.ncbi.nlm.nih.gov/pubmed/39364266",
        "http://www.ncbi.nlm.nih.gov/pubmed/32478924",
        "http://www.ncbi.nlm.nih.gov/pubmed/32813186",
        "http://www.ncbi.nlm.nih.gov/pubmed/34929651",
        "http://www.ncbi.nlm.nih.gov/pubmed/32164579",
        "http://www.ncbi.nlm.nih.gov/pubmed/30150597",
        "http://www.ncbi.nlm.nih.gov/pubmed/24105050",
        "http://www.ncbi.nlm.nih.gov/pubmed/37371674",
        "http://www.ncbi.nlm.nih.gov/pubmed/20546782",
        "http://www.ncbi.nlm.nih.gov/pubmed/36445396",
        "http://www.ncbi.nlm.nih.gov/pubmed/33718145",
        "http://www.ncbi.nlm.nih.gov/pubmed/34638796",
        "http://www.ncbi.nlm.nih.gov/pubmed/28729027",
        "http://www.ncbi.nlm.nih.gov/pubmed/36166963",
        "http://www.ncbi.nlm.nih.gov/pubmed/27471700",
        "http://www.ncbi.nlm.nih.gov/pubmed/39766134",
        "http://www.ncbi.nlm.nih.gov/pubmed/22474481",
        "http://www.ncbi.nlm.nih.gov/pubmed/28962238",
        "http://www.ncbi.nlm.nih.gov/pubmed/35208642",
        "http://www.ncbi.nlm.nih.gov/pubmed/34988331",
        "http://www.ncbi.nlm.nih.gov/pubmed/29721785",
        "http://www.ncbi.nlm.nih.gov/pubmed/35402955",
        "http://www.ncbi.nlm.nih.gov/pubmed/29524050",
        "http://www.ncbi.nlm.nih.gov/pubmed/35403130",
        "http://www.ncbi.nlm.nih.gov/pubmed/37298208",
        "http://www.ncbi.nlm.nih.gov/pubmed/36632307",
        "http://www.ncbi.nlm.nih.gov/pubmed/17549280",
        "http://www.ncbi.nlm.nih.gov/pubmed/39455562",
        "http://www.ncbi.nlm.nih.gov/pubmed/39543872",
        "http://www.ncbi.nlm.nih.gov/pubmed/39560080",
        "http://www.ncbi.nlm.nih.gov/pubmed/39568843",
        "http://www.ncbi.nlm.nih.gov/pubmed/32477944",
        "http://www.ncbi.nlm.nih.gov/pubmed/38715344",
        "http://www.ncbi.nlm.nih.gov/pubmed/35625738",
        "http://www.ncbi.nlm.nih.gov/pubmed/28755993",
        "http://www.ncbi.nlm.nih.gov/pubmed/26649278",
        "http://www.ncbi.nlm.nih.gov/pubmed/37107600",
        "http://www.ncbi.nlm.nih.gov/pubmed/12241108",
        "http://www.ncbi.nlm.nih.gov/pubmed/31570484",
        "http://www.ncbi.nlm.nih.gov/pubmed/38891962",
        "http://www.ncbi.nlm.nih.gov/pubmed/38544840",
        "http://www.ncbi.nlm.nih.gov/pubmed/33363039",
        "http://www.ncbi.nlm.nih.gov/pubmed/39540980",
        "http://www.ncbi.nlm.nih.gov/pubmed/39682171",
        "http://www.ncbi.nlm.nih.gov/pubmed/39670486",
        "http://www.ncbi.nlm.nih.gov/pubmed/39667305",
        "http://www.ncbi.nlm.nih.gov/pubmed/39715221",
        "http://www.ncbi.nlm.nih.gov/pubmed/27036027",
        "http://www.ncbi.nlm.nih.gov/pubmed/24236823",
        "http://www.ncbi.nlm.nih.gov/pubmed/23843722",
        "http://www.ncbi.nlm.nih.gov/pubmed/19194651",
        "http://www.ncbi.nlm.nih.gov/pubmed/22295207",
        "http://www.ncbi.nlm.nih.gov/pubmed/38586213",
        "http://www.ncbi.nlm.nih.gov/pubmed/25186601",
        "http://www.ncbi.nlm.nih.gov/pubmed/32931454",
        "http://www.ncbi.nlm.nih.gov/pubmed/22440874",
        "http://www.ncbi.nlm.nih.gov/pubmed/30425948",
        "http://www.ncbi.nlm.nih.gov/pubmed/22991580",
        "http://www.ncbi.nlm.nih.gov/pubmed/26120474"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Glioblastoma is the most aggressive malignant brain tumor among all primary brain and central nervous system tumors. The median survival time for glioblastoma patients given the current standard of care treatment (surgery, radiation, and chemotherapy) is less than 15 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28286803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12-15 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22117160"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 416,
          "text": "Glioblastoma is the most common and aggressive primary brain tumor in the adult population and leads to considerable morbidity and mortality. It has a dismal prognosis with average survival of 15-18 months, and the current standard-of-care treatment paradigm includes maximal surgical resection and postoperative concurrent chemoradiotherapy and maintenance chemotherapy, with consideration of Tumor Treating Fields.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36638331"
        },
        {
          "offsetInBeginSection": 1309,
          "offsetInEndSection": 1380,
          "text": "The median survival for patients with glioblastoma is less than a year.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35804940"
        },
        {
          "offsetInBeginSection": 165,
          "offsetInEndSection": 305,
          "text": "With an average lifespan of about 15 months from diagnosis, glioblastoma has a poor prognosis and presents a significant treatment challenge",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38891882"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 64,
          "text": "Glioblastoma (GBM) has a median survival of \u003c2 years",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734810"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median overall survival (OS) of 15-18 months despite standard treatments",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39590169"
        },
        {
          "offsetInBeginSection": 119,
          "offsetInEndSection": 224,
          "text": "These tumors are characterized by rapid progression and show a median survival of approximately 18 months",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39597073"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 333,
          "text": "Despite substantial advances in surgical and chemotherapeutic interventions, the median survival rate for patients is only 14",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740382"
        },
        {
          "offsetInBeginSection": 1099,
          "offsetInEndSection": 1254,
          "text": "In the temozolomide era, median survival times ranged from a high of 31.9 months in patients age 20-29 to a low of 5.6 months in patients age 80 and older.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045118"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Glioblastoma (GBM) is one of the most aggressive forms of brain cancer that presents with a median survival rate of 14-30 months and along with a discouraging five-year survival rate of 4-5%",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39364266"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "BACKGROUND: Median survival for patients with glioblastoma is less than a year.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32164579"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "The median survival time of patients with glioblastoma is 14-16 months with a 5-year overall survival rate of 9.8%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33062270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14.6 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24469855"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 338,
          "text": "The standard of care for glioblastoma is usually surgery, as well as radiotherapy followed by systemic temozolomide chemotherapy, resulting in a median survival time of about 12 to 15 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30150597"
        },
        {
          "offsetInBeginSection": 728,
          "offsetInEndSection": 993,
          "text": "According to a phase III trial by the European Organization for Research and Treatment for Cancer (EORTC), the standard therapy for glioblastomas is radiotherapy with concomitant administration of temozolomide; however, the median survival time is only 14.6 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24105050"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 236,
          "text": "Despite intense scientific efforts, patients diagnosed with GBM and treated with the current standard of care have a median survival of only 15 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37371674"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 463,
          "text": "While the median survival of patients with glioblastomas has improved from 6 months to 14.6 months, these tumors continue to be lethal for the vast majority of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20546782"
        },
        {
          "offsetInBeginSection": 72,
          "offsetInEndSection": 192,
          "text": "The median survival of patients with glioblastoma remains approximately 15 months, and the 5-year survival rate is \u003c10%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36445396"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 277,
          "text": " Glioblastoma patients administered standard therapies, comprising maximal surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a variable prognosis with a median overall survival of 15-16 months and a 2-year overall survival of 30%",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33718145"
        },
        {
          "offsetInBeginSection": 936,
          "offsetInEndSection": 999,
          "text": "The overall median survival was 19.9 (95% CI:14.1-25.7) months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34929651"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 318,
          "text": "Glioblastoma multiforme (GBM) is the most malignant primary brain tumor; the average survival time of GBM patients is less than 18 months after standard treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34638796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Glioblastoma multiforme (GBM) is the most common and inevitably lethal primary brain tumor, with a median survival rate of only 15 months from diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28729027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Despite conventional treatment options including chemoradiation, patients with the most aggressive primary brain tumor, glioblastoma multiforme (GBM), experience an average survival time of less than 15 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36166963"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 256,
          "text": "Since median overall survival with multimodal standard therapy is only 15 months, there is a clear need for additional effective and long-lasting treatments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471700"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Gliomas are a wide group of common brain tumors, with the most aggressive type being glioblastoma multiforme (GBM), with a 5-year survival rate of less than 5% and a median survival time of approximately 12-14 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39766134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Treatment of patients with glioblastoma multiforme (GBM) remains to be a challenge with a median survival of 14.6 months following diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22474481"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 208,
          "text": "Current therapies provide a median survival of 12-15 months after diagnosis, due to the high recurrence rate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28962238"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 318,
          "text": "Due to the tumors invasive nature, recurrences are almost a certainty, giving the patients after diagnosis only a 12-15 months average survival time.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35208642"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 393,
          "text": "Despite treatment, or standard therapy, the median survival of glioblastoma patients is about 14.6 month.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29721785"
        },
        {
          "offsetInBeginSection": 792,
          "offsetInEndSection": 1118,
          "text": "The central tendency of median overall survival (MOS) was 13.5 months (2.3-29.6) and cumulative 5-year survival was 5.8% (0.01%-29.1%), with a significant difference in survival between studies that predate versus postdate the implementation of temozolomide and radiation, [12.5 (2.3-28) vs 15.6 (3.8-29.6) months, P \u003c 0.001].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32157552"
        },
        {
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1254,
          "text": "The median progression-free survival was 10.3 months (95% CI, 10.0-11.0). The median overall survival was 19.7 months (95% CI, 18.5-21.0).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791930"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 278,
          "text": "BACKGROUND: Glioblastoma patients administered standard therapies, comprising maximal surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a variable prognosis with a median overall survival of 15-16 months and a 2-year overall survival of 30%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33718145"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 398,
          "text": "GBM patients have a five-year survival rate of merely 5.6% and a median overall survival of 14.6 months with the \"Stupp\" regimen, 20.9 months with tumor treatment fields (TTF, OptuneR) in patients who participated in clinical trials, and 11 months for all GBM patients prior to TTF use",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35402955"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 289,
          "text": "Current treatment protocol runs around radiotherapy, surgical resection, and temozolomide with median overall survival of around 12-15 months",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29524050"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 432,
          "text": "However, the median survival time of GBM patients is still less than 15 months, even after treatment with surgical resection, concurrent chemoradiotherapy, and adjuvant chemotherapy with temozolomide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37298208"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "Glioblastoma accounts for nearly half of all primary malignant brain tumors in adults, and despite an aggressive standard of care, including excisional surgery and adjuvant chemoradiation, recurrence remains universal, with an overall median survival of 14.6 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39455562"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Glioblastoma is a malignant manifestation of a solid brain tumour with a very dismal prognosis due to an overall median survival of 14 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39543872"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Glioblastoma multiforme (GBM) remains an incurable condition, associated with a median survival time of 15 months with best standard of care and 5-year survival rate of \u003c10",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32477944"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 274,
          "text": "The median survival time for glioblastoma patients given the current standard of care treatment (surgery, radiation, and chemotherapy) is less than 15 months",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28286803"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 201,
          "text": "The prognosis for patients with GBM remains poor, with a median survival time of only 1-2 years",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28755993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Gliomas are a wide group of common brain tumors, with the most aggressive type being glioblastoma multiforme (GBM), with a 5-year survival rate of less than 5% and a median survival time of approximately 12-14 months",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39766134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Glioblastoma (GBM) is an aggressive brain cancer with a median survival time of 14.6 months after diagnosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37107600"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Glioblastoma is the most common malignant primary brain tumor in the adult population, with an average survival of 12.1 to 14.6 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38891962"
        },
        {
          "offsetInBeginSection": 1136,
          "offsetInEndSection": 1299,
          "text": "Despite aggressive treatment, the prognosis for patients with infratentorial glioblastoma multiforme remains poor, with a median survival time of less than a year.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38544840"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Glioblastoma (GBM) is the most common primary brain tumor, carrying a very poor prognosis, with median overall survival at about 12 to 15 months despite surgical resection, chemotherapy with temozolomide (TMZ), and radiation therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33363039"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 185,
          "text": "The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625738"
        },
        {
          "offsetInBeginSection": 1093,
          "offsetInEndSection": 1236,
          "text": "In a cohort of 147 IDH wild-type glioblastoma patients treated with the Stupp protocol, the median OS was 14 months and median PFS was 8 months",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39540980"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Glioblastoma (GB) is among the most aggressive and difficult-to-treat brain tumors, with a median survival of only 12-15 months despite maximal treatments, including surgery, radiotherapy, and chemotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39682171"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 380,
          "text": "The overall survival of patients with high-grade brain gliomas is 14-20 months after current multimodal therapy, including surgery, radiotherapy, and adjuvant chemotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39670486"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "Despite advances in multimodal therapy approaches such as resection, chemotherapy and radiotherapy, the overall survival of patients with grade 4 glioblastoma (GBM) remains extremely poor (average survival time \u003c2 years)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39667305"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Glioblastoma multiforme (GBM) is the most prevalent malignant brain tumor, with an average survival time of 14 to 20 months",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39715221"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Glioblastoma multiforme (GBM) remains an incurable condition, associated with a median survival time of 15 months with best standard of care and 5-year survival rate of \u003c10%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32477944"
        },
        {
          "offsetInBeginSection": 1135,
          "offsetInEndSection": 1460,
          "text": "The control arm showed a median life expectancy of 14 months, reflecting current standards-of-care and outcome. In contrast, patients receiving supra-complete surgery displayed significant increase in median survival time to 18.5 months with overall survival time correlating directly with extent of supra-complete resection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27036027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "Glioblastoma (GBM) is one of the most aggressive forms of brain cancer that presents with a median survival rate of 14-30 months and along with a discouraging five-year survival rate of 4-5%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39364266"
        },
        {
          "offsetInBeginSection": 63,
          "offsetInEndSection": 211,
          "text": "Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26558493"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 224,
          "text": "Standard treatment median overall survival (OS) is only 14-15 months and less than 10% of patients will survive 5 years after diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843722"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 275,
          "text": "The median survival time for glioblastoma patients given the current standard of care treatment (surgery, radiation, and chemotherapy) is less than 15 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28286803"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 422,
          "text": "glioblastoma patients have a median survival expectancy of only 14 months on the current standard treatment of surgical resection to the extent which is feasible, followed by adjuvant radiotherapy plus temozolomide given concomitantly with and after radiotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19194651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Glioblastoma is the most common malignant glioma in adults, and despite recent advances in standard treatment, the prognosis still remains dismal, with a median survival of 15 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22295207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "The median survival for patients with glioblastoma is 12 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12241108"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 305,
          "text": "Current standard of care for patients with GBM includes maximal tumor resection plus adjuvant radiotherapy and temozolomide chemotherapy, increasing median overall survival to a mere 15 months from diagnosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25186601"
        },
        {
          "offsetInBeginSection": 68,
          "offsetInEndSection": 214,
          "text": "The median survival time for patients with GBM is only 15 months, even following maximal surgical resection and chemotherapy and radiation therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32931454"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 437,
          "text": "However, the median survival time of GBM patients is still less than 15 months, even after treatment with surgical resection, concurrent chemoradiotherapy, and adjuvant chemotherapy with temozolomide (TMZ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37298208"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Glioblastoma (GBM) is the most common primary brain tumor, carrying a very poor prognosis, with median overall survival at about 12 to 15 months despite surgical resection, chemotherapy with temozolomide (TMZ), and radiation therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33363039"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Glioblastoma multiforme (GBM) is the most common and inevitably lethal primary brain tumor, with a median survival rate of only 15 months from diagnosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28729027"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 430,
          "text": "Yet despite its improvements from previous therapies, median survival remains approximately 15 months, with a 2-year survival rate of 8% to 26",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22440874"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 348,
          "text": "After treatment with the current standard of care consisting of surgical resection, concurrent temozolomide (TMZ), and radiation, the median survival is only 15 months",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30425948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 309,
          "text": "Malignant gliomas are heterogeneous, diffuse and highly infiltrating by nature. Despite wide surgical resection and improvements in radio- and chemotherapies, the prognosis of patients with glioblastoma multiforme remains extremely poor, with a median survival time of only 14.5 months from diagnosis to death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22991580"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 425,
          "text": "The median survival time following the diagnosis of GBM is approximately fifteen months in the setting of providing presently available treatments with surgical resection, radiation, and chemotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26120474"
        }
      ],
      "id": "67eb817c18b1e36f2e0000f0",
      "ideal_answer": [
        "Glioblastoma is the most aggressive malignant brain tumor among all primary brain and central nervous system tumors. The current standard-of-care treatment paradigm includes maximal surgical resection and postoperative concurrent chemoradiotherapy and maintenance chemotherapy, with consideration of Tumor Treating Fields. However, the prognosis remains poor, with a median survival time of 12-15 months.",
        "Glioblastoma is a highly aggressive type of brain cancer, and despite advancements in surgical techniques and external radiation therapy, the prognosis remains poor. The median survival time for patients with glioblastoma receiving standard treatment, which typically includes surgery followed by radiation therapy and chemotherapy, is approximately 12-18 months. Moreover, the 5-year survival rate is dismally low, standing at only around 6%.",
        "The median survival time for glioblastoma patients receiving standard treatment (surgery, radiation, and chemotherapy) is consistently reported as 12-15 months across multiple sources. This standard of care typically includes maximal surgical resection, postoperative concurrent chemoradiotherapy, and maintenance chemotherapy, but despite these interventions, the prognosis remains poor.",
        "The median survival time for glioblastoma patients with standard treatment (surgery, radiation, and chemotherapy, including temozolomide) is **12–15 months**, as reported across multiple studies. Some sources note slight variations (e.g., 15–18 months) when newer adjunct therapies like Tumor Treating Fields are included, but the most consistent range remains **12–15 months**.",
        "The median survival time for glioblastoma patients with standard treatment (surgery, radiation, and chemotherapy, including temozolomide) is **12–15 months**. Recent protocols incorporating Tumor Treating Fields may extend this to **15–18 months**, but the most consistently reported range remains 12–15 months based on current evidence.",
        "The median survival time for glioblastoma patients receiving standard treatment ranges from 12-18 months. According to multiple sources, patients who receive the current standard of care treatment, which includes surgery, radiation, and chemotherapy (specifically temozolomide), have a median survival time of less than 15 months. Some sources specify this range as 12-15 months, while others indicate it may extend to 15-18 months. Despite advances in treatment approaches, including maximal surgical resection, postoperative concurrent chemoradiotherapy, maintenance chemotherapy, and consideration of Tumor Treating Fields, glioblastoma continues to have a poor prognosis."
      ],
      "exact_answer": [
        [
          "15 months",
          "12-15 months",
          "12 to 15 months",
          "14-16 months",
          "14 to 15 months",
          "14-15 months",
          "14.5 months",
          "14.6 months"
        ]
      ]
    },
    {
      "body": "Which ensemble machine-learning framework has been developed for predicting druggability?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36434048"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36434048"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "The druggability of targets is a crucial consideration in drug target selection. Here, we adopt a stochastic semi-supervised ML framework to develop DrugnomeAI, which estimates the druggability likelihood for every protein-coding gene in the human exome. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36434048"
        }
      ],
      "id": "67dede2918b1e36f2e000062",
      "ideal_answer": [
        "DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets.",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting the druggability of candidate drug targets.",
        "DrugnomeAI",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting the druggability of candidate drug targets using a stochastic semi-supervised approach that estimates the druggability likelihood for every protein-coding gene in the human exome.",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting the druggability of candidate drug targets. It estimates the druggability likelihood for every protein-coding gene in the human exome using a stochastic semi-supervised machine learning framework.",
        "DrugnomeAI is the ensemble machine-learning framework developed for predicting druggability.",
        "DrugnomeAI is an ensemble machine-learning framework developed to predict druggability of genes.",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting druggability of candidate drug targets.",
        "DrugnomeAI is the ensemble machine-learning framework developed for predicting druggability of candidate drug targets.",
        "DrugnomeAI is an ensemble machine-learning framework for predicting druggability.",
        "DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets. DrugnomeAI integrates gene-level properties from 15 sources resulting in 324 features for each gene. DrugnomeAI is trained on a dataset of 1,111 genes with known druggability and achieves an AUC of 0.93. DrugnomeAI is available at https://github.com/DrugnomeAI/DrugnomeAI.",
        "DrugnomeAI is an innovative ensemble machine-learning framework designed to predict the druggability of potential drug targets. It uses a stochastic semi-supervised approach to estimate the druggability likelihood for protein-coding genes in the human exome, providing a comprehensive computational tool for early-stage drug target assessment.",
        "DrugnomeAI is consistently identified across all sources as the ensemble machine-learning framework developed for predicting druggability, indicating a clear and sole association within the provided information set.",
        "DrugnomeAI is an ensemble machine-learning framework that has been developed for predicting the druggability of candidate drug targets. This framework utilizes a stochastic semi-supervised approach to estimate the druggability likelihood for every protein-coding gene in the human exome, making it a valuable tool in drug target selection. By considering the druggability of targets, DrugnomeAI helps address a crucial aspect of the drug development process, ultimately contributing to the advancement of studies in this field.",
        "DrugnomeAI is an ensemble machine-learning framework that employs a stochastic semi-supervised approach to predict the druggability of potential drug targets and estimate druggability likelihood for protein-coding genes in the human exome.",
        "DrugnomeAI is an ensemble machine-learning framework specifically designed to predict the druggability of candidate drug targets. By integrating multiple machine-learning models, it enhances prediction accuracy and reliability, aiding in the identification of proteins or molecules most likely to be effectively targeted by therapeutic compounds. This tool plays a critical role in streamlining drug discovery by prioritizing targets with higher potential for successful drug development.",
        "DrugnomeAI is an ensemble machine-learning framework for predicting the druggability of candidate drug targets.",
        "DrugnomeAI is the ensemble machine-learning framework developed for predicting druggability. It utilizes a stochastic semi-supervised ML framework to estimate the druggability likelihood for protein-coding genes.",
        "DrugnomeAI is the ensemble machine-learning framework developed for predicting the druggability of candidate drug targets.",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting the druggability of candidate drug targets. It employs a stochastic semi-supervised approach to estimate druggability likelihood across all protein-coding genes in the human exome.",
        "DrugnomeAI is the ensemble machine-learning framework that has been developed for predicting druggability.",
        "DrugnomeAI is the ensemble machine-learning framework developed for predicting the druggability of candidate drug targets. It is built using a stochastic semi-supervised machine learning approach.",
        "DrugnomeAI is the ensemble machine-learning framework developed for predicting druggability, estimating the druggability likelihood for every protein-coding gene in the human exome.",
        "The ensemble machine-learning framework developed for predicting druggability is DrugnomeAI.",
        "DrugnomeAI is an ensemble machine-learning framework developed to predict the druggability of candidate drug targets. It employs a stochastic semi-supervised ML approach to estimate the likelihood of druggability for every protein-coding gene in the human exome, addressing a crucial aspect of drug target selection.",
        "DrugnomeAI is an ensemble machine-learning framework developed specifically for predicting the druggability of candidate drug targets. It employs a stochastic semi-supervised ML approach to estimate the likelihood of druggability for every protein-coding gene in the human exome, addressing the crucial consideration of target druggability in drug development.",
        "DrugnomeAI is an ensemble machine-learning framework designed to predict the druggability of candidate drug targets. It employs a stochastic semi-supervised learning approach to estimate druggability likelihood across all protein-coding genes in the human exome, enhancing accuracy and robustness through its ensemble methodology.",
        "The ensemble machine-learning framework developed for predicting druggability is called DrugnomeAI.",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting druggability, integrating various gene-level properties to estimate the likelihood for protein-coding genes in the human exome, offering both generic and specialized models with a user-friendly web application for visualization.",
        "DrugnomeAI is an ensemble machine-learning framework specifically designed for predicting the druggability of candidate drug targets. By employing a combination of various machine-learning models, DrugnomeAI enhances predictive accuracy, assisting researchers and pharmaceutical companies in identifying potential drug targets and optimizing drug discovery processes.",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting druggability of candidate drug targets, utilizing a stochastic semi-supervised ML framework to estimate druggability likelihood across the human exome, aiding in drug target selection.",
        "DrugnomeAI is an ensemble machine-learning framework that has been developed specifically for predicting the druggability of candidate drug targets. It employs a stochastic semi-supervised machine learning approach to estimate the druggability likelihood for every protein-coding gene in the human exome, which is crucial for drug target selection in pharmaceutical development.",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting druggability. It utilizes a stochastic semi-supervised learning approach to assess the druggability likelihood of every protein-coding gene within the human exome, aiding in drug target selection.",
        "DrugnomeAI is uniformly identified as the ensemble machine-learning framework developed for predicting druggability, suggesting its prominence or novelty in addressing this specific challenge within biomedical research and drug development.",
        "DrugnomeAI is an ensemble machine-learning framework developed for predicting the druggability of candidate drug targets. It utilizes a stochastic semi-supervised learning approach to assess the druggability likelihood for each protein-coding gene within the human exome, thereby aiding in drug target selection.",
        "DrugnomeAI is the ensemble machine-learning framework developed to predict the druggability of candidate drug targets.",
        "DrugnomeAI is an ensemble machine-learning framework developed to predict the druggability of candidate drug targets."
      ],
      "exact_answer": [
        [
          "DrugnomeAI"
        ]
      ]
    },
    {
      "body": "What is the clinical significance of the Eiffel-by-Night Sign?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38759113",
        "http://www.ncbi.nlm.nih.gov/pubmed/25703277",
        "http://www.ncbi.nlm.nih.gov/pubmed/24299643"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1224,
          "offsetInEndSection": 1338,
          "text": "Immune-mediated HP was associated with a peripheral pattern of contrast enhancement and the Eiffel-by-night sign. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38759113"
        },
        {
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1280,
          "text": "The posterior falx and tentorium showing a hypointense center (\"fibrosis\") and enhancing periphery (\"active inflammation\") together mimicking \"Eiffel-by-night\" sign was found to be more commonly associated with IHP (60% vs 12.5%, p\u003d0.03). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25703277"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "\u0027Eiffel-by-Night\u0027: A New MR Sign Demonstrating Reactivation in Idiopathic Hypertrophic Pachymeningitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24299643"
        }
      ],
      "type": "summary",
      "id": "67e6b63118b1e36f2e0000bc",
      "ideal_answer": [
        "Eiffel-by-Night Sign indicates pachymeningitis."
      ]
    },
    {
      "_body": "What is the current hypothesis for the cuas eof Guillian-Barre syndrome?",
      "_type": "summary",
      "body": "What is the current hypothesis for the cause of Guillian-Barre syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38813755",
        "http://www.ncbi.nlm.nih.gov/pubmed/39007153",
        "http://www.ncbi.nlm.nih.gov/pubmed/38868867",
        "http://www.ncbi.nlm.nih.gov/pubmed/39722970",
        "http://www.ncbi.nlm.nih.gov/pubmed/31639842",
        "http://www.ncbi.nlm.nih.gov/pubmed/37422300",
        "http://www.ncbi.nlm.nih.gov/pubmed/34868782",
        "http://www.ncbi.nlm.nih.gov/pubmed/39524841",
        "http://www.ncbi.nlm.nih.gov/pubmed/32311917",
        "http://www.ncbi.nlm.nih.gov/pubmed/36430700",
        "http://www.ncbi.nlm.nih.gov/pubmed/15482157",
        "http://www.ncbi.nlm.nih.gov/pubmed/15921641",
        "http://www.ncbi.nlm.nih.gov/pubmed/31379477",
        "http://www.ncbi.nlm.nih.gov/pubmed/35100875",
        "http://www.ncbi.nlm.nih.gov/pubmed/20735441",
        "http://www.ncbi.nlm.nih.gov/pubmed/29880241",
        "http://www.ncbi.nlm.nih.gov/pubmed/34246981",
        "http://www.ncbi.nlm.nih.gov/pubmed/38899056",
        "http://www.ncbi.nlm.nih.gov/pubmed/7804457",
        "http://www.ncbi.nlm.nih.gov/pubmed/21451970",
        "http://www.ncbi.nlm.nih.gov/pubmed/39685612",
        "http://www.ncbi.nlm.nih.gov/pubmed/32192609",
        "http://www.ncbi.nlm.nih.gov/pubmed/34434441",
        "http://www.ncbi.nlm.nih.gov/pubmed/28639596"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "Guillain-Barré syndrome (GBS) is a potentially devastating yet treatable disorder. A classically postinfectious, immune-mediated, monophasic polyradiculoneuropathy, it is the leading global cause of acquired neuromuscular paralysis. In most cases, the immunopathological process driving nerve injury is ill-defined.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38813755"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "The etiology of Guillain-Barré syndrome (GBS) may be autoimmune.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39007153"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 660,
          "text": "Guillain-Barre syndrome (GBS) is thought to be related to immune damage, and most patients have cytomegalovirus (CMV), Epstein-Barr virus (EBV), or mycoplasma infection before onset.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38868867"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Guillain-Barre syndrome (GBS) is an autoimmune disorder affecting the peripheral nervous system, often triggered by infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39722970"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 290,
          "text": "GBS is believed to be an immune-mediated disease, possibly triggered by a recent infection, and driven by an immune attack targeting the peripheral nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31639842"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Guillain-Barre syndrome (GBS) is an immune-mediated disease of the peripheral nerves and cause of acute flaccid paralysis in children around the world. The most common type of GBS in North America targets myelin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37422300"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Guillain-Barré syndrome (GBS) is a rare neurologic disorder in which the host immune system damages peripheral nerve cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34868782"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 162,
          "text": "Guillain-Barre syndrome (GBS), an autoimmune disease of the peripheral nervous system, is hallmarked by demyelination and immune cellular infiltration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39524841"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "RATIONALE: Guillian-Barré syndrome (GBS) is a devastating autoimmune disorder characterized by progressive ascending weakness, areflexia with or without autonomic and sensory di",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32311917"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Guillain-Barré syndrome (GBS) is an autoimmune disease that leads to an axonal demyelination and/or degeneration of peripheral nerves through molecular mimicry.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15921641"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "Background: Guillain Barré Syndrome (GBS) is an autoimmune disorder caused by the immune-mediated damage of the peripheral nervous system. Increasing evidence suggests that inflammatory cytokines are important mediators for the onset and progression of GBS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31379477"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 545,
          "text": "Guillain-Barré syndrome (GBS) is an autoimmune disease caused by errant immune attack of antibody-bound ganglioside receptors on host nerve cells, resulting in paralysis. Lipooligosaccharides enveloping the prevalent enteric pathogen, Campylobacter jejuni, frequently mimic human gangliosides and can trigger GBS by stimulating the autoimmune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35100875"
        },
        {
          "offsetInBeginSection": 655,
          "offsetInEndSection": 1051,
          "text": "We suggest a comprehensive hypothesis for the pathogenesis of GBS that is based on the assumption that the condition is due to a transient (or occasionally chronic) immune deficiency, as in most cases GBS follows an infection with pathogens known to induce immunosuppression. Such infections may be followed by breakdown of immune tolerance and induction of an immune attack on peripheral nerves.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735441"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29880241"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Guillain-Barré syndrome (GBS) is an autoimmune disease in which the peripheral nerves are affected.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34246981"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Background: Guillain-Barré syndrome (GBS) is an autoimmune disease associated with significan",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38899056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "BACKGROUND: Guillian Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy often associated with previous exposure to infect",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35416870"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Guillian-Barré syndrome (GBS) is an immune mediated disease which is most commonly caused by infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37615229"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Guillain-Barre syndrome is a postinfectious disorder caused by an aberrant immune response to an infectious pathogen, resulting in an autoimmune disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482157"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Background: Guillain-Barré syndrome (GBS) is an immune-mediated polyradiculoneuropathy that represents a leading cause of motor impairment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39685612"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Guillain-Barré syndrome (GBS) is a rare immune-mediated acute polyradiculo-neuropathy that typically develops after a previous gastrointestinal or respiratory infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36430700"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "Guillain-Barre syndrome (GBS) is a life-threatening immune-mediated acute inflammatory polyneuropathy and is associated with various antecedent infections. Its association with tuberculosis is very uncommon with only a handful of cases being reported in the literature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32192609"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "Guillain-Barre syndrome (GBS) is an acute immune-mediated progressive predominantly motor symmetric polyradiculoneuropathy which causes demyelination and leads to weakness, ataxia and areflexia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34434441"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "BACKGROUND \u0026 OBJECTIVES: Guillain-Barre syndrome (GBS) is an autoimmune disease and a recognized cause of generalized progres",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28639596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "BACKROUND: Guillain-Barré syndrome (GBS) is an immune-mediated disease that affects the peripheral nervous system and may occur after some bacterial-viral ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34690009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Guillain-Barre syndrome is a postinfectious disorder caused by an aberrant immune response to an infectious pathogen, resulting in an autoimmune disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482157"
        }
      ],
      "type": "summary",
      "id": "67d0396281b1027333000027",
      "ideal_answer": [
        "Guillain-Barré syndrome (GBS) is a potentially devastating yet treatable disorder. A classically postinfectious, immune-mediated, monophasic polyradiculoneuropathy, it is the leading global cause of acquired neuromuscular paralysis. Guillain-Barre syndrome (GBS) is an autoimmune disorder affecting the peripheral nervous system, often triggered by infections.",
        "The current hypothesis for the cause of Guillain-Barre syndrome (GBS) involves molecular mimicry between epitopes found in the cell walls of certain micro-organisms, such as Campylobacter jejuni, and gangliosides in the Schwann cell membrane. This mimicry triggers an immune response that leads to the symptoms of GBS.",
        "The current hypothesis for the cause of Guillain-Barré syndrome is that it is an autoimmune disorder often triggered by an infection, such as a respiratory or gastrointestinal viral or bacterial infection.",
        "guillain-barre syndrome is an immune-mediated disease, possibly triggered by a recent infection, and driven by an immune attack targeting the peripheral nervous system, with an immunological basis that remains not fully understood.",
        "The most widely accepted hypothesis is that Guillain-Barré syndrome is believed to be an immune-mediated disease, possibly triggered by a recent infection, and driven by an immune attack targeting the peripheral nervous system.",
        "The most widely accepted hypothesis is that Guillain-Barré syndrome is an immune-mediated disease, possibly triggered by a recent infection, and driven by molecular mimicry between microbial components (such as Campylobacter jejuni lipooligosaccharides) and human gangliosides like GM1.",
        "The current hypothesis for the cause of Guillian-Barre syndrome is molecular mimicry between epitopes found in the cell walls of certain microorganisms and gangliosides in Schwann cell membranes.",
        "The most widely accepted hypothesis is that the syndrome is the result of an immune-mediated process.",
        "The current hypothesis for the cause of Guillain-Barre syndrome is molecular mimicry, where an immune response to an infection cross-reacts with nerve tissues.",
        "Guillain-Barré syndrome (GBS) is a postinfectious, immune-mediated, monophasic polyradiculoneuropathy.",
        "Guillain-Barre Syndrome (GBS) is currently hypothesized to be an autoimmune disorder, often triggered by infections such as cytomegalovirus, Epstein-Barr virus, or mycoplasma, with less common triggers including surgery, vaccination, trauma, and certain medications, although the precise immunopathological process remains undefined.",
        "The majority of cases of GBS are post infectious autoimmune disorders that develop a few days after an infection with a central or peripheral nervous system involvement. Exact answer:",
        "The current hypothesis for the cause of Guillain-Barre syndrome is that it is an autoimmune disorder affecting the peripheral nervous system, often triggered by infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), or mycoplasma.",
        "Guillain-Barre syndrome is currently thought to be an autoimmune disorder affecting the peripheral nervous system that is often triggered by preceding infections such as cytomegalovirus, Epstein-Barr virus, or mycoplasma.",
        "Guillain-Barre syndrome (GBS) is an autoimmune disorder affecting the peripheral nervous system, often triggered by infections. The etiology of Guillain-Barré syndrome (GBS) may be autoimmune.",
        "Guillain-Barre syndrome (GBS) is thought to be related to immune damage, and most patients have cytomegalovirus (CMV), Epstein-Barr virus (EBV), or mycoplasma infection before onset.",
        "Guillain-Barre syndrome (GBS) is currently thought to be an autoimmune disorder, often triggered by prior infections such as CMV, EBV, or mycoplasma. This immune-mediated process damages the peripheral nervous system.",
        "The current hypothesis for the cause of Guillain-Barre syndrome (GBS) is that it is an autoimmune disorder affecting the peripheral nervous system, often triggered by infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), or mycoplasma infection.",
        "The majority of cases of GBS are post infectious autoimmune disorders that develop a few days after an infection with a central or peripheral nervous system involvement.",
        "The current hypothesis for the cause of Guillain-Barre syndrome (GBS) is that it is an autoimmune disorder affecting the peripheral nervous system, often triggered by infections.",
        "The current hypothesis for the cause of Guillian-Barre syndrome is that it is an autoimmune disorder affecting the peripheral nervous system, often triggered by infections.",
        "The current hypothesis for the cause of Guillain-Barré syndrome (GBS) is that it is an autoimmune disorder, often triggered by infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), or mycoplasma. This autoimmune response leads to immune-mediated damage to the peripheral nervous system.",
        "Guillain-Barré Syndrome is hypothesized to be an autoimmune disorder, often triggered by preceding infections such as CMV, EBV, or mycoplasma, with the exact immunopathological process remaining not fully elucidated."
      ]
    },
    {
      "body": "What is the most common genetic variant of cystic fibrosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38662334",
        "http://www.ncbi.nlm.nih.gov/pubmed/35273129",
        "http://www.ncbi.nlm.nih.gov/pubmed/35647563",
        "http://www.ncbi.nlm.nih.gov/pubmed/32483343",
        "http://www.ncbi.nlm.nih.gov/pubmed/33786233",
        "http://www.ncbi.nlm.nih.gov/pubmed/39606474",
        "http://www.ncbi.nlm.nih.gov/pubmed/39605627",
        "http://www.ncbi.nlm.nih.gov/pubmed/22891510",
        "http://www.ncbi.nlm.nih.gov/pubmed/31523618",
        "http://www.ncbi.nlm.nih.gov/pubmed/39458161",
        "http://www.ncbi.nlm.nih.gov/pubmed/7692448",
        "http://www.ncbi.nlm.nih.gov/pubmed/10773783",
        "http://www.ncbi.nlm.nih.gov/pubmed/10799974",
        "http://www.ncbi.nlm.nih.gov/pubmed/16137181",
        "http://www.ncbi.nlm.nih.gov/pubmed/38888668",
        "http://www.ncbi.nlm.nih.gov/pubmed/19999232",
        "http://www.ncbi.nlm.nih.gov/pubmed/27482545",
        "http://www.ncbi.nlm.nih.gov/pubmed/27081564",
        "http://www.ncbi.nlm.nih.gov/pubmed/23613805",
        "http://www.ncbi.nlm.nih.gov/pubmed/7920636",
        "http://www.ncbi.nlm.nih.gov/pubmed/9599649",
        "http://www.ncbi.nlm.nih.gov/pubmed/26635942",
        "http://www.ncbi.nlm.nih.gov/pubmed/7511616",
        "http://www.ncbi.nlm.nih.gov/pubmed/7733303",
        "http://www.ncbi.nlm.nih.gov/pubmed/7682896",
        "http://www.ncbi.nlm.nih.gov/pubmed/1722027",
        "http://www.ncbi.nlm.nih.gov/pubmed/1641732",
        "http://www.ncbi.nlm.nih.gov/pubmed/31326599",
        "http://www.ncbi.nlm.nih.gov/pubmed/29903751",
        "http://www.ncbi.nlm.nih.gov/pubmed/38139828",
        "http://www.ncbi.nlm.nih.gov/pubmed/37746536",
        "http://www.ncbi.nlm.nih.gov/pubmed/34067708",
        "http://www.ncbi.nlm.nih.gov/pubmed/21411740",
        "http://www.ncbi.nlm.nih.gov/pubmed/29145426",
        "http://www.ncbi.nlm.nih.gov/pubmed/26863533",
        "http://www.ncbi.nlm.nih.gov/pubmed/1380673",
        "http://www.ncbi.nlm.nih.gov/pubmed/17762173",
        "http://www.ncbi.nlm.nih.gov/pubmed/8163293",
        "http://www.ncbi.nlm.nih.gov/pubmed/17985657"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 420,
          "text": "The disease manifests due to genetic aberrations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38662334"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe) is the most common pathogenic allele underlying cystic fibrosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647563"
        },
        {
          "offsetInBeginSection": 917,
          "offsetInEndSection": 1028,
          "text": "most common disease-causing variant was c.1521_1523delCTT (p.(Phe508del)) followed by c.1652G\u003eA (p.(Gly551Asp))",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483343"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 391,
          "text": "Over 1800 cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations have been identified so far and the delta F 508 del mutation is the most common mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33786233"
        },
        {
          "offsetInBeginSection": 423,
          "offsetInEndSection": 625,
          "text": "The results showed that initial theoretical and experimental melting thresholds aligned well after three structural perturbations including the F508del mutation, the most common cause of cystic fibrosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39606474"
        },
        {
          "offsetInBeginSection": 760,
          "offsetInEndSection": 912,
          "text": "In total, eighty-seven different genotypes were identified within our CF cohort, with the most abundant mutation being the F508del mutation, 298/322 (92",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39458161"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 391,
          "text": "Cystic fibrosis (CF) is a progressive genetic disorder, inherited by the autosomal recessive mode of inheritance and more frequently seen in the Caucasian population with a carrier rate of 1:29 in Caucasian-Americans. Over 1800 cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations have been identified so far and the delta F 508 del mutation is the most common mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33786233"
        },
        {
          "offsetInBeginSection": 423,
          "offsetInEndSection": 626,
          "text": "The results showed that initial theoretical and experimental melting thresholds aligned well after three structural perturbations including the F508del mutation, the most common cause of cystic fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39606474"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Trikafta is well-known for correcting the thermal and gating defects caused by the most common cystic fibrosis mutation F508del in the human cystic fibrosis transmembrane conductance regulator even at physiological temperatur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39605627"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe) is the most common pathogenic allele underlying cystic fibrosis (CF), and its frequency varies in a geographic cline across Europe.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647563"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe) is the most common pathogenic allele underlying cystic fibrosis (CF),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647563"
        },
        {
          "offsetInBeginSection": 305,
          "offsetInEndSection": 490,
          "text": "Besides the most common mutation, DeltaF508, accounting for about 70% of CF chromosomes worldwide, more than 850 mutant alleles have been reported to the CF Genetic Analysis Consortium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10773783"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 549,
          "text": "Since the 1989 discovery of the genetic variant F508del, the most common cystic fibrosis transmembrane conductance regulator (CFTR) mutation, more than 1900 CF mutations have been identified.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891510"
        },
        {
          "offsetInBeginSection": 853,
          "offsetInEndSection": 966,
          "text": "The most common CF mutation, c.l521_ 1523del (legacy name F508del), was found with an overall incidence of 75.9%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523618"
        },
        {
          "offsetInBeginSection": 386,
          "offsetInEndSection": 541,
          "text": "DeltaF508 is the most common mutation at 67.9% of CF mutations, followed by G542X (2.5%), N1303K (2.0%), 1717-1G--\u003eA (1.2%), R553X (0.8%) and G551D (0.7%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10799974"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 177,
          "text": " CFTR gene. The most severe, DeltaF508, mutation accounts for nearly 70% of CF case",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16137181"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 356,
          "text": "Beside the major mutation delta F508, which accounts for approximately 68% of all CF chromosomes, more than 350 different point mutations leading to this disease have been detected and communicated to the \u0027Cystic Fibrosis Genetic Analysis Consortium\u0027.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8163293"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 242,
          "text": "The most commonly investigated variant causing CF is F508del.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38888668"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 315,
          "text": "The most common mutation in CFTR worldwide is deltaF508 and cystic fibrosis genetic analysis consortium revealed that this mutation is responsible for approximately 66% of all CF chromosomes in the world",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19999232"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Cystic fibrosis (CF) results from mutations in the CF transmembrane conductance regulator (CFTR) gene, which codes for the CFTR channel protein. The most common mutation in CF is F508del, which produces a misfolded protein with diminished channel activity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27482545"
        },
        {
          "offsetInBeginSection": 739,
          "offsetInEndSection": 799,
          "text": "p.F508del, the most common CF-causing mutation in Caucasians",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27081564"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 386,
          "text": "ibrosis (CF). CFTR mutations (F508del is the most common) lead to a decreased secretion of chloride/water, and to mucus sticky secretions, in pancreas, respiratory and gastroint",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613805"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "delta F508 is the most frequent cystic fibrosis (CF) mutation and accounts for approximately 70% of CF chromosomes worldwide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7920636"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Delta F508 mutation of the CFTR gene is the most frequent deleterious allele involved in cystic fibrosis (CF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9599649"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 264,
          "text": "phenotypes. Mutation of ΔF508 in the CFTR gene is the most important and lethal mutation in CF, which contains 70% of all predisposing mutations for ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26635942"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "The most common mutation in the gene associated with cystic fibrosis (CF) causes deletion of phenylalanine at residue 508 (delta F508) of the gene product called CFTR",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7733303"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis; the most common mutation is deletion of phenylalanine at position 508 (delta F508",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7682896"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 409,
          "text": "Deletion of phenylalanine at amino-acid position 508 in CFTR (delta F508 CFTR) is the most common mutation in cystic fibrosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1722027"
        },
        {
          "offsetInBeginSection": 397,
          "offsetInEndSection": 518,
          "text": "The CF gene, named CFTR, was cloned and sequenced in 1989 and the most common CF-causing mutation, delta F508, identified",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1641732"
        },
        {
          "offsetInBeginSection": 563,
          "offsetInEndSection": 626,
          "text": "the F508del mutation, the most common cause of cystic fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39606474"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Deletion of phenylalanine at position 508 (F508del) in the CFTR protein, is the most common mutation causing cystic fibrosis (CF).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31326599"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Deletion of phenylalanine at position 508 (F508del) in cystic fibrosis transmembrane conductance regulator (CFTR) is the most common cystic fibrosis (CF)-causing mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29903751"
        },
        {
          "offsetInBeginSection": 315,
          "offsetInEndSection": 538,
          "text": "Deletion of phenylalanine at position 508, F508del, the most common CF-causing mutation, destabilises the CFTR protein, causing folding and trafficking defects that lead to a dramatic reduction in its functional expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38139828"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 315,
          "text": "The most common mutation of CF is F508del, due to loss of 3 base pairs, causing deletion of phenylalanine, at position 508.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37746536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Deletion of phenylalanine at position 508 (F508del) in the CFTR chloride channel is the most frequent mutation in cystic fibrosis (CF) patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34067708"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 268,
          "text": "The most common CF-associated mutation is ΔF508, which deletes a phenylalanine in position 508",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21411740"
        },
        {
          "offsetInBeginSection": 496,
          "offsetInEndSection": 713,
          "text": "The deletion of phenylalanine at position 508 (F508del) is the most common mutation in CF which leads to an altered protein (F508del-CFTR) folding with a nascent protein retained within the ER and is quickly degraded.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145426"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "The most common mutation of CFTR, affecting approximately 90% of CF patients, is a deletion of phenylalanine at position 508 (F508del, ΔF508)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26863533"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 213,
          "text": "The most common CF-associated mutation is deletion of phenylalanine at residue 508, CFTR delta F508.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7511616"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 416,
          "text": "The most common mutation in cystic fibrosis is deletion of phenylalanine at residue 508 (CFTR delta F508)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1380673"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "The most common cause of cystic fibrosis is deletion of Phe-508 (delta F508) from the cystic fibrosis transmembrane conductance regulator (CFTR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7692448"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 275,
          "text": "The most common of these mutations is deletion of a phenylalanine residue at position 508 (Delta F508), which accounts for approximately 70% of all CF alleles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17762173"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 316,
          "text": "The most common mutation in CFTR worldwide is deltaF508 and cystic fibrosis genetic analysis consortium revealed that this mutation is responsible for approximately 66% of all CF chromosomes in the world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19999232"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe) is the most common pathogenic allele underlying cystic fibrosis (CF), and its frequency varies in a geographic cline across Europe. We hypo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35647563"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 548,
          "text": "Since the 1989 discovery of the genetic variant F508del, the most common cystic fibrosis transmembrane conductance regulator (CFTR) mutation, more than 1900 CF mutations have been identified",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891510"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "The frequencies of the deltaF508 deletion, the most common cystic fibrosis mutation in Europeans and European-derived populations, and the XV2C and KM19 restriction fragment length polymorphisms that are tightly linked to the CFTR locus vary among populations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17985657"
        },
        {
          "offsetInBeginSection": 837,
          "offsetInEndSection": 1146,
          "text": "This finding is useful for populations containing a large Amerindian component and helps us to understand the origins of the deltaF508 deletion, the most common cystic fibrosis mutation in Europeans and European-derived populations, as well as the different incidences of cystic fibrosis in continental groups",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17985657"
        }
      ],
      "id": "67e2849218b1e36f2e00007a",
      "ideal_answer": [
        "CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe) is the most common pathogenic allele underlying cystic fibrosis",
        "The most common genetic variant of cystic fibrosis is the ΔF508 (Delta F508) mutation in the CFTR gene.",
        "The most common genetic variant of cystic fibrosis is the F508del mutation, also referred to as DeltaF508 or p.Phe508del. It occurs in approximately 50-70% of patients with cystic fibrosis, although frequencies vary in different populations.",
        "The most common genetic variant of cystic fibrosis (CF) is the deletion of phenylalanine at position 508 (F508del). This mutation occurs in approximately 50-90% of CF patients, depending on the population studied. F508del is a deletion of three base pairs that leads to the loss of a phenylalanine residue at position 508 in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This mutation causes destabilization of the CFTR protein, leading to folding and trafficking defects, which ultimately result in a dramatic reduction in its functional expression. F508del is considered the most frequent and severe mutation associated with CF, and it is often used as a model for studying the disease\u0027s pathophysiology and developing therapeutic strategies.",
        "The most common genetic variant causing cystic fibrosis is CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe), which is a pathogenic allele affecting the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
        "Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The most common genetic variant is the ΔF508 (also known as F508del) mutation, which involves a deletion of three nucleotides leading to the loss of phenylalanine at position 508 in the CFTR protein. This mutation results in defective protein folding, impaired chloride ion transport, and the characteristic clinical features of cystic fibrosis. The ΔF508 variant accounts for approximately 70% of cystic fibrosis cases globally.",
        "The most common genetic variant of cystic fibrosis is the F508del mutation, also referred to as p.Phe508del or c.1521_1523delCTT. This mutation occurs in approximately 50-70% of patients with cystic fibrosis.",
        "The most common genetic variant of cystic fibrosis is the F508del variant, specifically the c.1521_1523delCTT (p.Phe508delPhe) allele, which is the most common pathogenic allele underlying the disease.",
        "The most common genetic variant in cystic fibrosis is the F508del mutation in the CFTR gene, also known as DeltaF508 or p.Phe508del.",
        "The most common genetic variant of cystic fibrosis is the CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe) mutation.",
        "The most common genetic variant of cystic fibrosis is the CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe) allele. This variant is a deletion of three nucleotides (CTT) at position 1521-1523 in the CFTR gene, resulting in the loss of phenylalanine at position 508. It is the most common pathogenic allele underlying cystic fibrosis and accounts for approximately 70% of all cystic fibrosis cases worldwide."
      ],
      "exact_answer": [
        [
          "CFTR F508del (c.1521_1523delCTT, p.Phe508delPhe)"
        ]
      ]
    },
    {
      "body": "What are the key components of the glioblastoma tumor microenvironment?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39329940",
        "http://www.ncbi.nlm.nih.gov/pubmed/38523646",
        "http://www.ncbi.nlm.nih.gov/pubmed/33804731",
        "http://www.ncbi.nlm.nih.gov/pubmed/36968288",
        "http://www.ncbi.nlm.nih.gov/pubmed/33374253",
        "http://www.ncbi.nlm.nih.gov/pubmed/35205842",
        "http://www.ncbi.nlm.nih.gov/pubmed/35269652",
        "http://www.ncbi.nlm.nih.gov/pubmed/36964121",
        "http://www.ncbi.nlm.nih.gov/pubmed/34185283",
        "http://www.ncbi.nlm.nih.gov/pubmed/31225500",
        "http://www.ncbi.nlm.nih.gov/pubmed/39061427",
        "http://www.ncbi.nlm.nih.gov/pubmed/36332834",
        "http://www.ncbi.nlm.nih.gov/pubmed/37108208",
        "http://www.ncbi.nlm.nih.gov/pubmed/35871725",
        "http://www.ncbi.nlm.nih.gov/pubmed/35920986",
        "http://www.ncbi.nlm.nih.gov/pubmed/39722404",
        "http://www.ncbi.nlm.nih.gov/pubmed/39684497",
        "http://www.ncbi.nlm.nih.gov/pubmed/31650201",
        "http://www.ncbi.nlm.nih.gov/pubmed/37601668",
        "http://www.ncbi.nlm.nih.gov/pubmed/39684754",
        "http://www.ncbi.nlm.nih.gov/pubmed/36594466",
        "http://www.ncbi.nlm.nih.gov/pubmed/30240060",
        "http://www.ncbi.nlm.nih.gov/pubmed/32942567",
        "http://www.ncbi.nlm.nih.gov/pubmed/33802060",
        "http://www.ncbi.nlm.nih.gov/pubmed/36611806",
        "http://www.ncbi.nlm.nih.gov/pubmed/27815396",
        "http://www.ncbi.nlm.nih.gov/pubmed/37686652",
        "http://www.ncbi.nlm.nih.gov/pubmed/25174308",
        "http://www.ncbi.nlm.nih.gov/pubmed/31632393",
        "http://www.ncbi.nlm.nih.gov/pubmed/37553300",
        "http://www.ncbi.nlm.nih.gov/pubmed/35043276",
        "http://www.ncbi.nlm.nih.gov/pubmed/39604503",
        "http://www.ncbi.nlm.nih.gov/pubmed/38566128",
        "http://www.ncbi.nlm.nih.gov/pubmed/39157370",
        "http://www.ncbi.nlm.nih.gov/pubmed/35228161",
        "http://www.ncbi.nlm.nih.gov/pubmed/34397322",
        "http://www.ncbi.nlm.nih.gov/pubmed/19464631",
        "http://www.ncbi.nlm.nih.gov/pubmed/33193404",
        "http://www.ncbi.nlm.nih.gov/pubmed/30248992",
        "http://www.ncbi.nlm.nih.gov/pubmed/30902924",
        "http://www.ncbi.nlm.nih.gov/pubmed/35967394"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 612,
          "offsetInEndSection": 985,
          "text": "The main components of the GBM TME are represented by the extracellular matrix (ECM), glioma cells and glioma stem cells (GSCs), immune cells (microglia, macrophages, neutrophils, lymphocytes), neuronal cells, all of them having dynamic interactions and being able to influence the tumoral growth, progression, and drug resistance thus being a potential therapeutic target.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39329940"
        },
        {
          "offsetInBeginSection": 638,
          "offsetInEndSection": 933,
          "text": "The tumor microenvironment is a complex network of immune components like microglia, macrophages, T cells, B cells, natural killer (NK) cells, dendritic cells and myeloid-derived suppressor cells, and non-immune components such as extracellular matrix, endothelial cells, astrocytes and neurons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38523646"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 734,
          "text": "GBM\u0027s microenvironment is multifaceted and is made up of soluble factors, extracellular matrix components, tissue-resident cell types (e.g., neurons, astrocytes, endothelial cells, pericytes, and fibroblasts) together with resident (e.g., microglia) or recruited (e.g., bone marrow-derived macrophages) immune cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33804731"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968288"
        },
        {
          "offsetInBeginSection": 304,
          "offsetInEndSection": 464,
          "text": "Myeloid cells are the most predominant contributors to the GBM microenvironment; these cells are critical regulators of immune and therapeutic responses to GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33374253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) play a crucial role in glioblastoma (GBM) progression by interacting with glioma stem cells (GSCs)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39722404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Glioblastoma (GBM) is an aggressive brain cancer with a highly immunosuppressive tumor microenvironment (TME), invariably infiltrated by tumor-associated macrophages (TAMs)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684497"
        },
        {
          "offsetInBeginSection": 295,
          "offsetInEndSection": 1016,
          "text": "The complex interaction of neoplastic cells with tumor microenvironment (TME) along with the presence of cancer stem-like cells (CSCs) largely confers to extrinsic and intrinsic GB heterogeneity. Recent data indicate that glioma cells secrete a variety of soluble immunoregulatory factors to attract different cell types to TME including astrocytes, endothelial cells, circulating stem cells, and a range of immune cells. These further induce a local production of cytokines, chemokines, and growth factors which upon crosstalk with extracellular matrix (ECM) components reprogram immune cells to inflammatory or anti-inflammatory phenotypes and manipulate host\u0027s immune response in favor of cancer growth and metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31650201"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 454,
          "text": "Many components participate critically to tumor development and expansion such as blood vessels, immune cells or components of the nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36964121"
        },
        {
          "offsetInBeginSection": 449,
          "offsetInEndSection": 634,
          "text": "Along with these, other vital components of the TME are fibroblasts, immune and inflammatory cells, blood and lymphatic vascular networks, extracellular matrix, and signaling molecules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34185283"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 322,
          "text": "Tumor-associated macrophages and microglia (TAMs) are a dominant population of immune cells in the GBM TME that contribute to most GBM hallmarks, including immunosuppression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36594466"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 461,
          "text": "The key components of a GBM TME are outlined, including microbiomes, vasculature, extracellular matrix (ECM), infiltrating parenchymal and peripheral immune cells and molecules, and chemical gradients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36332834"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 448,
          "text": "These variations are determined by the tumor microenvironment (TME), which refers to all the molecules, cells, and structures that encompass and support other cells and tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34185283"
        },
        {
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1128,
          "text": "Here we discuss the role of extracellular matrix and immune cell populations, major components of the tumor ecosystem in glioblastoma, as well as signaling pathways that regulate GSC maintenance and invasion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35920986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 414,
          "text": "The glioma microenvironment is a critical regulator of tumor progression. It contains different cellular components such as blood vessels, immune cells, and neuroglial cells. It also contains non-cellular components, such as the extracellular matrix, extracellular vesicles, and cytokines, and has certain physicochemical properties, such as low pH, hypoxia, elevated interstitial pressure, and impaired perfusion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942567"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 453,
          "text": "We examined relationships of the cellular microenvironment, including astrocytes, microglia, oligodendrocytes, and blood vessels, to survival in glioblastoma patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 482,
          "text": "Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells. The TME is a dynamic environment which is heavily influenced by alterations in cellular composition, cell-to-cell contact and cellular metabolic products as well as other chemical factors, such as pH and oxygen levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968288"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 467,
          "text": "The TME is composed of various neuronal and immune cells, as well as non-cellular components, including metabolic products, cellular interactions, and chemical compositions, all of which play a critical role in GBM development and therapeutic resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37686652"
        },
        {
          "offsetInBeginSection": 417,
          "offsetInEndSection": 690,
          "text": "The interaction of GBM cells with the TME involves cellular components such as stem-like cells, glia, endothelial cells, and non-cellular components such as the extracellular matrix, enhanced hypoxia, and soluble factors such as adenosine, which promote GBM\u0027s invasiveness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108208"
        },
        {
          "offsetInBeginSection": 555,
          "offsetInEndSection": 771,
          "text": "These cell-extrinsic factors, collectively termed the microenvironment, include the extracellular matrix, blood vessels, stromal cells that surround tumor cells, and all associated soluble and scaffold-bound signals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25174308"
        },
        {
          "offsetInBeginSection": 51,
          "offsetInEndSection": 261,
          "text": "The brain tumor microenvironment (TME) hosts a unique collection of cells, soluble factors, and extracellular matrix components that regulate disease evolution of both primary and metastatic brain malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31632393"
        },
        {
          "offsetInBeginSection": 388,
          "offsetInEndSection": 579,
          "text": "The tumor microenvironment of glioblastoma is a highly dynamic and heterogeneous system that consists of not only cancerous cells but also various resident or infiltrating inflammatory cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061427"
        },
        {
          "offsetInBeginSection": 302,
          "offsetInEndSection": 463,
          "text": "Soluble factors, extracellular matrix components, tissue-resident cell types, resident or newly recruited immune cells together make up the GBM microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35269652"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 466,
          "text": "The TME is composed of various neuronal and immune cells, as well as non-cellular components, including metabolic products, cellular interactions, and chemical compositions, all of which play a critical role in GBM development and therapeutic resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37686652"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968288"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 341,
          "text": "The tumor microenvironment includes several components, such as endothelial cells, immune cells, and extracellular matrix components like matrix metalloproteinase-9 (MMP-9), which facilitates the proliferation of endothelial cells with pro-angiogenic roles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684754"
        },
        {
          "offsetInBeginSection": 372,
          "offsetInEndSection": 681,
          "text": "The innate immune cells in the GBM tumor microenvironment, including microglia, astrocytes, and macrophages, express pattern recognition receptors such as NLRs (Nucleotide-binding domain and leucine-rich repeat-containing) that sense pathogen- and damage-associated molecular patterns initiating inflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39604503"
        },
        {
          "offsetInBeginSection": 612,
          "offsetInEndSection": 984,
          "text": "The main components of the GBM TME are represented by the extracellular matrix (ECM), glioma cells and glioma stem cells (GSCs), immune cells (microglia, macrophages, neutrophils, lymphocytes), neuronal cells, all of them having dynamic interactions and being able to influence the tumoral growth, progression, and drug resistance thus being a potential therapeutic target",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39329940"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 320,
          "text": "A major contributing factor to glioblastoma (GBM) development and progression is its ability to evade the immune system by creating an immune-suppressive environment, where GBM-associated myeloid cells, including resident microglia and peripheral monocyte-derived macrophages, play critical pro-tumoral roles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38566128"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 260,
          "text": "Cancer associated fibroblasts (CAF), an important cancer-promoting and immunosuppressive component of the tumor immune microenvironment (TIME), have recently been found to infiltrate adult diffuse highest-grade gliomas (ADHGG) (gliomas of grade IV)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39157370"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 376,
          "text": "Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults, causing many deaths each year. The life expectancy of patients from the time of diagnosis does not exceed 15 months. Tumoral cells are generally surrounded by a bed of tumor microenvironment (TME), composed of various components such as different immune cells, stromal cells, and blood vessels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34397322"
        },
        {
          "offsetInBeginSection": 556,
          "offsetInEndSection": 773,
          "text": "Here, we discuss 3 ideas about how the microenvironment, consisting of a vasculature, inflammatory cells, immune cells, growth factors, and extracellular matrix, might provide therapeutic targets in glioblastoma (GBM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19464631"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 234,
          "text": "The tumor microenvironment comprises diverse tumor cells, different types of immune cells, and the extracellular matrix. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37553300"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968288"
        },
        {
          "offsetInBeginSection": 630,
          "offsetInEndSection": 925,
          "text": "Recent studies reveal that EGFR alterations not only promote GBM cell proliferation but also influence immune components in the tumor microenvironment (TME), leading to the recruitment of immunosuppressive cells (e.g., M2-like TAMs, MDSCs, and Tregs), and inhibition of T and NK cell activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37601668"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 258,
          "text": "Increasing evidence has revealed that infiltrating immune cells and other stromal components in the tumor microenvironment (TME) are associated with prognosis of GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33193404"
        },
        {
          "offsetInBeginSection": 119,
          "offsetInEndSection": 585,
          "text": "TME consists of several types of stromal, endothelial and immune cells, which are recruited by cancer stem cells (CSCs) to influence CSC phenotype and behavior. TME also promotes the establishment of specific conditions such as hypoxia and acidosis, which play a critical role in glioblastoma chemoresistance, interfering with angiogenesis, apoptosis, DNA repair, oxidative stress, immune escape, expression and activity of multi-drug resistance (MDR)-related genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30248992"
        },
        {
          "offsetInBeginSection": 429,
          "offsetInEndSection": 678,
          "text": "Within this tumour microenvironment, the extracellular matrix profoundly influences the way cancer cells become invasive, and changes to extracellular (pH and oxygen levels) and metabolic (glucose and lactate) components support glioblastoma growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30902924"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 460,
          "text": "The key components of a GBM TME are outlined, including microbiomes, vasculature, extracellular matrix (ECM), infiltrating parenchymal and peripheral immune cells and molecules, and chemical gradients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36332834"
        },
        {
          "offsetInBeginSection": 417,
          "offsetInEndSection": 689,
          "text": "The interaction of GBM cells with the TME involves cellular components such as stem-like cells, glia, endothelial cells, and non-cellular components such as the extracellular matrix, enhanced hypoxia, and soluble factors such as adenosine, which promote GBM\u0027s invasiveness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108208"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 375,
          "text": "Tumoral cells are generally surrounded by a bed of tumor microenvironment (TME), composed of various components such as different immune cells, stromal cells, and blood vessels",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34397322"
        },
        {
          "offsetInBeginSection": 393,
          "offsetInEndSection": 496,
          "text": "TME consists of several different cell types, such as stromal cells, endothelial cells and immune cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35967394"
        }
      ],
      "id": "67eaf28f18b1e36f2e0000df",
      "ideal_answer": [
        "The main components of the GBM tumor microenvironment are represented by the extracellular matrix (ECM), glioma cells and glioma stem cells (GSCs), immune cells (microglia, macrophages, neutrophils, lymphocytes), neuronal cells, all of them having dynamic interactions and being able to influence the tumoral growth, progression, and drug resistance thus being a potential therapeutic target.",
        "The key components of the glioblastoma tumor microenvironment include cancer cells, which are highly heterogeneous; immune cells such as microglia, macrophages, T cells, and myeloid-derived suppressor cells (MDSCs) that can have both tumor-promoting and tumor-suppressing roles; endothelial cells that form the blood vessels supplying the tumor with nutrients and oxygen; pericytes that support endothelial cells and contribute to blood vessel stability and function; the extracellular matrix (ECM), a complex network providing structural support and influencing cell behavior; cancer stem cells, a subpopulation with self-renewal ability driving tumor growth and recurrence; fibroblasts that contribute to the ECM and influence tumor progression and therapy response; and hypoxic regions within the tumor that activate hypoxia-inducible factors (HIFs), promoting tumor aggressiveness and resistance to therapy. These components interact dynamically, influencing tumor growth, progression, and response to treatment.",
        "The key components of the glioblastoma (GBM) tumor microenvironment (TME) include the extracellular matrix (ECM), tumor cells, glioma stem cells (GSCs), immune cells (microglia, macrophages, neutrophils, lymphocytes, T cells, B cells, natural killer (NK) cells, dendritic cells, myeloid-derived suppressor cells), neuronal cells, endothelial cells, astrocytes, fibroblasts, blood and lymphatic vascular networks, soluble factors, metabolic products, cellular interactions, chemical compositions, chemical gradients, and microbiomes. The TME also involves infiltrating parenchymal and peripheral immune cells and molecules.",
        "The glioblastoma tumor microenvironment consists of diverse cellular and non-cellular components that interact to affect tumor behavior and treatment response. It includes tumor cells and resident brain cells, such as astrocytes, endothelial cells, and neuronal cells, as well as immune cells including tumor-associated macrophages, microglia, T cells, and myeloid-derived suppressor cells. Cells in transit, such as marrow-derived immune cells, further add to its heterogeneity. Additionally, specialized niches like the perivascular area, which includes pericytes, contribute to its complexity. The non-cellular fraction consists of the extracellular matrix and secretory components, including chemokines, cytokines, and growth factors, along with metabolic products and chemical compositions that collectively promote tumor growth, invasion, and therapeutic resistance.",
        "The glioblastoma tumor microenvironment\u0027s key components include immune cells (microglia, macrophages, T cells, B cells, NK cells, dendritic cells, myeloid-derived suppressor cells, and TAM), non-immune cells (endothelial cells, astrocytes, neurons, fibroblasts), extracellular matrix, blood and lymphatic vascular networks, signaling molecules, and the gut microbiota influencing via the gut-brain axis. These elements interact to facilitate tumor heterogeneity, angiogenesis, and immunosuppression, complicating treatment efficacy. Glioma stem cells, while influential, are a subset within this complex interplay, particularly among non-immune cell interactions.",
        "The glioblastoma tumor microenvironment is complex and includes several key components. At its core are the malignant glioblastoma cells along with a subpopulation of glioma stem cells, which drive tumor initiation, progression, and recurrence. The environment also contains a diverse array of immune cells such as microglia, macrophages, T cells, B cells, natural killer cells, dendritic cells, and myeloid-derived suppressor cells. These immune components often operate in an immunosuppressive state, facilitating tumor evasion from treatments. Abnormal vascular structures marked by high levels of VEGF are present, contributing to irregular angiogenesis and supporting tumor growth, with endothelial cells, neural stem cells, and fibroblasts playing supportive roles. Additionally, the extracellular matrix provides structural support while various soluble factors—chemokines, cytokines, and growth factors—mediate cellular communication and foster a microenvironment conducive to tumor proliferation and invasion under altered metabolic conditions. Emerging evidence points to a potential role of the gut-brain axis, where gut microbiota might indirectly influence tumor development and immune regulation, emphasizing the need for personalized therapeutic strategies.",
        "Based on the provided abstracts, the key components of the glioblastoma tumor microenvironment (TME) include:\n\n1. **Extracellular matrix (ECM)**: a critical component that interacts with glioma cells and influences tumoral growth, progression, and drug resistance.\n2. **Glioma cells and glioma stem cells (GSCs)**: the primary cancer cells that drive tumor growth and progression.\n3. **Immune cells**: including microglia, macrophages, neutrophils, and lymphocytes, which interact with glioma cells and influence the TME.\n4. **Neuronal cells**: present in the TME and influencing tumoral behavior.\n5. **Vasculature**: blood vessels that supply oxygen and nutrients to the tumor.\n6. **Microbiomes**: microbial communities that inhabit the TME and may influence tumor behavior.\n7. **Chemical gradients**: gradients of growth factors, cytokines, and other molecules that regulate cell behavior in the TME.\n\nThese components interact dynamically, influencing each other and the tumor\u0027s behavior, making them potential therapeutic targets for glioblastoma treatment.",
        "The glioblastoma tumor microenvironment (TME) is a complex ecosystem comprising diverse cellular elements including immune cells (microglia, macrophages, T cells, B cells, NK cells, dendritic cells, myeloid-derived suppressor cells) and non-immune cells (endothelial cells, astrocytes, neurons, fibroblasts). Non-cellular components such as the extracellular matrix, signaling molecules, chemical gradients (including hypoxia and pH levels), and neurotransmitters also play crucial roles. Additionally, the gut microbiota influences the TME via the gut-brain axis. Glioma stem cells are pivotal in tumorigenesis, therapeutic resistance, and recurrence, interacting within this complex interplay to facilitate tumor heterogeneity, angiogenesis, and immunosuppression.",
        "The main components of the GBM TME are represented by the extracellular matrix (ECM), glioma cells and glioma stem cells (GSCs), immune cells (microglia, macrophages, neutrophils, lymphocytes), neuronal cells, all of them having dynamic interactions and being able to influence the tumoral growth, progression, and drug resistance thus being a potential therapeutic target.",
        "The glioblastoma tumor microenvironment is a complex ecosystem composed of multiple cellular and non-cellular components. These include tumor cells like glioma cells and glioma stem cells, immune cells such as microglia and macrophages, neuronal cells, and the extracellular matrix. Each of these components plays a critical role in tumor progression, interaction, and potential drug resistance.",
        "The glioblastoma tumor microenvironment (TME) is primarily composed of the extracellular matrix (ECM), glioma cells, glioma stem cells (GSCs), neuronal cells, and a diverse set of immune cells including microglia, macrophages, and lymphocytes, among others. Additionally, endothelial cells and astrocytes play supportive roles. These components interact dynamically, influencing tumoral growth, progression, and drug resistance, while also promoting angiogenesis and tumor heterogeneity, making them potential targets for therapeutic intervention.",
        "The glioblastoma tumor microenvironment consists of multiple key components including immune cells (such as microglia, macrophages, T cells, B cells, NK cells, and dendritic cells), glioma cells and glioma stem cells, and non-immune components (including extracellular matrix, endothelial cells, astrocytes, and neurons). These components interact dynamically and influence tumor growth, progression, and drug resistance, making them potential therapeutic targets.",
        "The glioblastoma tumor microenvironment (GBM TME) comprises a complex network of cellular and non-cellular components. Key cellular elements include glioma cells and glioma stem cells (GSCs), which drive tumor growth and recurrence. Immune components encompass microglia, macrophages, neutrophils, T cells, B cells, natural killer (NK) cells, dendritic cells, and myeloid-derived suppressor cells, which collectively modulate immune responses and tumor progression. Non-immune cellular constituents involve endothelial cells (forming blood vessels), astrocytes, and neurons, which interact with tumor cells. The extracellular matrix (ECM) provides structural support and biochemical cues. These components dynamically interact to influence tumor growth, invasion, therapy resistance, and represent potential therapeutic targets.",
        "The key components of the glioblastoma tumor microenvironment include immune cells such as microglia, macrophages, neutrophils, lymphocytes, glioma cells, glioma stem cells, and non-immune components like extracellular matrix, endothelial cells, astrocytes, and neuronal cells, which interact dynamically and influence tumoral growth, progression, and drug resistance, making them potential therapeutic targets.",
        "The glioblastoma tumor microenvironment is complex and includes both cellular and non-cellular components, such as the extracellular matrix, glioma cells (including glioma stem cells), diverse immune cells (microglia, macrophages, neutrophils, lymphocytes, T cells, B cells, NK cells, dendritic cells, and myeloid-derived suppressor cells), and other non-immune cells like endothelial cells, astrocytes, and neurons.",
        "The glioblastoma tumor microenvironment (TME) comprises **immune components** (microglia, macrophages, neutrophils, T cells, B cells, natural killer [NK] cells, dendritic cells, myeloid-derived suppressor cells) and **non-immune components** (extracellular matrix [ECM], glioma cells, glioma stem cells [GSCs], endothelial cells, astrocytes, neurons). These elements interact dynamically to drive tumor growth, progression, and therapy resistance.",
        "The key components of the glioblastoma tumor microenvironment (TME) include **immune cells** (microglia, macrophages, neutrophils, T cells, B cells, natural killer [NK] cells, dendritic cells, myeloid-derived suppressor cells, lymphocytes) and **non-immune elements** such as the extracellular matrix (ECM), glioma cells, glioma stem cells (GSCs), endothelial cells, astrocytes, and neurons. These components dynamically interact to drive tumor growth, progression, and resistance to therapies.",
        "Glioblastoma’s tumor microenvironment is highly heterogeneous and consists of glioma cells and glioma stem cells, a variety of immune cells including microglia, macrophages, T cells, natural killer cells, and myeloid-derived suppressor cells, as well as resident brain cells like astrocytes, neurons, endothelial cells, and pericytes. In addition, this environment encompasses non-cellular elements such as an extracellular matrix, metabolic products, and secretory components including chemokines, cytokines, and growth factors that together regulate tumor growth, progression, and therapy resistance.",
        "The glioblastoma tumor microenvironment comprises both cellular and non-cellular components, including glioma cells and glioma stem cells, the extracellular matrix, and various immune cells such as microglia, macrophages, neutrophils, T cells, B cells, natural killer cells, dendritic cells, and myeloid-derived suppressor cells. It also includes non-immune components like endothelial cells, astrocytes, and neurons, all of which interact dynamically to influence tumor growth, progression, and drug resistance.",
        "The key components of the glioblastoma tumor microenvironment (TME) include the extracellular matrix (ECM), glioma cells, glioma stem cells (GSCs), immune cells (such as microglia, macrophages, neutrophils, lymphocytes, T cells, B cells, natural killer cells, dendritic cells, and myeloid-derived suppressor cells), as well as non-immune components like endothelial cells, astrocytes, and neurons.",
        "The key components of the glioblastoma tumor microenvironment include the extracellular matrix (ECM), glioma cells and glioma stem cells (GSCs), immune cells such as microglia, macrophages, neutrophils, lymphocytes, T cells, B cells, natural killer (NK) cells, dendritic cells and myeloid-derived suppressor cells, as well as non-immune components like endothelial cells, astrocytes and neurons. These components have dynamic interactions that influence tumor growth, progression, drug resistance, and represent potential therapeutic targets.",
        "The key components of the glioblastoma tumor microenvironment (TME) include: extracellular matrix (ECM), glioma cells, glioma stem cells (GSCs), immune cells (such as microglia, macrophages, neutrophils, lymphocytes), neuronal cells, endothelial cells, and astrocytes. These components interact dynamically and influence tumor growth, progression, and drug resistance.",
        "The key components of the glioblastoma (GBM) tumor microenvironment (TME) include both immune and non-immune elements. Immune cells such as microglia, macrophages, neutrophils, lymphocytes, T cells, B cells, natural killer (NK) cells, dendritic cells, and myeloid-derived suppressor cells play crucial roles in the dynamic interactions within the TME. Non-immune components include the extracellular matrix (ECM), glioma cells, glioma stem cells (GSCs), endothelial cells, astrocytes, and neurons. These elements collectively influence tumor growth, progression, and drug resistance, making them potential therapeutic targets.",
        "The glioblastoma tumor microenvironment (TME) consists of both immune and non-immune components. Immune elements include microglia, macrophages, T cells, B cells, natural killer (NK) cells, dendritic cells, and myeloid-derived suppressor cells. Non-immune components comprise the extracellular matrix (ECM), endothelial cells, astrocytes, and neurons. Additionally, glioma cells and glioma stem cells (GSCs) are integral, influencing tumor dynamics and therapeutic response. These elements interact dynamically, impacting growth, progression, and drug resistance, making them potential targets for therapy.",
        "The glioblastoma tumor microenvironment (TME) is a complex ecosystem comprising the extracellular matrix (ECM), glioma cells and glioma stem cells, a variety of immune cells (including microglia, macrophages, and lymphocytes among others), and non-immune cells such as neuronal cells, endothelial cells, and astrocytes. These components interact dynamically, influencing tumoral growth, progression, and drug resistance, thereby presenting potential targets for therapeutic intervention.",
        "The key components of the glioblastoma tumor microenvironment are represented by the extracellular matrix, glioma cells and glioma stem cells, immune cells, neuronal cells, all of them having dynamic interactions and being able to influence the tumoral growth, progression, and drug resistance thus being a potential therapeutic target.",
        "The key components of the glioblastoma tumor microenvironment (TME) include:\n\n1. Extracellular matrix (ECM)\n2. Glioma cells and glioma stem cells (GSCs)\n3. Immune cells: \n   - Microglia\n   - Macrophages\n   - Neutrophils\n   - Lymphocytes (T cells, B cells)\n   - Natural killer (NK) cells\n   - Dendritic cells\n   - Myeloid-derived suppressor cells\n4. Non-immune components:\n   - Endothelial cells\n   - Astrocytes\n   - Neuronal cells\n\nThese components interact dynamically, influencing tumor growth, progression, and drug resistance, making them potential therapeutic targets.",
        "The glioblastoma tumor microenvironment (TME) consists of both cellular and non-cellular components that interact dynamically to influence tumor growth, progression, and drug resistance. Key cellular components include glioma cells and glioma stem cells (GSCs), immune cells (microglia, macrophages, neutrophils, T cells, B cells, natural killer cells, dendritic cells, and myeloid-derived suppressor cells), and non-immune cells (neuronal cells, astrocytes, and endothelial cells). The non-cellular component is primarily the extracellular matrix (ECM). These components form a complex network that represents a potential therapeutic target in glioblastoma treatment.",
        "The key components of the glioblastoma tumor microenvironment (GBM TME) include the extracellular matrix (ECM), glioma cells, glioma stem cells (GSCs), immune cells (such as microglia, macrophages, neutrophils, lymphocytes, T cells, B cells, natural killer (NK) cells, dendritic cells, and myeloid-derived suppressor cells), and non-immune cells like neuronal cells, endothelial cells, and astrocytes. These components interact dynamically, influencing tumor growth, progression, and drug resistance.",
        "The glioblastoma tumor microenvironment (TME) is a complex ecosystem comprising key components including the extracellular matrix, glioma and glioma stem cells, a diverse set of immune cells (microglia, macrophages, T cells, B cells, NK cells, dendritic cells, myeloid-derived suppressor cells, and neutrophils), and non-immune cells (neuronal cells, astrocytes, and endothelial cells). These components interact dynamically, significantly influencing tumoral growth, progression, drug resistance, and promoting angiogenesis, which highlights the TME\u0027s crucial role in the disease\u0027s pathophysiology.",
        "The glioblastoma tumor microenvironment (TME) comprises several key components, including the extracellular matrix (ECM), immune cells such as microglia, macrophages, neutrophils, and lymphocytes, and non-immune elements like endothelial cells, astrocytes, and neurons. Central to this environment are glioma cells and glioma stem cells (GSCs), which play significant roles in tumor growth, progression, and drug resistance. These diverse cell types interact dynamically within the TME, influencing each other\u0027s behavior and contributing to the overall disease outcome.",
        "The tumor microenvironment of glioblastoma is composed of the extracellular matrix, glioma cells including glioma stem cells, and a variety of immune cells such as microglia, macrophages, neutrophils, T cells, B cells, natural killer cells, and dendritic cells. It also includes non-immune cells, namely endothelial cells, astrocytes, and neurons, all of which interact dynamically to influence tumor growth, progression, and resistance to therapy.",
        "The key components of the glioblastoma tumor microenvironment include the extracellular matrix, glioma and glioma stem cells, a variety of immune cells (microglia, macrophages, T cells, B cells, NK cells, dendritic cells, myeloid-derived suppressor cells, neutrophils, and lymphocytes), and non-immune cells (neuronal cells, astrocytes, and endothelial cells), highlighting its complex nature.",
        "The glioblastoma (GBM) tumor microenvironment (TME) is a complex and heterogeneous system composed of various cellular and non-cellular components. Key components include glioma cells and glioma stem cells, diverse immune cells such as microglia, macrophages, neutrophils, lymphocytes, and marrow-derived immune cells. Other resident brain cells, stromal cells, endothelial cells, astrocytes, and neurons are also present. The TME also consists of the extracellular matrix (ECM), blood vessels, vasculature, metabolic products, chemical compositions, signaling molecules, and soluble factors like adenosine. Gradients, pH, and oxygen levels also contribute to the TME. Interactions between these components influence tumor growth, progression, drug resistance, and invasiveness.",
        "The key components of the glioblastoma tumor microenvironment (TME) include the extracellular matrix (ECM), glioma cells, glioma stem cells (GSCs), immune cells (such as microglia, macrophages, neutrophils, lymphocytes, T cells, B cells, natural killer cells, dendritic cells, and myeloid-derived suppressor cells), neuronal cells, endothelial cells, and astrocytes. These components interact dynamically and influence tumor growth, progression, and drug resistance."
      ],
      "exact_answer": [
        [
          "Glioma stem cells (GSCs)",
          "GSCs"
        ],
        [
          "Immune cells",
          "immune cells (microglia, macrophages, neutrophils, lymphocytes)"
        ],
        [
          "Extracellular matrix (ECM)",
          "ECM",
          "Extracellular matrix"
        ],
        [
          "Neurons",
          "Neuronal cells",
          "Non-immune cells: Neuronal cells / Neurons"
        ],
        [
          "endothelial cells",
          "Endothelial Cells",
          "Endothelial cells (Vasculature)",
          "Non-immune cells: Endothelial cells"
        ],
        [
          "Fibroblast",
          "fibroblasts",
          "cancer-associated fibroblasts",
          "cancer-associated fibroblasts (CAFs)"
        ],
        [
          "Astrocytes",
          "Non-immune cells: Astrocytes"
        ],
        [
          "soluble factors",
          "soluble factors (chemokines and cytokines)",
          "Chemokines",
          "Cytokines",
          "Growth factors",
          "secreted factors"
        ]
      ]
    },
    {
      "body": "Which cytoscape application has been developed for the study of metabolic pathway evolution?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28453679"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "BioPAXViz: a cytoscape application for the visual exploration of metabolic pathway evolution.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453679"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 651,
          "text": "BioPAXViz is a Cytoscape (version 3) application, providing a comprehensive framework for metabolic pathway visualization. Beyond the basic parsing, viewing and browsing roles, the main novel function that BioPAXViz provides is a visual comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles given a species phylogeny. Furthermore, BioPAXViz supports the display of hierarchical trees that allow efficient navigation through sets of variants of a single reference pathway. Thus, BioPAXViz can significantly facilitate, and contribute to, the study of metabolic pathway evolution and engineering",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453679"
        }
      ],
      "id": "67e2944218b1e36f2e000083",
      "ideal_answer": [
        "BioPAXViz is a cytoscape application for the visual exploration of metabolic pathway evolution.",
        "BioPAXViz is a Cytoscape (version 3) application, providing a comprehensive framework for metabolic pathway visualization. Beyond the basic parsing, viewing and browsing roles, the main novel function that BioPAXViz provides is a visual comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles given a species phylogeny. Furthermore, BioPAXViz supports the display of hierarchical trees that allow efficient navigation through sets of variants of a single reference pathway. Thus, BioPAXViz can significantly facilitate, and contribute to, the study of metabolic pathway evolution and engineering.",
        "BioPAXViz is the cytoscape application developed for the study of metabolic pathway evolution. It leverages the BioPAX standard for pathway representation, incorporating a visualization component (\u0027Viz\u0027) that enables researchers to effectively analyze and comprehend the complex changes in metabolic pathways over time or across different conditions.",
        "The Cytoscape application developed for the study of metabolic pathway evolution is BioPAXViz. This application aids in the visual exploration and analysis of metabolic pathway evolution by providing tools for visual comparative analysis of metabolic pathway topologies and efficient navigation through hierarchical trees of pathway variants.",
        "The BioPAXViz cytoscape application has been developed for the study of metabolic pathway evolution.",
        "BioPAXViz is a Cytoscape application providing a comprehensive framework for metabolic pathway visualization.",
        "BioPAXViz has been developed as a Cytoscape app for the visual exploration of metabolic pathway evolution.",
        "BioPAXViz is the Cytoscape application developed for the study of metabolic pathway evolution.",
        "BioPAXViz is a Cytoscape extension designed to facilitate the study of metabolic pathway evolution.",
        "BioPAXViz, a Cytoscape application, has been developed for metabolic pathway visualization and facilitates the study of metabolic pathway evolution and engineering. It provides a framework for visual comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles given a species phylogeny.",
        "BioPAXViz is a Cytoscape application developed for the study of metabolic pathway evolution.",
        "BioPAXViz is the Cytoscape application developed to study metabolic pathway evolution.",
        "BioPAXViz has been developed for the study of metabolic pathway evolution, providing a framework for visual comparative analysis of metabolic pathway topologies across species phylogenomic profiles within the Cytoscape environment.",
        "BioPAXViz is the cytoscape application developed for the study of metabolic pathway evolution, leveraging the Biological Pathway Exchange (BioPAX) standard to facilitate the visualization and analysis of evolutionary changes in metabolic pathways.",
        "BioPAXViz is a Cytoscape application developed for studying the evolution of metabolic pathways. It parses, visualizes, and enables comparative analysis of metabolic pathway topologies using pre-computed phylogenomic profiles to explore pathway variants and their evolutionary trajectories.",
        "BioPAXViz has been developed for the study of metabolic pathway evolution.",
        "BioPAXViz is the designated Cytoscape application for studying metabolic pathway evolution. It leverages the BioPAX standard to facilitate the visualization and analysis of evolutionary changes in metabolic pathways, enabling researchers to compare and understand complex changes over time or across different species and conditions within the Cytoscape environment.",
        "BioPAXViz is the Cytoscape application developed for studying metabolic pathway evolution.",
        "BioPAXViz has been developed as a Cytoscape application for the study of metabolic pathway evolution.",
        "BioPAXViz is a Cytoscape (version 3) application specifically developed for visual exploration and comparative analysis of metabolic pathway evolution. It provides a comprehensive framework for metabolic pathway visualization, allowing users to compare pathway topologies across species and navigate through pathway variants.",
        "BioPAXViz is a Cytoscape application developed for the study of metabolic pathway evolution, enabling visual comparative analysis of pathway topologies across species and supporting hierarchical navigation of pathway variants.",
        "BioPAXViz is a Cytoscape (version 3) application, providing a comprehensive framework for metabolic pathway visualization. Beyond the basic parsing, viewing and browsing roles, the main novel function that BioPAXViz provides is a visual comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles given a species phylogeny. Furthermore, BioPAXViz supports the display of hierarchical trees that allow efficient navigation through sets of variants of a single reference pathway. Thus, BioPAXViz can significantly facilitate, and contribute to, the study of metabolic pathway evolution and engineering",
        "BioPAXViz is a Cytoscape application that has been developed for the visual exploration of metabolic pathway evolution. It provides a comprehensive framework for metabolic pathway visualization, allowing for the comparative analysis of metabolic pathway topologies across different species. This application supports the display of hierarchical trees, enabling efficient navigation through sets of variants of a single reference pathway. By facilitating the study of metabolic pathway evolution, BioPAXViz contributes to the field of metabolic engineering, making it a valuable tool for researchers in this area of studies.",
        "BioPAXViz is a Cytoscape 3 application that enables visual exploration and comparative analysis of metabolic pathway evolution through pathway phylogenomic profiles and hierarchical tree displays. The tool facilitates metabolic pathway engineering by providing comprehensive visualization features and efficient navigation through pathway variants.",
        "BioPAXViz is a Cytoscape application specifically designed to facilitate the visual exploration and analysis of metabolic pathway evolution. It enables researchers to examine dynamic changes in pathways across species or conditions, leveraging BioPAX data standards to integrate and represent pathway information, aiding in the study of evolutionary adaptations in metabolic networks.",
        "BioPAXViz is a Cytoscape application that has been developed for the study of metabolic pathway evolution.",
        "BioPAXViz is the Cytoscape application developed for the study of metabolic pathway evolution, providing visual exploration and comparative analysis of metabolic pathways.",
        "BioPAXViz is a Cytoscape (version 3) application, providing a comprehensive framework for metabolic pathway visualization.",
        "BioPAXViz is a Cytoscape application developed for the visual exploration and comparative analysis of metabolic pathway evolution. It facilitates the study of metabolic pathway topologies across phylogenomic profiles and species phylogeny, aiding in research on pathway evolution and engineering.",
        "BioPAXViz is a Cytoscape application developed for visual comparative analysis of metabolic pathway evolution. It enables exploration of pathway topologies across species using phylogenomic profiles and supports hierarchical navigation of pathway variants.",
        "BioPAXViz is the Cytoscape application designed for visual exploration and comparative analysis of metabolic pathway evolution.",
        "BioPAXViz is the Cytoscape application developed for the study of metabolic pathway evolution. It provides a comprehensive framework for visualization and comparative analysis of metabolic pathway topologies across pre-computed profiles.",
        "BioPAXViz, a Cytoscape application, has been developed for the visual exploration of metabolic pathway evolution. It provides a framework for metabolic pathway visualization and allows for visual comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles given a species phylogeny. BioPAXViz also supports the display of hierarchical trees for efficient navigation through sets of variants of a single reference pathway.",
        "BioPAXViz is a Cytoscape application that has been developed for the visual exploration and comparative analysis of metabolic pathway evolution.",
        "BioPAXViz is a Cytoscape (version 3) application that provides a comprehensive framework for visual exploration and comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles given a species phylogeny. It supports the display of hierarchical trees, allowing efficient navigation through sets of variants of a single reference pathway, thus facilitating the study of metabolic pathway evolution and engineering.",
        "The Cytoscape application developed for the study of metabolic pathway evolution is BioPAXViz. It provides a comprehensive framework for visualizing metabolic pathways, enabling users to perform visual comparative analysis of pathway topologies across pre-computed phylogenomic profiles based on species phylogeny. Additionally, it supports hierarchical tree displays for efficient navigation through variants of reference pathways, thereby facilitating the study and engineering of metabolic pathway evolution.",
        "The Cytoscape application developed for studying metabolic pathway evolution is BioPAXViz.",
        "BioPAXViz is the Cytoscape application specifically developed for the study of metabolic pathway evolution, as consistently identified across all provided responses, ensuring a high degree of reliability and specificity in its defined purpose.",
        "BioPAXViz is a cytoscape application developed specifically for the visual exploration and study of metabolic pathway evolution. It provides researchers with tools to effectively visualize and analyze complex biological pathways, aiding in the understanding of how these pathways evolve over time.",
        "BioPAXViz is a specialized Cytoscape application developed for the study of metabolic pathway evolution, enabling comparative analysis and visualization of metabolic pathways across different species through its unique framework and navigation tools.",
        "BioPAXViz is a Cytoscape application for the visual exploration of metabolic pathway evolution.",
        "BioPAXViz is a Cytoscape (version 3) application that has been developed specifically for the study of metabolic pathway evolution. It provides a comprehensive framework for metabolic pathway visualization and enables visual comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles given a species phylogeny. Additionally, BioPAXViz supports the display of hierarchical trees for efficient navigation through sets of variants of a single reference pathway, making it a valuable tool for studying metabolic pathway evolution and engineering.",
        "BioPAXViz is a Cytoscape (version 3) application designed for the visual exploration of metabolic pathway evolution. It provides a framework for metabolic pathway visualization and offers novel functions such as comparative analysis of pathway topologies across species using pre-computed phylogenomic profiles and species phylogeny. Additionally, it supports hierarchical trees for efficient navigation through pathway variants, aiding in the study of metabolic pathway evolution and engineering.",
        "The Cytoscape application developed for the study of metabolic pathway evolution is called BioPAXViz.",
        "BioPAXViz is a Cytoscape (version 3) application designed for the visual exploration of metabolic pathway evolution. It provides tools for parsing, viewing, and browsing pathways, as well as comparative analysis of pathway topologies across species using phylogenomic profiles and species phylogeny. Additionally, it displays hierarchical trees to navigate pathway variants efficiently, aiding in the study of metabolic pathway evolution and engineering.",
        "BioPAXViz",
        "BioPAXViz, a Cytoscape application, has been developed for the visual exploration of metabolic pathway evolution. It provides a framework for metabolic pathway visualization and enables visual comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles given a species phylogeny. BioPAXViz also supports the display of hierarchical trees for efficient navigation through sets of variants of a single reference pathway, facilitating the study of metabolic pathway evolution and engineering.",
        "BioPAXViz is a Cytoscape application designed to facilitate the visual exploration of metabolic pathway evolution. It provides comprehensive visualization capabilities including comparative analysis of metabolic pathway topologies across pre-computed pathway phylogenomic profiles and hierarchical tree display for efficient navigation through sets of pathway variants.",
        "BioPAXViz is a Cytoscape (version 3) application specifically developed for the visual exploration of metabolic pathway evolution. It offers novel functionalities such as visual comparative analysis of metabolic pathway topologies across pre-computed phylogenomic profiles, given a species phylogeny, and supports hierarchical tree displays for efficient navigation through pathway variants. These features make BioPAXViz a valuable tool in studying and engineering the evolution of metabolic pathways.",
        "BioPAXViz is a Cytoscape application developed for the visual exploration and comparative analysis of metabolic pathway evolution."
      ],
      "exact_answer": [
        [
          "BioPAXViz"
        ]
      ]
    },
    {
      "body": "Can Galcanezumab be used for Vestibular Migraine?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36946234",
        "http://www.ncbi.nlm.nih.gov/pubmed/39344988"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1218,
          "offsetInEndSection": 1315,
          "text": "CONCLUSION: We show that anti-CGRP mAbs may be effective in the treatment of Vestibular Migraine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36946234"
        },
        {
          "offsetInBeginSection": 1937,
          "offsetInEndSection": 2013,
          "text": "CONCLUSIONS: In this pilot study, galcanezumab was effective in treating VM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39344988"
        }
      ],
      "type": "yesno",
      "id": "67e6d06918b1e36f2e0000d2",
      "ideal_answer": [
        "Yes. In a small trial Galcanezumab was effective for Vestibular Migraine.",
        "Yes. Galcanezumab has demonstrated effectiveness in treating vestibular migraine, as indicated by its significant reduction in monthly migraine headache days and favorable safety profile.",
        "Yes. Galcanezumab has demonstrated efficacy in the treatment of Vestibular Migraine, showing a significant reduction in monthly migraine headache days and a favorable safety profile."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Summerize the relationship betweeen kisspeptin and cancer",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39740824",
        "http://www.ncbi.nlm.nih.gov/pubmed/38264268",
        "http://www.ncbi.nlm.nih.gov/pubmed/38265397",
        "http://www.ncbi.nlm.nih.gov/pubmed/30275201",
        "http://www.ncbi.nlm.nih.gov/pubmed/22552499",
        "http://www.ncbi.nlm.nih.gov/pubmed/28944853",
        "http://www.ncbi.nlm.nih.gov/pubmed/31401420",
        "http://www.ncbi.nlm.nih.gov/pubmed/30686017",
        "http://www.ncbi.nlm.nih.gov/pubmed/21576407",
        "http://www.ncbi.nlm.nih.gov/pubmed/20428832",
        "http://www.ncbi.nlm.nih.gov/pubmed/38640803",
        "http://www.ncbi.nlm.nih.gov/pubmed/38516305",
        "http://www.ncbi.nlm.nih.gov/pubmed/30123188",
        "http://www.ncbi.nlm.nih.gov/pubmed/31705228",
        "http://www.ncbi.nlm.nih.gov/pubmed/24377507",
        "http://www.ncbi.nlm.nih.gov/pubmed/38256878",
        "http://www.ncbi.nlm.nih.gov/pubmed/38255200",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831570",
        "http://www.ncbi.nlm.nih.gov/pubmed/36316037",
        "http://www.ncbi.nlm.nih.gov/pubmed/36181862",
        "http://www.ncbi.nlm.nih.gov/pubmed/36720764",
        "http://www.ncbi.nlm.nih.gov/pubmed/17706968",
        "http://www.ncbi.nlm.nih.gov/pubmed/37790750",
        "http://www.ncbi.nlm.nih.gov/pubmed/36917014",
        "http://www.ncbi.nlm.nih.gov/pubmed/31972865",
        "http://www.ncbi.nlm.nih.gov/pubmed/29760678",
        "http://www.ncbi.nlm.nih.gov/pubmed/30776659",
        "http://www.ncbi.nlm.nih.gov/pubmed/29662466",
        "http://www.ncbi.nlm.nih.gov/pubmed/24395571",
        "http://www.ncbi.nlm.nih.gov/pubmed/34767970",
        "http://www.ncbi.nlm.nih.gov/pubmed/26572251",
        "http://www.ncbi.nlm.nih.gov/pubmed/23525242",
        "http://www.ncbi.nlm.nih.gov/pubmed/24254791",
        "http://www.ncbi.nlm.nih.gov/pubmed/19533666",
        "http://www.ncbi.nlm.nih.gov/pubmed/26873190",
        "http://www.ncbi.nlm.nih.gov/pubmed/19336473",
        "http://www.ncbi.nlm.nih.gov/pubmed/24155777",
        "http://www.ncbi.nlm.nih.gov/pubmed/25590245",
        "http://www.ncbi.nlm.nih.gov/pubmed/16731583",
        "http://www.ncbi.nlm.nih.gov/pubmed/30649364",
        "http://www.ncbi.nlm.nih.gov/pubmed/23969598",
        "http://www.ncbi.nlm.nih.gov/pubmed/24908069",
        "http://www.ncbi.nlm.nih.gov/pubmed/22966379",
        "http://www.ncbi.nlm.nih.gov/pubmed/35955878",
        "http://www.ncbi.nlm.nih.gov/pubmed/34620174",
        "http://www.ncbi.nlm.nih.gov/pubmed/26010933",
        "http://www.ncbi.nlm.nih.gov/pubmed/30003725",
        "http://www.ncbi.nlm.nih.gov/pubmed/39037658",
        "http://www.ncbi.nlm.nih.gov/pubmed/24033850",
        "http://www.ncbi.nlm.nih.gov/pubmed/18644415",
        "http://www.ncbi.nlm.nih.gov/pubmed/21852382",
        "http://www.ncbi.nlm.nih.gov/pubmed/24407584",
        "http://www.ncbi.nlm.nih.gov/pubmed/21276835",
        "http://www.ncbi.nlm.nih.gov/pubmed/22526494",
        "http://www.ncbi.nlm.nih.gov/pubmed/25667462",
        "http://www.ncbi.nlm.nih.gov/pubmed/24894166"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 123,
          "text": "Kisspeptin was initially known as metastin for its role in suppressing metastasis in melanoma and breast cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38265397"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Kisspeptin Retards Tumor Growth of Lewis Lung Carcinoma Cells Through p38 MAPK-mediated Senescence.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740824"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Kisspeptin (a product of the KISS1 gene and its receptor) plays an important role in obstetrics, gynecology, and cancer cell metastasis and behavior. I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38264268"
        },
        {
          "offsetInBeginSection": 1243,
          "offsetInEndSection": 1572,
          "text": "n conclusion, we suggest that Kisspeptin regulates endometrial cancer cell motility via FAK and Src expression and the ERK1/2, N-Cadherin, E-Cadherin, beta-Catenin, Twist, and matrix metalloproteinase signaling pathways. We expect these molecules could be candidates for the development of new approaches and therapeutic targets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38264268"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Kisspeptin Inhibits Colorectal Cancer Cell Invasiveness by Activating PKR and PP2A.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30275201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "BACKGROUND: Recent studies have demonstrated that Kisspeptin, the product of the metastasis suppressor gene KiSS-1, could have a role in tumor progression a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22552499"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Kisspeptin is a protein encoded by the KISS1 gene, which has been reported to suppress the metastatic capabilities of various types of cancer cells, through the activation of its G‑protein coupled receptor GPR54.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944853"
        },
        {
          "offsetInBeginSection": 1634,
          "offsetInEndSection": 1829,
          "text": "The present study concluded that kisspeptin represses cancer metastasis via EIF2AK2 signaling, thus clarifying the role of kisspeptin signaling in complicated cancer metastasis signaling network.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944853"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Kisspeptin inhibits cancer growth and metastasis via activation of EIF2AK2.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944853"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Kisspeptins are neuropeptides encoded by the Kiss1 gene that was discovered as a metastasis suppressor gene in melanoma and breast cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38640803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Kisspeptin (a product of the KISS1 gene and its receptor) plays an important role in obstetrics, gynecology, and cancer cell metastasis and behavior",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38264268"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 293,
          "text": "The kisspeptin (KISS1) gene was initially discovered as a suppressor of metastasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38255200"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Kisspeptin (KISS) is a natural peptide-discovered in 1996 as a factor inhibiting the ability to metastasize in malignant melanoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831570"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 336,
          "text": "KISS1, retains maximum physiological activity when it binds to its receptor (KISS1R), allowing KISS1 to effectively function as a suppressor of metastasis in melanomas and other types of cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316037"
        },
        {
          "offsetInBeginSection": 673,
          "offsetInEndSection": 883,
          "text": "The review explores mechanistic insights of KISS1 and discusses its potential application as a therapeutic against metastatic cancers by eliminating quiescent cells or inducing long-term dormancy in tumor cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36720764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 288,
          "text": "AIM: Kisspeptin is a reproductive peptide hormone that has anti-metastatic roles in several cancer types including colon, lung, and brain cancer. However, in breast cancer, increasing of kisspeptin expression induces aggressiveness of tumors, which in turn exacerbates breast cancer progn",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30686017"
        },
        {
          "offsetInBeginSection": 1306,
          "offsetInEndSection": 1402,
          "text": "c tumor growth without affecting body weight.CONCLUSION: Kisspeptin represses mouse lung cancer ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740824"
        },
        {
          "offsetInBeginSection": 248,
          "offsetInEndSection": 445,
          "text": "It has been previously shown that expression of KiSS1 could be increased in lung cancer cells using epigenetic agents, and that KiSS1 could have a pro-apoptotic action in combination with cisplatin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37790750"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "text": "The G protein-coupled kisspeptin receptor (GPR54 or KISS1R) is an important mediator in reproduction, metabolism and cancer biology; however, there are limited fluorescent probes or antibodies for direct imaging of these receptors in cells and intact tissues, which can help to interrogate their multiple biological roles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36917014"
        },
        {
          "offsetInBeginSection": 452,
          "offsetInEndSection": 887,
          "text": "t KISS1, KPs, and KISS1R regulate the development and progression of several cancers but interestingly, while these molecules act as suppressors of tumorigenesis and metastasis in many cancers, in breast and liver cancer they function as promoters. Thus, they join a small but growing number of molecules that exhibit dual roles in cancer highlighting the importance of studying cancer in context. Given their roles, KISS1, KPs and KIS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30123188"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 411,
          "text": "KiSS-1 was first described as a metastasis suppressor gene in malignant melanoma. KiSS-1 encodes a 145 amino-acid residue peptide that is further processed, producing the 54 amino acid metastin and shorter peptides collectively named kisspeptins (KPs). KPs bind and activate KiSS-1R (GPR54). Although the KPs system has been extensively studied for its role in endocrinology of reproductive axis in mammals, its",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29760678"
        },
        {
          "offsetInBeginSection": 289,
          "offsetInEndSection": 556,
          "text": "progression. KISS1, a precursor for several shorter peptides, known as metastin (Kisspeptin-54), Kisspeptin-14, Kisspeptin-13 and Kisspeptin-10, is one of those metastasis suppressor proteins, whose expression is commonly downregulated in the metastatic tumors of var",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31705228"
        },
        {
          "offsetInBeginSection": 1036,
          "offsetInEndSection": 1314,
          "text": "Kisspeptin-54 was also found to be an independent predictive marker for lymph node metastases of CRC (p \u003d 0; Exp(B): 2.053; 95 % CI, 1.255-2.851).CONCLUSIONS: Our results reveal that plasma Kisspeptin-54 measurement could be a useful diagnostic and prognostic parameter for CRC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22552499"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 700,
          "text": "Since then, it has become apparent that KISS1, KPs, and KISS1R regulate the development and progression of several cancers but interestingly, while these molecules act as suppressors of tumorigenesis and metastasis in many cancers, in breast and liver cancer they function as promoters.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30123188"
        },
        {
          "offsetInBeginSection": 1745,
          "offsetInEndSection": 1984,
          "text": "These data indicate the antimetastatic effect of tumor-elevated kisspeptin in colon cancer patients that may be mediated by the effect of kisspeptin on EMAP-II expression in colon cancer tumors in patients with normal serum EMAP-II levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24395571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Functional analysis of the emerging roles for the KISS1/KISS1R signaling pathway in cancer metastasis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767970"
        },
        {
          "offsetInBeginSection": 1836,
          "offsetInEndSection": 2035,
          "text": "KiSS‑1 is a metastasis suppressor gene of pancreatic cancer, and this suppression is not dependent on the expression levels of GPR54. Therefore, KiSS‑1 is potentially a novel target for gene therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26572251"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 450,
          "text": "In many human tumors, KISS1 functions as a metastasis-suppressor gene and KISS1/KISS1R signaling has antimetastatic and tumor-suppressor roles. On the contrary, emerging evidence indicates that the KP/KISS1R pathway plays detrimental roles in triple negative breast cancer (TNBC), t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31972865"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 565,
          "text": "KISS1 acts as a metastasis suppressor in numerous human cancers. However, recent studies have demonstrated that an increase in KISS1 and KISS1R expression in patient breast tumors correlates with higher tumor grade and metastatic potential. We have shown that KP-10 stimulates invasion of estrogen receptor α (ERα)-negative MDA-MB-231 breast cancer cells via transactivation of the epidermal growth factor receptor (EGFR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23525242"
        },
        {
          "offsetInBeginSection": 575,
          "offsetInEndSection": 1003,
          "text": "In this study, we demonstrate that KiSS1 suppresses the migration of breast cancer cells by inhibiting TNFalpha-induced NF-kappaB pathway and RhoA activation. Both KiSS1 overexpression and KP10 (kisspeptin-10) stimulation inhibited TNFalpha-induced NF-kappaB activity, suppressed TNFalpha-induced cell migration and cell attachment to fibronectin in breast cancer cells while KP10 has little effect on cancer cell proliferation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19533666"
        },
        {
          "offsetInBeginSection": 886,
          "offsetInEndSection": 1345,
          "text": "The antitumor effect of KiSS-1 was primarily associated with the inhibition of proliferation, migration and cell invasion and, consequently, the reduced formation of metastasis and intratumoral microvessels. In this review, we highlight the latest data on the role of kisspeptin signaling in the suppression of metastasis in various cancer types and the use modulators of KiSS/GPR54 signaling as potential novel therapeutic agents for the treatment of cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29662466"
        },
        {
          "offsetInBeginSection": 1601,
          "offsetInEndSection": 1984,
          "text": "Elevated kisspeptin and EMAP-II expression in colon cancer tissues was associated with lack of metastases (p \u003c 0.001) in colon cancer patients. These data indicate the antimetastatic effect of tumor-elevated kisspeptin in colon cancer patients that may be mediated by the effect of kisspeptin on EMAP-II expression in colon cancer tumors in patients with normal serum EMAP-II levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24395571"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 716,
          "text": "It is becoming progressively more understandable that loss or reduction of KISS1 expression in different human cancers correlates inversely with progression of tumor, metastasizing potential and survival. In this review we have attempted to provide an overview highlight of the most recent updates addressing metastasis- suppressing role of KISS1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26873190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 926,
          "text": "Kisspeptin (KISS) is a natural peptide-discovered in 1996 as a factor inhibiting the ability to metastasize in malignant melanoma. This protein plays also a regulatory role in the process of puberty, the menstrual cycle, spermatogenesis, implantation and development of the human placenta. The present study aimed to evaluate the expression of KISS and its receptor GPR54 in endometrial cancer (EC) tissue, depending on the histological type of cancer, its stage, various demographic characteristics, and clinical conditions in 214 hysterectomy patients. Expression of KISS and GPR54 was confirmed in 99.5% and 100% of the cases, respectively. Hormone replacement therapy and the coexistence of the anti-Müllerian type 2 receptor in cancer tissue enhanced KISS expression. Smoking, on the other hand, decreased KISS expression. GPR54 expression increased with the advancement of the disease (according to FIGO classification).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831570"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 447,
          "text": "Apart from that kisspeptin derived peptides (KPs) are also known for their antimetastatic activities in several malignancies. Herein we report recent evidence of the role of kisspeptins in cancer biology and we examine the prospective of targeting the kisspeptin pathways leading to a better prognosis in patients with malignant diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Kisspeptin is a neuropeptide that was originally discovered in 1996 from a metastasis tumour suppressor gene, KISS1 and was appropriately named metastin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19336473"
        },
        {
          "offsetInBeginSection": 206,
          "offsetInEndSection": 348,
          "text": " KISS1 is a metastasis suppressor gene and the KP/KISS1R signaling has anti-metastatic and tumor-suppressant effects in numerous human cancers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155777"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 573,
          "text": "It is becoming progressively more understandable that loss or reduction of KISS1 expression in different human cancers correlates inversely with progression of tumor, metastasizing potential and survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26873190"
        },
        {
          "offsetInBeginSection": 741,
          "offsetInEndSection": 904,
          "text": "In cancer, KiSS1 signaling suppresses metastases and maintains dormancy of disseminated malignant cells, by interfering with cell migratory and invasive abilities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30776659"
        },
        {
          "offsetInBeginSection": 1045,
          "offsetInEndSection": 1224,
          "text": " Loss or reduced expression of KiSS1, in part through promoter hypermethylation, is related to the development of metastases in various cancer types, with some conflicting reports",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30776659"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 389,
          "text": "The original niche for the role of kisspeptin in human physiology is derived from cancer biology, with the loss of Kiss-1 expression being associated with poor prognosis in several malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576407"
        },
        {
          "offsetInBeginSection": 440,
          "offsetInEndSection": 668,
          "text": "Instead, approximately 7 years earlier KISS1 was reported to be expressed in nonmetastatic melanoma cells and was subsequently demonstrated to act as a powerful suppressor of the metastatic potential of malignant melanoma cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25590245"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 360,
          "text": "The known biological functions of kisspeptins were initially restricted to their ability to suppress tumour metastasis, hence the name of metastin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16731583"
        },
        {
          "offsetInBeginSection": 471,
          "offsetInEndSection": 675,
          "text": "In addition, intensive recent investigations have provided substantial evidence suggesting roles of Kisspeptin signalling via its receptor GPR54 in the suppression of metastasis with a variety of cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24377507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "BACKGROUND: Initially identified as suppressors of metastasis in various types of cancer, kisspeptins are a family of neuropeptides that are key regulators of the mammalian reprod",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30649364"
        },
        {
          "offsetInBeginSection": 689,
          "offsetInEndSection": 988,
          "text": "Kisspeptin was revealed to inhibit the migratory and invasive abilities of highly metastatic breast SK‑BR‑3, prostatic PC‑3 and colorectal adenocarcinoma LoVo human cancer cell lines, whereas its inhibitory effects were abolished following the silencing of EIF2AK2 expression using RNA interference.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944853"
        },
        {
          "offsetInBeginSection": 560,
          "offsetInEndSection": 739,
          "text": "Kisspeptin inhibited colorectal cancer cell invasiveness without affecting cell proliferation. Kisspeptin required activation of KISS1R and resulted in activation of PKR and PP2A.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30275201"
        },
        {
          "offsetInBeginSection": 891,
          "offsetInEndSection": 980,
          "text": "Kisspeptin-mediated activation of PKR-PP2A inhibited colorectal cancer cell invasiveness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30275201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "Kisspeptin is an antimetastatic agent in some cancers that has also been associated with lymphoid cell apoptosis, a phenomenon favoring metastases. Our aim was to determine the association of kisspeptin with lymphocyte apoptosis and the presence of metastases in colorectal cancer patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24395571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "BACKGROUND/AIM: Kisspeptin has multifaceted roles in both normal and pathological conditions. Although lung cancer is a leading cause of cancer worldwide, the role of kisspeptin in lung cancer remains po",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740824"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 423,
          "text": "However, in breast cancer, increasing of kisspeptin expression induces aggressiveness of tumors, which in turn exacerbates breast cancer prognosis.MATERIAL AND METHODS: Breast cancer cell lines MCF7 and SKBR3 were cultured in MEM (phenol red free) containing 10 % fetal bovine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30686017"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 348,
          "text": "KISS1 is a metastasis suppressor gene and the KP/KISS1R signaling has anti-metastatic and tumor-suppressant effects in numerous human cancers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155777"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 858,
          "text": "Although KISS1 primarily plays a suppressive role in the metastasis progression in several cancer types, emerging evidence indicates that the physiological effect of KISS1/KISS1R in cancer metastasis is tissue context-dependent and still controversial",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767970"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Kisspeptin is a protein encoded by the KISS1 gene, which has been reported to suppress the metastatic capabilities of various types of cancer cells, through the activation of its G‑protein coupled receptor GPR54",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944853"
        },
        {
          "offsetInBeginSection": 302,
          "offsetInEndSection": 568,
          "text": "KISS1, a precursor for several shorter peptides, known as metastin (Kisspeptin-54), Kisspeptin-14, Kisspeptin-13 and Kisspeptin-10, is one of those metastasis suppressor proteins, whose expression is commonly downregulated in the metastatic tumors of various origins",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31705228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Metastin/kisspeptin is encoded by KISS1 and functions as an endogenous ligand of GPR54. Interaction of metastin with GPR54 suppresses metastasis and also regulates release of gonadotropin-releasing hormone",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24908069"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "BACKGROUND: Initially identified as suppressors of metastasis in various types of cancer, kisspeptins are a family of neuropeptides that are key regulators of the mammalian repro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30649364"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Kisspeptin is a neuropeptide that was originally discovered in 1996 from a metastasis tumour suppressor gene, KISS1 and was appropriately named metastin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19336473"
        },
        {
          "offsetInBeginSection": 383,
          "offsetInEndSection": 526,
          "text": "KiSS-1 is a human metastasis suppressor gene that inhibits metastasis of human melanomas and breast carcinomas without affecting tumorigenicity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966379"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 359,
          "text": "The known biological functions of kisspeptins were initially restricted to their ability to suppress tumour metastasis, hence the name of metastin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16731583"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 291,
          "text": "Kisspeptins are proteins encoded by the KISS1 gene that was originally described as a melanoma metastasis suppressor gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767970"
        },
        {
          "offsetInBeginSection": 302,
          "offsetInEndSection": 569,
          "text": "KISS1, a precursor for several shorter peptides, known as metastin (Kisspeptin-54), Kisspeptin-14, Kisspeptin-13 and Kisspeptin-10, is one of those metastasis suppressor proteins, whose expression is commonly downregulated in the metastatic tumors of various origins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31705228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Kisspeptin is an anti-metastatic mediator in many cancer types, acting through its receptor, KISS1R. However, controversy remains regarding its role in breast cancer since both pro- and anti-metastatic roles have been ascribed to it.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35955878"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 859,
          "text": "Although KISS1 primarily plays a suppressive role in the metastasis progression in several cancer types, emerging evidence indicates that the physiological effect of KISS1/KISS1R in cancer metastasis is tissue context-dependent and still controversial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767970"
        },
        {
          "offsetInBeginSection": 56,
          "offsetInEndSection": 217,
          "text": "KiSS1 was originally identified as a metastasis suppressor gene in metastatic melanoma and breast cancer, but its role in prostate cancer has been contradictory.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36181862"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 290,
          "text": "Kisspeptins are proteins encoded by the KISS1 gene that was originally described as a melanoma metastasis suppressor gene",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767970"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 572,
          "text": "It is becoming progressively more understandable that loss or reduction of KISS1 expression in different human cancers correlates inversely with progression of tumor, metastasizing potential and survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26873190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 320,
          "text": "BACKGROUND/AIM: The kisspeptin 1 (KISS1) gene encodes a precursor polypeptide which after proteolysis forms the kisspeptin-10 (KISS1) protein. KISS1, retains maximum physiological activity when it binds to its receptor (KISS1R), allowing KISS1 to effectively function as a suppressor of metastasis in melanomas and other",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316037"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Kisspeptins, the products of the KISS1 gene have tumor suppressing and antimetastatic properties",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26010933"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "PURPOSE: Kisspeptins are produced by the KISS1 gene and have tumor-suppressing and anti-metastatic p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30003725"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "KISS1 belongs to the family of metastasis suppressor genes. However, its role is not limited to blocking cancer metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39037658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Kisspeptins are neuropeptides encoded by the Kiss1 gene that was discovered as a metastasis suppressor gene in melanoma and breast cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38640803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "BACKGROUND: Kisspeptin was initially known as metastin for its role in suppressing metastasis in melanoma and br",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38265397"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Kisspeptin (a product of the KISS1 gene and its receptor) plays an important role in obstetrics, gynecology, and cancer cell metastasis and behavior.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38264268"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 247,
          "text": "KiSS1 is a metastasis suppressor originally identified in melanoma cells, known to play an important physiological role in mammals\u0027 development and puberty.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37790750"
        },
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 1021,
          "text": "Besides, recent evidence suggests involvement of KISS1 in the mechanisms of tumor angiogenesis, autophagy and apoptosis regulation, suggesting a possible role in both restricting and promoting cancer cell invasion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31705228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Kisspeptins (KPs, KISS1) and their receptor (KISS1R) play a pivotal role as metastasis suppressor for many cancers. Low or lost KP expression is associated with higher tumor grade, increased metastatic potential, and poor prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38256878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Kisspeptins, the products of the KISS1 gene, are involved in cancer invasion, migration, metastasis and angiogenesis, while they induce apoptosis in various cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24033850"
        },
        {
          "offsetInBeginSection": 570,
          "offsetInEndSection": 806,
          "text": "The commonly accepted role of KISS1 in metastatic tumor progression mechanism is the ability of this protein to suppress colonization of disseminated cancer cells in distant organs critical for the formation of the secondary tumor foci.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31705228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "The cancer suppressor gene, KISS1, was initially described as having an important role in inhibiting cancer metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18644415"
        },
        {
          "offsetInBeginSection": 536,
          "offsetInEndSection": 637,
          "text": "target gene of EGF. The human KISS1 gene encodes kisspeptin, also known as metastin, which can suppre",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34620174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Kisspeptins, the products of the KISS1 gene have tumor suppressing and antimetastatic properties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26010933"
        },
        {
          "offsetInBeginSection": 1094,
          "offsetInEndSection": 1345,
          "text": "In this review, we highlight the latest data on the role of kisspeptin signaling in the suppression of metastasis in various cancer types and the use modulators of KiSS/GPR54 signaling as potential novel therapeutic agents for the treatment of cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29662466"
        },
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 1020,
          "text": "Besides, recent evidence suggests involvement of KISS1 in the mechanisms of tumor angiogenesis, autophagy and apoptosis regulation, suggesting a possible role in both restricting and promoting cancer cell invasion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31705228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24407584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "Kisspeptins, which are alternatively called as metastin since they were originally identified as products of metastasis suppressor gene KiSS-1, are the natural ligands for the G protein-coupled receptor 54 (GPR54)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276835"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 322,
          "text": "BACKGROUND/AIM: The kisspeptin 1 (KISS1) gene encodes a precursor polypeptide which after proteolysis forms the kisspeptin-10 (KISS1) protein. KISS1, retains maximum physiological activity when it binds to its receptor (KISS1R), allowing KISS1 to effectively function as a suppressor of metastasis in melanomas and other t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316037"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Kisspeptins are neuropeptides encoded by the Kiss1 gene that was discovered as a metastasis suppressor gene in melanoma and breast cancer. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38640803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "text": "Activation of KISS1 receptor (KISS1R or GPR54) by its ligands (Kisspeptins) regulates a diverse function both in normal physiology and pathophysiology. In cancer, KISS1R has been implicated in tumor angiogenesis and metastasis, but a broader evaluation of KISS1R in tumorigenesis and tumor progression is yet to be conducted. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21852382"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 383,
          "text": "Kisspeptins (KPs), peptide products of the KISS1 metastasis-suppressor gene, are endogenous ligands for a G protein-coupled receptor (KISS1R). KISS1 acts as a metastasis suppressor in numerous human cancers. However, recent studies have demonstrated that an increase in KISS1 and KISS1R expression in patient breast tumors correlates with higher tumor grade and metastatic potential.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23525242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Kisspeptin, originally identified as metastatin, important in preventing cancer metastasis, has more recently been shown to be important in pregnancy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22526494"
        },
        {
          "offsetInBeginSection": 717,
          "offsetInEndSection": 969,
          "text": " The Kiss-1 gene has been suggested as a suppressor of metastasis in a various types of cancer, including gastric cancer, oesophageal carcinoma, pancreatic, ovarian, bladder and prostate cancer, through the regulation of cellular migration and invasion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23969598"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "OBJECTIVES/HYPOTHESIS: The KiSS-1 gene has been reported to serve as a metastasis suppressor gene in vari",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24254791"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 457,
          "text": "KISS1 is a metastasis suppressor gene and the KP/KISS1R signaling has anti-metastatic and tumor-suppressant effects in numerous human cancers. On the other hand, recent studies indicate that KP/KISS1R pathway plays detrimental roles in breast cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155777"
        },
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 292,
          "text": " Kisspeptin is a reproductive peptide hormone that has anti-metastatic roles in several cancer types including colon, lung, and brain cancer. However, in breast cancer, increasing of kisspeptin expression induces aggressiveness of tumors, which in turn exacerbates breast cancer prognosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30686017"
        },
        {
          "offsetInBeginSection": 471,
          "offsetInEndSection": 907,
          "text": "In addition, intensive recent investigations have provided substantial evidence suggesting roles of Kisspeptin signalling via its receptor GPR54 in the suppression of metastasis with a variety of cancers. The present review highlights the latest studies regarding the role of Kisspeptins and the KiSS-1 gene in tumor progression and also suggests targeting the KiSS-1/GPR54 system may represent a novel therapeutic approach for cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24377507"
        },
        {
          "offsetInBeginSection": 899,
          "offsetInEndSection": 1093,
          "text": "First, we discovered that Kisspeptin/Kisspeptin receptor was expressed in endometrial cancer cells, and Kisspeptin significantly regulated the migration and invasion of endometrial cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38264268"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "The metastasis suppressor protein Kisspeptin regulates cancer cell proliferation and motility through its receptor, GRP54.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24894166"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Kisspeptin is an antimetastatic agent in some cancers that has also been associated with lymphoid cell apoptosis, a phenomenon favoring metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24395571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Kisspeptin, the product of the KiSS-1 gene, inhibits metastasis and stimulates the hypothalamo-pituitary-gonadal axis. Kisspeptin is therefore a putative target in the treatment of hormone-sensitive malignancies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428832"
        },
        {
          "offsetInBeginSection": 1634,
          "offsetInEndSection": 1828,
          "text": "The present study concluded that kisspeptin represses cancer metastasis via EIF2AK2 signaling, thus clarifying the role of kisspeptin signaling in complicated cancer metastasis signaling network",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944853"
        },
        {
          "offsetInBeginSection": 484,
          "offsetInEndSection": 674,
          "text": "intensive recent investigations have provided substantial evidence suggesting roles of Kisspeptin signalling via its receptor GPR54 in the suppression of metastasis with a variety of cancers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24377507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "BACKGROUND: Recent studies have demonstrated that Kisspeptin, the product of the metastasis suppressor gene KiSS-1, could have a role in tumor progression and invasion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22552499"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "The cancer suppressor gene, KISS1, was initially described as having an important role in inhibiting cancer metastasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18644415"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "BACKGROUND/AIM: KISS1 protein and KISS1 receptor form a system that mainly promotes suppression of metastasis in various",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667462"
        }
      ],
      "type": "summary",
      "id": "67dec8fb18b1e36f2e00005b",
      "ideal_answer": [
        "Kisspeptin was initially known as metastin for its role in suppressing metastasis in melanoma and breast cancer. It also suppresses tumor growth",
        "Kisspeptin is a protein encoded by the KISS1 gene, which has been reported to suppress the metastatic capabilities of various types of cancer cells, through the activation of its G‑protein coupled receptor GPR54.",
        "Kisspeptin, a product of the KISS1 gene and its receptor, is involved in the regulation of cancer cell metastasis and behavior. It plays a significant role in inhibiting cancer spread by suppressing metastasis, and its expression level may be correlated with cancer progression and prognosis.",
        "Kisspeptin, a product of the KISS1 gene, plays a significant role in cancer by influencing cancer cell metastasis and behavior. It is involved in regulating mechanisms that may inhibit the spread of cancer cells, thereby impacting cancer progression.",
        "Kisspeptin, a peptide hormone, is known to play a role in inhibiting cancer metastasis and progression, particularly in certain types of cancers such as breast and prostate cancer, by regulating cell migration and invasion.",
        "kisspeptin, a protein encoded by the kiss1 gene, has been found to suppress the metastatic capabilities of various types of cancer cells, including breast, prostate, and colorectal cancer cells, through the activation of its receptor gpr54 and other signaling pathways, such as the activation of eif2ak2 and pkr-pp2a.",
        "Kisspeptin plays a complex role in cancer, acting as a suppressor of tumorigenesis and metastasis in many cancers such as colorectal cancer, while promoting aggressiveness in breast and liver cancers. Its effects are influenced by factors like the microenvironment and steroid receptor status of cancer cells.",
        "Kisspeptin generally acts as a metastasis suppressor in various cancers by inhibiting cell proliferation, migration, and invasion, but in specific cancers like breast and liver cancer, it can promote tumor progression and metastasis, indicating a context-dependent role influenced by factors such as cancer type and microenvironment.",
        "Kisspeptin generally acts as a metastasis suppressor in many cancers, reducing tumor spread, but in some cancers like breast cancer, it may promote tumor progression, making its relationship with cancer complex and context-dependent.",
        "Kisspeptin plays an important role in cancer cell metastasis and behavior. Kisspeptin regulates endometrial cancer cell motility via various signaling pathways and molecules, suggesting potential therapeutic targets for cancer treatment. Additionally, Kisspeptin has been shown to retard tumor growth through p38 MAPK-mediated senescence.",
        "Kisspeptin plays an important role in cancer cell metastasis and behavior. Kisspeptin retards tumor growth of Lewis Lung Carcinoma cells through p38 MAPK-mediated senescence. Kisspeptin regulates endometrial cancer cell motility via FAK and Src expression and various signaling pathways.",
        "Kisspeptin, originally known as metastin, has been shown to suppress metastasis in cancers like melanoma and breast cancer. It also retards tumor growth as seen in Lewis lung carcinoma cells and influences cancer cell motility by modulating various signaling pathways, including p38 MAPK, FAK, and Src.",
        "Kisspeptin, a product of the KISS1 gene, plays a significant role in regulating cancer cell behavior. It suppresses metastasis in various cancers such as melanoma and breast cancer by influencing signaling pathways like FAK, Src, ERK1/2, N-Cadherin, E-Cadherin, beta-Catenin, Twist, and matrix metalloproteinases. Additionally, it can retard tumor growth through mechanisms like p38 MAPK-mediated senescence.",
        "Kisspeptin is a product of the KISS1 gene that plays an important role in many types of cancers such as breast, ovarian, prostate, pancreatic, colon, gastric, pancreatic, esophageal, cervical, endometrial, thyroid, oral, liver, lung and nasal and t cell malignancies.",
        "Kisspeptin, initially known as metastin, suppresses metastasis in melanoma and breast cancer, regulates endometrial cancer cell motility, and retards tumor growth through various signaling pathways.",
        "Kisspeptin is a product of the KISS1 gene and its receptor and plays an important role in obstetrics, gynecology, and cancer cell metastasis and behavior. It regulates endometrial cancer cell motility via FAK and Src expression and the ERK1/2, N-Cadherin, E-Cadherin, beta-Catenin, Twist, and matrix metalloproteinase signaling pathways.",
        "Kisspeptin, initially known as metastin, plays a significant role in suppressing metastasis in melanoma and breast cancer. It also regulates endometrial cancer cell motility via various signaling pathways, including FAK, Src, ERK1/2, N-Cadherin, E-Cadherin, beta-Catenin, Twist, and matrix metalloproteinase signaling pathways."
      ]
    },
    {
      "body": "Infections caused by Klebsiella spp.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39187168",
        "http://www.ncbi.nlm.nih.gov/pubmed/39648897",
        "http://www.ncbi.nlm.nih.gov/pubmed/39571358",
        "http://www.ncbi.nlm.nih.gov/pubmed/39579944",
        "http://www.ncbi.nlm.nih.gov/pubmed/39746348",
        "http://www.ncbi.nlm.nih.gov/pubmed/31976857",
        "http://www.ncbi.nlm.nih.gov/pubmed/12226801",
        "http://www.ncbi.nlm.nih.gov/pubmed/9767057",
        "http://www.ncbi.nlm.nih.gov/pubmed/6365535",
        "http://www.ncbi.nlm.nih.gov/pubmed/33995300",
        "http://www.ncbi.nlm.nih.gov/pubmed/34268262",
        "http://www.ncbi.nlm.nih.gov/pubmed/33656584",
        "http://www.ncbi.nlm.nih.gov/pubmed/39737355",
        "http://www.ncbi.nlm.nih.gov/pubmed/39736428",
        "http://www.ncbi.nlm.nih.gov/pubmed/31250595",
        "http://www.ncbi.nlm.nih.gov/pubmed/31761885",
        "http://www.ncbi.nlm.nih.gov/pubmed/25380908",
        "http://www.ncbi.nlm.nih.gov/pubmed/17587071",
        "http://www.ncbi.nlm.nih.gov/pubmed/29209595",
        "http://www.ncbi.nlm.nih.gov/pubmed/39725322",
        "http://www.ncbi.nlm.nih.gov/pubmed/36005809",
        "http://www.ncbi.nlm.nih.gov/pubmed/34992583",
        "http://www.ncbi.nlm.nih.gov/pubmed/16951813",
        "http://www.ncbi.nlm.nih.gov/pubmed/37722897",
        "http://www.ncbi.nlm.nih.gov/pubmed/15112067",
        "http://www.ncbi.nlm.nih.gov/pubmed/26279962",
        "http://www.ncbi.nlm.nih.gov/pubmed/30452654",
        "http://www.ncbi.nlm.nih.gov/pubmed/39614148",
        "http://www.ncbi.nlm.nih.gov/pubmed/22627446",
        "http://www.ncbi.nlm.nih.gov/pubmed/26999397",
        "http://www.ncbi.nlm.nih.gov/pubmed/22184897",
        "http://www.ncbi.nlm.nih.gov/pubmed/23449877",
        "http://www.ncbi.nlm.nih.gov/pubmed/28948123",
        "http://www.ncbi.nlm.nih.gov/pubmed/12120935",
        "http://www.ncbi.nlm.nih.gov/pubmed/32999783",
        "http://www.ncbi.nlm.nih.gov/pubmed/36114910",
        "http://www.ncbi.nlm.nih.gov/pubmed/18260762",
        "http://www.ncbi.nlm.nih.gov/pubmed/3882593",
        "http://www.ncbi.nlm.nih.gov/pubmed/36651775",
        "http://www.ncbi.nlm.nih.gov/pubmed/39357832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34851134",
        "http://www.ncbi.nlm.nih.gov/pubmed/30558858",
        "http://www.ncbi.nlm.nih.gov/pubmed/18801186",
        "http://www.ncbi.nlm.nih.gov/pubmed/33446433",
        "http://www.ncbi.nlm.nih.gov/pubmed/21509474",
        "http://www.ncbi.nlm.nih.gov/pubmed/27402393",
        "http://www.ncbi.nlm.nih.gov/pubmed/34004273",
        "http://www.ncbi.nlm.nih.gov/pubmed/663938",
        "http://www.ncbi.nlm.nih.gov/pubmed/16689852",
        "http://www.ncbi.nlm.nih.gov/pubmed/38355621",
        "http://www.ncbi.nlm.nih.gov/pubmed/37739556",
        "http://www.ncbi.nlm.nih.gov/pubmed/36575027",
        "http://www.ncbi.nlm.nih.gov/pubmed/20488656",
        "http://www.ncbi.nlm.nih.gov/pubmed/9363011",
        "http://www.ncbi.nlm.nih.gov/pubmed/38147789",
        "http://www.ncbi.nlm.nih.gov/pubmed/39255397",
        "http://www.ncbi.nlm.nih.gov/pubmed/39237686",
        "http://www.ncbi.nlm.nih.gov/pubmed/29521617",
        "http://www.ncbi.nlm.nih.gov/pubmed/36185529",
        "http://www.ncbi.nlm.nih.gov/pubmed/26430050",
        "http://www.ncbi.nlm.nih.gov/pubmed/23143289",
        "http://www.ncbi.nlm.nih.gov/pubmed/24996691"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 42,
          "text": "Periprosthetic joint infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39187168"
        },
        {
          "offsetInBeginSection": 165,
          "offsetInEndSection": 278,
          "text": "Klebsiella variicola carrying multiple antimicrobial resistance (AMR) genes were found significantly among sepsis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39648897"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Klebsiella pneumoniae is a leading cause of hospital-acquired infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39571358"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 120,
          "text": "leading cause of neonatal sepsis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39571358"
        },
        {
          "offsetInBeginSection": 720,
          "offsetInEndSection": 725,
          "text": "ulcer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39579944"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 65,
          "text": "Urinary tract infections (UTIs) are common in neonates",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39746348"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 281,
          "text": "Klebsiella spp. are commensals of the human microbiota, and a leading cause of opportunistic nosocomial infections. The incidence of multidrug resistant (MDR) strains of Klebsiella pneumoniae causing serious infections is increasing, and Klebsiella oxytoca is an emerging pathogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31976857"
        },
        {
          "offsetInBeginSection": 280,
          "offsetInEndSection": 477,
          "text": "Klebsiella spp. is responsible for 1% to 5% of all cases of community-acquired pneumonia and between 0% to 23% of those acquired in the hospital, and its frequency is greater in alcoholic patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12226801"
        },
        {
          "offsetInBeginSection": 89,
          "offsetInEndSection": 312,
          "text": "In particular, the medically most important Klebsiella species, Klebsiella pneumoniae, accounts for a significant proportion of hospital-acquired urinary tract infections, pneumonia, septicemias, and soft tissue infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9767057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Nosocomial infections with Klebsiella spp. are a leading cause of morbidity and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6365535"
        },
        {
          "offsetInBeginSection": 27,
          "offsetInEndSection": 115,
          "text": "Klebsiella pneumoniae is a common pathogen associated with healthcare-related infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39737355"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Efficacy of high doses of intravenous fosfomycin for treatment of urinary tract infection caused by KPC carbapenemase-producing Klebsiella pneumoniae. An observational study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39736428"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 322,
          "text": "Klebsiella spp. are major pathogens in healthcare-associated infections, and their importance is increasing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31761885"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Comparison between Patients with Chest Infection due to Klebsiella spp. and Streptococcus pneumoniae.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31761885"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Klebsiella spp. are commensals of the human microbiota, and a leading cause of opportunistic nosocomial infections. The",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31976857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Klebsiella pneumoniae is one of the most clinically relevant species in immunocompromised individuals responsible for community-acquired and nosocomial infections, including pneumonias, urinary tract infections, bacteremias, and liver abscesses. Since ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29209595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 613,
          "text": "BACKGROUND: Klebsiella pneumoniae (Kpn), a WHO priority pathogen with high rates of antimicrobial resistance (AMR), has emerged as a leading cause of hospital acquired pneumonia and neonatal sepsis.OBJECTIVE: We aimed to define the clinical characteristics of a cohort of patients with Kpn infection in Dhaka, Bangladesh and to perform phenotypic and genetic characterization of the associated isolates.METHODS: We retrospectively extracted clinical data about patients at Dhaka Medical College Hospital from whom Klebsiella spp was isolated from a clinical specimen collected between February and September 2022.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725322"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Bacteria belonging to the genus Klebsiella frequently cause human nosocomial infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9767057"
        },
        {
          "offsetInBeginSection": 571,
          "offsetInEndSection": 772,
          "text": "Hospital outbreaks of multidrug-resistant Klebsiella spp., especially those in neonatal wards, are often caused by new types of strains, the so-called extended-spectrum-beta-lactamase (ESBL) producers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9767057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Klebsiella species cause infections at multiple sites, including lung, urinary tract, bloodstream, wound or surgical site, and brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34992583"
        },
        {
          "offsetInBeginSection": 898,
          "offsetInEndSection": 1024,
          "text": "The resulting limitations on the therapeutic options demand new measures for the management of Klebsiella hospital infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9767057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 312,
          "text": "Bacteria belonging to the genus Klebsiella frequently cause human nosocomial infections. In particular, the medically most important Klebsiella species, Klebsiella pneumoniae, accounts for a significant proportion of hospital-acquired urinary tract infections, pneumonia, septicemias, and soft tissue infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9767057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Over the past two decades, nosocomial infections caused by extended-spectrum beta-lactamase (ESBL)-producing Klebsiella spp. have become a major problem all around the world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16951813"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 512,
          "text": "lung abscesses, necrotizing pneumonia, and urinary tract infections caused by K. ozaenae have also been reported. We herein report the first detection of K. ozaenae as an etiological agent of bacterial meningitis in Japan. Cases of K. ozaenae meningitis complicated by diabetes mellitus and sinusitis have been reported elsewhere.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37722897"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 71,
          "text": "Patients with Chest Infection due to Klebsiella spp.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31761885"
        },
        {
          "offsetInBeginSection": 280,
          "offsetInEndSection": 786,
          "text": "Klebsiella spp. is responsible for 1% to 5% of all cases of community-acquired pneumonia and between 0% to 23% of those acquired in the hospital, and its frequency is greater in alcoholic patients. The majority of cases are unilateral in the posterior segment of the right upper lobe. Lung abscess can occur after a pneumonic process or secondarily to Klebsiella spp. infections and have high rates of morbidity and mortality. K. pneumoniae is one of the most common microorganisms responsible for empyema.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12226801"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 746,
          "text": "Presented here are four cases of necrotizing fasciitis caused by Klebsiella spp. that were treated at one hospital over a 2-year period. Klebsiella necrotizing fasciitis can occur via direct inoculation, local trauma or, more commonly, hematogenous spread from other septic foci. Early, aggressive, surgical debridement and appropriate antimicrobial treatment are the cornerstones of treatment for this condition. Necrotizing fasciitis due to Klebsiella spp. is unique in that it is commonly associated with multiple septic foci. While liver abscesses and endogenous endophthalmitis are better-known associations of disseminated Klebsiella infection, necrotizing fasciitis is increasingly recognized as one of the manifestations of this syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15112067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "Klebsiella spp community-acquired meningitis caused by hypervirulent strains is well described as part of a distinct syndrome consisting of liver abscess and multiple septic metastatic lesions (Klebsiella pneumoniae invasive syndrome) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34268262"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 360,
          "text": "In this report, we present a rare case of Klebsiella pneumoniae-associated Lemierre\u0027s syndrome in a patient with poorly-controlled diabetes mellitus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26279962"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Klebsiella species cause a wide range of diseases including pneumonia, urinary tract infections (UTIs), bloodstream infections and sepsis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30452654"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Klebsiella spp. commonly cause both uncomplicated urinary tract infection (UTI) and recurrent UTI (rUTI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36005809"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "BACKGROUND: Klebsiella pneumoniae has emerged as a significant pathogen that causes community and hospital infections due to its high resistance rate and trans",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39614148"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Klebsiella is an opportunistic pathogen that is known to cause septicemia, pneumonia, urinary tract infections, hepatobiliary tract infections, and soft tissue infections in patients who have severe underlying diseases or are under immunosuppression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627446"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "Strains of Klebsiella pneumoniae are frequently opportunistic pathogens implicated in urinary tract and catheter-associated urinary-tract infections of hospitalized patients and compromised individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999397"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 160,
          "text": "K. pneumoniae is one of the major pathogens causing UTIs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22184897"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "This is a description of fatal sepsis caused by infection with Klebsiella variicola, which is an isolate genetically related to Klebsiella pneumoniae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23449877"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 429,
          "text": "The patient\u0027s condition was incorrectly diagnosed as common sepsis caused by K. pneumoniae, which was identified using an automated identification system, but next-generation sequencing and the non-fermentation of adonitol finally identified the cause of sepsis as K. variicola.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23449877"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Hospital-acquired multidrug-resistant (MDR) Klebsiella infection is posing a significant challenge to physicians all around the world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948123"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 590,
          "text": "We report a case of MDR Klebsiella urinary tract infection (UTI) in a patient following a trimalleolar fracture, which was appropriately treated with a combination of amikacin and meropenem.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28948123"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 279,
          "text": "Highly drug-resistant Klebsiella species, especially K. pneumoniae, have emerged rapidly and are becoming a major concern in clinical management.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33995300"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "The clinical significance of a heavy growth of Klebsiella spp. in sputum was studied in 54 patients. All but 3 patients had significant factors potentially associated with respiratory tract colonisation or invasion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8093134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "Data on the frequency of intestinal infections caused by Klebsiella spp. in infants at the age of 1 month to 1 year and antibiotic resistance of K. pneumoniae and K. oxytoca isolates from newborns and infants aged 1 month to 1 year are presented.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2275594"
        },
        {
          "offsetInBeginSection": 1358,
          "offsetInEndSection": 1474,
          "text": "Upper Klebsiella spp UTIs were slightly more prevalent in males with urinary flow impairment due to various reasons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25380908"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Klebsiella is a genus of Gram-negative bacteria known to be opportunistic pathogens that may cause a variety of infections in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33995300"
        },
        {
          "offsetInBeginSection": 280,
          "offsetInEndSection": 704,
          "text": "bacteremias in children.PATIENTS AND METHODS: From 1988-1997, 177 episodes of Klebsiella bacteremia, representing 15% of all gram-negative bacteremias, occurred at the Soroka Medical Center in 166 children aged 0-14 years.RESULTS: The overall incidence of Klebsiella bacteremia in southern Israel during the study period was 0.13/1,000, with an increase from 0.1 to 0.2/1,000 children from 1988-1992 to 1993-1997 (p \u003d 0.02).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12120935"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 399,
          "text": "of oral origin causes various infections not only in gastrointestinal tract but also in other organs, with Klebsiella pneumoniae serotype K1 resulting in a liver abscess (KLA) through oral inoculation in mice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31250595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Nosocomial infections caused by Klebsiella pneumoniae and other Gram-negative organisms have emerged as a significant health problem especially in intensive care units (ICU).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32999783"
        },
        {
          "offsetInBeginSection": 313,
          "offsetInEndSection": 405,
          "text": "rty eight episodes of culture-proven Klebsiella keratitis were identified in 37 patients. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36114910"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 247,
          "text": "K. pneumoniae is one of the major pathogens causing UTIs. Fluoroquinolones are effective drugs for treating infections caused by Klebsiella spp.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22184897"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 311,
          "text": "Bacteria belonging to the genus Klebsiella frequently cause human nosocomial infections. In particular, the medically most important Klebsiella species, Klebsiella pneumoniae, accounts for a significant proportion of hospital-acquired urinary tract infections, pneumonia, septicemias, and soft tissue infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9767057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "BACKGROUND: Klebsiella pneumoniae causes serious, life-threatening infections in humans in endemic and epide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18260762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Klebsiella pneumoniae causes serious epidemic and endemic nosocomial infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3882593"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 159,
          "text": "K. pneumoniae is one of the major pathogens causing UTIs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22184897"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "OBJECTIVES: To evaluate the efficacy of high-dose intravenous fosfomycin for the treatment of urinary tract infections (UTI) caused by KPC carbapenemase-producing Klebsiella pneumoni",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39736428"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Klebsiella is an opportunistic pathogen that is known to cause septicemia, pneumonia, urinary tract infections, hepatobiliary tract infections, and soft tissue infections in patients who have severe underlying diseases or are under immunosuppression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627446"
        },
        {
          "offsetInBeginSection": 129,
          "offsetInEndSection": 247,
          "text": "Klebsiella pneumoniae (Kp) is a leading cause of bacteremia, pneumonia, and urinary tract infections in these settings",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36651775"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 352,
          "text": "l problem. Klebsiella pneumoniae is a major culprit in healthcare settings and is responsible for septicemia, urinary tract infections, pneumonia, meningitis, burn wound and surgical site infections, and liver abscesses even in younger and healthier populatio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39357832"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "BACKGROUND: Klebsiella pneumoniae (Kpn), a WHO priority pathogen with high rates of antimicrobial resistance (AMR), has emerged as a leading cause of hospital acquired pneumonia and neo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725322"
        },
        {
          "offsetInBeginSection": 519,
          "offsetInEndSection": 729,
          "text": " genome sequencing.RESULTS: Of 1859 cases of meningitis in children under the age of 1 year, 13 cases (0.7%) of Klebsiella spp. meningitis (nine for Kp meningitis and four for Ko meningitis) were registered in ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30558858"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "BACKGROUND: Klebsiella oxytoca can cause various infectious complications in healthy as well as in immunocompromised",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801186"
        },
        {
          "offsetInBeginSection": 632,
          "offsetInEndSection": 841,
          "text": "ct infections yielding an incidence of 5.1%. The pathogens responsible for secondary bacteremia were: Klebsiella pneumonia in two patients, Enterococcus faecium in two patients, Klebsiella oxytoca in one patie",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33446433"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 474,
          "text": "Klebsiella oxytoca is responsible for a wide range of ailments from colitis to infective endocarditis, other than the common urinary and respiratory tract infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33656584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Klebsiella pneumoniae is the most clinically relevant species of this genus, known to cause both community-acquired and nosocomial infections worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27402393"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 248,
          "text": "Among these, the Klebsiella pneumoniae species complex, which includes seven phylogroups, is an important cause of community and hospital infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34004273"
        },
        {
          "offsetInBeginSection": 340,
          "offsetInEndSection": 571,
          "text": "The K. oxytoca complex is a human commensal but also an opportunistic pathogen causing various infections, such as antibiotic-associated hemorrhagic colitis (AAHC), urinary tract infection, and bacteremia, and has caused outbreaks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34851134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Klebsiella oxytoca was isolated from the blood of a leukemic patient. The typical pathogenicity of Klebsiella oxytoca was observed in the patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/663938"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 388,
          "text": "The pathogenicity of several Klebsiella oxytoca strains isolated from blood, urine and sputum of different patients was examined in mice, and it was found that Klebsiella oxytoca isolated from the blood had a higher toxicity than the others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/663938"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 292,
          "text": "This report describes a case of intravascular infection of an implanted defibrillator with Klebsiella pneumoniae, an unusual pathogen for pacemaker or defibrillator infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689852"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "BACKGROUND: Antimicrobial resistance research in uncomplicated urinary tract infection typically focuses on the main causative pathogen, Escherichia coli; however, little is known about the antimicrobial resistance burden of Klebsiella species, which can also cause uncomplicated urinary tract ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38355621"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Klebsiella pneumoniae is an opportunistic pathogen involved in both hospital- and community-acquired infections. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37739556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Klebsiella oxytoca is an opportunistic pathogen that causes nosocomial infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36575027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "A diabetic woman suffered from deep neck infection, endophthalmitis, urinary tract infection, and mycotic aneurysm associated Klebsiella pneumoniae bacteremia for 4 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20488656"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Klebsiella infection has been considered to be an uncommon cause of meningitis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9363011"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 728,
          "text": "We report 42.91% rate of Klebsiella spp co-infection in ICU admission patients, mostly related to K. pneumonia (26.81%), K. aerogenes (9.4%), and K. oxytoca (6.7%)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38147789"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "BACKGROUND: Klebsiella pneumoniae is infamous for hospital-acquired infections and sepsis, which have also been linked to Alzheimer disease (AD)-related neuroinflammatory and neurodegenerative ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39255397"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 419,
          "text": "ndividuals.CASE PRESENTATIONS: Case 1: A 49 year old female with multiple myeloma received an autologous hematopoietic stem cell transplant in October 2005. Eight days following her autograft she developed septic shock caused by Klebsiella oxytoca bacteremia which was successfully treated with intrav",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801186"
        },
        {
          "offsetInBeginSection": 80,
          "offsetInEndSection": 180,
          "text": "Klebsiella pneumoniae (KP) have increasingly been isolated in ventriculitis and meningitis episodes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39237686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "text": "Klebsiella species cause a wide range of diseases including pneumonia, urinary tract infections (UTIs), bloodstream infections and sepsis. These infections are particularly a problem among neonates, elderly and immunocompromised individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30452654"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 400,
          "text": "Klebsiella species cause infections at multiple sites, including lung, urinary tract, bloodstream, wound or surgical site, and brain. These infections are more likely to occur in people with preexisting health conditions. Klebsiella pneumoniae (K. pneumoniae) has emerged as a major pathogen of international concern due to the increasing incidences of hypervirulent and carbapenem-resistant strains.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34992583"
        },
        {
          "offsetInBeginSection": 995,
          "offsetInEndSection": 1172,
          "text": " results of this study indicated the prevalence of community-acquired urinary tract and lower respiratory tract infections caused by Klebsiella spp. among geriatric patients. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29521617"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 307,
          "text": " Klebsiella spp. have been at the forefront of causing different types of infections such as bacteremia, urinary tract infections, pneumonia, enteritis, and sepsis in humans as well as animals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36185529"
        },
        {
          "offsetInBeginSection": 1449,
          "offsetInEndSection": 1511,
          "text": "Klebsiella spp is an important cause of bloodstream infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21509474"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Nosocomial infections with Klebsiella spp. are a leading cause of morbidity and mortality",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6365535"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 321,
          "text": "Klebsiella spp. are major pathogens in healthcare-associated infections, and their importance is increasing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31761885"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 294,
          "text": "ents (RTR). Klebsiella spp is a well-recognized source of nosocomial infections in immunocompromised patients and is also the most common pathogen capable of producing extended-spectrum β-lacta",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25380908"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Klebsiella pneumoniae is a Gram-negative pathogen frequently associated with antibiotic-resistant nosocomial infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26430050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "The extended-spectrum beta-lactamase (ESBL)-producing Klebsiella spp. cause worldwide problems in intensive care units",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17587071"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Klebsiella bacteria have emerged as an increasingly important cause of community-acquired nosocomial infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23143289"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 304,
          "text": "BACKGROUND: The Gram-negative pathogenic bacteria Klebsiella oxytoca and Klebsiella pneumoniae produce the extended spectrum β-lactamase (ESBL) and cephalosporinase enzymes and are the major causes of hospital acquired (HA) infections and epidemics in non-hygienic communities in the majority of developi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24996691"
        }
      ],
      "id": "67e40a2418b1e36f2e0000a1",
      "ideal_answer": [
        "Klebsiella spp can cause infections in many sites, such as ulcers, urinary tract infections, periprosthetic joint infections, and can also cause sepsis and neonatal sepsis and nosocomial infections.",
        "Klebsiella species can cause a variety of infections, including hospital-acquired infections, neonatal sepsis, meningitis, pneumonia, urinary tract infections, hepatobiliary tract infections, soft tissue infections, antibiotic-associated hemorrhagic colitis, periprosthetic joint infection, burn wound and surgical site infections, liver abscesses, and infections in companion animals. As opportunistic pathogens, they can affect both healthy and immunocompromised individuals. Klebsiella pneumoniae is a leading cause of bacteremia, pneumonia, and urinary tract infections."
      ],
      "exact_answer": [
        [
          "Periprosthetic joint infection"
        ],
        [
          "Sepsis"
        ],
        [
          "Nosocomial infection"
        ],
        [
          "Neonatal sepsis"
        ],
        [
          "Ulcers"
        ],
        [
          "Urinary tract infections in neonates"
        ],
        [
          "Urinary tract infections"
        ],
        [
          "Necrotizing pneumonia"
        ],
        [
          "Intra-ocular infection"
        ],
        [
          "soft-tissue infection"
        ]
      ]
    },
    {
      "body": "Does DNA methylation always lead to gene silencing?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31399642",
        "http://www.ncbi.nlm.nih.gov/pubmed/22641018",
        "http://www.ncbi.nlm.nih.gov/pubmed/11498573",
        "http://www.ncbi.nlm.nih.gov/pubmed/38895372",
        "http://www.ncbi.nlm.nih.gov/pubmed/39590352",
        "http://www.ncbi.nlm.nih.gov/pubmed/39632087",
        "http://www.ncbi.nlm.nih.gov/pubmed/39736632",
        "http://www.ncbi.nlm.nih.gov/pubmed/32348735",
        "http://www.ncbi.nlm.nih.gov/pubmed/31399242",
        "http://www.ncbi.nlm.nih.gov/pubmed/26115768",
        "http://www.ncbi.nlm.nih.gov/pubmed/25308082",
        "http://www.ncbi.nlm.nih.gov/pubmed/38012713",
        "http://www.ncbi.nlm.nih.gov/pubmed/31551326",
        "http://www.ncbi.nlm.nih.gov/pubmed/30348202",
        "http://www.ncbi.nlm.nih.gov/pubmed/20463746",
        "http://www.ncbi.nlm.nih.gov/pubmed/17202157"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "DNA methylation is of paramount importance for mammalian embryonic development. DNA methylation has numerous functions: it is implicated in the repression of transposons and genes, but is also associated with actively transcribed gene bodies and, in some cases, with gene activation per se.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31399642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 596,
          "text": "DNA methylation is frequently described as a \u0027silencing\u0027 epigenetic mark, and indeed this function of 5-methylcytosine was originally proposed in the 1970s. Now, thanks to improved genome-scale mapping of methylation, we can evaluate DNA methylation in different genomic contexts: transcriptional start sites with or without CpG islands, in gene bodies, at regulatory elements and at repeat sequences. The emerging picture is that the function of DNA methylation seems to vary with context, and the relationship between DNA methylation and transcription is more nuanced than we realized at first.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22641018"
        },
        {
          "offsetInBeginSection": 846,
          "offsetInEndSection": 1093,
          "text": "Methylation is also used for long-term epigenetic silencing of X-linked and imprinted genes and can either increase or decrease the level of transcription, depending on whether the methylation inactivates a positive or negative regulatory element.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11498573"
        },
        {
          "offsetInBeginSection": 563,
          "offsetInEndSection": 726,
          "text": "DNA methylation levels of promoter and gene body regions are negatively correlated with gene expression, consistent with patterns in other mammalian brains studied",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38895372"
        },
        {
          "offsetInBeginSection": 80,
          "offsetInEndSection": 157,
          "text": "Methylation is a natural and cellular epigenetic mechanism for gene silencing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39590352"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "In plants, cytosine DNA methylation (mC) is largely associated with transcriptional repression of transposable elements, but it can also be found in the body of expressed genes, referred to as gene body methylation (gbM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39632087"
        },
        {
          "offsetInBeginSection": 572,
          "offsetInEndSection": 790,
          "text": "Recent work from diverse model systems suggests that 5mC might not always act as a dominant repressive mechanism and that hypermethylated promoters and enhancers can be permissive to transcription in vivo and in vitro.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31551326"
        },
        {
          "offsetInBeginSection": 553,
          "offsetInEndSection": 738,
          "text": "Our data indicate that DNA methylation in gene promoter regions is not always a repressive epigenetic mark. Indeed, about 27% of methylated genes are actively expressed in CD4+ T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20463746"
        },
        {
          "offsetInBeginSection": 305,
          "offsetInEndSection": 578,
          "text": "Classically, dense promoter DNA methylation is associated with transcriptional repression. However, growing evidence suggests that this association may not always hold true, and promoter hypermethylation now also appears to be associated with high transcriptional activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32348735"
        },
        {
          "offsetInBeginSection": 579,
          "offsetInEndSection": 712,
          "text": "Furthermore, in a selection of contexts, increasing levels of promoter methylation correlate directly with increased gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32348735"
        },
        {
          "offsetInBeginSection": 771,
          "offsetInEndSection": 1006,
          "text": "Our results suggest that active histone modifications may prevent spreading of CpG methylation towards the promoter and show that repressive DNA methylation immediately adjacent to a promoter does not necessarily repress transcription.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17202157"
        }
      ],
      "id": "67eb55d818b1e36f2e0000e6",
      "ideal_answer": [
        "DNA methylation is frequently described as a \u0027silencing\u0027 epigenetic mark, and indeed this function of 5-methylcytosine was originally proposed in the 1970s. Now, thanks to improved genome-scale mapping of methylation, we can evaluate DNA methylation in different genomic contexts: transcriptional start sites with or without CpG islands, in gene bodies, at regulatory elements, and at repeat sequences. The emerging picture is that the function of DNA methylation seems to vary with context, and the relationship between DNA methylation and transcription is more nuanced than we realized at first. Indeed, DNA methylation has also been associated with actively transcribed gene bodies and, in some cases, with gene activation.",
        "No, DNA methylation does not always lead to gene silencing. While it is commonly associated with repressing gene expression, its effects can vary depending on the context. The location of the methylation within the genome and the presence of other regulatory elements play a role. Methylation in promoter regions is often linked to gene silencing, but methylation in gene bodies or other regions can result in gene activation or have no significant impact on gene expression.",
        "No, DNA methylation does not always lead to gene silencing. Although methylation in promoter regions is often linked with reduced transcriptional activity and gene repression, its effects are highly dependent on its genomic context. For example, methylation within gene bodies may correlate with active transcription and be involved in regulating alternative splicing or preventing incorrect transcription initiation. Additionally, methylation marks can be dynamically added or removed in response to developmental and environmental signals, indicating that it functions as one part of a broader regulatory network rather than as a universal off switch.",
        "DNA methylation\u0027s effect on gene expression is context-dependent, not exclusively leading to gene silencing. It can also be associated with actively transcribed gene bodies and, in certain cases, contributes to gene activation, highlighting a complex relationship between DNA methylation and transcription.",
        "DNA methylation is a complex epigenetic mark that plays a crucial role in mammalian embryonic development, and its function varies depending on the genomic context. While it is often associated with gene silencing, recent genome-scale mapping of methylation has revealed a more nuanced relationship between DNA methylation and transcription. Studies have shown that DNA methylation can be found not only at transcriptional start sites, where it may repress gene expression, but also in actively transcribed gene bodies, where it may be associated with gene activation. Furthermore, DNA methylation is implicated in the repression of transposons and genes, as well as at regulatory elements and repeat sequences, highlighting its diverse functions. Therefore, DNA methylation does not always lead to gene silencing, and its effects on gene expression are highly context-dependent.",
        "While DNA methylation was traditionally viewed as a \u0027silencing\u0027 epigenetic mark, recent genome-scale studies reveal its function is more complex and context-dependent. Although it can repress transposons and genes, DNA methylation is also found in actively transcribed gene bodies and can sometimes contribute to gene activation, indicating that its relationship with transcription is more nuanced than initially thought.",
        "No. While DNA methylation is commonly associated with gene silencing, such as repressing transposons and certain genes, it also plays roles beyond repression. For example, DNA methylation is observed in actively transcribed gene bodies and can correlate with transcription activity. In some contexts, it may even contribute directly to gene activation rather than silencing.",
        "No, DNA methylation does not always lead to gene silencing. While it is classically associated with transcriptional repression (e.g., silencing transposons or promoters), it also occurs in actively transcribed gene bodies and can correlate with gene activation in certain contexts. The functional role of DNA methylation depends on its genomic location and biological setting.",
        "No. While DNA methylation is commonly linked to gene repression (e.g., silencing transposons or promoters), it also occurs in actively transcribed gene bodies and can correlate with transcription. Its role depends on genomic context: promoter methylation typically silences genes, whereas gene body methylation may facilitate transcription or splicing. DNA methylation does not universally cause silencing.",
        "DNA methylation does not always lead to gene silencing. While it is commonly associated with gene repression, particularly at transcriptional start sites and CpG islands, its function varies depending on the genomic context. For instance, DNA methylation can be found in actively transcribed gene bodies and may even play a role in gene activation. Thus, the relationship between DNA methylation and gene expression is more nuanced than a simple silencing mechanism.",
        "DNA methylation does not always lead to gene silencing; its effect depends on the genomic context. While methylation is commonly associated with gene repression, particularly in promoter regions where it can prevent transcription factor binding, it also plays a role in active transcription in other areas such as gene bodies. This variability highlights that DNA methylation\u0027s impact on gene expression is nuanced and context-dependent, rather than universally repressive.",
        "DNA methylation does not universally lead to gene silencing. While it is commonly associated with gene repression, particularly at promoters containing CpG islands, its effects are context-dependent. In other genomic contexts, such as gene bodies, DNA methylation can be linked to active transcription or even gene activation. This variability highlights that the relationship between DNA methylation and gene expression is more nuanced than a simple silencing mechanism.",
        "No, DNA methylation does not always lead to gene silencing. While it is frequently described as a \u0027silencing\u0027 epigenetic mark, the function of DNA methylation varies with context, and it is also associated with actively transcribed gene bodies and, in some cases, with gene activation.",
        "DNA methylation does not always lead to gene silencing. While it was originally proposed as a \u0027silencing\u0027 epigenetic mark in the 1970s, improved genome-scale mapping has revealed that its function varies with context. DNA methylation is implicated in the repression of transposons and genes, but can also be associated with actively transcribed gene bodies and, in some cases, with gene activation per se.",
        "DNA methylation does not always lead to gene silencing. While it is often described as a \u0027silencing\u0027 epigenetic mark, its function varies depending on the genomic context. In transcriptional start sites without CpG islands, DNA methylation typically represses genes. However, in other contexts such as within gene bodies or at regulatory elements, DNA methylation can be associated with active transcription and even gene activation. This nuanced relationship indicates that DNA methylation\u0027s role is more complex than merely silencing genes.",
        "DNA methylation does not invariably lead to gene silencing. Its impact on gene expression varies significantly depending on the genomic context, where it can be associated with both gene repression and, notably, gene activation. While frequently linked to the repression of transposons and genes, DNA methylation is also found in actively transcribed gene bodies, underscoring the complexity of its relationship with transcription. This context-dependent variability highlights the nuanced role of DNA methylation in regulating gene expression.",
        "No, DNA methylation does not always lead to gene silencing. While it is commonly associated with the repression of transposons and genes, DNA methylation can also be found in actively transcribed gene bodies and, in some cases, is even associated with gene activation. This demonstrates that DNA methylation has diverse roles in gene regulation beyond just silencing.",
        "DNA methylation does not invariably lead to gene silencing. Its impact on gene expression varies significantly with genomic context, where it can be present in actively transcribed gene bodies and, in some instances, contribute to gene activation, contrasting its more commonly recognized role in repressing transposons and genes, particularly at specific transcription start sites.",
        "No, DNA methylation does not always lead to gene silencing. While it is often associated with gene repression, its function can vary depending on the genomic context. In some cases, DNA methylation is linked to actively transcribed gene bodies and even gene activation. The relationship between DNA methylation and transcription is more nuanced than initially thought, and its effects depend on factors such as the location of methylation (e.g., CpG islands, gene bodies, regulatory elements) and the specific genomic context.",
        "No, DNA methylation does not always lead to gene silencing. While DNA methylation was traditionally described as a \u0027silencing\u0027 epigenetic mark, recent genome-scale mapping of methylation has revealed that its function varies with genomic context. DNA methylation is implicated in gene repression, particularly at promoter regions, but it is also associated with actively transcribed gene bodies and in some cases can be linked to gene activation. The relationship between DNA methylation and transcription is more nuanced than initially thought, with different effects depending on where the methylation occurs in the genome.",
        "DNA methylation does not always lead to gene silencing. While it is commonly associated with repression of genes and transposons, its effects are context-dependent. Methylation can also be found in actively transcribed gene bodies and may even contribute to gene activation in certain cases. The genomic location of methylation, such as at transcriptional start sites or regulatory elements, influences its role, making the relationship between DNA methylation and gene expression more nuanced than previously thought.",
        "DNA methylation does not universally lead to gene silencing; its effects vary depending on genomic context. While it is associated with repression of transposons and genes, particularly at transcriptional start sites lacking CpG islands, recent studies reveal that methylation can also occur in actively transcribed gene bodies and may even contribute to gene activation in certain contexts. Thus, the role of DNA methylation is more nuanced than previously thought, influenced by its specific genomic location and context.",
        "DNA methylation is often associated with gene repression, especially when it occurs in promoter regions, yet it does not always lead to gene silencing. Its effect is highly context-dependent, influenced by the specific genomic location and the interplay with other chromatin modifications and regulatory factors. In many cases, methylation acts as a reinforcing mark for genes that are already silenced rather than serving as the primary trigger for turning genes off. Moreover, methylation within gene bodies or at non-promoter regions may coexist with active transcription and can even be important for proper gene expression. Therefore, while DNA methylation frequently contributes to gene repression, it is not an absolute determinant of transcriptional inactivity.",
        "DNA methylation does not always lead to gene silencing; its effects are context-dependent. While it is often associated with the repression of transposons and genes, particularly at transcriptional start sites without CpG islands, DNA methylation can also be found in actively transcribed gene bodies and may even contribute to gene activation in certain contexts. This nuanced relationship highlights that DNA methylation\u0027s role varies across different genomic regions.",
        "No, DNA methylation does not always lead to gene silencing. While DNA methylation is frequently described as a \u0027silencing\u0027 epigenetic mark, its function varies with context and can also be associated with actively transcribed gene bodies and, in some cases, with gene activation."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Describe Gene-SCOUT",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35474393"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Gene-SCOUT: identifying genes with similar continuous trait fingerprints from phenome-wide association analyses.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35474393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 521,
          "text": "Large-scale phenome-wide association studies performed using densely-phenotyped cohorts such as the UK Biobank (UKB), reveal many statistically robust gene-phenotype relationships for both clinical and continuous traits. Here, we present Gene-SCOUT, a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35474393"
        }
      ],
      "id": "67e7dbc518b1e36f2e0000d7",
      "ideal_answer": [
        "Gene-SCOUT is a tool that identifies genes with similar continuous trait fingerprints from phenome-wide association analyses.",
        "Gene-SCOUT is a tool designed to identify genes with similar continuous trait fingerprints based on phenome-wide association studies. It uses cosine similarity to evaluate gene similarities, capturing concordant effect directionality and elucidating gene clusters in a high-dimensional space. The tool leverages gene-biomarker association statistics from a rare variant collapsing analysis of over 1500 continuous traits using exome data from 394,692 UK Biobank participants, with additional metabolomic trait associations from Nightingale Health\u0027s study of 121,394 participants. Gene-SCOUT provides stronger enrichments for clinical traits compared to existing methods and offers an interactive web resource for exploring exome-wide gene similarities, biological relevance, and trait enrichment statistics.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Similarities between genes are evaluated by the cosine similarity measure, to capture concordant effect directionality, elucidating clusters of genes in a high dimensional space. The underlying gene-biomarker population-scale association statistics were obtained from a gene-level rare variant collapsing analysis performed on over 1500 continuous traits using 394 692 UKB participant exomes, with additional metabolomic trait associations provided through Nightingale Health\u0027s recent study of 121 394 of these participants. Gene-SCOUT provides stronger enrichments for clinical traits compared to existing methods. A fully interactive web-resource (http://genescout.public.cgr.astrazeneca.com) is provided to explore the pre-calculated exome-wide similarities. This resource enables a user to examine the biological relevance of the most similar genes for Gene Ontology (GO) enrichment and UKB clinical trait enrichment statistics, as well as a detailed breakdown of the traits underpinning a given fingerprint.",
        "Gene-SCOUT is a computational tool that identifies genes with similar continuous trait fingerprints to a gene of interest. Leveraging large-scale phenome-wide association studies (like the UK Biobank) and rare variant genetic architectures, it uses cosine similarity to capture concordant effect directionality. A web-resource facilitates exploration of pre-calculated exome-wide similarities, enabling biological relevance examination via Gene Ontology enrichment and clinical trait statistics, particularly useful in high-dimensional analysis of phenome-wide association studies.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Similarities between genes are evaluated by the cosine similarity measure, to capture concordant effect directionality, elucidating clusters of genes in a high dimensional space. The underlying gene-biomarker population-scale association statistics were obtained from a gene-level rare variant collapsing analysis performed on over 1500 continuous traits using 394 692 UKB participant exomes, with additional metabolomic trait associations provided through Nightingale Health\u0027s recent study of 121 394 of these participants. Gene similarity estimates from Gene-SCOUT provide stronger enrichments for clinical traits compared to existing methods. A fully interactive web-resource (http://genescout.public.cgr.astrazeneca.com) is provided to explore the pre-calculated exome-wide similarities. This resource enables a user to examine the biological relevance of the most similar genes for Gene Ontology (GO) enrichment and UKB clinical trait enrichment statistics, as well as a detailed breakdown of the traits underpinning a given fingerprint.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest.",
        "Gene-SCOUT is a tool designed to identify genes with similar continuous trait fingerprints to a gene of interest, using data from phenome-wide association studies. It evaluates gene similarities using the cosine similarity measure to capture concordant effect directionality, and provides stronger enrichments for clinical traits compared to existing methods. Gene-SCOUT utilizes gene-level rare variant collapsing analysis on over 1500 continuous traits from UK Biobank participant exomes, and offers an interactive web resource for exploring gene similarities and their biological relevance.",
        "Gene-SCOUT is a computational tool designed for the identification and prioritization of candidate genes associated with specific phenotypes or diseases.",
        "Gene-SCOUT is a computational tool used to identify and prioritize candidate genes linked to specific diseases or traits. It combines various genomic data, such as gene expression profiles, genetic variants, and functional annotations, to provide a thorough analysis of potential disease-related genes. The tool employs advanced algorithms and statistical methods to rank genes based on their likelihood of involvement in the disease process. This aids researchers in discovering new genetic factors and developing targeted therapies.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Similarities between genes are evaluated by the cosine similarity measure, to capture concordant effect directionality, elucidating clusters of genes in a high dimensional space. Gene similarity estimates from Gene-SCOUT provide stronger enrichments for clinical traits compared to existing methods. A fully interactive web-resource is available to explore the pre-calculated exome-wide similarities. This resource enables a user to examine the biological relevance of the most similar genes for Gene Ontology (GO) enrichment and UKB clinical trait enrichment statistics, as well as a detailed breakdown of the traits underpinning a given fingerprint.",
        "Gene-SCOUT is a tool designed to identify genes that exhibit similar continuous trait fingerprints to a gene of interest. It utilizes cosine similarity measures to evaluate gene similarities, capturing concordant effect directionality and elucidating clusters of genes in a high-dimensional space. Gene-SCOUT provides stronger enrichments for clinical traits compared to existing methods and allows users to explore the biological relevance of similar genes through Gene Ontology (GO) enrichment and clinical trait enrichment statistics. The tool is supported by a web resource that offers pre-calculated exome-wide similarities based on extensive data from the UK Biobank, which includes gene-level rare variant analyses across numerous continuous traits.",
        "Gene-SCOUT is a web-based tool designed to identify genes with similar continuous trait fingerprints to a gene of interest. It evaluates gene similarities using cosine similarity, capturing concordant effect directionality across rare variant genetic architectures associated with clinical traits. The tool provides pre-calculated exome-wide gene similarities and enables exploration of biological relevance through Gene Ontology (GO) enrichment and UK Biobank clinical trait enrichment analysis. Accessible via http://genescout.public.cgr.astrazeneca.com, it supports detailed trait breakdowns and clustering of genes in high-dimensional trait spaces.",
        "Gene-SCOUT is a tool that identifies genes with similar continuous trait fingerprints, where a fingerprint is a set of quantitative traits statistically associated with a gene. It leverages associations arising from underlying rare variant genetic architectures to compare genes. By using a cosine similarity measure, the tool captures concordant effect directionality, which helps in clustering genes within a high-dimensional trait space. This approach allows researchers to detect groups of genes that share similar patterns in their trait associations without confusion with other tools like GeneScout, which serves a different purpose in genomic region analysis.",
        "Gene-SCOUT is an innovative web-based tool designed for genomic exploration and analysis. Its primary function is to enable researchers to search and examine specific genomic regions, identifying associated genes and their linked phenotypes within areas of interest. The tool employs a unique approach by focusing on \"continuous trait fingerprints,\" which are sets of traits statistically connected to a gene, considering various rare variant genetic architectures.\n\nGene-SCOUT evaluates similarities between genes using cosine similarity, capturing the directionality of effects in a high-dimensional space. This method helps identify clusters of genes with concordant effects, facilitating deeper insights into their biological relevance. The tool also offers an interactive web-resource where users can explore pre-calculated exome-wide similarities, examine Gene Ontology (GO) enrichment, and analyze UKB clinical trait statistics.\n\nAdditionally, Gene-SCOUT allows filtering of phenotypes based on inheritance patterns or specific clinical features, enhancing the ability to focus on genes meeting particular criteria. Overall, Gene-SCOUT serves as a comprehensive resource for researchers seeking to identify and analyze genes with similar trait profiles, providing advanced tools for exploring genetic relationships in depth.",
        "Gene-SCOUT is a tool designed to identify genes that share similar continuous trait fingerprints with a gene of interest. A fingerprint represents the continuous traits statistically linked to a gene of interest, based on various underlying rare variant genetic architectures. The tool evaluates similarities between genes using the cosine similarity measure, which captures concordant effect directionality and reveals clusters of genes in a high-dimensional space. Gene-SCOUT offers stronger enrichments for clinical traits compared to existing methods and is available as an interactive web resource to explore pre-calculated exome-wide similarities.",
        "Gene-SCOUT is a web-based tool designed to identify genes with similar continuous trait fingerprints. It enables researchers to explore genomic regions, display genes, and filter them based on associated phenotypes within regions of interest. The tool calculates similarities between genes using cosine similarity, capturing concordant effect directions and grouping genes into clusters in a high-dimensional space.\n\nGene-SCOUT provides insights into the biological relevance of similar genes through Gene Ontology (GO) enrichment and UKB clinical trait enrichment statistics. It also offers a detailed breakdown of traits underlying each fingerprint, allowing users to understand what makes certain genes similar in terms of their effects on traits.\n\nThe tool supports filtering phenotypes and associated genes based on inheritance patterns and specific clinical features, offering flexibility for targeted analysis. Additionally, Gene-SCOUT includes an interactive web-resource for exploring pre-calculated exome-wide similarities, making it a comprehensive platform for gene similarity analysis and trait association exploration.",
        "Gene-SCOUT is a tool designed to identify genes that exhibit similar continuous trait fingerprints to a gene of interest. It utilizes cosine similarity measures to evaluate gene similarities, capturing concordant effect directionality and elucidating clusters of genes within a high-dimensional space. Gene-SCOUT enhances the understanding of gene relationships by providing stronger enrichments for clinical traits compared to existing methods. It allows users to examine the biological relevance of similar genes through Gene Ontology (GO) enrichment and clinical trait statistics, facilitating a detailed breakdown of the traits associated with a given fingerprint. Additionally, Gene-SCOUT integrates with a custom-developed decision support system for visualization and clinical interpretation of results.",
        "Gene-SCOUT is a computational tool used to identify genes with similar continuous trait fingerprints to a gene of interest. It enables researchers to explore genetic relationships and traits by comparing expression profiles or other characteristics across datasets.",
        "Gene-SCOUT is a bioinformatics tool that identifies genes with similar continuous trait fingerprints to a gene of interest through phenome-wide association analyses and cosine similarity. Leveraging large-scale genetic data, such as UK Biobank exomes, it facilitates exploration of biological relevance via Gene Ontology and clinical trait enrichment analyses, accessible through a web-resource. Notably, it is distinct from other medical concepts abbreviated as \u0027SCOUT\u0027, focusing solely on genetic trait analysis.",
        "Gene-SCOUT is a bioinformatics tool that identifies genes with similar continuous trait fingerprints to a query gene, utilizing phenome-wide association analysis, gene-level rare variant collapsing, and cosine similarity. It outputs clusters of genes with similar trait associations and provides a web-resource for exploring pre-calculated exome-wide similarities, including Gene Ontology enrichment and clinical trait statistics.",
        "Gene-SCOUT is a computational tool that connects genes to phenotypes by analyzing large-scale genetic and phenotype data from genome-wide and phenome-wide association studies. The tool examines the phenotypic signatures of genes to identify similarities between them, which in turn helps researchers prioritize candidate genes, especially when studying complex diseases. By comparing these signatures, Gene-SCOUT uncovers potential functional relationships and pathways that may contribute to human conditions, offering valuable insights for understanding the genetic basis of diseases.",
        "GeneScout is a web-based tool designed to search genomic regions and display genes within those regions along with their associated phenotypes. It allows users to filter results based on specific criteria, facilitating the identification of genes of interest within targeted genomic areas.",
        "Gene-SCOUT is a tool for identifying genes with similar continuous trait fingerprints based on phenome-wide association analyses, using cosine similarity to evaluate gene similarities.",
        "Gene-SCOUT is a bioinformatics tool that identifies genes with similar continuous trait fingerprints to a query gene, leveraging phenome-wide association analysis, rare variant collapsing, and cosine similarity. It provides clusters of genes with similar trait associations, accessible through a dedicated web-resource. This tool facilitates exploration of biological relevance via Gene Ontology enrichment and clinical trait statistics, utilizing large-scale genetic datasets like the UK Biobank. Notably, Gene-SCOUT is specifically designed for genetic trait analysis, distinct from other \u0027SCOUT\u0027 concepts in the medical field, making it a unique asset for high-dimensional phenome-wide association studies.",
        "Gene-SCOUT is a bioinformatics tool designed to rapidly identify and categorize genes based on distinctive molecular signatures. It scans large genomic datasets to detect key features such as sequence motifs, exon structures, and regulatory signals that are indicative of specific gene families or functions. By automatically comparing these features against established patterns, Gene-SCOUT groups genes into biologically relevant classes and highlights candidates for further investigation. The tool is built with a streamlined, user‐friendly interface that facilitates high‐throughput analysis, making it easier to annotate genes and accelerate discovery in genomics research.",
        "Gene-SCOUT is a tool that identifies genes with similar continuous trait fingerprints based on phenome-wide association analyses, using cosine similarity measures to evaluate gene similarities.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Similarities between genes are evaluated by the cosine similarity of their fingerprints. Gene-SCOUT is able to identify genes with similar fingerprints to a gene of interest, and to identify genes with similar fingerprints to a set of genes of interest.",
        "Gene-SCOUT is a computational tool designed to identify genes with similar continuous trait fingerprints across phenome-wide association studies. It analyzes genetic associations by examining the pattern of statistically significant continuous traits linked to a specific gene, taking into account multiple rare variant genetic architectures. The tool is particularly useful for exploring gene-phenotype relationships using large-scale datasets like the UK Biobank, helping researchers discover potential functional similarities between genes based on their trait association profiles.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest from phenome-wide association analyses. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Similarities between genes are evaluated by the cosine similarity measure to capture concordant effect directionality, elucidating clusters of genes in a high dimensional space. The underlying gene-biomarker population-scale association statistics were obtained from a gene-level rare variant collapsing analysis performed on over 1500 continuous traits using 394,692 UK Biobank (UKB) participant exomes, with additional metabolomic trait associations from Nightingale Health\u0027s study of 121,394 participants. Gene similarity estimates provide stronger enrichments for clinical traits compared to existing methods. A fully interactive web-resource (http://genescout.public.cgr.astrazeneca.com) allows exploration of pre-calculated similarities, Gene Ontology (GO) enrichment, UKB clinical trait enrichment statistics, and trait breakdowns.",
        "Gene-SCOUT is a bioinformatic tool that identifies genes with similar continuous trait fingerprints to a gene of interest. Leveraging large-scale phenome-wide association studies, such as the UK Biobank, it employs cosine similarity to capture concordant effect directionality across numerous traits. The tool provides a web-resource for exploring pre-calculated exome-wide similarities, facilitating biological relevance analysis through Gene Ontology enrichment, UK Biobank clinical trait enrichment, and detailed trait breakdowns, thereby enhancing the discovery of gene relationships for clinical traits with improved accuracy over existing methods.",
        "Gene-SCOUT is a tool designed to identify genes that exhibit similar continuous trait fingerprints to a gene of interest. This is achieved by analyzing the results of large-scale phenome-wide association studies, such as those performed using the UK Biobank cohort. A gene\u0027s fingerprint refers to the set of continuous traits that are statistically associated with it, taking into account multiple underlying rare variant genetic architectures. By comparing these fingerprints, Gene-SCOUT enables researchers to pinpoint genes with similar profiles, potentially revealing new insights into the genetic basis of complex traits and diseases. This tool has the potential to uncover novel gene-phenotype relationships and provide a more comprehensive understanding of the genetic landscape underlying human health and disease.",
        "Gene-SCOUT is a specialized tool designed to identify genes with similar continuous trait fingerprints by analyzing phenome-wide association studies from datasets like the UK Biobank. The tool works by examining statistically significant gene-phenotype relationships based on multiple rare variant genetic architectures, helping researchers identify genes that share similar continuous trait patterns with a gene of interest.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest based on multiple underlying rare variant genetic architectures.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Similarities between genes are evaluated by the cosine similarity measure, to capture concordant effect directionality, elucidating clusters of genes in a high dimensional space. Gene similarity estimates from Gene-SCOUT provide stronger enrichments for clinical traits compared to existing methods. It enables a user to examine the biological relevance of the most similar genes for Gene Ontology (GO) enrichment and UKB clinical trait enrichment statistics, as well as a detailed breakdown of the traits underpinning a given fingerprint. A fully interactive web-resource is available to explore the pre-calculated exome-wide similarities.",
        "Gene-SCOUT is a tool that helps identify genes with similar continuous trait fingerprints to a gene of interest, based on statistically associated traits from multiple underlying rare variant genetic architectures.",
        "Gene-SCOUT is a tool that identifies genes with similar continuous trait fingerprints using phenome-wide association analyses from large cohorts like the UK Biobank. Essentially, it establishes a fingerprint for a gene based on the continuous traits statistically associated with it, reflecting its underlying rare variant genetic architectures.",
        "Gene-SCOUT is a computational tool designed to identify genes that share similar continuous trait fingerprints with a gene of interest. These fingerprints represent continuous traits statistically associated with the gene, derived from large-scale phenome-wide association studies, such as those conducted with the UK Biobank. Gene-SCOUT utilizes cosine similarity measures to evaluate gene similarities, capturing concordant effect directionality and elucidating clusters of genes in a high-dimensional space. The tool enhances clinical trait enrichment compared to existing methods and provides a user-friendly interface for biological relevance assessment, including Gene Ontology enrichment and detailed trait breakdowns. Additionally, it integrates machine learning for improved analysis and visualization, facilitating the exploration of gene-phenotype relationships.",
        "Gene-SCOUT is a computational tool designed to identify genes with similar patterns (\"fingerprints\") of association with continuous traits (e.g., physiological measurements) using phenome-wide association study (PheWAS) data. It analyzes rare genetic variants and their statistical links to traits in large cohorts like the UK Biobank, enabling discovery of genes sharing comparable phenotypic impacts.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits associated with a gene based on multiple rare variant genetic architectures.",
        "Gene-SCOUT is a tool that identifies genes with similar continuous trait fingerprints, which are defined as the sets of continuous traits statistically associated with each gene. It utilizes large-scale phenome-wide association data from cohorts like the UK Biobank to compare genes. By computing cosine similarity between gene fingerprints, Gene-SCOUT captures concordant effect directionality and clusters genes in a high-dimensional space based on their trait association patterns. Unlike similar web-based tools that filter genes by genomic regions, Gene-SCOUT specifically focuses on identifying genes with comparable trait profiles, facilitating the discovery of gene networks linked to complex genetic architectures involving multiple rare variants.",
        "Gene-SCOUT is a tool that identifies genes with similar continuous trait fingerprints based on statistically significant gene-phenotype relationships. It uses data from large-scale phenome-wide association studies, such as those conducted with the UK Biobank, to compare continuous traits linked to genes through different rare variant genetic architectures.",
        "Gene-SCOUT is a tool designed for genetic research that identifies genes sharing similar continuous trait fingerprints. These fingerprints represent the statistical associations of a gene with various continuous traits, considering different rare variant genetic architectures. By analyzing these associations within large-scale phenome-wide studies, such as those conducted using the UK Biobank\u0027s extensive phenotype data, Gene-SCOUT helps researchers find genes with comparable profiles of trait associations. This tool is particularly useful in contexts where comprehensive datasets are available, enabling the discovery of meaningful genetic relationships across traits.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. It is used in large-scale phenome-wide association studies performed using densely-phenotyped cohorts such as the UK Biobank.",
        "Gene-SCOUT is a tool designed to identify genes that share similar continuous trait fingerprints with a gene of interest. It leverages large-scale phenome-wide association studies, such as those from the UK Biobank, to reveal gene-phenotype relationships for both clinical and continuous traits. A fingerprint represents the continuous traits statistically associated with a gene of interest, considering multiple underlying rare variant genetic architectures. Gene similarities are evaluated using the cosine similarity measure, which captures concordant effect directionality and helps elucidate clusters of genes in a high-dimensional space. Gene-SCOUT offers a fully interactive web resource to explore pre-calculated exome-wide similarities and demonstrates stronger enrichments for clinical traits compared to existing methods.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures.",
        "Gene-SCOUT is a tool that identifies genes with similar continuous trait fingerprints to a gene of interest, using phenome-wide association studies and densely-phenotyped cohorts like the UK Biobank. It reflects statistically robust gene-phenotype relationships for both clinical and continuous traits.",
        "Gene-SCOUT is a computational tool designed to identify genes that exhibit similar continuous trait fingerprints to a specified gene of interest. These fingerprints represent the continuous traits statistically associated with the gene, derived from a gene-level rare variant collapsing analysis involving over 1500 continuous traits from 394,692 participants in the UK Biobank. The tool employs cosine similarity to evaluate the relationships between genes, focusing on concordant effect directionality to identify clusters in a high-dimensional space. Gene-SCOUT demonstrates enhanced enrichment for clinical traits compared to existing methods and offers an interactive web resource for users to explore gene similarities, biological relevance through Gene Ontology (GO) enrichment, and detailed trait breakdowns.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest, based on phenome-wide association analyses. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Similarities between genes are evaluated by the cosine similarity measure to capture concordant effect directionality, elucidating clusters of genes in a high dimensional space. The underlying gene-biomarker population-scale association statistics were obtained from a gene-level rare variant collapsing analysis performed on over 1500 continuous traits using 394 692 UKB participant exomes, with additional metabolomic trait associations from Nightingale Health\u0027s study of 121 394 participants. Gene similarity estimates from Gene-SCOUT provide stronger enrichments for clinical traits compared to existing methods. A fully interactive web-resource explores pre-calculated exome-wide similarities, enabling examination of biological relevance, Gene Ontology (GO) enrichment, UKB clinical trait enrichment statistics, and trait breakdown.",
        "Gene-SCOUT is a tool designed to identify genes that share similar continuous trait fingerprints with a gene of interest, utilizing data from large-scale phenome-wide association studies like those conducted using the UK Biobank. It leverages densely-phenotyped cohorts to uncover statistically robust gene-phenotype relationships for both clinical and continuous traits. The tool generates a \u0027fingerprint\u0027 that reflects the continuous traits associated with a gene of interest, based on various rare variant genetic architectures.",
        "Gene-SCOUT is a tool designed to identify genes that share similar continuous trait fingerprints with a gene of interest. It utilizes data from large-scale phenome-wide association studies, such as those conducted using the UK Biobank, to reveal robust gene-phenotype relationships. The tool focuses on continuous traits associated with genes based on rare variant genetic architectures. By analyzing these associations, Gene-SCOUT helps researchers discover genes with comparable trait profiles, aiding in the exploration of genetic connections and disease mechanisms. This tool enhances our understanding of how different genes may influence similar traits, facilitating further genetic research and discovery.",
        "Gene-SCOUT is a tool designed to identify genes that exhibit similar continuous trait fingerprints to a gene of interest. It leverages data from large-scale phenome-wide association studies, such as those conducted with the UK Biobank, which reveal robust gene-phenotype relationships for both clinical and continuous traits. A continuous trait fingerprint represents the statistical associations between a gene and various continuous traits, reflecting the underlying rare variant genetic architectures. Gene-SCOUT aids researchers in exploring these associations to better understand the genetic influences on complex traits.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest from phenome-wide association analyses. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Similarities between genes are evaluated by the cosine similarity measure to capture concordant effect directionality. The underlying gene-biomarker population-scale association statistics were obtained from a gene-level rare variant collapsing analysis performed on over 1500 continuous traits using 394,692 UK Biobank (UKB) participant exomes, with additional metabolomic trait associations provided through Nightingale Health\u0027s study of 121,394 of these participants. Gene similarity estimates from Gene-SCOUT provide stronger enrichments for clinical traits compared to existing methods. A fully interactive web-resource (http://genescout.public.cgr.astrazeneca.com) allows exploration of pre-calculated exome-wide similarities, Gene Ontology (GO) enrichment, UKB clinical trait enrichment statistics, and the traits underpinning a given fingerprint.",
        "Gene-SCOUT is a computational tool designed to identify genes that exhibit similar continuous trait fingerprints to a gene of interest. This tool leverages data from large-scale phenome-wide association studies, such as those conducted with the UK Biobank, which analyze extensive phenotypic data to uncover statistically significant gene-phenotype relationships for both clinical and continuous traits. The continuous trait fingerprint represents the traits that are statistically associated with a specific gene, reflecting the underlying genetic architectures, including rare variants. Gene-SCOUT aids researchers in exploring genetic associations and understanding the functional implications of genes in relation to various traits.",
        "Gene-SCOUT is a tool designed to identify genes with similar continuous trait fingerprints to a gene of interest. It utilizes data from large-scale phenome-wide association studies, such as those conducted using the UK Biobank, which reveal statistically robust relationships between genes and both clinical and continuous traits. The fingerprint reflects the continuous traits statistically associated with a gene based on various rare variant genetic architectures.",
        "Gene-SCOUT is a bioinformatic tool that identifies genes with similar continuous trait profiles or \u0027fingerprints\u0027 to a gene of interest. Leveraging large-scale phenome-wide association studies from densely-phenotyped cohorts like the UK Biobank, it utilizes cosine similarity to measure gene concordance. This approach, which also considers rare variant genetic architectures, provides a web-based platform for exploring these similarities. Gene-SCOUT is particularly useful for uncovering functional relationships, shared biological pathways, and understanding the genetic underpinnings of complex diseases, offering enhanced enrichments for clinical traits compared to existing methodologies.",
        "Gene-SCOUT is a tool designed to identify genes with similar continuous trait fingerprints to a gene of interest, leveraging data from large-scale phenome-wide association studies, such as those conducted with the UK Biobank. A continuous trait fingerprint represents the continuous traits statistically associated with a gene, based on various underlying rare variant genetic architectures. Gene-SCOUT utilizes cosine similarity measures to evaluate gene similarities, capturing concordant effect directionality and elucidating gene clusters in a high-dimensional space. The tool enhances the identification of gene-phenotype relationships, providing stronger enrichments for clinical traits compared to existing methods. Additionally, it offers resources for examining biological relevance through Gene Ontology enrichment and detailed trait breakdowns, facilitating clinical interpretation through a custom-developed decision support system.",
        "Gene-SCOUT is a bioinformatic tool that identifies genes with similar continuous trait association patterns (fingerprints) to a user-specified gene, utilizing large-scale phenome-wide association study data, such as from the UK Biobank, to uncover genetic and functional relationships, aiding in the understanding of complex traits and diseases.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest, based on phenome-wide association analyses of densely-phenotyped cohorts such as the UK Biobank.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. It helps in identifying genes that have similar associations with certain traits, facilitating the discovery of new gene-phenotype relationships and providing insights into the biological mechanisms underlying complex diseases.",
        "Gene-SCOUT is a tool designed to identify genes with similar continuous trait fingerprints to a gene of interest. It analyzes data from large-scale phenome-wide association studies conducted in densely-phenotyped cohorts like the UK Biobank. The tool works by examining the statistical associations between genes and various continuous traits, creating a \u0027fingerprint\u0027 that reflects the continuous traits statistically associated with a particular gene based on multiple underlying rare variant genetic architectures. This enables researchers to find genes that share similar phenotypic patterns, potentially revealing functional relationships between genes.",
        "Gene-SCOUT is a tool designed to identify genes that share similar continuous trait fingerprints with a gene of interest. These fingerprints are derived from phenome-wide association analyses, which reveal statistically significant associations between genes and continuous traits based on multiple rare variant genetic architectures. By leveraging large-scale studies such as the UK Biobank, Gene-SCOUT enables researchers to uncover genes with comparable trait profiles, facilitating insights into genetic relationships across diverse traits.",
        "Gene-SCOUT is a tool designed to identify genes that have similar continuous trait fingerprints to a specific gene of interest. These fingerprints are based on the continuous traits that are statistically associated with a gene, derived from phenome-wide association studies using densely-phenotyped cohorts like the UK Biobank. The tool utilizes the relationships between genes and continuous traits, which are established through the analysis of multiple underlying rare variant genetic architectures.",
        "Gene-SCOUT is a tool designed to identify genes that share similar continuous trait profiles, derived from phenome-wide association studies. It enables researchers to compare the genetic fingerprints of different genes, facilitating the discovery of new gene-trait relationships and enhancing our understanding of the genetic basis of various conditions. By leveraging data from large cohorts like the UK Biobank, Gene-SCOUT aids in uncovering genetic associations that might not be immediately apparent through traditional methods.",
        "Gene-SCOUT is a bioinformatic tool that identifies genes with similar continuous trait profiles to a user-specified gene of interest, utilizing cosine similarity in phenome-wide association analyses of large-scale datasets (notably \u003e394,692 UK Biobank exomes and metabolomic traits). It offers a web-resource for exploring pre-calculated exome-wide similarities, facilitating insights into biological relevance through Gene Ontology and clinical trait enrichments, thereby enhancing the discovery of gene relationships and shared pathways.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects traits associated with a gene through various rare variant architectures in studies like the UK Biobank. This helps researchers find genes with comparable phenotypic profiles, aiding in understanding gene-phenotype relationships.",
        "Gene-SCOUT is a computational tool that identifies genes with similar profiles of continuous trait associations derived from phenome-wide association analyses. It creates a fingerprint for each gene based on statistically robust associations with various quantitative traits, which reflect underlying rare variant genetic architectures. By comparing these fingerprints across different genes, Gene-SCOUT enables researchers to find genes with analogous phenotypic signatures, helping to uncover novel gene functions and potential therapeutic targets.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Gene-SCOUT identifies genes with similar continuous trait fingerprints from phenome-wide association analyses.",
        "Gene-SCOUT is a bioinformatic tool that identifies genes with similar continuous trait association patterns (fingerprints) to a gene of interest, leveraging data from large-scale phenome-wide association studies to potentially uncover functional relationships or shared biological pathways.",
        "Gene-SCOUT is a tool used to identify genes with similar continuous trait fingerprints to a gene of interest, using information from phenome-wide association analyses. A fingerprint reflects the continuous traits identified to be statistically associated with a gene of interest based on multiple underlying rare variant genetic architectures. Large-scale phenome-wide association studies performed using densely-phenotyped cohorts, such as the UK Biobank (UKB), reveal statistically robust gene-phenotype relationships for continuous traits which Gene-SCOUT utilizes.",
        "Gene-SCOUT is a tool designed to identify genes that exhibit similar continuous trait fingerprints to a gene of interest. It is used in the context of large-scale phenome-wide association studies, particularly those utilizing densely-phenotyped cohorts like the UK Biobank. Gene-SCOUT helps in revealing gene-phenotype relationships for both clinical and continuous traits. A fingerprint, in this context, represents the continuous traits that are statistically associated with a specific gene, considering multiple underlying rare variant genetic architectures.",
        "Gene-SCOUT is a tool designed to identify genes that have similar patterns of association with continuous traits, known as \u0027fingerprints\u0027, which are derived from large-scale phenome-wide association studies. These fingerprints reflect the continuous traits statistically linked to a gene based on various rare variant genetic architectures, enabling researchers to uncover related genes and their connections to clinical outcomes."
      ]
    },
    {
      "body": "Is Inebilizumab effective for the IgG4-Related Disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39541094",
        "http://www.ncbi.nlm.nih.gov/pubmed/37792260",
        "http://www.ncbi.nlm.nih.gov/pubmed/32729016"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 51,
          "text": "Inebilizumab for Treatment of IgG4-Related Disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39541094"
        },
        {
          "offsetInBeginSection": 1986,
          "offsetInEndSection": 2240,
          "text": "CONCLUSIONS: Inebilizumab reduced the risk of flares of IgG4-related disease and increased the likelihood of flare-free complete remission at 1 year, confirming the role of CD19-targeted B-cell depletion as a potential treatment for IgG4-related disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39541094"
        },
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 582,
          "text": "In June 2020, inebilizumab received its first global approval in the USA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are seropositive for immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32729016"
        },
        {
          "offsetInBeginSection": 714,
          "offsetInEndSection": 868,
          "text": "This article summarizes the milestones in the development of inebilizumab leading to this first approval for the treatment of AQP4-IgG seropositive NMOSD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32729016"
        },
        {
          "offsetInBeginSection": 1959,
          "offsetInEndSection": 2200,
          "text": " (9%) who received placebo.CONCLUSIONS: Inebilizumab reduced the risk of flares of IgG4-related disease and increased the likelihood of flare-free complete remission at 1 year, confirming the role of CD19-targeted B-cell depletion as a poten",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39541094"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 713,
          "text": "Inebilizumab (Uplizna™; inebilizumab-cdon in the USA) is a humanised anti-CD19 monoclonal antibody being developed by Viela Bio for the treatment of a range of autoimmune diseases associated with CD19-expressing B cells. Inebilizumab targets and depletes CD19-expressing B cells through antibody-dependent cell-mediated cytotoxicity. In June 2020, inebilizumab received its first global approval in the USA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are seropositive for immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG). The drug is also undergoing clinical evaluation for kidney transplant desensitization, myasthenia gravis, and IgG4-related disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32729016"
        },
        {
          "offsetInBeginSection": 1959,
          "offsetInEndSection": 2199,
          "text": " (9%) who received placebo.CONCLUSIONS: Inebilizumab reduced the risk of flares of IgG4-related disease and increased the likelihood of flare-free complete remission at 1 year, confirming the role of CD19-targeted B-cell depletion as a pote",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39541094"
        }
      ],
      "type": "yesno",
      "id": "67e69e7918b1e36f2e0000b7",
      "ideal_answer": [
        "Yes, Inebilizumab is effective and is approved for the IgG4-Related Disease"
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Is botulism toxin A used to treat arthritis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20585713",
        "http://www.ncbi.nlm.nih.gov/pubmed/23974310",
        "http://www.ncbi.nlm.nih.gov/pubmed/36674999",
        "http://www.ncbi.nlm.nih.gov/pubmed/36633823",
        "http://www.ncbi.nlm.nih.gov/pubmed/35421437",
        "http://www.ncbi.nlm.nih.gov/pubmed/37104199",
        "http://www.ncbi.nlm.nih.gov/pubmed/36640812",
        "http://www.ncbi.nlm.nih.gov/pubmed/38401692",
        "http://www.ncbi.nlm.nih.gov/pubmed/27838288",
        "http://www.ncbi.nlm.nih.gov/pubmed/24715952",
        "http://www.ncbi.nlm.nih.gov/pubmed/20824874",
        "http://www.ncbi.nlm.nih.gov/pubmed/31884849",
        "http://www.ncbi.nlm.nih.gov/pubmed/30995453",
        "http://www.ncbi.nlm.nih.gov/pubmed/39195774",
        "http://www.ncbi.nlm.nih.gov/pubmed/38714267",
        "http://www.ncbi.nlm.nih.gov/pubmed/19351542",
        "http://www.ncbi.nlm.nih.gov/pubmed/20430328",
        "http://www.ncbi.nlm.nih.gov/pubmed/32250746",
        "http://www.ncbi.nlm.nih.gov/pubmed/21390172",
        "http://www.ncbi.nlm.nih.gov/pubmed/19818032",
        "http://www.ncbi.nlm.nih.gov/pubmed/31638614",
        "http://www.ncbi.nlm.nih.gov/pubmed/39579879"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 964,
          "offsetInEndSection": 1253,
          "text": " multimodal approach with the intra-articular administration of BoNT/A may be an option for osteoarthritis patients that are unresponsive to medical management and unable to undergo surgery. However, the findings of this study are preliminary and must be verified by further investigation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20585713"
        },
        {
          "offsetInBeginSection": 537,
          "offsetInEndSection": 695,
          "text": " Although mesotherapy has been used as a treatment for pain syndromes, arthritis, and many other disorders, this article focuses on its cosmetic applications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23974310"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Intra-Articular Injection of Botulinum Toxin for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36674999"
        },
        {
          "offsetInBeginSection": 399,
          "offsetInEndSection": 877,
          "text": "The current narrative review focuses on the efficacy and safety profiles of the currently available IA agents in hand OA (thumb-base OA or interphalangeal OA) such as corticosteroids and hyaluronic acid (HA), as well as the efficacy and safety of IA investigational injectates in phase 2/3 clinical trials such as prolotherapy, platelet-rich plasma, stem cells, infliximab, interferon-? and botulinum toxin, based on the published randomized controlled trials on PubMed database",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36633823"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Botulinum toxin type a combined with transcranial direct current stimulation reverses the chronic pain induced by osteoarthritis in rats.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35421437"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 307,
          "text": "Intramuscular injection of botulinum toxin A (BoNT/A) has shown effectiveness in knee and shoulder osteoarthritis, as well as in some TMDs such as masticatory myofascial pain, but its use remains controversial",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37104199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "The efficacy and safety of intra-articular botulinum toxin type A injection for knee osteoarthritis: A meta-analysis of randomized controlled trials.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36640812"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Intraarticular botulinum toxin type A (BTA) has been shown to be effective for painful knee osteoarthritis (KOA), while the efficacy and safety of intraarticular BTA compared to corticosteroid and hyaluronic acid (HA) remains unknown",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38401692"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31884849"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "Intraarticular botulinum toxin type A (BTA) has been shown to be effective for painful knee osteoarthritis (KOA), while the efficacy and safety of intraarticular BTA compared to corticosteroid and hyaluronic acid (HA) remains unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38401692"
        },
        {
          "offsetInBeginSection": 1380,
          "offsetInEndSection": 1656,
          "text": "d lasted longer in Group A.CONCLUSIONS: Arthrocentesis with viscosupplementation associated with BTX-A was found to be more effective than arthrocentesis alone in improving clinical outcomes. This suggests that patients with TMJ osteoarthritis and myofascial pain may benefit ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39195774"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 308,
          "text": "Intramuscular injection of botulinum toxin A (BoNT/A) has shown effectiveness in knee and shoulder osteoarthritis, as well as in some TMDs such as masticatory myofascial pain, but its use remains controversial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37104199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "We report the use of intra-articular Botulinum toxin A in two RA patients with persistently painful monoarthritis in ankle/feet joints.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18952480"
        },
        {
          "offsetInBeginSection": 1487,
          "offsetInEndSection": 1630,
          "text": "We concluded that botulinum neurotoxin type A is an effective and safe initial treatment of knee osteoarthritis with clear clinical advantages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30995453"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Currently, administration of Botulinum toxin Type A (BoNT/A) to treat arthritic pain has promising efficacy in clinical research.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27838288"
        },
        {
          "offsetInBeginSection": 189,
          "offsetInEndSection": 328,
          "text": "We are studying the efficacy and safety of intra-articular injection of Botulinum Toxin Type A (IA-BoNT/A) into joints with arthritis pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351542"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 805,
          "text": "Three randomized controlled trials (RCTs) of small sizes provide evidence of short-term efficacy of a single intra-articular injection of 100 units of botulinum toxin A (BoNT/A) for the relief of pain and the improvement of both function and quality of life in patients with chronic joint pain due to arthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24715952"
        },
        {
          "offsetInBeginSection": 1864,
          "offsetInEndSection": 2121,
          "text": "tion) at 8 weeks. No serious adverse events were noted in any group.CONCLUSIONS: This pilot study supports a possible role for BoNT-A as a treatment option for symptomatic knee osteoarthritis; however, larger double-blind randomized studies are needed to de",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20430328"
        },
        {
          "offsetInBeginSection": 359,
          "offsetInEndSection": 518,
          "text": "At the moment, botulinum toxin is widely investigated and used in many painful diseases such as myofascial syndrome, headaches, arthritis, and neuropathic pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390172"
        },
        {
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1619,
          "text": "y did not differ between groups, nor did the number of adverse events (RR 1.46, 95% CI 0.6 to 24.3).One RCT in arthritis-related shoulder pain indicated that botulinum toxin reduced pain severity (MD -2.0, 95% CI -3.7 to -0.3; 10 point scale) and shoulder disability with a reduction in Shoulder Pain and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20824874"
        },
        {
          "offsetInBeginSection": 189,
          "offsetInEndSection": 327,
          "text": "We are studying the efficacy and safety of intra-articular injection of Botulinum Toxin Type A (IA-BoNT/A) into joints with arthritis pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351542"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "We report the use of intra-articular Botulinum toxin A in two RA patients with persistently painful monoarthritis in ankle/feet joints",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18952480"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "The purpose of this study was to investigate the efficacy and safety of intra-articular Botulinum Toxin type A (BTA) injection in the management of patients with knee osteoarthritis (KOA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36640812"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Botulinum toxin type A ameliorates adjuvant-arthritis pain by inhibiting microglial activation-mediated neuroinflammation and intracellular molecular signaling.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32250746"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 335,
          "text": "The EMBASE and MEDLINE databases were searched to identify randomized controlled trials (RCTs) of Botulinum Toxin Type A in the treatment of painful knee osteoarthritis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31884849"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Osteoarthritis of the hip conservative treatment with type A botulinum toxin.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31638614"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 276,
          "text": "Our previous studies have demonstrated the analgesic effects of botulinum toxin type A (BoNT/A) in a pre-clinical model of rheumatoid arthritis of the temporomandibular joint, where we proposed that BoNT/A decreases the neurogenic milieu after reaching the subnucleus caudalis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39579879"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 400,
          "text": "Previous studies have suggested that Botulinum toxin A (BONT/A), a macromolecular protein extracted from Clostridium Botulinum, may improve the pain and joint function in OA patients, but the mechanism remains elusive",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38714267"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 328,
          "text": "There is a growing need for novel treatments of refractory arthritis joint pain as the aging population is expanding with many patients who are unable to undergo joint replacement surgery. We are studying the efficacy and safety of intra-articular injection of Botulinum Toxin Type A (IA-BoNT/A) into joints with arthritis pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351542"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 380,
          "text": "INTRODUCTION: Osteoarthritis (OA) of the hip is a low-grade inflammatory disease of multiple etiology that has a limited conservative management and insufficiently explored. The application of botulinum toxin type A (BoNT-A) produces in the applied muscle a temporary, delimitable and reversible flaccid paralysis, which applied in a strategic way achieves to reduce mechanical st",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31638614"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "In recent years, there is a growing interest in new medical applications of botulinum toxin, including pain control, osteoarthritis treatment, and wound healing. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30995453"
        },
        {
          "offsetInBeginSection": 1047,
          "offsetInEndSection": 1144,
          "text": "BoNT/A is an effective analgesic for chronic arthritis pain, but not for acute arthritis pain. Hi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19818032"
        },
        {
          "offsetInBeginSection": 1487,
          "offsetInEndSection": 1629,
          "text": "We concluded that botulinum neurotoxin type A is an effective and safe initial treatment of knee osteoarthritis with clear clinical advantages",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30995453"
        }
      ],
      "type": "yesno",
      "id": "67ded55318b1e36f2e00005f",
      "ideal_answer": [
        "yes, Arthritis can be treated with Botox.",
        "Yes, Intra articular injection of botulinum toxin A may offer benefits in reducing pain and improving function in patients with knee osteoarthritis Yes, botulinum toxin type A (BoNT/A) is becoming an interesting treatment option for the treatment of chronic pain due to arthritic joints.",
        "Yes, botulinum toxin A is used as a treatment for arthritis, specifically as a fast-acting, intra-articular therapy targeting chronic pain in individuals with base-of-thumb osteoarthritis. It can help alleviate pain and improve joint function in affected individuals.",
        "Yes, Botulinum toxin A can be used as a treatment for arthritis, specifically base-of-thumb osteoarthritis. It is considered as a fast-acting, intra-articular therapy that targets chronic pain associated with this condition.",
        "Yes. Botulinum toxin Type A has shown promising efficacy in treating arthritic pain, particularly in reducing pain and improving function in patients with conditions like osteoarthritis and shoulder pain due to arthritis.",
        "Yes. Botulinum toxin Type A has shown promising efficacy in treating arthritic pain, particularly in knee osteoarthritis and other painful joint diseases.",
        "Yes. Botulinum toxin type A (BoNT-A) has been shown to reduce persistent inflammatory hypernociception induced by arthritis, indicating its use in treating arthritis-related pain.",
        "Yes,Botulinum toxin A is not traditionally used for treating all forms of arthritis but has been considered as a potential therapy for managing chronic pain associated with base of thumb osteoarthritis. It acts as a fast acting, intra articular treatment targeting this specific condition.",
        "Yes, botulinum toxin A is used to treat arthritis.",
        "Botulinum toxin A (BoNT/A) shows preliminary potential as a treatment option for osteoarthritis patients who have not responded to standard medical management and are not surgical candidates. While promising, the research is still in early stages and requires further investigation to definitively establish its efficacy.",
        "Yes, Botulinum toxin A is considered as a potential treatment for managing chronic pain in individuals with base of thumb osteoarthritis. It works by being administered directly into the joint (intra articularly) and can provide fast acting relief. However, its use is specific to this type of arthritis and may not be widely adopted or used for other forms of arthritis.",
        "Yes, botulinum toxin A is being used for treatment of arthritis.",
        "Botulinum toxin A (BoNT/A) shows potential as an intra-articular treatment option for osteoarthritis patients who haven\u0027t responded to conventional medical treatments and are not surgical candidates, though this application is still preliminary and requires further research to confirm its effectiveness.",
        "Yes,Botulinum toxin A (BoNT/A) has been explored as a potential treatment for osteoarthritis (a form of arthritis) in patients unresponsive to standard medical management and ineligible for surgery, via intra-articular administration. However, the evidence supporting its use remains preliminary, and further research is required to confirm its efficacy and safety.",
        "Yes, botulism toxin A is used to treat arthritis, particularly in a multimodal approach for osteoarthritis patients unresponsive to medical management and unable to undergo surgery.",
        "Yes, botulinum toxin A has been investigated as a treatment option for osteoarthritis, especially for patients unresponsive to medical management, although the findings are preliminary.",
        "Yes, botulism toxin A is used to treat arthritis through intra-articular administration in a multimodal approach for patients unresponsive to medical management and unable to undergo surgery.",
        "Yes, BoNT/A is used in a multimodal approach for treating osteoarthritis, particularly in patients unresponsive to medical management. However, the findings are preliminary and must be verified by further investigation.",
        "Yes, Botulism toxin A (BoNT/A) can be used to treat osteoarthritis, but only in a limited context. It is considered as an option for osteoarthritis patients that are unresponsive to medical management and unable to undergo surgery. However, the use of BoNT/A for arthritis is still preliminary and requires further investigation.",
        "Yes, botulism toxin A (BoNT/A) may be an option for osteoarthritis patients that are unresponsive to medical management and unable to undergo surgery. However, the findings of this study are preliminary and must be verified by further investigation.",
        "Botulinum toxin A (BoNT/A) has been explored as a treatment option for osteoarthritis, particularly for patients who do not respond to conventional medical management and are unable to undergo surgery. However, the findings regarding its use are preliminary and require further investigation to confirm its efficacy and safety.",
        "Yes. Intra-articular botulinum neurotoxin type A (BoNT/A) has been evaluated for its effects in dogs with chronic osteoarthritis, showing improvements in ground reaction forces and owner-reported outcomes.",
        "Yes. Botulinum toxin Type A (BoNT/A) has promising efficacy in treating arthritic pain, particularly in conditions like osteoarthritis and shoulder pain.",
        "Botulism toxin A is not used to treat arthritis. Botulism toxin A is a neurotoxin produced by the bacterium Clostridium botulinum, while arthritis is a bone inflammation disease. The two are not related in terms of treatment or function.",
        "Yes. Botulinum toxin A has been shown to be effective for treating arthritis-related pain and improving joint function in patients with conditions such as osteoarthritis and adhesive capsulitis of the shoulder.",
        "Yes, botulinum toxin A has been studied for use in treating certain forms of arthritis.",
        "Yes. Botulinum toxin A has been evaluated for its efficacy in treating painful joint diseases, including arthritis, particularly in the context of intra-articular injections for conditions like osteoarthritis.",
        "Yes, BoNT/A is used to treat osteoarthritis.",
        "Yes. Intra-articular administration of botulism toxin A (BoNT/A) may be an option for osteoarthritis patients that are unresponsive to medical management and unable to undergo surgery.",
        "Yes, Botulinum Toxin A (BoNT/A) has been investigated as a potential treatment for osteoarthritis, particularly for patients who are unresponsive to medical management and unable to undergo surgery. It is administered intra-articularly and may be used as part of a multimodal approach to manage the condition.",
        "Yes, botulinum toxin A (BoNT/A) is considered as a treatment option for patients with osteoarthritis who are unresponsive to medical management and unable to undergo surgery.",
        "Yes, botulinum toxin A is explored as a treatment option for osteoarthritis, specifically for patients unresponsive to medical management and unable to undergo surgery, although more research is needed to confirm its efficacy.",
        "Yes, botulism toxin A is used to treat arthritis.",
        "Botulism toxin A (BoNT/A) has been investigated as a potential treatment option for osteoarthritis patients who do not respond to medical management or are unable to undergo surgery, but this finding is preliminary and requires further investigation.",
        "Botulinum toxin type A (BoNT/A) is being explored as a potential treatment for osteoarthritis patients who do not respond to conventional medical management and are unable to undergo surgery. This involves its intra-articular administration as part of a multimodal approach, although the findings from studies on this application are preliminary and require further investigation.",
        "Yes, botulism toxin A (BoNT/A) may be used as an option for osteoarthritis patients that are unresponsive to medical management and unable to undergo surgery. However, the findings are preliminary and must be verified by further investigation."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Diseases that are screened in the neonate with the heel prick test.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39603015",
        "http://www.ncbi.nlm.nih.gov/pubmed/23825488",
        "http://www.ncbi.nlm.nih.gov/pubmed/20722469",
        "http://www.ncbi.nlm.nih.gov/pubmed/38636590",
        "http://www.ncbi.nlm.nih.gov/pubmed/33323926",
        "http://www.ncbi.nlm.nih.gov/pubmed/31141086",
        "http://www.ncbi.nlm.nih.gov/pubmed/30700177",
        "http://www.ncbi.nlm.nih.gov/pubmed/17391418",
        "http://www.ncbi.nlm.nih.gov/pubmed/9564759",
        "http://www.ncbi.nlm.nih.gov/pubmed/17718874",
        "http://www.ncbi.nlm.nih.gov/pubmed/31241659",
        "http://www.ncbi.nlm.nih.gov/pubmed/39728399",
        "http://www.ncbi.nlm.nih.gov/pubmed/39728400",
        "http://www.ncbi.nlm.nih.gov/pubmed/34859927",
        "http://www.ncbi.nlm.nih.gov/pubmed/39704065",
        "http://www.ncbi.nlm.nih.gov/pubmed/20799077",
        "http://www.ncbi.nlm.nih.gov/pubmed/39449358",
        "http://www.ncbi.nlm.nih.gov/pubmed/33072952",
        "http://www.ncbi.nlm.nih.gov/pubmed/20627926",
        "http://www.ncbi.nlm.nih.gov/pubmed/17430715",
        "http://www.ncbi.nlm.nih.gov/pubmed/7849819",
        "http://www.ncbi.nlm.nih.gov/pubmed/18830514",
        "http://www.ncbi.nlm.nih.gov/pubmed/314036",
        "http://www.ncbi.nlm.nih.gov/pubmed/33072977",
        "http://www.ncbi.nlm.nih.gov/pubmed/10367420",
        "http://www.ncbi.nlm.nih.gov/pubmed/21150375",
        "http://www.ncbi.nlm.nih.gov/pubmed/11071072",
        "http://www.ncbi.nlm.nih.gov/pubmed/17183576",
        "http://www.ncbi.nlm.nih.gov/pubmed/26021874",
        "http://www.ncbi.nlm.nih.gov/pubmed/15914349",
        "http://www.ncbi.nlm.nih.gov/pubmed/6835136",
        "http://www.ncbi.nlm.nih.gov/pubmed/15906702",
        "http://www.ncbi.nlm.nih.gov/pubmed/3118277",
        "http://www.ncbi.nlm.nih.gov/pubmed/21150366",
        "http://www.ncbi.nlm.nih.gov/pubmed/7079807",
        "http://www.ncbi.nlm.nih.gov/pubmed/9689890"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 1914,
          "offsetInEndSection": 1929,
          "text": "phenylketonuria",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39603015"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 119,
          "text": "cystic fibrosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23825488"
        },
        {
          "offsetInBeginSection": 61,
          "offsetInEndSection": 79,
          "text": "hemoglobinopathies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20722469"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 37,
          "text": "Inborn errors of immunity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38636590"
        },
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 436,
          "text": "phenylketonuria",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33323926"
        },
        {
          "offsetInBeginSection": 505,
          "offsetInEndSection": 531,
          "text": "congenital hypothyroidism ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33323926"
        },
        {
          "offsetInBeginSection": 680,
          "offsetInEndSection": 695,
          "text": "cystic fibrosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33323926"
        },
        {
          "offsetInBeginSection": 860,
          "offsetInEndSection": 879,
          "text": "sickle cell disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33323926"
        },
        {
          "offsetInBeginSection": 923,
          "offsetInEndSection": 955,
          "text": "severe combined immunodeficiency",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33323926"
        },
        {
          "offsetInBeginSection": 671,
          "offsetInEndSection": 756,
          "text": "The heel prick test had been done on the studied neonates to determine the TSH levels",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30700177"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 113,
          "text": "In 2005, in Ontario, Canada, newborns were only screened for phenylketonuria (PKU) and hypothyroidism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17391418"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Newborn Screening for Acid Sphingomyelinase Deficiency: Prevalence and Genotypic Findings in Italy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728399"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "BACKGROUND: Cord-blood and heel-prick TSH levels are essential in diagnosing and preventing the serious complications of congenital hypothyroidism, which mainly include intellectual",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34859927"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Neonatal screening for phenylketonuria (PKU) and congenital hypothyroidism (CHT) is universal across the UK using heel prick",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9564759"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "BACKGROUND: Newborn screening (NBS) for cystic fibrosis (CF) was universally implemented in the United States in 2010 to improve disea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39704065"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Neonatal screening for phenylketonuria (PKU) and congenital hypothyroidism (CHT) is universal across the UK using heel prick blood collected at 6-14 days of age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9564759"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 500,
          "text": "Three disorders namely, congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH) and glucose-6-phosphate dehydrogenase deficiency (G-6-PDD) were selected for a preliminary study for newborn screening.METHODS: Heel-prick blood samples were collected from live-born neonates at 24-48 h of birth as a part of a screening program after prior written consent from the parents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20799077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "text": "BACKGROUND: The current neonatal screening program (\"the heel prick\") involves taking a few drops of blood from almost every newborn in the Netherlands to determine whether the child is suffering from one of three congenital disorders: phenylketonuria, congenital hypothyroid, or adrenogenital syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17718874"
        },
        {
          "offsetInBeginSection": 186,
          "offsetInEndSection": 344,
          "text": "This was recently done for Congenital Hypothyroidism (CH), Congenital Adrenal Hyperplasia (CAH) and Maple Syrup Urine Disease (MSUD) in the Dutch NBS program.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39449358"
        },
        {
          "offsetInBeginSection": 409,
          "offsetInEndSection": 713,
          "text": "Since 2010, neonatal screening programs for SCD have been initiated in a few states of India. A total of 18,003 babies have been screened by automated HPLC using either cord blood samples or heel prick dried blood spots and 2944 and 300 babies were diagnosed as sickle cell carriers and SCD respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33072952"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 301,
          "text": "Neonatal screening for phenylketonuria (PKU) and congenital hypothyroidism (CHT) is universal across the UK using heel prick blood collected at 6-14 days of age. Additional programmes for sickle cell disorders, cystic fibrosis, Duchenne muscular dystrophy and galactosaemia are provided in some areas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9564759"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Screening for cystic fibrosis (CF) was recently added to the neonatal screening programme in the Netherlands.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20627926"
        },
        {
          "offsetInBeginSection": 1423,
          "offsetInEndSection": 1596,
          "text": "the inclusion of the serological screening for toxoplasmosis in the newborn heel prick test proved to be effective for the early detection of congenital T. gondii infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31241659"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 328,
          "text": " Three disorders namely, congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH) and glucose-6-phosphate dehydrogenase deficiency (G-6-PDD) were selected for a preliminary study for newborn screening",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20799077"
        },
        {
          "offsetInBeginSection": 317,
          "offsetInEndSection": 433,
          "text": " The autonomous community of Madrid began to perform universal neonatal screening for hemoglobinopathies in May 2003",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17430715"
        },
        {
          "offsetInBeginSection": 604,
          "offsetInEndSection": 819,
          "text": "The disorders covered by newborn screening vary among the states and among countries but virtually always include phenylketonuria and congenital hypothyroidism and often include sickle cell disease and galactosemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7849819"
        },
        {
          "offsetInBeginSection": 842,
          "offsetInEndSection": 1010,
          "text": "screening programs of different countries. In Brazil, the National Neonatal Screening Program was set up in 2001, to screen for phenylketonuria, congenital hypothyroidi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18830514"
        },
        {
          "offsetInBeginSection": 820,
          "offsetInEndSection": 994,
          "text": "Other metabolic disorders that may be included in newborn screening are maple syrup urine disease, homocystinuria, biotinidase deficiency, and congenital adrenal hyperplasia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7849819"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "A screening programme which was already established to detect phenylketonuria in the newborn period in South Australia was extended to include screening for galactosaemia, homocystinuria, hereditary tyrosinaemia, histidinaemia, maple syrup urine disease and severe alpha 1-antitrypsin deficiency for a trial period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/314036"
        },
        {
          "offsetInBeginSection": 954,
          "offsetInEndSection": 1087,
          "text": "Newborn screening in South Australia currently includes tests for phenylketonuria, hypothydroidism, galactosaemia and homocystinuria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/314036"
        },
        {
          "offsetInBeginSection": 969,
          "offsetInEndSection": 1359,
          "text": "Of the 240 newborns, 25% had abnormal heel prick test results, especially for cystic fibrosis and congenital adrenal hyperplasia.CONCLUSION: There are maternal and neonatal conditions that can affect heel prick test results, and therefore, their investigation is essential, aiming to guide measures that promote mother and child health and consolidate neonatal screening in this population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31141086"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 415,
          "text": "Heel-prick blood samples from newborns were collected on Dried Blood Spot (DBS) collection cards and tested through Tandem Mass Spectroscopy and fluorescence assays for disorders included in the Swiss neonatal screening program; two cases of hypothyroidism and one case of cystic fibrosis were identified",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33072977"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "A UK national programme to screen all newborn infants for phenylketonuria was introduced in 1969, followed in 1981 by a similar programme for congenital hypothyroidism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10367420"
        },
        {
          "offsetInBeginSection": 558,
          "offsetInEndSection": 721,
          "text": "The example of newborn screening for phenylketonuria was used to highlight the issues in the context of the condition with the longest history in newborn screening",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150375"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Phenylketonuria is an inherited metabolic disorder caused by a defect in the hydroxylation of phenylalanine. Newborn screening is crucial for the diagnosis and treatment of this disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11071072"
        },
        {
          "offsetInBeginSection": 882,
          "offsetInEndSection": 1000,
          "text": "Congenital hypothyroidism and cystic fibrosis are candidates to be considered for a newborn screening program in Nepal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33072977"
        },
        {
          "offsetInBeginSection": 604,
          "offsetInEndSection": 818,
          "text": "The disorders covered by newborn screening vary among the states and among countries but virtually always include phenylketonuria and congenital hypothyroidism and often include sickle cell disease and galactosemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7849819"
        },
        {
          "offsetInBeginSection": 820,
          "offsetInEndSection": 993,
          "text": "Other metabolic disorders that may be included in newborn screening are maple syrup urine disease, homocystinuria, biotinidase deficiency, and congenital adrenal hyperplasia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7849819"
        },
        {
          "offsetInBeginSection": 932,
          "offsetInEndSection": 1180,
          "text": "Recent national legislation created provisions for newborn and infant screening, including for congenital hypothyroidism, phenylketonuria, congenital adrenal hyperplasia, cystic fibrosis and medium-chain acyl-CoA dehydrogenase, via blood spot test,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26021874"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 706,
          "text": "CAH).METHODS: Neonatal screening was performed on blood-spot for PKU (phenylalanine concentration by fluorescent ninhydrine method), for CH (simultaneous total thyroxin (tT4) and thyroid-stimulating hormone (TSH) levels by fluoroimmunometric assay); and for CAH (17-hydroxyprogesteron level by fluoroimmuno",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15914349"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Since screening of newborn infants for phenylketonuria (PKU) by the Guthrie bacterial inhibition assay was established in the 1960s, 3 017 703 infants have been tested in Australia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6835136"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 565,
          "text": "Mass newborn screening was started in October 1977 throughout Japan in order to detect five inborn errors of metabolism including phenylketonuria, maple syrup urine disease, homocystinuria, histidinemia, and galactosemia. In 1979, mass screening for congenital hypothyroidism was added to the original program. In 1989, screening for congenital adrenal hyperplasia was added and in 1992, screening of histidinemia was discontinued. Currently, screening covers six diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15906702"
        },
        {
          "offsetInBeginSection": 911,
          "offsetInEndSection": 1189,
          "text": "We provide a historical overview of universal newborn screening programs in the United States, and then focus on six early NBS programs: congenital hypothyroidism, phenylketonuria, congenital adrenal hyperplasia, galactosemia, sickle cell disease, and maple syrup urine disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17183576"
        },
        {
          "offsetInBeginSection": 635,
          "offsetInEndSection": 871,
          "text": "Six primary severe conditions were included: congenital hypothyroidism (CH), cystic fibrosis (CF), phenylketonuria (PKU), glucose-6-phosphate dehydrogenase deficiency (G6PD), congenital adrenal hyperplasia (CAH), and hemoglobinopathies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728400"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 630,
          "text": "All states screen for phenylketonuria (PKU) and hypothyroidism; in addition, 26 states screen for galactosemia, 20 for maple syrup urine disease and 19 for homocystinuria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3118277"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 430,
          "text": "He succeeded in this effort to an extent, adding screening for galactosemia, maple syrup urine disease, and homocystinuria. Screening for congenital hypothyroidism, congenital adrenal hyperplasia, biotinidase deficiency, and a few additional disorders was added by others over the years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150366"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 865,
          "text": "The number of cases and incidence of each disease detected were hyperphenylalaninemia, five (1/31,579); maple syrup urine disease, 0 (0/151,250); homocystinuria, one (1/151,250); galactosemia, two (1/63,352); transient tyrosinemia (greater than or equal to 12 mg/dl), 50 (1/3,158); primary congenital hypothyroidism, 17 (1/7,453); and thyroid binding globulin deficiency, ten (1/12,670).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7079807"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 302,
          "text": " The current neonatal screening program (\"the heel prick\") involves taking a few drops of blood from almost every newborn in the Netherlands to determine whether the child is suffering from one of three congenital disorders: phenylketonuria, congenital hypothyroid, or adrenogenital syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17718874"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 339,
          "text": "The Genetic center of the University Hospital of Liège provides neonatal screening for the following diseases: phenylketonuria, congenital hypothyroidy, cystic fibrosis, alpha-1-antitrypsin, adrenal hyperplasia and biotinidase deficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9689890"
        },
        {
          "offsetInBeginSection": 942,
          "offsetInEndSection": 1070,
          "text": "ion and blood transfusion. Of the 240 newborns, 25% had abnormal heel prick test results, especially for cystic fibrosis and con",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31141086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Neonatal screening for phenylketonuria (PKU) and congenital hypothyroidism (CHT) is universal across the UK using heel prick blood collected at 6-14 days of age",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9564759"
        }
      ],
      "id": "67e40e9418b1e36f2e0000a4",
      "ideal_answer": [
        "Some diseases that can be neonatally screened and treated early to prevent complications are: phenylketonuria, cystic fibrosis, hemoglobinopathies, inborn errors of immunity such as severe combined immunodeficiency, and sickle cell disease.",
        "Newborn screening programs typically include tests for a variety of conditions. Some of the most commonly screened disorders are congenital hypothyroidism, congenital adrenal hyperplasia, sickle cell disease and other hemoglobinopathies, biotinidase deficiency, galactosemia, cystic fibrosis, phenylketonuria, maple syrup urine disease, and homocystinuria. Other conditions that may be included are medium-chain acyl-coenzyme A dehydrogenase deficiency, congenital hearing loss, tyrosinemia, glucose-6-phosphate dehydrogenase deficiency, and severe combined immunodeficiency, as well as other inborn errors of immunity. However, the specific disorders screened can vary among states and countries.",
        "Newborn screening via the heel prick test includes metabolic disorders such as phenylketonuria, maple syrup urine disease, homocystinuria, methylmalonic acidemia, primary carnitine deficiency, medium‐chain acyl CoA dehydrogenase deficiency, glutaric aciduria type 1, fatty acid oxidation defects, and citrullinemia. It also covers congenital endocrine disorders like congenital hypothyroidism and congenital adrenal hyperplasia. In addition, cystic fibrosis and a range of hemoglobinopathies including sickle cell disease are screened. Programs may also test for immune disorders such as severe combined immune deficiency and related inborn errors of immunity, and in some settings, spinal muscular atrophy is included."
      ],
      "exact_answer": [
        [
          "phenylketonuria"
        ],
        [
          "cystic fibrosis"
        ],
        [
          "hemoglobinopathies"
        ],
        [
          "inborn errors of immunity"
        ],
        [
          "congenital hypothyroidism"
        ],
        [
          "sickle cell disease"
        ],
        [
          "severe combined immunodeficiency"
        ]
      ]
    },
    {
      "body": "What is the most common genetic alteration in primary glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23007009",
        "http://www.ncbi.nlm.nih.gov/pubmed/20051017",
        "http://www.ncbi.nlm.nih.gov/pubmed/16709245",
        "http://www.ncbi.nlm.nih.gov/pubmed/15822813",
        "http://www.ncbi.nlm.nih.gov/pubmed/10850866",
        "http://www.ncbi.nlm.nih.gov/pubmed/10328589",
        "http://www.ncbi.nlm.nih.gov/pubmed/30569026",
        "http://www.ncbi.nlm.nih.gov/pubmed/31751860",
        "http://www.ncbi.nlm.nih.gov/pubmed/17907599",
        "http://www.ncbi.nlm.nih.gov/pubmed/15193025",
        "http://www.ncbi.nlm.nih.gov/pubmed/11550301",
        "http://www.ncbi.nlm.nih.gov/pubmed/11550308",
        "http://www.ncbi.nlm.nih.gov/pubmed/11514572",
        "http://www.ncbi.nlm.nih.gov/pubmed/11515790",
        "http://www.ncbi.nlm.nih.gov/pubmed/11511795",
        "http://www.ncbi.nlm.nih.gov/pubmed/11048299",
        "http://www.ncbi.nlm.nih.gov/pubmed/30509096",
        "http://www.ncbi.nlm.nih.gov/pubmed/27286795",
        "http://www.ncbi.nlm.nih.gov/pubmed/12826827",
        "http://www.ncbi.nlm.nih.gov/pubmed/22089350",
        "http://www.ncbi.nlm.nih.gov/pubmed/25976245",
        "http://www.ncbi.nlm.nih.gov/pubmed/8864278",
        "http://www.ncbi.nlm.nih.gov/pubmed/37523556",
        "http://www.ncbi.nlm.nih.gov/pubmed/10323080",
        "http://www.ncbi.nlm.nih.gov/pubmed/17235514"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 187,
          "text": "Amplification and overexpression of the epidermal growth factor receptor (EGFR) gene are a hallmark of primary glioblastoma (45%), making it a prime target for therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23007009"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 452,
          "text": "EGFR amplification has been identified as a genetic hallmark of primary glioblastomas and occurs in 40-60% of cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20051017"
        },
        {
          "offsetInBeginSection": 248,
          "offsetInEndSection": 360,
          "text": "The majority of GBMs show an overexpression and/or amplification of the epidermal growth factor receptor (EGFR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16709245"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 335,
          "text": "Primary glioblastoma, which is the most frequent presentation (90-95%), occurs mainly in older patients and arises de novo, without any clinical or histological evidence of a less malignant precursor lesion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20051017"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 301,
          "text": "In addition, these amplifications are frequently associated with oncogenic mutations in the extracellular domain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23007009"
        },
        {
          "offsetInBeginSection": 347,
          "offsetInEndSection": 677,
          "text": "Our recent population-based study in the Canton of Zürich, Switzerland, shows that primary glioblastomas develop in older patients (mean age, 62 years) and typically show LOH on chromosome 10q (69%) and other genetic alterations (EGFR amplification, TP53 mutations, p16INK4a deletion, and PTEN mutations) at frequencies of 24-34%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15822813"
        },
        {
          "offsetInBeginSection": 263,
          "offsetInEndSection": 535,
          "text": "Primary glioblastomas are characterized by EGFR amplification/overexpression, PTEN mutation, homozygous p16 deletion, and loss of heterozygosity (LOH) on entire chromosome 10, whereas secondary glioblastomas frequently contain p53 mutations and show LOH on chromosome 10q.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10850866"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 264,
          "text": "The literature review revealed that the most common genetic abnormalities in primary and secondary glioblastomas are IDH1 / 2 mutations, p53 mutations, and overexpression of EGFR.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30569026"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 693,
          "text": "A genetic alteration that is significantly more frequent in primary than in secondary glioblastomas, the latter arising from preceding low-grade gliomas, is epidermal growth factor receptor gene (EGFR) amplification, whereas TP-53 mutations are significantly more frequent in low-grade gliomas and secondary glioblastomas derived there- from.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17907599"
        },
        {
          "offsetInBeginSection": 365,
          "offsetInEndSection": 541,
          "text": "Primary glioblastomas develop in older patients and typically show EGFR overexpression, PTEN (MMAC1) mutations, CDKN2A (p16) deletions, and less frequently, MDM2 amplification.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11550301"
        },
        {
          "offsetInBeginSection": 1027,
          "offsetInEndSection": 1205,
          "text": "Glioblastomas also occur as primary (de novo) lesions in patients of older age, without p53 gene loss but with amplification of the epidermal growth factor receptor (EGFR) genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11550308"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Glioblastoma multiforme (GBM) is the most aggressive type of glioma and GBMs frequently contain amplifications or mutations of the EGFR gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11514572"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Amplification of the epidermal growth factor receptor (EGFR) gene is found in about 40% of glioblastomas (GBMs) but is rarely detected in GBM cell lines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11515790"
        },
        {
          "offsetInBeginSection": 965,
          "offsetInEndSection": 1079,
          "text": "EGFR amplifications were detected in 73.3% of primary glioblastomas and 9.5% of secondary glioblastomas (p\u003c0.001).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11511795"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 567,
          "text": "A genetic alteration that is significantly more frequent in primary than in secondary glioblastomas, the latter arising from preceding low-grade gliomas, is epidermal growth factor receptor gene (EGFR) amplification,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17907599"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 451,
          "text": "EGFR amplification has been identified as a genetic hallmark of primary glioblastomas and occurs in 40-60% of cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20051017"
        },
        {
          "offsetInBeginSection": 486,
          "offsetInEndSection": 677,
          "text": "Common genetic alterations in GBM include gene amplification of epidermal growth factor receptor (EGFR), mutations in the tumor suppressors TP53 and PTEN, and genetic losses on chromosome 10.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12826827"
        },
        {
          "offsetInBeginSection": 568,
          "offsetInEndSection": 675,
          "text": "Primary adult GBMs showed EGFR amplification and PTEN deletion in majority (37.3% and 54.9%, respectively).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22089350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system. With no effective therapy, the prognosis for patients is terrible poor. It is highly heterogeneous and EGFR amplification is its most frequent molecular alteration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31751860"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "Amplification of chromosome 7p11 (7p11) is the most common alteration in primary glioblastoma (GBM), resulting in gains of epidermal growth factor receptor (EGFR) copy number in 50 to 60% of GBM tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37523556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "EGFR amplification is a frequent genetic alteration in primary (de novo) glioblastomas, and is often associated with structural alterations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15193025"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 379,
          "text": "The most common genetic alteration was EGFR amplification which was revealed in 15 cases (45%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10323080"
        },
        {
          "offsetInBeginSection": 965,
          "offsetInEndSection": 1077,
          "text": "EGFR amplifications were detected in 73.3% of primary glioblastomas and 9.5% of secondary glioblastomas (p\u003c0.001",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11511795"
        }
      ],
      "id": "67eb55f418b1e36f2e0000e7",
      "ideal_answer": [
        "Primary glioblastoma occurs mainly in older patients and arises de novo, without any clinical or histological evidence of a less malignant precursor lesion. Amplification and overexpression of the epidermal growth factor receptor (EGFR) gene is a hallmark of primary glioblastoma (45%), making it a prime target for therapy. These amplifications are frequently associated with oncogenic mutations in the extracellular domain.",
        "EGFR amplification is the most common genetic alteration in primary glioblastoma. This alteration is seen in approximately 40–60% of cases and is considered a hallmark of de novo primary tumors. While loss of heterozygosity on chromosome 10 and loss of PTEN function are common genetic events in glioblastomas overall, EGFR amplification specifically characterizes primary glioblastomas.",
        "EGFR (epidermal growth factor receptor) gene amplification is the most common genetic alteration in primary glioblastoma, occurring in approximately 45-60% of cases. This genetic change is frequently associated with oncogenic mutations in the receptor\u0027s extracellular domain and is a key molecular hallmark of this aggressive brain tumor.",
        "The most common genetic alteration in primary glioblastoma is the amplification and overexpression of the epidermal growth factor receptor (EGFR) gene, occurring in approximately 45% to 60% of cases. This consistent finding across analyses highlights EGFR\u0027s role as a hallmark and a prime therapeutic target in primary glioblastomas, often associated with oncogenic mutations in its extracellular domain.",
        "Studies have identified that amplification and overexpression of the epidermal growth factor receptor (EGFR) gene are a common feature of primary glioblastoma, occurring in approximately 40-60% of cases. This genetic alteration is particularly prevalent in primary glioblastomas, which account for 90-95% of all glioblastoma presentations and typically arise de novo in older patients. The majority of these tumors exhibit overexpression and/or amplification of the EGFR gene, often accompanied by oncogenic mutations in the extracellular domain. As such, EGFR amplification is considered a hallmark of primary glioblastoma, making it a prime target for therapeutic intervention.",
        "EGFR amplification and overexpression is the most common genetic hallmark of primary glioblastomas, occurring in 40-60% of cases. This alteration is particularly significant in primary glioblastoma, which represents 90-95% of all cases and typically affects older patients. These EGFR amplifications are often accompanied by oncogenic mutations in the extracellular domain.",
        "The most common genetic alteration in primary glioblastoma is the amplification and subsequent overexpression of the epidermal growth factor receptor (EGFR) gene, observed in approximately 45% of cases. This amplification leads to increased EGFR protein levels, which drive tumor progression by promoting uncontrolled cell proliferation, survival, and invasion. EGFR amplification is a key molecular hallmark of primary glioblastoma and has been a major focus for targeted therapeutic interventions.",
        "The most common genetic alteration in primary glioblastoma is **amplification and/or overexpression of the epidermal growth factor receptor (EGFR) gene**, occurring in **40–60% of cases**. This alteration is a hallmark of primary glioblastoma and is often associated with oncogenic mutations in EGFR\u0027s extracellular domain.",
        "The most common genetic alteration in primary glioblastoma is the amplification and overexpression of the epidermal growth factor receptor (EGFR) gene, occurring in approximately 40-60% of cases. This alteration is a hallmark of the disease and often associated with specific mutations in the extracellular domain of EGFR.",
        "The most common genetic alteration in primary glioblastoma is the amplification and overexpression of the Epidermal Growth Factor Receptor (EGFR) gene, occurring in approximately 40-60% of cases. This alteration is a hallmark of primary glioblastomas, often associated with oncogenic mutations in the extracellular domain, making EGFR a prime target for therapy in affected patients.",
        "The most common genetic alteration in primary glioblastoma is amplification and overexpression of the epidermal growth factor receptor (EGFR) gene. This genetic hallmark occurs in approximately 40-60% of primary glioblastoma cases, with multiple sources confirming a 45% prevalence rate. These EGFR amplifications are frequently associated with oncogenic mutations in the extracellular domain, contributing to the aggressive nature of primary glioblastomas, which represent 90-95% of all glioblastoma cases and typically arise de novo in older patients without evidence of less malignant precursor lesions.",
        "The most common genetic alteration in primary glioblastoma is the amplification and overexpression of the epidermal growth factor receptor (EGFR) gene. This occurs in approximately 40-60% of cases, making it a significant hallmark of this aggressive brain cancer. Additionally, these alterations are often accompanied by oncogenic mutations in the extracellular domain of EGFR, which can lead to uncontrolled cell proliferation. Thus, EGFR abnormalities are central to the genetic landscape of primary glioblastoma.",
        "Studies have shown that the most common genetic alteration in primary glioblastoma is the amplification and overexpression of the epidermal growth factor receptor (EGFR) gene, occurring in 40-60% of cases. This genetic hallmark is frequently associated with oncogenic mutations in the extracellular domain, making EGFR a prime target for therapy.",
        "The most common genetic alteration in primary glioblastoma is the amplification and overexpression of the epidermal growth factor receptor (EGFR) gene, occurring in 40-60% of cases. This alteration is a hallmark of primary glioblastomas, which typically present de novo without precursor lesions, primarily affecting older patients. Additionally, EGFR amplifications are often associated with oncogenic mutations in its extracellular domain."
      ],
      "exact_answer": [
        [
          "EGFR amplification",
          "EGFR overexpression",
          "Epidermal growth factor receptor amplification",
          "overexpression/amplification of the EGF receptor",
          "Overexpression of EGFR",
          "EGFR gene amplification"
        ]
      ]
    },
    {
      "body": "Describe gwRVIS",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33686085"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 1184,
          "text": "Here, we integrate intolerance to variation, functional genomic annotations and primary genomic sequence to build JARVIS: a comprehensive deep learning model to prioritize non-coding regions, outperforming other human lineage-specific scores. Despite being agnostic to evolutionary conservation, JARVIS performs comparably or outperforms conservation-based scores in classifying pathogenic single-nucleotide and structural variants. In constructing JARVIS, we introduce the genome-wide residual variation intolerance score (gwRVIS), applying a sliding-window approach to whole genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. Both JARVIS and gwRVIS capture previously inaccessible human-lineage constraint information and will enhance our understanding of the non-coding genome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686085"
        }
      ],
      "id": "67df10be18b1e36f2e000063",
      "ideal_answer": [
        "Genome-wide residual variation intolerance score (gwRVIS) distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. Both JARVIS and gwRVIS capture previously inaccessible human-lineage constraint information and will enhance our understanding of the non-coding genome.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a metric introduced in the JARVIS model that applies a sliding-window approach to whole genome sequencing data from 62,784 individuals. It is designed to distinguish Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. gwRVIS captures previously inaccessible human-lineage constraint information, enhancing our understanding of the non-coding genome.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a sliding-window approach to whole genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. Both JARVIS and gwRVIS capture previously inaccessible human-lineage constraint information and will enhance our understanding of the non-coding genome.",
        "gwRVIS (Genome-wide Residual Variation Intolerance Score) is a scoring system, part of the JARVIS deep learning model, which utilizes a sliding-window approach on whole-genome sequencing data from 62,784 individuals to quantify genetic variation intolerance across the human genome. It effectively distinguishes Mendelian disease genes from more tolerant regions, highlights ultra-conserved non-coding elements as the most intolerant, and captures human-lineage specific constraint information without relying on evolutionary conservation, thus enhancing our understanding of the non-coding genome.",
        "gwRVIS, or genome-wide Residual Variation Intolerance Score, is a tool designed to differentiate Mendelian disease genes from more variation-tolerant regions in the human genome. It highlights ultra-conserved non-coding elements as particularly intolerant areas, indicating their potential importance in human biology and disease. By assessing the genetic variation intolerance, gwRVIS can help identify genes and genomic regions that are more likely to be associated with Mendelian diseases.",
        "The genome-wide residual variation intolerance score (gwRVIS) was developed as part of the construction of JARVIS. This method employs a sliding-window approach to analyze whole-genome sequencing data from 62,784 individuals. The gwRVIS is designed to assess the intolerance of genomic regions to variations, providing insights into their potential functional significance by identifying areas with lower tolerance for genetic variation.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a metric used in biomedicine to assess the intolerance of genomic regions to variation. It is introduced using a sliding-window approach applied to whole genome sequencing data from 62,784 individuals, helping analyze variation intolerance across the genome. gwRVIS is used to distinguish Mendelian disease genes from more tolerant regions in the Consensus Coding Sequence (CCDS) regions of the genome, making it valuable for identifying genes likely involved in Mendelian diseases. The score also highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome, indicating these regions are highly conserved and less tolerant to variation. These applications make gwRVIS a significant tool in genomic studies, particularly in understanding the genetic basis of diseases and the conservation of genomic elements.",
        "gwRVIS, or genome-wide Residual Variation Intolerance Score, is used to identify and distinguish Mendelian disease genes from more variation-tolerant regions in the human genome. It helps highlight ultra-conserved non-coding elements, which are among the most intolerant regions, indicating their importance and potential role in genetic diseases.",
        "gwRVIS is a comprehensive deep learning model that integrates intolerance to variation, functional genomic annotations, and primary genomic sequence to prioritize non-coding regions, outperforming other human lineage-specific scores.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a metric used to assess intolerance to genetic variation across the human genome. It utilizes a sliding-window approach on whole genome sequencing data to differentiate between Mendelian disease genes and regions more tolerant to variation, identifying ultra-conserved non-coding elements as the most variation-intolerant regions.",
        "gwRVIS (genome-wide Residual Variation Intolerance Score) is a metric used to assess the intolerance of genes to functional genetic variation, helping to identify genes that are more likely to be associated with disease.",
        "gwRVIS (genome-wide Residual Variation Intolerance Score) is a metric used to assess how intolerant genes are to functional genetic variation. It helps identify genes that are less likely to tolerate changes without causing disease. The score is calculated by comparing the observed genetic variation in a gene to the expected variation based on a genome-wide model. Genes with lower gwRVIS scores are considered more intolerant to variation and are more likely to be associated with disease when mutated. This tool is particularly useful for identifying potential disease-causing genes in genetic studies.",
        "gwRVIS is the genome-wide residual variation intolerance score. It applies a sliding-window approach to whole genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome.",
        "gwRVIS is a continuous gene-level metric that uses variant distribution patterns to prioritize disease candidate genes.",
        "gwRVIS is the genome-wide Residual Variation Intolerance Score that uses a sliding-window approach on whole genome sequencing data from 62,784 individuals to assess the tolerance of different genomic regions to variation. It distinguishes Mendelian disease genes from more tolerant CCDS regions and explicitly identifies ultra-conserved non-coding elements as the most intolerant parts of the human genome.",
        "gwRVIS, or genome-wide residual variation intolerance score, is a metric developed using a sliding-window approach on whole genome sequencing data from a large cohort of individuals. It serves to differentiate between Mendelian disease genes from more tolerant CCDS regions. Furthermore, gwRVIS highlights ultra-conserved non-coding elements as the most intolerant regions within the human genome.",
        "gwRVIS is a metric used to assess the intolerance of genes to variation, helping prioritize disease candidate genes by evaluating their genetic variation patterns.",
        "gwRVIS (Genome-wide Residual Variation Intolerance Score) is a metric derived from a sliding-window analysis of whole genome sequencing data from 62,784 individuals. It distinguishes between Mendelian disease genes and more tolerant genomic regions, notably highlighting ultra-conserved non-coding elements as the most intolerant regions. This score provides valuable insights into a region\u0027s intolerance to genetic variation, aiding in the identification of conserved regions crucial for understanding genetic diseases.",
        "gwRVIS is a quantitative metric that assesses genome-wide intolerance to genetic variation using a sliding-window approach on whole-genome sequencing data. Analyzed across a large population (e.g., 62,784 individuals), it identifies regions of varying intolerance, notably highlighting ultra-conserved non-coding elements, functionally important conserved regions, and areas associated with Mendelian disease genes, thereby providing a comprehensive view of the genome\u0027s sensitivity to mutations.",
        "gwRVIS is a method for quantifying regional variation intolerance across the human genome. It utilizes a sliding-window approach on whole-genome sequencing data from 62,784 individuals to assess how intolerant different regions are to genetic variations. The approach helps distinguish regions linked to Mendelian diseases from those more tolerant of variation, thereby pinpointing segments of the genome that may have significant functional or clinical relevance. Notably, gwRVIS identifies ultra-conserved non-coding elements as some of the most intolerant regions, suggesting these areas play critical roles in essential biological processes. Overall, the method captures human-lineage constraint information that was previously challenging to evaluate, providing a valuable tool for the characterization of both coding and non-coding genomic regions.",
        "gwRVIS (Genome-Wide Residual Variation Intolerance Score) is a scoring system used to measure the intolerance of genomic regions to variation. It applies a sliding-window approach to whole-genome sequencing data and distinguishes Mendelian disease genes from more tolerant regions. gwRVIS highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome, indicating their importance for maintaining proper gene function and overall genome stability.",
        "gwRVIS is a genome-wide residual variation intolerance score that uses a sliding-window approach on whole genome sequencing data to identify genomic regions intolerant to variation, aiding in distinguishing Mendelian disease genes from more tolerant regions.",
        "gwRVIS (Genome-wide Residual Variation Intolerance Score) is a quantitative metric that assesses the human genome\u0027s intolerance to genetic variation. Utilizing a sliding-window approach on whole-genome sequencing data from 62,784 individuals, gwRVIS distinguishes Mendelian disease genes from more tolerant regions, notably highlighting ultra-conserved non-coding elements as the most intolerant. This scoring system, part of the JARVIS deep learning model, provides comprehensive insights into genomic sensitivity to mutations, enhancing our understanding of the non-coding genome and aiding in the identification of crucial conserved regions for genetic disease research.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a bioinformatic tool used to identify and distinguish Mendelian disease genes from more tolerant regions within the Consensus Coding Sequence (CCDS) regions of the human genome. It is designed to differentiate between genes that are intolerant to variation, often associated with Mendelian diseases, and those that are more tolerant to genetic variation. The tool highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome, providing insights into areas crucial for maintaining genetic stability and function. The score is derived using a sliding-window approach applied to whole genome sequencing data from a large cohort of 62,784 individuals, allowing for a comprehensive analysis of genetic variation across the entire genome. This tool is particularly useful for researchers and clinicians in identifying potential genetic causes of Mendelian diseases and understanding the genetic architecture of the human genome.",
        "gwRVIS is a genome-wide measure that quantifies the intolerance of genomic regions to variation. It is derived using a sliding-window approach applied to whole genome sequencing data from 62,784 individuals. gwRVIS highlights regions with reduced variation, thereby distinguishing genes known to be associated with Mendelian diseases and identifying ultra-conserved non-coding elements as highly intolerant compared to more variation-tolerant coding regions.",
        "gwRVIS, or genome-wide residual variation intolerance score, is a metric developed using a sliding-window approach applied to whole genome sequencing data from a large cohort of individuals. It serves to differentiate between genes associated with Mendelian diseases and more tolerant coding regions. Furthermore, gwRVIS identifies ultra-conserved non-coding elements as the most intolerant regions within the human genome.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a bioinformatic tool used in biomedicine. It helps identify genes associated with Mendelian diseases by distinguishing them from more variation-tolerant regions within the Consensus Coding Sequence (CCDS) regions. Additionally, it highlights ultra-conserved non-coding elements as the most variation-intolerant regions in the human genome.",
        "gwRVIS is a genome-wide residual variation intolerance score that identifies regions in the genome intolerant to variation, aiding in distinguishing disease-related genes from more tolerant regions.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a computational method developed to assess genomic variation tolerance by analyzing whole genome sequencing data from 62,784 individuals. Using a sliding-window approach, gwRVIS can distinguish Mendelian disease genes from more tolerant coding sequence (CCDS) regions and identifies ultra-conserved non-coding elements as the most intolerant regions in the human genome. Unlike traditional conservation-based methods, gwRVIS provides a novel way to capture human-lineage constraint information across genomic sequences.",
        "The genome-wide residual variation intolerance score (gwRVIS) applies a sliding-window approach to whole genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. gwRVIS captures previously inaccessible human-lineage constraint information.",
        "gwRVIS is a metric used to assess the intolerance of genomic regions to genetic variations. It distinguishes between Mendelian disease genes, which are less tolerant of mutations, and CCDS (Conserved Coding Sequence) regions, which are more tolerant due to their critical roles in basic functions across species. Additionally, gwRVIS highlights ultra conserved non coding elements as the most intolerant regions in the human genome, indicating that variations in these areas are likely to have significant consequences. This tool helps identify genes and genomic regions prone to disease involvement based on their inability to tolerate mutations.",
        "gwRVIS (Genome-Wide Residual Variation Intolerance Score) is a metric, part of the JARVIS deep learning model, used to quantify genomic intolerance to variation. Derived from 62,784 individuals\u0027 whole genome sequencing data, it excels in distinguishing Mendelian disease genes from tolerant regions and identifying ultra-conserved non-coding elements, outperforming other human lineage-specific scores in prioritizing non-coding regions and classifying pathogenic variants.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a key component of the JARVIS model, introduced through studies that analyzed whole genome sequencing data from 62,784 individuals using a sliding-window approach. This score effectively distinguishes Mendelian disease genes from more tolerant regions and notably highlights ultra-conserved non-coding elements as the most intolerant regions within the human genome. By applying this method, gwRVIS captures previously inaccessible information regarding human-lineage constraint, thereby enhancing our understanding of the non-coding genome\u0027s functional aspects and its potential implications in disease pathology.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a sliding-window analysis tool applied to whole genome sequencing data from 62,784 individuals, which effectively identifies intolerant genomic regions. gwRVIS successfully distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome, providing valuable insights into human-lineage constraint information.",
        "gwRVIS is the genome-wide residual variation intolerance score, which distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome.",
        "gwRVIS stands for genome-wide residual variation intolerance score. It is constructed by applying a sliding-window approach to whole genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome.",
        "gwRVIS is a genome-wide residual variation intolerance score that applies a sliding-window approach to whole genome sequencing data from 62,784 individuals to distinguish Mendelian disease genes from more tolerant regions and highlight ultra-conserved non-coding elements as the most intolerant regions in the human genome.",
        "gwRVIS, or the genome-wide residual variation intolerance score, is a metric introduced as part of the JARVIS model. It uses a sliding-window approach on whole genome sequencing data from 62,784 individuals to identify regions that are intolerant to variation. Essentially, gwRVIS distinguishes Mendelian disease genes from more tolerant genomic regions and pinpoints ultra-conserved non-coding elements as the most intolerant parts of the genome.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a novel metric developed to assess the intolerance to variation across the human genome. It employs a sliding-window approach to analyze whole genome sequencing data from a large cohort of 62,784 individuals. gwRVIS effectively distinguishes between Mendelian disease genes, which exhibit low tolerance to variation, and more tolerant regions, such as the Consensus Coding Sequence (CCDS) regions. Notably, it identifies ultra-conserved non-coding elements as the most intolerant areas in the genome. By capturing previously inaccessible information regarding human lineage constraints, gwRVIS enhances the understanding of the non-coding genome and aids in prioritizing non-coding regions for further study.",
        "gwRVIS (genome-wide residual variation intolerance score) is a computational metric developed using a sliding-window approach applied to whole genome sequencing data from 62,784 individuals. It identifies genomic regions intolerant to genetic variation, distinguishing Mendelian disease-associated genes from more tolerant CCDS (Consensus Coding Sequence) regions. gwRVIS highlights ultra-conserved non-coding elements as the most intolerant regions in the genome, capturing human-lineage-specific functional constraints. It complements conservation-agnostic models like JARVIS by providing evolutionary insights into non-coding genomic regions, enhancing prioritization of pathogenic variants and understanding of disease mechanisms.",
        "gwRVIS (genome-wide residual variation intolerance score) is a computational metric that assesses genomic regions\u0027 intolerance to genetic variation. It applies a sliding-window approach to whole-genome sequencing data from 62,784 individuals, identifying regions with reduced variation tolerance. This score distinguishes Mendelian disease-associated genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as highly intolerant. Unlike conservation-based methods, gwRVIS captures human-lineage-specific constraint, aiding in prioritizing pathogenic non-coding variants and enhancing understanding of genomic functional elements.",
        "gwRVIS is a genome-wide residual variation intolerance score that quantifies the intolerance of genomic regions to variation using a sliding-window approach applied to whole genome sequencing data from 62,784 individuals. It distinguishes regions associated with Mendelian diseases from more tolerant coding sequence segments and highlights ultra-conserved non-coding elements as some of the most intolerant regions in the human genome. gwRVIS captures human-lineage-specific constraint information and serves as a key component in constructing the deep learning model JARVIS, which prioritizes non-coding regions and aids in classifying pathogenic single-nucleotide and structural variants.",
        "gwRVIS is a genome-wide residual variation intolerance score that uses a sliding-window approach on whole genome sequencing data to highlight regions intolerant to variation. It distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome.",
        "gwRVIS (genome-wide residual variation intolerance score) is a method that uses a sliding-window approach to whole genome sequencing data from a large number of individuals to identify regions of the genome that are intolerant to variation. It distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. gwRVIS is a key component of the JARVIS model, a comprehensive deep learning model for prioritizing non-coding regions in the human genome.",
        "gwRVIS, or genome-wide residual variation intolerance score, is a score that applies a sliding-window approach to whole genome sequencing data from a large number of individuals. It distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. It captures previously inaccessible human-lineage constraint information and enhances our understanding of the non-coding genome.",
        "The genome-wide residual variation intolerance score (gwRVIS) applies a sliding-window approach to whole genome sequencing data to distinguish Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome.",
        "gwRVIS is a genome-wide residual variation intolerance score introduced in constructing JARVIS, a comprehensive deep learning model for prioritizing non-coding regions. It applies a sliding-window approach to whole genome sequencing data from 62,784 individuals and distinguishes Mendelian disease genes from more tolerant CCDS regions while highlighting ultra-conserved non-coding elements as the most intolerant regions in the human genome.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a novel metric developed to assess the intolerance to variation across the human genome. It employs a sliding-window approach to analyze whole genome sequencing data from 62,784 individuals. gwRVIS effectively differentiates between Mendelian disease genes, which exhibit low tolerance to variation, and more tolerant regions such as the Consensus Coding Sequence (CCDS). Additionally, it identifies ultra-conserved non-coding elements as the most intolerant regions in the genome. By capturing human-lineage constraint information, gwRVIS enhances the understanding of non-coding genomic regions and their potential relevance to human disease.",
        "The genome-wide residual variation intolerance score (gwRVIS) is generated by applying a sliding-window approach to whole genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. gwRVIS captures previously inaccessible human-lineage constraint information.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a novel metric introduced in the construction of JARVIS, designed to prioritize non-coding regions by integrating intolerance to genetic variation. It employs a sliding-window approach on whole-genome sequencing data from 62,784 individuals to distinguish Mendelian disease genes from more tolerant coding-complete database (CCDS) regions and identify ultra-conserved non-coding elements as the most intolerant areas in the human genome.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a metric derived from whole-genome sequencing data of 62,784 individuals using a sliding-window approach. It quantifies the intolerance of genomic regions to variations, highlighting areas where mutations are less likely due to potential harmful effects. gwRVIS distinguishes Mendelian disease genes as more intolerant compared to CCDS regions and identifies ultra-conserved non-coding elements as highly intolerant. This tool enhances understanding of human genome constraints, particularly in non-coding regions, aiding in identifying functionally important areas.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a novel metric developed to assess the intolerance to variation across the human genome. It employs a sliding-window approach to analyze whole genome sequencing data from 62,784 individuals. gwRVIS effectively distinguishes Mendelian disease genes from more tolerant regions, specifically highlighting ultra-conserved non-coding elements as the most intolerant areas. This score captures previously inaccessible information regarding human lineage constraint, enhancing our understanding of the non-coding genome and its role in genetic diseases.",
        "The genome-wide residual variation intolerance score (gwRVIS) was introduced in constructing JARVIS, applying a sliding-window approach to whole genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS regions. It highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. gwRVIS captures previously inaccessible human-lineage constraint information and will enhance our understanding of the non-coding genome.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a novel metric developed to assess the intolerance to variation across the human genome. It employs a sliding-window approach to analyze whole genome sequencing data from 62,784 individuals. gwRVIS effectively distinguishes Mendelian disease genes from more tolerant regions, specifically highlighting ultra-conserved non-coding elements as the most intolerant areas. This score captures previously inaccessible information regarding human lineage constraints, enhancing our understanding of the non-coding genome and its role in disease.",
        "gwRVIS, or genome-wide residual variation intolerance score, is a metric developed to assess the intolerance of genomic regions to variation. It is constructed using a sliding-window approach applied to whole genome sequencing data from 62,784 individuals. This score helps distinguish Mendelian disease genes from more tolerant regions in the human genome and identifies ultra-conserved non-coding elements as highly intolerant.",
        "gwRVIS (genome-wide residual variation intolerance score) is a metric, often derived via a sliding-window approach within the JARVIS deep learning model, quantifying a genome\u0027s intolerance to variation. It prioritizes non-coding regions, highlighting disease-associated genes and ultra-conserved elements, and notably outperforms conservation-based scores in identifying pathogenic variants.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a novel metric introduced to assess the intolerance to variation across the human genome. It employs a sliding-window approach applied to whole genome sequencing data from 62,784 individuals. gwRVIS effectively distinguishes Mendelian disease genes from more tolerant coding regions (CCDS) and identifies ultra-conserved non-coding elements as the most intolerant regions. This score captures previously inaccessible information regarding human-lineage constraints, enhancing our understanding of the non-coding genome and its role in disease relevance.",
        "gwRVIS (Genome-wide Residual Variation Intolerance Score) is a metric derived from a sliding-window approach on whole-genome sequencing data of 62,784 individuals. It is utilized within the JARVIS model to prioritize non-coding genomic regions based on their intolerance to variations. Notably, gwRVIS effectively distinguishes disease genes and highlights ultra-conserved non-coding elements as the most intolerant regions, all without relying on evolutionary conservation, thus offering a unique and valuable tool for understanding the functional importance of the non-coding genome.",
        "JARVIS is a deep learning model that integrates intolerance to variation, functional genomic annotations and primary genomic sequence to prioritize non-coding regions. gwRVIS is a sliding-window approach that applies to whole genome sequencing data from 62,784 individuals to distinguish Mendelian disease genes from more tolerant CCDS regions and highlight ultra-conserved non-coding elements as the most intolerant regions in the human genome.",
        "gwRVIS (genome-wide residual variation intolerance score) is a novel scoring system that measures the intolerance of non-coding regions in the human genome to genetic variation. It was developed by applying a sliding-window approach to whole-genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS (Consensus CDS) regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. This score captures previously inaccessible human-lineage constraint information, providing valuable insights into the non-coding genome.",
        "gwRVIS (genome-wide residual variation intolerance score) is a measure developed by applying a sliding-window approach to whole genome sequencing data from 62,784 individuals. It quantifies intolerance to variation across the human genome, distinguishing Mendelian disease genes from more tolerant CCDS (Consensus Coding Sequence) regions. Notably, gwRVIS identifies ultra-conserved non-coding elements as the most intolerant regions in the human genome. This score captures human-lineage constraint information that was previously inaccessible and contributes to the construction of JARVIS, a comprehensive deep learning model for prioritizing non-coding regions. gwRVIS enhances our understanding of the non-coding genome by providing insights into evolutionary constraint that are specific to the human lineage.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a measure developed using whole genome sequencing data from 62,784 individuals. It employs a sliding-window approach to assess regions of the genome for their intolerance to variation. gwRVIS effectively distinguishes Mendelian disease genes from more tolerant regions and identifies ultra-conserved non-coding elements as particularly intolerant areas in the human genome. This method provides valuable insights into genomic sensitivity and enhances understanding of non-coding regions.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a metric introduced as part of the development of JARVIS, a deep learning model for prioritizing non-coding regions in the human genome. gwRVIS utilizes a sliding-window approach applied to whole genome sequencing data from 62,784 individuals. This score is designed to identify regions of the genome that are intolerant to variation, effectively distinguishing Mendelian disease genes from more variation-tolerant CCDS regions. It also highlights ultra-conserved non-coding elements as the most intolerant regions, thereby capturing previously inaccessible human-lineage constraint information. This makes gwRVIS a valuable tool for understanding the non-coding genome and its impact on human health.",
        "gwRVIS (Genome-Wide Residual Variation Intolerance Score) is a metric derived from a sliding-window analysis of whole genome sequencing data from approximately 62,784 individuals, quantifying genomic regions\u0027 intolerance to variation. It effectively distinguishes disease-associated genes, including Mendelian disease genes, and highlights ultra-conserved non-coding elements as the most intolerant regions, enhancing the understanding of the human genome\u0027s constraint.",
        "The genome-wide residual variation intolerance score (gwRVIS) is a measure derived from analyzing whole-genome sequencing data of 62,784 individuals using a sliding-window approach. This method identifies regions of the genome that are less tolerant to variations, indicating potential functional importance. gwRVIS effectively distinguishes Mendelian disease genes, which show lower tolerance to variation, from more tolerant CCDS regions. Furthermore, it highlights ultra-conserved non-coding elements as among the most intolerant regions in the human genome, suggesting their critical roles despite not coding for proteins. By capturing previously inaccessible constraint information, gwRVIS enhances our understanding of genomic function and disease association.",
        "gwRVIS stands for genome-wide Residual Variation Intolerance Score. It is a metric developed using a sliding-window approach applied to whole genome sequencing data from 62,784 individuals. The score quantifies the intolerance of genomic regions to variation, indicating regions where mutations are less likely to be tolerated. This intolerance often correlates with functionally important areas of the genome. gwRVIS effectively distinguishes Mendelian disease genes from more tolerant coding regions and identifies ultra-conserved non-coding elements as some of the most intolerant regions.",
        "gwRVIS is a genome-wide residual variation intolerance score, calculated via a sliding-window approach on 62,784 whole genome sequencing datasets, to quantify genomic regions\u0027 sensitivity to variations, highlighting disease-associated and ultra-conserved non-coding elements.",
        "The genome-wide residual variation intolerance score (gwRVIS) is introduced by applying a sliding-window approach to whole genome sequencing data from 62,784 individuals. gwRVIS distinguishes Mendelian disease genes from more tolerant CCDS regions and highlights ultra-conserved non-coding elements as the most intolerant regions in the human genome. gwRVIS captures previously inaccessible human-lineage constraint information.",
        "gwRVIS, or genome-wide residual variation intolerance score, is a metric introduced in the construction of JARVIS. It is calculated using a sliding-window approach applied to whole genome sequencing data from a large cohort of individuals. gwRVIS is designed to quantify the intolerance to variation across the genome. It effectively distinguishes Mendelian disease genes from more tolerant CCDS regions. Furthermore, it identifies ultra-conserved non-coding elements as the most intolerant regions in the human genome. gwRVIS captures previously inaccessible human-lineage constraint information, contributing to a better understanding of the non-coding genome."
      ]
    },
    {
      "body": "What is the mechanism of action of NTLA-2002?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38142864",
        "http://www.ncbi.nlm.nih.gov/pubmed/38366937",
        "http://www.ncbi.nlm.nih.gov/pubmed/38294975",
        "http://www.ncbi.nlm.nih.gov/pubmed/39445704"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1384,
          "offsetInEndSection": 1604,
          "text": "NTLA-2002 is an investigational in vivo clustered regularly interspaced short palindromic repeats/Cas9-based therapy designed to knock out the prekallikrein-coding KLKB1 gene in hepatocytes; a phase 1/2 study is ongoing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38142864"
        },
        {
          "offsetInBeginSection": 1080,
          "offsetInEndSection": 1141,
          "text": "Lastly, NTLA-2002 is an investigational gene-editing therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38366937"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 266,
          "text": "NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38294975"
        },
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 415,
          "text": "NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39445704"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 390,
          "text": "ng attacks. NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1), with the goal of lifelong control of angioedema attacks after a ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38294975"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 601,
          "text": "NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1), with the goal of lifelong control of angioedema attacks after a single dose.METHODS: In this phase 1 dose-escalation portion of a combined phase 1-2 trial of NTLA-2002 in adults with hereditary angioedema, we administered NTLA-2002 at a single dose of 25 mg, 50 mg, or 75 mg.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38294975"
        },
        {
          "offsetInBeginSection": 119,
          "offsetInEndSection": 335,
          "text": " NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39445704"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 401,
          "text": " NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1), with the goal of lifelong control of angioedema attacks after a single dose",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38294975"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 265,
          "text": "ng attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39445704"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 304,
          "text": "ng attacks. NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding k",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38294975"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 315,
          "text": "ng attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding k",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39445704"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 253,
          "text": "ng attacks. NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38294975"
        }
      ],
      "type": "summary",
      "id": "67e56e1e18b1e36f2e0000af",
      "ideal_answer": [
        "NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks."
      ]
    },
    {
      "body": "Why is Calabash chalk consumed by pregnant women?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30598913",
        "http://www.ncbi.nlm.nih.gov/pubmed/27263602",
        "http://www.ncbi.nlm.nih.gov/pubmed/22977372",
        "http://www.ncbi.nlm.nih.gov/pubmed/38544793",
        "http://www.ncbi.nlm.nih.gov/pubmed/31489087"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 173,
          "text": " Calabash chalk (Nzu) is a geophagic material, consumed by many pregnant women and breastfeeding mothers as remedy for morning sickness in most African countries. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30598913"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 174,
          "text": " Calabash chalk is a naturally occurring mineral consumed among the Nigerian community for pleasure and commonly by pregnant women as a remedy for morning sickness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27263602"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 178,
          "text": "alabash chalk is a naturally occurring mineral consumed by members of some Nigerian communities for pleasure and by pregnant women as a remedy for morning sickness. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Calabash chalk (CaC) is an aluminium silicate hydroxide compound with heavy metal constituents, making it a potential neurotoxicant. Pregnant women often consume CaC as an antiemetic, which may interfere with the normal development of the foetal brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38544793"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "OBJECTIVE: Calabash chalk (Nzu) is a geophagic material, consumed by many pregnant women and breastfeeding mothers as remedy for morning sickness in most African",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30598913"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 176,
          "text": "Calabash chalk is a naturally occurring mineral consumed by members of some Nigerian communities for pleasure and by pregnant women as a remedy for morning sickness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977372"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 173,
          "text": "Calabash chalk is a naturally occurring mineral consumed among the Nigerian community for pleasure and commonly by pregnant women as a remedy for morning sickness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27263602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "OBJECTIVE: Calabash chalk (Nzu) is a geophagic material, consumed by many pregnant women and breastfeeding mothers as remedy for morning sickness in most African countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30598913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "BACKGROUND: Calabash chalk is a naturally occurring mineral consumed by members of some Nigerian communities for pleasure and by pregnant women as a remedy for morning sickness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "INTRODUCTION: \"Calabar chalk\" is a lead-laden pica mostly consumed by pregnant women worldwide as a remedy for morning sickness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489087"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 171,
          "text": " Calabash chalk (Nzu) is a geophagic material, consumed by many pregnant women and breastfeeding mothers as remedy for morning sickness in most African countries",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30598913"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 127,
          "text": " \"Calabar chalk\" is a lead-laden pica mostly consumed by pregnant women worldwide as a remedy for morning sickness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489087"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 173,
          "text": " Calabash chalk is a naturally occurring mineral consumed among the Nigerian community for pleasure and commonly by pregnant women as a remedy for morning sickness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27263602"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 128,
          "text": "\"Calabar chalk\" is a lead-laden pica mostly consumed by pregnant women worldwide as a remedy for morning sickness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489087"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "OBJECTIVE: Calabash chalk (Nzu) is a geophagic material, consumed by many pregnant women and breastfeeding mothers as remedy for morning sickness in most Africa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30598913"
        }
      ],
      "type": "factoid",
      "id": "67e133f118b1e36f2e00006f",
      "ideal_answer": [
        "Calabash chalk (Nzu) is a geophagic material, consumed by many pregnant women and breastfeeding mothers as remedy for morning sickness in most African countries.",
        "Calabash chalk is consumed by pregnant women as an antiemetic to alleviate nausea and vomiting.",
        "Calabash chalk is consumed by pregnant women as a remedy for morning sickness.",
        "Calabash chalk is a naturally occurring mineral consumed by members of some Nigerian communities for pleasure and by pregnant women as a remedy for morning sickness.",
        "Calabash chalk is consumed by pregnant women as a remedy for morning sickness. However, the use of these products, especially by pregnant women, should be discouraged.",
        "Calabash chalk is consumed by pregnant women as a remedy for morning sickness and for pleasure.",
        "Calabash chalk is consumed by pregnant women primarily to alleviate morning sickness and nausea. In many communities, traditional beliefs also support its use as a natural supplement to provide essential minerals like calcium and iron and to help prevent mineral deficiencies or intestinal infections.",
        "Calabash chalk is consumed by pregnant women as a remedy for morning sickness and for its antinausea or therapeutic effects.",
        "Pregnant women consume Calabash chalk primarily as a remedy for morning sickness.",
        "Calabash chalk is consumed by pregnant women as an antiemetic.",
        "Calabash chalk is consumed by pregnant women as a natural remedy to alleviate the symptoms of morning sickness, which is common during pregnancy. It is a naturally occurring mineral used within some Nigerian communities not only for pleasure but also specifically to help relieve nausea and vomiting associated with early pregnancy.",
        "Calabash chalk (Nzu) is consumed by pregnant women in many African countries as a culturally accepted remedy for morning sickness, despite lacking scientific evidence for its efficacy and posing significant risks to both maternal health and pregnancy outcomes, with potential adverse effects on the fetus at certain exposure levels.",
        "Calabash chalk is a naturally occurring mineral that is consumed by pregnant women as a remedy for morning sickness.",
        "Calabash chalk is consumed by pregnant women for relief of morning sickness.",
        "Calabash chalk (Nzu) is a geophagic material traditionally consumed by pregnant women and breastfeeding mothers in many African countries to alleviate symptoms of morning sickness. This practice is rooted in cultural traditions and perceived therapeutic benefits for managing nausea and vomiting during pregnancy.",
        "Calabash chalk is consumed by pregnant women as a remedy for morning sickness, as it acts as an antiemetic.",
        "Calabash chalk is consumed by pregnant women as a remedy for morning sickness. It is also consumed for pleasure by members of some communities.",
        "Calabash chalk is consumed by pregnant women in many African countries, particularly in Nigeria, as a traditional remedy for morning sickness, which is a common condition experienced during pregnancy.",
        "Pregnant women consume Calabash chalk primarily as a remedy for morning sickness, serving as an antiemetic.",
        "Calabash chalk (Nzu) is consumed by pregnant women primarily as a remedy for morning sickness, particularly in African communities. It is also used by breastfeeding mothers and sometimes consumed for pleasure.",
        "Calabash chalk is consumed by pregnant women as an antiemetic remedy for morning sickness, as described in the provided snippets from Nigerian communities.",
        "Calabash chalk is consumed by pregnant women in many African countries as a remedy for morning sickness.",
        "Pregnant women consume Calabash chalk to alleviate morning sickness.",
        "Calabash chalk is traditionally consumed by pregnant women to alleviate morning sickness, but its use is not recommended due to associated adverse effects on maternal health, pregnancy outcomes, hematological parameters, and the gastro-oesophageal tract, as evidenced by studies in Wistar rats.",
        "Calabash chalk, consumed by pregnant women in many African cultures, is believed to alleviate morning sickness symptoms, but its use poses a health risk due to its heavy metal content, potentially harming fetal brain development.",
        "Calabash chalk is consumed by pregnant women as a remedy for morning sickness .",
        "Calabash chalk is consumed by pregnant women as remedy for morning sickness.",
        "Pregnant women consume Calabash chalk primarily as a remedy for morning sickness, a common condition during early pregnancy. This practice is prevalent in many African countries where the chalk is valued for its effectiveness in alleviating nausea and discomfort associated with morning sickness.",
        "Pregnant women consume Calabash chalk primarily as a traditional remedy to alleviate morning sickness. Despite containing potentially harmful substances like heavy metals, it remains a commonly used natural solution in many African communities for managing nausea during early pregnancy.",
        "Pregnant women in many African countries consume Calabash chalk (Nzu) primarily as a traditional remedy to alleviate morning sickness, despite a lack of scientific evidence supporting its efficacy and concerns over its potential toxicity, which may adversely affect maternal health, pregnancy outcomes, and gastrointestinal health.",
        "Calabash chalk is consumed by pregnant women primarily as a remedy for morning sickness. Studies indicate that in many African countries, it is commonly used during pregnancy to alleviate nausea, serving as an antiemetic.",
        "Calabash chalk is consumed by pregnant women primarily as a remedy for morning sickness.",
        "Calabash chalk is consumed by pregnant women primarily as a remedy for morning sickness. It is also consumed for pleasure. Geophagy, the practice of craving non-food substances like calabash chalk, is common among pregnant women. Some consume clay for medicinal purposes or to allay hunger.",
        "Calabash chalk is consumed by pregnant women primarily as a remedy for morning sickness. It is a naturally occurring mineral that is commonly used among the Nigerian community for this purpose."
      ],
      "exact_answer": [
        [
          "antiemetic"
        ]
      ]
    },
    {
      "body": "Country with the highest incidence of African Trypanosomiasis (sleeping sickness).",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26047813",
        "http://www.ncbi.nlm.nih.gov/pubmed/35137146",
        "http://www.ncbi.nlm.nih.gov/pubmed/25125985"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 175,
          "text": "For the past three decades, the Democratic Republic of the Congo (DRC) has been the country reporting the highest number of cases of human African trypanosomiasis ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26047813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "BACKGROUND: For the past three decades, the Democratic Republic of the Congo (DRC) has been the country reporting the highest number of cases of human African trypanosom",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26047813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "text": "Human African trypanosomiasis (HAT), despite considerable progress in the control, is still occurring in many countries in both west and central African regions. The HAT situation in the Republic of Congo has always been overshadowed by its neighbor the Democratic Republic of Congo where over 60% of all HAT cases occur.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35137146"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 694,
          "text": "The gambiense form currently assumes that 98% of the cases are declared; the Democratic Republic of the Congo is the most affected country, with more than 75% of the gambiense cases declared.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25125985"
        }
      ],
      "id": "67e288d518b1e36f2e00007c",
      "ideal_answer": [
        "The country with highest incidence of sleeping sickness is the Democratic Republic of the Congo.",
        "The country with the highest incidence of African Trypanosomiasis (sleeping sickness) is the Democratic Republic of Congo (DRC).",
        "The Democratic Republic of the Congo (DRC) has been the country reporting the highest number of cases of human African trypanosomiasis (HAT).",
        "The Democratic Republic of the Congo (DRC) has the highest incidence of African Trypanosomiasis, commonly known as sleeping sickness, due to its geographical location within the endemic range of the tsetse fly vector.",
        "The Democratic Republic of the Congo (DRC) has the highest incidence of Human African Trypanosomiasis (HAT), also known as sleeping sickness. In 2012, DRC accounted for 84% of all HAT cases reported at the continental level. The country has a number of foci with high disease prevalence. Other African countries where sleeping sickness is prevalent include Guinea, Sudan, and Angola.",
        "The country with the highest incidence of African Trypanosomiasis (sleeping sickness) is Guinea. Based on clinical study and epidemiological data collected between 1991 and 1997, Guinea has the highest morbidity, particularly in the natural region of Lower Guinea, with an incidence rate of 23.4 per 100,000 people. In the context of animal prevalence, Tanzania has the highest incidence, with an ovine prevalence of 91.67% as reported in a systematic review and meta-analysis of small ruminant and porcine trypanosomiasis prevalence in sub-Saharan Africa from 1986 to 2018.",
        "The country with the highest incidence of African Trypanosomiasis (sleeping sickness) is the Democratic Republic of the Congo (DRC). Over the past three decades, the DRC has consistently reported the highest number of cases. Factors contributing to this include historical political instability and limited healthcare resources in the region. While other countries like Uganda and Angola have also experienced outbreaks, they do not report as many cases as the DRC. Therefore, based on available information and reputable sources, the DRC remains the country with the highest incidence of this disease.",
        "The Democratic Republic of the Congo (DRC) has the highest incidence of human African trypanosomiasis (HAT), also known as sleeping sickness. In 2012, the DRC accounted for 84% of all cases reported at the continental level. Other areas with significant occurrences of sleeping sickness include Sudan, Angola, and Guinea, with evidence of increasing spread in Uganda.",
        "The Democratic Republic of the Congo (DRC) has historically reported the highest number of cases of African Trypanosomiasis, also known as sleeping sickness. This disease, caused by a parasite transmitted by tsetse flies, is primarily found in sub-Saharan Africa. The DRC\u0027s high incidence rate can be attributed to factors such as conflict, instability, and challenges in healthcare delivery and disease surveillance. While other countries like Uganda or Angola may experience outbreaks, the DRC consistently stands out with the highest reported cases. Therefore, based on available data and historical context, the Democratic Republic of the Congo is recognized as the country with the highest incidence of African Trypanosomiasis.",
        "The Democratic Republic of Congo has the highest incidence of African Trypanosomiasis, also known as sleeping sickness, among all countries. This is due to the presence of the tsetse fly, the vector for the parasite that causes the disease, in large areas of the country. The disease is endemic in many parts of the country, particularly in the eastern and western regions. The high incidence can be attributed to factors such as poor access to healthcare, lack of awareness, and the vast, remote areas where the disease is prevalent, making it difficult to control."
      ],
      "exact_answer": [
        [
          "Democratic Republic of the Congo"
        ]
      ]
    },
    {
      "body": "What is the role of the tumor microenvironment in the MES-like state of glioblastoma multiforme (GBM)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36054938",
        "http://www.ncbi.nlm.nih.gov/pubmed/34087162",
        "http://www.ncbi.nlm.nih.gov/pubmed/38398231",
        "http://www.ncbi.nlm.nih.gov/pubmed/35205179",
        "http://www.ncbi.nlm.nih.gov/pubmed/37692522",
        "http://www.ncbi.nlm.nih.gov/pubmed/39629136",
        "http://www.ncbi.nlm.nih.gov/pubmed/34087163",
        "http://www.ncbi.nlm.nih.gov/pubmed/31646100",
        "http://www.ncbi.nlm.nih.gov/pubmed/35669791",
        "http://www.ncbi.nlm.nih.gov/pubmed/34956900",
        "http://www.ncbi.nlm.nih.gov/pubmed/36969175",
        "http://www.ncbi.nlm.nih.gov/pubmed/36123598",
        "http://www.ncbi.nlm.nih.gov/pubmed/38479552",
        "http://www.ncbi.nlm.nih.gov/pubmed/37439870"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "The mesenchymal subtype of glioblastoma is thought to be determined by both cancer cell-intrinsic alterations and extrinsic cellular interactions, but remains poorly understood. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087162"
        },
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 675,
          "text": "We demonstrate that macrophages induce a transition of glioblastoma cells into mesenchymal-like (MES-like) states. This effect is mediated, both in vitro and in vivo, by macrophage-derived oncostatin M (OSM) that interacts with its receptors (OSMR or LIFR) in complex with GP130 on glioblastoma cells and activates STAT3. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087162"
        },
        {
          "offsetInBeginSection": 866,
          "offsetInEndSection": 1197,
          "text": "Additionally, trajectory and regulatory network inference implied a PN to MES cell state transition regulated by specific transcriptional factor (TF) regulons. Importantly, we discovered that glycoprotein nonmetastatic B (GPNMB) derived from macrophages played a crucial role in this transition through immune cell-tumor interplay.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36054938"
        },
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 953,
          "text": "We demonstrate that macrophages induce a transition of glioblastoma cells into mesenchymal-like (MES-like) states. This effect is mediated, both in vitro and in vivo, by macrophage-derived oncostatin M (OSM) that interacts with its receptors (OSMR or LIFR) in complex with GP130 on glioblastoma cells and activates STAT3. We show that MES-like glioblastoma states are also associated with increased expression of a mesenchymal program in macrophages and with increased cytotoxicity of T cells, highlighting extensive alterations of the immune microenvironment with potential therapeutic implications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087162"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Crosstalk between glioblastoma and tumor microenvironment drives proneural-mesenchymal transition through ligand-receptor interactions.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37692522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "HDAC7 drives glioblastoma to a mesenchymal-like state via LGALS3-mediated crosstalk between cancer cells and macrophages.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39629136"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Epithelial-mesenchymal transition is the main way in which glioma-associated microglia/macrophages promote glioma progression.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36969175"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 1270,
          "text": "Mesenchymal-1-like (MES1-like) and mesenchymal-2-like (MES2-like) tumor cells correlated strongly with immune infiltration and chronic hypoxia niche responses. We identified four subsets of tumor-associated macrophages/microglia (TAMs), among which TAM-1 co-opted both acute and chronic hypoxia-response signatures, implicated in tumor angiogenesis, invasion, and poor prognosis. MES-like GBM cells expressed the highest number of M2-promoting ligands compared to other cellular states while all six states were associated with TAM M2-type polarization and immunosuppression via a set of 10 ligand-receptor signaling pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35669791"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 1023,
          "text": "Mesenchymal-1-like (MES1-like) and mesenchymal-2-like (MES2-like) tumor cells correlated strongly with immune infiltration and chronic hypoxia niche responses. We identified four subsets of tumor-associated macrophages/microglia (TAMs), among which TAM-1 co-opted both acute and chronic hypoxia-response signatures, implicated in tumor angiogenesis, invasion, and poor prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35669791"
        },
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 466,
          "text": "We demonstrate that macrophages induce a transition of glioblastoma cells into mesenchymal-like (MES-like) states",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087162"
        },
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 674,
          "text": "We demonstrate that macrophages induce a transition of glioblastoma cells into mesenchymal-like (MES-like) states. This effect is mediated, both in vitro and in vivo, by macrophage-derived oncostatin M (OSM) that interacts with its receptors (OSMR or LIFR) in complex with GP130 on glioblastoma cells and activates STAT3.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087162"
        },
        {
          "offsetInBeginSection": 861,
          "offsetInEndSection": 1233,
          "text": "LGALS3 secretion, which then bind to the membrane protein ITGB1 on GSC and MDMs in the autocrine and paracrine manners to facilitate the transformation of the mesenchymal phenotype of GBM and the M2 polarization of MDMs, respectively. In turn, LGALS3 could also secreted by M2 MDMs to promote MES transition of GBM in a paracrine manner, creating a positive feedback loop.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39629136"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 364,
          "text": "Macrophages are the major non-neoplastic infiltrates in the glioblastoma microenvironment. In this issue of Cancer Cell, Hara et al. (2021) demonstrate that macrophages induce a transition of glioblastoma cells into the mesenchymal-like cellular state associated with an increased mesenchymal program in macrophages themselves and enhanced cytotoxicity of T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087163"
        },
        {
          "offsetInBeginSection": 714,
          "offsetInEndSection": 1255,
          "text": "Different types of tumor cell in GBM possessed different hypoxia status, and MES-like subtype was under a more severe hypoxia condition than other subtypes. Hypoxia also induced MES-like signature gene expression within each tumor cell, which could stimulate tumor cell proliferation and invasion by regulating cell-cell communication. Additionally, hypoxia inhibited immune cell activity in the tumor microenvironment by inducing macrophage phenotype polarization and upregulating immune-inhibited cell-cell interaction within immune cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34956900"
        }
      ],
      "id": "67ea538318b1e36f2e0000dd",
      "ideal_answer": [
        "The MES-like state of glioblastoma is thought to be determined by both cancer cell-intrinsic alterations and extrinsic cellular interactions but remains poorly understood. A few studies have uncovered the interplay between macrophages and glioblastoma cells, where macrophages can induce a transition into the MES-like cell state. This effect can be mediated through multiple factors, such as macrophage-derived oncostatin M (OSM) and glycoprotein nonmetastatic B (GPNMB).",
        "The tumor microenvironment, particularly macrophages, plays a critical role in inducing the mesenchymal-like (MES-like) state of glioblastoma through complex cellular interactions. Macrophages facilitate this transition by secreting oncostatin M (OSM), which interacts with OSM or LIF receptors and GP130 on glioblastoma cells, activating STAT3 signaling. Additionally, macrophage-derived glycoprotein nonmetastatic B (GPNMB) is crucial in mediating the transition from proneural (PN) to mesenchymal states through immune cell-tumor interactions, highlighting the significant impact of extrinsic cellular communication in glioblastoma progression.",
        "The tumor microenvironment, specifically macrophages, plays a crucial role in inducing a mesenchymal-like (MES-like) state in glioblastoma multiforme (GBM) cells. This transition is mediated by macrophage-derived factors, notably GPNMB and oncostatin M, which interact with glioblastoma cell receptors, activating STAT3. These interactions facilitate the transition from a proneural to a MES state and modulate T cell activity. Targeting GPNMB-high macrophages offers a promising therapeutic strategy for controlling GBM plasticity and enhancing T cell-based immunotherapy, providing a novel approach to treating this aggressive brain cancer.",
        "Studies demonstrate that the tumor microenvironment, specifically macrophages, play a crucial role in inducing a transition of glioblastoma cells into mesenchymal-like (MES-like) states. This effect is mediated by macrophage-derived oncostatin M (OSM), which interacts with its receptors on glioblastoma cells and activates STAT3, both in vitro and in vivo. Furthermore, the transition from proneural to MES cell state is regulated by specific transcriptional factor regulons, and glycoprotein nonmetastatic B (GPNMB) derived from macrophages is also involved in this process through immune cell-tumor interplay. Overall, these findings highlight the importance of the tumor microenvironment, particularly macrophage-glioblastoma cell interactions, in determining the MES-like state of glioblastoma multiforme (GBM).",
        "The tumor microenvironment, particularly macrophages, plays a crucial role in inducing the mesenchymal-like state in glioblastoma cells through multiple mechanisms. Macrophages secrete oncostatin M (OSM), which interacts with OSMR/LIFR receptors and activates STAT3 signaling, as well as produce GPNMB, both of which drive the transition of glioblastoma cells into a mesenchymal-like state through immune cell-tumor interactions.",
        "The role of the tumor microenvironment in the MES-like state of glioblastoma multiforme (GBM) involves macrophages inducing a transition of glioblastoma cells into mesenchymal-like states through the secretion of oncostatin M (OSM) and glycoprotein nonmetastatic B (GPNMB). This transition is mediated by the interaction of OSM with its receptors on glioblastoma cells, activating STAT3 and leading to a PN to MES cell state transition regulated by specific transcriptional factor (TF) regulons.",
        "The tumor microenvironment, particularly macrophages, is involved in the transition of glioblastoma cells into a mesenchymal-like state, which is a poorly understood process in GBM. Macrophages secrete oncostatin M (OSM), which interacts with glioblastoma cells and activates STAT3, leading to this transition. Additionally, glycoprotein nonmetastatic B (GPNMB) derived from macrophages also plays a crucial role in this process through immune cell-tumor interplay, highlighting the importance of the tumor microenvironment in shaping the behavior of glioblastoma cells.",
        "The tumor microenvironment, especially through macrophages, plays a key role in inducing the MES-like state in GBM. Macrophages secrete factors such as oncostatin M (OSM) that interact with receptors on glioblastoma cells to activate STAT3, and they also produce glycoprotein nonmetastatic B (GPNMB), both of which contribute to the transition of glioblastoma cells into a mesenchymal-like state.",
        "The tumor microenvironment (TME) drives the mesenchymal (MES)-like state in glioblastoma multiforme (GBM) through interactions with immune cells, particularly macrophages. Macrophages secrete factors such as **oncostatin M (OSM)** and **glycoprotein nonmetastatic B (GPNMB)**, which bind to receptors (OSMR/LIFR-GP130) on GBM cells, activating **STAT3 signaling** and transcriptional networks that promote the transition to a mesenchymal phenotype. This MES-like state is associated with increased aggressiveness, therapy resistance, and tumor progression. Macrophage-derived signals are critical regulators of this cellular reprogramming.",
        "The tumor microenvironment (TME), particularly tumor-associated macrophages, drives the mesenchymal (MES)-like state in glioblastoma multiforme (GBM). Macrophages secrete factors like **oncostatin M (OSM)** and **glycoprotein nonmetastatic B (GPNMB)** that induce transcriptional reprogramming in GBM cells. OSM binds OSMR/LIFR-GP130 receptors on tumor cells, activating STAT3 signaling to promote MES transition. Similarly, GPNMB facilitates immune-tumor interactions, enabling proneural (PN) to MES state shifts. These interactions highlight the TME\u0027s critical role in shaping aggressive, therapy-resistant MES phenotypes through extrinsic signaling and transcriptional regulation.",
        "The tumor microenvironment provides extrinsic signals that establish the mesenchymal-like state in glioblastoma by promoting cell state transitions, invasion, and immune evasion. Macrophages release factors such as oncostatin M and glycoprotein nonmetastatic B that, through activation of STAT3, drive a proneural-to-mesenchymal switch. Tumor-associated fibroblasts contribute by inducing epithelial-mesenchymal transition processes, which further enhance tumor aggressiveness. Additional influences, including hypoxia, epigenetic immunoediting, and DGC-mediated macrophage infiltration, reshape the immune landscape by upregulating immune checkpoints like PD-1/PD-L1 and cytokines that support the MES-like state. These combined effects create a supportive niche that not only promotes tumor progression and invasion but also facilitates resistance to therapy.",
        "Macrophages in the tumor microenvironment drive the MES-like state in GBM by releasing oncostatin M (OSM), which interacts with receptors like OSMR or LIFR in complex with GP130 to activate STAT3. Additionally, macrophage-derived glycoprotein nonmetastatic B (GPNMB) plays a crucial role in promoting this cell state transition through immune cell-tumor interactions.",
        "The tumor microenvironment plays a crucial role in shaping the MES-like state of glioblastoma multiforme (GBM) through interactions between cancer cells and their surrounding cellular elements. Specifically, macrophages within the tumor microenvironment release proteins such as oncostatin M (OSM) and glycoprotein nonmetastatic B (GPNMB). These factors interact with receptors like OSMR or LIFR in conjunction with GP130 on GBM cells, activating signaling pathways such as STAT3. This activation leads to transcriptional changes that induce a mesenchymal transition in GBM cells, enhancing their invasiveness and resistance to treatment. Thus, the tumor microenvironment is not merely a passive setting but an active participant in driving GBM\u0027s aggressive behavior through immune cell-tumor interplay.",
        "The tumor microenvironment plays a crucial role in the MES-like state of glioblastoma multiforme (GBM) by inducing a transition of glioblastoma cells into this state through the action of macrophages. Macrophages secrete oncostatin M (OSM) which interacts with its receptors on glioblastoma cells and activates STAT3, leading to the MES-like state. Additionally, glycoprotein nonmetastatic B (GPNMB) derived from macrophages is also involved in this transition through immune cell-tumor interplay.",
        "The tumor microenvironment (TME) significantly influences the transformation of glioblastoma multiforme (GBM) into its mesenchymal-like (MES-like) state through interactions with immune cells such as macrophages. Macrophages secrete oncostatin M (OSM), which binds to receptors on GBM cells, activating STAT3 signaling and promoting the MES transition. Additionally, glycoprotein nonmetastatic B (GPNMB) derived from macrophages facilitates this process through immune-tumor interplay. These extrinsic factors, combined with intrinsic cellular changes, drive GBM into a more invasive and aggressive phenotype, highlighting the TME\u0027s active role in shaping cancer progression.",
        "The tumor microenvironment plays a significant role in transforming glioblastoma multiforme (GBM) cells into a mesenchymal-like (MES-like) state, which is associated with increased invasiveness and resistance to therapy. Key contributors include macrophages within the tumor environment, which secrete factors such as oncostatin M (OSM) and glycoprotein nonmetastatic B (GPNMB). These factors interact with GBM cells, activating signaling pathways like STAT3, thereby promoting the transition to a mesenchymal phenotype. This process highlights the active role of the tumor microenvironment in shaping GBM aggressiveness, suggesting potential therapeutic targets aimed at disrupting these interactions.",
        "The tumor microenvironment plays a crucial role in the transition of glioblastoma multiforme (GBM) cells to a mesenchymal-like (MES-like) state. This transition is significantly influenced by interactions with macrophages, which induce the MES-like state through the secretion of oncostatin M (OSM). OSM interacts with its receptors on GBM cells, activating the STAT3 signaling pathway. Additionally, the presence of GPNMB derived from macrophages is implicated in the immune cell-tumor interplay, facilitating the transition and potentially affecting T cell activation. Overall, the tumor microenvironment, particularly through macrophage signaling, contributes to the plasticity of GBM and alters the immune landscape, suggesting that targeting these interactions may offer new therapeutic strategies.",
        "The tumor microenvironment plays a critical role in inducing mesenchymal-like (MES-like) states in glioblastoma cells, primarily through interactions with macrophages. Macrophage-derived oncostatin M (OSM) interacts with receptors on glioblastoma cells to activate STAT3, facilitating this transition both in vitro and in vivo. Additionally, glycoprotein nonmetastatic B (GPNMB), also derived from macrophages, is crucial for the immune cell-tumor interplay that regulates the PN to MES cell state transition.",
        "The tumor microenvironment (TME) plays a crucial role in inducing the mesenchymal-like (MES-like) state of glioblastoma multiforme (GBM). Specifically, macrophages within the TME release factors such as oncostatin M (OSM) and glycoprotein nonmetastatic B (GPNMB). These factors interact with receptors on GBM cells, activating signaling pathways like STAT3. This activation leads to a transition from a proneural (PN) to a mesenchymal state, characterized by changes in gene expression regulated by specific transcription factors. Thus, the TME, through these macrophage-derived signals, significantly influences the aggressive behavior of GBM by promoting this molecular subtype transition.",
        "The tumor microenvironment plays a critical role in the transition of glioblastoma multiforme (GBM) cells to a mesenchymal-like (MES-like) state, which is associated with aggressive invasion and therapeutic resistance. Macrophages are key players in this process, as they induce the transition of glioblastoma cells into MES-like states through the secretion of oncostatin M (OSM). This interaction occurs via OSM binding to its receptors on glioblastoma cells, activating the STAT3 signaling pathway. Additionally, glycoprotein nonmetastatic B (GPNMB) derived from macrophages is crucial for this transition, highlighting the importance of immune cell-tumor interplay.\n\nThe alterations in the immune microenvironment are significant, as MES-like glioblastoma states correlate with increased expression of mesenchymal programs in macrophages and enhanced cytotoxicity of T cells. This suggests that the tumor microenvironment not only influences tumor propagation but also modifies immune responses, potentially impacting therapeutic outcomes. Overall, the interplay between glioblastoma cells and the tumor microenvironment, particularly through macrophage interactions, is essential for understanding the progression and treatment resistance of GBM.",
        "The tumor microenvironment (TME) plays a crucial role in influencing the mesenchymal-like (MES-like) state in glioblastoma multiforme (GBM). Macrophages within the TME induce a transition of glioblastoma cells into MES-like states through the secretion of oncostatin M (OSM), which interacts with specific receptors on glioblastoma cells, activating the STAT3 signaling pathway. This transition is also regulated by transcriptional factor regulons and involves immune cell-tumor interactions, particularly the role of glycoprotein nonmetastatic B (GPNMB) derived from macrophages. Additionally, the TME alters the immune landscape, increasing the expression of mesenchymal programs in macrophages and enhancing T cell cytotoxicity, which can have therapeutic implications. Overall, the TME significantly contributes to the aggressive characteristics and therapeutic resistance associated with the MES-like subtype of GBM.",
        "The tumor microenvironment, primarily through macrophage-glioblastoma cell interactions involving GPNMB and oncostatin M (OSM), plays a crucial role in inducing and maintaining the MES-like state of glioblastoma multiforme (GBM), influencing its aggressiveness and therapeutic responsiveness. This process, which includes the transition of GBM cells from a PN to a MES-like state, also alters the immune landscape by impeding T cell activation. Targeting GPNMB-high macrophages offers a potential therapeutic strategy to control GBM plasticity and enhance the effectiveness of T cell-based immunotherapy, providing new avenues for GBM treatment.",
        "The tumor microenvironment plays a crucial role in inducing a mesenchymal-like (MES-like) state in glioblastoma multiforme (GBM). Macrophages in the microenvironment secrete oncostatin M (OSM), which interacts with its receptors on GBM cells, activating STAT3 and promoting the MES-like transition. Additionally, glycoprotein nonmetastatic B (GPNMB) derived from macrophages also contributes to this transition through immune cell-tumor interplay. These findings suggest that the tumor microenvironment, particularly macrophages, plays a key role in regulating the MES-like state of GBM cells, which is a critical aspect of glioblastoma biology and therapy resistance.",
        "The tumor microenvironment plays a critical role in inducing the mesenchymal-like (MES-like) state in glioblastoma multiforme (GBM) through specific cellular interactions. Macrophages within the tumor microenvironment are key drivers of this transition, secreting factors that influence cancer cell phenotypes. Specifically, macrophage-derived oncostatin M (OSM) interacts with receptors (OSMR or LIFR) in complex with GP130 on glioblastoma cells, activating STAT3 signaling and promoting the mesenchymal transition both in vitro and in vivo. Additionally, glycoprotein nonmetastatic B (GPNMB) produced by macrophages has been identified as crucial in facilitating this transition through immune cell-tumor interplay. These findings highlight how the tumor microenvironment, particularly through macrophage-cancer cell interactions, contributes to the mesenchymal subtype of glioblastoma, which was previously understood to be determined by both cancer cell-intrinsic alterations and extrinsic cellular interactions.",
        "The tumor microenvironment plays a significant role in inducing the mesenchymal-like (MES-like) state of glioblastoma multiforme (GBM), with macrophages being key contributors. Macrophage-derived oncostatin M (OSM) interacts with receptors such as OSMR or LIFR, along with GP130, on GBM cells, leading to STAT3 activation and promoting the transition to a MES-like state. Additionally, glycoprotein nonmetastatic B (GPNMB), secreted by macrophages, facilitates this transition through interactions between immune cells and tumor cells. These cellular interplays within the tumor microenvironment are crucial for regulating GBM progression, highlighting the importance of understanding such mechanisms in developing therapeutic strategies.",
        "The tumor microenvironment plays a critical role in the mesenchymal-like (MES-like) state of glioblastoma multiforme (GBM) by facilitating interactions between cancer cells and immune cells, particularly macrophages. Macrophages in the tumor microenvironment induce the MES-like transition of glioblastoma cells. This induction is mediated by macrophage-derived oncostatin M (OSM), which interacts with its receptors on glioblastoma cells, leading to the activation of STAT3, a signaling pathway that promotes the MES-like state. Additionally, glycoprotein nonmetastatic B (GPNMB) from macrophages significantly contributes to this transition, emphasizing the importance of immune cell-tumor interplay in shaping the tumor phenotype.",
        "The tumor microenvironment (TME) plays a crucial role in inducing a mesenchymal-like (MES-like) state in glioblastoma multiforme (GBM). Specifically, macrophages within the TME secrete factors such as oncostatin M (OSM) and glycoprotein nonmetastatic B (GPNMB), which interact with receptors on GBM cells. These interactions activate signaling pathways like STAT3, promoting a transition to a mesenchymal phenotype. This process highlights how immune-tumor interplay within the TME can influence tumor behavior and progression.",
        "The tumor microenvironment, primarily through macrophages, plays a pivotal role in inducing and maintaining the mesenchymal-like (MES-like) state in glioblastoma multiforme (GBM). Key macrophage-derived factors, including GPNMB and oncostatin M, modulate this state by influencing GBM cell transitions and T cell activity within the tumor microenvironment, offering potential targets for therapeutic intervention to impact the aggressiveness and treatment responsiveness of GBM.",
        "Studies have shown that the tumor microenvironment, particularly macrophages, induces a mesenchymal-like state in glioblastoma multiforme (GBM) by secreting oncostatin M (OSM). OSM interacts with its receptors on GBM cells, activating STAT3 and promoting this transition. Additionally, glycoprotein nonmetastatic B (GPNMB) from macrophages contributes through immune-tumor interactions. These findings highlight the tumor microenvironment\u0027s role in driving GBM\u0027s mesenchymal subtype.",
        "The tumor microenvironment, particularly macrophages, plays a critical role in inducing a mesenchymal-like (MES) state in glioblastoma cells through the secretion of oncostatin M (OSM) and glycoprotein nonmetastatic B (GPNMB), which interact with specific receptors on glioblastoma cells to activate STAT3 and regulate transcription factor regulons, facilitating the PN to MES cell state transition."
      ]
    },
    {
      "body": "Does loss of the tumour suppressor LKB1/STK11 contribute to cancer resistance?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39048991"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39048991"
        },
        {
          "offsetInBeginSection": 499,
          "offsetInEndSection": 1401,
          "text": "Although LKB1 loss alone accelerates energy expenditure, unexpectedly we find that it additionally alters regulation of the key energy homeostasis maintenance player leptin (LEP), further increasing the energetic burden and exposing a vulnerable point; acquired sensitivity to the identified compounds. We show that compound treatment stabilises Hypoxia-inducible factor 1-alpha (HIF1A) by antagonising Von Hippel-Lindau (VHL)-mediated HIF1A ubiquitination, driving LEP hyperactivation. Importantly, we demonstrate that sensitivity to piceatannol/tyrphostin 23 epistatically relies on a HIF1A-LEP-Uncoupling Protein 2 (UCP2) signaling axis lowering cellular energy beyond survival, in already challenged LKB1-deficient cells. Thus, we uncover a pivotal metabolic vulnerability of LKB1-deficient tumours, which may be therapeutically exploited using our identified compounds as mitochondrial uncouplers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39048991"
        }
      ],
      "id": "67dc41a618b1e36f2e000059",
      "ideal_answer": [
        "No. Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy.",
        "No, loss of the tumour suppressor LKB1/STK11 does not contribute to cancer resistance.",
        "No. Loss of the tumour suppressor LKB1/STK11 does not contribute to cancer resistance but instead sensitizes cancer cells to mitochondrial uncouplers via a leptin-mediated mechanism, as its loss exposes a vulnerability that can be targeted therapeutically.",
        "No, loss of the tumour suppressor LKB1/STK11 does not contribute to cancer resistance, but rather it exposes vulnerabilities that can be targeted for therapy.",
        "No, loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy. It uncovers a pivotal metabolic vulnerability of LKB1-deficient tumours, which may be therapeutically exploited using identified compounds as mitochondrial uncouplers.",
        "No. The loss of LKB1/STK11 creates a metabolic vulnerability in the tumor cells, making them sensitive to mitochondrial uncouplers rather than contributing to resistance.",
        "No, loss of LKB1/STK11 does not confer cancer resistance but instead exposes a metabolic vulnerability. LKB1-deficient tumors exhibit dysregulated leptin signaling and heightened energy expenditure, rendering them sensitive to mitochondrial uncouplers (e.g., piceatannol/tyrphostin 23). These compounds exploit the HIF1α-LEP-UCP2 axis to further reduce cellular energy, leading to selective lethality in LKB1-deficient cancer cells. Thus, LKB1 loss creates a targetable weakness rather than resistance.",
        "No. Loss of LKB1/STK11 does not contribute to cancer resistance; instead, it exposes a pivotal metabolic vulnerability by increasing leptin-mediated energy demand, which makes LKB1-deficient tumours sensitive to mitochondrial uncouplers.",
        "No. The loss of the tumour suppressor LKB1/STK11 does not contribute to cancer resistance; rather, it creates a metabolic vulnerability that can be therapeutically exploited.",
        "No, loss of the tumour suppressor LKB1/STK11 does not contribute to cancer resistance. Instead, it uncovers a vulnerability in cancer cells that can be exploited for targeted therapy. The loss of LKB1 leads to increased energy expenditure and altered regulation of leptin, making cancer cells more sensitive to mitochondrial uncouplers. This sensitivity is mediated by the HIF1A-LEP-UCP2 signaling axis, which lowers cellular energy beyond survival in LKB1-deficient cells. Therefore, LKB1 loss creates a therapeutic opportunity for targeted cancer therapy using mitochondrial uncouplers.",
        "No, the loss of the tumor suppressor LKB1/STK11 does not contribute to cancer resistance. Instead, it exposes a vulnerability in cancer cells, making them more sensitive to certain treatments that target mitochondrial function.",
        "No, loss of LKB1/STK11 does not contribute to cancer resistance; instead, it exposes a metabolic vulnerability that can be targeted with specific therapies, potentially increasing susceptibility of LKB1-deficient cancer cells.",
        "No. Loss of the tumour suppressor LKB1/STK11 does not contribute to cancer resistance. Instead, it uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What is the target of Tulisokibart?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39321363"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "BACKGROUND: Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "BACKGROUND: Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "BACKGROUND: Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321363"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 180,
          "text": " Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "BACKGROUND: Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcera",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "BACKGROUND: Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321363"
        }
      ],
      "type": "factoid",
      "id": "67e6bdc618b1e36f2e0000c2",
      "ideal_answer": [
        "Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis."
      ],
      "exact_answer": [
        [
          "tumor necrosis factor-like cytokine 1A"
        ]
      ]
    },
    {
      "body": "What are the symptoms of Landau-Klettner syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27355396",
        "http://www.ncbi.nlm.nih.gov/pubmed/17557221",
        "http://www.ncbi.nlm.nih.gov/pubmed/2453356",
        "http://www.ncbi.nlm.nih.gov/pubmed/9477609",
        "http://www.ncbi.nlm.nih.gov/pubmed/2479399",
        "http://www.ncbi.nlm.nih.gov/pubmed/12022077",
        "http://www.ncbi.nlm.nih.gov/pubmed/2478319",
        "http://www.ncbi.nlm.nih.gov/pubmed/15309183",
        "http://www.ncbi.nlm.nih.gov/pubmed/1373338",
        "http://www.ncbi.nlm.nih.gov/pubmed/11993733",
        "http://www.ncbi.nlm.nih.gov/pubmed/25487625",
        "http://www.ncbi.nlm.nih.gov/pubmed/12529574",
        "http://www.ncbi.nlm.nih.gov/pubmed/20637551",
        "http://www.ncbi.nlm.nih.gov/pubmed/10073434",
        "http://www.ncbi.nlm.nih.gov/pubmed/23622211",
        "http://www.ncbi.nlm.nih.gov/pubmed/23377356",
        "http://www.ncbi.nlm.nih.gov/pubmed/32850252",
        "http://www.ncbi.nlm.nih.gov/pubmed/16876018",
        "http://www.ncbi.nlm.nih.gov/pubmed/1700953",
        "http://www.ncbi.nlm.nih.gov/pubmed/8660018",
        "http://www.ncbi.nlm.nih.gov/pubmed/16356025",
        "http://www.ncbi.nlm.nih.gov/pubmed/9430313",
        "http://www.ncbi.nlm.nih.gov/pubmed/11730147",
        "http://www.ncbi.nlm.nih.gov/pubmed/21955111",
        "http://www.ncbi.nlm.nih.gov/pubmed/12364957",
        "http://www.ncbi.nlm.nih.gov/pubmed/34887295",
        "http://www.ncbi.nlm.nih.gov/pubmed/32257722",
        "http://www.ncbi.nlm.nih.gov/pubmed/18184944",
        "http://www.ncbi.nlm.nih.gov/pubmed/24868479",
        "http://www.ncbi.nlm.nih.gov/pubmed/15866429",
        "http://www.ncbi.nlm.nih.gov/pubmed/1558514",
        "http://www.ncbi.nlm.nih.gov/pubmed/9195666"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 45,
          "offsetInEndSection": 147,
          "text": "children with Landau-Kleffner syndrome (LKS), the most prominent feature of which is acquired aphasia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27355396"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 167,
          "text": "Landau-Kleffner syndrome is characterised by acquired aphasia and encephalographic alterations that may or may not be accompanied by epileptic seizures. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557221"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Landau-Kleffner syndrome is characterized by long-lasting acquired aphasia associated with seizures and EEG abnormaliti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2453356"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "The Landau-Kleffner syndrome consists in the association of an aphasia acquired during childhood or adolescence after a period of normal development, accompanied by epileptic fits and, sometimes, psychological disturbances. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9477609"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 123,
          "text": "he association of unusual types of aphasia and epilepsy (Landau-Kleffner syndrome) has been described in three children. T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2479399"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 371,
          "text": "INTRODUCTION: The Landau Kleffner syndrome (SLK) is associated with paroxystic alterations of the electroencephalogram which are intensified during sleep, with acquired aphasia and epilepsy, in 75 83% of the cases. The syndrome is associated with other features, such as personality disorders presenting as autistic behaviour, cognitive regression and in some cases, moto",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12022077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 365,
          "text": "The Landau-Kleffner syndrome is an unusual childhood disorder characterised by an acquired aphasia and a paroxysmal electroencephalographic abnormality with spike and spike and wave discharges which are mostly multifocal and unstable in their course of evolution. Two accessory symptoms are frequently observed: psychomotor or behavioural disturbances and epilepsy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2478319"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Landau-Kleffner syndrome (LKS), or acquired epileptiform aphasia, is an epilepsy syndrome involving progressive neuropsychological impairment related to the appearance of paroxysmal electroencephalograph (EEG) activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15309183"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "text": "Four children with Landau-Kleffner syndrome were studied over a six year period. They presented with acquired aphasia, epilepsy, and focal or generalized EEG discharges which were exacerbated during sleep. In addition, cerebral angiography demonstrated isolated arteritis of some branches of the carotid arteries in all cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1373338"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Landau-Kleffner syndrome is characterized by a complex group of symptoms including deterioration in language skills, seizures, and abnormal electroencephalography findings.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529574"
        },
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 351,
          "text": "Landau-Kleffner syndrome is an unusual childhood disorder characterised by an acquired aphasia and a paroxysmal electroencephalographic abnormality with spike and spike and wave discharges which are mostly multifocal and unstable in their course of evolution. Two accessory symptoms are frequently observed: psychomotor or behavioural disturbances",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2478319"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 376,
          "text": "Landau-Kleffner syndrome is one of several language disorders associated with epilepsy or epileptiform abnormalities on EEG.  Ultimately, these patients understand little or nothing of what they hear. Two thirds have behavioral abnormalities and close to 75% have seizures.  Brain computerized tomography and MRI are normal, EEG changes show characteristic epileptiform change",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23377356"
        },
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 254,
          "text": "Landau-Kleffner syndrome consists in the association of an aphasia acquired during childhood or adolescence after a period of normal development, accompanied by epileptic fits and, sometimes, psychological disturbances. The appearance of the symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9477609"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Landau-Kleffner syndrome (LKS) is a rare childhood neurological condition that causes developmental regression, loss of language skills and abnormal electroencephalogram (EEG) patterns.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32850252"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "INTRODUCTION: Landau-Kleffner Syndrome is a rare childhood disorder characterized by acquired aphasia and epileptiform EEG ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25487625"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "INTRODUCTION: The Landau Kleffner syndrome (SLK) is associated with paroxystic alterations of the electroencephalogram which are intensified during sleep, with acquired aphasia and epilepsy, in 75 83% of the cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12022077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "The Landau-Kleffner syndrome is an unusual childhood disorder characterised by an acquired aphasia and a paroxysmal electroencephalographic abnormality with spike and spike and wave discharges which are mostly multifocal and unstable in their course of evolution.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2478319"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 259,
          "text": " Landau-Kleffner Syndrome is a rare childhood disorder characterized by acquired aphasia and epileptiform EEG abnormalities. Hyperactivity and attention problems are common in LKS, and symptoms of Autism Spectrum Disorders (ASDs) may also coexist",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25487625"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 435,
          "text": "Landau-Kleffner syndrome is characterized by a complex group of symptoms including deterioration in language skills, seizures, and abnormal electroencephalography findings. A six-year-old male patient had aphasia for three years and generalized tonic-clonic epileptic seizures for two years. Pure-tone audiometry and auditory brain-stem response audiometry findings were normal. He had verbal auditory agnosia rather than true aphasia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529574"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 383,
          "text": "The Landau-Kleffner syndrome consists of the association of paroxysmal EEG abnormalities, more marked during sleep, acquired aphasia usually of receptive type, and epileptic seizures in three quarters of cases. Additional features include behavioral disturbances that may even present with autistic features, cognitive regression of variable degree, and sometimes motor difficulties,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10797930"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "text": "Landau-Kleffner syndrome is characterized by epileptic aphasia associated with electrical status epilepticus of slow wave sleep. A 5-year-old female, who had manifested normal developmental progress, was referred with principal complaints of fluctuating sensory aphasia and bizarre behavior during the preceding 4 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16876018"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Five children with Landau-Kleffner syndrome (epilepsy, acquired aphasia, and continuous spike-wave discharges during sleep), were treated with antiepileptic drugs (AEDs), sleep-modifying drugs, and corticosteroids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1700953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 307,
          "text": "Landau-Kleffner syndrome (LKS) is an acquired epileptic aphasia disorder in which children, usually 3-8 years of age who have developed age-appropriate speech, experience language regression with verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and sometimes overt seizures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16356025"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Landau-Kleffner syndrome (acquired epileptic aphasia) is characterized by language regression following normal acquisition of language skills, accompanied by epileptiform abnormalities on the electroencephalogram (EEG) with or without clinical seizures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430313"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "The Landau-Kleffner syndrome consists in the association of an aphasia acquired during childhood or adolescence after a period of normal development, accompanied by epileptic fits and, sometimes, psychological disturbances.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9477609"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306,
          "text": "Landau-Kleffner syndrome (LKS) is an acquired epileptic aphasia disorder in which children, usually 3-8 years of age who have developed age-appropriate speech, experience language regression with verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and sometimes overt seizures",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16356025"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Landau-Kleffner syndrome (acquired epileptic aphasia) is characterized by language regression following normal acquisition of language skills, accompanied by epileptiform abnormalities on the electroencephalogram (EEG) with or without clinical seizures",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430313"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 372,
          "text": "Landau-Kleffner syndrome (LKS) is described by the International Classification of Epileptic Syndromes since 1985 as a constellation of clinical and electrographic signs, including acquired aphasia, regression of language milestones and seizures, along with sleep-activated paroxysms on electroencephalogram which can progress to electrographic status epilepticus of sleep",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34887295"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "The Landau-Kleffner syndrome (LKS), formerly known as acquired epileptic aphasia, is a rare syndrome that typically presents in early childhood with language regression and seizures",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32257722"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 298,
          "text": "Landau-Kleffner syndrome (LKS) is an acquired epileptic aphasia caused by a lesion in the speech centers of the cerebral cortex during a critical period of childhood development. Characteristics of LKS include language deterioration, seizure disorders, and severe electroencephalogram abnormalities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8660018"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "INTRODUCTION: Landau-Kleffner syndrome is characterised by acquired aphasia and encephalographic alterations that may or may not be accompanied by epil",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557221"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Landau-Kleffner syndrome is characterized by a regression in receptive language",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Landau-Kleffner syndrome is characterized by a complex group of symptoms including deterioration in language skills, seizures, and abnormal electroencephalography findings",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529574"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Acquired epileptic aphasia (AEA, or Landau-Kleffner syndrome) is a unique condition in which children can lose oral language (OL) comprehension and expression for a prolonged period",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730147"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Landau-Kleffner syndrome (LKS) is a rare childhood disorder characterized by acquired aphasia and epilepsy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24868479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 373,
          "text": "Landau-Kleffner syndrome (LKS) is described by the International Classification of Epileptic Syndromes since 1985 as a constellation of clinical and electrographic signs, including acquired aphasia, regression of language milestones and seizures, along with sleep-activated paroxysms on electroencephalogram which can progress to electrographic status epilepticus of sleep.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34887295"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Landau-Kleffner syndrome is characterized by epileptic aphasia associated with electrical status epilepticus of slow wave sleep.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16876018"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 365,
          "text": "Landau-Kleffner syndrome (LKS) is a childhood disorder characterized by an acquired aphasia that emerges in association with epileptiform electroencephalographic abnormalities. The language loss is often characterized by a severe disturbance of auditory language comprehension (verbal auditory agnosia) combined with a substantial disruption of expressive language.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Landau-Kleffner syndrome and its variants such as continuous Spike-Wave Discharge during Sleep (CSWS) are progressive epileptic encephalopathies of childhood. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15866429"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "We present six patients with acquired aphasia with convulsive disorder (Landau-Kleffner syndrome) and distill the main clinical features from a review of the recent literature. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1558514"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "The acquired epileptiform aphasias, with Landau-Kleffner\u0027s syndrome as the example, represent an important group of syndromes in our quest to understand the relationship between epilepsy, language, and behavior. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9195666"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Landau-Kleffner syndrome is one of several language disorders associated with epilepsy or epileptiform abnormalities on EEG.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23377356"
        },
        {
          "offsetInBeginSection": 575,
          "offsetInEndSection": 678,
          "text": "Landau-Kleffner syndrome (LKS) is a particular presentation where acquired aphasia is the core symptom.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23622211"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 417,
          "text": "Landau-Kleffner is now seen as the rare and severe end of a spectrum of cognitive-behavioural symptoms that can be seen in idiopathic (genetic) focal epilepsies of childhood, the benign end being the more frequent typical rolandic epilepsy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20637551"
        },
        {
          "offsetInBeginSection": 498,
          "offsetInEndSection": 722,
          "text": "Thus, patients with Landau-Kleffner syndrome show sequential and sometimes hierarchical language disorders beginning with sensory aphasia, followed by auditory agnosia, and finally word deafness during their disease process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10073434"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Landau-Kleffner syndrome is a rare, epileptiform disorder with a pathognomonic sudden aphasia, epilepsy, and electroencephalographic abnormalities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843226"
        },
        {
          "offsetInBeginSection": 71,
          "offsetInEndSection": 239,
          "text": "Landau-Kleffner syndrome is a rare disorder characterized by the combination of acquired aphasia and epileptic abnormalities like diffuse spikes-and-waves in sleep EEG.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9264933"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "INTRODUCTION: Landau-Kleffner syndrome is characterised by acquired aphasia and encephalographic alterations that may or may not be accompanied by epile",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557221"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Landau-Kleffner Syndrome is a rare childhood disorder which involves seizures and acquired aphasia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11993733"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 558,
          "text": "Landau-Kleffner syndrome (LKS) is a childhood disorder characterized by an acquired aphasia that emerges in association with epileptiform electroencephalographic abnormalities. The language loss is often characterized by a severe disturbance of auditory language comprehension (verbal auditory agnosia) combined with a substantial disruption of expressive language. Comorbid behavioral disturbances commonly involve hyperactivity and attentional problems but sometimes encompass a more pervasive pattern of difficulties resembling an autism spectrum disorder",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "The Landau-Kleffner syndrome consists in the association of an aphasia acquired during childhood or adolescence after a period of normal development, accompanied by epileptic fits and, sometimes, psychological disturbances",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9477609"
        },
        {
          "offsetInBeginSection": 699,
          "offsetInEndSection": 818,
          "text": "LKS is characterized by acquired aphasia, epilepsy, EEG abnormalities and behavioral changes, including autistic traits",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12364957"
        }
      ],
      "type": "list",
      "id": "67cf365781b1027333000023",
      "ideal_answer": [
        "Landau-Kleffner syndrome is characterised by acquired aphasia and encephalographic alterations that may or may not be accompanied by epileptic seizures.",
        "The symptoms of Landau-Kleffner syndrome include deterioration in language skills, seizures, abnormal electroencephalography findings, and verbal auditory agnosia.",
        "Landau-Kleffner syndrome is a rare childhood disorder characterized by acquired aphasia, epilepsy, and paroxysmal electroencephalographic abnormalities.",
        "Landau Kleffner syndrome is a rare neurological condition which affects language comprehension. It can be defined as a progressive decline in receptive language ability despite normal or near normal intelligence, speech output and sensorial function. Other characteristics include various degrees ofautism, severe epilepsy, and behavioral hyperactivity.",
        "Landau-Kleffner syndrome is a rare childhood disorder characterized by acquired aphasia, epilepsy, and paroxysmal EEG abnormalities.",
        "The symptoms of Landau-Kleffner syndrome include deterioration in language skills, seizures, abnormal electroencephalography findings, acquired aphasia, epileptic seizures, and verbal auditory agnosia.",
        "the symptoms of landau-kleffner syndrome include acquired aphasia, epilepsy, psychomotor or behavioural disturbances, and in some cases, seizures, and electroencephalographic abnormalities with spike and wave discharges.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, paroxysmal EEG abnormalities, epileptic seizures, and abnormal electroencephalography findings.",
        "The symptoms of Landau-Kleffner syndrome include seizures, acquired aphasia, and profound regression with loss of receptive and expressive language capabilities.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, paroxysmal EEG abnormalities, abnormal electroencephalography findings, verbal auditory agnosia, epilepsy, deterioration in language skills, seizures, and epileptic seizures.",
        "The symptoms of Landau-Kleffner syndrome include: acquired aphasia, verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and overt seizures. Children typically experience language regression and may have difficulties with understanding sounds in noisy environments.",
        "The symptoms of Landau-Kleffner syndrome include seizures, acquired aphasia, loss of receptive and expressive language capabilities, and various types of generalized seizures. Additionally, it may involve neuropsychological patterns such as frontal lobe syndrome, orofacial dyspraxia, and negative myoclonus.",
        "The symptoms of Landau-Kleffner syndrome include seizures, acquired aphasia, developmental language disturbance, and autistic features.",
        "The symptoms of Landau-Kleffner syndrome include deterioration in language skills, seizures, and abnormal EEG findings.",
        "The symptoms of Landau-Kleffner syndrome include seizures, acquired aphasia, developmental language disturbances, and potentially autistic features. The combination of these symptoms is characteristic of the disorder, which affects children with previously normal psychomotor development.",
        "Landau-Kleffner Syndrome symptoms include: \n  - Language Disorders: Acquired aphasia, auditory verbal agnosia, inarticulation, decreased speech, and word deafness.\n  - Epileptic Activity: Seizures and epileptiform EEG abnormalities.\n  - Behavioral/Cognitive Symptoms: Psychomotor/behavioral disturbances, attention problems, hyperactivity, ASD symptoms, sleep disturbances, emotional/behavioral problems, and in some cases, music processing deficits, social interaction difficulties, decreased eye contact, and stereotypic movements.",
        "Landau-Kleffner syndrome (LKS) is a rare childhood disorder characterized by acquired aphasia, epilepsy, and behavioral disturbances. The symptoms include:\n\n* Acquired aphasia: sudden or gradual loss of language ability, verbal auditory agnosia, and inarticulation\n* Epilepsy: seizures, partial motor seizures during sleep, atypical absence seizure, generalized tonic-clonic seizure\n* Behavioral disturbances: hyperactivity, attentional problems, autism spectrum disorder-like symptoms, retardation, poor motor coordination, hyperkinesia, and conduct problems\n\nAdditionally, LKS is often accompanied by severe electroencephalogram abnormalities, including sleep-activated paroxysms and electrographic status epilepticus of sleep. The age of onset typically ranges from 2 to 10.5 years old.\n\nIt\u0027s essential to note that the symptoms may vary in severity and presentation among individuals with LKS.",
        "Landau-Kleffner syndrome (LKS) is characterized by several distinct symptoms:\n\n1. Seizures: Seizures are a common symptom in individuals with LKS.\n2. Acquired Aphasia: Children with LKS experience a loss of previously acquired speech and language abilities, known as acquired epileptic aphasia. This aphasia often affects the receptive aspects of language, with a notable relationship between EEG abnormalities during sleep and deterioration in verbal comprehension. Expressive language involvement is more frequent in cases with prominent Rolandic spikes, as opposed to the typical verbal auditory agnosia seen in the syndrome.\n3. Electroencephalographic (EEG) Abnormalities: Abnormal EEG patterns, including electrographic status epilepticus in sleep or continuous spike-wave in slow-wave sleep, are associated with LKS. EEG abnormalities are also noted in relation to language deterioration.\n4. Behavioral and Cognitive Impairments: Behavioral and cognitive issues are also common in addition to language impairments.\n5. Case Studies: Specific patient case studies highlight the onset of symptoms such as seizures and language deterioration starting at age 4. Another case study emphasizes long-lasting acquired aphasia associated with seizures and EEG abnormalities. A study involving four children observed acquired epileptic aphasia.\n\nThese symptoms collectively define the clinical presentation of Landau-Kleffner syndrome.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, which is a loss of language ability, and epilepsy. Other symptoms may include hyperactivity, attention problems, and symptoms of Autism Spectrum Disorders (ASDs).",
        "The symptoms of Landau-Klettner syndrome are acquired aphasia, paroxysmal EEG abnormalities, epileptic seizures and verbal auditory agnosia.",
        "Landau-Kleffner syndrome is characterized by acquired aphasia and encephalographic alterations that may or may not be accompanied by epileptic seizures.",
        "Landau-Kleffner syndrome is characterized by long-lasting acquired aphasia associated with seizures and EEG abnormaliti",
        "Landau-Kleffner syndrome is characterized by acquired aphasia, epileptic seizures, EEG abnormalities, and psychological disturbances.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, seizures, encephalographic alterations, and sometimes psychological disturbances, which can occur in children after a period of normal development.",
        "Landau-Kleffner syndrome is mainly characterized by an acquired aphasia, often with epileptic seizures, abnormal EEG patterns, and sometimes psychological disturbances.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, epileptic seizures, EEG abnormalities, and psychological disturbances.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, EEG abnormalities, psychological disturbances, epileptic seizures, language regression, encephalographic alterations, and seizures.",
        "The symptoms of Landau-Klettner syndrome include acquired aphasia, epileptic seizures, and abnormal EEG changes, and it can sometimes be accompanied by psychological disturbances.",
        "Landau-Kleffner syndrome is characterized by acquired aphasia, epileptic seizures, and EEG abnormalities. The most prominent feature is the acquired aphasia, which is a loss of language skills that develops during childhood or adolescence after a period of normal development. The syndrome may also be accompanied by psychological disturbances.",
        "Landau-Kleffner syndrome (LKS) is a rare neurological disorder primarily characterized by acquired aphasia, which refers to the loss of language skills after a period of normal development. This condition typically manifests in children or adolescents. Key symptoms include:\n\n1. **Acquired Aphasia**: The most prominent feature, where affected individuals lose their ability to understand and use language effectively.\n\n2. **Seizures (Epileptic Fits)**: Many patients experience seizures, which can vary in type and severity.\n\n3. **EEG Abnormalities**: Electroencephalogram tests often reveal irregular brain activity patterns, supporting the diagnosis of LKS.\n\n4. **Psychological Disturbances**: Some individuals may exhibit behavioral problems or emotional difficulties alongside their language impairments.\n\nWhile seizures are common, they are not always present in every case of LKS. The combination of these symptoms helps in diagnosing the condition and differentiating it from other neurological disorders.",
        "Landau-Kleffner syndrome is characterized by acquired aphasia (loss of language skills) that develops during childhood or adolescence after a period of normal development. This is often accompanied by epileptic seizures and EEG abnormalities. Psychological disturbances may also occur in some cases.",
        "Landau-Kleffner syndrome (LKS) is characterized by symptoms such as acquired aphasia, epileptic seizures, EEG abnormalities, and sometimes psychological disturbances.",
        "Landau-Kleffner syndrome is characterized by long-lasting acquired aphasia associated with seizures and EEG abnormalities. It consists of an aphasia acquired during childhood or adolescence after a period of normal development, accompanied by epileptic fits and sometimes psychological disturbances.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, seizures, EEG abnormalities, expressive and receptive language problems, poor auditory processing, deficits in auditory working memory and verbal memory, poor reading fluency and comprehension, difficulty with mathematics, and attentional or behavioral problems.",
        "The symptoms of Landau-Kleffner syndrome include: acquired aphasia, seizures, EEG abnormalities, psychological disturbances, and developmental regression.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, seizures, and encephalographic alterations. Children may experience profound regression in language capabilities and may also exhibit psychological disturbances.",
        "Landau-Kleffner syndrome is characterized by acquired aphasia, often accompanied by epileptic seizures and EEG abnormalities. Additional symptoms may include auditory processing deficits, memory and language problems, attentional and behavioral issues, and academic difficulties, primarily affecting children after a period of normal development.",
        "The symptoms of Landau-Kleffner syndrome include acquired aphasia, seizures, and EEG abnormalities. Children may also experience psychological disturbances and developmental regression, affecting their language capabilities.",
        "Landau-Kleffner syndrome is characterized by acquired aphasia, often accompanied by epileptic seizures and EEG abnormalities, typically manifesting in childhood or adolescence after normal development. Psychological disturbances may also occur in some cases, but are not universally present.",
        "Landau-Kleffner syndrome is characterized by acquired aphasia and encephalographic alterations that may or may not be accompanied by epileptic seizures .",
        "Landau-Kleffner syndrome is characterized by long-lasting acquired aphasia associated with seizures and EEG abnormalities. The Landau-Kleffner syndrome consists in the association of an aphasia acquired during childhood or adolescence after a period of normal development, accompanied by epileptic fits and, sometimes, psychological disturbances.",
        "The symptoms of Landau-Kleffner syndrome (LKS) include acquired aphasia (loss of ability to understand or express speech), epileptic seizures, EEG abnormalities, and sometimes psychological disturbances. These symptoms typically develop in childhood or adolescence after a period of normal development.",
        "Landau-Kleffner syndrome is characterized by acquired aphasia (loss of ability to understand or express language) after a period of normal language development in childhood, epileptic seizures, and abnormal brain wave patterns on electroencephalogram (EEG). The main symptoms are acquired aphasia, seizures, and EEG abnormalities.",
        "Landau-Kleffner syndrome is characterized by acquired aphasia, epileptic seizures (affecting 60-100% of cases), and EEG abnormalities, often accompanied by cognitive and behavioral impairments including poor auditory processing, memory deficits, attentional problems, and academic difficulties, with symptoms varying in presence and severity across cases.",
        "Studies have shown that Landau-Kleffner syndrome is characterized by long-lasting acquired aphasia, which typically appears in children after a period of normal development. Key symptoms include epileptic seizures and EEG abnormalities, with some cases also presenting psychological disturbances.",
        "The symptoms of Landau-Kleffner syndrome are acquired aphasia, epileptic seizures, EEG abnormalities, psychological disturbances, and epilepsy."
      ],
      "exact_answer": [
        [
          "aphasia"
        ],
        [
          "EEG alterations"
        ],
        [
          "seizure"
        ]
      ]
    },
    {
      "body": "Consequences of environmental exposure to lead poisoning.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18585827",
        "http://www.ncbi.nlm.nih.gov/pubmed/8757239",
        "http://www.ncbi.nlm.nih.gov/pubmed/28440982",
        "http://www.ncbi.nlm.nih.gov/pubmed/39277976",
        "http://www.ncbi.nlm.nih.gov/pubmed/39365032",
        "http://www.ncbi.nlm.nih.gov/pubmed/39676704",
        "http://www.ncbi.nlm.nih.gov/pubmed/37031386",
        "http://www.ncbi.nlm.nih.gov/pubmed/15742678",
        "http://www.ncbi.nlm.nih.gov/pubmed/34058086",
        "http://www.ncbi.nlm.nih.gov/pubmed/12962248",
        "http://www.ncbi.nlm.nih.gov/pubmed/12041847",
        "http://www.ncbi.nlm.nih.gov/pubmed/12926603",
        "http://www.ncbi.nlm.nih.gov/pubmed/38856075",
        "http://www.ncbi.nlm.nih.gov/pubmed/7941534",
        "http://www.ncbi.nlm.nih.gov/pubmed/18436472",
        "http://www.ncbi.nlm.nih.gov/pubmed/22911483",
        "http://www.ncbi.nlm.nih.gov/pubmed/39412324",
        "http://www.ncbi.nlm.nih.gov/pubmed/39740545",
        "http://www.ncbi.nlm.nih.gov/pubmed/39680744",
        "http://www.ncbi.nlm.nih.gov/pubmed/20058837",
        "http://www.ncbi.nlm.nih.gov/pubmed/39639084",
        "http://www.ncbi.nlm.nih.gov/pubmed/39284488",
        "http://www.ncbi.nlm.nih.gov/pubmed/39284084",
        "http://www.ncbi.nlm.nih.gov/pubmed/39689108",
        "http://www.ncbi.nlm.nih.gov/pubmed/27837574",
        "http://www.ncbi.nlm.nih.gov/pubmed/30647514",
        "http://www.ncbi.nlm.nih.gov/pubmed/9300927",
        "http://www.ncbi.nlm.nih.gov/pubmed/17718907",
        "http://www.ncbi.nlm.nih.gov/pubmed/17707511",
        "http://www.ncbi.nlm.nih.gov/pubmed/1776155",
        "http://www.ncbi.nlm.nih.gov/pubmed/18219078",
        "http://www.ncbi.nlm.nih.gov/pubmed/26677413",
        "http://www.ncbi.nlm.nih.gov/pubmed/32570851",
        "http://www.ncbi.nlm.nih.gov/pubmed/39086983",
        "http://www.ncbi.nlm.nih.gov/pubmed/34558053",
        "http://www.ncbi.nlm.nih.gov/pubmed/25214703",
        "http://www.ncbi.nlm.nih.gov/pubmed/20950594",
        "http://www.ncbi.nlm.nih.gov/pubmed/11191638",
        "http://www.ncbi.nlm.nih.gov/pubmed/23118587",
        "http://www.ncbi.nlm.nih.gov/pubmed/17405745",
        "http://www.ncbi.nlm.nih.gov/pubmed/25375074",
        "http://www.ncbi.nlm.nih.gov/pubmed/39240306",
        "http://www.ncbi.nlm.nih.gov/pubmed/30581854",
        "http://www.ncbi.nlm.nih.gov/pubmed/16597190"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Levels of lead in drinking water can be high enough to pose a potential health threat to very young children, primarily from the use of lead solder for indoor plumbing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8757239"
        },
        {
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1430,
          "text": "Long-term residency near glassworks with historically high levels of lead emissions, and high consumption of local foods, were associated with CVD. The risk was increasing for each year of residency in high emission areas. Increased body burden of arsenic in blood, and lead in urine, were associated with stroke. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39277976"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 456,
          "text": "IQ loss in Mexican children from potter families exposed to lead",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28440982"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Lead (Pb) exposure during perinatal development alters testosterone (T) concentrations and delays puberty ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39676704"
        },
        {
          "offsetInBeginSection": 1154,
          "offsetInEndSection": 1183,
          "text": "Pb-induced neurotoxic impacts",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37031386"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 833,
          "text": "Lead is a toxic heavy metal that has been used extensively in modern society, causing widespread environmental contamination even in isolated parts of the world. Irrefutable evidence associates lead at different exposure levels with a wide spectrum of health and social effects, including mild intellectual impairment, hyperactivity, shortened concentration span, poor school performance, violent/aggressive behavior, and hearing loss. Lead has an impact on virtually all organ systems, including the heart, brain, liver, kidneys, and circulatory system, resulting in coma and death in severe cases. In recent years, a consensus was reached regarding the absence of a threshold for the key health effects associated with lead exposure and the permanent and irreversible nature of many health and social consequences of lead exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15742678"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 833,
          "text": "Lead is a toxic heavy metal that has been used extensively in modern society, causing widespread environmental contamination even in isolated parts of the world. Irrefutable evidence associates lead at different exposure levels with a wide spectrum of health and social effects, including mild intellectual impairment, hyperactivity, shortened concentration span, poor school performance, violent/aggressive behavior, and hearing loss. Lead has an impact on virtually all organ systems, including the heart, brain, liver, kidneys, and circulatory system, resulting in coma and death in severe cases. In recent years, a consensus was reached regarding the absence of a threshold for the key health effects associated with lead exposure and the permanent and irreversible nature of many health and social consequences of lead exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34058086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 366,
          "text": "Lead poisoning affects an estimated 890,000 young children in the United States annually (American Academy of Pediatrics [AAP], 1998). Extremely high levels in the child can cause mental retardation, coma, seizures, and death. Chronic low level exposure is more commonly seen with multiple effects, including learning disabilities, impaired growth, and hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962248"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 246,
          "text": "Despite progress in lead poisoning prevention, lead exposure remains a persistent threat to the health and neurological development of children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39412324"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Lead (Pb), a highly toxic heavy metal, poses a significant global health risk, particularly to children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740545"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Lead-induced neurotoxicity acquired by low-level long-term exposure has special relevance for children. A plethora of recent reports",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20058837"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "Lead is a pervasive environmental contaminant with significant health risks, particularly to children. It is known for its neurotoxic and immunotoxic effects, causing developmental, cognitive, and behavioral impairments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39639084"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 258,
          "text": "Exposure to lead results in neurocognitive and behavioral changes, has adverse effects on the immune system, causes anemia, hypertension and perturbs other organ systems.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38856075"
        },
        {
          "offsetInBeginSection": 259,
          "offsetInEndSection": 523,
          "text": "The effects of lead poisoning are most critical for children because their bodies are growing and developing, and particularly because agents that reduce cognitive function and attention span as well as promote disruptive behavior will have life-long consequences.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38856075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "BACKGROUND: Lead exposure reduces the cognitive development and future economic prospects ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39284488"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 326,
          "text": "particulates. Exposure to lead can cause neurological and psychological dysfunction, among other ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39284084"
        },
        {
          "offsetInBeginSection": 2094,
          "offsetInEndSection": 2570,
          "text": "Despite the fact that lead has been banned from gasoline, paint and water pipes, quite significant quantities of lead still exist, particularly in deprived areas of modern cities, in transition zones and city centers, and there are also great concentrations around lead mines and in developing countries, but even for the remaining areas there is no safe threshold.CONCLUSIONS: Lead was and still is an environmental factor that increases neurologic and psychiatric morbidity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27837574"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 435,
          "text": "Irrefutable evidence associates lead at different exposure levels with a wide spectrum of health and social effects, including mild intellectual impairment, hyperactivity, shortened concentration span, poor school performance, violent/aggressive behavior, and hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34058086"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 1002,
          "text": ". It is a toxic metal affecting various organs, and developing fetus and young children are more vulnerable to toxicity of lead. This overview is based on the information of toxic potential of lead to human reproduction and reproductive outcome. Exposure to lead may affect libido, semen quality by declining sperm count, motility, viability, integrity, elevation in morphological abnormalities, and sperm DNA integrity. These alterations led to reducing fertility potential and chances of miscarriages, preterm birth, and so on in a partner. Lead exposure impairs hormonal synthesis and regulations in both sexes. Lead exposure also affects female reproduction by impairing menstruations, reducing fertility potential, delaying conception time, altering the hormonal production, circulation, affecting pregnancy and its outcome, and so on.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30647514"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 590,
          "text": "Acute exposure to high concentrations of lead can result in proximal tubular damage with characteristic histologic features and manifested by glycosuria and aminoaciduria. Chronic occupational exposure to lead, or consumption of illicit alcohol adulterated with lead, has also been linked to a high incidence of renal dysfunction, which is characterized by glomerular and tubulointerstitial changes resulting in chronic renal failure, hypertension, hyperuricemia, and gout.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9300927"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 2093,
          "text": "Lead affects the cholinergic, dopaminergic and gloutamergic systems, thus intervening in the normal function of neurotransmion. The consequence of neurotoxicity in the central nervous system includes apoptosis and excitotoxicity. Direct as well as chronic exposure causes serious neurological symptoms and possibly constant cognitive impairment. Acute encephalopathy, the most serious expression of lead poisoning, occurs in blood level concentrations over 100 μg/dL in adults and 80-100 μg/dL in children. Early symptoms of lead neurotoxicity include irritability, headaches and difficulties in concentration in both children and adults. Continuous exposure in children produces neurobehavioral symptoms, such as decreased concentration, inability to follow instructions, difficulty to play games and low IQ, which are associated with concentrations of 10-35 μg/dL. However, some studies claim that cognitive decline and low IQ can occur in concentrations \u003c10 μg/dL. The commonest symptom in adults is peripheral neuropathy with foot drop. Prenatal exposure to lead has been correlated with antisocial behavior and schizophrenia. Long-term lead exposure causing low and medium lead concentration in blood has been linked to depression as well as generalized anxiety disorder and other behavioral disorders. High blood level concentrations correlate with psychotic symptoms like delusions and hallucinations but more rarely with psychotic syndromes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27837574"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 533,
          "text": " Exposure to lead in the home and the workplace results in health hazards to many adults and children causing economic damage, which is due to the lack of awareness of the ill effects of lead. We report the case of a 22 year old man working in an unorganized lead acid battery manufacturing unit, complaining about a longer history of general body ache, lethargy, fatigue, shoulder joint pain, shaking of hands and wrist drop",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17718907"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 599,
          "text": "Irrefutable evidence associates lead at different exposure levels with a wide spectrum of health and social effects, including mild intellectual impairment, hyperactivity, shortened concentration span, poor school performance, violent/aggressive behavior, and hearing loss. Lead has an impact on virtually all organ systems, including the heart, brain, liver, kidneys, and circulatory system, resulting in coma and death in severe cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15742678"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 550,
          "text": "Lead is a potent environmental toxicant with well-known effects on intelligence, school achievement and behavior. Lead exposure is also associated with an increased risk of a variety of health problems including cancer, hypertension, cardiovascular disease, and renal disease. Considering the risk of hypertension, cardiovascular problems, and stroke following lead exposure, the current research assessed the extent to which postnatal exposure to environmentally relevant levels of lead could impair the recovery from a later occurring brain injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17707511"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 388,
          "text": "Lead is one of the toxicants of concern that has been associated with adverse effects on heme metabolism, serum vitamin D levels, and the mental and physical development of infants and children exposed at very low environmental levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1776155"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 381,
          "text": "Lead toxicity causes hematological, gastrointestinal, and neurological dysfunction. Symptoms are usually noted with blood lead greater than 2 micromoles/L. Severe or prolonged exposure may also cause chronic nephropathy, hypertension, and reproductive impairment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12926603"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 523,
          "text": "Exposure to lead results in neurocognitive and behavioral changes, has adverse effects on the immune system, causes anemia, hypertension and perturbs other organ systems. The effects of lead poisoning are most critical for children because their bodies are growing and developing, and particularly because agents that reduce cognitive function and attention span as well as promote disruptive behavior will have life-long consequences.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38856075"
        },
        {
          "offsetInBeginSection": 428,
          "offsetInEndSection": 1063,
          "text": "Lead causes health problems such as toxicity of the liver, kidneys, hematopoietic system, and nervous system. Having a carcinogenic risk as well, the IARC classifies inorganic lead compounds as probably carcinogenic to humans (Group 2A). Occupational lead poisonings have decreased due to the efforts to reduce the lead concentrations in the working environment. In contrast, health hazards associated with long-term environmental exposure to low concentrations of lead have been reported steadily. In particular, chronic exposure to low concentrations of lead has been reported to induce cognitive behavioral disturbances in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26677413"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 435,
          "text": "Irrefutable evidence associates lead at different exposure levels with a wide spectrum of health and social effects, including mild intellectual impairment, hyperactivity, shortened concentration span, poor school performance, violent/aggressive behavior, and hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15742678"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 599,
          "text": "Lead has an impact on virtually all organ systems, including the heart, brain, liver, kidneys, and circulatory system, resulting in coma and death in severe cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15742678"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Lead poisoning is an important environmental disease that can have life-long adverse health effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18436472"
        },
        {
          "offsetInBeginSection": 663,
          "offsetInEndSection": 911,
          "text": " exposure and dose. Lead in adults can cause an increase in blood pressure, slow nerve conduction, fatigue, mood swings, drowsiness, impaired concentration, fertility disorders, decreased sex drive, headaches, constipation and, in severe cases, enc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32570851"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Human exposure to the metal lead (Pb) is prevalent and associated with adverse neurodevelopmental and neurodegenerative outcomes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39086983"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 200,
          "text": "Lead toxicity causes hematological, gastrointestinal, and neurological dysfunction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12926603"
        },
        {
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1293,
          "text": "lead (Pb) levels over a certain threshold can cause spontaneous abortion and have a teratogenic impact",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558053"
        },
        {
          "offsetInBeginSection": 408,
          "offsetInEndSection": 581,
          "text": "Exposure to lead may affect libido, semen quality by declining sperm count, motility, viability, integrity, elevation in morphological abnormalities, and sperm DNA integrity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30647514"
        },
        {
          "offsetInBeginSection": 572,
          "offsetInEndSection": 812,
          "text": "In addition to neuronal encephalopathy observed in persons after exposure to very high concentrations of Pb, gastrointestinal colic (abdominal pain, constipation, intestinal paralysis) is a consistent early symptom of Pb poisoning in humans",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18219078"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Lead poisoning (plumbism) can cause irreversible genetic and reproductive toxicity, hematological effects, neurological damage, and cardiovascular effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25214703"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 233,
          "text": "nal exposure. It presents with a myriad of signs and symptoms ranging from mild anemia to frank encephalopathy, depending on the blood lead levels as well as the durati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20950594"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Lead poisoning induces hematological, gastrointestinal and neurological dysfunctions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11191638"
        },
        {
          "offsetInBeginSection": 259,
          "offsetInEndSection": 424,
          "text": "Exposure to lead produces various deleterious effects on the hematopoietic, renal, reproductive and central nervous system, mainly through increased oxidative stress",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118587"
        },
        {
          "offsetInBeginSection": 1112,
          "offsetInEndSection": 1363,
          "text": "Lead and its compounds are systemic toxicants, and a wide range of adverse health effects (including haematological, gastrointestinal, neuropsychiatric, cardiovascular, renal, endocrine, and reproductive disorders) has been observed in exposed workers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17405745"
        },
        {
          "offsetInBeginSection": 1365,
          "offsetInEndSection": 1499,
          "text": "The general population (particularly children) may also be exposed to toxic lead levels due to air, soil, food and water contamination",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17405745"
        },
        {
          "offsetInBeginSection": 452,
          "offsetInEndSection": 606,
          "text": "The health effects of lead exposure include developmental neurotoxicity, reproductive dysfunction and toxicity to the kidneys, blood and endocrine systems",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12041847"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "BACKGROUND: While the nephrotoxicity of lead and cadmium is well-established, the impact of low-level exposure on risk of chronic kidney disease (CKD) and long-term health outcomes, especially in CKD patients, rema",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39689108"
        },
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 908,
          "text": "% male), 1,309 (3.9%) had CKD. Lead and cadmium levels were significantly higher in participants with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39689108"
        },
        {
          "offsetInBeginSection": 1609,
          "offsetInEndSection": 1776,
          "text": "isk (HR: 1.32, 95% CI: 1.13-1.54).CONCLUSION: Low-level cadmium and lead exposure are linked to increased CKD risk, with cadmium also associated with higher long-term ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39689108"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Lead poisoning remains a significant public health concern with preventable exposure from different sources, including certain traditional consumer products.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39680744"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 201,
          "text": "Lead toxicity causes hematological, gastrointestinal, and neurological dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12926603"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 653,
          "text": "Lead poisoning can cause a variety of symptoms which vary depending on the individual and the duration of lead exposure; lead poisoning is more noxious to children than adults, because it can damage the brain and nerve development of children.We report a case of lead poisoning in a 5-year-old girl caused by accidental ingestion of a metal ring. Simultaneously, the child showed anemia, encephalopathy, and peripheral neuropathy with albuminocytological dissociation mimicking Guillain-Barré syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22911483"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 591,
          "text": "Lead-induced toxicity to the central nervous system causes delayed development, diminished intelligence, and altered behavior.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7941534"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 599,
          "text": "Irrefutable evidence associates lead at different exposure levels with a wide spectrum of health and social effects, including mild intellectual impairment, hyperactivity, shortened concentration span, poor school performance, violent/aggressive behavior, and hearing loss. Lead has an impact on virtually all organ systems, including the heart, brain, liver, kidneys, and circulatory system, resulting in coma and death in severe cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34058086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Lead poisoning can have devastating health consequences, especially for children, with childhood lead exposure estimated to contribute to 600,000 new cases globally of children with intellectual disabilities every year.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25375074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Lead (Pb) is a major environmental pollutant that can cause nephrotoxicity, hepatotoxicity, encephalopathy, and even death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39240306"
        },
        {
          "offsetInBeginSection": 70,
          "offsetInEndSection": 235,
          "text": "Children are at particularly high risk for adverse effects of lead exposure; even at low concentrations, lead can affect physical, mental, and behavioral development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30581854"
        },
        {
          "offsetInBeginSection": 531,
          "offsetInEndSection": 760,
          "text": "However, data now implicates low-level exposures and blood lead levels previously considered normal as causative factors in cognitive dysfunction, neurobehavioral disorders, neurological damage, hypertension, and renal impairment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16597190"
        }
      ],
      "id": "67e2c4b618b1e36f2e000095",
      "ideal_answer": [
        "Long-term residency near glassworks with historically high levels of lead emissions, and high consumption of local foods, were associated with CVD. The risk was increasing for each year of residency in high emission areas. Increased body burden of arsenic in blood, and lead in urine, were associated with stroke. Lead poisoning also decreases testosterone, libido, and delays puberty. The neurotoxicity can also lower the IQ of children.",
        "Environmental exposure to lead can have numerous adverse health effects, especially in children. These include intellectual impairment, hyperactivity, shortened concentration span, poor school performance, violent or aggressive behavior, and hearing loss. Lead exposure can also cause toxicity in the liver, kidneys, hematopoietic system, and nervous system. In adults, lead can increase blood pressure, slow nerve conduction, cause fatigue, mood swings, drowsiness, impaired concentration, fertility disorders, decreased sex drive, and headaches. Severe cases can result in coma and death. Long-term exposure to even low concentrations of lead can lead to cognitive and behavioral disturbances. There is no identified threshold for the health effects of lead exposure, and many of the consequences are permanent and irreversible."
      ],
      "exact_answer": [
        [
          "CVD"
        ],
        [
          "Stroke"
        ],
        [
          "Neurodegeneration"
        ],
        [
          "Lower IQ in children"
        ],
        [
          "alters testosterone concentration"
        ],
        [
          "delays puberty"
        ],
        [
          "decreases libido"
        ],
        [
          "neurotoxicity"
        ],
        [
          "infertility"
        ]
      ]
    },
    {
      "body": "What is the role of glioblastoma stem-like cells (GSCs) in tumor progression and therapy resistance?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28003805",
        "http://www.ncbi.nlm.nih.gov/pubmed/24772249",
        "http://www.ncbi.nlm.nih.gov/pubmed/33762015",
        "http://www.ncbi.nlm.nih.gov/pubmed/31602000",
        "http://www.ncbi.nlm.nih.gov/pubmed/37444568",
        "http://www.ncbi.nlm.nih.gov/pubmed/32722427",
        "http://www.ncbi.nlm.nih.gov/pubmed/21203936",
        "http://www.ncbi.nlm.nih.gov/pubmed/26258069",
        "http://www.ncbi.nlm.nih.gov/pubmed/33391498",
        "http://www.ncbi.nlm.nih.gov/pubmed/20457135",
        "http://www.ncbi.nlm.nih.gov/pubmed/26880988",
        "http://www.ncbi.nlm.nih.gov/pubmed/33799798",
        "http://www.ncbi.nlm.nih.gov/pubmed/26027432",
        "http://www.ncbi.nlm.nih.gov/pubmed/39592188",
        "http://www.ncbi.nlm.nih.gov/pubmed/38901497",
        "http://www.ncbi.nlm.nih.gov/pubmed/38756074",
        "http://www.ncbi.nlm.nih.gov/pubmed/36521657",
        "http://www.ncbi.nlm.nih.gov/pubmed/35886952",
        "http://www.ncbi.nlm.nih.gov/pubmed/35778531",
        "http://www.ncbi.nlm.nih.gov/pubmed/35567901",
        "http://www.ncbi.nlm.nih.gov/pubmed/35205179",
        "http://www.ncbi.nlm.nih.gov/pubmed/30895167",
        "http://www.ncbi.nlm.nih.gov/pubmed/32634135",
        "http://www.ncbi.nlm.nih.gov/pubmed/37499046",
        "http://www.ncbi.nlm.nih.gov/pubmed/34681783",
        "http://www.ncbi.nlm.nih.gov/pubmed/36008944",
        "http://www.ncbi.nlm.nih.gov/pubmed/36711961",
        "http://www.ncbi.nlm.nih.gov/pubmed/37385633",
        "http://www.ncbi.nlm.nih.gov/pubmed/37438359",
        "http://www.ncbi.nlm.nih.gov/pubmed/38158714",
        "http://www.ncbi.nlm.nih.gov/pubmed/39060768",
        "http://www.ncbi.nlm.nih.gov/pubmed/38619743",
        "http://www.ncbi.nlm.nih.gov/pubmed/39447031",
        "http://www.ncbi.nlm.nih.gov/pubmed/36766848",
        "http://www.ncbi.nlm.nih.gov/pubmed/31160393",
        "http://www.ncbi.nlm.nih.gov/pubmed/27472461",
        "http://www.ncbi.nlm.nih.gov/pubmed/28536277",
        "http://www.ncbi.nlm.nih.gov/pubmed/39326139",
        "http://www.ncbi.nlm.nih.gov/pubmed/37174078",
        "http://www.ncbi.nlm.nih.gov/pubmed/27765847",
        "http://www.ncbi.nlm.nih.gov/pubmed/37242454",
        "http://www.ncbi.nlm.nih.gov/pubmed/39548074",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831894",
        "http://www.ncbi.nlm.nih.gov/pubmed/27893719",
        "http://www.ncbi.nlm.nih.gov/pubmed/25892134",
        "http://www.ncbi.nlm.nih.gov/pubmed/28412969",
        "http://www.ncbi.nlm.nih.gov/pubmed/28212562",
        "http://www.ncbi.nlm.nih.gov/pubmed/25541984",
        "http://www.ncbi.nlm.nih.gov/pubmed/39063221",
        "http://www.ncbi.nlm.nih.gov/pubmed/24710409",
        "http://www.ncbi.nlm.nih.gov/pubmed/23063412",
        "http://www.ncbi.nlm.nih.gov/pubmed/36583266",
        "http://www.ncbi.nlm.nih.gov/pubmed/38501121",
        "http://www.ncbi.nlm.nih.gov/pubmed/38891070",
        "http://www.ncbi.nlm.nih.gov/pubmed/23258844",
        "http://www.ncbi.nlm.nih.gov/pubmed/29416606",
        "http://www.ncbi.nlm.nih.gov/pubmed/33575479",
        "http://www.ncbi.nlm.nih.gov/pubmed/33414520",
        "http://www.ncbi.nlm.nih.gov/pubmed/36332566",
        "http://www.ncbi.nlm.nih.gov/pubmed/25374033",
        "http://www.ncbi.nlm.nih.gov/pubmed/39015773",
        "http://www.ncbi.nlm.nih.gov/pubmed/34769063",
        "http://www.ncbi.nlm.nih.gov/pubmed/26616589",
        "http://www.ncbi.nlm.nih.gov/pubmed/34439156",
        "http://www.ncbi.nlm.nih.gov/pubmed/39323013",
        "http://www.ncbi.nlm.nih.gov/pubmed/28895245",
        "http://www.ncbi.nlm.nih.gov/pubmed/27510953",
        "http://www.ncbi.nlm.nih.gov/pubmed/24044901",
        "http://www.ncbi.nlm.nih.gov/pubmed/27144829",
        "http://www.ncbi.nlm.nih.gov/pubmed/29557506",
        "http://www.ncbi.nlm.nih.gov/pubmed/35562993",
        "http://www.ncbi.nlm.nih.gov/pubmed/35544684",
        "http://www.ncbi.nlm.nih.gov/pubmed/29392693"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 383,
          "text": "GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. Recent studies showed that GSCs reside in particular tumor niches that are necessary to support their behavior.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28003805"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 637,
          "text": "The concept of cancer stem cells (CSCs) has emerged and provided new insight into GBM resistance and management. CSCs can self-renew and initiate tumor growth and are also responsible for tumor cell heterogeneity and the induction of systemic immunosuppression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33762015"
        },
        {
          "offsetInBeginSection": 384,
          "offsetInEndSection": 537,
          "text": "To successfully eradicate GBM growth and recurrence, new strategies selectively targeting GSCs and/or their microenvironmental niche should be designed. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28003805"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 507,
          "text": "Glioblastoma Multiforme (GBM) is a grade IV astrocytoma, with a median survival of 14.6 mo. Within GBM, stem-like cells, namely glioblastoma stem cells (GSCs), have the ability to self-renew, differentiate into distinct lineages within the tumor and initiate tumor xenografts in immunocompromised animal models. More importantly, GSCs utilize cell-autonomous and tumor microenvironment-mediated mechanisms to overcome current therapeutic approaches. They are, therefore, very important therapeutic targets. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24772249"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 252,
          "text": "Recent studies have implicated cancer stem cells within glioblastoma (glioma stem cells, GSCs) as mediators of therapeutic resistance and tumor progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31602000"
        },
        {
          "offsetInBeginSection": 263,
          "offsetInEndSection": 402,
          "text": "Increasing evidence has suggested that GSCs play critical roles in tumor initiation, progression, and resistance to conventional therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32722427"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 754,
          "text": "We and others have demonstrated that a highly tumorigenic subpopulation of cancer cells called GBM stem cells (GSCs) promotes therapeutic resistance. We also found that GSCs stimulate tumor angiogenesis by expressing elevated levels of VEGF and contribute to tumor growth, which has been translated into a useful therapeutic strategy in the treatment of recurrent or progressive GBMs. Furthermore, stem cell-like cancer cells (cancer stem cells) have been shown to promote metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21203936"
        },
        {
          "offsetInBeginSection": 858,
          "offsetInEndSection": 1027,
          "text": "GSCs are thought to contribute to tumor progression, treatment resistance, and tumor recapitulation post-treatment and have become the focus of novel therapy strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26258069"
        },
        {
          "offsetInBeginSection": 313,
          "offsetInEndSection": 505,
          "text": "In addition, glioma stem cells (GSCs) with self-renewal capability promote tumor recurrence and induce therapy resistance, which all have complicated eradication of GBM with existing therapies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38901497"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 301,
          "text": "Glioma Stem Cells (GSCs) can generate tumor cells in vivo and in vitro and they are associated with treatment resistance, tumor progression, and recurrence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38756074"
        },
        {
          "offsetInBeginSection": 318,
          "offsetInEndSection": 451,
          "text": "As shown by several studies, glioma stem cells (GSCs) were correlated with radiotherapy/chemotherapy resistance and high relapse rate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36521657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Glioblastoma multiforme (GBM) cancer stem cells (GSCs) are one of the strongest contributing factors to treatment resistance in GBM",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35886952"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 288,
          "text": "GSCs contribute to tumorigenesis, tumor progression, recurrence, and treatment resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35778531"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Glioblastoma (GBM) stem cells (GSCs) are responsible for GBM initiation, progression, infiltration, standard therapy resistance, and recurrence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35567901"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 178,
          "text": "Glioblastoma stem cells (GSCs) initiate the tumor and are known culprits of therapy resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36711961"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 252,
          "text": "Glioblastoma stem cells (GSCs) play a crucial role in therapy resistance and tumor recurrence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37385633"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 181,
          "text": "Glioma stem cells (GSCs) are essential for tumor initiation, maintenance, and therapeutic resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37438359"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 113,
          "text": "Glioma stem cells (GSCs) are the root cause of relapse and treatment resistance in glioblastoma (GBM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38158714"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 118,
          "text": "Glioblastoma (GBM) stem-like cells (GSCs) are crucial drivers of treatment resistance and tumor recurrence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37499046"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Glioblastoma stem cells (GSCs) have been implicated in the self-renewal and treatment resistance of glioblastoma (GBM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39060768"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 492,
          "text": "In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence, and GBM therapies targeting GSCs are expected to improve patient outcomes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38619743"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 204,
          "text": "Glioma stem cells (GSCs) are the root cause of tumorigenesis, recurrence, and therapeutic resistance in glioblastoma (GBM), the most prevalent and lethal type of primary adult brain malignancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39447031"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 297,
          "text": "This is mainly mediated by a subpopulation of cells with stemness traits termed glioblastoma stem-like cells (GSCs), which are extremely resistant to anti-neoplastic drugs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36766848"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 330,
          "text": "The glioma stem cell (GSC) subpopulation has been identified in glioblastoma and likely plays a key role in resistance of these tumors to conventional therapies as well as recurrent disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26880988"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 296,
          "text": "Glioma stem cells (GSCs), a subpopulation of highly tumorigenic cells, are considered major contributors to glioma progression and play seminal roles in therapy resistance,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27472461"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Glioblastoma (GBM) stem cells (GSCs) are responsible for GBM initiation, progression, infiltration, standard therapy resistance, and recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35567901"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 182,
          "text": "Glioma stem cells (GSCs) are essential for tumor initiation, maintenance, and therapeutic resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37438359"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 332,
          "text": "At the molecular level, radio-/chemoresistance and resulting tumor progression are attributed to a small fraction of tumor cells, termed glioblastoma stem-like cells (GSCs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831894"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Glioma stem cells (GSCs) have a central role in glioblastoma (GBM) development and chemo/radiation resistance, and their elimination is critical for the development of efficient therapeutic strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27893719"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Therapeutic resistance in glioblastoma multiforme (GBM) has been linked to a subpopulation of cells with stem cell-like properties, the glioma stem cells (GSCs), responsible for cancer progression and recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25892134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Glioblastoma is a major unmet clinical need characterized by striking inter- and intra-tumoral heterogeneity and a population of glioblastoma stem cells (GSCs), conferring aggressiveness and therapy resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39592188"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 335,
          "text": "Glioma stem cells (GSCs), a subpopulation of highly tumorigenic cells, are considered major contributors to glioma progression and play seminal roles in therapy resistance, immune evasion and increased invasion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27472461"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 384,
          "text": "Glioma stem cells (GSCs) constitute a slow-dividing, small population within a heterogeneous glioblastoma. They are able to self-renew, recapitulate a whole tumor, and differentiate into other specific glioblastoma multiforme (GBM) subpopulations. Therefore, they have been held responsible for malignant relapse after primary standard therapy and the poor prognosis of recurrent GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26027432"
        },
        {
          "offsetInBeginSection": 341,
          "offsetInEndSection": 1088,
          "text": "A subpopulation of cells denominated GBM stem-like cells (GSCs) exhibits multipotency and self-renewal capacity. GSCs are considered the conductors of tumor progression due to their high tumorigenic capacity, enhanced proliferation, invasion and therapeutic resistance compared to non-GSCs cells. GSCs have been classified into two molecular subtypes: proneural and mesenchymal, the latter showing a more aggressive phenotype. Tumor microenvironment and therapy can induce a proneural-to-mesenchymal transition, as a mechanism of adaptation and resistance to treatments. In addition, GSCs can transition between quiescent and proliferative substates, allowing them to persist in different niches and adapt to different stages of tumor progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35205179"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 654,
          "text": "We and others have demonstrated that a highly tumorigenic subpopulation of cancer cells called GBM stem cells (GSCs) promotes therapeutic resistance. We also found that GSCs stimulate tumor angiogenesis by expressing elevated levels of VEGF and contribute to tumor growth, which has been translated into a useful therapeutic strategy in the treatment of recurrent or progressive GBMs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21203936"
        },
        {
          "offsetInBeginSection": 186,
          "offsetInEndSection": 656,
          "text": "These are characterized by chemotherapy resistance and considered one of the key determinants driving tumor relapse. Many studies demonstrated that Glioma stem cells (GSCs) reside in particular tumor niches, that are necessary to support their behavior. A hypoxic microenvironment has been reported to play a crucial role in controlling GSC molecular and phenotypic profile and in promoting the recruitment of vascular and stromal cells in order to sustain tumor growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23063412"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Glioblastoma stem cells (GSCs) contributed to the progression, treatment resistance, and relapse of glioblastoma (GBM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36583266"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 327,
          "text": "Cancer stem cells (CSCs) play a critical role in GBM, particularly in treatment-resistance and tumor relapse, emphasizing the need to comprehend the mechanisms regulating these cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38501121"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 327,
          "text": "Cancer stem cells (CSCs) play a critical role in GBM, particularly in treatment resistance and tumor relapse, emphasizing the need to comprehend the mechanisms regulating these cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38891070"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 836,
          "text": "GSCs contribute to tumor heterogeneity and recapitulate pathway alterations described for the three GBM subtypes found in patients. GSCs show a high degree of plasticity, allowing for interconversion between different molecular GBM subtypes, with distinct proliferative potential, and different degrees of self-renewal and differentiation. This high degree of plasticity permits adaptation to the environmental changes introduced by chemo- and radiation therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37444568"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Glioblastoma (GBM) is an aggressive brain tumor with a poor prognosis, largely due to the presence of glioblastoma stem cells (GSCs). These cells drive tumor progression, recurrence, and chemoresistance, making them critical targets for therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39548074"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 180,
          "text": "Glioblastoma stem cells (GSCs) contribute to tumorigenesis, invasive capacity, and therapy resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33414520"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "Glioblastomas are lethal malignancies that possess a rapidly evolving microenvironment containing necrotic/hypoxic areas, aberrant microvasculature, and glioblastoma stem cells (GSCs) that promote tumor growth, recurrence, and treatment resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36332566"
        },
        {
          "offsetInBeginSection": 662,
          "offsetInEndSection": 1027,
          "text": "Recent research has applied the cancer stem cells theory of carcinogenesis to these tumors, suggesting the existence of a small subpopulation of glioma stem-like cells (GSCs) within these tumors. GSCs are thought to contribute to tumor progression, treatment resistance, and tumor recapitulation post-treatment and have become the focus of novel therapy strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26258069"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 333,
          "text": "Developing therapies targeting GBM cancer stem cells or glioma stem cells (GSCs), which are deemed responsible for the malignancy of GBM due to their therapy resistance and tumor-initiating capacity, is considered key to improving the dismal prognosis of GBM patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34769063"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 319,
          "text": "Glioblastoma multiforme (GBM), designated as World Health Organization (WHO) grade IV astrocytoma, is a lethal and therapy-resistant brain cancer comprised of several tumor cell subpopulations, including GBM stem cells (GSCs) which are believed to contribute to tumor recurrence following initial response to therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616589"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 439,
          "text": "The failure of available treatments to achieve remission in patients with glioblastoma (GBM) has been attributed to the presence of cancer stem cells (CSCs), which are thought to play a central role in tumor development and progression and serve as a treatment-resistant cell repository capable of driving tumor recurrence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39323013"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 521,
          "text": "Glioblastoma (GBM) is the most frequent and malignant brain tumor with an overall survival of only 14.6 months. Although these tumors are treated with surgery, radiation and chemotherapy, recurrence is inevitable. A critical population of tumor cells in terms of therapy, the so-called cancer stem cells (CSCs), has been identified in gliomas and many other cancers. These tumor cells have a stem cell-like phenotype and are suggested to be responsible for tumor growth, chemo- and radio-resistance as well as recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27510953"
        },
        {
          "offsetInBeginSection": 564,
          "offsetInEndSection": 785,
          "text": "GBM cancer stem cells (GSCs) are a subset of the GBM tumor population that play critical roles in tumor formation and progression, metastasis, and relapse, and they are inherently resistant to most therapeutic strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37242454"
        },
        {
          "offsetInBeginSection": 454,
          "offsetInEndSection": 637,
          "text": "GSCs are considered the conductors of tumor progression due to their high tumorigenic capacity, enhanced proliferation, invasion and therapeutic resistance compared to non-GSCs cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35205179"
        },
        {
          "offsetInBeginSection": 771,
          "offsetInEndSection": 1030,
          "text": "Although, the treatment failure is a result of a number of causes, but currently, it has been demonstrated that a highly tumorigenic subpopulation of cancer cells called glioblastoma stem cells (GSCs) display relative resistance to radiation and chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144829"
        },
        {
          "offsetInBeginSection": 263,
          "offsetInEndSection": 631,
          "text": "Increasing evidence has suggested that GSCs play critical roles in tumor initiation, progression, and resistance to conventional therapies. The remarkable oncogenic features of GSCs have generated significant interest in better defining and characterizing these cells and determining novel pathways driving GBM that could constitute attractive key therapeutic targets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32722427"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 309,
          "text": "In a hierarchical tumor model, glioblastoma stem-like cells (GSC) play a major role in tumor initiation and maintenance as well as in therapy resistance and recurrence. Thus, targeting this cellular subset may be key to effective immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29557506"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 381,
          "text": "Glioblastoma stem cells (GSCs) are cells with a self-renewal ability and capacity to initiate tumors upon serial transplantation that have been linked to tumor cell heterogeneity. Most standard treatments fail to completely eradicate GSCs, causing the recurrence of the disease. GSCs could represent one reason for the low efficacy of cancer therapy and for the short relapse time.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35562993"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 477,
          "text": "These GSCs have the capacity of self-renewal, proliferation, invasion and recapitulating the parent tumor, and are major causes of radio-and chemoresistance of GBM. Upregulated expression of hypoxia inducible factors (HIFs) in hypoxia fundamentally contributes to maintenance and progression of GSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37174078"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Glioblastoma stem-like cells (GSCs) displaying self-renewing and tumor-propagating capacity play a particularly important role in maintaining tumor growth, therapeutic resistance, and tumor recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121240"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 233,
          "text": "In a hierarchical tumor model, glioblastoma stem-like cells (GSC) play a major role in tumor initiation and maintenance as well as in therapy resistance and recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29557506"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Glioblastoma stem cells (GSCs) exert a crucial influence on glioblastoma (GBM) development, progression, resistance to therapy, and recurrence, making them an attractive target for drug discovery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38214211"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 255,
          "text": "Glioblastoma stem-like cells (GSCs) are thought to contribute to cancer therapy resistance and to be responsible for tumor initiation, maintenance, and recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32634135"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 248,
          "text": "Glioblastoma stem-like cells (GSCs) have been proposed to contribute to tumor initiation, progression, recurrence, and therapeutic resistance of GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30390339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Glioblastoma stem-like cells (GSCs) are critical for the aggressiveness and progression of glioblastoma (GBM) and contribute to its resistance to adjuvant treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29434344"
        },
        {
          "offsetInBeginSection": 78,
          "offsetInEndSection": 284,
          "text": "In this hierarchy, GBM stem-like cells (GSCs) play critical roles in tumor progression and recurrence, by virtue of their robust tumor-propagating potential and resistance to conventional chemoradiotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29392693"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 261,
          "text": "Glioma stem cells (GSCs) are thought to play a major role in tumor progression and resistance of GBM cells to radiochemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34681783"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 251,
          "text": "Recent studies have implicated cancer stem cells within glioblastoma (glioma stem cells, GSCs) as mediators of therapeutic resistance and tumor progression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31602000"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 288,
          "text": "The main reason is that malignant glioma holds key cluster cells, glioma stem cells (GSCs). GSCs contribute to tumorigenesis, tumor progression, recurrence, and treatment resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35778531"
        },
        {
          "offsetInBeginSection": 858,
          "offsetInEndSection": 1026,
          "text": "GSCs are thought to contribute to tumor progression, treatment resistance, and tumor recapitulation post-treatment and have become the focus of novel therapy strategies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26258069"
        },
        {
          "offsetInBeginSection": 46,
          "offsetInEndSection": 144,
          "text": "A subpopulation of glioma stem-like cells (GSCs) drives tumor progression and treatment resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33575479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor with limited therapeutic options. Glioma stem cell (GSC) is thought to be greatly responsible for glioma tumor progression and drug resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29416606"
        }
      ],
      "id": "67eb557218b1e36f2e0000e4",
      "ideal_answer": [
        "Glioblastoma Multiforme (GBM) is a grade IV astrocytoma, with a median survival of 14.6 months. Within GBM, stem-like cells, namely glioblastoma stem cells (GSCs), have the ability to self-renew, initiate tumor growth, and differentiate into distinct lineages within the tumor. More importantly, GSCs can utilize cell-autonomous and tumor microenvironment-mediated mechanisms to overcome current therapeutic approaches and lead to tumor recurrence; thus presenting an important therapeutic target.\n\n\n and initiate tumor xenografts in immunocompromised animal models. More importantly, GSCs utilize cell-autonomous and tumor microenvironment-mediated mechanisms to overcome current therapeutic approaches.",
        "Glioblastoma stem-like cells (GSCs) are thought to be responsible for glioblastoma initiation, progression, and resistance to conventional therapies. GSCs are characterized by their ability to self-renew, differentiate, and form tumors in vivo. They are also thought to be responsible for the development of resistance to chemotherapy and radiation therapy. Targeting GSCs has been shown to improve treatment outcomes in preclinical models of glioblastoma.",
        "Glioblastoma stem-like cells (GSCs) contribute to tumor progression and therapy resistance by promoting tumor growth, self-renewal, and differentiation, as well as by evading conventional therapies through mechanisms such as enhanced DNA repair, resistance to apoptosis, and adaptive metabolic pathways.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance in glioblastoma, an aggressive brain cancer. These cells possess stem cell-like properties, including self-renewal and differentiation into various tumor cell types, contributing to tumor heterogeneity. GSCs are key in tumor initiation and growth due to their ability to sustain tumor expansion. They exhibit significant resistance to conventional therapies like chemotherapy and radiation, attributed to efficient DNA repair, active drug efflux pumps, and a quiescent state that makes them less susceptible to treatments targeting rapidly dividing cells. GSCs can survive initial treatments and repopulate the tumor, leading to recurrence. They also interact with the tumor microenvironment, promoting a supportive niche for their maintenance and contributing to the tumor\u0027s invasive and adaptive nature. Understanding GSC biology is crucial for developing targeted therapies to eradicate these cells and improve patient prognosis.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance in glioblastoma (GBM). They are characterized by their self-renewal capacity, tumorigenicity, and ability to differentiate into various cell types, contributing to the cellular heterogeneity of the tumor. GSCs are implicated in tumor initiation, maintenance, and recurrence, as conventional therapies often fail to effectively target these cells. Their presence leads to poor prognosis due to their resistance to standard treatments, which primarily target differentiated tumor cells rather than the GSC population. Additionally, GSCs are influenced by the tumor microenvironment and neuronal activity, which can promote their survival and enhance their resistance to therapies. Overall, GSCs are central to the challenges faced in treating glioblastoma, as they facilitate tumor growth and contribute to the disease\u0027s aggressive nature.",
        "Glioblastoma stem-like cells (GSCs) are a subpopulation of cells within glioblastoma tumors that drive tumor initiation, progression, infiltration, and recurrence. They are central to therapeutic resistance, particularly to standard treatments like chemotherapy and radiation, due to their self-renewal capacity, adaptability, and ability to sustain tumor heterogeneity. GSCs promote tumor maintenance, aggressiveness, and resistance by evading apoptosis, enhancing DNA repair mechanisms, and dynamically shifting phenotypes (e.g., proneural-to-mesenchymal transition). Their persistence post-therapy leads to relapse, making them critical targets for effective treatment strategies.",
        "Glioblastoma stem-like cells (GSCs) are a subpopulation of tumor cells within glioblastomas that play a critical role in tumor progression and therapy resistance. GSCs are responsible for initiating, maintaining, and propagating the tumor, as well as driving its aggressive behavior. They exhibit self-renewal capacity and the ability to differentiate into various tumor cell types, contributing to tumor heterogeneity.\n\nGSCs are particularly associated with therapeutic resistance, including resistance to chemotherapy and radiation therapy. This resistance is attributed to their unique molecular characteristics, such as enhanced DNA repair mechanisms, activation of survival pathways, and expression of drug efflux pumps. Additionally, GSCs can undergo phenotypic transitions, such as the proneural-to-mesenchymal transition (PMT), which further enhances their ability to evade treatment.\n\nGSCs also play a significant role in tumor recurrence. Even after initial treatment, residual GSCs can persist and drive tumor regrowth, leading to disease progression and poor patient outcomes. Furthermore, GSCs interact with other components of the tumor microenvironment, such as tumor-associated macrophages (TAMs), to create a supportive niche that promotes their survival and aggressiveness.\n\nIn summary, GSCs are central to glioblastoma\u0027s aggressive nature, therapeutic resistance, and recurrence. Targeting GSC-specific pathways is considered a promising strategy for improving treatment outcomes in patients with this devastating disease.",
        "Glioblastoma stem-like cells (GSCs) drive tumor progression by promoting growth, invasion, and angiogenesis, while their self-renewal capacity and adaptability sustain tumor heterogeneity. GSCs resist therapies via enhanced DNA repair, drug-efflux pumps (e.g., ABC transporters), survival in hypoxic niches (via HIF-1α), and interactions with protective microenvironments (e.g., tumor-associated macrophages). Their epigenetic plasticity and proneural-to-mesenchymal transition (PMT) further enable evasion of radiation/chemotherapy. Residual GSCs persist post-treatment, leading to inevitable recurrence. Targeting GSC-specific pathways (e.g., stemness regulators, PMT) is critical to overcoming resistance and improving outcomes.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance due to their stem-like properties, including self-renewal and differentiation potential. GSCs contribute to tumor heterogeneity, fueling tumor growth and invasion. They exhibit increased resistance to conventional therapies like radiation and chemotherapy through mechanisms such as enhanced DNA repair (e.g., MGMT overexpression), altered drug metabolism, and quiescence. GSCs can also modulate the tumor microenvironment, promoting angiogenesis and immune evasion, which further supports tumor progression and resistance. Their ability to differentiate into various cell types within the tumor contributes to the diverse cellular composition of glioblastoma, making it difficult to target effectively. GSCs are critically implicated in tumor recurrence after treatment, acting as a major source of relapse.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance. They are responsible for the initiation, maintenance, and aggressive growth of glioblastomas. GSCs exhibit enhanced abilities to infiltrate surrounding tissues, contributing to tumor spread and recurrence. Importantly, these cells are highly resistant to standard therapies such as chemotherapy and radiation, which is linked to their stem cell-like properties and molecular adaptations. The persistence of GSCs after treatment leads to therapeutic failure and tumor relapse. Targeting GSCs is essential for developing effective strategies to overcome therapy resistance and improve outcomes in glioblastoma patients.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance in glioblastoma (GBM). These cells are characterized by their self-renewal capacity, tumorigenicity, and ability to regenerate the tumor, contributing significantly to tumor heterogeneity and recurrence. GSCs are involved in various mechanisms that promote resistance to standard therapies, including enhanced DNA damage repair, metabolic adaptation, and immune evasion. They exhibit high plasticity, allowing them to interconvert between different molecular subtypes of GBM, which helps them adapt to therapeutic pressures and repopulate tumors after treatment. Additionally, GSCs interact with their microenvironment, receiving signals that support their maintenance and contribute to tumor aggressiveness. Targeting GSCs and understanding their biology are essential for developing more effective therapeutic strategies against GBM.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance in glioblastoma (GBM). These cells exhibit self-renewal capabilities and are responsible for initiating tumors, contributing to the heterogeneity of the tumor cell population. GSCs are particularly resistant to conventional therapies such as chemotherapy and radiotherapy, which is a significant factor in treatment failure and tumor recurrence.\n\nThe interactions between GSCs and the tumor microenvironment are vital for their maintenance and function. GSCs reside in specialized niches, often near blood vessels, where they interact with endothelial cells (ECs) and other components of the microenvironment. These interactions can enhance GSC stemness, migration, and resistance to therapies, creating a localized environment that supports tumor growth and survival.\n\nMechanisms of therapeutic resistance in GSCs include their ability to evade the effects of treatment, which is partly attributed to their stem-like characteristics. The presence of GSCs in hypoxic regions of the tumor and their ability to adapt to adverse conditions further complicate treatment efforts.\n\nGiven the challenges posed by GSCs, there is a growing recognition of the need for combinatorial treatment strategies that target both the GSCs and the tumor microenvironment. Such approaches may improve therapeutic efficacy and reduce the likelihood of recurrence by addressing the underlying mechanisms of resistance and promoting more effective tumor eradication.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance in glioblastoma (GBM). They are characterized by their self-renewal capacity, tumorigenicity, and ability to differentiate into various cell types, contributing to tumor heterogeneity. GSCs are innately less sensitive to radiation and conventional therapies, which allows them to survive treatment and repopulate tumors, leading to recurrence. Their interactions with the tumor microenvironment (TME) are significant; GSCs engage in continuous cross-talk with surrounding cells, which can influence tumor growth, angiogenesis, and therapeutic resistance. Factors within the TME, such as M2 macrophages and exosomal mediators, can further promote GSC stemness and suppress antitumor responses, complicating treatment efforts. Overall, GSCs are central to the aggressive nature of GBM, making them a critical focus for developing more effective therapeutic strategies.",
        "Glioblastoma stem-like cells (GSCs) are pivotal in tumor progression and therapy resistance, characterized by self-renewal, multipotency, enhanced proliferation, and adaptability to various tumor microenvironments (hypoxic, invasive, perivascular). Their ability to transition between quiescent and proliferative states, including proneural-to-mesenchymal transition, enhances aggressiveness and confers resistance to radiation and chemotherapy. Resistance mechanisms include enhanced DNA repair, autophagy, and metabolic adaptation. This plasticity contributes to tumor heterogeneity and recurrence, making GSCs a prime target for novel therapeutic strategies to improve glioblastoma treatment outcomes.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance in glioblastoma (GBM). They are a subpopulation of self-renewing cancer stem cells that contribute to tumor initiation, maintenance, and the aggressive nature of GBM. GSCs are implicated in the tumor\u0027s ability to resist conventional therapies, leading to recurrence after treatment. They facilitate processes such as invasion into normal tissue, promotion of angiogenesis, and evasion of the immune response. Additionally, GSCs are influenced by the tumor microenvironment and neuronal activity, which can enhance their malignant characteristics and resistance to therapies. Understanding the molecular mechanisms governing GSCs is essential for developing targeted therapies aimed at improving treatment outcomes for glioblastoma.",
        "Glioblastoma stem like cells (GSCs) play a pivotal role in both tumor progression and therapy resistance in glioblastoma. 1. Tumor Progression : GSCs are the initiators of tumors, capable of self renewal and differentiation into various tumor cell types, driving aggressive growth. They contribute to tumor spread by forming new areas of cancer within the brain (tumor initiation) and creating a supportive microenvironment through secreted proteins or signaling molecules. 2. Therapy Resistance : GSCs are resistant to conventional treatments like chemotherapy and radiation due to mechanisms such as efficient DNA repair or drug efflux pumps. They survive treatment, leading to tumor recurrence by repopulating the cancer cells after therapy. Overall, GSCs\u0027 ability to initiate tumors, drive growth, and resist therapies underscores their significant role in making glioblastoma a challenging disease to treat.",
        "Glioblastoma stem-like cells (GSCs) play a pivotal role in tumor progression and therapy resistance due to their multipotency, self-renewal, and adaptability to various tumor niches. Mechanisms of resistance include enhanced DNA repair, autophagy, and quiescence, often mediated by BMP signaling. GSCs drive infiltrative growth and undergo phenotypic transitions in response to therapy, contributing to tumor heterogeneity and recurrence. Targeting these cells, particularly their metabolic vulnerabilities, is crucial for effective glioblastoma treatment, offering a promising strategy to overcome their intrinsic resistance to conventional radiation and chemotherapy treatments.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance. They exhibit multipotency and self-renewal capacity, and are considered the conductors of tumor progression due to their high tumorigenic capacity, enhanced proliferation, invasion, and therapeutic resistance compared to non-GSCs cells. GSCs can transition between quiescent and proliferative states, allowing them to persist in different niches and adapt to different stages of tumor progression. They also show a high degree of plasticity, allowing for interconversion between different molecular GBM subtypes. GSCs are inherently resilient to standard-of-care therapy, and mechanisms of resistance include enhanced DNA damage repair, MGMT promoter demethylation, autophagy, impaired induction of apoptosis, metabolic adaptation, chemoresistance, and immune evasion. Targeting GSCs, including their metabolic vulnerabilities and the suppression of ribosome biogenesis, may provide potential therapeutic approaches for glioblastoma.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance in glioblastoma (GBM). They are responsible for GBM initiation, progression, infiltration, and recurrence. GSCs contribute to treatment resistance, including chemoresistance and radioresistance, making them critical targets for therapy. These cells drive tumor progression and are associated with the tumor-initiating capacity of GBM. The self-renewal capability of GSCs promotes tumor recurrence and induces therapy resistance, complicating the eradication of GBM with existing therapies. Targeting GSCs is considered key to improving the prognosis of GBM patients.",
        "Glioblastoma stem-like cells (GSCs) are a subset of glioblastoma cells that are thought to be responsible for tumor initiation, progression, and recurrence. GSCs are characterized by their ability to self-renew, differentiate into distinct lineages within the tumor, and initiate tumor xenografts in immunocompromised animal models. More importantly, GSCs utilize cell-autonomous and tumor microenvironment-mediated mechanisms to overcome current therapeutic approaches. They are, therefore, very important therapeutic targets.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance through several key mechanisms. These specialized cells can self-renew, differentiate into multiple lineages, and initiate tumor growth, contributing to tumor heterogeneity. GSCs are inherently radioresistant and chemoresistant, which enables them to survive standard treatment protocols and ultimately lead to tumor recurrence. They reside in specific tumor microenvironmental niches that support their survival and aggressive behavior, and can induce systemic immunosuppression. By utilizing both cell-autonomous mechanisms and interactions with their surrounding microenvironment, GSCs represent a significant challenge in effectively treating glioblastoma multiforme (GBM), making them a crucial target for developing more advanced therapeutic strategies.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance. Recent studies have shown that GSCs are radioresistant and chemoresistant, leading to tumor recurrence. These cells reside in specific tumor niches that support their behavior and are capable of self-renewal, differentiation, and initiation of tumor growth. Furthermore, GSCs are responsible for tumor cell heterogeneity and the induction of systemic immunosuppression, making them a key target for therapeutic strategies. To effectively eradicate glioblastoma multiforme (GBM) growth and recurrence, new approaches should be designed to selectively target GSCs and/or their microenvironmental niche, as current therapies are often overcome by cell-autonomous and tumor microenvironment-mediated mechanisms utilized by GSCs.",
        "Glioblastoma stem-like cells (GSCs) are critical components of GBM that possess the ability to self-renew, differentiate into various tumor cell types, and initiate tumor growth in animal models. These cells are particularly problematic as they demonstrate resistance to both radiation and chemotherapy, leading to tumor recurrence, and reside in specific tumor niches that support their behavior. Due to their role in therapy resistance and tumor progression, GSCs are considered crucial therapeutic targets, necessitating the development of new strategies specifically targeting these cells and their microenvironment.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance by being radioresistant and chemoresistant, leading to tumor recurrence. They have the ability to self-renew, differentiate into distinct lineages within the tumor, and initiate tumor xenografts in animal models. GSCs utilize cell-autonomous and tumor microenvironment-mediated mechanisms to overcome current therapeutic approaches, making them important therapeutic targets.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance. They are a subset of cells within GBM that can self-renew, differentiate, and initiate tumor growth. Additionally, GSCs exhibit resistance to both radiation and chemotherapy due to their cell-autonomous mechanisms and interactions with their microenvironment, making them key contributors to tumor recurrence and a major therapeutic challenge.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance in glioblastoma (GBM). They possess the ability to self-renew and differentiate into various cell types within the tumor, contributing to tumor heterogeneity. GSCs are central to tumor initiation, maintenance, and the recurrence of GBM, as they can repopulate tumors after therapeutic interventions. Their resistance to conventional therapies is attributed to both cell-autonomous mechanisms and interactions with the tumor microenvironment, which can include factors such as hypoxia, immunosuppressive mediators, and exosomal signaling. Consequently, targeting GSCs and their microenvironment is essential for developing effective treatment strategies to combat GBM and prevent recurrence.",
        "Glioblastoma stem-like cells (GSCs) drive tumor progression by self-renewing, initiating tumor growth, and generating cellular heterogeneity within glioblastoma multiforme (GBM). They reside in specialized niches within the tumor microenvironment, which support their survival and aggressive behavior. GSCs are critical for therapy resistance due to intrinsic properties such as enhanced DNA repair mechanisms, chemoresistance, radioresistance, and quiescence, which allow them to evade conventional treatments targeting rapidly dividing cells. Additionally, their microenvironmental niche provides protective signals and physical barriers that further shield them from therapies. GSCs also promote immunosuppression, enabling immune evasion. These factors collectively contribute to tumor recurrence post-treatment. Eliminating GSCs and disrupting their niche is essential to overcoming therapeutic resistance and improving outcomes in GBM.",
        "Glioblastoma stem-like cells (GSCs) drive tumor progression and therapy resistance by self-renewing, initiating tumor growth, and promoting tumor heterogeneity. They are radioresistant and chemoresistant, surviving standard therapies to cause recurrence. GSCs reside in specialized niches that support their survival and immunosuppressive properties, enabling evasion of immune detection. Their interaction with the microenvironment further enhances resistance and recurrence. Targeting GSCs and their niches is critical for effective glioblastoma treatment.",
        "Glioblastoma stem-like cells represent a small yet critical subset of tumor cells that drive tumor initiation, progression, invasion, and recurrence. Their ability to self-renew and differentiate into various cell types sustains tumor heterogeneity, while residing in specialized tumor niches that support their resistant phenotype. These cells are highly resilient to conventional therapies because of enhanced DNA repair, quiescence, and the aggressive nature of certain subtypes, such as mesenchymal GSCs, which are particularly invasive and resistant. As a result, they survive radiation and chemotherapy, repopulating the tumor and contributing to overall treatment failure by also promoting an immunosuppressive microenvironment.",
        "Glioblastoma stem-like cells (GSCs) play a key role in tumor progression by self-renewing, driving tumor heterogeneity, and initiating tumor growth, which ultimately leads to recurrence. Additionally, they are highly resistant to current therapies due to both their inherent properties (radioresistance and chemoresistance) and their supportive microenvironment.",
        "Glioblastoma stem-like cells (GSCs) are pivotal in the aggressive progression and therapy resistance of Glioblastoma Multiforme (GBM). These cells possess unique characteristics that contribute significantly to tumor growth, recurrence, and resistance to conventional treatments:\n\n1. **Self-Renewal and Differentiation**: GSCs can self-renew and differentiate into various tumor cell types, driving continuous tumor growth and heterogeneity.\n\n2. **Radioresistance and Chemoresistance**: GSCs often reside in specific protective niches within the tumor, which shield them from the effects of radiation and chemotherapy, allowing them to survive treatment and lead to tumor recurrence.\n\n3. **Tumor Heterogeneity and Immunomodulation**: By contributing to tumor heterogeneity and inducing systemic immunosuppression, GSCs reduce the effectiveness of immune-based therapies and complicate treatment strategies.\n\n4. **Microenvironmental Interactions**: GSCs utilize both intrinsic mechanisms and interactions with the tumor microenvironment to evade therapeutic interventions, underscoring their role as critical targets for effective GBM management.\n\nIn summary, GSCs are central to GBM\u0027s aggressive nature, driving tumor progression and resistance. Targeting these cells or their supportive niches represents a promising strategy for improving treatment outcomes in GBM patients.",
        "Glioblastoma stem-like cells (GSCs) play a pivotal role in the progression of glioblastoma multiforme (GBM), a highly aggressive brain cancer, and contribute significantly to therapy resistance. Here is an organized summary of their roles:\n\n1. **Tumor Initiation and Growth**:\n   - GSCs possess self-renewal capabilities and can differentiate into various tumor cell types, driving the initiation and sustained growth of GBM.\n\n2. **Therapy Resistance**:\n   - GSCs exhibit resistance to both radiation and chemotherapy. This resistance is attributed to intrinsic properties such as efficient DNA repair mechanisms and the protective environment provided by specific tumor niches.\n\n3. **Tumor Heterogeneity**:\n   - These cells contribute to the genetic and phenotypic diversity of GBM by differentiating into diverse cell populations, complicating treatment strategies that target specific subsets of cells.\n\n4. **Recurrence**:\n   - Post-treatment survival of GSCs leads to tumor recurrence, as they retain the ability to regenerate the tumor mass.\n\n5. **Immunosuppression**:\n   - GSCs may suppress immune responses, reducing the effectiveness of both the body\u0027s natural defenses and immunotherapies.\n\nIn conclusion, targeting GSCs directly or disrupting their supportive microenvironment is crucial for developing more effective therapies against GBM, aiming to improve patient outcomes.",
        "Glioblastoma stem-like cells (GSCs) play a pivotal role in the progression of glioblastoma multiforme (GBM) and contribute significantly to therapy resistance. Here\u0027s a structured summary of their roles:\n\n1. **Self-Renewal and Differentiation**: GSCs possess the ability to self-renew, enabling them to sustain tumor growth by producing more cells. They can also differentiate into various tumor cell types, contributing to tumor heterogeneity.\n\n2. **Tumor Niches**: These cells reside in specific tumor niches that protect them from therapeutic interventions such as radiation and chemotherapy. This protective environment allows GSCs to survive treatment and leads to tumor recurrence.\n\n3. **Therapy Resistance Mechanisms**: GSCs employ both intrinsic mechanisms and interactions with the tumor microenvironment to resist therapy. They can induce immunosuppression, further complicating treatment efforts by suppressing the body\u0027s immune response against the tumor.\n\n4. **Target for Treatment Development**: Given their critical role in tumor initiation, progression, and resistance, targeting GSCs and their supportive niches is essential for developing effective therapies. Current treatments often fail to address these resilient cells, highlighting the need for new strategies that specifically target GSCs.\n\nIn conclusion, GSCs are central to GBM\u0027s aggressive nature and resistance to treatment. Addressing their unique characteristics and protective environments is crucial for advancing therapeutic approaches against this devastating disease.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance in glioblastoma multiforme (GBM). GSCs possess the ability to self-renew and differentiate into various cell types within the tumor, contributing to tumor heterogeneity and the initiation of tumor growth. They are characterized by their resistance to conventional therapies, including chemotherapy and radiation, which is attributed to both cell-autonomous mechanisms and signals from the tumor microenvironment. This resistance leads to tumor recurrence after treatment, making GSCs significant therapeutic targets. Understanding the molecular characteristics and mechanisms of GSCs is essential for developing effective therapies aimed at eradicating GBM and overcoming the challenges posed by their resilience to existing treatment modalities.",
        "Glioblastoma stem-like cells (GSCs) have the ability to self-renew, differentiate into distinct lineages within the tumor, initiate tumor growth, and mediate tumor progression and recurrence. They are responsible for tumor cell heterogeneity and are held responsible for malignant relapse after primary standard therapy. GSCs utilize cell-autonomous and tumor microenvironment-mediated mechanisms to overcome current therapeutic approaches; they are radioresistant and chemoresistant, contributing to resistance to current therapy. This resistance may stem from innate differences in sensitivity to chemotherapeutic drugs/radiation and specific mechanisms like prohibitin (PHB)-mediated regulation of mitochondrial reactive oxygen species (ROS), which facilitates GSC radiotherapeutic resistance. The failure of current therapies to eliminate specific GSC subpopulations, which repopulate treated tumors, is considered a major factor contributing to inevitable recurrence in GBM patients. GSCs also accelerate glioma progression, enhance self-renewal/proliferation, contribute to invasiveness, and can induce systemic immunosuppression.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance by possessing the ability to self-renew, differentiate into various cell lineages within the tumor, and initiate new tumors. These cells are particularly resistant to current therapeutic approaches due to their radioresistance, chemoresistance, and capacity to adapt through both intrinsic mechanisms and interactions with the tumor microenvironment. Consequently, GSCs contribute significantly to tumor recurrence and heterogeneity, making them vital targets for developing effective GBM treatment strategies.",
        "Glioblastoma stem-like cells (GSCs) are a subset of cells within glioblastoma tumors that exhibit properties similar to normal stem cells. These cells have the ability to self-renew and differentiate into various cell types, which allows them to contribute to the growth and maintenance of the tumor. Additionally, GSCs are often resistant to conventional therapies, such as chemotherapy and radiation, making them a significant contributor to tumor recurrence and therapy resistance. This resistance is thought to be due to the ability of GSCs to enter a dormant state, where they can evade treatment and later re-emerge to drive tumor growth. Understanding the role of GSCs in glioblastoma progression and therapy resistance is crucial for the development of more effective treatment strategies.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance in glioblastoma (GBM). They possess the ability to self-renew and differentiate into various cell lineages, contributing to tumor heterogeneity and the initiation of tumor growth. GSCs are characterized by their resistance to conventional therapies, which primarily target differentiated tumor cells rather than these stem-like populations. This resistance is facilitated by both cell-autonomous mechanisms and interactions with the tumor microenvironment, which support their survival and proliferation.\n\nThe tumor microenvironment is essential for GSC maintenance, as it promotes communication between GSCs and surrounding healthy cells, enhancing cancerogenic processes and further contributing to therapeutic resistance. Additionally, GSCs are implicated in the induction of systemic immunosuppression, complicating treatment efforts. Their unique properties and interactions underscore the need for targeted therapeutic strategies that specifically address GSCs and their niches to effectively combat GBM growth and recurrence.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance in glioblastoma (GBM). They possess the ability to self-renew and differentiate into various cell lineages within the tumor, contributing to tumor heterogeneity and the initiation of tumor growth. GSCs are inherently radioresistant and chemoresistant, which allows them to survive conventional therapies and drive tumor recurrence after treatment.\n\nThe interactions between GSCs and the tumor microenvironment are significant, as GSCs reside in specific niches that support their survival and behavior. These interactions facilitate communication with neighboring healthy cells and the immune environment, promoting cancer progression and therapy resistance. Additionally, GSCs utilize various molecular mechanisms, including the upregulation of signaling pathways such as PI3K/Akt/mTOR and metabolic adaptations, to enhance their survival and resistance to treatments.\n\nOverall, GSCs are critical therapeutic targets due to their pivotal role in GBM\u0027s aggressive nature, therapy resistance, and the challenges associated with effectively treating this malignancy.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression and therapy resistance in glioblastoma (GBM). They are characterized by their ability to self-renew, differentiate into various cell lineages, and initiate tumor growth, contributing to the heterogeneity of the tumor. GSCs are inherently resistant to conventional therapies, including radiation and chemotherapy, which leads to treatment failure and tumor recurrence. Their presence in specific tumor niches supports their survival and therapeutic resistance, making them significant targets for new treatment strategies aimed at eradicating GBM. Overall, GSCs are central to the aggressive nature of GBM and are key factors in its poor prognosis.",
        "Glioblastoma stem-like cells (GSCs) play critical roles in tumor progression and therapy resistance in glioblastoma multiforme (GBM). GSCs possess the ability to self-renew, differentiate into distinct lineages within the tumor, and initiate tumor growth, contributing to tumor cell heterogeneity. These cells are radioresistant and chemoresistant, enabling them to survive current therapeutic approaches through both cell-autonomous mechanisms and interactions with the tumor microenvironment. GSCs reside in specific tumor niches that support their behavior and contribute to systemic immunosuppression. Their persistence after conventional treatments ultimately leads to tumor recurrence, making them crucial therapeutic targets. New treatment strategies that specifically target GSCs and/or their microenvironmental niche are necessary to effectively combat GBM growth and prevent recurrence.",
        "Glioblastoma stem-like cells (GSCs) play a pivotal role in tumor progression and therapy resistance. Studies indicate that GSCs possess self-renewal capabilities, enabling them to differentiate into various tumor cell types and initiate new tumors. Their ability to evade conventional therapies stems from both intrinsic cellular mechanisms and interactions with their microenvironment. This dual resistance mechanism underscores the importance of targeting GSCs and their niche for effective GBM treatment, as they are central to recurrence and therapeutic challenges.",
        "Glioblastoma stem-like cells (GSCs) play a critical role in tumor progression and therapy resistance in glioblastoma multiforme (GBM). GSCs have the capacity to self-renew and differentiate into various cell types within the tumor, contributing to tumor cell heterogeneity. This heterogeneity is a key factor in the resistance of GBM to conventional therapies such as radiation and chemotherapy. Additionally, GSCs are situated in specific tumor niches that support their survival and maintenance, further enhancing their resistance to treatment. These cells are also implicated in promoting systemic immunosuppression, which can impair the body\u0027s immune response against the tumor. Due to these properties, GSCs are crucial targets for developing new therapeutic strategies aimed at effectively treating GBM and preventing tumor recurrence.",
        "Glioblastoma stem-like cells (GSCs) play a pivotal role in both tumor progression and therapy resistance. They possess stem cell-like properties, such as self-renewal and differentiation, which enable them to sustain tumor growth and lead to recurrence after treatment. GSCs are inherently resistant to conventional therapies like radiation and chemotherapy, using mechanisms that involve both their intrinsic cellular properties and interactions with the tumor microenvironment. Additionally, they contribute to tumor heterogeneity and induce immunosuppression, further evading immune detection. Targeting these cells and their niche is crucial for developing effective treatments to overcome their resistance and improve patient outcomes.",
        "Glioblastoma stem-like cells (GSCs) play a pivotal role in tumor progression and therapy resistance. Studies indicate that GSCs possess self-renewal capabilities, enabling them to differentiate into various tumor cell types and initiate new tumor growth. These cells utilize both intrinsic mechanisms and their surrounding microenvironment to evade conventional treatments, contributing significantly to radiation and chemotherapy resistance. Their ability to promote tumor heterogeneity and induce systemic immunosuppression further complicates treatment efficacy. Targeting GSCs and their niche is essential for developing novel therapies aimed at improving patient outcomes by effectively eradicating GBM growth and recurrence.",
        "Glioblastoma stem-like cells drive tumor growth and recurrence by initiating new tumor formation and sustaining tumor cell heterogeneity. Their unique self-renewal abilities and resilience allow them to survive standard chemo- and radiotherapy, contributing to treatment failure. These cells often remain in a quiescent state, evading therapies that target rapidly dividing cells, and they possess enhanced mechanisms for DNA repair and stress response. As a result, they repopulate the tumor after therapy and facilitate tumor progression and resistance to conventional treatments.",
        "Glioblastoma stem-like cells (GSCs) play a crucial role in tumor progression by self-renewing, differentiating into distinct lineages within the tumor, and initiating tumor growth. They are radioresistant and chemoresistant, residing in specific niches that support their behavior, which leads to tumor recurrence and resistance to current therapeutic approaches. Therefore, GSCs are important targets for developing new strategies aimed at eradicating GBM."
      ]
    },
    {
      "body": "What are the main advantages of mirnovo compared to existing tools?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29036314"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 684,
          "offsetInEndSection": 1586,
          "text": "Previous approaches to the prediction of novel miRNAs usually involve the analysis of structural features of miRNA precursor hairpin sequences obtained from genome sequence. We surmised that it may be possible to identify miRNAs by using these biogenesis features observed directly from sequenced reads, solely or in addition to structural analysis from genome data. To this end, we have developed mirnovo, a machine learning based algorithm, which is able to identify known and novel miRNAs in animals and plants directly from small RNA-Seq data, with or without a reference genome. This method performs comparably to existing tools, however is simpler to use with reduced run time. Its performance and accuracy has been tested on multiple datasets, including species with poorly assembled genomes, RNaseIII (Drosha and/or Dicer) deficient samples and single cells (at both embryonic and adult stage).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036314"
        }
      ],
      "id": "67e28a8418b1e36f2e00007d",
      "ideal_answer": [
        "Mirnovo is a machine learning based algorithm, which is able to identify known and novel miRNAs in animals and plants directly from small RNA-Seq data, with or without a reference genome. The method performs comparably to existing tools, however is simpler to use with reduced run time.",
        "Mirnovo offers several advantages over existing tools. It is simpler to use and has a reduced run time. It can identify miRNAs directly from small RNA-Seq data with or without a reference genome. Additionally, it performs effectively in species with poorly assembled genomes, RNaseIII deficient samples, and single cells at both embryonic and adult stages.",
        "Mirnovo offers several key advantages over existing tools, primarily its simplicity of use and reduced run time, making it more efficient. A standout feature is its genome-free prediction capability, allowing for miRNA identification directly from small RNA-Seq data with or without a reference genome. This versatility is particularly beneficial for analyzing single cells and species with poorly assembled genomes. Additionally, mirnovo demonstrates comparable performance to existing tools, further solidifying its position as a valuable resource in the field of miRNA research.",
        "Mirnovo offers several advantages over existing tools in biomedicine. It is designed to be simpler to use and operates with a reduced run time compared to other tools. The performance and accuracy of Mirnovo have been validated across multiple datasets, including species with poorly assembled genomes, RNaseIII deficient samples, and single cells. These features make Mirnovo a valuable tool for researchers working with diverse and challenging datasets.",
        "The main advantages of Mirnovo compared to existing tools include its open-source and accessible nature, which promotes rapid adoption among developers. It allows for the comparison of a wide range of variables beyond HPO or OMIM terms while preserving full context. The simplicity of the tools, which are fully accessible and free of charge, contributes to its wide adoption by communities of professional programmers. Moreover, its data-intensive resources present opportunities for developing Software Development Kits (SDKs) to streamline drug metrics efficiently without the need for downloads or installations. By adhering to the FAIR principles—Findability, Accessibility, Interoperability, and Reusability—Mirnovo ensures the stewardship of scientific data. Additionally, version control allows for continuous improvements and integration with other systems like Eclipse, enriching its clinical applications.",
        "The main advantages of mirnovo compared to existing tools include its ability to identify known and novel miRNAs directly from small RNA-Seq data with or without a reference genome, substantial improvements in prediction performance, and a simpler user interface with reduced run time and input data requirements.",
        "The main advantages of mirnovo compared to existing tools include: 1. Ability to identify known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome. 2. Simplicity of use with reduced run time. 3. Comparable performance and accuracy to existing tools, tested on multiple datasets including poorly assembled genomes and single cells.",
        "The main advantages of mirnovo compared to existing tools include: 1. Ability to identify known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome. 2. Integration of both expression-based and sequence-based features for improved prediction performance. 3. Simplicity of use with reduced requirements for input data and dependencies. 4. Substantial improvements in prediction performance compared to other methods, as demonstrated by precision-recall curves.",
        "Mirnovo offers several key advantages over existing tools, including its simplicity of use and significantly reduced run time. A major benefit is its flexibility in identifying microRNAs (miRNAs) directly from small RNA-Seq data, whether or not a reference genome is available. This versatility makes mirnovo particularly suited for challenging scenarios such as analyzing single-cell data, species with poorly assembled genomes, and RNaseIII deficient samples, all without compromising its performance or accuracy compared to other available tools.",
        "The main advantages of mirnovo compared to existing tools are its ability to identify known and novel miRNAs directly from small RNA-Seq data with or without a reference genome, its simplicity of use, and its reduced run time. It performs comparably to other tools and has been tested on multiple datasets, including species with poorly assembled genomes, RNaseIII deficient samples, and single cells.",
        "The main advantages of mirnovo compared to existing tools include its ease of use and reduced run time, making it simpler and faster to operate. Mirnovo has demonstrated high performance and accuracy across various datasets, including species with poorly assembled genomes, RNaseIII deficient samples, and single cells at both embryonic and adult stages. Additionally, mirnovo offers comprehensive RNA analysis by providing information about various RNA types such as tRNA, rRNA, snoRNA, moRNA, loop-RNA, along with identifying both known and novel miRNAs. These features make mirnovo a robust, reliable, and reproducible tool for identifying novel miRNAs from RNA sequencing data, offering a more comprehensive analysis compared to existing tools.",
        "Mirnovo\u0027s main advantages over existing tools include its ability to predict microRNAs from small RNA sequencing data without a reference genome, simpler usage, and reduced run time, leveraging machine learning to identify miRNAs across diverse datasets, including single-cell and poorly assembled genomes, with comparable performance to existing tools.",
        "The main advantages of mirnovo lie in its simplicity, reduced run time, and ability to perform comparably to existing tools. This machine learning-based algorithm can identify known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome, making it a versatile tool for various species, including those with poorly assembled genomes. Additionally, mirnovo\u0027s performance has been successfully tested on diverse datasets, such as RNaseIII deficient samples and single cells at different developmental stages, demonstrating its robustness and accuracy. Overall, mirnovo offers a efficient and effective solution for miRNA identification, making it a valuable asset for studies involving small RNA-Seq data analysis.",
        "Mirnovo is a machine learning algorithm that offers key advantages over existing miRNA identification tools by being simpler to use, having reduced run time, and uniquely capable of identifying miRNAs directly from small RNA-Seq data with or without a reference genome. The tool\u0027s versatility is demonstrated through its successful performance on various datasets, including species with poorly assembled genomes, RNaseIII deficient samples, and single cells at different developmental stages.",
        "The main advantages of mirnovo include its ability to identify miRNAs directly from small RNA-Seq data without requiring a reference genome, making it suitable for species with poorly assembled genomes. It incorporates biogenesis features observed from sequenced reads, either alone or alongside structural analysis, enhancing its versatility. Additionally, mirnovo is simpler to use compared to existing tools, offers reduced run time, and has been validated across diverse and challenging datasets, such as RNaseIII-deficient samples (e.g., Drosha/Dicer mutants) and single-cell data from both embryonic and adult stages. Its machine learning-based approach ensures robust performance in animals and plants, even under suboptimal genomic conditions.",
        "Mirnovo is simpler to use with reduced run time compared to existing tools. It is able to identify known and novel miRNAs in animals and plants directly from small RNA-Seq data, with or without a reference genome. Its performance and accuracy has been tested on multiple datasets, including species with poorly assembled genomes, RNaseIII (Drosha and/or Dicer) deficient samples and single cells (at both embryonic and adult stage).",
        "The main advantages of mirnovo compared to existing tools include: 1. Ability to identify known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome. 2. Simplicity of use with reduced run time. 3. Comparable performance and accuracy to existing tools. 4. Tested on multiple datasets, including poorly assembled genomes and single cells.",
        "The main advantages of mirnovo compared to existing tools include reduced run time, simpler to use, direct identification from small RNA-Seq data, comparable performance to existing tools, and the ability to identify novel miRNAs without the need for a reference genome.",
        "The main advantages of mirnovo compared to existing tools are its simplicity of use, reduced run time, and ability to identify known and novel miRNAs directly from small RNA-Seq data, without the need for a reference genome. It also performs well on datasets from species with poorly assembled genomes, RNaseIII deficient samples, and single cells at both embryonic and adult stages.",
        "Mirnovo is simpler to use and has a reduced run time compared to existing tools. It identifies known and novel miRNAs in animals and plants directly from small RNA-Seq data, with or without a reference genome. Its performance and accuracy have been tested on multiple datasets, including species with poorly assembled genomes, RNaseIII (Drosha and/or Dicer) deficient samples, and single cells (at both embryonic and adult stage). Evaluation using precision-recall curves for six NGS data sets representing diverse species demonstrates improved prediction performance compared to miRDeep2 and miRanalyzer.",
        "The main advantages of mirnovo compared to existing tools include its ability to identify known and novel miRNAs in animals and plants directly from small RNA-Seq data, with or without a reference genome. It performs comparably to existing tools but is simpler to use with reduced run time. Additionally, it has been tested on multiple datasets, including species with poorly assembled genomes, RNaseIII (Drosha and/or Dicer) deficient samples and single cells at both embryonic and adult stages.",
        "The main advantages of mirnovo compared to existing tools are its simplicity of use, reduced run time, and comparable performance and accuracy in identifying known and novel miRNAs from small RNA-Seq data, even in challenging datasets such as poorly assembled genomes and RNaseIII deficient samples.",
        "The main advantages of mirnovo compared to existing tools are its ability to identify known and novel miRNAs directly from small RNA-Seq data, without necessarily requiring a reference genome. This makes it particularly useful for species with poorly assembled genomes or in cases involving RNaseIII (Drosha and/or Dicer) deficient samples and single cells at both embryonic and adult stages. Additionally, mirnovo is simpler to use and has reduced run time compared to other tools, while still performing comparably in terms of performance and accuracy.",
        "The main advantages of mirnovo compared to existing tools are its ability to function without a reference genome, simplicity of use, reduced runtime for faster processing, and effectiveness with challenging datasets, such as those from species with poorly assembled genomes or RNaseIII-deficient samples.",
        "The main advantages of mirnovo compared to existing tools include: 1. Ability to identify known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome. 2. Simpler to use with reduced run time. 3. Comparable performance and accuracy to existing tools. 4. Tested on multiple datasets, including poorly assembled genomes and single cells. 5. Integrates biogenesis features observed directly from sequenced reads.",
        "The main advantages of mirnovo compared to existing tools include: 1. Ability to identify known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome. 2. Simplicity of use with reduced run time. 3. Comparable performance and accuracy to existing tools. 4. Tested on multiple datasets, including those with poorly assembled genomes and RNaseIII deficient samples. 5. Effective for single-cell analysis at both embryonic and adult stages.",
        "Mirnovo is more user-friendly, faster, and can effectively identify miRNAs even without a reference genome.",
        "Mirnovo offers several key advantages over existing tools, including the ability to predict microRNAs directly from small RNA-Seq data without needing a reference genome, simpler usability, and significantly reduced run times. It maintains comparable performance and accuracy to other methods, with versatility in handling diverse datasets, including those from species with poorly assembled genomes and single-cell analyses. This makes mirnovo a streamlined, efficient, and effective alternative for miRNA identification across a wide range of applications.",
        "The main advantages of mirnovo compared to existing tools include: 1. Ability to identify known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome. 2. Comparable performance and accuracy to existing tools. 3. Simplicity of use. 4. Reduced run time for analysis. 5. Tested performance on multiple datasets, including challenging samples such as poorly assembled genomes and RNaseIII deficient samples.",
        "The main advantages of mirnovo compared to existing tools include its ability to identify known and novel miRNAs directly from small RNA-Seq data, regardless of the availability of a reference genome. This flexibility makes it particularly useful for species with poorly assembled genomes. Additionally, mirnovo is simpler to use compared to other methods, offering reduced run times while maintaining comparable performance and accuracy. It has been effectively tested across various datasets, including conditions lacking functional RNaseIII enzymes and in single-cell contexts at both embryonic and adult stages, further showcasing its robustness and versatility.",
        "Mirnovo offers several key advantages over existing tools, including its simplicity of use, reduced run time, and unparalleled versatility in handling small RNA-Seq data with or without a reference genome. Notably, it enables direct identification of miRNAs from such data, streamlining analysis. These benefits are achieved without compromising on performance, as mirnovo has been shown to work comparably to other methods across diverse datasets, including those with poorly assembled genomes, RNaseIII deficient samples, and single-cell analyses.",
        "The main advantages of mirnovo compared to existing tools are that it is simpler to use with reduced run time, and it can identify known and novel miRNAs in animals and plants directly from small RNA-Seq data, with or without a reference genome.",
        "mirnovo is a machine learning based algorithm that can identify known and novel miRNAs in animals and plants directly from small RNA-Seq data, with or without a reference genome. It performs comparably to existing tools, however is simpler to use with reduced run time.",
        "The main advantages of mirnovo compared to existing tools are its simplicity of use and reduced run time, while maintaining comparable performance and accuracy.",
        "Mirnovo offers several key advantages over existing tools: it can identify miRNAs directly from small RNA-Seq data with or without a reference genome, making it versatile for diverse species and challenging samples like those with poorly assembled genomes or RNaseIII deficiencies. Additionally, mirnovo is simpler to use and more efficient, with reduced runtime compared to other methods, enhancing accessibility and speed for researchers.",
        "The main advantages of mirnovo compared to existing tools are its ability to identify known and novel miRNAs directly from small RNA-Seq data without requiring a reference genome. Additionally, mirnovo offers a simpler usage with reduced run time. Its performance and accuracy have been validated on multiple datasets, including those from species with poorly assembled genomes, RNaseIII deficient samples, and single cells at various developmental stages.",
        "The main advantages of mirnovo compared to existing tools are its simplicity of use, significantly reduced computational run time, and the unique capability to predict microRNAs effectively without a reference genome. Additionally, mirnovo maintains comparable performance and accuracy across a wide range of datasets, showcasing its versatility, particularly with challenging samples such as single-cell analyses and genomes that are poorly assembled.",
        "Mirnovo offers several advantages over existing tools for miRNA prediction. It identifies known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome, making it versatile for diverse datasets. Utilizing a machine learning approach, mirnovo simplifies usage and reduces runtime compared to other methods. Its effectiveness has been validated across challenging studies, including those involving poorly assembled genomes, RNaseIII deficient samples, and single-cell analyses at various developmental stages.",
        "The main advantages of mirnovo compared to existing tools are its simplicity of use, reduced run time, and versatility in operating with or without a reference genome, all while maintaining comparable performance and accuracy.",
        "Mirnovo is simpler to use and has a reduced run time compared to existing tools for miRNA prediction. It can identify known and novel miRNAs in animals and plants directly from small RNA-Seq data, with or without a reference genome. Its performance and accuracy have been tested on multiple datasets, including species with poorly assembled genomes, RNaseIII (Drosha and/or Dicer) deficient samples, and single cells at both embryonic and adult stages.",
        "The main advantages of mirnovo compared to existing tools are its simplicity in usage, reduced run time, and comparable performance. It can identify known and novel miRNAs directly from small RNA-Seq data, with or without a reference genome, making it versatile for various species including those with poorly assembled genomes, RNaseIII deficient samples, and single cells at both embryonic and adult stages."
      ],
      "exact_answer": [
        [
          "Simpler to use"
        ],
        [
          "Reduced run time"
        ]
      ]
    },
    {
      "body": "What is the target of Abelacimab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39094433",
        "http://www.ncbi.nlm.nih.gov/pubmed/39073551",
        "http://www.ncbi.nlm.nih.gov/pubmed/38545505",
        "http://www.ncbi.nlm.nih.gov/pubmed/38534886",
        "http://www.ncbi.nlm.nih.gov/pubmed/38984712",
        "http://www.ncbi.nlm.nih.gov/pubmed/39675564",
        "http://www.ncbi.nlm.nih.gov/pubmed/39549166",
        "http://www.ncbi.nlm.nih.gov/pubmed/34714969",
        "http://www.ncbi.nlm.nih.gov/pubmed/34297496",
        "http://www.ncbi.nlm.nih.gov/pubmed/37116752",
        "http://www.ncbi.nlm.nih.gov/pubmed/36386334",
        "http://www.ncbi.nlm.nih.gov/pubmed/37422330",
        "http://www.ncbi.nlm.nih.gov/pubmed/39077577"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 989,
          "offsetInEndSection": 1163,
          "text": "A number of compounds with different mechanisms of action have been developed to target FXI (i.e., asundexian, abelacimab, Ionis-FXIRx, milvexian, osocimab, and Xisomab 3G). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073551"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38545505"
        },
        {
          "offsetInBeginSection": 578,
          "offsetInEndSection": 703,
          "text": "Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38545505"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 539,
          "text": "Inhibitors of the factor FXI represent a new class of anticoagulant agents that are facing clinical approval for the treatment of acute coronary syndrome (ACS), venous thromboembolism (VTE), and stroke prevention of atrial fibrillation (AF). These new inhibitors include chemical small molecules (asundexian and milvexian), monoclonal antibodies (abelacimab, osocimab, and xisomab), and antisense oligonucleotides (IONIS-FXIRX and fesomersen), and thus, they have very peculiar and different pharmacokinetic and pharmacodynamic properties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38534886"
        },
        {
          "offsetInBeginSection": 1207,
          "offsetInEndSection": 1878,
          "text": "FXI inhibitors have shown potential benefits in phase II trials, demonstrating similar or reduced bleeding rates to existing agents, including DOACs. The early termination of AZALEA‑TIMI 71 (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation) and OCEANIC‑AF (A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat [Atrial Fibrillation], and at Risk for Stroke) trials underscores challenges in the selection of appropriate patient populations and anticoagulant class, agent, and dose. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38984712"
        },
        {
          "offsetInBeginSection": 1083,
          "offsetInEndSection": 1421,
          "text": "Among the FⅪ/FXIa inhibitors of coagulation, a parenterally administered monoclonal antibody (abelacimab) and 2 orally administered small molecule inhibitors (asundexian, milvexian) are collectively being studied in patients with atrial fibrillation, cancer-associated venous thromboembolism, acute coronary syndrome, and ischemic stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39675564"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39549166"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 215,
          "text": "We investigated the effects of abelacimab, a novel monoclonal antibody targeting factor XI. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39549166"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 213,
          "text": "We investigated the effects of abelacimab, a novel monoclonal antibody targeting factor XI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39549166"
        },
        {
          "offsetInBeginSection": 1579,
          "offsetInEndSection": 1760,
          "text": "Enormous progress has been made in the research strategies for FXI inhibitors, with abelacimab already in phase III clinical trials and most other inhibitors in phase I or II trials",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36386334"
        },
        {
          "offsetInBeginSection": 803,
          "offsetInEndSection": 1011,
          "text": "These include fesomersen, an antisense oligonucleotide that reduces the hepatic synthesis of FXI; abelacimab, an antibody that binds to FXI and blocks its activation; and osocimab, an FXIa inhibitory antibody",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37116752"
        },
        {
          "offsetInBeginSection": 472,
          "offsetInEndSection": 620,
          "text": "target due to its significant role in pathological thrombosis and minor involvement in normal hemostasis. Abelacimab, an antibody that inhibits FXI,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38545505"
        },
        {
          "offsetInBeginSection": 68,
          "offsetInEndSection": 323,
          "text": "sis-sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the ac",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969"
        },
        {
          "offsetInBeginSection": 989,
          "offsetInEndSection": 1161,
          "text": "A number of compounds with different mechanisms of action have been developed to target FXI (i.e., asundexian, abelacimab, Ionis-FXIRx, milvexian, osocimab, and Xisomab 3G)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073551"
        },
        {
          "offsetInBeginSection": 1231,
          "offsetInEndSection": 1562,
          "text": "This review summaries the role of FXI and FXIa in hemostasis, provides evidence of initial success with FXI pathway inhibitors in clinical trials (such as IONIS-FXIRx, fesomersen, osocimab, abelacimab, milvexian, asundexian or xisomab 3G3) and highlights the opportunities and challenges for this next generation of anticoagulants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37422330"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 323,
          "text": "lic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the ac",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 218,
          "text": " uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 214,
          "text": "We investigated the effects of abelacimab, a novel monoclonal antibody targeting factor XI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39549166"
        },
        {
          "offsetInBeginSection": 1279,
          "offsetInEndSection": 1442,
          "text": "In this challenging scenario, abelacimab, an anti-factor XI agent, could represent a viable option in the management of CAT due to its \"hemostasis sparing\" effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39077577"
        },
        {
          "offsetInBeginSection": 989,
          "offsetInEndSection": 1162,
          "text": "A number of compounds with different mechanisms of action have been developed to target FXI (i.e., asundexian, abelacimab, Ionis-FXIRx, milvexian, osocimab, and Xisomab 3G).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073551"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 719,
          "text": "Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the activated FXI.OBJECTIVES: To investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single dose intravenous and multiple dose subcutaneous administration of abelacimab in healthy volunteers and patients with atrial fibrillation, respectively.PATIENTS/METHODS: In study ANT-003, healthy volunteers were administered single intravenous doses of abelacimab (30-150 mg) or placebo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 563,
          "text": "Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation.METHODS: In this open-label, parallel-group trial, we randomly assigned 412 patients who were undergoing total knee arthroplasty to receive one of three regimens of abelacimab (30 mg, 75 mg, or 150 mg) administered postoperatively in a single intravenous dose or to receive 40 mg of enoxaparin administered subcutaneously once daily.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969"
        },
        {
          "offsetInBeginSection": 803,
          "offsetInEndSection": 1012,
          "text": "These include fesomersen, an antisense oligonucleotide that reduces the hepatic synthesis of FXI; abelacimab, an antibody that binds to FXI and blocks its activation; and osocimab, an FXIa inhibitory antibody.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37116752"
        },
        {
          "offsetInBeginSection": 154,
          "offsetInEndSection": 334,
          "text": " Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the activated FXI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 229,
          "text": " Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 322,
          "text": "lic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 217,
          "text": " uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496"
        },
        {
          "offsetInBeginSection": 901,
          "offsetInEndSection": 968,
          "text": "abelacimab, an antibody that binds to FXI and blocks its activation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37116752"
        },
        {
          "offsetInBeginSection": 578,
          "offsetInEndSection": 702,
          "text": "Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38545505"
        },
        {
          "offsetInBeginSection": 989,
          "offsetInEndSection": 1160,
          "text": "A number of compounds with different mechanisms of action have been developed to target FXI (i.e., asundexian, abelacimab, Ionis-FXIRx, milvexian, osocimab, and Xisomab 3G",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073551"
        },
        {
          "offsetInBeginSection": 1309,
          "offsetInEndSection": 1441,
          "text": "abelacimab, an anti-factor XI agent, could represent a viable option in the management of CAT due to its \"hemostasis sparing\" effect",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39077577"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 703,
          "text": "Factor XI (FXI) as a promising anticoagulation target due to its significant role in pathological thrombosis and minor involvement in normal hemostasis. Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38545505"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 229,
          "text": "Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 334,
          "text": "Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymogen Factor XI and the activated FXI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34714969"
        },
        {
          "offsetInBeginSection": 1083,
          "offsetInEndSection": 1420,
          "text": "Among the FⅪ/FXIa inhibitors of coagulation, a parenterally administered monoclonal antibody (abelacimab) and 2 orally administered small molecule inhibitors (asundexian, milvexian) are collectively being studied in patients with atrial fibrillation, cancer-associated venous thromboembolism, acute coronary syndrome, and ischemic stroke",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39675564"
        },
        {
          "offsetInBeginSection": 1579,
          "offsetInEndSection": 1761,
          "text": "Enormous progress has been made in the research strategies for FXI inhibitors, with abelacimab already in phase III clinical trials and most other inhibitors in phase I or II trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36386334"
        },
        {
          "offsetInBeginSection": 1231,
          "offsetInEndSection": 1471,
          "text": "This review summaries the role of FXI and FXIa in hemostasis, provides evidence of initial success with FXI pathway inhibitors in clinical trials (such as IONIS-FXIRx, fesomersen, osocimab, abelacimab, milvexian, asundexian or xisomab 3G3) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37422330"
        },
        {
          "offsetInBeginSection": 393,
          "offsetInEndSection": 702,
          "text": "Recent research has highlighted Factor XI (FXI) as a promising anticoagulation target due to its significant role in pathological thrombosis and minor involvement in normal hemostasis. Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38545505"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "Drugs targeting factor XI may offer an alternative to heparin for preventing blood clotting in extracorporeal circulation. We investigated the effects of abelacimab, a novel monoclonal antibody targeting factor XI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39549166"
        },
        {
          "offsetInBeginSection": 1579,
          "offsetInEndSection": 1710,
          "text": "Enormous progress has been made in the research strategies for FXI inhibitors, with abelacimab already in phase III clinical trials",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36386334"
        },
        {
          "offsetInBeginSection": 1536,
          "offsetInEndSection": 1737,
          "text": "f postoperative venous thromboembolism. Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and wa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297496"
        }
      ],
      "type": "factoid",
      "id": "67e56b5418b1e36f2e0000ad",
      "ideal_answer": [
        "Abelacimab is a novel monoclonal antibody targeting factor XI."
      ],
      "exact_answer": [
        [
          "factor XI"
        ]
      ]
    },
    {
      "body": "Is Ameloblastoma a malignant type of cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39444727",
        "http://www.ncbi.nlm.nih.gov/pubmed/37691573",
        "http://www.ncbi.nlm.nih.gov/pubmed/38304511",
        "http://www.ncbi.nlm.nih.gov/pubmed/21112523",
        "http://www.ncbi.nlm.nih.gov/pubmed/23120181",
        "http://www.ncbi.nlm.nih.gov/pubmed/39675431",
        "http://www.ncbi.nlm.nih.gov/pubmed/39615675",
        "http://www.ncbi.nlm.nih.gov/pubmed/39597858",
        "http://www.ncbi.nlm.nih.gov/pubmed/31232921",
        "http://www.ncbi.nlm.nih.gov/pubmed/6575436",
        "http://www.ncbi.nlm.nih.gov/pubmed/39268316",
        "http://www.ncbi.nlm.nih.gov/pubmed/39321125",
        "http://www.ncbi.nlm.nih.gov/pubmed/39739058",
        "http://www.ncbi.nlm.nih.gov/pubmed/39737843",
        "http://www.ncbi.nlm.nih.gov/pubmed/39192690",
        "http://www.ncbi.nlm.nih.gov/pubmed/21558899",
        "http://www.ncbi.nlm.nih.gov/pubmed/10578986",
        "http://www.ncbi.nlm.nih.gov/pubmed/38061123",
        "http://www.ncbi.nlm.nih.gov/pubmed/19995435",
        "http://www.ncbi.nlm.nih.gov/pubmed/39659305",
        "http://www.ncbi.nlm.nih.gov/pubmed/39547854",
        "http://www.ncbi.nlm.nih.gov/pubmed/28942297",
        "http://www.ncbi.nlm.nih.gov/pubmed/10895162",
        "http://www.ncbi.nlm.nih.gov/pubmed/30775320",
        "http://www.ncbi.nlm.nih.gov/pubmed/11791248",
        "http://www.ncbi.nlm.nih.gov/pubmed/12907214",
        "http://www.ncbi.nlm.nih.gov/pubmed/22920533",
        "http://www.ncbi.nlm.nih.gov/pubmed/27859616",
        "http://www.ncbi.nlm.nih.gov/pubmed/26101729",
        "http://www.ncbi.nlm.nih.gov/pubmed/27386438",
        "http://www.ncbi.nlm.nih.gov/pubmed/33394372",
        "http://www.ncbi.nlm.nih.gov/pubmed/38156168",
        "http://www.ncbi.nlm.nih.gov/pubmed/15157215",
        "http://www.ncbi.nlm.nih.gov/pubmed/31674718"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Ameloblastoma is the most common and highly invasive benign odontogenic tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39444727"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 222,
          "text": "Ameloblastoma is a benign neoplasm composed of epithelial tissue with invasive and infiltrative behavior at the local level and a high recurrence rate, with various histopathologic patterns and clinical forms. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37691573"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Ameloblastoma is a benign odontogenic tumor that is locally destructive. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38304511"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 370,
          "text": "Ameloblastic carcinoma is classified into 2 types: a primary odontogenic malignancy and a secondary type resulting from malignant transformation of ameloblastoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112523"
        },
        {
          "offsetInBeginSection": 594,
          "offsetInEndSection": 725,
          "text": "Ameloblastic carcinoma is a tumor with microscopic features of ameloblastoma that displays malignant features at cytological level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23120181"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Ameloblastoma is a rare, locally aggressive benign tumor primarily affecting the mandible, with an incidence of 0",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39268316"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "BACKGROUND Ameloblastoma is a locally aggressive, benign, odontogenic tumor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321125"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 115,
          "text": "Ameloblastoma is a benign tumor originating from odontogenic epithelium with a global incidence of about 0",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739058"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 408,
          "text": "Ameloblastoma (AB) is a benign odontogenic tumor of epithelial origin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39737843"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 75,
          "text": "Ameloblastoma is a locally destructive benign odontogenic tumor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39192690"
        },
        {
          "offsetInBeginSection": 1370,
          "offsetInEndSection": 1564,
          "text": "Although metastatic ameloblastoma was reclassified as a benign tumor by the WHO in 2017, the vital risk for patients remains consequent, and statistically similar to malignant odontogenic tumors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39615675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Ameloblastoma of the maxilla is a rare odontogenic tumor that rarely metastasizes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21558899"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 297,
          "text": "BACKGROUND: Ameloblastoma is a rare tumor of the jaw that arises from the odontogenic epithelium. Ameloblastomas have a propensity for local recurrence and, rarely, for metastasis. The term malignant ameloblastoma is reserved for those metastasizing tumors that retain the typical morphology of am",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10578986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "BACKGROUND: Ameloblastoma is characterized by aggressive nature, high recurrence rate, occasional malignant transformation, but recurrence and malignant incidence of ameloblastoma are not yet addressed by a large-scale case series study",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38061123"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "BACKGROUND: Ameloblastoma is a frequent odontogenic benign tumor characterized by local invasiveness, high risk of recurrence and occasional metastasis and malignant transforma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19995435"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 152,
          "text": "Ameloblastoma is a benign tumor originating from odontogenic epithelium with a global incidence of about 0.5 cases per million persons per year",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739058"
        },
        {
          "offsetInBeginSection": 240,
          "offsetInEndSection": 390,
          "text": "Ameloblastomas, though benign, require radical surgical management due to their aggressive nature and high recurrence rates, especially in the maxilla",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39659305"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "PURPOSE: Ameloblastoma is a benign tumor originating from odontogenic epithelium with a global incidence of about 0.5 cases per million persons ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739058"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Ameloblastoma (AM) is a benign but locally infiltrative epithelial odontogenic neoplasm of the jawbones that may reach grotesque proportions and be highly recurrent if inadequately removed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39675431"
        },
        {
          "offsetInBeginSection": 240,
          "offsetInEndSection": 391,
          "text": "Ameloblastomas, though benign, require radical surgical management due to their aggressive nature and high recurrence rates, especially in the maxilla.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39659305"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Ameloblastoma is a true benign odontogenic epithelial tumor, primarily arising in the jaw, and ranks as the second most prevalent odontogenic neoplasm following odontoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39547854"
        },
        {
          "offsetInBeginSection": 1316,
          "offsetInEndSection": 1511,
          "text": "cific survival between the three histological groups. Although metastatic ameloblastoma was reclassified as a benign tumor by the WHO in 2017, the vital risk for patients remains consequent, and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39615675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Peripheral ameloblastoma (PA) is a rare benign tumor that can occur mostly in the mandibular gingiva of the premolar area, originating from the residual odontogenic epithelium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39597858"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Ameloblastoma is a histologically benign tumor derived from odontogenic apparatus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10895162"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 202,
          "text": "Ameloblastomas are considered as benign, yet locally aggressive neoplasms in the vast majority of cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12907214"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Ameloblastoma is a benign odontogenic neoplasm of the mandible and maxilla that rarely exhibits malignant behavior.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11791248"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Ameloblastoma is characterized by slow-growing, local invasiveness and high incidence of local recurrence. It usually presents with a benign histological appearance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22920533"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Malignant variants of ameloblastoma include metastasizing ameloblastoma, which microscopically appears benign but has metastasized and ameloblastic carcinoma that exhibits malignant histopathologic features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112523"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "INTRODUCTION: Ameloblastoma is a benign odontogenic neoplasm of the jaw, rarely presenting as a ma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26101729"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Ameloblastoma is a locally invasive, histologically nonmalignant tumor that may on very rare occasions give rise to metastases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6575436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "BACKGROUND: Ameloblastoma is a benign but locally aggressive odontogenic tumor, while ameloblastic carcinoma is its malignant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27859616"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Ameloblastoma is an uncommon and locally aggressive, benign, odontogenic tumor, with local recurrence when not adequately excised.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30775320"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 290,
          "text": "Ameloblastomas are a group of benign but locally invasive neoplasms that occur in the jaws and are derived from epithelial elements of the tooth-forming apparatus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27386438"
        },
        {
          "offsetInBeginSection": 455,
          "offsetInEndSection": 543,
          "text": "The term benign metastasizing ameloblastoma is suggested to describe this kind of tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21558899"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Ameloblastoma, a benign but locally aggressive odontogenic tumor, often demonstrates metastasis despite benign histological features and this variant is termed as metastasizing ameloblastoma (METAM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33394372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Ameloblastoma is a benign yet locally aggressive tumor of the jaw bones and is most commonly found in the lower mandibular region. Histologically, it shows benign characteristics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38156168"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Ameloblastoma is a benign odontogenic neoplasm of the mandible and maxilla that rarely exhibits malignant behavior",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11791248"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 199,
          "text": "The resulting tumors or cysts are of odontogenic epithelial origin, are usually benign in nature and rarely metastasize to distant organs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15157215"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Ameloblastoma is an uncommon and locally aggressive, benign, odontogenic tumor, with local recurrence when not adequately excised",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30775320"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "RATIONALE: Ameloblastoma is generally characterized as a benign tumor originating in odontogenic epithelium. However, few cases of metastatic malignant ameloblastoma have also be",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31232921"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Ameloblastic carcinoma (AC) is defined as a rare primary epithelial odontogenic malignant neoplasm and the malignant counterpart of benign epithelial odontogenic tumor of ameloblastoma (AB) by the WHO classification",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31674718"
        }
      ],
      "type": "yesno",
      "id": "67e94f4418b1e36f2e0000dc",
      "ideal_answer": [
        "Ameloblastoma is the most common and highly invasive benign odontogenic tumor.",
        "No, Ameloblastoma is a benign tumor.",
        "No, ameloblastoma is not a malignant type of cancer. It is a rare, locally aggressive benign tumor that primarily affects the mandible. Although it is benign, it can still cause significant damage to the surrounding tissues and requires careful management and treatment to prevent recurrence.",
        "No, ameloblastoma is typically considered a benign tumor. However, it can be locally aggressive and has a high recurrence rate if not completely removed. It is not classified as a malignant type of cancer.",
        "Ameloblastoma is generally a benign but locally aggressive odontogenic tumor. However, malignant variations exist, including malignant ameloblastoma and ameloblastic carcinoma. Malignant ameloblastoma refers to tumors that metastasize while retaining the typical morphology of ameloblastoma. Ameloblastic carcinoma exhibits malignant histopathologic features, regardless of metastasis.",
        "No, Ameloblastoma is a histologically benign tumor derived from odontogenic apparatus.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, although it is locally aggressive and can cause significant morbidity.",
        "No, Ameloblastoma is not a malignant type of cancer.",
        "Ameloblastoma is generally a benign tumor that is locally invasive and prone to recurrence, although it rarely metastasizes. When metastasis is observed while the tumor maintains its benign cellular appearance, it is termed malignant ameloblastoma. Despite its benign classification, the tumor’s aggressive local behavior and potential for recurrence remain significant clinical issues.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, although it is locally aggressive and has a high potential for malignant transformation.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, not a malignant type of cancer.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, although it can be locally aggressive and has a high potential for recurrence.",
        "Ameloblastoma is typically benign, but it can have malignant variants.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, although it can exhibit aggressive behavior and has a high recurrence rate.",
        "Ameloblastoma is primarily a benign tumor, but it has rare malignant variants, including Metastasizing Ameloblastoma and Ameloblastic Carcinoma, which occur in approximately 1.6-2.2% of cases, indicating that while its primary nature is non-cancerous, a small percentage can exhibit malignant behavior.",
        "Ameloblastoma is generally a benign tumor that originates from the tissues involved in tooth development. Although it can be locally aggressive and cause significant jawbone damage, it is not typically classified as a malignant cancer. Rarely, a variant called ameloblastic carcinoma may occur, which exhibits malignant characteristics and has the potential to metastasize. However, this malignant form is very uncommon compared to the usual benign behavior of ameloblastomas.",
        "No, Ameloblastoma is classified as a benign tumor, meaning it does not spread to other parts of the body like malignant cancers do. Although it can be locally aggressive, it remains non cancerous.",
        "No, Ameloblastoma is a benign type of cancer.",
        "Ameloblastoma is not a malignant cancer, but a benign odontogenic tumor. Although it is locally invasive and can cause significant tissue destruction, it does not metastasize like malignant cancers. It is characterized by its ability to infiltrate surrounding bone and tissues, with a high potential for local recurrence, but it is not considered a true malignant neoplasm.",
        "No, Ameloblastoma is not a malignant type of cancer; it is a rare, locally aggressive benign tumor that primarily affects the mandible. Although it can grow into surrounding tissues (locally aggressive), it does not spread to distant parts of the body (metastasize), which distinguishes it from malignant cancers.",
        "No, Ameloblastoma is a benign but not malignant tumor.",
        "No, Ameloblastoma is a benign odontogenic tumor.",
        "Ameloblastoma is not a malignant cancer, but rather a benign odontogenic tumor; however, it exhibits locally invasive and destructive behavior with a high recurrence rate. Despite being classified as benign, it is the most common and highly invasive odontogenic tumor that requires careful medical attention due to its infiltrative nature.",
        "No, Ameloblastoma is a benign odontogenic tumor, not a malignant type of cancer.",
        "Ameloblastoma is classified as a benign tumor, which means it is not malignant. It is a type of odontogenic tumor that is locally destructive and has a high recurrence rate, but it is not considered a cancerous or malignant type of tumor.",
        "No. Ameloblastoma is a benign odontogenic tumor, meaning it does not exhibit malignant behavior though it can be locally invasive.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, although it is locally invasive and has a high recurrence rate.",
        "No, ameloblastoma is not a malignant cancer. It is classified as a **benign odontogenic tumor**, though it exhibits **locally invasive and destructive behavior** with a high recurrence rate. While aggressive, it does not metastasize like malignant cancers.",
        "No. Ameloblastoma is a benign odontogenic tumor with locally invasive behavior, as described in the reference snippets.",
        "No, Ameloblastoma is a benign tumor, not a malignant type of cancer.",
        "No, Ameloblastoma is a benign odontogenic tumor that is locally destructive and highly invasive but not malignant.",
        "No, ameloblastoma is not malignant; it\u0027s a benign but locally destructive tumor.",
        "Ameloblastoma is a benign odontogenic tumor known for its locally destructive behavior. Despite being classified as benign, it exhibits invasive and infiltrative characteristics at the local level and has a high recurrence rate. It is recognized as the most common and highly invasive benign odontogenic tumor, with various histopathologic patterns and clinical forms.",
        "Ameloblastoma is classified as a benign tumor, specifically an odontogenic neoplasm. While it exhibits aggressive local behavior, such as invasiveness and a tendency to recur, it does not metastasize, which distinguishes it from malignant cancers. Therefore, Ameloblastoma is not considered a malignant type of cancer.",
        "Ameloblastoma is not classified as a malignant type of cancer. It is a benign odontogenic tumor that arises from the dental follicle or the enamel organ, and it is characterized by its slow growth and local invasiveness. Despite its association with the term \"cancer,\" Ameloblastoma does not behave like malignant tumors, which are known for their ability to invade surrounding tissues, metastasize, and grow rapidly.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, although it can exhibit invasive behavior and has a high recurrence rate.",
        "Ameloblastoma is a benign neoplasm, which means it is not malignant or cancerous. It originates from the odontogenic epithelium, a specific type of tissue involved in tooth development. While the context discusses the role of CYLD in cancer research, it does not imply that Ameloblastoma is a type of cancer.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, although it can exhibit locally aggressive behavior and a high recurrence rate.",
        "Ameloblastoma is a benign tumor, not malignant.",
        "Ameloblastoma is consistently classified as a benign odontogenic tumor, characterized by its locally invasive behavior and high recurrence rate, despite which it is not considered malignant; treatment approaches include both conservative and radical surgeries, with emerging potential for personalized medicine targeting specific genetic mutations.",
        "No. Ameloblastoma is classified as a benign odontogenic tumor, although it can exhibit locally aggressive behavior and has a high recurrence rate.",
        "Ameloblastoma is not a malignant type of cancer, but rather a benign odontogenic tumor characterized by its locally destructive and infiltrative behavior, leading to a high recurrence rate. Despite its aggressive nature at the local level, it does not metastasize to distant sites, distinguishing it from malignant cancers.",
        "No, ameloblastoma is a benign neoplasm composed of epithelial tissue with invasive and infiltrative behavior at the local level and a high recurrence rate, with various histopathologic patterns and clinical forms.",
        "No, Ameloblastoma is a benign tumor that originates from the odontogenic epithelium.",
        "No, Ameloblastoma is not a malignant type of cancer. According to the provided texts, it is described as a \"benign odontogenic tumor\" or a \"benign neoplasm\", which means it is non-cancerous. Although it can be locally invasive and have a high recurrence rate, it does not have the ability to metastasize or spread to other parts of the body like malignant cancers do.",
        "Ameloblastoma is a benign odontogenic tumor, meaning it is not classified as a malignant type of cancer. However, it is known for its locally invasive and infiltrative behavior, contributing to a high recurrence rate. Despite being benign, its aggressive local growth necessitates careful management due to potential tissue destruction and the likelihood of recurrence.",
        "No, ameloblastoma is not a malignant type of cancer; it is a benign tumor. However, it is locally invasive and has a high recurrence rate.",
        "Ameloblastoma is not a malignant type of cancer. It is classified as a benign odontogenic tumor. Although it can be locally invasive and destructive, and has a high recurrence rate, it does not metastasize, which is a key characteristic of malignant cancers. Therefore, Ameloblastoma is considered a benign neoplasm despite its invasive behavior.",
        "Ameloblastoma is not a malignant type of cancer; it is a benign odontogenic tumor characterized by locally invasive and infiltrative behavior, with a notable high recurrence rate, but without metastatic potential typical of malignant cancers.",
        "No, Ameloblastoma is not a malignant type of cancer; it is a benign odontogenic tumor.",
        "Ameloblastoma is a benign odontogenic tumor characterized by its locally destructive behavior, high recurrence rate, and invasive nature at the local level. It is composed of epithelial tissue and is considered the most common highly invasive benign odontogenic tumor.",
        "Ameloblastoma is not a malignant type of cancer; it is classified as a benign odontogenic tumor. Despite being benign, ameloblastomas are known for their locally destructive nature and high recurrence rate due to their invasive and infiltrative behavior at the local level. They are the most common and highly invasive among benign odontogenic tumors.",
        "No, Ameloblastoma is not a malignant type of cancer. It is the most common and highly invasive benign odontogenic tumor, composed of epithelial tissue with invasive and infiltrative behavior at the local level and a high recurrence rate."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What is the treatment for paracetamol intoxication?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38525861",
        "http://www.ncbi.nlm.nih.gov/pubmed/37247196",
        "http://www.ncbi.nlm.nih.gov/pubmed/31688944",
        "http://www.ncbi.nlm.nih.gov/pubmed/24930458",
        "http://www.ncbi.nlm.nih.gov/pubmed/7491847",
        "http://www.ncbi.nlm.nih.gov/pubmed/22697593",
        "http://www.ncbi.nlm.nih.gov/pubmed/7753607",
        "http://www.ncbi.nlm.nih.gov/pubmed/7701645",
        "http://www.ncbi.nlm.nih.gov/pubmed/37683599",
        "http://www.ncbi.nlm.nih.gov/pubmed/39727662",
        "http://www.ncbi.nlm.nih.gov/pubmed/10434788",
        "http://www.ncbi.nlm.nih.gov/pubmed/3552583",
        "http://www.ncbi.nlm.nih.gov/pubmed/34957591",
        "http://www.ncbi.nlm.nih.gov/pubmed/23964853",
        "http://www.ncbi.nlm.nih.gov/pubmed/31361324",
        "http://www.ncbi.nlm.nih.gov/pubmed/16225094",
        "http://www.ncbi.nlm.nih.gov/pubmed/29096991",
        "http://www.ncbi.nlm.nih.gov/pubmed/39598160",
        "http://www.ncbi.nlm.nih.gov/pubmed/39051728",
        "http://www.ncbi.nlm.nih.gov/pubmed/38854233",
        "http://www.ncbi.nlm.nih.gov/pubmed/38340270",
        "http://www.ncbi.nlm.nih.gov/pubmed/519312",
        "http://www.ncbi.nlm.nih.gov/pubmed/20350475",
        "http://www.ncbi.nlm.nih.gov/pubmed/35849165",
        "http://www.ncbi.nlm.nih.gov/pubmed/6394298",
        "http://www.ncbi.nlm.nih.gov/pubmed/33388821",
        "http://www.ncbi.nlm.nih.gov/pubmed/26653695",
        "http://www.ncbi.nlm.nih.gov/pubmed/1683827",
        "http://www.ncbi.nlm.nih.gov/pubmed/25083244",
        "http://www.ncbi.nlm.nih.gov/pubmed/26602168",
        "http://www.ncbi.nlm.nih.gov/pubmed/20095817",
        "http://www.ncbi.nlm.nih.gov/pubmed/21854081",
        "http://www.ncbi.nlm.nih.gov/pubmed/22593093",
        "http://www.ncbi.nlm.nih.gov/pubmed/37260659",
        "http://www.ncbi.nlm.nih.gov/pubmed/25767408",
        "http://www.ncbi.nlm.nih.gov/pubmed/20332167",
        "http://www.ncbi.nlm.nih.gov/pubmed/20071472",
        "http://www.ncbi.nlm.nih.gov/pubmed/34420083",
        "http://www.ncbi.nlm.nih.gov/pubmed/10634007",
        "http://www.ncbi.nlm.nih.gov/pubmed/30274302",
        "http://www.ncbi.nlm.nih.gov/pubmed/39166871",
        "http://www.ncbi.nlm.nih.gov/pubmed/3994080",
        "http://www.ncbi.nlm.nih.gov/pubmed/19007345",
        "http://www.ncbi.nlm.nih.gov/pubmed/38444903",
        "http://www.ncbi.nlm.nih.gov/pubmed/31578621"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 181,
          "text": "Administration of acetylcysteine is the standard of care for this intoxication",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38525861"
        },
        {
          "offsetInBeginSection": 415,
          "offsetInEndSection": 461,
          "text": "administration of intravenous N-acetylcysteine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37247196"
        },
        {
          "offsetInBeginSection": 21,
          "offsetInEndSection": 96,
          "text": "N-acetylcystein has been used as an antidote after paracetamol intoxication",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31688944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Treatment of paracetamol intoxication consists of administration of N-acetylcysteine, preferably shortly after paracetamol ingestion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "N-acetylcysteine is a good and reasonable specific antidotum in case of paracetamol intoxication. It is very active when administered within eight hours after intoxication. It can be used as well as in intravenous as peroral administration. There are few side effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7491847"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Acetylcysteine is an effective antidote for paracetamol (acetaminophen) poisoning, but different treatment criteria exist internationally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22697593"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Criteria for acetylcysteine treatment and clinical outcomes after paracetamol poisoning.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22697593"
        },
        {
          "offsetInBeginSection": 794,
          "offsetInEndSection": 1419,
          "text": "When intoxication with paracetamol is presumed, administration of N-acetylcysteine is vital. N-acetylcysteine therapy should be initiated not later than 15 hours after paracetamol intake. Moreover, the antitoxic effect has been observed even when N-acetylcysteine therapy is initiated 24-36 hours after presumed paracetamol intake. Measures of preventing further absorption of paracetamol from the gastrointestinal tract should be taken. Activated charcoal should be given if less than two hours have passed since paracetamol intake. Between two and four hours following paracetamol intake gastric lavage should be performed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7753607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Large paracetamol overdose-Higher dose acetylcysteine is required.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34957591"
        },
        {
          "offsetInBeginSection": 726,
          "offsetInEndSection": 867,
          "text": "ONMEM (ver 7.2). The primary outcome was administration of NAC, which was determined based on a serum paracetamol concentration greater than ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964853"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "Treatment of paracetamol intoxication consists of administration of N-acetylcysteine, preferably shortly after paracetamol ingestion. In most countries, the decision to treat patients with N-acetylcysteine depends on the paracetamol plasma concentration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Treatment of paracetamol intoxication with N-acetylcysteine (NAC) is standard in Denmark. NAC is considered safe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10434788"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 354,
          "text": "t in death. To reduce the effects of acetaminophen overdose, N-acetylcysteine (NAC) has been established as the preferred intervention to prevent l",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39727662"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "N-acetylcysteine (NAC) has established use as an antidote for acetaminophen overdose and treatment for pulmonary conditions and nephropathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39598160"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "BACKGROUND: Prompt acetylcysteine treatment with standard doses (300 mg/kg over 21 h in divided doses) is almost universally effective in preventing hepatotoxicity after paracetamol (acetaminophe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39051728"
        },
        {
          "offsetInBeginSection": 617,
          "offsetInEndSection": 817,
          "text": "In instances where acute overdose with acetaminophen serves as the instigating factor, N-acetylcysteine (NAC) emerges as a pivotal component of management, as indicated by the Rumack-Matthew nomogram.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38854233"
        },
        {
          "offsetInBeginSection": 1207,
          "offsetInEndSection": 1406,
          "text": "NAC assumes a critical role in ameliorating the detrimental effects of acetaminophen overdose, particularly in averting liver damage, thus holding significant importance in patient care and recovery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38854233"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 226,
          "text": " countries. N-acetylcysteine (NAC) is a highly effective antidote for acetaminophen hepatotoxicity, typically initiated in the emergency",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38340270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/519312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "One hundred cases of severe paracetamol poisoning were treated with intravenous N-acetylcysteine (acetyl-cysteine).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/519312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "N-acetylcysteine is a good and reasonable specific antidotum in case of paracetamol intoxication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7491847"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Since the late 1970s N-acetylcystein has been used as an antidote after paracetamol intoxication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31688944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Treatment of paracetamol intoxication with N-acetylcysteine (NAC) is standard in Denmark.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10434788"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Danish paracetamol (PCM) poisoned patients are treated with N-acetylcysteine (NAC) intravenously for 36 hours.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20350475"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "N-acetylcysteine (NAC) is the only approved drug for the treatment of acetaminophen (APAP) intoxication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35849165"
        },
        {
          "offsetInBeginSection": 1131,
          "offsetInEndSection": 1285,
          "text": "N-acetylcysteine soon became the treatment of choice for paracetamol overdose and given early it was very effective when administered either IV or orally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37683599"
        },
        {
          "offsetInBeginSection": 794,
          "offsetInEndSection": 981,
          "text": "When intoxication with paracetamol is presumed, administration of N-acetylcysteine is vital. N-acetylcysteine therapy should be initiated not later than 15 hours after paracetamol intake.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7701645"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "N-acetylcysteine (NAC) is the treatment of choice for acetaminophen overdose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6394298"
        },
        {
          "offsetInBeginSection": 1344,
          "offsetInEndSection": 1481,
          "text": "be managed with caution. The treatment of choice for paracetamol poisoning is N-acetylcysteine, a specific antidote which reduces paracet",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388821"
        },
        {
          "offsetInBeginSection": 236,
          "offsetInEndSection": 309,
          "text": "N-Acetylcysteine is the recommended antidote for acetaminophen poisoning.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653695"
        },
        {
          "offsetInBeginSection": 1200,
          "offsetInEndSection": 1295,
          "text": "The mainstay of treatment for acetaminophen intoxication is a 17-dose course of acetylcysteine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1683827"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 371,
          "text": "Acetylcysteine has long been recognized as an effective antidote, via oral or intravenous administration, minimizing the risk and severity of acute liver injury if administered sufficiently early after a paracetamol overdose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25083244"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 589,
          "text": "N-acetylcysteine (NAC), a GSH precursor, is the only currently approved antidote for an acetaminophen overdose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26602168"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 294,
          "text": "centers. Acetylcysteine is indicated for the antidotal treatment of acetaminophen poisoning to prevent or minimize acetaminophen-related hepato",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20095817"
        },
        {
          "offsetInBeginSection": 794,
          "offsetInEndSection": 1125,
          "text": "When intoxication with paracetamol is presumed, administration of N-acetylcysteine is vital. N-acetylcysteine therapy should be initiated not later than 15 hours after paracetamol intake. Moreover, the antitoxic effect has been observed even when N-acetylcysteine therapy is initiated 24-36 hours after presumed paracetamol intake.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7701645"
        },
        {
          "offsetInBeginSection": 1126,
          "offsetInEndSection": 1419,
          "text": "Measures of preventing further absorbtion of paracetamol from the gastrointestinal tract should be taken. Activated charcoal should be given if less than two hours have passed since paracetamol intake. Between two and four hours following paracetamol intake gastric lavage should be performed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7701645"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Treatment of paracetamol intoxication with N-acetylcysteine (NAC) is standard in Denmark. NAC is considered safe with relatively few side effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10434788"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Five patients in whom the serum paracetamol levels or the amount of ingested paracetamol was high enough to cause severe liver injury were treated with N-acetyl-cysteine (NAC) and a molecular absorbant recirculating system (MARS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12969110"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 316,
          "text": "It was not until 60 hours later that therapy with acetylcysteine was initiated. Paracetamol intoxication has a long latency period. If there is no intervention, severe hepatic damage can develop within three days.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22753188"
        },
        {
          "offsetInBeginSection": 870,
          "offsetInEndSection": 1040,
          "text": "The final conclusion is to continue using the guidelines of the Dutch National Poisons Information Centre for N-acetylcysteine administration in paracetamol intoxication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930458"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 641,
          "text": "But no treatment with N-acetylcysteine at higher paracetamol plasma concentrations may lead to unnecessary severe morbidity and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930458"
        },
        {
          "offsetInBeginSection": 642,
          "offsetInEndSection": 869,
          "text": "In this review, we provide an overview on the severity and prevalence of adverse side effects after N-acetylcysteine administration and the consequences these side effects may have for the treatment of paracetamol intoxication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930458"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 254,
          "text": "In most countries, the decision to treat patients with N-acetylcysteine depends on the paracetamol plasma concentration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "CONTEXT: Current treatment of paracetamol (acetaminophen) poisoning involves initiating a 3-phase N-acetylcysteine (NAC) infusion after comparing a plasma concentration, taken ≥ 4 h post-overdose, to a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21854081"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "N-acetylcysteine (NAC) is the treatment of choice for acetaminophen poisoning; standard 72-h oral or 21-h intravenous protocols are most frequently used",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22593093"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "BACKGROUND: Acetaminophen overdose is a leading cause of acute liver failure in developing countries. N-acetylcysteine (NAC) is a highly effective antidote for acetaminophen hepatotoxicity, typically initiated in the emergenc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38340270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Introduction: N-acetylcysteine (NAC) is the first-line treatment for acetaminophen (",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37260659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "N-acetylcysteine (NAC) is used widely and effectively in oral and intravenous forms as a specific antidote for acetaminophen poisoning",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25767408"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 232,
          "text": "N-acetylcysteine (NAC) should be employed as the antidote in case of acetaminophen poisoning within the first 8-10 hours",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20332167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "BACKGROUND: Intravenous N-acetylcysteine (IV-NAC) is widely recognized as the antidote of choice for acetaminop",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071472"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "N-acetylcysteine (NAC) is the only clinically approved antidote against acetaminophen (APAP) hepatotoxicity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34420083"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Acetaminophen overdose is a common intoxication in daily practice the standard treatment is N-acetylcysteine (NAC) antidotal therapy for possible poisoning",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10634007"
        },
        {
          "offsetInBeginSection": 1344,
          "offsetInEndSection": 1480,
          "text": "be managed with caution. The treatment of choice for paracetamol poisoning is N-acetylcysteine, a specific antidote which reduces parace",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388821"
        },
        {
          "offsetInBeginSection": 1131,
          "offsetInEndSection": 1284,
          "text": "N-acetylcysteine soon became the treatment of choice for paracetamol overdose and given early it was very effective when administered either IV or orally",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37683599"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Acute paracetamol poisoning due to a single overdose may be effectively treated by the early administration of N-acetylcysteine (NAC) as an antidote",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30274302"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 236,
          "text": "N-acetylcysteine (NAC), the primary treatment of acetaminophen toxicity, may have perioperative indications, including analgesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39166871"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 301,
          "text": "N-acetylcysteine (NAC) is the specific antidote available for serious overdoses of acetaminophen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3994080"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "OBJECTIVES: The objective was to evaluate the effectiveness of intravenous N-acetylcysteine (IV NAC; 300 mg/kg over 21 hours) in early acute acetaminophen (APAP) overdo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007345"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Acetaminophen ingestion is routinely managed with the antidote, N-acetylcysteine (NAC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38444903"
        },
        {
          "offsetInBeginSection": 1467,
          "offsetInEndSection": 1838,
          "text": "We conclude that the therapeutical approach should consider possibly shortening of the time since drug ingestion to hospitalization and institution of specific treatment (N-acetylcysteine) as well as minimalization of the paracetamol dose, which could be absorbed, by different methods of elimination from the GI tract (eg., gastric lavage, activated charcoal laxatives).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225094"
        },
        {
          "offsetInBeginSection": 925,
          "offsetInEndSection": 1096,
          "text": " substances can cause fatal intoxications. Important antidotes are naloxone for opiods, acetylcystein for paracetamol, fomepizole and ethanol for toxic alcohols and diazep",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29096991"
        },
        {
          "offsetInBeginSection": 371,
          "offsetInEndSection": 476,
          "text": "Paracetamol overdose can cause severe liver damage unless treated early with the antidote acetylcysteine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31361324"
        },
        {
          "offsetInBeginSection": 1344,
          "offsetInEndSection": 1581,
          "text": "be managed with caution. The treatment of choice for paracetamol poisoning is N-acetylcysteine, a specific antidote which reduces paracetamol hepatotoxic effects. N-Acetylcysteine should be given according to specific regimens through we",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Acute paracetamol poisoning due to a single overdose may be effectively treated by the early administration of N-acetylcysteine (NAC) as an antidote.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30274302"
        },
        {
          "offsetInBeginSection": 794,
          "offsetInEndSection": 981,
          "text": "When intoxication with paracetamol is presumed, administration of N-acetylcysteine is vital. N-acetylcysteine therapy should be initiated not later than 15 hours after paracetamol intake.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7753607"
        },
        {
          "offsetInBeginSection": 1115,
          "offsetInEndSection": 1284,
          "text": "The treatment of paracetamol intoxication should include gastric lavage, which has been shown to be of value for up to 6 hours after ingestion of a paracetamol overdose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3552583"
        },
        {
          "offsetInBeginSection": 1052,
          "offsetInEndSection": 1209,
          "text": "Treatment consists of instant withdrawal of the suspected drug and administration of acetylcysteine as early as possible in case of paracetamol intoxication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9333916"
        },
        {
          "offsetInBeginSection": 1098,
          "offsetInEndSection": 1196,
          "text": "In paracetamol intoxication, the rapid administration of N-acetylcysteine is a classical antidote.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15674089"
        },
        {
          "offsetInBeginSection": 794,
          "offsetInEndSection": 886,
          "text": "When intoxication with paracetamol is presumed, administration of N-acetylcysteine is vital.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7701645"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Treatment of paracetamol intoxication consists of administration of N-acetylcysteine, preferably shortly after paracetamol ingestion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "N-acetylcysteine is a good and reasonable specific antidotum in case of paracetamol intoxication. It is very active when administered within eight hours after intoxication. It can be used as well as in intravenous as peroral administration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7491847"
        },
        {
          "offsetInBeginSection": 794,
          "offsetInEndSection": 1124,
          "text": "When intoxication with paracetamol is presumed, administration of N-acetylcysteine is vital. N-acetylcysteine therapy should be initiated not later than 15 hours after paracetamol intake. Moreover, the antitoxic effect has been observed even when N-acetylcysteine therapy is initiated 24-36 hours after presumed paracetamol intake",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7753607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Treatment of paracetamol intoxication with N-acetylcysteine (NAC) is standard in Denmark",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10434788"
        },
        {
          "offsetInBeginSection": 371,
          "offsetInEndSection": 475,
          "text": "Paracetamol overdose can cause severe liver damage unless treated early with the antidote acetylcysteine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31361324"
        },
        {
          "offsetInBeginSection": 1200,
          "offsetInEndSection": 1294,
          "text": "The mainstay of treatment for acetaminophen intoxication is a 17-dose course of acetylcysteine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1683827"
        },
        {
          "offsetInBeginSection": 903,
          "offsetInEndSection": 984,
          "text": "For paracetamol poisoning, intravenous acetylcysteine is available as an antidote",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31578621"
        }
      ],
      "id": "67e2cd8b18b1e36f2e000097",
      "ideal_answer": [
        "The treatment for paracetamol intoxication typically involves the administration of N-acetylcysteine (NAC), which acts as an antidote to the toxic effects of acetaminophen overdose. NAC replenishes glutathione levels, helping to detoxify harmful metabolites and prevent liver damage. The two-bag NAC regimen is a commonly used method to manage acetaminophen toxicity safely and effectively, consisting of an initial loading dose followed by two separate infusions to ensure proper detoxification and recovery.",
        "The primary treatment for paracetamol intoxication is N-acetylcysteine (NAC) administration, ideally within 8-10 hours post-ingestion, via intravenous or oral routes. Treatment decisions are guided by paracetamol plasma concentration, individual risk factors (e.g., alcohol use, malnutrition, pre-existing liver conditions), and country-specific guidelines. Adjunctive measures may include gastric lavage (within 1-6 hours) and activated charcoal (within 1-2 hours). Supportive care is crucial for fluid replacement, monitoring liver and renal function, and managing potential side effects (occurring in 10-15% of cases), with medical toxicology service support recommended for optimal management.",
        "The standard treatment for paracetamol (acetaminophen) intoxication is the administration of acetylcysteine. This antidote works by replenishing hepatic glutathione stores, which are critical for detoxifying the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) produced during paracetamol metabolism. Acetylcysteine is most effective when administered within 8–10 hours of overdose but is still beneficial even if delayed. It can be given intravenously or orally, depending on clinical circumstances.",
        "The primary treatment for paracetamol (acetaminophen) intoxication is the administration of N-acetylcysteine (NAC). This medication works by providing a precursor to glutathione, an essential antioxidant in the liver. By increasing glutathione levels, NAC helps detoxify the toxic metabolites of paracetamol, thereby reducing the risk of liver damage. The administration of NAC should ideally begin as soon as possible after ingestion to maximize its effectiveness. While other supportive measures like activated charcoal or liver-protective agents may be used in certain situations, NAC remains the standard and most effective treatment for paracetamol overdose."
      ],
      "exact_answer": [
        [
          "N-acetylcysteine",
          "Activated charcoal",
          "gastric lavage",
          "Liver transplantation"
        ]
      ]
    },
    {
      "body": "What are some immunosuppressive cytokines secreted by tumors to induce the activation of regulatory T-cells and evade the immune system?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24582432",
        "http://www.ncbi.nlm.nih.gov/pubmed/24213679",
        "http://www.ncbi.nlm.nih.gov/pubmed/17305474",
        "http://www.ncbi.nlm.nih.gov/pubmed/19430886",
        "http://www.ncbi.nlm.nih.gov/pubmed/22465232",
        "http://www.ncbi.nlm.nih.gov/pubmed/38380317",
        "http://www.ncbi.nlm.nih.gov/pubmed/21249423",
        "http://www.ncbi.nlm.nih.gov/pubmed/34195245",
        "http://www.ncbi.nlm.nih.gov/pubmed/22639159",
        "http://www.ncbi.nlm.nih.gov/pubmed/38038865",
        "http://www.ncbi.nlm.nih.gov/pubmed/34068008",
        "http://www.ncbi.nlm.nih.gov/pubmed/36581707",
        "http://www.ncbi.nlm.nih.gov/pubmed/37175653",
        "http://www.ncbi.nlm.nih.gov/pubmed/34711823",
        "http://www.ncbi.nlm.nih.gov/pubmed/35202639",
        "http://www.ncbi.nlm.nih.gov/pubmed/38287007",
        "http://www.ncbi.nlm.nih.gov/pubmed/9754446",
        "http://www.ncbi.nlm.nih.gov/pubmed/12820727",
        "http://www.ncbi.nlm.nih.gov/pubmed/27075020",
        "http://www.ncbi.nlm.nih.gov/pubmed/35659268",
        "http://www.ncbi.nlm.nih.gov/pubmed/36096533",
        "http://www.ncbi.nlm.nih.gov/pubmed/38062276",
        "http://www.ncbi.nlm.nih.gov/pubmed/16818744",
        "http://www.ncbi.nlm.nih.gov/pubmed/18483277",
        "http://www.ncbi.nlm.nih.gov/pubmed/21757379",
        "http://www.ncbi.nlm.nih.gov/pubmed/27939507",
        "http://www.ncbi.nlm.nih.gov/pubmed/28432279",
        "http://www.ncbi.nlm.nih.gov/pubmed/10456656",
        "http://www.ncbi.nlm.nih.gov/pubmed/19105214",
        "http://www.ncbi.nlm.nih.gov/pubmed/20305684",
        "http://www.ncbi.nlm.nih.gov/pubmed/22680926",
        "http://www.ncbi.nlm.nih.gov/pubmed/23359769",
        "http://www.ncbi.nlm.nih.gov/pubmed/30941308",
        "http://www.ncbi.nlm.nih.gov/pubmed/37988561",
        "http://www.ncbi.nlm.nih.gov/pubmed/17017974",
        "http://www.ncbi.nlm.nih.gov/pubmed/23465357",
        "http://www.ncbi.nlm.nih.gov/pubmed/26330296",
        "http://www.ncbi.nlm.nih.gov/pubmed/17975134",
        "http://www.ncbi.nlm.nih.gov/pubmed/22193988",
        "http://www.ncbi.nlm.nih.gov/pubmed/25505237",
        "http://www.ncbi.nlm.nih.gov/pubmed/24076584",
        "http://www.ncbi.nlm.nih.gov/pubmed/33127257",
        "http://www.ncbi.nlm.nih.gov/pubmed/23723999",
        "http://www.ncbi.nlm.nih.gov/pubmed/25040972",
        "http://www.ncbi.nlm.nih.gov/pubmed/39693872",
        "http://www.ncbi.nlm.nih.gov/pubmed/37937579",
        "http://www.ncbi.nlm.nih.gov/pubmed/37817381",
        "http://www.ncbi.nlm.nih.gov/pubmed/33182039",
        "http://www.ncbi.nlm.nih.gov/pubmed/12967780",
        "http://www.ncbi.nlm.nih.gov/pubmed/25356878",
        "http://www.ncbi.nlm.nih.gov/pubmed/9181454",
        "http://www.ncbi.nlm.nih.gov/pubmed/18799145",
        "http://www.ncbi.nlm.nih.gov/pubmed/10757348",
        "http://www.ncbi.nlm.nih.gov/pubmed/19414323"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 979,
          "text": "Despite recent advances in treatment, the prognosis for glioblastoma multiforme (GBM) remains poor. The lack of response to treatment in GBM patients may be attributed to the immunosuppressed microenvironment that is characteristic of invasive glioma. Regulatory T-cells (Tregs) are immunosuppressive T-cells that normally prevent autoimmunity when the human immune response is evoked; however, there have been strong correlations between glioma-induced immunosuppression and Tregs. In fact, induction of Treg activity has been correlated with glioma development in both murine models and patients. While the exact mechanisms by which regulatory T-cells function require further elucidation, various cytokines such as interleukin-10 (IL-10) and transforming growth factor-β (TFG-β) have been implicated in these processes and are currently under investigation. In addition, hypoxia is characteristic of tumor development and is also correlated with downstream induction of Tregs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24582432"
        },
        {
          "offsetInBeginSection": 719,
          "offsetInEndSection": 920,
          "text": "These iTreg, expanding in response to tumor antigens and cytokines such as TGF-β or IL-10, are presumably responsible for the suppression of anti-tumor immune responses and for successful tumor escape.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24213679"
        },
        {
          "offsetInBeginSection": 483,
          "offsetInEndSection": 640,
          "text": "Some of these immunosuppressive mechanisms include the production of cytokines such as TGF-beta and the recruitment or differentiation of regulatory T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17305474"
        },
        {
          "offsetInBeginSection": 1164,
          "offsetInEndSection": 1401,
          "text": "TGF-beta1expression and secretion from glioma cells was found to be up-regulated by conditioned media from CD3-activated T cells, suggesting that this immunosuppressive cytokine is not secreted constitutively but in response to immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19430886"
        },
        {
          "offsetInBeginSection": 1220,
          "offsetInEndSection": 1448,
          "text": "They mediate powerful suppression of effector T cells via diverse mechanisms, produce immunosuppressive cytokines, notably TGF-β as well as prostaglandin E2 and adenosine, and are resistant to apoptosis or oncological therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22465232"
        },
        {
          "offsetInBeginSection": 918,
          "offsetInEndSection": 1209,
          "text": "Examples of these immunosuppressive mechanisms include the production of inhibitory cytokines such as interleukin 10 (IL-10) and transforming growth factor beta (TGF-β) that inhibit the production of pro-inflammatory cytokines and dampen the activation and proliferation of effector T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38380317"
        },
        {
          "offsetInBeginSection": 794,
          "offsetInEndSection": 1013,
          "text": "For instance, ccRCC cells produce cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which suppress immune cell activation and promote the differentiation of regulatory T cells (Tregs)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37175653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Presence of TGFβ in the tumor microenvironment is one of the most relevant cancer immune-escape mechanisms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34711823"
        },
        {
          "offsetInBeginSection": 706,
          "offsetInEndSection": 899,
          "text": "Furthermore, TGF-β signaling can induce drug resistance of PCa cells, and can lead to immune evasion via reducing the anti-tumor activity of cytotoxic T cells and stimulating regulatory T cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35202639"
        },
        {
          "offsetInBeginSection": 1184,
          "offsetInEndSection": 1400,
          "text": "The secretion of CXCL12 recruits regulatory T cells (Tregs), leading to Treg infiltration and increased TGF-β secretion in the microenvironment and promotes the formation of a tumor immunosuppressive microenvironment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38287007"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Presence of TGFβ in the tumor microenvironment is one of the most relevant cancer immune-escape mechanisms. TGFβ is secreted in an inactive form, and its activation within the tumor may depend on different cell types and mechanisms than its production.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34711823"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34711823"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Breast cancer stem cells generate immune-suppressive T regulatory cells by secreting TGFβ to evade immune-elimination",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38038865"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "The transforming growth factor beta (TGF-β) signaling plays a critical role in immune evasion and tumor progression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38062276"
        },
        {
          "offsetInBeginSection": 1210,
          "offsetInEndSection": 1395,
          "text": "These findings suggest that tumor growth facilitates the induction or recruitment of CD4+ regulatory T cells that secrete IL-10 and TGF-beta and suppress effector CD8+ T cell responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16818744"
        },
        {
          "offsetInBeginSection": 1396,
          "offsetInEndSection": 1601,
          "text": "However, CD8+ T regulatory cells expressing IL-10 and TGF-beta are also recruited or activated by the immunosuppressive environment of the lung, where they may suppress the induction of antitumor immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16818744"
        },
        {
          "offsetInBeginSection": 1355,
          "offsetInEndSection": 1543,
          "text": "Our search for the underlying mechanism further unveiled the role of CSC-shed immune-suppressive cytokine TGFβ, which was further increased by chemotherapy, in generating tumor Treg cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38038865"
        },
        {
          "offsetInBeginSection": 1289,
          "offsetInEndSection": 1500,
          "text": "Further investigation revealed that tumor burden upregulated Treg cell populations and stimulated the production of the immunosuppressive cytokines transforming growth factor (TGF)-beta and IL-10 in these cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20305684"
        },
        {
          "offsetInBeginSection": 1398,
          "offsetInEndSection": 1806,
          "text": "Tumor immune escape can be diminished by targeting various immunosuppressive mechanisms used by different tumors, such as tumor production of immunosuppressive cytokines (e.g., interleukin 10, and Transforming Growth Factor-beta, which can promote activity of immunosuppressive regulatory T cells), or by inhibiting production of inflammatory prostanoids with combined cyclooxygenase/lipoxygenase inhibitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22680926"
        },
        {
          "offsetInBeginSection": 323,
          "offsetInEndSection": 625,
          "text": "Immunosuppression is frequently accompanied by the attraction of immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), M2 tumor-associated macrophages (TAMs), T regulatory cells (Tregs), N2 neutrophils, and by the release of immunosuppressive cytokines (TGF-β, IL-10) and chemokines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30941308"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 464,
          "text": "Malignant cells often secrete large amounts of TGF-beta that act on nontransformed cells present in the tumor mass as well as distal cells in the host to suppress antitumor immune responses creating an environment of immune tolerance, augmenting angiogenesis, invasion and metastasis, and increasing tumor extracellular matrix deposition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17975134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 251,
          "text": "Presence of TGFβ in the tumor microenvironment is one of the most relevant cancer immune-escape mechanisms. TGFβ is secreted in an inactive form, and its activation within the tumor may depend on different cell types and mechanisms than its production",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34711823"
        },
        {
          "offsetInBeginSection": 792,
          "offsetInEndSection": 954,
          "text": "These findings reveal that T cell production of TGF-β1 is an essential requirement for tumors to evade immunosurveillance independent of TGF-β produced by tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21757379"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 528,
          "text": "Immunomodulatory cytokines, such as transforming growth factor-β, interleukin (IL)-10, and IL-35, soluble factors, such as adenosine, immunosuppressive cells, such as regulatory T cells, NKT cells and myeloid-derived suppressor cells (MDSCs), are the main orchestra leaders involved in immune suppression in cancer by which tumor cells can freely expand without immune cell-mediated interference",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330296"
        },
        {
          "offsetInBeginSection": 1556,
          "offsetInEndSection": 1710,
          "text": "These results were consistent with a stronger suppression of responder cells\u0027 proliferation and the secretion of immunosuppressive cytokines (IL10, TGFB1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25505237"
        },
        {
          "offsetInBeginSection": 514,
          "offsetInEndSection": 753,
          "text": "They not only promote the expression of immune checkpoint ligands (e.g., PD-L1, CD47, Gal-9, and CD276) on cancer cell surfaces, but also enhance the secretion of immunosuppressive cytokines (e.g., TGF-β, IL-6, IL-10, VEGF, and chemokines)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37817381"
        },
        {
          "offsetInBeginSection": 1278,
          "offsetInEndSection": 1437,
          "text": "The pancreas tumor cells secrete immunosuppressive cytokines, including IL-10 and TGF-beta that are partly responsible for the down-regulation of CTL activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12820727"
        },
        {
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1191,
          "text": "Also, tumor cells can acquire attributes that interfere with an immune response, including down-regulation of MHC molecules or other molecules involved in antigen processing; secretion of the immunosuppressive cytokine TGFbeta; and expression of the apoptosis-inducing surface molecule, Fas ligand.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9754446"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 410,
          "text": "A large number of immune/inflammatory cells (including tumor associated macrophages, neutrophils and myeloid derived suppressor cells) as well as cytokines (such as IL-6, IL-10, TGF-β) are present in the tumor microenvironment, which results in both a chronic inflammatory state and immunosuppression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33182039"
        },
        {
          "offsetInBeginSection": 771,
          "offsetInEndSection": 975,
          "text": "The regulatory functions of dendritic cells include the induction of T cell anergy, of T cells with regulatory properties and of T cells that produce immunosuppressive cytokines such as IL-10 or TGF-beta.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12967780"
        },
        {
          "offsetInBeginSection": 574,
          "offsetInEndSection": 750,
          "text": "The most extensively studied immunosuppressive molecules secreted by tumors are transforming growth factor-beta (TGF beta), interleukin 10 (IL-10), and prostaglandin E2 (PGE2).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9181454"
        },
        {
          "offsetInBeginSection": 640,
          "offsetInEndSection": 894,
          "text": "Furthermore, secreted factors like TGF-β, COX-2 and IL-10, altered costimulatory molecules and inhibition of STAT-3 all contribute to the recruitment and expansion of regulatory T cells, which further modulate the immunosuppressive environment of glioma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639159"
        },
        {
          "offsetInBeginSection": 245,
          "offsetInEndSection": 343,
          "text": "In addition, many tumors express or induce immunosuppressive cytokines such as TGF-beta and IL-10.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18799145"
        },
        {
          "offsetInBeginSection": 718,
          "offsetInEndSection": 1014,
          "text": "Expression of transforming growth factor beta (TGF-beta) and interleukin 10 (IL-10), the potent immunosuppressive factors, was detected in the parental tumor cell line RLmale 1 (a murine T leukemia cell line), as well as in the tumor region, the levels of which correlated with tumor progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10757348"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "Tumors produce several factors, such as Prostaglandins (PGs), Interleukin (IL)-10, Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor (TGF)-beta, which may directly or indirectly inhibit the immune response and may hamper immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17017974"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "It has been suggested that immunosuppressive cytokines such as transforming growth factor beta (TGF-beta) and interleukin 10 play an important role in the induction and/or maintenance of regulatory T-cells (Tregs) in patients with cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19414323"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 1190,
          "text": "Evasion of the host immune attack might be induced by the following groups of mechanisms: (a) tumor dependent (genomic instability, HLA class I antigen abnormalities, upregulation of fetal type nonclassical HLA class I molecules, epitope immunodominance, apoptosis inhibition by defective death receptor signaling, apoptosis of activated T cells, tumor cannibalism and constitutive activation of signal transducer, and activator of transcription-3 (Stat 3) and nuclear factor-kappaB (NF-kappaB) signaling); (b) host dependent (CD4+CD25+ regulatory T cells (T reg), CD4+ T cells anergy, Th2 antitumor immunity diversion and myeloid suppressor cells); (c) tumor and host dependent (lack of co-stimulation molecules, immunosuppressive cytokines (vascular endothelial growth factor (VEGF), interleukin (IL)-10, prostaglandin (PG)E2, transforming growth factor (TGF)-beta)).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19105214"
        },
        {
          "offsetInBeginSection": 803,
          "offsetInEndSection": 1025,
          "text": "The most important factors leading to tumor escape are TGF-β-induced immunosuppression, conversion of helper T cells into regulatory T cells, and the limitation of immune cell access to the full tumor at large tumor sizes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22051568"
        },
        {
          "offsetInBeginSection": 683,
          "offsetInEndSection": 1077,
          "text": "Interleukin-4 (IL-4) and IL-10, belonging to Th2, and transforming growth factor-beta (TGF-beta), belonging to T regulatory (Tr) 1 cytokines, are known to suppress the development of NK, NK T cells, as well as CTLs and to block Th0 cell differentiation to Th1 cells, suggesting that tumor cells can evade the innate and acquired immunity by virtue of cells producing these inhibitory cytokines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10433355"
        }
      ],
      "id": "67eb7cf718b1e36f2e0000ef",
      "ideal_answer": [
        "Despite recent advances in treatment, the prognosis for glioblastoma multiforme (GBM) remains poor. The lack of response to treatment in GBM patients may be attributed to the immunosuppressed microenvironment that is characteristic of invasive glioma. Regulatory T-cells (Tregs) are immunosuppressive T-cells that normally prevent autoimmunity when the human immune response is evoked; however, there have been strong correlations between glioma-induced immunosuppression and Tregs. In fact, induction of Treg activity has been correlated with glioma development in both murine models and patients. While the exact mechanisms by which regulatory T-cells function require further elucidation, various cytokines such as interleukin-10 (IL-10) and transforming growth factor-β (TFG-β) have been implicated in these processes and are currently under investigation. In addition, hypoxia is characteristic of tumor development and is also correlated with downstream induction of Tregs.",
        "Tumors secrete immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) to induce regulatory T-cell (Treg) activity, which contributes to an immunosuppressive microenvironment. These cytokines suppress immune responses, enabling tumors like glioblastoma multiforme (GBM) to evade detection and destruction by the immune system. IL-10 and TGF-β are directly implicated in promoting Treg-mediated immunosuppression in glioma models and patients, though their exact mechanisms are still under investigation. Hypoxia in tumors further exacerbates this process by indirectly driving Treg induction.",
        "Based on the provided context, tumors secrete specific immunosuppressive cytokines to induce regulatory T-cell (Treg) activation as part of their immune evasion strategy. The two primary cytokines mentioned are interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), which have been implicated in the processes by which regulatory T-cells function to create an immunosuppressed microenvironment. This immunosuppression is particularly relevant in glioblastoma multiforme (GBM), where the poor treatment response may be attributed to this immunosuppressed state. Additionally, hypoxic conditions characteristic of tumor development have been correlated with downstream induction of Tregs, further contributing to immune evasion.",
        "Tumors secrete immunosuppressive cytokines such as Transforming Growth Factor-beta (TGF-β) and Interleukin-10 (IL-10) to activate regulatory T-cells (Tregs), which help the tumor evade immune detection. These cytokines promote the differentiation and function of Tregs, suppressing anti-tumor immunity. Additionally, hypoxia in the tumor microenvironment enhances this process by fostering conditions that increase Treg activity, further dampening the immune response against the tumor."
      ],
      "exact_answer": [
        [
          "IL-10",
          "Interleukin 10",
          "Interleukin 10 (IL-10)"
        ],
        [
          "TGF-β",
          "TGF-beta",
          "Transforming growth factor beta",
          "Transforming growth factor beta (TGF-β)"
        ],
        [
          "PGE2",
          "Prostaglandin E2"
        ]
      ]
    },
    {
      "body": "Do CNVs contribute to the genetic architecture of familial generalized and focal epilepsies?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38101940"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1270,
          "offsetInEndSection": 2021,
          "text": "The overall CNV landscape in common familial epilepsies is similar to that of sporadic epilepsies, with large recurrent deletions at 15q11, 15q13, and 16p13 contributing in 2.5%-3% of families. CNVs that interrupt known epilepsy genes and rare, large CNVs were also identified. Multiple etiologies were found in a subset of families, emphasizing the importance of genetic testing for multiple affected family members. Rare CNVs found in a single proband remain difficult to interpret and require larger cohorts to confirm their potential role in disease. Overall, our work indicates that CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, supporting the role for clinical testing in affected individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38101940"
        }
      ],
      "id": "67e2d99318b1e36f2e00009e",
      "ideal_answer": [
        "Yes. CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, supporting the role for clinical testing in affected individuals.",
        "Yes, Copy Number Variants (CNVs) contribute to the genetic architecture of both familial generalized and focal epilepsies. This is supported by their association with specific genomic locations (e.g., 15q13.3, 15q11.2, 16p13.11), their impact on known epilepsy genes, and their presence in a notable subset of affected families, particularly those with additional neurodevelopmental disorders, indicating a complex genetic etiology.",
        "Yes, CNVs (Copy Number Variants) contribute to the complex genetic architecture of familial generalized and focal epilepsies. This suggests that CNVs play a role in the genetic underpinnings of these conditions, supporting the importance of clinical testing in individuals affected by these types of epilepsies.",
        "Yes, CNVs (copy number variations) contribute to the complex genetic architecture of familial generalized and focal epilepsies. This suggests that clinical testing for CNVs could be beneficial for individuals affected by these types of epilepsies, aiding in their diagnosis and possibly understanding the underlying genetic causes.",
        "Yes, CNVs contribute to the genetic architecture of familial generalized and focal epilepsies.",
        "Yes, copy number variations (CNVs) contribute to the genetic architecture of familial generalized and focal epilepsies. CNVs, which involve deletions or duplications of large DNA segments, can disrupt genes involved in neuronal signaling and brain development, influencing epilepsy susceptibility.",
        "Yes, CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies. The overall CNV landscape in common familial epilepsies is similar to that of sporadic epilepsies, with large recurrent deletions at 15q11, 15q13, and 16p13 contributing in 2.5%-3% of families. CNVs likely to contribute to epilepsy risk or etiology were identified in the probands of 43 of 1116 (3.9%) families, including known recurrent CNVs (16p13.11 deletion, 15q13.3 deletion, 15q11.2 deletion, 16p11.2 duplication, 1q21.1 duplication, and 5-Mb duplication of 15q11q13).",
        "Yes. CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, indicating their role in the genetic risk and etiology of these conditions.",
        "Yes, copy number variants (CNVs) contribute to the genetic architecture of familial generalized and focal epilepsies. CNVs, including rare genic deletions and microdeletions (e.g., 15q13.3), are recognized as risk factors, explaining ~3-19% of cases. Large deletions (\u003e400 kb) and specific CNVs (e.g., *CHRNA7* variants) are associated with genetic generalized epilepsy (GGE) and rolandic epilepsy (RE), acting as risk alleles or contributing to complex inheritance patterns.",
        "Yes, copy number variations (CNVs) contribute to the genetic architecture of both familial generalized and focal epilepsies. Recurrent CNVs (e.g., at 15q13.3, 16p13.11) are implicated in generalized epilepsies like childhood absence epilepsy and juvenile myoclonic epilepsy, acting as risk alleles with incomplete penetrance. In focal epilepsies, CNVs in genes/networks regulating synaptic transmission and neuronal excitability are reported, though they occur less frequently than in generalized forms. Rare CNVs account for ~3% of cases overall, with large deletions (\u003e400 kb) showing higher burden in both generalized and focal epilepsies compared to controls. While CNVs (inherited or de novo) contribute to polygenic risk, their impact is heterogeneous and smaller than monogenic single-nucleotide variants. Specific loci like 15q13.3 microdeletions highlight CNV-mediated complex inheritance patterns in these disorders.",
        "Yes, copy number variants (CNVs) contribute to the complex genetic architecture of familial generalized and focal epilepsies. Studies analyzing exome sequence data from multiplex families and first-degree relative pairs with genetic generalized epilepsies or nonacquired focal epilepsies support this. Research indicates that CNVs play a role in the genetic risk and etiology of both rare and common epilepsies, suggesting the utility of clinical testing in affected individuals.",
        "Yes. CNVs contribute to the genetic architecture of familial generalized and focal epilepsies, supporting their association and role in the risk or etiology in families.",
        "Yes. CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, supporting their role in clinical testing for affected individuals.",
        "Yes, CNVs do contribute to familial generalized and focal epilepsies.",
        "Yes, Copy Number Variants (CNVs) contribute to the genetic architecture of both familial generalized and focal epilepsies, affecting approximately 2.5-3.9% of families. These contributions often manifest as large recurrent deletions or interruptions of known epilepsy genes, notably at genomic hotspots such as 15q13.3, 15q11.2, and 16p13.11. This understanding underscores the importance of genetic testing for affected individuals to uncover CNV-related epilepsy risks.",
        "Yes, Copy Number Variations (CNVs) contribute to the genetic architecture of both familial generalized and focal epilepsies. Approximately 2.5%-3% of families are estimated to have their disease risk influenced by CNVs, which often manifest as either known recurrent CNVs or disruptions to monogenic epilepsy genes in a subset of affected families, thereby playing a significant, albeit minority, role in the overall genetic landscape of these conditions.",
        "Yes, studies have shown that copy number variants (CNVs) contribute to the genetic architecture of familial generalized and focal epilepsies. Individuals with these epilepsies tend to have an increased burden of CNVs, indicating that structural genomic changes are significant in disease susceptibility. Specific recurrent CNVs, such as microdeletions at certain genomic regions, have been repeatedly detected in cases of common epilepsies, including those with focal onset. Additionally, family-based genetic analyses, supported by exome sequencing and segregation studies, reinforce the role of CNVs as important genetic factors in familial forms of epilepsy. Overall, the evidence suggests that CNVs increase the overall genetic burden and add complexity to the genetic landscape in these epilepsy types.",
        "Yes, CNVs (copy number variations) are identified as contributing factors to the genetic architecture of familial generalized and focal epilepsies. These variations can involve duplications or deletions of DNA segments, affecting gene dosage and potentially leading to altered protein function that contributes to seizure development.",
        "Yes, according to the provided texts, Copy Number Variations (CNVs) do contribute to the genetic architecture of familial generalized and focal epilepsies. Specifically, large recurrent deletions at 15q11, 15q13, and 16p13 have been identified as contributing to 2.5%-3% of families with these conditions. Additionally, CNVs are considered the commonest known genetic cause of the epilepsies.",
        "Yes, copy number variations (CNVs) significantly contribute to the genetic architecture of familial generalized and focal epilepsies. CNVs are recognized as the most common genetic cause of these epilepsies. Large recurrent deletions at chromosomal regions 15q11, 15q13, and 16p13 are found in a notable percentage of families with these conditions. Specific CNVs, such as microdeletions at 15q13.3 and 16p13.11, are recurrently associated with epilepsy. Patients with genetic generalized epilepsy have the highest CNV burden among epilepsy categories. Rare, large CNVs and those interrupting known epilepsy genes have been identified through exome sequence analysis and validation studies. Approximately 8.9% of individuals with familial generalized and focal epilepsies carry one or more rare genic CNVs not present in controls, indicating a significant role for these variants. Genome-wide association studies and whole-genome oligonucleotide array comparative genomic hybridization have been instrumental in identifying these CNVs. These findings underscore the importance of CNVs in the genetic landscape of familial generalized and focal epilepsies, highlighting their role in the etiology and potential for guiding therapeutic strategies.",
        "Yes. CNVs contribute to the genetic architecture of familial generalized and focal epilepsies.",
        "Yes, Copy Number Variants (CNVs) contribute significantly to the genetic architecture of familial generalized and focal epilepsies. Large recurrent deletions at 15q11, 15q13, and 16p13 contribute to 2.5%-3% of families with these epilepsies. Microdeletions at 15q13.3 and 16p13.11 have also been identified as contributing factors. Genetic generalized epilepsy patients have the highest CNV burden, followed by developmental and epileptic encephalopathy patients. Significant loci for both genetic generalized and lesional focal epilepsy patients have been identified. CNVs interrupting known epilepsy genes and rare, large CNVs have been found. Rare CNVs are important in many subtypes of idiopathic epilepsies, suggesting common genetic factors. CNVs and rare variants of higher effect size have been identified for genetic generalized epilepsy, childhood absence epilepsy, and other common epilepsy phenotypes. Genomic CNVs are significant genetic risk factors for common focal and generalized epilepsies. Recurrent microdeletions on chromosomes 15q13.3, 16p13.11, and 15q11.2 are significant genetic factors for idiopathic generalized epilepsy. Whole-genome studies have shown that rare CNVs contribute to a broad range of generalized and focal epilepsies, with 8.9% of individuals with idiopathic epilepsy having one or more rare copy number changes involving at least one gene.",
        "Yes, CNVs contribute to the genetic architecture of both familial generalized and focal epilepsies, affecting approximately 3.9% of studied families. These include known recurrent CNVs and those disrupting monogenic epilepsy genes, highlighting the complexity of epilepsy genetics. The CNV landscape in familial epilepsies mirrors that of sporadic cases, with large recurrent deletions impacting a small percentage of families. This understanding supports the importance of comprehensive genetic testing for affected individuals, acknowledging the multifaceted etiology of these conditions.",
        "Yes. The study indicates that copy number variations (CNVs) contribute to the complex genetic architecture of familial generalized and focal epilepsies. Specific recurrent deletions at 15q11, 15q13, and 16p13 were found in 2.5%-3% of families, and CNVs disrupting known epilepsy genes or involving rare, large genomic alterations were identified. Additionally, the presence of multiple genetic etiologies in some families underscores the role of CNVs in these disorders. While rare CNVs in isolated cases require further validation, the findings support the contribution of CNVs to familial epilepsies and highlight the importance of clinical genetic testing.",
        "Yes, CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, supporting the role for clinical testing in affected individuals. The overall CNV landscape in common familial epilepsies is similar to that of sporadic epilepsies, with large recurrent deletions at 15q11, 15q13, and 16p13 contributing in 2.5%-3% of families.",
        "Yes, CNVs do contribute to the complex genetic architecture of familial generalized and focal epilepsies, as shown by the identification of large recurrent deletions and other rare CNVs in affected families.",
        "Yes, CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies.",
        "Yes, CNVs contribute to the genetic architecture of familial generalized and focal epilepsies. Recurrent deletions at 15q11, 15q13, and 16p13 are implicated in ~2.5-3% of families. Additional CNVs disrupting known epilepsy genes and rare, large CNVs were identified, supporting their role in disease complexity. Multiple genetic etiologies were observed in some families, underscoring the need for genetic testing in affected individuals. Clinical relevance is confirmed, though interpretation of rare, single-proband CNVs requires further validation.",
        "Yes, copy number variants (CNVs) contribute to the genetic architecture of familial generalized and focal epilepsies. Recurrent deletions at 15q11, 15q13, and 16p13 are implicated in 2.5%-3% of families. CNVs disrupting known epilepsy genes and rare large CNVs were also identified. While multiple genetic etiologies exist in some families, these findings confirm CNVs as contributors to the complex genetic basis of these epilepsies.",
        "Yes, copy number variants significantly contribute to the genetic architecture of familial generalized and focal epilepsies. Recurrent CNVs, including deletions at 15q11, 15q13, and 16p13, are identified in approximately 2.5%–3% of affected families. Both inherited and de novo CNVs disrupt key epilepsy genes and alter gene dosage, complicating the overall genetic landscape. Genetic testing has proven valuable for detecting these variants, although some CNVs, particularly those observed in single cases, remain difficult to interpret without larger cohorts.",
        "Yes, copy number variants (CNVs) contribute to the complex genetic architecture of familial generalized and focal epilepsies. Studies reveal that the overall CNV landscape in common familial epilepsies is similar to that of sporadic epilepsies, with large recurrent deletions at 15q11, 15q13, and 16p13 contributing in 2.5%-3% of families. CNVs that interrupt known epilepsy genes and rare, large CNVs have also been identified.",
        "Yes, CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, supporting the role for clinical testing in affected individuals.",
        "Yes. CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, as indicated by their identification in affected families and their potential role in epilepsy risk and etiology.",
        "Yes, Copy Number Variations (CNVs) have been implicated in the genetic architecture of familial generalized and focal epilepsies. For instance, a 5-bp repeat expansion in the SAMD12 gene on chromosome 8q24.11-q24.12 is the material basis for a familial adult myoclonic epilepsy. This demonstrates that CNVs can contribute to the genetic basis of these types of epilepsies.",
        "Yes. CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies, indicating their role in the genetic basis of these conditions.",
        "Yes, CNVs contribute to the genetic architecture of these epilepsies.",
        "Yes, CNVs contribute to the genetic architecture of familial generalized and focal epilepsies, affecting approximately 3.9% of studied families through large recurrent deletions and disruptions in known epilepsy genes, highlighting the need for comprehensive genetic testing due to the complex etiology.",
        "Yes, CNVs (copy number variations) contribute to the genetic architecture of familial generalized and focal epilepsies. The context indicates that the CNV landscape in familial epilepsies is similar to that in sporadic epilepsies, with specific large recurrent deletions at chromosomal locations such as 15q11, 15q13, and 16p13 being identified in a significant percentage (2.5%-3%) of families. Furthermore, CNVs interrupting known epilepsy genes, as well as rare and large CNVs, have been identified in familial cases. This underscores the complexity and significance of CNVs in the genetic makeup of these epilepsies, supporting the need for clinical genetic testing among affected family members.",
        "Yes, Copy Number Variations (CNVs) contribute to the genetic architecture of both familial generalized and focal epilepsies. Evidence from recurrent deletions and CNVs disrupting known epilepsy genes supports this role. While the impact of CNVs can be complex and vary, with some having a clearer association than others, their overall contribution is established. The challenge in interpreting rare CNVs in individual cases underscores the need for comprehensive genetic testing to fully understand their influence in familial generalized and focal epilepsies.",
        "Yes, CNVs contribute to the genetic architecture of familial generalized and focal epilepsies. The research indicates that the CNV landscape in common familial epilepsies is similar to that of sporadic epilepsies, with large recurrent deletions at specific chromosomal locations (15q11, 15q13, and 16p13) contributing in 2.5%-3% of families. Additionally, CNVs that interrupt known epilepsy genes and rare, large CNVs were identified in familial cases. The evidence supports the role of CNVs in the complex genetic architecture of these familial epilepsies, which has implications for clinical genetic testing in affected individuals.",
        "Yes, Copy Number Variations (CNVs) contribute to the genetic architecture of familial generalized and focal epilepsies. They are associated with large recurrent deletions in specific regions, such as 15q11, 15q13, and 16p13, which affect a small percentage of families. Additionally, CNVs can disrupt known epilepsy genes and include rare, large variations. While some cases involve multiple genetic factors, the role of rare CNVs requires further study to confirm their significance. Overall, CNVs are recognized as part of the complex genetic landscape of these epilepsies.",
        "Yes, CNVs contribute to the genetic architecture of familial generalized and focal epilepsies, but their impact is complex and varies, with some CNVs having a clearer association than others.",
        "Yes, CNVs contribute to the complex genetic architecture of familial generalized and focal epilepsies. The CNV landscape in common familial epilepsies is similar to that of sporadic epilepsies, with recurrent deletions at 15q11, 15q13, and 16p13 contributing in a percentage of families. CNVs that interrupt known epilepsy genes and rare, large CNVs were also identified."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Plaques en Prairie Fauchée are specific to which disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33850722",
        "http://www.ncbi.nlm.nih.gov/pubmed/28785283"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 458,
          "text": "The painful lesions also called \"Plaques en prairie fauchée\", occur in the context of the discovery of a postive HIV serology. The diagnosis of secondary syphilis was confirmed by a positive syphilis serology (nontreponemal RPR test title of 64) and a positive Treponema pallidum PCR, amplifying the tpp47 gene, on a tongue swab. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33850722"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Secondary Syphilis Presenting as Glossodynia, Plaques en Prairie Fauchée, and a Split Papule at the Oral Commissure: Case Report and Review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28785283"
        },
        {
          "offsetInBeginSection": 577,
          "offsetInEndSection": 922,
          "text": "Examination revealed painful, shallow erosions on the posterior aspect of the tongue, in a pattern of plaques en prairie fauchée. A painful split papule (fausse perlèche or false angular cheilitis) was also present in the left commissure. There were no cutaneous lesions. The oral lesions were considered highly suggestive of secondary syphilis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28785283"
        }
      ],
      "type": "factoid",
      "id": "67e5712e18b1e36f2e0000b2",
      "ideal_answer": [
        "Plaques en Prairie Fauchée are specific to secondary syphilis."
      ],
      "exact_answer": [
        [
          "secondary syphilis"
        ]
      ]
    },
    {
      "body": "Please list the complications associaated with Plastic Multilayer Closure(PMC) when used for surgery",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37979696",
        "http://www.ncbi.nlm.nih.gov/pubmed/36817713",
        "http://www.ncbi.nlm.nih.gov/pubmed/26214326"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 585,
          "text": " PMC requires extensive soft tissue manipulation compared with standard orthopedic spine surgeon closure (SOC) and can result in extended operative times, increased transfusion rates, and more frequent returns to the operating room.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37979696"
        },
        {
          "offsetInBeginSection": 692,
          "offsetInEndSection": 1274,
          "text": "6 with OC and 40 with PMC. There was a significant increase in operating room (OR) time with PMC compared with OC (6.7±1.2 vs 7.3±1.3, p\u003d0.016). There was no difference in complication rate, mean postoperative day of complication or unplanned return to the OR for OC and PMC, respectively. There was a slightly significant increase in the number of patients going home with a drain in the PMC cohort compared with the OC cohort (2.1% vs 15%, p\u003d0.046).Conclusions: PMC demonstrated longer OR times than OC and did not demonstrate a statistically significant reduction in wound compli",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36817713"
        },
        {
          "offsetInBeginSection": 345,
          "offsetInEndSection": 736,
          "text": "However, PMC requires extensive soft tissue manipulation compared with standard orthopedic spine surgeon closure (SOC) and can result in extended operative times, increased transfusion rates, and more frequent returns to the operating room.PURPOSE: From 2016 to 2019, our institution implemented a perioperative protocol designed to decrease postoperative complication rates in NMS patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37979696"
        },
        {
          "offsetInBeginSection": 982,
          "offsetInEndSection": 1313,
          "text": "There was a slightly significant increase in the number of patients going home with a drain in the PMC cohort compared with the OC cohort (2.1% vs 15%, p\u003d0.046).Conclusions: PMC demonstrated longer OR times than OC and did not demonstrate a statistically significant reduction in wound complications or unplanned returns to the OR.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36817713"
        },
        {
          "offsetInBeginSection": 1493,
          "offsetInEndSection": 1842,
          "text": "The unanticipated return to the operating room rate was 11.9% (5/42) for the nonstandardized closure patients versus 0% (0/34) for the plastic multilayered closure patients (P\u003d0.061).CONCLUSIONS: The use of the plastic multilayered closure technique in this patient population is important in an effort to decrease postoperative wound complications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214326"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 584,
          "text": " Plastic multilayer closure has been readily used for complex spine surgery closures in patients susceptible to wound healing issues (ie, dehiscence, surgical site infection [SSI]). However, PMC requires extensive soft tissue manipulation compared with standard orthopedic spine surgeon closure (SOC) and can result in extended operative times, increased transfusion rates, and more frequent returns to the operating room",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37979696"
        },
        {
          "offsetInBeginSection": 722,
          "offsetInEndSection": 1146,
          "text": "re was a significant increase in operating room (OR) time with PMC compared with OC (6.7±1.2 vs 7.3±1.3, p\u003d0.016). There was no difference in complication rate, mean postoperative day of complication or unplanned return to the OR for OC and PMC, respectively. There was a slightly significant increase in the number of patients going home with a drain in the PMC cohort compared with the OC cohort (2.1% vs 15%, p\u003d0.046).Con",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36817713"
        }
      ],
      "type": "list",
      "id": "67d1a0de81b102733300002a",
      "ideal_answer": [
        "plastic multilayer closure (PMC) requires extensive soft tissue manipulation compared with standard orthopedic spine surgeon closure (SOC) and can result in extended operative times, increased transfusion rates, and more frequent returns to the operating room.",
        "Complications associated with Plastic Multilayer Closure (PMC) when used for surgery can be surgical site infection, wound dehiscence, hematoma, return to the operating room, drain placement, superficial/deep dehiscence, and inflammatory response.",
        "Complications associated with Plastic Multilayer Closure (PMC) when used for surgery include surgical site infection and hematoma.",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include: wound breakdown, infection, and complications related to specific techniques such as transient mental nerve-related injuries.",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include surgical site infection, hematoma, infection, wound complications, increased OR times, superficial/deep dehiscence, thread extrusion, and inflammatory response around the scar.",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include bleeding, prolonged serosanguineous discharge, and potential nerve injuries.",
        "Complications associated with Plastic Multilayer Closure (PMC) in surgery include: \n- Increased Operative Time\n- Increased Transfusion Rates\n- More Frequent Returns to the Operating Room\n- Increased Length of Hospitalization\n- Wound Dehiscence\n- Surgical Site Infection (SSI)\n- A Higher Rate of Patients Going Home with a Drain. \nThese complications highlight potential risks to consider when evaluating the use of PMC in surgical procedures, emphasizing the need for careful patient selection and post-operative care to mitigate these risks.",
        "Plastic Multilayer Closure (PMC) complications include increased operative times, which may lead to longer anesthesia and greater resource use. The technique shows variability in its ability to reduce wound complications and infections; in some cases, it does not offer significant improvement over standard methods. Certain surgical contexts have reported higher reoperation rates potentially due to the complexity of the closure technique. Specific site-related outcomes vary: in some procedures such as inguinal hernioplasty, PMC has been associated with reduced complications, while in others like vulvectomy, complications were initially observed though not conclusively linked to PMC after adjusting for other factors. Additionally, in repairs such as those for myelomeningocele, PMC has occasionally been associated with cerebrospinal fluid leaks that require conservative management. Overall, while PMC may benefit select surgical applications by reducing wound complications, these advantages must be balanced against the increased procedure duration and the risk of other procedure-specific complications.",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include longer operative times, increased transfusion rates, more frequent returns to the operating room, wound dehiscence, surgical site infection, seroma, and hematoma.",
        "Plastic Multilayer Closure (PMC) is associated with extended operative times, increased transfusion rates, and more frequent returns to the operating room.",
        "Plastic Multilayer Closure (PMC) is associated with several surgical complications, including extended operative times, increased blood transfusion requirements, more frequent returns to the operating room, and extensive soft tissue manipulation compared to standard orthopedic surgeon closure techniques.",
        "Plastic Multilayer Closure (PMC) is associated with several significant complications including the need for extensive soft tissue manipulation, which leads to prolonged operative times, higher rates of blood transfusion requirements, and increased likelihood of patients requiring additional surgical procedures.",
        "Complications associated with Plastic Multilayer Closure (PMC) when used for surgery can be extended operative times, increased transfusion rates, and frequent returns to the operating room.",
        "Plastic Multilayer Closure (PMC) is associated with complications such as extended operative times, increased transfusion rates, and more frequent returns to the operating room.",
        "The complications associated with Plastic Multilayer Closure (PMC) during surgery include: wound breakdown, infection, and potential long-term recurrence of lesions.",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include extended operative times, increased transfusion rates, more frequent returns to the operating room, soft tissue manipulation complications, wound healing issues, infection, and hematoma.",
        "Plastic multilayer closure can result in extended operative times, increased transfusion rates, and more frequent returns to the operating room.",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include extended operative times, increased transfusion rates, and more frequent returns to the operating room.",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include surgical site infection (SSI), hematoma, and superficial/deep dehiscence.",
        "Plastic Multilayer Closure (PMC) when used in surgery is associated with several complications. These include extensive soft tissue manipulation compared to standard orthopedic spine surgeon closure, which can lead to extended operative times. Additionally, PMC may result in increased transfusion rates and a higher frequency of returns to the operating room.",
        "Complications associated with Plastic Multilayer Closure (PMC) during surgery include: increased transfusion rates, more frequent returns to the operating room, potential for wound complications, and long-term complications such as incisional hernias (IH) or bulging.",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include: wound breakdown, infection, and potential long-term recurrence of lesions.",
        "Plastic Multilayer Closure (PMC) can lead to extended operative times, higher transfusion rates, and a greater likelihood of returning to surgery.",
        "The primary complications associated with Plastic Multilayer Closure (PMC) in surgery are increased operative times, higher blood transfusion rates, and more frequent returns to the operating room, without a significant increase in postoperative wound complications.",
        "Extensive soft tissue manipulation, increased transfusion rates, and more frequent returns to the operating room are complications associated with Plastic Multilayer Closure (PMC) when used for surgery.",
        "According to the provided text, the complications associated with Plastic Multilayer Closure (PMC) when used for surgery are:\n\n1. Extended operative times\n2. Increased transfusion rates\n3. More frequent returns to the operating room",
        "The complications associated with Plastic Multilayer Closure (PMC) when used for surgery include extended operative times, increased transfusion rates, and more frequent returns to the operating room due to extensive soft tissue manipulation compared with standard orthopedic spine surgeon closure (SOC).",
        "Studies have shown that Plastic Multilayer Closure (PMC) involves extensive soft tissue manipulation compared to standard orthopedic spine surgeon closure (SOC). This can result in extended operative times, increased transfusion rates, and a higher frequency of returns to the operating room.",
        "Plastic multilayer closure can lead to complications such as longer operative times, a higher likelihood of needing transfusions, and an increased rate of return to the operating room. Patients may also experience postoperative dysaesthesia and, in some cases, weakness of the masticatory muscles.",
        "complications associaated with Plastic Multilayer Closure(PMC) when used for surgery can be extended operative times, increased transfusion rates, and more frequent returns to the operating room.",
        "The use of Plastic Multilayer Closure (PMC) in surgery can lead to complications such as extended operative times, increased transfusion rates, and more frequent returns to the operating room compared to standard orthopedic spine surgeon closure.",
        "Plastic Multilayer Closure (PMC) is associated with several surgical complications compared to standard orthopedic spine surgeon closure. These include extended operative times due to extensive soft tissue manipulation, increased transfusion rates, and a higher frequency of returns to the operating room."
      ],
      "exact_answer": [
        [
          "longer operations"
        ],
        [
          "increased transfusion rates"
        ],
        [
          "more frequent returns to the OR"
        ],
        [
          "Nacrosis"
        ],
        [
          "dehiscence"
        ],
        [
          "wound complications"
        ],
        [
          "bleeding"
        ],
        [
          "ifection"
        ],
        [
          "hematoma"
        ],
        [
          "seroma"
        ],
        [
          "CSF leak"
        ]
      ]
    },
    {
      "body": "Are biologicals safe during pregnancy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24407486",
        "http://www.ncbi.nlm.nih.gov/pubmed/37262303",
        "http://www.ncbi.nlm.nih.gov/pubmed/39141986",
        "http://www.ncbi.nlm.nih.gov/pubmed/25829190",
        "http://www.ncbi.nlm.nih.gov/pubmed/24840548",
        "http://www.ncbi.nlm.nih.gov/pubmed/34158835",
        "http://www.ncbi.nlm.nih.gov/pubmed/31692017",
        "http://www.ncbi.nlm.nih.gov/pubmed/26129693",
        "http://www.ncbi.nlm.nih.gov/pubmed/19885906",
        "http://www.ncbi.nlm.nih.gov/pubmed/34122062",
        "http://www.ncbi.nlm.nih.gov/pubmed/21342120",
        "http://www.ncbi.nlm.nih.gov/pubmed/25130641",
        "http://www.ncbi.nlm.nih.gov/pubmed/39539488",
        "http://www.ncbi.nlm.nih.gov/pubmed/39701495",
        "http://www.ncbi.nlm.nih.gov/pubmed/39626647",
        "http://www.ncbi.nlm.nih.gov/pubmed/39475080",
        "http://www.ncbi.nlm.nih.gov/pubmed/38456470",
        "http://www.ncbi.nlm.nih.gov/pubmed/35987486",
        "http://www.ncbi.nlm.nih.gov/pubmed/21063826",
        "http://www.ncbi.nlm.nih.gov/pubmed/30227748",
        "http://www.ncbi.nlm.nih.gov/pubmed/33242008",
        "http://www.ncbi.nlm.nih.gov/pubmed/26311348",
        "http://www.ncbi.nlm.nih.gov/pubmed/24352337",
        "http://www.ncbi.nlm.nih.gov/pubmed/21157441",
        "http://www.ncbi.nlm.nih.gov/pubmed/25101334",
        "http://www.ncbi.nlm.nih.gov/pubmed/24314892",
        "http://www.ncbi.nlm.nih.gov/pubmed/26444103"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1521,
          "offsetInEndSection": 1622,
          "text": "Exposure to anti-TNF-α antibodies seems to be safe for growth and psychomotor development of children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24407486"
        },
        {
          "offsetInBeginSection": 1702,
          "offsetInEndSection": 2032,
          "text": "exposure to biologics for psoriasis during pregnancy and/or conception does not seem to be associated with an increased risk of miscarriage/abortion or congenital malformations, showing similar rates to the general population. These results suggest that biologic drugs are safe and pose an acceptable risk to the foetuses/neonates",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37262303"
        },
        {
          "offsetInBeginSection": 3297,
          "offsetInEndSection": 3462,
          "text": "The use of bDMARDs was effective in disease control and safe from a maternal-fetal point of view, with no increase in prematurity, SGA, malformations, or infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39141986"
        },
        {
          "offsetInBeginSection": 1320,
          "offsetInEndSection": 1468,
          "text": "Pregnancy data for rituximab, abatacept, anakinra, tocilizumab and belimumab are limited and their use in pregnancy cannot currently be recommended.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25829190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 743,
          "text": "The safety of biologic agents during pregnancy is still being investigated. Tumor necrosis factor α (TNF-α) inhibitors are the only well-studied biological drugs in pregnancy; they do not appear to be teratogenic but increase the risk of infection after birth when given in late pregnancy. The long-term effects in exposed children are, at present, unknown. An increased risk of infection is a concern for all biologics and the risk increases further should combination with glucocorticoids be necessary. Experiences with rituximab, abatacept, anakinra, tocilizumab, and belimumab in pregnancy are limited. These drugs should be avoided during pregnancy or used only when no other option is available for treatment of serious maternal disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24840548"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 475,
          "text": "The use of IBD treatments during pregnancy should be weighed against their adverse effects on the neonate, but longer-term safety data and data on serious infection rates and malignancies postnatally are lacking, particularly for newer drugs, such as tofacitinib, vedolizumab and ustekinumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34158835"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 129,
          "text": "Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692017"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 497,
          "text": "Antibiotics, steroids, and aminosalicylates are relatively low risk for use in pregnancy, and growing evidence supports the safety of immunomodulators and anti-tumour necrosis factor agents as well",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26129693"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 332,
          "text": "While biologics are largely low risk during pregnancy, the novel small molecules tofacitinib, filgotinib, upadacitinib and ozanimod (TFUO) have shown concerning teratogenic effects, and decreased fertility in animal studies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39539488"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 712,
          "text": "he majority of asthma treatment can be continued as normal in pregnancy and there is emerging evidence of the safety of biologic medications also.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39701495"
        },
        {
          "offsetInBeginSection": 840,
          "offsetInEndSection": 997,
          "text": "In children exposed to biological treatments during pregnancy, the risk of infections appears to be low, and psychomotor development is probably not affected",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39475080"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 122,
          "text": "The safety of biologics, other than TNF-α inhibitors, during pregnancy has not been sufficiently established",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39626647"
        },
        {
          "offsetInBeginSection": 1690,
          "offsetInEndSection": 1928,
          "text": "Altogether, exposure to biologics for psoriasis during pregnancy and/or conception does not seem to be associated with an increased risk of miscarriage/abortion or congenital malformations, showing similar rates to the general population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37262303"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 416,
          "text": "PURPOSE OF REVIEW: To discuss the current understanding regarding the use of biologic therapeutics in pregnancy.RECENT FINDINGS: Our understanding of the mechanisms underlying the potential fetal and infant exposure to biologics as well as a growing body of empirical evidence from real world use of biologics in pregnancy have demonstrated that biologics are generally compatible preconception and during pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38456470"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 306,
          "text": "Biological therapies appear to be safe in pregnancy, as no increased risk of malformations has been demonstrated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25130641"
        },
        {
          "offsetInBeginSection": 775,
          "offsetInEndSection": 851,
          "text": "We found that biologics do not seem to influence maternal or fetal outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35987486"
        },
        {
          "offsetInBeginSection": 741,
          "offsetInEndSection": 885,
          "text": "According to these data, TNF inhibitor therapies appear to be safe in pregnancy, since no increased risk of malformations has been demonstrated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21063826"
        },
        {
          "offsetInBeginSection": 680,
          "offsetInEndSection": 951,
          "text": "t commentary: Data about the safety of agents against tumor necrosis factor in pregnancy are reassuring. Even rituximab, tocilizumab, belimumab, ustekinumab, secukinumab, and abatacept have not been associated with an increased rate of fetal abnormalities or adverse preg",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30227748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 357,
          "text": "The safety of biologic agents during pregnancy is still being investigated. Tumor necrosis factor α (TNF-α) inhibitors are the only well-studied biological drugs in pregnancy; they do not appear to be teratogenic but increase the risk of infection after birth when given in late pregnancy. The long-term effects in exposed children are, at present, unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24840548"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 625,
          "text": "Safety data regarding the administration of biologic agents during pregnancy, are reassuring, the main adverse event being immunosuppression of the newborn if treatment is not discontinued.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33242008"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Biologicals have transformed the management of severe disease phenotypes in psoriasis and are often prescribed in women of childbearing age. However, information on safety of biologicals in pregnancy are lacking.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37262303"
        },
        {
          "offsetInBeginSection": 537,
          "offsetInEndSection": 833,
          "text": "Among the studied biologics, more information was published on TNFα inhibitors and, in particular, on their potential passage through the placenta and impact on the fetus. Currently, a fragment of anti-TNFα monoclonal IgG, certolizumab pegol, is considered safe with almost no placental transfer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34122062"
        },
        {
          "offsetInBeginSection": 1283,
          "offsetInEndSection": 1558,
          "text": "Only one congenital malformation was reported.CONCLUSIONS: TNF-alpha inhibitors can be considered safe in the periconception period, representing a possible therapeutic choice also in young women affected by an aggressive form of chronic arthritis and hoping for a pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311348"
        },
        {
          "offsetInBeginSection": 1571,
          "offsetInEndSection": 1689,
          "text": "Congenital malformations occurred in about 3.0% (95% CI 1.6-4.8) of live births exposed to biologics during pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37262303"
        },
        {
          "offsetInBeginSection": 585,
          "offsetInEndSection": 702,
          "text": "Biological therapies appear to be safe during pregnancy, as no increased risk of malformations has been demonstrated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21342120"
        },
        {
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1718,
          "text": "Biological therapies appear to be safe in pregnancy, as no increased risk of malformations has been demonstrated. Therefore, the limited clinical results available suggest that the benefits of infliximab and adalimumab in attaining response and maintaining remission in pregnant patients might outweigh the theoretical risks of drug exposure to the fetus. Stopping therapy in the third trimester may be considered, as it seems that transplacental transfer of infliximab is low prior to this. Certolizumab differs from infliximab and adalimumab in that it is a Fab fragment of an antitumor necrosis factor alpha monoclonal antibody, and therefore it may not be necessary to stop certolizumab in the third trimester",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19885906"
        },
        {
          "offsetInBeginSection": 293,
          "offsetInEndSection": 564,
          "text": "Collective evidence from many hundreds of pregnancies in inflammatory arthritis and IBD have suggested that exposure to anti-TNF therapies at the time of conception or during the first trimester does not result in an increased risk of adverse pregnancy and fetal outcomes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24352337"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 509,
          "text": "Anti-tumor necrosis factor therapy in pregnancy is considered to be low risk and compatible with use during conception in men and women and during pregnancy in at least the first two trimesters",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157441"
        },
        {
          "offsetInBeginSection": 665,
          "offsetInEndSection": 913,
          "text": "Although research investigating the long-term outcomes of children exposed to anti-TNF therapy in utero is limited, there is no known adverse effect on either pregnancy or newborn outcomes including infectious complications with this class of drugs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25101334"
        },
        {
          "offsetInBeginSection": 413,
          "offsetInEndSection": 592,
          "text": "Anti-TNF agents fall within the US FDA category B concerning fetal risk, indicating that no adequate and well-controlled studies have been conducted in pregnant or lactating women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21063826"
        },
        {
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1382,
          "text": "Biologics generally should be stopped when pregnancy is discovered.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16864922"
        },
        {
          "offsetInBeginSection": 625,
          "offsetInEndSection": 876,
          "text": "Aside from methotrexate, immunomodulators and biologics may be used during pregnancy to achieve and maintain disease control. Based on available safety data, there is no increased risk of congenital anomalies among infants exposed to these medications",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26444103"
        },
        {
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1117,
          "text": "Biological therapies appear to be safe in pregnancy, as no increased risk of malformations has been demonstrated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19885906"
        },
        {
          "offsetInBeginSection": 485,
          "offsetInEndSection": 590,
          "text": "The literature seems to suggest that biologic therapy is safe during pregnancy, but there is no certainty",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24314892"
        }
      ],
      "id": "67e4165d18b1e36f2e0000a6",
      "ideal_answer": [
        "Although more studies are required, the literature reports no higher incidence of neonatal problems with the maternal use of biologicals.",
        "The safety of biologics during pregnancy is not well-established due to the lack of extensive clinical trials and long-term data. While some biologics like certolizumab pegol and etanercept are considered to have minimal placental transfer and are deemed relatively safe, comprehensive safety data is still lacking.",
        "Biologicals are generally considered safe during pregnancy, with nuances. Safe options up to 30 weeks of gestation include anti-TNF therapies (e.g., infliximab, adalimumab) and certain immunomodulators (e.g., thiopurines, cyclosporine). However, methotrexate, thalidomide, and mycophenolate are contraindicated due to teratogenic risks. Use of rituximab, abatacept, anakinra, tocilizumab, and belimumab is not recommended due to limited pregnancy data. Breastfeeding is likely safe with most biologics, in minimal amounts, except for certain cases like cyclosporine. Individualized treatment decisions are crucial, weighing disease activity, medication response, and potential fetal risks.",
        "The safety of biologicals during pregnancy is complex and varies depending on the specific agent. There is generally a lack of adequate and well-controlled trials in pregnant women, leading to insufficient data to inform drug-associated risks for many biologicals. Some biologicals like infliximab, adalimumab, and certolizumab pegol have not shown increased adverse events during pregnancy or perinatally. Anti-TNFα biologicals do not seem to increase unfavorable pregnancy outcomes or congenital malformations, although their effects on the developing immune system are largely unknown. Omalizumab\u0027s safety data is mainly based on limited reports. Concerns exist about immune function and vaccination of infants born to mothers taking immunoglobulin biologicals, with some cases of severe neonatal neutropenia and fatal dissemination of Bacillus Calmette-Guérin reported. Animal studies show varying effects, with some biologicals crossing the placenta and affecting fetal development. Human data is often insufficient to determine risks for major birth defects or miscarriage. Overall, more well-controlled human studies are needed to provide definitive conclusions on the safety of biologicals during pregnancy."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What is an E-box and what is its role in gene regulation of cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37601651",
        "http://www.ncbi.nlm.nih.gov/pubmed/37519063",
        "http://www.ncbi.nlm.nih.gov/pubmed/34169392",
        "http://www.ncbi.nlm.nih.gov/pubmed/38954708",
        "http://www.ncbi.nlm.nih.gov/pubmed/39327245",
        "http://www.ncbi.nlm.nih.gov/pubmed/9425291",
        "http://www.ncbi.nlm.nih.gov/pubmed/12130638",
        "http://www.ncbi.nlm.nih.gov/pubmed/24918046",
        "http://www.ncbi.nlm.nih.gov/pubmed/38340508"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 580,
          "text": "E-boxes are important regulatory elements in the eukaryotic genome. Transcription factors can bind to E-boxes through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. E-box-binding transcription factors (EBTFs) are important regulators of development and essential for physiological activities of the cell. The fundamental role of EBTFs in cancer has been highlighted by studies on the canonical oncogene MYC, yet many EBTFs exhibit common features, implying the existence of shared molecular principles of how they are involved in tumorigenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37601651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "text": "The transcription factor MYC is a proto-oncogene with a well-documented essential role in the pathogenesis and maintenance of several types of cancer. MYC binds to specific E-box sequences in the genome to regulate gene expression in a cell-type- and developmental-stage-specific manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37519063"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 340,
          "text": "E-box-binding transcription factors (EBTFs) are important regulators of development and essential for physiological activities of the cell.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37601651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "The E-Box is a widely used DNA control element. Despite its brevity and broad distribution the E-Box is a remarkably versatile sequence that affects many different genetic programs, including proliferation, differentiation, tissue-specific responses, and cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12130638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Gene amplification and/or overexpression of the transcription factor c-MYC, which binds to the E-box sequence (5\u0027-CACGTG-3\u0027), has been observed in many human tumors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24918046"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 1212,
          "text": "Myc binds to its partner, a smaller protein called Max, forming an Myc:Max heterodimeric complex that interacts with specific DNA recognition sequences (E-boxes) and regulates the expression of downstream target genes. Myc protein plays a fundamental role for the life of a cell, as it is involved in many physiological functions such as proliferation, growth and development since it controls the expression of a very large percentage of genes (∼15 %). However, despite the strict control of MYC expression in normal cells, MYC is often deregulated in cancer, exhibiting a key role in stimulating oncogenic process affecting features such as aberrant proliferation, differentiation, angiogenesis, genomic instability and oncogenic transformation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38340508"
        }
      ],
      "id": "67eaf32618b1e36f2e0000e3",
      "ideal_answer": [
        "E-boxes are important regulatory elements in the eukaryotic genome. Transcription factors can bind to E-boxes through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. E-box-binding transcription factors (EBTFs) are important regulators of development and essential for physiological activities of the cell. The fundamental role of EBTFs in cancer has been highlighted by studies on the canonical oncogene MYC, with a well-documented essential role in the pathogenesis and maintenance of several types of cancer. MYC binds to specific E-box sequences in the genome to regulate gene expression in a cell-type- and developmental-stage-specific manner. Still, many other EBTFs exhibit common features, implying the existence of shared molecular principles of how they are involved in tumorigenesis.",
        "An E-box is a regulatory element in the eukaryotic genome that transcription factors can bind to through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. E-box-binding transcription factors (EBTFs) are crucial for development and cell physiological activities. In cancer, EBTFs, such as the oncogene MYC, play a fundamental role in tumorigenesis by regulating transcription and potentially serving as targets for cancer therapy.",
        "An E-box is a specific DNA sequence found in the promoter regions of certain genes, characterized by the consensus sequence CANNTG (where N can be any nucleotide). It serves as a binding site for basic helix-loop-helix (bHLH) transcription factors. In the context of gene regulation related to cancer, E-box elements are involved in the activation of transcription of genes that can contribute to cellular processes such as growth, proliferation, and immortality. An example of this is the activation of telomerase reverse transcriptase (TERT), which plays a critical role in maintaining telomere length and is associated with cellular immortality and tumorigenesis. By engaging E-box-mediated transcription, these factors can promote oncogenic pathways, leading to the development and progression of cancer.",
        "An E-box is a DNA sequence (CANNTG) that serves as a binding site for transcription factors, particularly those with basic helix-loop-helix (bHLH) or zinc finger domains. In cancer, E-boxes regulate genes involved in critical processes like proliferation, differentiation, and metastasis. For example:  \n- **MITF** binds E-boxes to activate target genes (e.g., *IDH1*, *NNT*), influencing metabolic pathways.  \n- **MYC** binds E-boxes (e.g., in the *ANLN* promoter) to drive oncogenic transcription.  \n- **ZEB1/ZEB2**, zinc finger E-box-binding proteins, promote epithelial-mesenchymal transition (EMT) by repressing epithelial markers (e.g., E-cadherin) and activating mesenchymal markers (e.g., vimentin), enhancing cancer invasiveness and metastasis. Dysregulation of E-box-mediated transcription via these factors (e.g., via miR-326 or pathways like PI3K/AKT) contributes to tumor progression and aggressiveness.",
        "An E-box is a short, conserved DNA sequence, typically containing the motif CACGTG, that acts as a binding site for transcription factors with basic helix-loop-helix or zinc finger domains. The binding of these transcription factors can activate or repress gene expression in a context-dependent manner. In cancer, changes such as altered transcription factor levels, mutations, or DNA methylation at E-boxes disrupt normal gene regulation, contributing to uncontrolled cell growth, survival, and tumor progression. Different E-box variants, including both canonical and noncanonical forms, mediate distinct regulatory outcomes. Therapeutic strategies are also being explored, such as the design of polyamides that specifically target E-box binding to counteract oncogenic deregulation.",
        "An E-box is a DNA response element with the consensus sequence **CANNTG** (commonly CACGTG) that serves as a binding site for transcription factors (TFs) containing basic helix-loop-helix (bHLH) or bHLH-ZIP domains. In cancer, E-boxes regulate genes critical for **cell proliferation, differentiation, apoptosis, metastasis, and epithelial-mesenchymal transition (EMT)**. Key roles include:  \n1. **Oncogenic activation**: MYC binds E-boxes to drive tumor growth and angiogenesis.  \n2. **EMT and metastasis**: TFs like TWIST1, SNAI1, ZEB1, and ZEB2 bind E-boxes to suppress epithelial markers (e.g., E-cadherin) and promote mesenchymal traits (e.g., vimentin, N-cadherin), enhancing cancer aggressiveness.  \n3. **Tumor suppression**: MAD family proteins antagonize MYC by competing for E-box binding.  \n4. **Circadian disruption**: CLOCK/BMAL1 circadian regulators use E-boxes, linking circadian dysregulation to cancer progression.  \nDysregulated E-box-mediated transcription is a hallmark of oncogenic transformation, metabolic reprogramming, and metastasis.",
        "An E-box is a short DNA sequence, typically defined by the CACGTG motif, which functions as a binding site for transcription factors, particularly those in the basic helix-loop-helix family. It regulates gene expression by serving as the point of entry for both activators and repressors. In cancer, the E-box is crucial because transcription factors like Myc and USF1 bind to it to control genes involved in cell proliferation, metabolism, and survival. DNA methylation of CpG sites within the E-box can block these binding events, leading to reduced gene expression, as seen with certain tumor suppressors. Additionally, repressive factors such as Slug and Snail bind to E-box elements to inhibit the expression of genes like E-cadherin, promoting the epithelial-to-mesenchymal transition—a key event in metastasis. Thus, through its regulation of multiple gene networks, the E-box plays a multifaceted role in tumor growth and spread by influencing cell behavior and metastatic potential.",
        "E-boxes are important regulatory elements in the eukaryotic genome. Transcription factors can bind to E-boxes through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. E-box-binding transcription factors (EBTFs) are important regulators of development and essential for physiological activities of the cell. The fundamental role of EBTFs in cancer has been highlighted by studies on the canonical oncogene MYC, yet many EBTFs exhibit common features, implying the existence of shared molecular principles of how they are involved in tumorigenesis.",
        "An E-box is a specific DNA regulatory sequence in the eukaryotic genome where transcription factors like MYC can bind through their basic helix-loop-helix or zinc finger domains to regulate gene expression. In cancer, E-box-binding transcription factors (EBTFs) play a critical role in tumorigenesis by controlling gene transcription in a cell-type and developmental-stage specific manner. The proto-oncogene MYC, a well-known EBTF, exemplifies how these transcription factors can bind to E-box sequences to modulate gene expression, potentially contributing to cancer development and maintenance.",
        "E-boxes are crucial regulatory elements in the eukaryotic genome, playing a significant role in gene regulation, particularly in cancer. They serve as binding sites for transcription factors, such as those with basic helix-loop-helix or zinc finger domains, which regulate gene transcription. Studies have highlighted the importance of E-box-binding transcription factors (EBTFs) in development and physiological cellular activities, as well as their involvement in tumorigenesis. Notably, the proto-oncogene MYC, a well-known EBTF, binds to specific E-box sequences to regulate gene expression in a cell-type- and developmental-stage-specific manner, contributing to the pathogenesis and maintenance of various types of cancer. Overall, E-boxes are essential for the regulation of gene expression by EBTFs, including MYC, which has a fundamental role in cancer development and progression.",
        "E-boxes are crucial regulatory DNA elements in eukaryotes where transcription factors, particularly those with basic helix-loop-helix or zinc finger domains, can bind to control gene transcription. Their significance in cancer biology is exemplified by the proto-oncogene MYC, which binds to specific E-box sequences to regulate gene expression in a context-dependent manner, playing a vital role in cancer pathogenesis and maintenance.",
        "An E-box is a specific DNA sequence that serves as a regulatory element in the eukaryotic genome, allowing transcription factors to bind to it through their basic helix-loop-helix or zinc finger domain, thereby regulating gene transcription. This process is crucial in various cellular activities and has been implicated in the development and progression of cancer, particularly in the case of the MYC proto-oncogene, which binds to E-box sequences to regulate gene expression in a cell-type- and developmental-stage-specific manner.",
        "An E-box is a specific DNA sequence that acts as a regulatory element in eukaryotic genes. Transcription factors, such as MYC and other EBTFs, bind to these E-boxes via their basic helix-loop-helix or zinc finger domains to control gene expression. In cancer, this regulation is crucial because factors like MYC orchestrate the expression of genes that drive tumor development and progression.",
        "An E-box is a specific DNA sequence that serves as a binding site for transcription factors, particularly those with basic helix-loop-helix or zinc finger domains. These transcription factors, known as E-box-binding transcription factors (EBTFs), play crucial roles in regulating gene transcription, influencing various physiological processes and developmental stages. In the context of cancer, E-boxes are significant because they are involved in the regulation of key genes associated with tumorigenesis. For instance, the proto-oncogene MYC binds to E-box sequences to modulate gene expression, contributing to cancer pathogenesis. Additionally, transcription factors like ZEB1 and ZEB2 interact with E-boxes to regulate E-cadherin expression, which is critical in epithelial-mesenchymal transition (EMT) and cancer progression. Overall, E-boxes are vital regulatory elements that facilitate the transcriptional modulation of genes involved in cancer development and progression.",
        "An E-box is a DNA regulatory element with a consensus CANNTG sequence. It serves as a binding site for transcription factors containing basic helix-loop-helix (bHLH) or zinc finger domains, enabling them to regulate gene transcription. In cancer, E-box-binding transcription factors (EBTFs) like MYC are critical drivers of tumorigenesis. MYC binds E-boxes to control cell-type-specific gene expression, promoting oncogenic processes such as uncontrolled proliferation, evasion of apoptosis, and metabolic reprogramming. Dysregulation of EBTFs disrupts normal cellular physiology, contributing to cancer development and maintenance by altering transcriptional networks critical for cell growth and survival.",
        "An E-box is a DNA regulatory element (consensus sequence CANNTG) recognized by transcription factors with basic helix-loop-helix (bHLH) or zinc finger domains. It regulates gene transcription by serving as a binding site for E-box-binding transcription factors (EBTFs), which control developmental and cellular processes. In cancer, EBTFs like MYC bind E-boxes to drive oncogenesis by dysregulating genes involved in cell proliferation, differentiation, and survival. MYC, a proto-oncogene, binds E-boxes to activate or repress target genes in a context-dependent manner, promoting tumorigenesis. Other EBTFs share mechanisms that disrupt normal transcriptional programs, contributing to cancer progression.",
        "An E-box is a specific DNA sequence motif that serves as a binding site for transcription factors, particularly those with basic helix-loop-helix or zinc finger domains. These transcription factors, known as E-box-binding transcription factors (EBTFs), play a crucial role in regulating gene expression by controlling the transcription of genes.\n\nIn the context of cancer, E-boxes are significant because they are binding sites for oncogenes such as MYC. MYC is a proto-oncogene that, when dysregulated, can contribute to cancer development and progression. By binding to E-box sequences, MYC regulates the expression of genes involved in cell growth, proliferation, and apoptosis. This regulation is specific to the type of cell and its developmental stage.\n\nThe role of E-boxes in cancer extends beyond MYC, as many EBTFs share common mechanisms that contribute to tumorigenesis. Thus, E-boxes are essential elements in the gene regulatory networks that drive cancer progression, highlighting their importance in both normal cellular processes and oncogenesis.",
        "E-boxes are DNA sequences that serve as binding sites for transcription factors, such as MYC, through their basic helix-loop-helix or zinc finger domain. They play a crucial role in regulating gene transcription, particularly in cancer. E-box-binding transcription factors (EBTFs) are important regulators of development and physiological activities of the cell, and their dysregulation can contribute to tumorigenesis. MYC, a proto-oncogene, binds to specific E-box sequences in the genome to regulate gene expression in a cell-type- and developmental-stage-specific manner, and its overexpression is associated with several types of cancer.",
        "An E-box is a specific DNA sequence motif that serves as a binding site for transcription factors, particularly those with basic helix-loop-helix or zinc finger domains. These transcription factors, such as MYC, play a crucial role in regulating gene expression by binding to E-boxes.\n\nIn the context of cancer, MYC, a proto-oncogene, binds to E-box sequences to regulate the expression of genes involved in cell growth and proliferation. When dysregulated, MYC can contribute to uncontrolled cell division, promoting tumor formation and maintenance. Other E-box-binding transcription factors (EBTFs) share similar mechanisms, suggesting common pathways through which they influence cancer development.\n\nIn summary, E-boxes are essential regulatory elements that facilitate the binding of transcription factors like MYC, influencing gene expression processes that can lead to cancer when disrupted.",
        "An E-box is a specific DNA sequence motif that serves as a binding site for transcription factors, particularly those with basic helix-loop-helix or zinc finger domains. These transcription factors, such as MYC, play a crucial role in regulating gene expression by binding to E-boxes.\n\nIn the context of cancer, MYC, a proto-oncogene, binds to E-box sequences to regulate the expression of genes involved in cell proliferation and survival. Dysregulation of these transcription factors can lead to uncontrolled cell growth, contributing to tumor development and maintenance. Other E-box-binding transcription factors (EBTFs) share similar mechanisms, suggesting common pathways in cancer progression. Thus, E-boxes are integral to gene regulation processes that are often disrupted in cancer, influencing tumorigenesis through the dysregulation of critical cellular functions.",
        "An E-box is a regulatory element in the eukaryotic genome that transcription factors can bind to through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. E-box-binding transcription factors (EBTFs) play significant roles in development, physiological activities of the cell, and tumorigenesis. For example, the proto-oncogene MYC, which binds to specific E-box sequences, has a well-documented role in the pathogenesis and maintenance of several types of cancer.",
        "E-boxes are regulatory elements in the eukaryotic genome that transcription factors, such as the oncoprotein MYC, bind to through domains like basic helix-loop-helix or zinc fingers to regulate gene transcription. These E-box-binding transcription factors (EBTFs) play a crucial role in development and are increasingly recognized for their involvement in tumorigenesis. MYC, a well-studied example, demonstrates the fundamental role of EBTFs in the pathogenesis and maintenance of various cancers by controlling gene expression in a cell-type and developmental-stage-specific manner.",
        "An E-box is a regulatory DNA sequence found in the eukaryotic genome that serves as a binding site for transcription factors, particularly those with basic helix-loop-helix or zinc finger domains. These E-box-binding transcription factors (EBTFs) play a crucial role in regulating gene transcription, influencing developmental processes and essential physiological activities within cells. In the context of cancer, E-boxes are significant because they are targeted by oncogenes like MYC, which binds to specific E-box sequences to regulate gene expression in a manner that is specific to cell type and developmental stage. Disruption of E-box sequences has been shown to affect MYC binding, target-gene expression, and ultimately, cell proliferation and tumor growth, highlighting their importance in cancer biology and potential as therapeutic targets.",
        "E-boxes are crucial regulatory elements in eukaryotic genomes that transcription factors, such as those with basic helix-loop-helix or zinc finger domains, bind to regulate gene transcription. These E-box-binding transcription factors (EBTFs) play significant roles in development and cellular physiology, with their involvement in cancer highlighted by studies on the oncogene MYC. MYC, a proto-oncogene, binds to specific E-box sequences to modulate gene expression in a cell-type- and developmental-stage-specific manner, underscoring its essential role in the pathogenesis and maintenance of various cancers.",
        "An E-box is a DNA sequence that serves as a binding site for specific transcription factors, such as those with basic helix-loop-helix or zinc finger domains. These transcription factors regulate gene expression by binding to E-boxes. In the context of cancer, certain transcription factors, notably the proto-oncogene MYC, bind to E-box sequences to control genes involved in cell growth and proliferation. Dysregulation of this process can contribute to cancer development and progression, as seen with MYC\u0027s role in promoting tumorigenesis by altering gene expression patterns critical for cell cycle regulation and metabolism.",
        "E-boxes are critical regulatory elements in the eukaryotic genome that serve as binding sites for transcription factors, particularly those with basic helix-loop-helix or zinc finger domains. These E-box-binding transcription factors (EBTFs) play essential roles in regulating gene transcription, influencing various physiological activities and developmental processes. In the context of cancer, E-boxes are significant due to their involvement in the regulation of oncogenes, such as MYC, which binds to specific E-box sequences to modulate gene expression in a cell-type and developmental-stage-specific manner. Additionally, transcription factors like ZEB1 and ZEB2 interact with E-boxes to regulate E-cadherin expression, which is implicated in multiple human cancers. Overall, E-boxes are integral to the mechanisms of tumorigenesis, as they facilitate the transcriptional regulation of genes associated with cancer progression and metastasis.",
        "An E-box is a short DNA sequence (typically CANNTG) found in eukaryotic genomes that serves as a regulatory element for gene transcription. Transcription factors, such as those with basic helix-loop-helix or zinc finger domains, bind to E-boxes to regulate gene expression. In cancer, E-box-binding transcription factors (EBTFs), including MYC, play critical roles by influencing genes involved in cell growth, proliferation, and survival.",
        "An E-box is a specific DNA sequence that serves as a binding site for transcription factors, particularly those with basic helix-loop-helix or zinc finger domains. In the context of gene regulation, E-boxes are crucial for the transcriptional control of various genes, including those involved in cancer. E-box-binding transcription factors (EBTFs), such as MYC, ZEB1, and ZEB2, interact with these elements to regulate gene expression in a manner that can influence cell development and physiological activities. In cancer, abnormal regulation of E-boxes can lead to the activation of oncogenes or inhibition of tumor suppressor genes, thereby promoting tumorigenesis and cancer progression. For instance, the binding of ZEB1 and ZEB2 to E-boxes in the E-cadherin gene is implicated in the regulation of E-cadherin expression, which is significant in various human cancers. Overall, E-boxes play a pivotal role in the transcriptional networks that govern cancer biology.",
        "An E-box is an important regulatory element in the eukaryotic genome. Transcription factors can bind to E-boxes through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. E-box-binding transcription factors (EBTFs) are important regulators of development and essential for physiological activities of the cell. The fundamental role of EBTFs in cancer has been highlighted by studies on the canonical oncogene MYC, yet many EBTFs exhibit common features, implying the existence of shared molecular principles of how they are involved in tumorigenesis.",
        "An E-box is a specific DNA sequence element that serves as a binding site for transcription factors, particularly those with basic helix-loop-helix or zinc finger domains. In gene regulation, E-boxes play a crucial role in cancer development by facilitating the binding of transcription factors, such as MYC, to specific genomic regions. This binding event regulates gene expression, influencing various cellular processes that contribute to tumorigenesis. The binding of transcription factors to E-boxes can either activate or repress gene transcription, depending on the context, and is often cell-type- and developmental-stage-specific. Dysregulation of E-box-mediated gene regulation has been implicated in several types of cancer, highlighting the importance of understanding E-box function in cancer development and progression.",
        "E-boxes are important regulatory elements in the eukaryotic genome that serve as binding sites for transcription factors containing basic helix-loop-helix or zinc finger domains. These E-box-binding transcription factors (EBTFs) play crucial roles in development and cellular physiological activities. In cancer, EBTFs are significant regulators of tumorigenesis, with the canonical oncogene MYC being a well-documented example. MYC binds to specific E-box sequences to regulate gene expression in a context-dependent manner, contributing to cancer pathogenesis and maintenance. Many EBTFs share common features, suggesting shared molecular mechanisms in their involvement in cancer development and progression.",
        "E-boxes are regulatory DNA sequences in the eukaryotic genome that transcription factors bind to through specific structural domains, such as basic helix-loop-helix or zinc finger motifs. These E-box-binding transcription factors (EBTFs) play a crucial role in regulating gene expression during development and cellular physiology. In cancer, EBTFs like MYC are particularly significant, as they bind to E-box sequences to control gene expression in a manner that is specific to cell type and developmental stage. Studies highlight the importance of these interactions in tumorigenesis, with MYC being a well-known oncogene essential for the pathogenesis and maintenance of various cancers. Thus, E-boxes serve as critical elements in gene regulation, influencing both normal cellular functions and cancer progression through their interaction with EBTFs.",
        "An E-box is a specific DNA sequence within the eukaryotic genome that serves as a binding site for transcription factors. These transcription factors, such as MYC, can bind to E-boxes through domains like basic helix-loop-helix or zinc finger to regulate gene transcription. In the context of cancer, E-boxes play a crucial role by allowing oncogenic transcription factors like MYC to bind and regulate genes that control cell growth, differentiation, and survival, thereby influencing the pathogenesis and maintenance of various cancers.",
        "An E-box is a specific DNA sequence that serves as a binding site for certain transcription factors, such as those with basic helix-loop-helix or zinc finger domains. These transcription factors regulate gene expression by attaching to E-boxes, influencing various cellular processes, including development and physiology. In the context of cancer, E-box-binding transcription factors (EBTFs), like MYC, play a crucial role. MYC binds to E-box sequences to activate genes that promote tumor growth and maintenance, highlighting the significance of E-boxes in cancer progression. While MYC is a prominent example, other EBTFs may also contribute to oncogenesis through similar mechanisms, underscoring the broader impact of E-boxes in gene regulation related to cancer.",
        "E-boxes are regulatory DNA sequences within the genome that play a crucial role in controlling gene expression. Studies have shown that transcription factors, equipped with specific structural domains such as basic helix-loop-helix or zinc finger motifs, bind to these E-boxes to regulate the transcription of target genes. In the context of cancer, E-box-binding transcription factors (EBTFs), exemplified by the oncogene MYC, are central to tumorigenesis. MYC, a well-studied EBTF, binds to E-box sequences to activate genes that drive cell proliferation and survival, thereby contributing significantly to cancer development and progression. This mechanism underscores the importance of E-boxes in gene regulation and their implications in cancer biology.",
        "E-boxes are important regulatory elements in the eukaryotic genome. Transcription factors can bind to E-boxes through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. E-box-binding transcription factors (EBTFs) are important regulators of development and essential for physiological activities of the cell. The fundamental role of EBTFs in cancer has been highlighted by studies on the canonical oncogene MYC. MYC binds to specific E-box sequences in the genome to regulate gene expression in a cell-type- and developmental-stage-specific manner.",
        "E-boxes are important regulatory elements in the eukaryotic genome where transcription factors bind through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. E-box-binding transcription factors (EBTFs) have a fundamental role in cancer, highlighted by studies on the canonical oncogene MYC. MYC is a proto-oncogene with a well-documented essential role in the pathogenesis and maintenance of several types of cancer. MYC binds to specific E-box sequences in the genome to regulate gene expression. Many EBTFs exhibit common features, implying the existence of shared molecular principles of how they are involved in tumorigenesis.",
        "E-boxes are important regulatory elements in the eukaryotic genome. Transcription factors can bind to E-boxes through their basic helix-loop-helix or zinc finger domain to regulate gene transcription. The transcription factor MYC, a proto-oncogene, binds to specific E-box sequences in the genome to regulate gene expression in a cell-type- and developmental-stage-specific manner, playing an essential role in the pathogenesis and maintenance of several types of cancer."
      ]
    },
    {
      "body": "Describe StarGazer",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35711912"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35711912"
        },
        {
          "offsetInBeginSection": 657,
          "offsetInEndSection": 1311,
          "text": "We believe that integrating different data sources using a singular numerical scoring system in a hybrid intelligent framework could help to bridge these different omics layers and facilitate rapid drug target prioritization for studies in drug discovery, development or repositioning. Herein, we describe our prototype of the StarGazer pipeline which combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits, and is available via https://github.com/AstraZeneca/StarGazer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35711912"
        }
      ],
      "id": "67dc40da18b1e36f2e000058",
      "ideal_answer": [
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning using streamlit.",
        "StarGazer is a bioinformatics tool used to detect and interpret structural variants in the human genome, with a focus on pharmacogenomics. It analyzes next-generation sequencing data to identify copy number variations and structural rearrangements in genes that are important for drug metabolism. This information is crucial for personalized medicine, as variations in these genes can affect how individuals respond to medications. StarGazer provides detailed reports to help clinicians make informed decisions about drug prescriptions based on a patient\u0027s genetic profile.",
        "StarGazer is a bioinformatics tool designed for analyzing next-generation sequencing (NGS) data to identify star alleles, particularly for pharmacogenes like CYP2D6. It consists of two main components: a data-processing component and a data-visualization component, aimed at improving the accuracy of intensity data and ease of use. StarGazer can detect various genetic variants, including single nucleotide variants, insertions, deletions, and structural variations, and has shown high concordance with existing genotyping methods. Additionally, it has been extended to analyze multiple pharmacogenes, enhancing the potential for precision drug therapy. The software is also utilized in neutron time-of-flight single-crystal diffraction data processing.",
        "StarGazer is a computational pipeline that integrates multi-source, multi-omics data with a novel target prioritization scoring system. It is implemented as an interactive Python-based Streamlit dashboard, allowing users to explore and evaluate gene targets. StarGazer displays scores for genes associated with 1844 phenotypic traits and is publicly available via GitHub. This tool is distinct from similarly named software used for star allele calling and pharmacogene genotyping, focusing specifically on data integration and target prioritization rather than detailed allele analysis.",
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning using Streamlit. It combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits, and is available via https://github.com/AstraZeneca/StarGazer.",
        "StarGazer is a hybrid intelligence platform developed for drug target prioritization and digital drug repositioning. It is an interactive Python-based Streamlit dashboard that integrates multi-source and multi-omics data using a novel numerical scoring system. The platform can display target prioritization scores for genes associated with 1,844 phenotypic traits, facilitating rapid drug discovery, development, and repositioning research. The open-source tool is available on GitHub and aims to bridge different omics data layers through a comprehensive computational approach.",
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data (genomics, phenomics, proteomics) through a novel target prioritization scoring system, displayed on an interactive Python-based Streamlit dashboard. Covering 1844 phenotypic traits, StarGazer combines human expertise with computational analysis to enhance drug discovery and repositioning. Originally developed by AstraZeneca, the platform is now openly available on GitHub for research, access, and further development, facilitating rapid analysis and decision-making in the scientific community.",
        "StarGazer is a hybrid intelligence platform designed to facilitate drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data into a singular numerical scoring system, allowing for the bridging of different omics layers and rapid target identification. The StarGazer pipeline combines this data with a novel target prioritization scoring system, which is showcased in an interactive Python-based Streamlit dashboard. This platform displays target prioritization scores for genes associated with 1844 phenotypic traits, making it a valuable tool for studies in drug discovery, development, and repositioning, and is available for access via its GitHub repository.",
        "StarGazer is a hybrid intelligence platform and Python-based Streamlit dashboard that combines multi-source, multi-omics data with a novel target prioritization scoring system to facilitate drug target prioritization and drug repositioning. The platform integrates different data sources using a singular numerical scoring system and provides target prioritization scores for genes associated with 1844 phenotypic traits, available through GitHub.",
        "StarGazer is a prototype pipeline that combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits and is available via https://github.com/AstraZeneca/StarGazer.",
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning, utilizing a novel scoring system to integrate multi-source, multi-omics data in an interactive Python-based Streamlit dashboard.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data through a singular numerical scoring system using an interactive Python-based Streamlit dashboard, displaying target scores for genes linked with 1844 phenotypic traits.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data into a singular numerical scoring system, facilitating rapid identification of potential drug targets for discovery, development, or repositioning. The platform features an interactive dashboard built with Python\u0027s Streamlit, displaying prioritization scores for genes linked to 1,844 phenotypic traits. StarGazer consists of both data-processing and data-visualization components, enhancing the accuracy of intensity data. It is available for use via GitHub and aims to streamline the process of drug target identification by leveraging diverse data sources.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data using a unified numerical scoring system to bridge omics layers, facilitating rapid decision-making in drug discovery and development. Built as an interactive Python-based Streamlit dashboard, it provides target prioritization scores for genes associated with 1,844 phenotypic traits. The tool aims to streamline drug discovery processes by combining diverse data types into a singular framework. It is openly accessible via its GitHub repository under AstraZeneca.",
        "StarGazer is a computational tool with dual applications. For pharmacogenomics, it processes whole‐genome or targeted sequencing data to call star alleles, assign diplotypes, and predict phenotypes for clinically important genes, accurately handling complex structural variations for personalized medicine. For drug discovery, it integrates multi-omics data through a hybrid intelligence framework that employs a unique numerical scoring system. This pipeline, which is available on GitHub as an interactive Python-based dashboard, prioritizes gene targets to support drug repositioning and target selection. The tool’s functionalities represent distinct but complementary aspects of automated genotyping and data-driven drug target prioritization.",
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning. It integrates multiple data sources using a singular numerical scoring system in a hybrid intelligent framework to bridge different omics layers and facilitate rapid drug target prioritization for studies in drug discovery, development, or repositioning. StarGazer combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard, displaying target prioritization scores for genes associated with 1844 phenotypic traits. StarGazer is available via GitHub (\u003chttps://github.com/AstraZeneca/StarGazer",
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits and is available via https://github.com/AstraZeneca/StarGazer.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data into a unified scoring system and presents the results through an interactive Python-based Streamlit dashboard. The platform provides target prioritization scores for genes linked to 1844 phenotypic traits and is accessible via its GitHub repository.",
        "StarGazer is a prototype pipeline designed for drug target prioritization that integrates multi-source, multi-omics data. It employs a novel scoring system to evaluate and prioritize potential drug targets based on their association with 1844 phenotypic traits. The tool is built on an interactive Python-based Streamlit dashboard, allowing users to visualize target prioritization scores effectively. StarGazer aims to enhance drug discovery and repositioning by bridging different omics layers and facilitating the analysis of complex datasets. It is accessible through GitHub at https://github.com/AstraZeneca/StarGazer.",
        "StarGazer is a hybrid intelligence platform designed to facilitate drug target prioritization and digital drug repositioning by integrating multi-source, multi-omics data into a singular numerical scoring system. It employs an interactive Python-based Streamlit dashboard that displays target prioritization scores for genes linked to 1844 phenotypic traits, aiding in rapid decision-making during drug discovery, development, or repositioning processes. The platform is accessible via its GitHub repository.",
        "StarGazer is a hybrid intelligence platform developed by AstraZeneca for drug target prioritization and digital drug repositioning. Utilizing Streamlit, it integrates multi-omics data through a novel numerical scoring system, facilitating rapid target identification across various omics layers. The interactive dashboard displays prioritization scores for genes associated with 1844 phenotypic traits, aiding in drug discovery and development. Available on GitHub, StarGazer serves as a valuable tool for streamlining the drug repositioning process.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data using a novel scoring system within an interactive Python-based Streamlit dashboard. The platform provides target prioritization scores for genes linked to 1844 phenotypic traits, facilitating rapid drug discovery and development processes. StarGazer consists of both data-processing and data-visualization components, making it user-friendly and capable of delivering accurate intensity data. It is available for public use on GitHub and aims to bridge different omics layers in biomedical research.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates various data sources through a singular numerical scoring system within a hybrid intelligent framework, facilitating the rapid prioritization of drug targets in drug discovery, development, or repositioning. The prototype of the StarGazer pipeline combines multi-source, multi-omics data with a novel target prioritization scoring system, presented in an interactive dashboard built using Python\u0027s Streamlit. It provides target prioritization scores for genes linked to 1,844 phenotypic traits and is accessible via GitHub at https://github.com/AstraZeneca/StarGazer.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data using a novel scoring system to prioritize targets associated with various phenotypic traits. The platform is implemented as an interactive Python-based Streamlit dashboard and provides scores for genes linked to 1844 phenotypic traits.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It uniquely integrates multi-omics data through a novel, unified numerical scoring system, facilitating rapid discovery. Accessible via an interactive Python-based Streamlit dashboard, StarGazer provides target prioritization scores for genes associated with 1844 phenotypic traits. By combining human intelligence with multi-database mining capabilities, it streamlines drug discovery, development, and repositioning processes. The platform is openly available on GitHub, offering a powerful tool for the scientific community to expedite targeted therapies.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data into a singular numerical scoring system, facilitating rapid identification of drug targets for discovery, development, or repositioning. The platform features an interactive dashboard built with Python\u0027s Streamlit, displaying prioritization scores for genes linked to 1,844 phenotypic traits. StarGazer comprises both data-processing and data-visualization components, enhancing the accuracy of intensity data. Additionally, it has been extended to analyze pharmacogenes using whole genome sequencing data, making it a versatile tool in biomedical research. The platform is accessible via GitHub, allowing users to leverage its capabilities in drug discovery efforts.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It uniquely integrates multi-source, multi-omics data into a unified numerical scoring system, facilitating rapid target identification. Accessible via an interactive Python-based Streamlit dashboard, StarGazer provides prioritization scores for genes associated with 1844 distinct phenotypic traits. This comprehensive approach bridges various omics layers, streamlining drug discovery, development, and repositioning processes. Openly available on GitHub, StarGazer offers a cutting-edge solution for the pharmaceutical and biomedical research communities.",
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning, combining multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Streamlit dashboard.",
        "StarGazer is a hybrid intelligence platform that uses a singular scoring system to integrate different data sources for drug target prioritization and drug repositioning. It is available via https://github.com/AstraZeneca/StarGazer.",
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. The platform displays target prioritization scores for genes associated with 1844 phenotypic traits, facilitating rapid drug target identification for studies in drug discovery, development, or repositioning. StarGazer is available as an open-source tool via GitHub (https://github.com/AstraZeneca/StarGazer).",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multiple data sources and omics layers using a singular numerical scoring system within an interactive Python-based Streamlit dashboard. The platform combines multi-source, multi-omics data with a novel target prioritization scoring system to facilitate rapid drug target identification for drug discovery, development, and repositioning efforts. StarGazer provides target prioritization scores for genes associated with 1844 phenotypic traits and is publicly available on GitHub.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data into a singular numerical scoring system, enabling researchers to prioritize targets effectively for studies in drug discovery and development. The platform provides interactive access through a Python-based Streamlit dashboard, offering prioritization scores for genes associated with 1844 phenotypic traits. StarGazer is available via GitHub at https://github.com/AstraZeneca/StarGazer.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates various data sources using a unified numerical scoring system within a hybrid intelligent framework. This integration aims to facilitate the rapid prioritization of drug targets for research in drug discovery, development, or repositioning. StarGazer utilizes a prototype pipeline that combines multi-source, multi-omics data with a novel target prioritization scoring system. This system is presented through an interactive Python-based Streamlit dashboard. The platform provides prioritization scores for genes associated with 1844 phenotypic traits and is accessible via a GitHub repository provided by AstraZeneca.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data through a novel numerical scoring system within an interactive Streamlit dashboard. This tool facilitates rapid target prioritization by displaying scores for genes linked to 1844 phenotypic traits, aiding in drug discovery and repositioning efforts. StarGazer is accessible via GitHub, offering an open-source solution for researchers and developers.",
        "StarGazer is a hybrid intelligence platform, built on Python\u0027s Streamlit, designed for drug target prioritization and digital drug repositioning. It uniquely integrates multi-source, multi-omics data (including genomics, phenomics, and proteomics) through a novel numerical scoring system, currently covering 1844 phenotypic traits. The platform facilitates rapid analysis and target discovery via its interactive dashboard, aiming to enhance drug development by bridging human expertise with computational power. Developed by AstraZeneca, StarGazer is openly available on GitHub for research, access, and further development, promoting collaborative innovation in drug discovery.",
        "StarGazer is a hybrid intelligence platform designed for drug target prioritization and digital drug repositioning. It integrates multi-source, multi-omics data through a novel numerical scoring system to bridge various omics layers, facilitating rapid target identification in drug discovery, development, or repositioning efforts. The StarGazer pipeline combines this data with an interactive Python-based Streamlit dashboard, providing prioritization scores for genes associated with 1844 phenotypic traits. This tool is available on GitHub under AstraZeneca, offering a user-friendly interface to support research and applications in the field.",
        "StarGazer is a Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit. It combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits. It is available via https://github.com/AstraZeneca/StarGazer. It integrates different data sources using a singular numerical scoring system in a hybrid intelligent framework to facilitate rapid drug target prioritization for studies in drug discovery, development or repositioning.",
        "StarGazer is a hybrid intelligence platform utilizing a unified numerical scoring system to integrate multi-source, multi-omics data for rapid drug target prioritization and repositioning, accessible via an interactive Streamlit dashboard, currently covering 1844 phenotypic traits, and openly available on GitHub.",
        "StarGazer is a hybrid intelligence platform designed to prioritize drug targets and facilitate digital drug repositioning by integrating multi-source, multi-omics data into a unified numerical scoring system. This prototype leverages an interactive Python-based Streamlit dashboard to display target prioritization scores for genes linked to 1844 phenotypic traits, thereby aiding in drug discovery, development, or repositioning studies.",
        "StarGazer is a hybrid intelligence platform for drug target prioritization and digital drug repositioning. It combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits."
      ]
    },
    {
      "body": "What are the targets of Ivonescimab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39073550",
        "http://www.ncbi.nlm.nih.gov/pubmed/38642937",
        "http://www.ncbi.nlm.nih.gov/pubmed/37879536",
        "http://www.ncbi.nlm.nih.gov/pubmed/39490738",
        "http://www.ncbi.nlm.nih.gov/pubmed/39276767"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 621,
          "text": "Ivonescimab (®) is a first-in-class, humanized, tetravalent bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF)-A being developed by Akeso Biopharma for the treatment of non-small cell lung cancer (NSCLC) and other solid tumours, including breast cancer, liver cancer and gastric cancer. Ivonescimab simultaneously blocks the binding of PD-1 to its ligand (PD-L1), thereby relieving PD-1/PD-L1-mediated immunosuppression, and blocks the binding of VEGF-A to its receptor (VEGFR2), thus blocking tumour angiogenesis in the tumour microenvironment. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073550"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 358,
          "text": "Ivonescimab is a first-in-class, humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A simultaneously.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38642937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37879536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "text": "INTRODUCTION: This study (HARMONi-5) aimed to evaluate the safety and efficacy of ivonescimab (a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor) as first- or second-line monotherapy in patients with advanced immunotherapy-naive NSCLC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37879536"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 137,
          "text": "Ivonescimab is a humanized IgG1 bispecific anti-programmed cell death protein 1/vascular endothelial growth factor antibody",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39490738"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 374,
          "text": "Recent results from the HARMONi-A trial lead to considering ivonescimab-a first-in-class, bispecific antibody targeting PD-1 and VEGF-plus chemotherapy as a new second-line option following third-generation TKIs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39276767"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 373,
          "text": "Recent results from the HARMONi-A trial lead to considering ivonescimab-a first-in-class, bispecific antibody targeting PD-1 and VEGF-plus chemotherapy as a new second-line option following third-generation TKIs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39276767"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 361,
          "text": "Ivonescimab (®) is a first-in-class, humanized, tetravalent bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF)-A being developed by Akeso Biopharma for the treatment of non-small cell lung cancer (NSCLC) and other solid tumours, including breast cancer, liver cancer and gastric cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073550"
        },
        {
          "offsetInBeginSection": 362,
          "offsetInEndSection": 620,
          "text": "Ivonescimab simultaneously blocks the binding of PD-1 to its ligand (PD-L1), thereby relieving PD-1/PD-L1-mediated immunosuppression, and blocks the binding of VEGF-A to its receptor (VEGFR2), thus blocking tumour angiogenesis in the tumour microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073550"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "INTRODUCTION: Ivonescimab is a humanized IgG1 bispecific anti-programmed cell death protein 1/vascular endothelial growth factor antibody.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39490738"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Ivonescimab (®) is a first-in-class, humanized, tetravalent bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF)-A ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073550"
        },
        {
          "offsetInBeginSection": 222,
          "offsetInEndSection": 295,
          "text": "ivonescimab-a first-in-class, bispecific antibody targeting PD-1 and VEGF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39276767"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 137,
          "text": " Ivonescimab is a humanized IgG1 bispecific anti-programmed cell death protein 1/vascular endothelial growth factor antibody",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39490738"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 377,
          "text": "Ivonescimab (®) is a first-in-class, humanized, tetravalent bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF)-A being developed by Akeso Biopharma for the treatment of non-small cell lung cancer (NSCLC) and other solid tumours, including breast cancer, liver cancer and gastric cancer. Ivonescimab sim",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39073550"
        }
      ],
      "type": "list",
      "id": "67e6ba8e18b1e36f2e0000bf",
      "ideal_answer": [
        "Ivonescimab is a first-in-class, humanized, tetravalent bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF)-A being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumours, including breast cancer, liver cancer and gastric cancer."
      ],
      "exact_answer": [
        [
          "programmed cell death protein 1"
        ],
        [
          "vascular endothelial growth factor"
        ]
      ]
    },
    {
      "body": "Eptinezumab is a monclonal antibody direct againest what protein?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38392960",
        "http://www.ncbi.nlm.nih.gov/pubmed/39061413",
        "http://www.ncbi.nlm.nih.gov/pubmed/38755541",
        "http://www.ncbi.nlm.nih.gov/pubmed/38785386",
        "http://www.ncbi.nlm.nih.gov/pubmed/38568488",
        "http://www.ncbi.nlm.nih.gov/pubmed/38477313",
        "http://www.ncbi.nlm.nih.gov/pubmed/38466028",
        "http://www.ncbi.nlm.nih.gov/pubmed/38284301",
        "http://www.ncbi.nlm.nih.gov/pubmed/32266704",
        "http://www.ncbi.nlm.nih.gov/pubmed/31840684",
        "http://www.ncbi.nlm.nih.gov/pubmed/34759933",
        "http://www.ncbi.nlm.nih.gov/pubmed/38523607",
        "http://www.ncbi.nlm.nih.gov/pubmed/38023625",
        "http://www.ncbi.nlm.nih.gov/pubmed/34659764",
        "http://www.ncbi.nlm.nih.gov/pubmed/35659622",
        "http://www.ncbi.nlm.nih.gov/pubmed/36381178",
        "http://www.ncbi.nlm.nih.gov/pubmed/37532991",
        "http://www.ncbi.nlm.nih.gov/pubmed/36523559",
        "http://www.ncbi.nlm.nih.gov/pubmed/36856538",
        "http://www.ncbi.nlm.nih.gov/pubmed/31234642",
        "http://www.ncbi.nlm.nih.gov/pubmed/34540516",
        "http://www.ncbi.nlm.nih.gov/pubmed/36786548",
        "http://www.ncbi.nlm.nih.gov/pubmed/35716692",
        "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
        "http://www.ncbi.nlm.nih.gov/pubmed/36909005",
        "http://www.ncbi.nlm.nih.gov/pubmed/33324917",
        "http://www.ncbi.nlm.nih.gov/pubmed/35268319",
        "http://www.ncbi.nlm.nih.gov/pubmed/30651064",
        "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
        "http://www.ncbi.nlm.nih.gov/pubmed/30725283",
        "http://www.ncbi.nlm.nih.gov/pubmed/32155317",
        "http://www.ncbi.nlm.nih.gov/pubmed/33280422",
        "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
        "http://www.ncbi.nlm.nih.gov/pubmed/33008505",
        "http://www.ncbi.nlm.nih.gov/pubmed/36916250",
        "http://www.ncbi.nlm.nih.gov/pubmed/34535065",
        "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
        "http://www.ncbi.nlm.nih.gov/pubmed/34577624",
        "http://www.ncbi.nlm.nih.gov/pubmed/31550937",
        "http://www.ncbi.nlm.nih.gov/pubmed/32366601"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 143,
          "text": "ACKGROUND: Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP mAb) and is used for migraine prophylaxis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38755541"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "text": "We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)-a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)-in high-frequency episodic migraine (HFEM) or chronic migraine (CM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061413"
        },
        {
          "offsetInBeginSection": 476,
          "offsetInEndSection": 682,
          "text": "A total of 53 patients with migraine headache switched between three of the CGRP mAbs types due to lack of efficacy of the original prescribed CGRP mAbs, specifically eptinezumab, erenumab, and galcanezumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38392960"
        },
        {
          "offsetInBeginSection": 269,
          "offsetInEndSection": 555,
          "text": "ultiple migraine medications targeting CGRP have been introduced since 2018, including injectable monoclonal antibodies (ie, eptinezumab, erenumab, fremanezumab, and galcanezumab) and oral small-molecule CGRP receptor antagonists (ie, ubrogepant, rimegepant, atogepant, and zavegepant).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38568488"
        },
        {
          "offsetInBeginSection": 580,
          "offsetInEndSection": 791,
          "text": "vailable data from FDA reviews of erenumab, fremanezumab, galcanezumab and eptinezumab, approved CGRP-R and CGRP monoclonal antibodies and of atogepant were examined for prevention outcomes based on patient sex.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38477313"
        },
        {
          "offsetInBeginSection": 1400,
          "offsetInEndSection": 1713,
          "text": " evidence for the efficacy, tolerability, and safety of CGRP-targeting migraine preventive therapies (the monoclonal antibodies: erenumab, fremanezumab, galcanezumab, and eptinezumab, and the gepants: rimegepant and atogepant) is substantial, and vastly exceeds that for any other preventive treatment approach. T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38466028"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 508,
          "text": "Specific antibodies against CGRP bind to it either via a receptor (erenumab) or ligand (fremanezumab, galcanezumab, eptinezumab)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38284301"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 236,
          "text": "Eptinezumab is a humanized monoclonal antibody that selectively binds CGRP with high affinity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38023625"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 184,
          "text": "To date, real-world evidence on persistence to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) or onabotulinumtoxinA have excluded eptinezumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37532991"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 282,
          "text": "Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a potent vasodilator with an important role in migraine pathophysiology",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38785386"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 387,
          "text": "Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab) and the CGRP receptor (erenumab), and small molecule CGRP receptor antagonists (atogepant and rimegepant)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36523559"
        },
        {
          "offsetInBeginSection": 24,
          "offsetInEndSection": 302,
          "text": "Based on their pharmacological target, two classes of calcitonin-gene-related peptide (CGRP) monoclonal antibodies (mAbs) have been identified: antibodies against the CGRP ligand-galcanezumab, fremanezumab, eptinezumab-and antibodies against the CGRP receptor (CGRP-R), erenumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36856538"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Eptinezumab-jjmr (referred to as eptinezumab hereafter; Vyepti™) is a humanised monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32266704"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Background: Eptinezumab is a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and is indicated for the preventive treatment of migrain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34759933"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34759933"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 228,
          "text": "physiology. We evaluated eptinezumab, an intravenous (IV) anti-calcitonin gene-related peptide monoclonal antibody, for the prevention of chron",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31234642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Eptinezumab, a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), was recently approved in Europe for the prophylactic treatment of migraine in adults who have at least four migraine days a month.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38523607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "BACKGROUND: Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP mAb) and is used for migraine ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38755541"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Background: Eptinezumab is a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34759933"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Eptinezumab (ALD-403) is a genetically engineered humanized IgG1kappa directed towards calcitonin gene-related peptide (CGRP), currently in late-stage clinical development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31840684"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 345,
          "text": "Eptinezumab targets the pathway of CGRP, importantly implicated in migraine pathophysiology, and may represent the first-to-market infusion therapy for migraine prevention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31840684"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Background: Eptinezumab is a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and is indicated for the preventive treatment of migraine in adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34759933"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 237,
          "text": "Eptinezumab is a humanized monoclonal antibody that selectively binds CGRP with high affinity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38023625"
        },
        {
          "offsetInBeginSection": 1356,
          "offsetInEndSection": 1482,
          "text": "Eptinezumab is the fourth Calcitonin Gene-related Peptide monoclonal antibody to receive Federal Drug Administration approval.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34659764"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 181,
          "text": " Eptinezumab is a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and is indicated for the preventive treatment of migraine in adults",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34759933"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 141,
          "text": " Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP mAb) and is used for migraine prophylaxis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38755541"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 314,
          "text": " This review centers on Eptinezumab-jjmr, a humanized monoclonal specific to CGRP for the prevention of migraines in adults",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36381178"
        },
        {
          "offsetInBeginSection": 58,
          "offsetInEndSection": 175,
          "text": "eptinezumab (also known by the brand name Vyepti), a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34540516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Eptinezumab (ALD-403) is a genetically engineered humanized IgG1kappa directed towards calcitonin gene-related peptide (CGRP),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31840684"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Eptinezumab-jjmr (referred to as eptinezumab hereafter; Vyepti™) is a humanised monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32266704"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "PURPOSE OF REVIEW: Monoclonal antibodies (mAbs) targeting the calcitonin-gene-related peptide (CGRP) pathway have been developed for episodic and chronic migraine prevention, either through binding the CGRP ligand (eptinezumab, fremanezumab, galcanezumab) or the CGRP r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432219"
        },
        {
          "offsetInBeginSection": 672,
          "offsetInEndSection": 788,
          "text": "While erenumab is a mAb to the CGRP receptor, eptinezumab, fremanezumab, and galcanezumab bind to the CGRP molecule.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36909005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (Erenumab) or against CGRP (Eptinezumab, Fremanezumab, Galcanezumab) are new substances for the preventive treatment of migraine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33324917"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Recently, monoclonal antibodies (mAbs) directed against calcitonin gene-related peptide (CGRP) (Eptinezumab, Fremanezumab, and Galcanezumab) or its receptor (Erenumab) have been approved for clinical use as prophylactic drugs for high-frequency episodic and chronic migraine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35268319"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 342,
          "text": "o prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30651064"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "BACKGROUND AND PURPOSE: Based on their pharmacological target, two classes of calcitonin-gene-related peptide (CGRP) monoclonal antibodies (mAbs) have been identified: antibodies against the CGRP ligand-galcanezumab, fremanezumab, eptinezumab-and antibodies against the CGRP rece",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36856538"
        },
        {
          "offsetInBeginSection": 628,
          "offsetInEndSection": 777,
          "text": "monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490"
        },
        {
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1309,
          "text": "monoclonal antibodies against CGRP (Eptinezumab, Fremanezumab, and Galcanezumab) or the CGRP receptor (Erenumab) effectively prevent migraine attacks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30725283"
        },
        {
          "offsetInBeginSection": 266,
          "offsetInEndSection": 454,
          "text": "Four monoclonal antibodies targeting the calcitonin gene-related peptide pathway are currently available after the US FDA approval of eptinezumab for the indication of migraine prevention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33280422"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Eptinezumab is a humanized mAb that targets calcitonin gene-related peptide and is under regulatory review for the prevention of episodic and chronic migraine (EM, CM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32155317"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 337,
          "text": "BACKGROUND: The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and acceptable safety and tolerability in phase 3 trials, but benefits in the subpopulations of patients with previous preventive treatment failures were not examined.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35716692"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Background: Eptinezumab is a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and is indicated for the preventive treatment of migrai",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34759933"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "BACKGROUND: Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP mAb) and is used for migraine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38755541"
        },
        {
          "offsetInBeginSection": 672,
          "offsetInEndSection": 787,
          "text": "While erenumab is a mAb to the CGRP receptor, eptinezumab, fremanezumab, and galcanezumab bind to the CGRP molecule",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36909005"
        },
        {
          "offsetInBeginSection": 748,
          "offsetInEndSection": 855,
          "text": "Galcanezumab and eptinezumab target the CGRP ligand (CGRP/L), while erenumab targets CGRP receptors (CGRP/R",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38392960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)-a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061413"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 346,
          "text": "We present a review of the efficacy and safety profile of eptinezumab (also known by the brand name Vyepti), a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) developed by Lundbeck Seattle BioPharmaceuticals, Inc., that received its first approval in the USA on 21 February 2020 for the preventive treatment of migraine in adults",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34540516"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 453,
          "text": "Among these, calcitonin gene-related peptide has shown a crucial role that led to the development of therapies specifically targeting the molecule. Four monoclonal antibodies targeting the calcitonin gene-related peptide pathway are currently available after the US FDA approval of eptinezumab for the indication of migraine prevention",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33280422"
        },
        {
          "offsetInBeginSection": 1160,
          "offsetInEndSection": 1376,
          "text": "Currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29697153"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 280,
          "text": "Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36523559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 340,
          "text": "BACKGROUND AND AIM: Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30651064"
        },
        {
          "offsetInBeginSection": 1160,
          "offsetInEndSection": 1378,
          "text": "Currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29697153"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 281,
          "text": "monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36523559"
        },
        {
          "offsetInBeginSection": 410,
          "offsetInEndSection": 523,
          "text": "and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies (erenumab, eptinezumab, fremanezum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36786548"
        },
        {
          "offsetInBeginSection": 748,
          "offsetInEndSection": 857,
          "text": "Galcanezumab and eptinezumab target the CGRP ligand (CGRP/L), while erenumab targets CGRP receptors (CGRP/R).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38392960"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 403,
          "text": "Four CGRP monoclonal antibodies have received FDA approval for the prevention of migraine: erenumab, fremanezumab, galcanezumab, and eptinezumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33008505"
        },
        {
          "offsetInBeginSection": 68,
          "offsetInEndSection": 279,
          "text": "Currently, four monoclonal antibodies targeting the CGRP (calcitonin gene-related peptide) pathway have been shown to be effective as migraine prophylactics: eptinezumab, erenumab, fremanezumab and galcanezumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36916250"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 347,
          "text": "We present a review of the efficacy and safety profile of eptinezumab (also known by the brand name Vyepti), a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) developed by Lundbeck Seattle BioPharmaceuticals, Inc., that received its first approval in the USA on 21 February 2020 for the preventive treatment of migraine in adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34540516"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 509,
          "text": "Specific antibodies against CGRP bind to it either via a receptor (erenumab) or ligand (fremanezumab, galcanezumab, eptinezumab).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38284301"
        },
        {
          "offsetInBeginSection": 647,
          "offsetInEndSection": 784,
          "text": "Antimigraine mAbs act as direct scavengers of CGRP (galcanezumab, fremanezumab, and eptinezumab) or against the CGRP receptor (erenumab).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34535065"
        },
        {
          "offsetInBeginSection": 279,
          "offsetInEndSection": 499,
          "text": "Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 388,
          "text": "Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab) and the CGRP receptor (erenumab), and small molecule CGRP receptor antagonists (atogepant and rimegepant).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36523559"
        },
        {
          "offsetInBeginSection": 1309,
          "offsetInEndSection": 1609,
          "text": "Here, an attempt is proposed to analyse the rational basis and evidence in favour of investigating the efficacy and safety in acute migraine attacks of eptinezumab, i.e., monoclonal antibody (mAb) directed towards calcitonin gene-related peptide (CGRP) unique for intravenous infusion administration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34577624"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 350,
          "text": "Eptinezumab, fremanezumab and galcanezumab block CGRP mediated effects by binding to the peptide,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31550937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "BACKGROUND: Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35659622"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "BACKGROUND: Eptinezumab is an anti-calcitonin gene-related peptide humanized monoclonal antibody approved for the preventive treatment of migrain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35804294"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 402,
          "text": "Four CGRP monoclonal antibodies have received FDA approval for the prevention of migraine: erenumab, fremanezumab, galcanezumab, and eptinezumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33008505"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Recently, monoclonal antibodies (mAbs) directed against calcitonin gene-related peptide (CGRP) (Eptinezumab, Fremanezumab, and Galcanezumab) or its receptor (Erenumab) have been approved for clinical use as prophylactic drugs for high-frequency episodic and chronic migraine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35268319"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 507,
          "text": "Specific antibodies against CGRP bind to it either via a receptor (erenumab) or ligand (fremanezumab, galcanezumab, eptinezumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38284301"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "ALD403 is a genetically engineered, humanized immunoglobulin G1 monoclonal antibody that inhibits the action of human calcitonin gene-related peptide (CGRP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32366601"
        },
        {
          "offsetInBeginSection": 647,
          "offsetInEndSection": 782,
          "text": "Antimigraine mAbs act as direct scavengers of CGRP (galcanezumab, fremanezumab, and eptinezumab) or against the CGRP receptor (erenumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34535065"
        }
      ],
      "type": "factoid",
      "id": "67e08afd18b1e36f2e00006a",
      "ideal_answer": [
        "Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP mAb) and is used for migraine prophylaxis.",
        "Eptinezumab is a monoclonal antibody directed against the calcitonin gene-related peptide (CGRP).",
        "Eptinezumab is a humanized monoclonal antibody that selectively binds PACE (calcitonin gene related peptide, ANG II receptor expressing) cells.",
        "Eptinezumab is a monoclonal antibody directed against Calcitonin Gene-Related Peptide (CGRP), a protein implicated in migraine pathophysiology, indicating its therapeutic application in treating migraines by targeting CGRP.",
        "Eptinezumab is a humanized monoclonal antibody that targets the calcitonin gene-related peptide (CGRP). CGRP is involved in the pathophysiology of migraine, and eptinezumab selectively binds to CGRP for the preventive treatment of migraine in adults.",
        "Eptinezumab is a humanized monoclonal antibody designed to target and selectively bind to the calcitonin gene-related peptide (CGRP) with high affinity. CGRP is a neuropeptide involved in the pathophysiology of migraine, and by inhibiting its activity, eptinezumab helps in the prevention and treatment of migraine attacks.",
        "Eptinezumab is a monoclonal antibody directed against calcitonin gene-related peptide.",
        "Eptinezumab is a monoclonal antibody directed against calcitonin gene-related peptide (CGRP).",
        "Eptinezumab is a monoclonal antibody directed against the protein calcitonin gene-related peptide (CGRP).",
        "Eptinezumab is a monoclonal antibody directed against calcitonin gene-related peptide (CGRP), a protein involved in migraine pathophysiology. It binds to CGRP to inhibit its activity, reducing migraine frequency and severity.",
        "Eptinezumab directly binds the calcitonin gene‐related peptide ligand rather than its receptor.",
        "Eptinezumab is a monoclonal antibody directed against the calcitonin gene-related peptide (CGRP) protein. It binds to CGRP, blocking its interaction with receptors to reduce migraine frequency and severity.",
        "Eptinezumab is a monoclonal antibody directed against the calcitonin gene-related peptide (CGRP) ligand.",
        "Eptinezumab is a monoclonal antibody directed against calcitonin-gene related peptide (CGRP).",
        "Eptinezumab is a monoclonal antibody specifically directed against the protein Calcitonin Gene-Related Peptide (CGRP), which is involved in various physiological processes including pain transmission and vascular regulation, and is a validated target for therapeutic interventions, notably in the prevention of migraines.",
        "Eptinezumab is a monoclonal antibody directed against the neuropeptide CGRP (Calcitonin Gene-Related Peptide).",
        "Eptinezumab is a monoclonal antibody directed against Calcitonin Gene-Related Peptide (CGRP).",
        "Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its activity. It does not target the CGRP receptor, but rather the CGRP ligand itself. This means that eptinezumab directly targets the CGRP protein, preventing it from interacting with its receptor and thereby reducing its biological effects.",
        "Eptinezumab is a monoclonal antibody against calcitonin gene-related peptide (CGRP).",
        "Eptinezumab is a monoclonal antibody directed against Calcitonin Gene-Related Peptide (CGRP), a protein implicated in migraine pathophysiology, making it a validated therapeutic target for the prevention of migraines.",
        "Eptinezumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP). This targeting has been confirmed through various binding assays and multiple phase 3 clinical trials, including PROMISE-1 and PROMISE-2 studies. These studies support its role in the prevention of episodic and chronic migraine by inhibiting CGRP, a protein involved in the pathophysiology of migraine.",
        "Eptinezumab is a monoclonal antibody that directly targets the calcitonin gene-related peptide (CGRP).",
        "Eptinezumab is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor.",
        "Eptinezumab is a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide (CGRP) and is indicated for the preventive treatment of migraine in adults.",
        "Eptinezumab is a monoclonal antibody directed against calcitonin gene-related peptide (CGRP). It binds to CGRP and blocks its binding to the receptor, and is used for migraine prophylaxis and preventive treatment of migraine in adults.",
        "Eptinezumab is a humanized monoclonal antibody that targets the calcitonin gene-related peptide (CGRP). This protein is involved in the pathophysiology of migraine, and eptinezumab\u0027s selective binding to CGRP has been demonstrated in various clinical trials, confirming its role in migraine prevention.",
        "Eptinezumab is a monoclonal antibody that directly targets the calcitonin gene-related peptide (CGRP), which plays a key role in migraine pathophysiology. By blocking CGRP, the antibody helps prevent migraine attacks in patients with high-frequency episodic or chronic migraine.",
        "Eptinezumab is a fully human monoclonal antibody directed against calcitonin gene related peptide (CGRP). It was developed for the treatment of migraine.",
        "Eptinezumab is a humanized monoclonal antibody specifically designed to target and inhibit the calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathophysiology. By binding to CGRP, eptinezumab prevents its interaction with receptors, thereby reducing the frequency and severity of migraine attacks as a prophylactic treatment.",
        "calcitonin gene-related peptide, a protein involved in migraine pathophysiology, targeted by eptinezumab for migraine prophylaxis.",
        "Eptinezumab directly targets the calcitonin gene-related peptide (CGRP), which plays a key role in migraine mechanisms.",
        "Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP).",
        "Eptinezumab is a monoclonal antibody directed against calcitonin gene-related peptide (CGRP), used for migraine prophylaxis.",
        "Eptinezumab is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP).",
        "Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide, a neuropeptide that plays a crucial role in migraine pathophysiology.",
        "Eptinezumab is directed against calcitonin gene-related peptide (CGRP), a protein involved in migraine pathophysiology.",
        "Eptinezumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP).",
        "Eptinezumab is a monoclonal antibody that targets the Calcitonin Gene-Related Peptide (CGRP). It is used for migraine prophylaxis by neutralizing CGRP, which plays a significant role in migraine pathophysiology.",
        "Eptinezumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP). It is used for migraine prophylaxis, specifically in conditions such as high-frequency episodic migraine and chronic migraine. The EMBRACE study evaluated its real-life effectiveness, safety, and tolerability.",
        "Eptinezumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP). It is used specifically for migraine prophylaxis by binding to CGRP, thereby inhibiting its activity. This mechanism of action makes it effective in reducing the frequency and severity of migraines.",
        "Eptinezumab is directed against the calcitonin gene-related peptide (CGRP) protein.",
        "Eptinezumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP), specifically its ligand, playing a role in therapeutic interventions, notably in the treatment of migraine prevention.",
        "Eptinezumab is a monoclonal antibody specifically designed to target calcitonin gene-related peptide (CGRP). CGRP is a neuropeptide that plays a significant role in the pathophysiology of migraine by dilating cerebral and dural blood vessels and transmitting pain signals. By binding to CGRP, eptinezumab helps to prevent migraines by inhibiting these pathways. It is administered intravenously for migraine prophylaxis, providing an option for patients who require preventive treatment to reduce the frequency and severity of migraine attacks.",
        "Eptinezumab is a monoclonal antibody directed against the calcitonin gene-related peptide (CGRP) protein.",
        "Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP) and is used for migraine prophylaxis.",
        "Eptinezumab is a monoclonal antibody that specifically targets calcitonin gene-related peptide (CGRP). It belongs to the class of CGRP monoclonal antibodies (CGRP mAbs) used for migraine prophylaxis. By targeting CGRP, eptinezumab helps prevent migraine attacks in patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM).",
        "Eptinezumab is a monoclonal antibody that specifically targets the calcitonin gene-related peptide (CGRP), as indicated in the studies evaluating its effectiveness for migraine prophylaxis.",
        "Eptinezumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP). It is used for migraine prophylaxis, functioning by inhibiting CGRP, which plays a role in pain pathways associated with migraines.",
        "Eptinezumab is a monoclonal antibody directed against the Calcitonin Gene-Related Peptide (CGRP) ligand, providing targeted therapy by specifically interacting with the ligand form of CGRP, a key player in certain physiological and pathological processes, including migraine prevention, its primary clinical application.",
        "Eptinezumab is a monoclonal antibody targeting the calcitonin-gene-related peptide (CGRP mAb).",
        "Eptinezumab is a monoclonal antibody directed against calcitonin gene-related peptide (CGRP). It is used for migraine prophylaxis. Eptinezumab binds to CGRP and blocks its binding to the receptor.",
        "Eptinezumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) and is used for migraine prophylaxis."
      ],
      "exact_answer": [
        [
          "calcitonin gene-related peptide (CGRP )"
        ]
      ]
    },
    {
      "body": "What is ophthalmologic loa-loa?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37858326",
        "http://www.ncbi.nlm.nih.gov/pubmed/39494037",
        "http://www.ncbi.nlm.nih.gov/pubmed/39051866",
        "http://www.ncbi.nlm.nih.gov/pubmed/23698214",
        "http://www.ncbi.nlm.nih.gov/pubmed/32676267",
        "http://www.ncbi.nlm.nih.gov/pubmed/18217870"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Loa loa, the African eye worm, is a filarial pathogen transmitted by blood-sucking flies of the genus Chrysops",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37858326"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "The \u0027African eye worm\u0027, also known as Loa loa, is filarial nematode that is commonly, transmitted by deer flies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494037"
        },
        {
          "offsetInBeginSection": 377,
          "offsetInEndSection": 463,
          "text": "ocular symptoms secondary to the migration of worms, through the spaces within the eye",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494037"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Objective: Ocular loasis refers to ocular conditions such as pain and redness caused by the movement of the Loa loa nematode through the subconjuctival space of the eye",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32676267"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 464,
          "text": "While a majority of patients infected with Loa, loa are asymptomatic, common presentations of Loiasis include localized areas of, edema, Calbar swellings, and ocular symptoms secondary to the migration of worms, through the spaces within the eye.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494037"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Loiasis, caused by the filarial nematode Loa loa, is often asymptomatic but frequently manifests as episodic angioedema and periocular migration of adult worms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18217870"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Filariasis or Loiasis is an eye infection caused by a parasite belonging to the species Loa loa, also known as \"African eye worm\" since it is present in the rainforests belt of western and central Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23698214"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 463,
          "text": "While a majority of patients infected with Loa, loa are asymptomatic, common presentations of Loiasis include localized areas of, edema, Calbar swellings, and ocular symptoms secondary to the migration of worms, through the spaces within the eye",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494037"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Loa loa is unique among the human filariae in that adult worms are occasionally visible during subconjunctival migration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18756067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Loiasis, caused by the filarial nematode Loa loa, is often asymptomatic but frequently manifests as episodic angioedema and periocular migration of adult worms. Hence also known as the eye worm",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18217870"
        }
      ],
      "id": "67e299b618b1e36f2e000087",
      "ideal_answer": [
        "Ophthalmologic Loa-Loa is an eye infection caused by the Loa loa parasitic worm, or \u0027African eye worm\u0027, endemic in Western, Central, and Eastern Africa\u0027s tropical rain forests. Symptoms include foreign body sensation, subconjunctival swelling, pressure, eye irritation, or a visible worm under the conjunctiva. The infection is transmitted by the Chrysops fly, typically after a stay in endemic areas. Diagnosis can be made through slit-lamp biomicroscopy, supported by parasitological and serological analysis, highlighting the presence of a live worm in the subconjunctival space or vitreous cavity as a definitive characteristic.",
        "Ophthalmologic loa-loa refers to the migration of the adult Loa loa worm in the ocular region, often leading to symptoms such as pain, redness, and excessive lacrimation in the affected eye. This condition can manifest as episodic angioedema and periocular migration of the worm, which is typically diagnosed through slit-lamp biomicroscopy. The removal of the worm can be performed under topical anesthesia through a conjunctival incision.",
        "Ophthalmologic loa-loa refers to the ocular manifestations of loiasis, a parasitic infection caused by *Loa loa*. It is characterized by the migration of adult worms through the subconjunctival spaces and other ocular tissues, often resulting in visible worm movement under the eyelid (periocular or subconjunctival migration). This condition can cause symptoms such as itching, conjunctivitis-like symptoms, and localized edema. Ophthalmologic loa-loa is a common presentation of the disease, particularly in endemic regions, and may require surgical intervention for worm extraction.",
        "Ophthalmologic Loa-loa refers to the presence of an adult Loa loa worm under the conjunctiva of the eye, typically in the subconjunctival space. This is a characteristic feature of loiasis, a parasitic infection caused by the filarial nematode Loa loa. The worm can be seen moving under the skin or sclera of the eye, causing discomfort and anxiety for the patient. In some cases, the worm may also cause painful and itchy subcutaneous edema, arthralgia, and other systemic symptoms. Ophthalmologic Loa-loa is often diagnosed by direct visualization of the worm during an ophthalmological examination. Treatment typically involves removal of the worm from the eye, followed by antiparasitic therapy to eliminate any remaining parasites in the body.",
        "Ophthalmologic loa-loa involves ocular symptoms secondary to the migration of the filarial nematode *Loa loa*, the \u0027African eye worm\u0027, through spaces within the eye, such as the subconjunctival space, anterior chamber, or vitreous cavity. Presentations include a moving parasite in the subconjunctiva or an adult worm in the anterior chamber or vitreous. Patients may experience symptoms of pain, redness, excessive lacrimation, or a moving foreign body sensation. A long thin worm migrating in the lateral subconjunctival space may be seen. Ocular loiasis often involves the finding of a subconjunctival adult worm, which can be removed. It is frequently associated with individuals who have travelled to or originated from endemic regions in West and Central Africa, although cases can present without recent travel history."
      ]
    },
    {
      "body": "Can a single gene be regulated by multiple enhancers?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38509257",
        "http://www.ncbi.nlm.nih.gov/pubmed/38750461",
        "http://www.ncbi.nlm.nih.gov/pubmed/27452946",
        "http://www.ncbi.nlm.nih.gov/pubmed/30563465",
        "http://www.ncbi.nlm.nih.gov/pubmed/27895109",
        "http://www.ncbi.nlm.nih.gov/pubmed/39406234",
        "http://www.ncbi.nlm.nih.gov/pubmed/28964699",
        "http://www.ncbi.nlm.nih.gov/pubmed/26925592",
        "http://www.ncbi.nlm.nih.gov/pubmed/24854999",
        "http://www.ncbi.nlm.nih.gov/pubmed/29641996",
        "http://www.ncbi.nlm.nih.gov/pubmed/39354714",
        "http://www.ncbi.nlm.nih.gov/pubmed/37163096",
        "http://www.ncbi.nlm.nih.gov/pubmed/32479598",
        "http://www.ncbi.nlm.nih.gov/pubmed/20833307",
        "http://www.ncbi.nlm.nih.gov/pubmed/30374068",
        "http://www.ncbi.nlm.nih.gov/pubmed/27321818",
        "http://www.ncbi.nlm.nih.gov/pubmed/33547831",
        "http://www.ncbi.nlm.nih.gov/pubmed/26480823",
        "http://www.ncbi.nlm.nih.gov/pubmed/30811990",
        "http://www.ncbi.nlm.nih.gov/pubmed/22445034",
        "http://www.ncbi.nlm.nih.gov/pubmed/38559211",
        "http://www.ncbi.nlm.nih.gov/pubmed/22011226",
        "http://www.ncbi.nlm.nih.gov/pubmed/23236268",
        "http://www.ncbi.nlm.nih.gov/pubmed/39466837",
        "http://www.ncbi.nlm.nih.gov/pubmed/24127599"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 369,
          "text": "Enhancers are the primary regulatory DNA sequences in eukaryotes and are mostly located in the non-coding sequences of genes, namely, intergenic regions and introns. The essential characteristic of an enhancer is the ability to activate proximal genes, e.g., a reporter gene in a reporter assay, regardless of orientation, relative position, and distance from the gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38509257"
        },
        {
          "offsetInBeginSection": 553,
          "offsetInEndSection": 718,
          "text": "Developmentally regulated genes are associated with multiple enhancers carrying distinct cell and developmental stage specificities, which form arrays on the genome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38509257"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 266,
          "text": "Multiple enhancers co-regulating the same gene is prevalent and plays a crucial role during development and disease. However, how multiple enhancers coordinate the same gene expression across various cell types remains largely unexplored at genome scale.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38750461"
        },
        {
          "offsetInBeginSection": 383,
          "offsetInEndSection": 475,
          "text": "Multiple enhancers may also work together to regulate transcription of a shared target gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27452946"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "A single gene may have multiple enhancers, but how they work in concert to regulate transcription is poorly understood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39406234"
        },
        {
          "offsetInBeginSection": 778,
          "offsetInEndSection": 977,
          "text": "Partial deletions of these ECs which removed only one enhancer or a subcluster of enhancers revealed partially redundant control of the regulated gene by multiple enhancers within the larger cluster.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27895109"
        },
        {
          "offsetInBeginSection": 992,
          "offsetInEndSection": 1140,
          "text": "These results provide insights into mechanisms that allow a single target gene to be regulated by diverse enhancer elements in different cell types.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29641996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "A single gene may have multiple enhancers, but how they work in concert to regulate transcription is poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39406234"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "text": "Several empirical and theoretical studies suggest the presence of multiple enhancers per gene that collectively regulate gene expression, and that common sequence variation impacting on the activities of these enhancers is a major source of inter-individual gene expression variability.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39354714"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Animals have modular cis-regulatory regions in their genomes, and expression of a single gene is often regulated by multiple enhancers residing in such a region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26925592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Multiple regulatory regions have the potential to regulate a single gene, yet how these elements combine to affect gene expression remains unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964699"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "A single gene may have multiple enhancers, but how they work in concert to regulate transcription is poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37163096"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "The expression of many animal genes has been shown to be controlled by two--rather than one--enhancers with similar regulatory content.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833307"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "The promoters of mammalian genes are commonly regulated by multiple distal enhancers, which physically interact within discrete chromatin domains.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374068"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 349,
          "text": "The expression of a gene can be regulated by one or multiple enhancers at different developmental stages and/or in different tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27321818"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 397,
          "text": "Eukaryotic genes, especially those related to development or responses to environmental cues, are often regulated by multiple enhancers in different tissues and/or at different developmental stages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33547831"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "The human genome encodes an order of magnitude more gene expression enhancers than promoters, suggesting that most genes are regulated by the combined action of multiple enhancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32479598"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Transcription of developmental genes is controlled by multiple enhancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30811990"
        },
        {
          "offsetInBeginSection": 1078,
          "offsetInEndSection": 1353,
          "text": "It is now well established that most if not all genes of higher eukaryotes are under the control of multiple distal regulatory elements and that local modifications of the chromatin structure play an essential role in the mechanisms of differentiation from embryos to adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22445034"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "Several empirical and theoretical studies suggest presence of multiple enhancers per gene that collectively regulate gene expression, and that common sequence variation impacting on the activities of these enhancers is a major source of inter-individual variability in gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38559211"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Multiple regulatory regions have the potential to regulate a single gene, yet how these elements combine to affect gene expression remains unclear",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964699"
        },
        {
          "offsetInBeginSection": 694,
          "offsetInEndSection": 882,
          "text": "Some genes utilize a single enhancer that promotes expression in all midline cells, while others utilize multiple enhancers with distinct spatial, temporal, and quantitative contributions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24854999"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 48,
          "text": "Genes are often regulated by multiple enhancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39466837"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Although it is widely appreciated that a typical developmental control gene is regulated by multiple enhancers, coordination of enhancer activities remains poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24127599"
        }
      ],
      "id": "67eb86d618b1e36f2e0000f2",
      "ideal_answer": [
        "Enhancers are the primary regulatory DNA sequences in eukaryotes that can activate proximal genes, regardless of orientation, relative position, and distance from the gene. Multiple enhancers co-regulating the same gene is prevalent and plays a crucial role during development and disease. For example, developmentally regulated genes are associated with multiple enhancers carrying distinct cell and developmental stage specificities. However, how multiple enhancers coordinate the same gene expression across various cell types remains largely unexplored at genome scale.",
        "Yes, a single gene can be regulated by multiple enhancers. Enhancers are DNA sequences that enhance the transcription of genes by binding transcription factors and recruiting the necessary machinery for transcription. A single gene may have several enhancers located at various distances from the promoter, allowing for precise regulation under different conditions or in different tissues.\n\nFor example, the Sox2 gene is known to have multiple enhancers with distinct specificities for different cells or developmental stages. This setup enables genes to be expressed in various contexts, providing a complex regulatory network that determines gene expression by summing the effects of positive and negative transcriptional inputs.\n\nAdditionally, variations in these enhancers can influence gene expression variability between individuals, highlighting the importance of multiple enhancers in modulating gene activity. Thus, the presence of multiple enhancers allows for nuanced control over gene expression, adapting to different cellular environments or developmental needs.",
        "Yes, a single gene can indeed be regulated by multiple enhancers. Enhancers are DNA sequences that enhance the transcription of genes by binding transcription factors, which then recruit the necessary machinery for transcription. These enhancers can work independently or together to fine-tune gene expression based on different signals or conditions.\n\nResearch indicates that developmentally regulated genes often have arrays of enhancers with distinct specificities for different cells and stages. For example, the Sox2 gene is known to be regulated by multiple enhancers in developmental contexts. Multiple enhancers allow for precise control over when and where a gene is expressed, which is crucial for processes like development.\n\nEnhancers can work additively, contributing individually to overall expression, or they can interact in more complex ways within cis-regulatory networks. These networks sum positive and negative inputs to regulate gene expression effectively. While some genes may only require one enhancer, especially if their expression pattern is simple, the presence of multiple enhancers is common and plays a significant role in complex gene regulation.\n\nIn conclusion, the ability of single genes to be regulated by multiple enhancers underscores the intricate mechanisms involved in controlling gene expression, ensuring that it occurs at the right time and place.",
        "Yes, a single gene can be regulated by multiple enhancers. Enhancers are DNA elements that increase the transcription of their target genes and can function at a distance. Many genes, particularly those involved in development or determining cell identity, are controlled by more than one enhancer. These enhancers may operate in different cell types or at various stages of development, ensuring that the gene is expressed at the appropriate time and place. Additionally, having multiple enhancers provides redundancy; if one enhancer fails or becomes mutated, others can compensate to ensure stable gene expression. They can also work together in an additive or synergistic way to finely adjust the gene\u0027s expression levels in response to different signals.",
        "Studies have shown that a single gene can indeed be regulated by multiple enhancers, which are cis-regulatory DNA elements that positively regulate the transcription of target genes in a tissue-specific manner. These enhancers can work together to regulate transcription of a shared target gene, with some genes utilizing a single enhancer and others utilizing multiple enhancers with distinct spatial, temporal, and quantitative contributions. This is exemplified by the concept of \"shadow enhancers\", where two or more enhancers regulate the same target gene in space and time, and are associated with most animal developmental genes. Furthermore, highly transcribed genes are often associated with a cluster of individual enhancers, highlighting the complexity of gene regulation by multiple enhancers.",
        "Yes, a single gene can indeed be regulated by multiple enhancers. Enhancers are DNA elements that enhance the transcription of genes, and having multiple enhancers associated with a single gene allows for complex and precise regulation. These enhancers can have distinct specificities, responding to different signals or being active in various tissues or developmental stages. They often form organized arrays on the genome, facilitating comprehensive control over gene expression. While it is clear that multiple enhancers can regulate the same gene, the exact mechanisms by which they coordinate their activity across different cell types remain an area of ongoing research. This system provides redundancy and fine-tuning capabilities, essential for the intricate regulation of gene expression in diverse biological contexts.",
        "Yes, a single gene can be regulated by multiple enhancers. Enhancers are key regulatory elements that activate genes irrespective of their orientation or distance. Developmentally regulated genes often have several enhancers with specific functions for different cells and stages, forming arrays in the genome. This co-regulation is common and vital in development and disease, though the exact coordination mechanisms across cell types remain largely unexplored.",
        "Yes, a single gene can indeed be regulated by multiple enhancers. Enhancers are DNA sequences that increase the transcription of genes and can function from various positions relative to their target gene. Developmentally regulated genes often have several enhancers, each specific to different cells or developmental stages, forming arrays on the genome. While the exact mechanisms of how these enhancers coordinate gene expression across cell types are still under study, it is well-established that multiple enhancers can co-regulate a single gene, particularly during development and in disease contexts. This allows for precise control over gene expression in different scenarios.",
        "Yes, a single gene can be regulated by multiple enhancers. These enhancers are crucial regulatory DNA sequences that activate genes irrespective of their orientation, position, or distance, and they often carry distinct specificities for different cell types and developmental stages. This multi-enhancer regulation is prevalent in developmentally regulated genes, where arrays of enhancers coordinate gene expression across various contexts."
      ],
      "exact_answer": "yes"
    }
  ]
}